{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "import pandas as pd\n",
    "import numpy as np\n",
    "import sys\n",
    "import os"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "ourdata = pd.read_csv('data/drug_riskscores.csv')\n",
    "ourdata['drug'] = ourdata['drug'].str.lower()\n",
    "drugs = list(ourdata['drug'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [],
   "source": [
    "from calc_relative_risks_drugs import *"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Drug target 1,25(oh)2d3 not found. Exiting ...\n",
      "\n",
      "Drug target 17-hydroxyprogesterone not found. Exiting ...\n",
      "\n",
      "Drug target 18f-flutemetamol not found. Exiting ...\n",
      "\n",
      "Drug target 2-hydroxysuccinaldehyde not found. Exiting ...\n",
      "\n",
      "Drug target 4-ap not found. Exiting ...\n",
      "\n",
      "Drug target 4-methylpyrazole not found. Exiting ...\n",
      "\n",
      "Drug target 5-asa not found. Exiting ...\n",
      "\n",
      "Drug target 5-fu not found. Exiting ...\n",
      "\n",
      "Drug target 5-aminolevulinic not found. Exiting ...\n",
      "\n",
      "Drug target 5-aza-2'-deoxycytidine not found. Exiting ...\n",
      "\n",
      "Drug target 5-azacytidine not found. Exiting ...\n",
      "\n",
      "Drug target a77 not found. Exiting ...\n",
      "\n",
      "Drug target acth(1-39 not found. Exiting ...\n",
      "\n",
      "Drug target amd3100 not found. Exiting ...\n",
      "\n",
      "Drug target an2690 not found. Exiting ...\n",
      "\n",
      "Drug target abarelix not found. Exiting ...\n",
      "\n",
      "Drug target anidulafungin not found. Exiting ...\n",
      "\n",
      "Drug target bcnu not found. Exiting ...\n",
      "\n",
      "Drug target benicar-hct not found. Exiting ...\n",
      "\n",
      "Drug target bivalirudin not found. Exiting ...\n",
      "\n",
      "Drug target cas not found. Exiting ...\n",
      "\n",
      "Drug target cgp not found. Exiting ...\n",
      "\n",
      "Drug target cancidas not found. Exiting ...\n",
      "\n",
      "Drug target carfilzomib not found. Exiting ...\n",
      "\n",
      "Drug target colimycin not found. Exiting ...\n",
      "\n",
      "Drug target d-penicillamine not found. Exiting ...\n",
      "\n",
      "Drug target dfmo not found. Exiting ...\n",
      "\n",
      "Drug target enfuvirtide not found. Exiting ...\n",
      "\n",
      "Drug target eptifibatide not found. Exiting ...\n",
      "\n",
      "Drug target famp not found. Exiting ...\n",
      "\n",
      "Drug target fk463 not found. Exiting ...\n",
      "\n",
      "Drug target fty720 not found. Exiting ...\n",
      "\n",
      "Drug target fe(iii not found. Exiting ...\n",
      "\n",
      "Drug target forteo not found. Exiting ...\n",
      "\n",
      "Drug target ge-132 not found. Exiting ...\n",
      "\n",
      "Drug target goserelin not found. Exiting ...\n",
      "\n",
      "Drug target histrelin not found. Exiting ...\n",
      "\n",
      "Drug target hoe not found. Exiting ...\n",
      "\n",
      "Drug target humalog not found. Exiting ...\n",
      "\n",
      "Drug target ici not found. Exiting ...\n",
      "\n",
      "Drug target implanon not found. Exiting ...\n",
      "\n",
      "Drug target insulin not found. Exiting ...\n",
      "\n",
      "Drug target k779 not found. Exiting ...\n",
      "\n",
      "Drug target l-dmp not found. Exiting ...\n",
      "\n",
      "Drug target l-threo-dops not found. Exiting ...\n",
      "\n",
      "Drug target lmwh not found. Exiting ...\n",
      "\n",
      "Drug target ly146032 not found. Exiting ...\n",
      "\n",
      "Drug target lantus not found. Exiting ...\n",
      "\n",
      "Drug target leuprorelin not found. Exiting ...\n",
      "\n",
      "Drug target lisinopril not found. Exiting ...\n",
      "\n",
      "Drug target lovaza not found. Exiting ...\n",
      "\n",
      "Drug target lu not found. Exiting ...\n",
      "\n",
      "Drug target lyxumia not found. Exiting ...\n",
      "\n",
      "Drug target mdv3100 not found. Exiting ...\n",
      "\n",
      "Drug target meropenem not found. Exiting ...\n",
      "\n",
      "Drug target metrodin not found. Exiting ...\n",
      "\n",
      "Drug target mndpdp not found. Exiting ...\n",
      "\n",
      "Drug target n-acetylcysteine not found. Exiting ...\n",
      "\n",
      "Drug target nafarelin not found. Exiting ...\n",
      "\n",
      "Drug target novolog not found. Exiting ...\n",
      "\n",
      "Drug target nuvocid not found. Exiting ...\n",
      "\n",
      "Drug target octreotide not found. Exiting ...\n",
      "\n",
      "Drug target oestrogen not found. Exiting ...\n",
      "\n",
      "Drug target optison not found. Exiting ...\n",
      "\n",
      "Drug target org not found. Exiting ...\n",
      "\n",
      "Drug target pci-32765 not found. Exiting ...\n",
      "\n",
      "Drug target pep005 not found. Exiting ...\n",
      "\n",
      "Drug target pge1 not found. Exiting ...\n",
      "\n",
      "Drug target pge2 not found. Exiting ...\n",
      "\n",
      "Drug target photofrin not found. Exiting ...\n",
      "\n",
      "Drug target promacta not found. Exiting ...\n",
      "\n",
      "Drug target refludan not found. Exiting ...\n",
      "\n",
      "Drug target revasc not found. Exiting ...\n",
      "\n",
      "Drug target romidepsin not found. Exiting ...\n",
      "\n",
      "Drug target som230 not found. Exiting ...\n",
      "\n",
      "Drug target su5416 not found. Exiting ...\n",
      "\n",
      "Drug target saxagliptin not found. Exiting ...\n",
      "\n",
      "Drug target signifor not found. Exiting ...\n",
      "\n",
      "Drug target stalevo not found. Exiting ...\n",
      "\n",
      "Drug target supremon not found. Exiting ...\n",
      "\n",
      "Drug target tmc207 not found. Exiting ...\n",
      "\n",
      "Drug target tmc435 not found. Exiting ...\n",
      "\n",
      "Drug target tr-700 not found. Exiting ...\n",
      "\n",
      "Drug target tadenan not found. Exiting ...\n",
      "\n",
      "Drug target triptorelin not found. Exiting ...\n",
      "\n",
      "Drug target udca not found. Exiting ...\n",
      "\n",
      "Drug target vacv not found. Exiting ...\n",
      "\n",
      "Drug target vancocine not found. Exiting ...\n",
      "\n",
      "Drug target vitrum not found. Exiting ...\n",
      "\n",
      "Drug target westcort not found. Exiting ...\n",
      "\n",
      "Drug target abacavir not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó abiraterone *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: bosutinib with relative risk of -10.097 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: dofetilide with relative risk of -10.229 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: clarithromycin with relative risk of -10.286 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: olmesartan with relative risk of -12.725 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: estramustine with relative risk of -26.386 of abiraterone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 6: estramustine with relative risk of -26.386 of abiraterone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 7: estramustine with relative risk of -26.386 of abiraterone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 8: auranofin with relative risk of -27.814 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: auranofin with relative risk of -27.814 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: auranofin with relative risk of -27.814 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: dantrolene with relative risk of -28.606 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: dantrolene with relative risk of -28.606 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: dantrolene with relative risk of -28.606 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: risedronate with relative risk of -28.895 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: risedronate with relative risk of -28.895 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: risedronate with relative risk of -28.895 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: donepezil with relative risk of -29.287 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: donepezil with relative risk of -29.287 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: donepezil with relative risk of -29.287 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: sertraline with relative risk of -34.222 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: sertraline with relative risk of -34.222 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: sertraline with relative risk of -34.222 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: sertraline with relative risk of -34.222 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: sertraline with relative risk of -34.222 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: irbesartan with relative risk of -34.590 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: irbesartan with relative risk of -34.590 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: irbesartan with relative risk of -34.590 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: irbesartan with relative risk of -34.590 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: irbesartan with relative risk of -34.590 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: mometasone with relative risk of -36.065 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: mometasone with relative risk of -36.065 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: mometasone with relative risk of -36.065 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: mometasone with relative risk of -36.065 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: mometasone with relative risk of -36.065 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: regadenoson with relative risk of -36.243 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: regadenoson with relative risk of -36.243 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: regadenoson with relative risk of -36.243 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: regadenoson with relative risk of -36.243 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: regadenoson with relative risk of -36.243 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: azelastine with relative risk of -36.761 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: azelastine with relative risk of -36.761 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: azelastine with relative risk of -36.761 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: azelastine with relative risk of -36.761 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: azelastine with relative risk of -36.761 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: posaconazole with relative risk of -37.450 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: posaconazole with relative risk of -37.450 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: posaconazole with relative risk of -37.450 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: posaconazole with relative risk of -37.450 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: posaconazole with relative risk of -37.450 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: ibutilide with relative risk of -38.383 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: ibutilide with relative risk of -38.383 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: ibutilide with relative risk of -38.383 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 53: ibutilide with relative risk of -38.383 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 54: ibutilide with relative risk of -38.383 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 55: telmisartan with relative risk of -45.160 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 56: telmisartan with relative risk of -45.160 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 57: telmisartan with relative risk of -45.160 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 58: telmisartan with relative risk of -45.160 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 59: telmisartan with relative risk of -45.160 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 60: milnacipran with relative risk of -46.827 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 61: milnacipran with relative risk of -46.827 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 62: milnacipran with relative risk of -46.827 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 63: milnacipran with relative risk of -46.827 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 64: milnacipran with relative risk of -46.827 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 65: tolmetin with relative risk of -47.694 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 66: tolmetin with relative risk of -47.694 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 67: tolmetin with relative risk of -47.694 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 68: tolmetin with relative risk of -47.694 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 69: tolmetin with relative risk of -47.694 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 70: progesterone with relative risk of -48.032 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 71: progesterone with relative risk of -48.032 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 72: progesterone with relative risk of -48.032 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 73: progesterone with relative risk of -48.032 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 74: progesterone with relative risk of -48.032 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 75: lubiprostone with relative risk of -48.928 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 76: lubiprostone with relative risk of -48.928 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 77: lubiprostone with relative risk of -48.928 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 78: lubiprostone with relative risk of -48.928 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 79: lubiprostone with relative risk of -48.928 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 80: dapagliflozin with relative risk of -49.578 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 81: dapagliflozin with relative risk of -49.578 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 82: dapagliflozin with relative risk of -49.578 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 83: dapagliflozin with relative risk of -49.578 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 84: dapagliflozin with relative risk of -49.578 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 85: misoprostol with relative risk of -49.925 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 86: misoprostol with relative risk of -49.925 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 87: misoprostol with relative risk of -49.925 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 88: misoprostol with relative risk of -49.925 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 89: misoprostol with relative risk of -49.925 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 90: cisatracurium with relative risk of -51.678 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 91: cisatracurium with relative risk of -51.678 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 92: cisatracurium with relative risk of -51.678 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 93: cisatracurium with relative risk of -51.678 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 94: cisatracurium with relative risk of -51.678 of abiraterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.099\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó acamprosate *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: bicalutamide with relative risk of -11.315 of acamprosate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: scopolamine with relative risk of -13.221 of acamprosate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: naratriptan with relative risk of -14.015 of acamprosate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.455\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "c:\\Users\\Admin\\OneDrive\\Masa√ºst√º\\SYSBIO\\p\\459-drug-proj\\calc_relative_risks_drugs.py:24: RuntimeWarning: divide by zero encountered in log\n",
      "  drug_df['scaled_risk_score_log'] = np.log(drug_df.loc[:,'scaled_risk_score'].to_numpy(dtype=float))\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó acebutolol *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: ropivacaine with relative risk of -9.070 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: levonorgestrel with relative risk of -9.178 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: penbutolol with relative risk of -9.428 of acebutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 4: lurasidone with relative risk of -9.460 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: lansoprazole with relative risk of -10.009 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: trovafloxacin with relative risk of -10.586 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: didanosine with relative risk of -18.019 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: didanosine with relative risk of -18.019 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: sertraline with relative risk of -21.564 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: sertraline with relative risk of -21.564 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: sertraline with relative risk of -21.564 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: irbesartan with relative risk of -22.116 of acebutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 13: irbesartan with relative risk of -22.116 of acebutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 14: irbesartan with relative risk of -22.116 of acebutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 15: regadenoson with relative risk of -22.359 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: regadenoson with relative risk of -22.359 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: regadenoson with relative risk of -22.359 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: mometasone with relative risk of -22.583 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: mometasone with relative risk of -22.583 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: mometasone with relative risk of -22.583 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: azelastine with relative risk of -23.351 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: azelastine with relative risk of -23.351 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: azelastine with relative risk of -23.351 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: posaconazole with relative risk of -23.476 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: posaconazole with relative risk of -23.476 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: posaconazole with relative risk of -23.476 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: etoposide with relative risk of -23.696 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: etoposide with relative risk of -23.696 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: etoposide with relative risk of -23.696 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: ibutilide with relative risk of -24.670 of acebutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 31: ibutilide with relative risk of -24.670 of acebutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 32: ibutilide with relative risk of -24.670 of acebutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 33: tropisetron with relative risk of -24.754 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: tropisetron with relative risk of -24.754 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: tropisetron with relative risk of -24.754 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: paliperidone with relative risk of -24.840 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: paliperidone with relative risk of -24.840 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: paliperidone with relative risk of -24.840 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: glimepiride with relative risk of -24.888 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: glimepiride with relative risk of -24.888 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: glimepiride with relative risk of -24.888 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: pentoxifylline with relative risk of -24.938 of acebutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 43: pentoxifylline with relative risk of -24.938 of acebutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 44: pentoxifylline with relative risk of -24.938 of acebutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 45: fenofibrate with relative risk of -26.239 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: fenofibrate with relative risk of -26.239 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: fenofibrate with relative risk of -26.239 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: terbutaline with relative risk of -26.867 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: terbutaline with relative risk of -26.867 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: terbutaline with relative risk of -26.867 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: esmolol with relative risk of -27.830 of acebutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 52: esmolol with relative risk of -27.830 of acebutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 53: esmolol with relative risk of -27.830 of acebutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 54: ivacaftor with relative risk of -29.119 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 55: ivacaftor with relative risk of -29.119 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 56: ivacaftor with relative risk of -29.119 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 57: everolimus with relative risk of -29.240 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 58: everolimus with relative risk of -29.240 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 59: everolimus with relative risk of -29.240 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 60: azilsartan with relative risk of -29.289 of acebutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 61: azilsartan with relative risk of -29.289 of acebutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 62: azilsartan with relative risk of -29.289 of acebutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 63: zolmitriptan with relative risk of -29.929 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 64: zolmitriptan with relative risk of -29.929 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 65: zolmitriptan with relative risk of -29.929 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 66: brinzolamide with relative risk of -31.628 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 67: brinzolamide with relative risk of -31.628 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 68: brinzolamide with relative risk of -31.628 of acebutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 69: valsartan with relative risk of -32.117 of acebutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 70: valsartan with relative risk of -32.117 of acebutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 71: valsartan with relative risk of -32.117 of acebutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 72: felodipine with relative risk of -inf of acebutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 73: felodipine with relative risk of -inf of acebutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 74: felodipine with relative risk of -inf of acebutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.189\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target acetaminophen not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó acitretin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: clozapine with relative risk of -9.370 of acitretin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: bimatoprost with relative risk of -10.361 of acitretin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: vandetanib with relative risk of -10.647 of acitretin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: azathioprine with relative risk of -18.949 of acitretin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: azathioprine with relative risk of -18.949 of acitretin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: nifedipine with relative risk of -19.978 of acitretin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: nifedipine with relative risk of -19.978 of acitretin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: phentolamine with relative risk of -21.254 of acitretin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: phentolamine with relative risk of -21.254 of acitretin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: nilutamide with relative risk of -22.826 of acitretin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: nilutamide with relative risk of -22.826 of acitretin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: calcipotriol with relative risk of -inf of acitretin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: dermatology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.027\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó aclidinium *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: irbesartan with relative risk of -9.727 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: ribavirin with relative risk of -10.974 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: bumetanide with relative risk of -11.499 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: argatroban with relative risk of -11.794 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: nevirapine with relative risk of -11.850 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: lapatinib with relative risk of -11.918 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: quinidine with relative risk of -12.264 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: losartan with relative risk of -12.317 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: celecoxib with relative risk of -12.360 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: perindopril with relative risk of -12.439 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: temsirolimus with relative risk of -13.036 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: amisulpride with relative risk of -13.075 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: latanoprost with relative risk of -13.172 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: domperidone with relative risk of -13.535 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: lidocaine with relative risk of -13.720 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: caffeine with relative risk of -14.059 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: bromfenac with relative risk of -15.690 of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: felodipine with relative risk of -inf of aclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target actinomycin not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó acyclovir *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: ropivacaine with relative risk of -9.475 of acyclovir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: ibandronate with relative risk of -9.500 of acyclovir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: imatinib with relative risk of -9.617 of acyclovir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: gemcitabine with relative risk of -10.131 of acyclovir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: gefitinib with relative risk of -10.139 of acyclovir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: atosiban with relative risk of -11.328 of acyclovir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: vincristine with relative risk of -11.539 of acyclovir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: desvenlafaxine with relative risk of -12.421 of acyclovir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: amoxicillin with relative risk of -12.923 of acyclovir | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 10: diltiazem with relative risk of -13.166 of acyclovir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: nebivolol with relative risk of -13.652 of acyclovir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: aminophylline with relative risk of -17.381 of acyclovir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: aminophylline with relative risk of -17.381 of acyclovir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: finasteride with relative risk of -18.955 of acyclovir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: finasteride with relative risk of -18.955 of acyclovir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: trimetrexate with relative risk of -19.202 of acyclovir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: trimetrexate with relative risk of -19.202 of acyclovir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: valdecoxib with relative risk of -19.759 of acyclovir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: valdecoxib with relative risk of -19.759 of acyclovir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: alendronate with relative risk of -20.136 of acyclovir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: alendronate with relative risk of -20.136 of acyclovir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: dihydroergotamine with relative risk of -20.367 of acyclovir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: dihydroergotamine with relative risk of -20.367 of acyclovir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: clopidogrel with relative risk of -22.059 of acyclovir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: clopidogrel with relative risk of -22.059 of acyclovir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: ramipril with relative risk of -22.095 of acyclovir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: ramipril with relative risk of -22.095 of acyclovir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.029\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó adapalene *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: lenalidomide with relative risk of -8.334 of adapalene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: regorafenib with relative risk of -9.601 of adapalene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: bexarotene with relative risk of -9.612 of adapalene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: penbutolol with relative risk of -9.832 of adapalene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: fluvastatin with relative risk of -10.591 of adapalene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: sitagliptin with relative risk of -11.539 of adapalene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: liraglutide with relative risk of -11.865 of adapalene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: amiodarone with relative risk of -16.364 of adapalene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: amiodarone with relative risk of -16.364 of adapalene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target adefovir not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó adenosine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: glycopyrrolate with relative risk of -18.842 of adenosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: glycopyrrolate with relative risk of -18.842 of adenosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó afatinib *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: irbesartan with relative risk of -9.727 of afatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: azelastine with relative risk of -10.076 of afatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: pentoxifylline with relative risk of -10.551 of afatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: ribavirin with relative risk of -10.974 of afatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: bumetanide with relative risk of -11.499 of afatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: loratadine with relative risk of -11.555 of afatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: argatroban with relative risk of -11.794 of afatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: nevirapine with relative risk of -11.850 of afatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: lapatinib with relative risk of -11.918 of afatinib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 10: losartan with relative risk of -12.317 of afatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: celecoxib with relative risk of -12.360 of afatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: perindopril with relative risk of -12.439 of afatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: beclomethasone with relative risk of -12.638 of afatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: budesonide with relative risk of -13.005 of afatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: temsirolimus with relative risk of -13.036 of afatinib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 16: amisulpride with relative risk of -13.075 of afatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: latanoprost with relative risk of -13.172 of afatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: pergolide with relative risk of -13.517 of afatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: domperidone with relative risk of -13.535 of afatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: lidocaine with relative risk of -13.720 of afatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: felodipine with relative risk of -inf of afatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.049\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó albendazole *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: anagrelide with relative risk of -10.757 of albendazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: iloperidone with relative risk of -11.086 of albendazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: cyclobenzaprine with relative risk of -11.374 of albendazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: captopril with relative risk of -23.016 of albendazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: captopril with relative risk of -23.016 of albendazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: captopril with relative risk of -23.016 of albendazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: treprostinil with relative risk of -24.083 of albendazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: treprostinil with relative risk of -24.083 of albendazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: treprostinil with relative risk of -24.083 of albendazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: atorvastatin with relative risk of -24.402 of albendazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: atorvastatin with relative risk of -24.402 of albendazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: atorvastatin with relative risk of -24.402 of albendazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: cetrorelix with relative risk of -25.226 of albendazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: cetrorelix with relative risk of -25.226 of albendazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: cetrorelix with relative risk of -25.226 of albendazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: telithromycin with relative risk of -25.280 of albendazole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 17: telithromycin with relative risk of -25.280 of albendazole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 18: telithromycin with relative risk of -25.280 of albendazole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.051\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó alendronate *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: ropivacaine with relative risk of -7.868 of alendronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: ibandronate with relative risk of -7.897 of alendronate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: orthopedics\n",
      "Rank 3: atosiban with relative risk of -9.718 of alendronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: vincristine with relative risk of -9.930 of alendronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: desloratadine with relative risk of -10.168 of alendronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: desvenlafaxine with relative risk of -10.812 of alendronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: amoxicillin with relative risk of -11.314 of alendronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: diltiazem with relative risk of -11.557 of alendronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: nebivolol with relative risk of -12.042 of alendronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: acyclovir with relative risk of -17.954 of alendronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: acyclovir with relative risk of -17.954 of alendronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: imatinib with relative risk of -23.148 of alendronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: imatinib with relative risk of -23.148 of alendronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: imatinib with relative risk of -23.148 of alendronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: gemcitabine with relative risk of -25.453 of alendronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: gemcitabine with relative risk of -25.453 of alendronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: gemcitabine with relative risk of -25.453 of alendronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: ramipril with relative risk of -27.362 of alendronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: ramipril with relative risk of -27.362 of alendronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: ramipril with relative risk of -27.362 of alendronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: gefitinib with relative risk of -32.472 of alendronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: gefitinib with relative risk of -32.472 of alendronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: gefitinib with relative risk of -32.472 of alendronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: gefitinib with relative risk of -32.472 of alendronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: clopidogrel with relative risk of -35.030 of alendronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: clopidogrel with relative risk of -35.030 of alendronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: clopidogrel with relative risk of -35.030 of alendronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: clopidogrel with relative risk of -35.030 of alendronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: dihydroergotamine with relative risk of -41.825 of alendronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: dihydroergotamine with relative risk of -41.825 of alendronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: dihydroergotamine with relative risk of -41.825 of alendronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: dihydroergotamine with relative risk of -41.825 of alendronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: dihydroergotamine with relative risk of -41.825 of alendronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: trimetrexate with relative risk of -49.287 of alendronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: trimetrexate with relative risk of -49.287 of alendronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: trimetrexate with relative risk of -49.287 of alendronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: trimetrexate with relative risk of -49.287 of alendronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: trimetrexate with relative risk of -49.287 of alendronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: trimetrexate with relative risk of -49.287 of alendronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: valdecoxib with relative risk of -49.844 of alendronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: valdecoxib with relative risk of -49.844 of alendronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: valdecoxib with relative risk of -49.844 of alendronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: valdecoxib with relative risk of -49.844 of alendronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: valdecoxib with relative risk of -49.844 of alendronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: valdecoxib with relative risk of -49.844 of alendronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: finasteride with relative risk of -65.566 of alendronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: finasteride with relative risk of -65.566 of alendronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: finasteride with relative risk of -65.566 of alendronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: finasteride with relative risk of -65.566 of alendronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: finasteride with relative risk of -65.566 of alendronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: finasteride with relative risk of -65.566 of alendronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: finasteride with relative risk of -65.566 of alendronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 53: finasteride with relative risk of -65.566 of alendronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 54: aminophylline with relative risk of -74.857 of alendronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 55: aminophylline with relative risk of -74.857 of alendronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 56: aminophylline with relative risk of -74.857 of alendronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 57: aminophylline with relative risk of -74.857 of alendronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 58: aminophylline with relative risk of -74.857 of alendronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 59: aminophylline with relative risk of -74.857 of alendronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 60: aminophylline with relative risk of -74.857 of alendronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 61: aminophylline with relative risk of -74.857 of alendronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 62: aminophylline with relative risk of -74.857 of alendronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.106\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target alfentanil not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó alfuzosin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: irbesartan with relative risk of -104.927 of alfuzosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: irbesartan with relative risk of -104.927 of alfuzosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: irbesartan with relative risk of -104.927 of alfuzosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: irbesartan with relative risk of -104.927 of alfuzosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: irbesartan with relative risk of -104.927 of alfuzosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: irbesartan with relative risk of -104.927 of alfuzosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: irbesartan with relative risk of -104.927 of alfuzosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: irbesartan with relative risk of -104.927 of alfuzosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: irbesartan with relative risk of -104.927 of alfuzosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: irbesartan with relative risk of -104.927 of alfuzosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: irbesartan with relative risk of -104.927 of alfuzosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: irbesartan with relative risk of -104.927 of alfuzosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: irbesartan with relative risk of -104.927 of alfuzosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: irbesartan with relative risk of -104.927 of alfuzosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: irbesartan with relative risk of -104.927 of alfuzosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: irbesartan with relative risk of -104.927 of alfuzosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: sertraline with relative risk of -105.758 of alfuzosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: sertraline with relative risk of -105.758 of alfuzosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: sertraline with relative risk of -105.758 of alfuzosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: sertraline with relative risk of -105.758 of alfuzosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: sertraline with relative risk of -105.758 of alfuzosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: sertraline with relative risk of -105.758 of alfuzosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: sertraline with relative risk of -105.758 of alfuzosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: sertraline with relative risk of -105.758 of alfuzosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: sertraline with relative risk of -105.758 of alfuzosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: sertraline with relative risk of -105.758 of alfuzosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: sertraline with relative risk of -105.758 of alfuzosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: sertraline with relative risk of -105.758 of alfuzosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: sertraline with relative risk of -105.758 of alfuzosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: sertraline with relative risk of -105.758 of alfuzosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: sertraline with relative risk of -105.758 of alfuzosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: sertraline with relative risk of -105.758 of alfuzosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: ciclesonide with relative risk of -108.974 of alfuzosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: ciclesonide with relative risk of -108.974 of alfuzosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: ciclesonide with relative risk of -108.974 of alfuzosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: ciclesonide with relative risk of -108.974 of alfuzosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: ciclesonide with relative risk of -108.974 of alfuzosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: ciclesonide with relative risk of -108.974 of alfuzosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: ciclesonide with relative risk of -108.974 of alfuzosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: ciclesonide with relative risk of -108.974 of alfuzosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: ciclesonide with relative risk of -108.974 of alfuzosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: ciclesonide with relative risk of -108.974 of alfuzosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: ciclesonide with relative risk of -108.974 of alfuzosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: ciclesonide with relative risk of -108.974 of alfuzosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: ciclesonide with relative risk of -108.974 of alfuzosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: ciclesonide with relative risk of -108.974 of alfuzosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: ciclesonide with relative risk of -108.974 of alfuzosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: ciclesonide with relative risk of -108.974 of alfuzosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: tadalafil with relative risk of -119.888 of alfuzosin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Prostatic Hypertrophy,urology\n",
      "Rank 50: tadalafil with relative risk of -119.888 of alfuzosin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Prostatic Hypertrophy,urology\n",
      "Rank 51: tadalafil with relative risk of -119.888 of alfuzosin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Prostatic Hypertrophy,urology\n",
      "Rank 52: tadalafil with relative risk of -119.888 of alfuzosin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Prostatic Hypertrophy,urology\n",
      "Rank 53: tadalafil with relative risk of -119.888 of alfuzosin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Prostatic Hypertrophy,urology\n",
      "Rank 54: tadalafil with relative risk of -119.888 of alfuzosin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Prostatic Hypertrophy,urology\n",
      "Rank 55: tadalafil with relative risk of -119.888 of alfuzosin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Prostatic Hypertrophy,urology\n",
      "Rank 56: tadalafil with relative risk of -119.888 of alfuzosin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Prostatic Hypertrophy,urology\n",
      "Rank 57: tadalafil with relative risk of -119.888 of alfuzosin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Prostatic Hypertrophy,urology\n",
      "Rank 58: tadalafil with relative risk of -119.888 of alfuzosin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Prostatic Hypertrophy,urology\n",
      "Rank 59: tadalafil with relative risk of -119.888 of alfuzosin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Prostatic Hypertrophy,urology\n",
      "Rank 60: tadalafil with relative risk of -119.888 of alfuzosin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Prostatic Hypertrophy,urology\n",
      "Rank 61: tadalafil with relative risk of -119.888 of alfuzosin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Prostatic Hypertrophy,urology\n",
      "Rank 62: tadalafil with relative risk of -119.888 of alfuzosin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Prostatic Hypertrophy,urology\n",
      "Rank 63: tadalafil with relative risk of -119.888 of alfuzosin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Prostatic Hypertrophy,urology\n",
      "Rank 64: tadalafil with relative risk of -119.888 of alfuzosin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Prostatic Hypertrophy,urology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.06\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target aliskiren not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó allopurinol *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: clozapine with relative risk of -8.678 of allopurinol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: cytarabine with relative risk of -9.353 of allopurinol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: formoterol with relative risk of -9.630 of allopurinol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: frovatriptan with relative risk of -9.792 of allopurinol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: nimodipine with relative risk of -10.119 of allopurinol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: nabumetone with relative risk of -10.305 of allopurinol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: rheumatology\n",
      "Rank 7: atomoxetine with relative risk of -10.334 of allopurinol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: cilostazol with relative risk of -10.570 of allopurinol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: mafenide with relative risk of -10.784 of allopurinol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: avanafil with relative risk of -10.844 of allopurinol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: urology\n",
      "Rank 11: candesartan with relative risk of -11.185 of allopurinol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: hydrochlorothiazide with relative risk of -21.771 of allopurinol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: hydrochlorothiazide with relative risk of -21.771 of allopurinol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.084\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó almotriptan *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: nimodipine with relative risk of -10.812 of almotriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: avanafil with relative risk of -11.537 of almotriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: buspirone with relative risk of -11.548 of almotriptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.182\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó alogliptin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: fluoxetine with relative risk of -10.247 of alogliptin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: simvastatin with relative risk of -36.275 of alogliptin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 3: simvastatin with relative risk of -36.275 of alogliptin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 4: simvastatin with relative risk of -36.275 of alogliptin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 5: simvastatin with relative risk of -36.275 of alogliptin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 6: dolasetron with relative risk of -37.010 of alogliptin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: dolasetron with relative risk of -37.010 of alogliptin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: dolasetron with relative risk of -37.010 of alogliptin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: dolasetron with relative risk of -37.010 of alogliptin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.454\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó alosetron *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "Drug target alprazolam not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó ambrisentan *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: regadenoson with relative risk of -8.647 of ambrisentan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: sertraline with relative risk of -8.999 of ambrisentan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: mometasone with relative risk of -9.242 of ambrisentan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: posaconazole with relative risk of -9.679 of ambrisentan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: irbesartan with relative risk of -9.727 of ambrisentan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: azelastine with relative risk of -10.076 of ambrisentan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: crizotinib with relative risk of -10.375 of ambrisentan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: ibutilide with relative risk of -11.114 of ambrisentan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: asenapine with relative risk of -11.624 of ambrisentan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: amsacrine with relative risk of -11.630 of ambrisentan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: carbamazepine with relative risk of -11.698 of ambrisentan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: dofetilide with relative risk of -11.839 of ambrisentan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: sulfasalazine with relative risk of -11.908 of ambrisentan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: tolvaptan with relative risk of -12.970 of ambrisentan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: cimetidine with relative risk of -14.309 of ambrisentan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó amiloride *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: diclofenac with relative risk of -10.508 of amiloride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: pentostatin with relative risk of -10.843 of amiloride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: lamotrigine with relative risk of -11.793 of amiloride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: norfloxacin with relative risk of -12.352 of amiloride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó aminophylline *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: ropivacaine with relative risk of -7.868 of aminophylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: ibandronate with relative risk of -7.897 of aminophylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: cytarabine with relative risk of -8.437 of aminophylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: paclitaxel with relative risk of -8.628 of aminophylline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Non-Small Cell Lung Carcinoma\n",
      "Rank 5: formoterol with relative risk of -8.717 of aminophylline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Pulmonary Emphysema,pulmonary\n",
      "Rank 6: frovatriptan with relative risk of -8.879 of aminophylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: nimodipine with relative risk of -9.205 of aminophylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: atosiban with relative risk of -9.718 of aminophylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: vincristine with relative risk of -9.930 of aminophylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: desloratadine with relative risk of -10.168 of aminophylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: rasagiline with relative risk of -10.189 of aminophylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: rivastigmine with relative risk of -10.309 of aminophylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: sotalol with relative risk of -10.334 of aminophylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: rofecoxib with relative risk of -10.384 of aminophylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: pimozide with relative risk of -10.456 of aminophylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: desvenlafaxine with relative risk of -10.812 of aminophylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: capsaicin with relative risk of -10.908 of aminophylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: amoxicillin with relative risk of -11.314 of aminophylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: diltiazem with relative risk of -11.557 of aminophylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: nebivolol with relative risk of -12.042 of aminophylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: fosinoprilat with relative risk of -13.190 of aminophylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: acyclovir with relative risk of -17.954 of aminophylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: acyclovir with relative risk of -17.954 of aminophylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: imatinib with relative risk of -23.148 of aminophylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: imatinib with relative risk of -23.148 of aminophylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: imatinib with relative risk of -23.148 of aminophylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: gefitinib with relative risk of -23.670 of aminophylline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Non-Small Cell Lung Carcinoma\n",
      "Rank 28: gefitinib with relative risk of -23.670 of aminophylline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Non-Small Cell Lung Carcinoma\n",
      "Rank 29: gefitinib with relative risk of -23.670 of aminophylline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Non-Small Cell Lung Carcinoma\n",
      "Rank 30: gemcitabine with relative risk of -25.453 of aminophylline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Non-Small Cell Lung Carcinoma\n",
      "Rank 31: gemcitabine with relative risk of -25.453 of aminophylline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Non-Small Cell Lung Carcinoma\n",
      "Rank 32: gemcitabine with relative risk of -25.453 of aminophylline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Non-Small Cell Lung Carcinoma\n",
      "Rank 33: ramipril with relative risk of -27.362 of aminophylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: ramipril with relative risk of -27.362 of aminophylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: ramipril with relative risk of -27.362 of aminophylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: dihydroergotamine with relative risk of -32.646 of aminophylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: dihydroergotamine with relative risk of -32.646 of aminophylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: dihydroergotamine with relative risk of -32.646 of aminophylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: dihydroergotamine with relative risk of -32.646 of aminophylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: trimetrexate with relative risk of -39.743 of aminophylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: trimetrexate with relative risk of -39.743 of aminophylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: trimetrexate with relative risk of -39.743 of aminophylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: trimetrexate with relative risk of -39.743 of aminophylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: trimetrexate with relative risk of -39.743 of aminophylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: valdecoxib with relative risk of -40.300 of aminophylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: valdecoxib with relative risk of -40.300 of aminophylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: valdecoxib with relative risk of -40.300 of aminophylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: valdecoxib with relative risk of -40.300 of aminophylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: valdecoxib with relative risk of -40.300 of aminophylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: clopidogrel with relative risk of -44.902 of aminophylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: clopidogrel with relative risk of -44.902 of aminophylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: clopidogrel with relative risk of -44.902 of aminophylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 53: clopidogrel with relative risk of -44.902 of aminophylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 54: clopidogrel with relative risk of -44.902 of aminophylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 55: finasteride with relative risk of -55.629 of aminophylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 56: finasteride with relative risk of -55.629 of aminophylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 57: finasteride with relative risk of -55.629 of aminophylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 58: finasteride with relative risk of -55.629 of aminophylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 59: finasteride with relative risk of -55.629 of aminophylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 60: finasteride with relative risk of -55.629 of aminophylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 61: finasteride with relative risk of -55.629 of aminophylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 62: alendronate with relative risk of -77.612 of aminophylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 63: alendronate with relative risk of -77.612 of aminophylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 64: alendronate with relative risk of -77.612 of aminophylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 65: alendronate with relative risk of -77.612 of aminophylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 66: alendronate with relative risk of -77.612 of aminophylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 67: alendronate with relative risk of -77.612 of aminophylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 68: alendronate with relative risk of -77.612 of aminophylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 69: alendronate with relative risk of -77.612 of aminophylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 70: alendronate with relative risk of -77.612 of aminophylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.135\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó amiodarone *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: paroxetine with relative risk of -6.168 of amiodarone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: regorafenib with relative risk of -6.714 of amiodarone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: bexarotene with relative risk of -6.728 of amiodarone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: zileuton with relative risk of -8.902 of amiodarone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: liraglutide with relative risk of -8.974 of amiodarone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: linagliptin with relative risk of -9.880 of amiodarone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: sorafenib with relative risk of -15.227 of amiodarone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: sorafenib with relative risk of -15.227 of amiodarone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: dexamethasone with relative risk of -15.799 of amiodarone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: dexamethasone with relative risk of -15.799 of amiodarone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: adapalene with relative risk of -16.117 of amiodarone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: adapalene with relative risk of -16.117 of amiodarone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: tizanidine with relative risk of -23.723 of amiodarone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: tizanidine with relative risk of -23.723 of amiodarone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: tizanidine with relative risk of -23.723 of amiodarone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: tizanidine with relative risk of -23.723 of amiodarone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: nisoldipine with relative risk of -24.824 of amiodarone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 18: nisoldipine with relative risk of -24.824 of amiodarone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 19: nisoldipine with relative risk of -24.824 of amiodarone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 20: nisoldipine with relative risk of -24.824 of amiodarone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 21: irinotecan with relative risk of -28.013 of amiodarone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: irinotecan with relative risk of -28.013 of amiodarone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: irinotecan with relative risk of -28.013 of amiodarone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: irinotecan with relative risk of -28.013 of amiodarone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: ketoprofen with relative risk of -28.243 of amiodarone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: ketoprofen with relative risk of -28.243 of amiodarone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: ketoprofen with relative risk of -28.243 of amiodarone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: ketoprofen with relative risk of -28.243 of amiodarone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: sitagliptin with relative risk of -29.621 of amiodarone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: sitagliptin with relative risk of -29.621 of amiodarone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: sitagliptin with relative risk of -29.621 of amiodarone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: sitagliptin with relative risk of -29.621 of amiodarone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: propafenone with relative risk of -29.714 of amiodarone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 34: propafenone with relative risk of -29.714 of amiodarone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 35: propafenone with relative risk of -29.714 of amiodarone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 36: propafenone with relative risk of -29.714 of amiodarone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 37: fluvastatin with relative risk of -74.116 of amiodarone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 38: fluvastatin with relative risk of -74.116 of amiodarone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 39: fluvastatin with relative risk of -74.116 of amiodarone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 40: fluvastatin with relative risk of -74.116 of amiodarone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 41: fluvastatin with relative risk of -74.116 of amiodarone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 42: fluvastatin with relative risk of -74.116 of amiodarone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 43: fluvastatin with relative risk of -74.116 of amiodarone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 44: fluvastatin with relative risk of -74.116 of amiodarone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 45: fluvastatin with relative risk of -74.116 of amiodarone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 46: fluvastatin with relative risk of -74.116 of amiodarone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 47: fluvastatin with relative risk of -74.116 of amiodarone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 48: lenalidomide with relative risk of -127.357 of amiodarone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: lenalidomide with relative risk of -127.357 of amiodarone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: lenalidomide with relative risk of -127.357 of amiodarone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: lenalidomide with relative risk of -127.357 of amiodarone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: lenalidomide with relative risk of -127.357 of amiodarone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 53: lenalidomide with relative risk of -127.357 of amiodarone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 54: lenalidomide with relative risk of -127.357 of amiodarone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 55: lenalidomide with relative risk of -127.357 of amiodarone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 56: lenalidomide with relative risk of -127.357 of amiodarone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 57: lenalidomide with relative risk of -127.357 of amiodarone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 58: lenalidomide with relative risk of -127.357 of amiodarone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 59: lenalidomide with relative risk of -127.357 of amiodarone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 60: lenalidomide with relative risk of -127.357 of amiodarone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 61: lenalidomide with relative risk of -127.357 of amiodarone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 62: lenalidomide with relative risk of -127.357 of amiodarone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 63: lenalidomide with relative risk of -127.357 of amiodarone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 64: lenalidomide with relative risk of -127.357 of amiodarone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 65: lenalidomide with relative risk of -127.357 of amiodarone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 66: lenalidomide with relative risk of -127.357 of amiodarone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 67: lenalidomide with relative risk of -127.357 of amiodarone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 68: penbutolol with relative risk of -148.854 of amiodarone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 69: penbutolol with relative risk of -148.854 of amiodarone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 70: penbutolol with relative risk of -148.854 of amiodarone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 71: penbutolol with relative risk of -148.854 of amiodarone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 72: penbutolol with relative risk of -148.854 of amiodarone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 73: penbutolol with relative risk of -148.854 of amiodarone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 74: penbutolol with relative risk of -148.854 of amiodarone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 75: penbutolol with relative risk of -148.854 of amiodarone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 76: penbutolol with relative risk of -148.854 of amiodarone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 77: penbutolol with relative risk of -148.854 of amiodarone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 78: penbutolol with relative risk of -148.854 of amiodarone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 79: penbutolol with relative risk of -148.854 of amiodarone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 80: penbutolol with relative risk of -148.854 of amiodarone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 81: penbutolol with relative risk of -148.854 of amiodarone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 82: penbutolol with relative risk of -148.854 of amiodarone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 83: penbutolol with relative risk of -148.854 of amiodarone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 84: penbutolol with relative risk of -148.854 of amiodarone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 85: penbutolol with relative risk of -148.854 of amiodarone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 86: penbutolol with relative risk of -148.854 of amiodarone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 87: penbutolol with relative risk of -148.854 of amiodarone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 88: penbutolol with relative risk of -148.854 of amiodarone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 89: penbutolol with relative risk of -148.854 of amiodarone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 90: penbutolol with relative risk of -148.854 of amiodarone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.175\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó amisulpride *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: azelastine with relative risk of -8.980 of amisulpride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: pentoxifylline with relative risk of -9.454 of amisulpride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: loratadine with relative risk of -10.457 of amisulpride | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: afatinib with relative risk of -10.875 of amisulpride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: quinidine with relative risk of -11.165 of amisulpride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: beclomethasone with relative risk of -11.539 of amisulpride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: budesonide with relative risk of -11.907 of amisulpride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: pergolide with relative risk of -12.419 of amisulpride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: aclidinium with relative risk of -12.464 of amisulpride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: caffeine with relative risk of -12.960 of amisulpride | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: bromfenac with relative risk of -14.591 of amisulpride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: bumetanide with relative risk of -19.069 of amisulpride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: bumetanide with relative risk of -19.069 of amisulpride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: argatroban with relative risk of -19.652 of amisulpride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: argatroban with relative risk of -19.652 of amisulpride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: nevirapine with relative risk of -19.708 of amisulpride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: nevirapine with relative risk of -19.708 of amisulpride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: ribavirin with relative risk of -19.931 of amisulpride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: ribavirin with relative risk of -19.931 of amisulpride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: perindopril with relative risk of -20.702 of amisulpride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: perindopril with relative risk of -20.702 of amisulpride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: lapatinib with relative risk of -20.875 of amisulpride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: lapatinib with relative risk of -20.875 of amisulpride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: losartan with relative risk of -21.273 of amisulpride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: losartan with relative risk of -21.273 of amisulpride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: domperidone with relative risk of -21.798 of amisulpride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: domperidone with relative risk of -21.798 of amisulpride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: temsirolimus with relative risk of -21.993 of amisulpride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: temsirolimus with relative risk of -21.993 of amisulpride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: irbesartan with relative risk of -22.116 of amisulpride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: irbesartan with relative risk of -22.116 of amisulpride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: irbesartan with relative risk of -22.116 of amisulpride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: lidocaine with relative risk of -22.676 of amisulpride | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 34: lidocaine with relative risk of -22.676 of amisulpride | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 35: celecoxib with relative risk of -31.777 of amisulpride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: celecoxib with relative risk of -31.777 of amisulpride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: celecoxib with relative risk of -31.777 of amisulpride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: latanoprost with relative risk of -32.588 of amisulpride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: latanoprost with relative risk of -32.588 of amisulpride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: latanoprost with relative risk of -32.588 of amisulpride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: felodipine with relative risk of -inf of amisulpride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: felodipine with relative risk of -inf of amisulpride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.114\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó amlexanox *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: sunitinib with relative risk of -11.045 of amlexanox | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó amlodipine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: pramipexole with relative risk of -11.929 of amlodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: docetaxel with relative risk of -12.046 of amlodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: etodolac with relative risk of -12.358 of amlodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: metaproterenol with relative risk of -12.759 of amlodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: duloxetine with relative risk of -12.992 of amlodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: bupropion with relative risk of -13.123 of amlodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: repaglinide with relative risk of -13.133 of amlodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: dalbavancin with relative risk of -13.460 of amlodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: trospium with relative risk of -13.502 of amlodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó amoxapine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: penbutolol with relative risk of -10.524 of amoxapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: eletriptan with relative risk of -14.109 of amoxapine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.333\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó amoxicillin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: aminophylline with relative risk of -9.523 of amoxicillin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: ropivacaine with relative risk of -10.167 of amoxicillin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: ibandronate with relative risk of -10.192 of amoxicillin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: imatinib with relative risk of -10.310 of amoxicillin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: gemcitabine with relative risk of -10.824 of amoxicillin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: gefitinib with relative risk of -10.832 of amoxicillin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: trimetrexate with relative risk of -10.939 of amoxicillin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: finasteride with relative risk of -11.097 of amoxicillin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: valdecoxib with relative risk of -11.496 of amoxicillin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: acyclovir with relative risk of -11.705 of amoxicillin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 11: dihydroergotamine with relative risk of -11.922 of amoxicillin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: atosiban with relative risk of -12.021 of amoxicillin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: vincristine with relative risk of -12.233 of amoxicillin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: alendronate with relative risk of -12.279 of amoxicillin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: ramipril with relative risk of -12.733 of amoxicillin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: desvenlafaxine with relative risk of -13.114 of amoxicillin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: clopidogrel with relative risk of -13.390 of amoxicillin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: diltiazem with relative risk of -13.859 of amoxicillin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: nebivolol with relative risk of -14.345 of amoxicillin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.028\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target amphotericin not found. Exiting ...\n",
      "\n",
      "Drug target amprenavir not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó amsacrine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: regadenoson with relative risk of -8.647 of amsacrine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: sertraline with relative risk of -8.999 of amsacrine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: mometasone with relative risk of -9.242 of amsacrine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: posaconazole with relative risk of -9.679 of amsacrine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: irbesartan with relative risk of -9.727 of amsacrine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: azelastine with relative risk of -10.076 of amsacrine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: crizotinib with relative risk of -10.375 of amsacrine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: ibutilide with relative risk of -11.114 of amsacrine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: asenapine with relative risk of -11.624 of amsacrine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: carbamazepine with relative risk of -11.698 of amsacrine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: dofetilide with relative risk of -11.839 of amsacrine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: sulfasalazine with relative risk of -11.908 of amsacrine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: tolvaptan with relative risk of -12.970 of amsacrine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: ambrisentan with relative risk of -12.988 of amsacrine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: cimetidine with relative risk of -14.309 of amsacrine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: hematologic malignancy\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.02\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó anagrelide *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: albendazole with relative risk of -11.636 of anagrelide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: cyclobenzaprine with relative risk of -11.779 of anagrelide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: captopril with relative risk of -15.906 of anagrelide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: captopril with relative risk of -15.906 of anagrelide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: treprostinil with relative risk of -16.667 of anagrelide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: treprostinil with relative risk of -16.667 of anagrelide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: atorvastatin with relative risk of -17.343 of anagrelide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: atorvastatin with relative risk of -17.343 of anagrelide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: cetrorelix with relative risk of -17.810 of anagrelide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: cetrorelix with relative risk of -17.810 of anagrelide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: telithromycin with relative risk of -17.998 of anagrelide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: telithromycin with relative risk of -17.998 of anagrelide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: iloperidone with relative risk of -21.141 of anagrelide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: iloperidone with relative risk of -21.141 of anagrelide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó anastrozole *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: nizatidine with relative risk of -13.575 of anastrozole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target anthracycline not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó apixaban *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: teniposide with relative risk of -10.129 of apixaban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: balsalazide with relative risk of -10.842 of apixaban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: bosentan with relative risk of -11.654 of apixaban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: tegaserod with relative risk of -12.970 of apixaban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target apomorphine not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó apraclonidine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: ibandronate with relative risk of -7.897 of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: miglustat with relative risk of -8.022 of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: pentoxifylline with relative risk of -8.256 of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: formoterol with relative risk of -8.717 of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: dabigatran with relative risk of -9.627 of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: estramustine with relative risk of -9.680 of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: zonisamide with relative risk of -9.885 of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: etravirine with relative risk of -10.164 of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: linezolid with relative risk of -10.330 of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: tiotropium with relative risk of -10.551 of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: febuxostat with relative risk of -12.597 of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: eplerenone with relative risk of -16.801 of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: eplerenone with relative risk of -16.801 of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: exemestane with relative risk of -18.113 of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: exemestane with relative risk of -18.113 of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: indacaterol with relative risk of -24.984 of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: indacaterol with relative risk of -24.984 of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: indacaterol with relative risk of -24.984 of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: ciclesonide with relative risk of -68.521 of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: ciclesonide with relative risk of -68.521 of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: ciclesonide with relative risk of -68.521 of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: ciclesonide with relative risk of -68.521 of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: ciclesonide with relative risk of -68.521 of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: ciclesonide with relative risk of -68.521 of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: ciclesonide with relative risk of -68.521 of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: ciclesonide with relative risk of -68.521 of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: ciclesonide with relative risk of -68.521 of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: ciclesonide with relative risk of -68.521 of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: meloxicam with relative risk of -81.320 of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: meloxicam with relative risk of -81.320 of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: meloxicam with relative risk of -81.320 of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: meloxicam with relative risk of -81.320 of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: meloxicam with relative risk of -81.320 of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: meloxicam with relative risk of -81.320 of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: meloxicam with relative risk of -81.320 of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: meloxicam with relative risk of -81.320 of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: meloxicam with relative risk of -81.320 of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: meloxicam with relative risk of -81.320 of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: darifenacin with relative risk of -82.634 of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: darifenacin with relative risk of -82.634 of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: darifenacin with relative risk of -82.634 of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: darifenacin with relative risk of -82.634 of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: darifenacin with relative risk of -82.634 of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: darifenacin with relative risk of -82.634 of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: darifenacin with relative risk of -82.634 of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: darifenacin with relative risk of -82.634 of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: darifenacin with relative risk of -82.634 of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: darifenacin with relative risk of -82.634 of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: axitinib with relative risk of -85.446 of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: axitinib with relative risk of -85.446 of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: axitinib with relative risk of -85.446 of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: axitinib with relative risk of -85.446 of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 53: axitinib with relative risk of -85.446 of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 54: axitinib with relative risk of -85.446 of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 55: axitinib with relative risk of -85.446 of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 56: axitinib with relative risk of -85.446 of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 57: axitinib with relative risk of -85.446 of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 58: axitinib with relative risk of -85.446 of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 59: vinorelbine with relative risk of -87.200 of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 60: vinorelbine with relative risk of -87.200 of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 61: vinorelbine with relative risk of -87.200 of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 62: vinorelbine with relative risk of -87.200 of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 63: vinorelbine with relative risk of -87.200 of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 64: vinorelbine with relative risk of -87.200 of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 65: vinorelbine with relative risk of -87.200 of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 66: vinorelbine with relative risk of -87.200 of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 67: vinorelbine with relative risk of -87.200 of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 68: vinorelbine with relative risk of -87.200 of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 69: granisetron with relative risk of -88.088 of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 70: granisetron with relative risk of -88.088 of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 71: granisetron with relative risk of -88.088 of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 72: granisetron with relative risk of -88.088 of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 73: granisetron with relative risk of -88.088 of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 74: granisetron with relative risk of -88.088 of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 75: granisetron with relative risk of -88.088 of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 76: granisetron with relative risk of -88.088 of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 77: granisetron with relative risk of -88.088 of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 78: granisetron with relative risk of -88.088 of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 79: pinaverium with relative risk of -91.224 of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 80: pinaverium with relative risk of -91.224 of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 81: pinaverium with relative risk of -91.224 of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 82: pinaverium with relative risk of -91.224 of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 83: pinaverium with relative risk of -91.224 of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 84: pinaverium with relative risk of -91.224 of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 85: pinaverium with relative risk of -91.224 of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 86: pinaverium with relative risk of -91.224 of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 87: pinaverium with relative risk of -91.224 of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 88: pinaverium with relative risk of -91.224 of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 89: desoximetasone with relative risk of -inf of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 90: desoximetasone with relative risk of -inf of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 91: desoximetasone with relative risk of -inf of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 92: desoximetasone with relative risk of -inf of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 93: desoximetasone with relative risk of -inf of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 94: desoximetasone with relative risk of -inf of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 95: desoximetasone with relative risk of -inf of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 96: desoximetasone with relative risk of -inf of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 97: desoximetasone with relative risk of -inf of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 98: desoximetasone with relative risk of -inf of apraclonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó apremilast *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: idarubicin with relative risk of -9.983 of apremilast | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: bicalutamide with relative risk of -11.315 of apremilast | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: letrozole with relative risk of -12.803 of apremilast | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: gemfibrozil with relative risk of -12.858 of apremilast | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: maprotiline with relative risk of -12.954 of apremilast | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: fosinopril with relative risk of -13.119 of apremilast | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target aprepitant not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó argatroban *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: azelastine with relative risk of -8.694 of argatroban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: ibandronate with relative risk of -8.808 of argatroban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: crizotinib with relative risk of -8.990 of argatroban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: terbutaline with relative risk of -9.397 of argatroban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: ketorolac with relative risk of -9.873 of argatroban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: nabumetone with relative risk of -10.305 of argatroban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: dronedarone with relative risk of -10.584 of argatroban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: afatinib with relative risk of -10.587 of argatroban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: estramustine with relative risk of -10.594 of argatroban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: quinidine with relative risk of -10.877 of argatroban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: etravirine with relative risk of -11.080 of argatroban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: linezolid with relative risk of -11.246 of argatroban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: beclomethasone with relative risk of -11.252 of argatroban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: fluconazole with relative risk of -11.342 of argatroban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: bisoprolol with relative risk of -11.593 of argatroban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: budesonide with relative risk of -11.619 of argatroban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: doxazosin with relative risk of -11.925 of argatroban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: pergolide with relative risk of -12.131 of argatroban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: aclidinium with relative risk of -12.176 of argatroban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: caffeine with relative risk of -12.672 of argatroban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: irbesartan with relative risk of -14.123 of argatroban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: irbesartan with relative risk of -14.123 of argatroban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: bromfenac with relative risk of -14.304 of argatroban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: miglustat with relative risk of -16.506 of argatroban | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: hematology\n",
      "Rank 25: miglustat with relative risk of -16.506 of argatroban | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: hematology\n",
      "Rank 26: bumetanide with relative risk of -18.376 of argatroban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: bumetanide with relative risk of -18.376 of argatroban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: loratadine with relative risk of -18.432 of argatroban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: loratadine with relative risk of -18.432 of argatroban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: nevirapine with relative risk of -19.015 of argatroban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: nevirapine with relative risk of -19.015 of argatroban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: ribavirin with relative risk of -19.237 of argatroban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: ribavirin with relative risk of -19.237 of argatroban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: celecoxib with relative risk of -19.931 of argatroban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: celecoxib with relative risk of -19.931 of argatroban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: perindopril with relative risk of -20.009 of argatroban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: perindopril with relative risk of -20.009 of argatroban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: lapatinib with relative risk of -20.182 of argatroban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: lapatinib with relative risk of -20.182 of argatroban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: losartan with relative risk of -20.580 of argatroban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: losartan with relative risk of -20.580 of argatroban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: amisulpride with relative risk of -20.645 of argatroban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: amisulpride with relative risk of -20.645 of argatroban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: latanoprost with relative risk of -20.742 of argatroban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: latanoprost with relative risk of -20.742 of argatroban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: temsirolimus with relative risk of -21.300 of argatroban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: temsirolimus with relative risk of -21.300 of argatroban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: lidocaine with relative risk of -21.983 of argatroban | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: hematology\n",
      "Rank 49: lidocaine with relative risk of -21.983 of argatroban | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: hematology\n",
      "Rank 50: pentoxifylline with relative risk of -23.552 of argatroban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: pentoxifylline with relative risk of -23.552 of argatroban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: pentoxifylline with relative risk of -23.552 of argatroban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 53: domperidone with relative risk of -31.565 of argatroban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 54: domperidone with relative risk of -31.565 of argatroban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 55: domperidone with relative risk of -31.565 of argatroban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 56: felodipine with relative risk of -inf of argatroban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 57: felodipine with relative risk of -inf of argatroban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.027\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó aripiprazole *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: indapamide with relative risk of -13.107 of aripiprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó asenapine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: regadenoson with relative risk of -7.041 of asenapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: sertraline with relative risk of -7.398 of asenapine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: mometasone with relative risk of -7.637 of asenapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: posaconazole with relative risk of -8.074 of asenapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: irbesartan with relative risk of -8.126 of asenapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: azelastine with relative risk of -8.472 of asenapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: crizotinib with relative risk of -8.767 of asenapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: ruxolitinib with relative risk of -8.903 of asenapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: ibutilide with relative risk of -9.509 of asenapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: amsacrine with relative risk of -10.020 of asenapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: carbamazepine with relative risk of -10.089 of asenapine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,neurology/psychiatry\n",
      "Rank 12: dofetilide with relative risk of -10.229 of asenapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: cetirizine with relative risk of -10.260 of asenapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: sulfasalazine with relative risk of -10.299 of asenapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: tolvaptan with relative risk of -11.361 of asenapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: ambrisentan with relative risk of -11.379 of asenapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: cimetidine with relative risk of -12.700 of asenapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: telithromycin with relative risk of -15.698 of asenapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: telithromycin with relative risk of -15.698 of asenapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: nabumetone with relative risk of -16.804 of asenapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: nabumetone with relative risk of -16.804 of asenapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.162\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target atazanavir not found. Exiting ...\n",
      "\n",
      "Drug target atenolol not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó atomoxetine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: ibandronate with relative risk of -8.808 of atomoxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: cytarabine with relative risk of -9.353 of atomoxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: formoterol with relative risk of -9.630 of atomoxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: frovatriptan with relative risk of -9.792 of atomoxetine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 5: nimodipine with relative risk of -10.119 of atomoxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: cilostazol with relative risk of -10.570 of atomoxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: allopurinol with relative risk of -10.638 of atomoxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: avanafil with relative risk of -10.844 of atomoxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: hydrochlorothiazide with relative risk of -12.121 of atomoxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: tasimelteon with relative risk of -19.378 of atomoxetine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: tasimelteon with relative risk of -19.378 of atomoxetine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: mafenide with relative risk of -30.201 of atomoxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: mafenide with relative risk of -30.201 of atomoxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: mafenide with relative risk of -30.201 of atomoxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: candesartan with relative risk of -40.944 of atomoxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: candesartan with relative risk of -40.944 of atomoxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: candesartan with relative risk of -40.944 of atomoxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: candesartan with relative risk of -40.944 of atomoxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.126\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó atorvastatin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: nifedipine with relative risk of -8.222 of atorvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Angina Pectoris, Variant,Hypertensive disease,Angina Pectoris,cardiology\n",
      "Rank 2: nabumetone with relative risk of -8.611 of atorvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: danazol with relative risk of -8.638 of atorvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 4: dabigatran with relative risk of -8.839 of atorvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 5: phentolamine with relative risk of -9.209 of atorvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 6: cyclobenzaprine with relative risk of -9.381 of atorvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: exenatide with relative risk of -9.921 of atorvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: conivaptan with relative risk of -9.933 of atorvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: fosinopril with relative risk of -10.030 of atorvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 10: iloperidone with relative risk of -15.700 of atorvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: iloperidone with relative risk of -15.700 of atorvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: anagrelide with relative risk of -16.468 of atorvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: anagrelide with relative risk of -16.468 of atorvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: albendazole with relative risk of -24.406 of atorvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: albendazole with relative risk of -24.406 of atorvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: albendazole with relative risk of -24.406 of atorvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: telithromycin with relative risk of -117.564 of atorvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: telithromycin with relative risk of -117.564 of atorvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: telithromycin with relative risk of -117.564 of atorvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: telithromycin with relative risk of -117.564 of atorvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: telithromycin with relative risk of -117.564 of atorvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: telithromycin with relative risk of -117.564 of atorvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: telithromycin with relative risk of -117.564 of atorvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: telithromycin with relative risk of -117.564 of atorvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: telithromycin with relative risk of -117.564 of atorvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: telithromycin with relative risk of -117.564 of atorvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: telithromycin with relative risk of -117.564 of atorvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: telithromycin with relative risk of -117.564 of atorvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: telithromycin with relative risk of -117.564 of atorvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: telithromycin with relative risk of -117.564 of atorvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: telithromycin with relative risk of -117.564 of atorvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: telithromycin with relative risk of -117.564 of atorvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: treprostinil with relative risk of -121.020 of atorvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: treprostinil with relative risk of -121.020 of atorvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: treprostinil with relative risk of -121.020 of atorvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: treprostinil with relative risk of -121.020 of atorvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: treprostinil with relative risk of -121.020 of atorvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: treprostinil with relative risk of -121.020 of atorvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: treprostinil with relative risk of -121.020 of atorvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: treprostinil with relative risk of -121.020 of atorvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: treprostinil with relative risk of -121.020 of atorvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: treprostinil with relative risk of -121.020 of atorvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: treprostinil with relative risk of -121.020 of atorvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: treprostinil with relative risk of -121.020 of atorvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: treprostinil with relative risk of -121.020 of atorvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: treprostinil with relative risk of -121.020 of atorvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: treprostinil with relative risk of -121.020 of atorvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: treprostinil with relative risk of -121.020 of atorvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: cetrorelix with relative risk of -122.163 of atorvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: cetrorelix with relative risk of -122.163 of atorvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: cetrorelix with relative risk of -122.163 of atorvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: cetrorelix with relative risk of -122.163 of atorvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 53: cetrorelix with relative risk of -122.163 of atorvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 54: cetrorelix with relative risk of -122.163 of atorvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 55: cetrorelix with relative risk of -122.163 of atorvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 56: cetrorelix with relative risk of -122.163 of atorvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 57: cetrorelix with relative risk of -122.163 of atorvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 58: cetrorelix with relative risk of -122.163 of atorvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 59: cetrorelix with relative risk of -122.163 of atorvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 60: cetrorelix with relative risk of -122.163 of atorvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 61: cetrorelix with relative risk of -122.163 of atorvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 62: cetrorelix with relative risk of -122.163 of atorvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 63: cetrorelix with relative risk of -122.163 of atorvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 64: cetrorelix with relative risk of -122.163 of atorvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 65: captopril with relative risk of -164.510 of atorvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 66: captopril with relative risk of -164.510 of atorvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 67: captopril with relative risk of -164.510 of atorvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 68: captopril with relative risk of -164.510 of atorvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 69: captopril with relative risk of -164.510 of atorvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 70: captopril with relative risk of -164.510 of atorvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 71: captopril with relative risk of -164.510 of atorvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 72: captopril with relative risk of -164.510 of atorvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 73: captopril with relative risk of -164.510 of atorvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 74: captopril with relative risk of -164.510 of atorvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 75: captopril with relative risk of -164.510 of atorvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 76: captopril with relative risk of -164.510 of atorvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 77: captopril with relative risk of -164.510 of atorvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 78: captopril with relative risk of -164.510 of atorvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 79: captopril with relative risk of -164.510 of atorvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 80: captopril with relative risk of -164.510 of atorvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 81: captopril with relative risk of -164.510 of atorvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 82: captopril with relative risk of -164.510 of atorvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 83: captopril with relative risk of -164.510 of atorvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 84: captopril with relative risk of -164.510 of atorvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 85: captopril with relative risk of -164.510 of atorvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.504\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó atosiban *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: aminophylline with relative risk of -9.523 of atosiban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: ropivacaine with relative risk of -10.167 of atosiban | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: ibandronate with relative risk of -10.192 of atosiban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: imatinib with relative risk of -10.310 of atosiban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: gemcitabine with relative risk of -10.824 of atosiban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: gefitinib with relative risk of -10.832 of atosiban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: trimetrexate with relative risk of -10.939 of atosiban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: finasteride with relative risk of -11.097 of atosiban | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 9: valdecoxib with relative risk of -11.496 of atosiban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: acyclovir with relative risk of -11.705 of atosiban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: dihydroergotamine with relative risk of -11.922 of atosiban | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: vincristine with relative risk of -12.233 of atosiban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: alendronate with relative risk of -12.279 of atosiban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: ramipril with relative risk of -12.733 of atosiban | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 15: desvenlafaxine with relative risk of -13.114 of atosiban | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 16: clopidogrel with relative risk of -13.390 of atosiban | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology,neurology/psychiatry\n",
      "Rank 17: amoxicillin with relative risk of -13.617 of atosiban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: diltiazem with relative risk of -13.859 of atosiban | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 19: nebivolol with relative risk of -14.345 of atosiban | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.289\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target atovaquone not found. Exiting ...\n",
      "\n",
      "Drug target atracurium not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó atropine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: regadenoson with relative risk of -8.647 of atropine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: sertraline with relative risk of -8.999 of atropine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: mometasone with relative risk of -9.242 of atropine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: posaconazole with relative risk of -9.679 of atropine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: irbesartan with relative risk of -9.727 of atropine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: azelastine with relative risk of -10.076 of atropine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: ophthalmology\n",
      "Rank 7: tropisetron with relative risk of -10.479 of atropine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: ruxolitinib with relative risk of -10.512 of atropine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: lurasidone with relative risk of -10.558 of atropine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: lansoprazole with relative risk of -11.107 of atropine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: ibutilide with relative risk of -11.114 of atropine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: risperidone with relative risk of -11.175 of atropine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: ketorolac with relative risk of -11.258 of atropine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: clarithromycin with relative risk of -11.894 of atropine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: clonidine with relative risk of -11.931 of atropine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: dutasteride with relative risk of -12.086 of atropine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: leflunomide with relative risk of -12.233 of atropine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: doxorubicin with relative risk of -12.242 of atropine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: vernakalant with relative risk of -12.281 of atropine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: flecainide with relative risk of -12.956 of atropine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: vilazodone with relative risk of -13.644 of atropine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: pindolol with relative risk of -13.800 of atropine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.045\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó auranofin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: bosutinib with relative risk of -10.608 of auranofin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: dofetilide with relative risk of -10.740 of auranofin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: clarithromycin with relative risk of -10.796 of auranofin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: olmesartan with relative risk of -13.236 of auranofin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: sertraline with relative risk of -21.564 of auranofin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: sertraline with relative risk of -21.564 of auranofin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: sertraline with relative risk of -21.564 of auranofin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: irbesartan with relative risk of -22.116 of auranofin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: irbesartan with relative risk of -22.116 of auranofin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: irbesartan with relative risk of -22.116 of auranofin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: regadenoson with relative risk of -22.359 of auranofin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: regadenoson with relative risk of -22.359 of auranofin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: regadenoson with relative risk of -22.359 of auranofin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: mometasone with relative risk of -22.583 of auranofin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: mometasone with relative risk of -22.583 of auranofin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: mometasone with relative risk of -22.583 of auranofin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: azelastine with relative risk of -23.351 of auranofin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: azelastine with relative risk of -23.351 of auranofin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: azelastine with relative risk of -23.351 of auranofin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: posaconazole with relative risk of -23.476 of auranofin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: posaconazole with relative risk of -23.476 of auranofin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: posaconazole with relative risk of -23.476 of auranofin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: ibutilide with relative risk of -24.670 of auranofin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: ibutilide with relative risk of -24.670 of auranofin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: ibutilide with relative risk of -24.670 of auranofin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: telmisartan with relative risk of -28.046 of auranofin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: telmisartan with relative risk of -28.046 of auranofin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: telmisartan with relative risk of -28.046 of auranofin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: tolmetin with relative risk of -28.278 of auranofin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Rheumatoid Arthritis,rheumatology\n",
      "Rank 30: tolmetin with relative risk of -28.278 of auranofin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Rheumatoid Arthritis,rheumatology\n",
      "Rank 31: tolmetin with relative risk of -28.278 of auranofin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Rheumatoid Arthritis,rheumatology\n",
      "Rank 32: milnacipran with relative risk of -28.509 of auranofin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: rheumatology\n",
      "Rank 33: milnacipran with relative risk of -28.509 of auranofin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: rheumatology\n",
      "Rank 34: milnacipran with relative risk of -28.509 of auranofin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: rheumatology\n",
      "Rank 35: progesterone with relative risk of -28.615 of auranofin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: progesterone with relative risk of -28.615 of auranofin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: progesterone with relative risk of -28.615 of auranofin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: estramustine with relative risk of -28.689 of auranofin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: estramustine with relative risk of -28.689 of auranofin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: estramustine with relative risk of -28.689 of auranofin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: abiraterone with relative risk of -29.125 of auranofin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: abiraterone with relative risk of -29.125 of auranofin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: abiraterone with relative risk of -29.125 of auranofin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: lubiprostone with relative risk of -29.511 of auranofin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: lubiprostone with relative risk of -29.511 of auranofin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: lubiprostone with relative risk of -29.511 of auranofin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: dapagliflozin with relative risk of -30.162 of auranofin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: dapagliflozin with relative risk of -30.162 of auranofin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: dapagliflozin with relative risk of -30.162 of auranofin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: misoprostol with relative risk of -30.509 of auranofin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: misoprostol with relative risk of -30.509 of auranofin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: misoprostol with relative risk of -30.509 of auranofin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 53: dantrolene with relative risk of -30.908 of auranofin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 54: dantrolene with relative risk of -30.908 of auranofin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 55: dantrolene with relative risk of -30.908 of auranofin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 56: risedronate with relative risk of -31.197 of auranofin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 57: risedronate with relative risk of -31.197 of auranofin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 58: risedronate with relative risk of -31.197 of auranofin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 59: donepezil with relative risk of -31.589 of auranofin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 60: donepezil with relative risk of -31.589 of auranofin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 61: donepezil with relative risk of -31.589 of auranofin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 62: cisatracurium with relative risk of -32.261 of auranofin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 63: cisatracurium with relative risk of -32.261 of auranofin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 64: cisatracurium with relative risk of -32.261 of auranofin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.04\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó avanafil *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: cytarabine with relative risk of -9.640 of avanafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: formoterol with relative risk of -9.918 of avanafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: frovatriptan with relative risk of -10.080 of avanafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: atomoxetine with relative risk of -10.622 of avanafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: degarelix with relative risk of -10.661 of avanafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: cilostazol with relative risk of -10.858 of avanafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: allopurinol with relative risk of -10.926 of avanafil | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: urology\n",
      "Rank 8: mafenide with relative risk of -11.072 of avanafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: buspirone with relative risk of -11.142 of avanafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: candesartan with relative risk of -11.473 of avanafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: almotriptan with relative risk of -12.292 of avanafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: hydrochlorothiazide with relative risk of -12.409 of avanafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: nimodipine with relative risk of -18.382 of avanafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: nimodipine with relative risk of -18.382 of avanafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.044\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó axitinib *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: tadalafil with relative risk of -7.683 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: ibandronate with relative risk of -7.803 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: miglustat with relative risk of -7.927 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: pentoxifylline with relative risk of -8.161 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: formoterol with relative risk of -8.622 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: dabigatran with relative risk of -9.531 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: estramustine with relative risk of -9.585 of axitinib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 8: zonisamide with relative risk of -9.790 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: etravirine with relative risk of -10.069 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: linezolid with relative risk of -10.235 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: tiotropium with relative risk of -10.456 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: febuxostat with relative risk of -12.502 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: eplerenone with relative risk of -16.601 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: eplerenone with relative risk of -16.601 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: exemestane with relative risk of -17.913 of axitinib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 16: exemestane with relative risk of -17.913 of axitinib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 17: indacaterol with relative risk of -24.666 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: indacaterol with relative risk of -24.666 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: indacaterol with relative risk of -24.666 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: ciclesonide with relative risk of -66.125 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: ciclesonide with relative risk of -66.125 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: ciclesonide with relative risk of -66.125 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: ciclesonide with relative risk of -66.125 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: ciclesonide with relative risk of -66.125 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: ciclesonide with relative risk of -66.125 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: ciclesonide with relative risk of -66.125 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: ciclesonide with relative risk of -66.125 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: ciclesonide with relative risk of -66.125 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: ciclesonide with relative risk of -66.125 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: meloxicam with relative risk of -78.922 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: meloxicam with relative risk of -78.922 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: meloxicam with relative risk of -78.922 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: meloxicam with relative risk of -78.922 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: meloxicam with relative risk of -78.922 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: meloxicam with relative risk of -78.922 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: meloxicam with relative risk of -78.922 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: meloxicam with relative risk of -78.922 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: meloxicam with relative risk of -78.922 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: meloxicam with relative risk of -78.922 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: darifenacin with relative risk of -80.236 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: darifenacin with relative risk of -80.236 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: darifenacin with relative risk of -80.236 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: darifenacin with relative risk of -80.236 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: darifenacin with relative risk of -80.236 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: darifenacin with relative risk of -80.236 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: darifenacin with relative risk of -80.236 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: darifenacin with relative risk of -80.236 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: darifenacin with relative risk of -80.236 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: darifenacin with relative risk of -80.236 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: vinorelbine with relative risk of -84.803 of axitinib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 51: vinorelbine with relative risk of -84.803 of axitinib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 52: vinorelbine with relative risk of -84.803 of axitinib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 53: vinorelbine with relative risk of -84.803 of axitinib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 54: vinorelbine with relative risk of -84.803 of axitinib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 55: vinorelbine with relative risk of -84.803 of axitinib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 56: vinorelbine with relative risk of -84.803 of axitinib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 57: vinorelbine with relative risk of -84.803 of axitinib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 58: vinorelbine with relative risk of -84.803 of axitinib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 59: vinorelbine with relative risk of -84.803 of axitinib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 60: granisetron with relative risk of -85.690 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 61: granisetron with relative risk of -85.690 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 62: granisetron with relative risk of -85.690 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 63: granisetron with relative risk of -85.690 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 64: granisetron with relative risk of -85.690 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 65: granisetron with relative risk of -85.690 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 66: granisetron with relative risk of -85.690 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 67: granisetron with relative risk of -85.690 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 68: granisetron with relative risk of -85.690 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 69: granisetron with relative risk of -85.690 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 70: apraclonidine with relative risk of -85.847 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 71: apraclonidine with relative risk of -85.847 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 72: apraclonidine with relative risk of -85.847 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 73: apraclonidine with relative risk of -85.847 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 74: apraclonidine with relative risk of -85.847 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 75: apraclonidine with relative risk of -85.847 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 76: apraclonidine with relative risk of -85.847 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 77: apraclonidine with relative risk of -85.847 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 78: apraclonidine with relative risk of -85.847 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 79: apraclonidine with relative risk of -85.847 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 80: pinaverium with relative risk of -88.826 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 81: pinaverium with relative risk of -88.826 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 82: pinaverium with relative risk of -88.826 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 83: pinaverium with relative risk of -88.826 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 84: pinaverium with relative risk of -88.826 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 85: pinaverium with relative risk of -88.826 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 86: pinaverium with relative risk of -88.826 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 87: pinaverium with relative risk of -88.826 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 88: pinaverium with relative risk of -88.826 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 89: pinaverium with relative risk of -88.826 of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 90: desoximetasone with relative risk of -inf of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 91: desoximetasone with relative risk of -inf of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 92: desoximetasone with relative risk of -inf of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 93: desoximetasone with relative risk of -inf of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 94: desoximetasone with relative risk of -inf of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 95: desoximetasone with relative risk of -inf of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 96: desoximetasone with relative risk of -inf of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 97: desoximetasone with relative risk of -inf of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 98: desoximetasone with relative risk of -inf of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 99: desoximetasone with relative risk of -inf of axitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.088\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó azathioprine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: clozapine with relative risk of -7.583 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: bimatoprost with relative risk of -8.570 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: vandetanib with relative risk of -8.857 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: phentolamine with relative risk of -17.065 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: phentolamine with relative risk of -17.065 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: acitretin with relative risk of -17.069 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: acitretin with relative risk of -17.069 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: nilutamide with relative risk of -18.636 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: nilutamide with relative risk of -18.636 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: nifedipine with relative risk of -23.542 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: nifedipine with relative risk of -23.542 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: nifedipine with relative risk of -23.542 of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: calcipotriol with relative risk of -inf of azathioprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target azelaic not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó azelastine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: ibandronate with relative risk of -6.753 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: crizotinib with relative risk of -6.916 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: penbutolol with relative risk of -7.095 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: ribavirin with relative risk of -7.510 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: risperidone with relative risk of -7.716 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: atropine with relative risk of -8.065 of azelastine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: ophthalmology\n",
      "Rank 7: loratadine with relative risk of -8.095 of azelastine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Rhinitis, Vasomotor,Hay fever,Allergic Conjunctivitis,Allergic rhinitis (disorder)\n",
      "Rank 8: asenapine with relative risk of -8.163 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: amsacrine with relative risk of -8.164 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: carbamazepine with relative risk of -8.235 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: bosutinib with relative risk of -8.241 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: argatroban with relative risk of -8.332 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: sulfasalazine with relative risk of -8.444 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: lapatinib with relative risk of -8.454 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: afatinib with relative risk of -8.508 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: varenicline with relative risk of -8.512 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: flutamide with relative risk of -8.520 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: naltrexone with relative risk of -8.570 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: leflunomide with relative risk of -8.769 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: doxorubicin with relative risk of -8.777 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: bezafibrate with relative risk of -8.792 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: vernakalant with relative risk of -8.815 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: losartan with relative risk of -8.853 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: ixabepilone with relative risk of -8.875 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: celecoxib with relative risk of -8.897 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: perindopril with relative risk of -8.976 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: cladribine with relative risk of -9.031 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: beclomethasone with relative risk of -9.172 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: flecainide with relative risk of -9.490 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: tolvaptan with relative risk of -9.505 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: ambrisentan with relative risk of -9.522 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: budesonide with relative risk of -9.539 of azelastine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic rhinitis (disorder)\n",
      "Rank 33: temsirolimus with relative risk of -9.572 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: amisulpride with relative risk of -9.612 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: latanoprost with relative risk of -9.709 of azelastine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: ophthalmology\n",
      "Rank 36: benazepril with relative risk of -9.713 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: nicotine with relative risk of -9.847 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: desonide with relative risk of -9.902 of azelastine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic rhinitis (disorder)\n",
      "Rank 39: pergolide with relative risk of -10.052 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: domperidone with relative risk of -10.072 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: vilazodone with relative risk of -10.178 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: lidocaine with relative risk of -10.256 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: pindolol with relative risk of -10.334 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: toremifene with relative risk of -10.466 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: cimetidine with relative risk of -10.844 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: olmesartan with relative risk of -10.869 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: darifenacin with relative risk of -11.714 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: darifenacin with relative risk of -11.714 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: brimonidine with relative risk of -14.260 of azelastine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: ophthalmology\n",
      "Rank 50: brimonidine with relative risk of -14.260 of azelastine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: ophthalmology\n",
      "Rank 51: cyclophosphamide with relative risk of -14.319 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: cyclophosphamide with relative risk of -14.319 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 53: cetirizine with relative risk of -14.621 of azelastine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic Conjunctivitis,Hay fever,Allergic rhinitis (disorder),Rhinitis, Vasomotor\n",
      "Rank 54: cetirizine with relative risk of -14.621 of azelastine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic Conjunctivitis,Hay fever,Allergic rhinitis (disorder),Rhinitis, Vasomotor\n",
      "Rank 55: tazarotene with relative risk of -14.833 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 56: tazarotene with relative risk of -14.833 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 57: dofetilide with relative risk of -14.995 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 58: dofetilide with relative risk of -14.995 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 59: dapsone with relative risk of -15.093 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 60: dapsone with relative risk of -15.093 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 61: erlotinib with relative risk of -15.131 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 62: erlotinib with relative risk of -15.131 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 63: vemurafenib with relative risk of -15.163 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 64: vemurafenib with relative risk of -15.163 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 65: capecitabine with relative risk of -15.300 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 66: capecitabine with relative risk of -15.300 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 67: isradipine with relative risk of -15.838 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 68: isradipine with relative risk of -15.838 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 69: rotigotine with relative risk of -16.498 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 70: rotigotine with relative risk of -16.498 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 71: sumatriptan with relative risk of -16.509 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 72: sumatriptan with relative risk of -16.509 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 73: citalopram with relative risk of -16.533 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 74: citalopram with relative risk of -16.533 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 75: doxepin with relative risk of -16.706 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 76: doxepin with relative risk of -16.706 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 77: ticagrelor with relative risk of -18.301 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 78: ticagrelor with relative risk of -18.301 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 79: ticagrelor with relative risk of -18.301 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 80: estramustine with relative risk of -20.184 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 81: estramustine with relative risk of -20.184 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 82: estramustine with relative risk of -20.184 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 83: ivacaftor with relative risk of -20.612 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 84: ivacaftor with relative risk of -20.612 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 85: ivacaftor with relative risk of -20.612 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 86: bumetanide with relative risk of -20.617 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 87: bumetanide with relative risk of -20.617 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 88: bumetanide with relative risk of -20.617 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 89: auranofin with relative risk of -21.607 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 90: auranofin with relative risk of -21.607 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 91: auranofin with relative risk of -21.607 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 92: nevirapine with relative risk of -21.660 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 93: nevirapine with relative risk of -21.660 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 94: nevirapine with relative risk of -21.660 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 95: delavirdine with relative risk of -22.197 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 96: delavirdine with relative risk of -22.197 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 97: delavirdine with relative risk of -22.197 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 98: dantrolene with relative risk of -22.399 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 99: dantrolene with relative risk of -22.399 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 100: dantrolene with relative risk of -22.399 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 101: risedronate with relative risk of -22.688 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 102: risedronate with relative risk of -22.688 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 103: risedronate with relative risk of -22.688 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 104: clonidine with relative risk of -22.838 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 105: clonidine with relative risk of -22.838 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 106: clonidine with relative risk of -22.838 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 107: donepezil with relative risk of -23.080 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 108: donepezil with relative risk of -23.080 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 109: donepezil with relative risk of -23.080 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 110: brinzolamide with relative risk of -23.119 of azelastine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: ophthalmology\n",
      "Rank 111: brinzolamide with relative risk of -23.119 of azelastine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: ophthalmology\n",
      "Rank 112: brinzolamide with relative risk of -23.119 of azelastine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: ophthalmology\n",
      "Rank 113: fondaparinux with relative risk of -23.448 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 114: fondaparinux with relative risk of -23.448 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 115: fondaparinux with relative risk of -23.448 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 116: acebutolol with relative risk of -23.464 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 117: acebutolol with relative risk of -23.464 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 118: acebutolol with relative risk of -23.464 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 119: valsartan with relative risk of -23.607 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 120: valsartan with relative risk of -23.607 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 121: valsartan with relative risk of -23.607 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 122: metoprolol with relative risk of -26.699 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 123: metoprolol with relative risk of -26.699 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 124: metoprolol with relative risk of -26.699 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 125: metoprolol with relative risk of -26.699 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 126: milrinone with relative risk of -27.121 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 127: milrinone with relative risk of -27.121 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 128: milrinone with relative risk of -27.121 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 129: milrinone with relative risk of -27.121 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 130: tamsulosin with relative risk of -28.447 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 131: tamsulosin with relative risk of -28.447 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 132: tamsulosin with relative risk of -28.447 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 133: tamsulosin with relative risk of -28.447 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 134: everolimus with relative risk of -28.804 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 135: everolimus with relative risk of -28.804 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 136: everolimus with relative risk of -28.804 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 137: everolimus with relative risk of -28.804 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 138: terbutaline with relative risk of -31.367 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 139: terbutaline with relative risk of -31.367 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 140: terbutaline with relative risk of -31.367 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 141: terbutaline with relative risk of -31.367 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 142: terbutaline with relative risk of -31.367 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 143: naproxen with relative risk of -32.515 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 144: naproxen with relative risk of -32.515 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 145: naproxen with relative risk of -32.515 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 146: naproxen with relative risk of -32.515 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 147: naproxen with relative risk of -32.515 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 148: pemetrexed with relative risk of -32.594 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 149: pemetrexed with relative risk of -32.594 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 150: pemetrexed with relative risk of -32.594 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 151: pemetrexed with relative risk of -32.594 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 152: pemetrexed with relative risk of -32.594 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 153: pentoxifylline with relative risk of -33.280 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 154: pentoxifylline with relative risk of -33.280 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 155: pentoxifylline with relative risk of -33.280 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 156: pentoxifylline with relative risk of -33.280 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 157: pentoxifylline with relative risk of -33.280 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 158: pentoxifylline with relative risk of -33.280 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 159: ruxolitinib with relative risk of -33.732 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 160: ruxolitinib with relative risk of -33.732 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 161: ruxolitinib with relative risk of -33.732 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 162: ruxolitinib with relative risk of -33.732 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 163: ruxolitinib with relative risk of -33.732 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 164: esmolol with relative risk of -33.936 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 165: esmolol with relative risk of -33.936 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 166: esmolol with relative risk of -33.936 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 167: esmolol with relative risk of -33.936 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 168: esmolol with relative risk of -33.936 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 169: milnacipran with relative risk of -34.615 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 170: milnacipran with relative risk of -34.615 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 171: milnacipran with relative risk of -34.615 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 172: milnacipran with relative risk of -34.615 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 173: milnacipran with relative risk of -34.615 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 174: azilsartan with relative risk of -35.395 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 175: azilsartan with relative risk of -35.395 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 176: azilsartan with relative risk of -35.395 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 177: azilsartan with relative risk of -35.395 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 178: azilsartan with relative risk of -35.395 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 179: tolmetin with relative risk of -35.481 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 180: tolmetin with relative risk of -35.481 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 181: tolmetin with relative risk of -35.481 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 182: tolmetin with relative risk of -35.481 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 183: tolmetin with relative risk of -35.481 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 184: progesterone with relative risk of -35.819 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 185: progesterone with relative risk of -35.819 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 186: progesterone with relative risk of -35.819 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 187: progesterone with relative risk of -35.819 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 188: progesterone with relative risk of -35.819 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 189: abiraterone with relative risk of -36.328 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 190: abiraterone with relative risk of -36.328 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 191: abiraterone with relative risk of -36.328 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 192: abiraterone with relative risk of -36.328 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 193: abiraterone with relative risk of -36.328 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 194: lubiprostone with relative risk of -36.715 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 195: lubiprostone with relative risk of -36.715 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 196: lubiprostone with relative risk of -36.715 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 197: lubiprostone with relative risk of -36.715 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 198: lubiprostone with relative risk of -36.715 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 199: zolmitriptan with relative risk of -37.132 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 200: zolmitriptan with relative risk of -37.132 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 201: zolmitriptan with relative risk of -37.132 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 202: zolmitriptan with relative risk of -37.132 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 203: zolmitriptan with relative risk of -37.132 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 204: dapagliflozin with relative risk of -37.365 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 205: dapagliflozin with relative risk of -37.365 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 206: dapagliflozin with relative risk of -37.365 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 207: dapagliflozin with relative risk of -37.365 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 208: dapagliflozin with relative risk of -37.365 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 209: misoprostol with relative risk of -37.712 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 210: misoprostol with relative risk of -37.712 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 211: misoprostol with relative risk of -37.712 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 212: misoprostol with relative risk of -37.712 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 213: misoprostol with relative risk of -37.712 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 214: cisatracurium with relative risk of -39.465 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 215: cisatracurium with relative risk of -39.465 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 216: cisatracurium with relative risk of -39.465 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 217: cisatracurium with relative risk of -39.465 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 218: cisatracurium with relative risk of -39.465 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 219: trovafloxacin with relative risk of -40.412 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 220: trovafloxacin with relative risk of -40.412 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 221: trovafloxacin with relative risk of -40.412 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 222: trovafloxacin with relative risk of -40.412 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 223: trovafloxacin with relative risk of -40.412 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 224: trovafloxacin with relative risk of -40.412 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 225: didanosine with relative risk of -42.441 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 226: didanosine with relative risk of -42.441 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 227: didanosine with relative risk of -42.441 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 228: didanosine with relative risk of -42.441 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 229: didanosine with relative risk of -42.441 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 230: didanosine with relative risk of -42.441 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 231: gabapentin with relative risk of -43.315 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 232: gabapentin with relative risk of -43.315 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 233: gabapentin with relative risk of -43.315 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 234: gabapentin with relative risk of -43.315 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 235: gabapentin with relative risk of -43.315 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 236: gabapentin with relative risk of -43.315 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 237: clarithromycin with relative risk of -43.664 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 238: clarithromycin with relative risk of -43.664 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 239: clarithromycin with relative risk of -43.664 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 240: clarithromycin with relative risk of -43.664 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 241: clarithromycin with relative risk of -43.664 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 242: clarithromycin with relative risk of -43.664 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 243: lurasidone with relative risk of -47.334 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 244: lurasidone with relative risk of -47.334 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 245: lurasidone with relative risk of -47.334 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 246: lurasidone with relative risk of -47.334 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 247: lurasidone with relative risk of -47.334 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 248: lurasidone with relative risk of -47.334 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 249: lurasidone with relative risk of -47.334 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 250: indomethacin with relative risk of -48.030 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 251: indomethacin with relative risk of -48.030 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 252: indomethacin with relative risk of -48.030 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 253: indomethacin with relative risk of -48.030 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 254: indomethacin with relative risk of -48.030 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 255: indomethacin with relative risk of -48.030 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 256: indomethacin with relative risk of -48.030 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 257: levonorgestrel with relative risk of -48.997 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 258: levonorgestrel with relative risk of -48.997 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 259: levonorgestrel with relative risk of -48.997 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 260: levonorgestrel with relative risk of -48.997 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 261: levonorgestrel with relative risk of -48.997 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 262: levonorgestrel with relative risk of -48.997 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 263: levonorgestrel with relative risk of -48.997 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 264: dutasteride with relative risk of -50.807 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 265: dutasteride with relative risk of -50.807 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 266: dutasteride with relative risk of -50.807 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 267: dutasteride with relative risk of -50.807 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 268: dutasteride with relative risk of -50.807 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 269: dutasteride with relative risk of -50.807 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 270: dutasteride with relative risk of -50.807 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 271: ketorolac with relative risk of -51.153 of azelastine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic Conjunctivitis\n",
      "Rank 272: ketorolac with relative risk of -51.153 of azelastine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic Conjunctivitis\n",
      "Rank 273: ketorolac with relative risk of -51.153 of azelastine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic Conjunctivitis\n",
      "Rank 274: ketorolac with relative risk of -51.153 of azelastine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic Conjunctivitis\n",
      "Rank 275: ketorolac with relative risk of -51.153 of azelastine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic Conjunctivitis\n",
      "Rank 276: ketorolac with relative risk of -51.153 of azelastine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic Conjunctivitis\n",
      "Rank 277: ketorolac with relative risk of -51.153 of azelastine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic Conjunctivitis\n",
      "Rank 278: ketorolac with relative risk of -51.153 of azelastine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic Conjunctivitis\n",
      "Rank 279: telmisartan with relative risk of -57.364 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 280: telmisartan with relative risk of -57.364 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 281: telmisartan with relative risk of -57.364 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 282: telmisartan with relative risk of -57.364 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 283: telmisartan with relative risk of -57.364 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 284: telmisartan with relative risk of -57.364 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 285: telmisartan with relative risk of -57.364 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 286: telmisartan with relative risk of -57.364 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 287: ropivacaine with relative risk of -60.655 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 288: ropivacaine with relative risk of -60.655 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 289: ropivacaine with relative risk of -60.655 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 290: ropivacaine with relative risk of -60.655 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 291: ropivacaine with relative risk of -60.655 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 292: ropivacaine with relative risk of -60.655 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 293: ropivacaine with relative risk of -60.655 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 294: ropivacaine with relative risk of -60.655 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 295: ropivacaine with relative risk of -60.655 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 296: lansoprazole with relative risk of -77.874 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 297: lansoprazole with relative risk of -77.874 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 298: lansoprazole with relative risk of -77.874 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 299: lansoprazole with relative risk of -77.874 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 300: lansoprazole with relative risk of -77.874 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 301: lansoprazole with relative risk of -77.874 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 302: lansoprazole with relative risk of -77.874 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 303: lansoprazole with relative risk of -77.874 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 304: lansoprazole with relative risk of -77.874 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 305: lansoprazole with relative risk of -77.874 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 306: lansoprazole with relative risk of -77.874 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 307: etoposide with relative risk of -87.075 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 308: etoposide with relative risk of -87.075 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 309: etoposide with relative risk of -87.075 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 310: etoposide with relative risk of -87.075 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 311: etoposide with relative risk of -87.075 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 312: etoposide with relative risk of -87.075 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 313: etoposide with relative risk of -87.075 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 314: etoposide with relative risk of -87.075 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 315: etoposide with relative risk of -87.075 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 316: etoposide with relative risk of -87.075 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 317: etoposide with relative risk of -87.075 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 318: etoposide with relative risk of -87.075 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 319: etoposide with relative risk of -87.075 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 320: fenofibrate with relative risk of -89.618 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 321: fenofibrate with relative risk of -89.618 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 322: fenofibrate with relative risk of -89.618 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 323: fenofibrate with relative risk of -89.618 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 324: fenofibrate with relative risk of -89.618 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 325: fenofibrate with relative risk of -89.618 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 326: fenofibrate with relative risk of -89.618 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 327: fenofibrate with relative risk of -89.618 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 328: fenofibrate with relative risk of -89.618 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 329: fenofibrate with relative risk of -89.618 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 330: fenofibrate with relative risk of -89.618 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 331: fenofibrate with relative risk of -89.618 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 332: fenofibrate with relative risk of -89.618 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 333: glimepiride with relative risk of -100.893 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 334: glimepiride with relative risk of -100.893 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 335: glimepiride with relative risk of -100.893 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 336: glimepiride with relative risk of -100.893 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 337: glimepiride with relative risk of -100.893 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 338: glimepiride with relative risk of -100.893 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 339: glimepiride with relative risk of -100.893 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 340: glimepiride with relative risk of -100.893 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 341: glimepiride with relative risk of -100.893 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 342: glimepiride with relative risk of -100.893 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 343: glimepiride with relative risk of -100.893 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 344: glimepiride with relative risk of -100.893 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 345: glimepiride with relative risk of -100.893 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 346: glimepiride with relative risk of -100.893 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 347: glimepiride with relative risk of -100.893 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 348: paliperidone with relative risk of -115.473 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 349: paliperidone with relative risk of -115.473 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 350: paliperidone with relative risk of -115.473 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 351: paliperidone with relative risk of -115.473 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 352: paliperidone with relative risk of -115.473 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 353: paliperidone with relative risk of -115.473 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 354: paliperidone with relative risk of -115.473 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 355: paliperidone with relative risk of -115.473 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 356: paliperidone with relative risk of -115.473 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 357: paliperidone with relative risk of -115.473 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 358: paliperidone with relative risk of -115.473 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 359: paliperidone with relative risk of -115.473 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 360: paliperidone with relative risk of -115.473 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 361: paliperidone with relative risk of -115.473 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 362: paliperidone with relative risk of -115.473 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 363: paliperidone with relative risk of -115.473 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 364: paliperidone with relative risk of -115.473 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 365: tropisetron with relative risk of -122.790 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 366: tropisetron with relative risk of -122.790 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 367: tropisetron with relative risk of -122.790 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 368: tropisetron with relative risk of -122.790 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 369: tropisetron with relative risk of -122.790 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 370: tropisetron with relative risk of -122.790 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 371: tropisetron with relative risk of -122.790 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 372: tropisetron with relative risk of -122.790 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 373: tropisetron with relative risk of -122.790 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 374: tropisetron with relative risk of -122.790 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 375: tropisetron with relative risk of -122.790 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 376: tropisetron with relative risk of -122.790 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 377: tropisetron with relative risk of -122.790 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 378: tropisetron with relative risk of -122.790 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 379: tropisetron with relative risk of -122.790 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 380: tropisetron with relative risk of -122.790 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 381: tropisetron with relative risk of -122.790 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 382: tropisetron with relative risk of -122.790 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 383: sertraline with relative risk of -169.283 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 384: sertraline with relative risk of -169.283 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 385: sertraline with relative risk of -169.283 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 386: sertraline with relative risk of -169.283 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 387: sertraline with relative risk of -169.283 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 388: sertraline with relative risk of -169.283 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 389: sertraline with relative risk of -169.283 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 390: sertraline with relative risk of -169.283 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 391: sertraline with relative risk of -169.283 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 392: sertraline with relative risk of -169.283 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 393: sertraline with relative risk of -169.283 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 394: sertraline with relative risk of -169.283 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 395: sertraline with relative risk of -169.283 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 396: sertraline with relative risk of -169.283 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 397: sertraline with relative risk of -169.283 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 398: sertraline with relative risk of -169.283 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 399: sertraline with relative risk of -169.283 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 400: sertraline with relative risk of -169.283 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 401: sertraline with relative risk of -169.283 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 402: sertraline with relative risk of -169.283 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 403: sertraline with relative risk of -169.283 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 404: sertraline with relative risk of -169.283 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 405: sertraline with relative risk of -169.283 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 406: sertraline with relative risk of -169.283 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 407: sertraline with relative risk of -169.283 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 408: sertraline with relative risk of -169.283 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 409: sertraline with relative risk of -169.283 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 410: posaconazole with relative risk of -181.172 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 411: posaconazole with relative risk of -181.172 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 412: posaconazole with relative risk of -181.172 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 413: posaconazole with relative risk of -181.172 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 414: posaconazole with relative risk of -181.172 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 415: posaconazole with relative risk of -181.172 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 416: posaconazole with relative risk of -181.172 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 417: posaconazole with relative risk of -181.172 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 418: posaconazole with relative risk of -181.172 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 419: posaconazole with relative risk of -181.172 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 420: posaconazole with relative risk of -181.172 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 421: posaconazole with relative risk of -181.172 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 422: posaconazole with relative risk of -181.172 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 423: posaconazole with relative risk of -181.172 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 424: posaconazole with relative risk of -181.172 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 425: posaconazole with relative risk of -181.172 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 426: posaconazole with relative risk of -181.172 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 427: posaconazole with relative risk of -181.172 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 428: posaconazole with relative risk of -181.172 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 429: posaconazole with relative risk of -181.172 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 430: posaconazole with relative risk of -181.172 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 431: posaconazole with relative risk of -181.172 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 432: posaconazole with relative risk of -181.172 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 433: posaconazole with relative risk of -181.172 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 434: posaconazole with relative risk of -181.172 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 435: irbesartan with relative risk of -184.404 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 436: irbesartan with relative risk of -184.404 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 437: irbesartan with relative risk of -184.404 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 438: irbesartan with relative risk of -184.404 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 439: irbesartan with relative risk of -184.404 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 440: irbesartan with relative risk of -184.404 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 441: irbesartan with relative risk of -184.404 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 442: irbesartan with relative risk of -184.404 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 443: irbesartan with relative risk of -184.404 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 444: irbesartan with relative risk of -184.404 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 445: irbesartan with relative risk of -184.404 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 446: irbesartan with relative risk of -184.404 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 447: irbesartan with relative risk of -184.404 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 448: irbesartan with relative risk of -184.404 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 449: irbesartan with relative risk of -184.404 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 450: irbesartan with relative risk of -184.404 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 451: irbesartan with relative risk of -184.404 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 452: irbesartan with relative risk of -184.404 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 453: irbesartan with relative risk of -184.404 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 454: irbesartan with relative risk of -184.404 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 455: irbesartan with relative risk of -184.404 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 456: irbesartan with relative risk of -184.404 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 457: irbesartan with relative risk of -184.404 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 458: irbesartan with relative risk of -184.404 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 459: irbesartan with relative risk of -184.404 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 460: irbesartan with relative risk of -184.404 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 461: irbesartan with relative risk of -184.404 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 462: irbesartan with relative risk of -184.404 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 463: irbesartan with relative risk of -184.404 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 464: ibutilide with relative risk of -184.894 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 465: ibutilide with relative risk of -184.894 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 466: ibutilide with relative risk of -184.894 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 467: ibutilide with relative risk of -184.894 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 468: ibutilide with relative risk of -184.894 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 469: ibutilide with relative risk of -184.894 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 470: ibutilide with relative risk of -184.894 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 471: ibutilide with relative risk of -184.894 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 472: ibutilide with relative risk of -184.894 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 473: ibutilide with relative risk of -184.894 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 474: ibutilide with relative risk of -184.894 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 475: ibutilide with relative risk of -184.894 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 476: ibutilide with relative risk of -184.894 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 477: ibutilide with relative risk of -184.894 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 478: ibutilide with relative risk of -184.894 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 479: ibutilide with relative risk of -184.894 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 480: ibutilide with relative risk of -184.894 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 481: ibutilide with relative risk of -184.894 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 482: ibutilide with relative risk of -184.894 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 483: ibutilide with relative risk of -184.894 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 484: ibutilide with relative risk of -184.894 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 485: ibutilide with relative risk of -184.894 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 486: ibutilide with relative risk of -184.894 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 487: ibutilide with relative risk of -184.894 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 488: ibutilide with relative risk of -184.894 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 489: ibutilide with relative risk of -184.894 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 490: mometasone with relative risk of -186.963 of azelastine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic rhinitis (disorder)\n",
      "Rank 491: mometasone with relative risk of -186.963 of azelastine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic rhinitis (disorder)\n",
      "Rank 492: mometasone with relative risk of -186.963 of azelastine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic rhinitis (disorder)\n",
      "Rank 493: mometasone with relative risk of -186.963 of azelastine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic rhinitis (disorder)\n",
      "Rank 494: mometasone with relative risk of -186.963 of azelastine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic rhinitis (disorder)\n",
      "Rank 495: mometasone with relative risk of -186.963 of azelastine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic rhinitis (disorder)\n",
      "Rank 496: mometasone with relative risk of -186.963 of azelastine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic rhinitis (disorder)\n",
      "Rank 497: mometasone with relative risk of -186.963 of azelastine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic rhinitis (disorder)\n",
      "Rank 498: mometasone with relative risk of -186.963 of azelastine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic rhinitis (disorder)\n",
      "Rank 499: mometasone with relative risk of -186.963 of azelastine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic rhinitis (disorder)\n",
      "Rank 500: mometasone with relative risk of -186.963 of azelastine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic rhinitis (disorder)\n",
      "Rank 501: mometasone with relative risk of -186.963 of azelastine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic rhinitis (disorder)\n",
      "Rank 502: mometasone with relative risk of -186.963 of azelastine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic rhinitis (disorder)\n",
      "Rank 503: mometasone with relative risk of -186.963 of azelastine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic rhinitis (disorder)\n",
      "Rank 504: mometasone with relative risk of -186.963 of azelastine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic rhinitis (disorder)\n",
      "Rank 505: mometasone with relative risk of -186.963 of azelastine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic rhinitis (disorder)\n",
      "Rank 506: mometasone with relative risk of -186.963 of azelastine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic rhinitis (disorder)\n",
      "Rank 507: mometasone with relative risk of -186.963 of azelastine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic rhinitis (disorder)\n",
      "Rank 508: mometasone with relative risk of -186.963 of azelastine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic rhinitis (disorder)\n",
      "Rank 509: mometasone with relative risk of -186.963 of azelastine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic rhinitis (disorder)\n",
      "Rank 510: mometasone with relative risk of -186.963 of azelastine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic rhinitis (disorder)\n",
      "Rank 511: mometasone with relative risk of -186.963 of azelastine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic rhinitis (disorder)\n",
      "Rank 512: mometasone with relative risk of -186.963 of azelastine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic rhinitis (disorder)\n",
      "Rank 513: mometasone with relative risk of -186.963 of azelastine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic rhinitis (disorder)\n",
      "Rank 514: mometasone with relative risk of -186.963 of azelastine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic rhinitis (disorder)\n",
      "Rank 515: mometasone with relative risk of -186.963 of azelastine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic rhinitis (disorder)\n",
      "Rank 516: mometasone with relative risk of -186.963 of azelastine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic rhinitis (disorder)\n",
      "Rank 517: regadenoson with relative risk of -188.286 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 518: regadenoson with relative risk of -188.286 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 519: regadenoson with relative risk of -188.286 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 520: regadenoson with relative risk of -188.286 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 521: regadenoson with relative risk of -188.286 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 522: regadenoson with relative risk of -188.286 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 523: regadenoson with relative risk of -188.286 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 524: regadenoson with relative risk of -188.286 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 525: regadenoson with relative risk of -188.286 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 526: regadenoson with relative risk of -188.286 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 527: regadenoson with relative risk of -188.286 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 528: regadenoson with relative risk of -188.286 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 529: regadenoson with relative risk of -188.286 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 530: regadenoson with relative risk of -188.286 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 531: regadenoson with relative risk of -188.286 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 532: regadenoson with relative risk of -188.286 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 533: regadenoson with relative risk of -188.286 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 534: regadenoson with relative risk of -188.286 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 535: regadenoson with relative risk of -188.286 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 536: regadenoson with relative risk of -188.286 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 537: regadenoson with relative risk of -188.286 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 538: regadenoson with relative risk of -188.286 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 539: regadenoson with relative risk of -188.286 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 540: regadenoson with relative risk of -188.286 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 541: regadenoson with relative risk of -188.286 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 542: regadenoson with relative risk of -188.286 of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 543: felodipine with relative risk of -inf of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 544: felodipine with relative risk of -inf of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 545: felodipine with relative risk of -inf of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 546: felodipine with relative risk of -inf of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 547: felodipine with relative risk of -inf of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 548: felodipine with relative risk of -inf of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 549: felodipine with relative risk of -inf of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 550: felodipine with relative risk of -inf of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 551: felodipine with relative risk of -inf of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 552: felodipine with relative risk of -inf of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 553: felodipine with relative risk of -inf of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 554: felodipine with relative risk of -inf of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 555: felodipine with relative risk of -inf of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 556: felodipine with relative risk of -inf of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 557: felodipine with relative risk of -inf of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 558: felodipine with relative risk of -inf of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 559: felodipine with relative risk of -inf of azelastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.084\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó azilsartan *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: levonorgestrel with relative risk of -8.486 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: penbutolol with relative risk of -8.738 of azilsartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 3: trovafloxacin with relative risk of -9.894 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: clarithromycin with relative risk of -10.104 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: perindopril with relative risk of -10.648 of azilsartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 6: lurasidone with relative risk of -15.960 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: lurasidone with relative risk of -15.960 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: lansoprazole with relative risk of -16.153 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: lansoprazole with relative risk of -16.153 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: didanosine with relative risk of -16.410 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: didanosine with relative risk of -16.410 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: etoposide with relative risk of -20.701 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: etoposide with relative risk of -20.701 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: etoposide with relative risk of -20.701 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: darifenacin with relative risk of -22.569 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: darifenacin with relative risk of -22.569 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: darifenacin with relative risk of -22.569 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: ropivacaine with relative risk of -23.006 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: ropivacaine with relative risk of -23.006 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: ropivacaine with relative risk of -23.006 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: fenofibrate with relative risk of -23.245 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: fenofibrate with relative risk of -23.245 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: fenofibrate with relative risk of -23.245 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: ivacaftor with relative risk of -26.124 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: ivacaftor with relative risk of -26.124 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: ivacaftor with relative risk of -26.124 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: zolmitriptan with relative risk of -26.933 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: zolmitriptan with relative risk of -26.933 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: zolmitriptan with relative risk of -26.933 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: brimonidine with relative risk of -27.524 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: brimonidine with relative risk of -27.524 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: brimonidine with relative risk of -27.524 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: tazarotene with relative risk of -28.097 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: tazarotene with relative risk of -28.097 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: tazarotene with relative risk of -28.097 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: dapsone with relative risk of -28.358 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: dapsone with relative risk of -28.358 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: dapsone with relative risk of -28.358 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: brinzolamide with relative risk of -28.633 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: brinzolamide with relative risk of -28.633 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: brinzolamide with relative risk of -28.633 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: acebutolol with relative risk of -28.978 of azilsartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 43: acebutolol with relative risk of -28.978 of azilsartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 44: acebutolol with relative risk of -28.978 of azilsartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 45: isradipine with relative risk of -29.102 of azilsartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 46: isradipine with relative risk of -29.102 of azilsartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 47: isradipine with relative risk of -29.102 of azilsartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 48: valsartan with relative risk of -29.121 of azilsartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 49: valsartan with relative risk of -29.121 of azilsartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 50: valsartan with relative risk of -29.121 of azilsartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 51: irbesartan with relative risk of -32.800 of azilsartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 52: irbesartan with relative risk of -32.800 of azilsartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 53: irbesartan with relative risk of -32.800 of azilsartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 54: irbesartan with relative risk of -32.800 of azilsartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 55: irbesartan with relative risk of -32.800 of azilsartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 56: regadenoson with relative risk of -34.452 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 57: regadenoson with relative risk of -34.452 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 58: regadenoson with relative risk of -34.452 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 59: regadenoson with relative risk of -34.452 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 60: regadenoson with relative risk of -34.452 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 61: azelastine with relative risk of -34.970 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 62: azelastine with relative risk of -34.970 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 63: azelastine with relative risk of -34.970 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 64: azelastine with relative risk of -34.970 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 65: azelastine with relative risk of -34.970 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 66: posaconazole with relative risk of -35.659 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 67: posaconazole with relative risk of -35.659 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 68: posaconazole with relative risk of -35.659 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 69: posaconazole with relative risk of -35.659 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 70: posaconazole with relative risk of -35.659 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 71: everolimus with relative risk of -36.587 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 72: everolimus with relative risk of -36.587 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 73: everolimus with relative risk of -36.587 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 74: everolimus with relative risk of -36.587 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 75: sertraline with relative risk of -40.588 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 76: sertraline with relative risk of -40.588 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 77: sertraline with relative risk of -40.588 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 78: sertraline with relative risk of -40.588 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 79: sertraline with relative risk of -40.588 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 80: sertraline with relative risk of -40.588 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 81: mometasone with relative risk of -42.861 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 82: mometasone with relative risk of -42.861 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 83: mometasone with relative risk of -42.861 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 84: mometasone with relative risk of -42.861 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 85: mometasone with relative risk of -42.861 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 86: mometasone with relative risk of -42.861 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 87: ibutilide with relative risk of -45.302 of azilsartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 88: ibutilide with relative risk of -45.302 of azilsartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 89: ibutilide with relative risk of -45.302 of azilsartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 90: ibutilide with relative risk of -45.302 of azilsartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 91: ibutilide with relative risk of -45.302 of azilsartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 92: ibutilide with relative risk of -45.302 of azilsartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 93: tropisetron with relative risk of -46.604 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 94: tropisetron with relative risk of -46.604 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 95: tropisetron with relative risk of -46.604 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 96: tropisetron with relative risk of -46.604 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 97: tropisetron with relative risk of -46.604 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 98: tropisetron with relative risk of -46.604 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 99: paliperidone with relative risk of -46.885 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 100: paliperidone with relative risk of -46.885 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 101: paliperidone with relative risk of -46.885 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 102: paliperidone with relative risk of -46.885 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 103: paliperidone with relative risk of -46.885 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 104: paliperidone with relative risk of -46.885 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 105: pentoxifylline with relative risk of -46.982 of azilsartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 106: pentoxifylline with relative risk of -46.982 of azilsartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 107: pentoxifylline with relative risk of -46.982 of azilsartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 108: pentoxifylline with relative risk of -46.982 of azilsartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 109: pentoxifylline with relative risk of -46.982 of azilsartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 110: pentoxifylline with relative risk of -46.982 of azilsartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 111: glimepiride with relative risk of -47.364 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 112: glimepiride with relative risk of -47.364 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 113: glimepiride with relative risk of -47.364 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 114: glimepiride with relative risk of -47.364 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 115: glimepiride with relative risk of -47.364 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 116: glimepiride with relative risk of -47.364 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 117: terbutaline with relative risk of -52.244 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 118: terbutaline with relative risk of -52.244 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 119: terbutaline with relative risk of -52.244 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 120: terbutaline with relative risk of -52.244 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 121: terbutaline with relative risk of -52.244 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 122: terbutaline with relative risk of -52.244 of azilsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 123: esmolol with relative risk of -56.202 of azilsartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 124: esmolol with relative risk of -56.202 of azilsartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 125: esmolol with relative risk of -56.202 of azilsartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 126: esmolol with relative risk of -56.202 of azilsartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 127: esmolol with relative risk of -56.202 of azilsartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 128: esmolol with relative risk of -56.202 of azilsartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 129: felodipine with relative risk of -inf of azilsartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 130: felodipine with relative risk of -inf of azilsartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 131: felodipine with relative risk of -inf of azilsartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 132: felodipine with relative risk of -inf of azilsartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 133: felodipine with relative risk of -inf of azilsartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 134: felodipine with relative risk of -inf of azilsartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.22\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target azithromycin not found. Exiting ...\n",
      "\n",
      "Drug target aztreonam not found. Exiting ...\n",
      "\n",
      "Drug target baclofen not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó balsalazide *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: teniposide with relative risk of -9.030 of balsalazide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: bosentan with relative risk of -10.555 of balsalazide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: apixaban with relative risk of -11.729 of balsalazide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: tegaserod with relative risk of -11.871 of balsalazide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: rocuronium with relative risk of -12.175 of balsalazide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó beclomethasone *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: irbesartan with relative risk of -9.727 of beclomethasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: azelastine with relative risk of -10.076 of beclomethasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: pentoxifylline with relative risk of -10.551 of beclomethasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: ribavirin with relative risk of -10.974 of beclomethasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: bumetanide with relative risk of -11.499 of beclomethasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: loratadine with relative risk of -11.555 of beclomethasone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: allergy\n",
      "Rank 7: argatroban with relative risk of -11.794 of beclomethasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: nevirapine with relative risk of -11.850 of beclomethasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: lapatinib with relative risk of -11.918 of beclomethasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: afatinib with relative risk of -11.974 of beclomethasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: losartan with relative risk of -12.317 of beclomethasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: celecoxib with relative risk of -12.360 of beclomethasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: perindopril with relative risk of -12.439 of beclomethasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: budesonide with relative risk of -13.005 of beclomethasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: temsirolimus with relative risk of -13.036 of beclomethasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: amisulpride with relative risk of -13.075 of beclomethasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: latanoprost with relative risk of -13.172 of beclomethasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: pergolide with relative risk of -13.517 of beclomethasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: domperidone with relative risk of -13.535 of beclomethasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: lidocaine with relative risk of -13.720 of beclomethasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: felodipine with relative risk of -inf of beclomethasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.046\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó belinostat *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: fludarabine with relative risk of -12.191 of belinostat | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: hematologic malignancy\n",
      "Rank 2: palonosetron with relative risk of -13.362 of belinostat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: timolol with relative risk of -13.412 of belinostat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: quinapril with relative risk of -13.910 of belinostat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.48\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó benazepril *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: regadenoson with relative risk of -8.647 of benazepril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: sertraline with relative risk of -8.999 of benazepril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: azelastine with relative risk of -10.076 of benazepril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: ropivacaine with relative risk of -10.167 of benazepril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: ibandronate with relative risk of -10.192 of benazepril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: naproxen with relative risk of -10.392 of benazepril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: ruxolitinib with relative risk of -10.512 of benazepril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: lurasidone with relative risk of -10.558 of benazepril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: ticagrelor with relative risk of -10.968 of benazepril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 10: erlotinib with relative risk of -11.283 of benazepril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: delavirdine with relative risk of -11.290 of benazepril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: gabapentin with relative risk of -11.546 of benazepril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: telmisartan with relative risk of -11.674 of benazepril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 14: clarithromycin with relative risk of -11.894 of benazepril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: clonidine with relative risk of -11.931 of benazepril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 16: varenicline with relative risk of -11.975 of benazepril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: rotigotine with relative risk of -12.650 of benazepril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: doxepin with relative risk of -12.858 of benazepril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.073\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target benazeprilat not found. Exiting ...\n",
      "\n",
      "Drug target bendamustine not found. Exiting ...\n",
      "\n",
      "Drug target benzydamine not found. Exiting ...\n",
      "\n",
      "Drug target bepridil not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó betaxolol *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: tizanidine with relative risk of -7.402 of betaxolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: vismodegib with relative risk of -7.899 of betaxolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: bromocriptine with relative risk of -9.700 of betaxolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: nedocromil with relative risk of -13.441 of betaxolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: ophthalmology\n",
      "Rank 5: nedocromil with relative risk of -13.441 of betaxolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: ophthalmology\n",
      "Rank 6: trazodone with relative risk of -18.470 of betaxolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: trazodone with relative risk of -18.470 of betaxolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: trazodone with relative risk of -18.470 of betaxolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: olopatadine with relative risk of -24.945 of betaxolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: ophthalmology\n",
      "Rank 10: olopatadine with relative risk of -24.945 of betaxolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: ophthalmology\n",
      "Rank 11: olopatadine with relative risk of -24.945 of betaxolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: ophthalmology\n",
      "Rank 12: riluzole with relative risk of -30.338 of betaxolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: riluzole with relative risk of -30.338 of betaxolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: riluzole with relative risk of -30.338 of betaxolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: riluzole with relative risk of -30.338 of betaxolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: topiramate with relative risk of -43.976 of betaxolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: topiramate with relative risk of -43.976 of betaxolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: topiramate with relative risk of -43.976 of betaxolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: topiramate with relative risk of -43.976 of betaxolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: topiramate with relative risk of -43.976 of betaxolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: topiramate with relative risk of -43.976 of betaxolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: loperamide with relative risk of -48.591 of betaxolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: loperamide with relative risk of -48.591 of betaxolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: loperamide with relative risk of -48.591 of betaxolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: loperamide with relative risk of -48.591 of betaxolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: loperamide with relative risk of -48.591 of betaxolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: loperamide with relative risk of -48.591 of betaxolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: loperamide with relative risk of -48.591 of betaxolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: quinaprilat with relative risk of -64.351 of betaxolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: quinaprilat with relative risk of -64.351 of betaxolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: quinaprilat with relative risk of -64.351 of betaxolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: quinaprilat with relative risk of -64.351 of betaxolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: quinaprilat with relative risk of -64.351 of betaxolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: quinaprilat with relative risk of -64.351 of betaxolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: quinaprilat with relative risk of -64.351 of betaxolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: quinaprilat with relative risk of -64.351 of betaxolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: efinaconazole with relative risk of -inf of betaxolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: efinaconazole with relative risk of -inf of betaxolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: efinaconazole with relative risk of -inf of betaxolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: efinaconazole with relative risk of -inf of betaxolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: efinaconazole with relative risk of -inf of betaxolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.175\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó bexarotene *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: amiodarone with relative risk of -8.261 of bexarotene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: idarubicin with relative risk of -8.374 of bexarotene | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: hematologic malignancy\n",
      "Rank 3: fluvastatin with relative risk of -9.676 of bexarotene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: sitagliptin with relative risk of -10.623 of bexarotene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: adapalene with relative risk of -10.899 of bexarotene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: liraglutide with relative risk of -10.949 of bexarotene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: buspirone with relative risk of -18.607 of bexarotene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: buspirone with relative risk of -18.607 of bexarotene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: lenalidomide with relative risk of -20.522 of bexarotene | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Multiple Myeloma,hematologic malignancy\n",
      "Rank 10: lenalidomide with relative risk of -20.522 of bexarotene | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Multiple Myeloma,hematologic malignancy\n",
      "Rank 11: lenalidomide with relative risk of -20.522 of bexarotene | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Multiple Myeloma,hematologic malignancy\n",
      "Rank 12: penbutolol with relative risk of -21.705 of bexarotene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: penbutolol with relative risk of -21.705 of bexarotene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: penbutolol with relative risk of -21.705 of bexarotene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: regorafenib with relative risk of -27.409 of bexarotene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: regorafenib with relative risk of -27.409 of bexarotene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: regorafenib with relative risk of -27.409 of bexarotene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.233\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó bezafibrate *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: etoposide with relative risk of -8.636 of bezafibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: regadenoson with relative risk of -8.647 of bezafibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: sertraline with relative risk of -8.999 of bezafibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: mometasone with relative risk of -9.242 of bezafibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: posaconazole with relative risk of -9.679 of bezafibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: irbesartan with relative risk of -9.727 of bezafibrate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 7: azelastine with relative risk of -10.076 of bezafibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: ropivacaine with relative risk of -10.167 of bezafibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: glimepiride with relative risk of -10.259 of bezafibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: naproxen with relative risk of -10.392 of bezafibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: paliperidone with relative risk of -10.454 of bezafibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: tropisetron with relative risk of -10.479 of bezafibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: lurasidone with relative risk of -10.558 of bezafibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: didanosine with relative risk of -10.672 of bezafibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: lansoprazole with relative risk of -11.107 of bezafibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: ibutilide with relative risk of -11.114 of bezafibrate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 17: fenofibrate with relative risk of -11.179 of bezafibrate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypercholesterolemia,Hyperlipidemia\n",
      "Rank 18: ketorolac with relative risk of -11.258 of bezafibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: bumetanide with relative risk of -11.499 of bezafibrate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 20: gabapentin with relative risk of -11.546 of bezafibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: telmisartan with relative risk of -11.674 of bezafibrate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 22: cetirizine with relative risk of -11.869 of bezafibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: dutasteride with relative risk of -12.086 of bezafibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: zolmitriptan with relative risk of -12.304 of bezafibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: citalopram with relative risk of -12.685 of bezafibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: felodipine with relative risk of -inf of bezafibrate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.111\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó bicalutamide *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: idarubicin with relative risk of -8.885 of bicalutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: ivermectin with relative risk of -10.763 of bicalutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: sildenafil with relative risk of -10.962 of bicalutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: letrozole with relative risk of -11.704 of bicalutamide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 5: gemfibrozil with relative risk of -11.760 of bicalutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: maprotiline with relative risk of -11.856 of bicalutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: acamprosate with relative risk of -11.973 of bicalutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: fosinopril with relative risk of -12.020 of bicalutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: scopolamine with relative risk of -12.122 of bicalutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: apremilast with relative risk of -12.659 of bicalutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: naratriptan with relative risk of -12.916 of bicalutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.083\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó bimatoprost *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: clozapine with relative risk of -8.965 of bimatoprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: acitretin with relative risk of -10.105 of bimatoprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: azathioprine with relative risk of -10.194 of bimatoprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: nifedipine with relative risk of -10.211 of bimatoprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: vandetanib with relative risk of -10.242 of bimatoprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: phentolamine with relative risk of -11.199 of bimatoprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: nilutamide with relative risk of -11.672 of bimatoprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: galantamine with relative risk of -12.052 of bimatoprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: calcipotriol with relative risk of -inf of bimatoprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó bisoprolol *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: clofarabine with relative risk of -8.756 of bisoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: paroxetine with relative risk of -9.010 of bisoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: miglustat with relative risk of -9.629 of bisoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: crizotinib with relative risk of -9.682 of bisoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: terbutaline with relative risk of -10.090 of bisoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: ketorolac with relative risk of -10.565 of bisoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: loratadine with relative risk of -10.862 of bisoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: nabumetone with relative risk of -10.997 of bisoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: argatroban with relative risk of -11.101 of bisoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: dronedarone with relative risk of -11.277 of bisoprolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 11: estramustine with relative risk of -11.287 of bisoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: fluconazole with relative risk of -12.035 of bisoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: moxifloxacin with relative risk of -12.121 of bisoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: domperidone with relative risk of -12.842 of bisoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: prasugrel with relative risk of -12.960 of bisoprolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 16: ibandronate with relative risk of -17.251 of bisoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: ibandronate with relative risk of -17.251 of bisoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: pentoxifylline with relative risk of -17.716 of bisoprolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 19: pentoxifylline with relative risk of -17.716 of bisoprolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.077\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target bleomycin not found. Exiting ...\n",
      "\n",
      "Drug target boceprevir not found. Exiting ...\n",
      "\n",
      "Drug target bortezomib not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó bosentan *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: teniposide with relative risk of -10.822 of bosentan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: balsalazide with relative risk of -11.535 of bosentan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: apixaban with relative risk of -13.520 of bosentan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: tegaserod with relative risk of -13.663 of bosentan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó bosutinib *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: regadenoson with relative risk of -8.647 of bosutinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: sertraline with relative risk of -8.999 of bosutinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: mometasone with relative risk of -9.242 of bosutinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: posaconazole with relative risk of -9.679 of bosutinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: irbesartan with relative risk of -9.727 of bosutinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: azelastine with relative risk of -10.076 of bosutinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: tolmetin with relative risk of -10.653 of bosutinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: auranofin with relative risk of -10.700 of bosutinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: progesterone with relative risk of -10.991 of bosutinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: ibutilide with relative risk of -11.114 of bosutinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: milnacipran with relative risk of -11.395 of bosutinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: dantrolene with relative risk of -11.491 of bosutinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: abiraterone with relative risk of -11.500 of bosutinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: telmisartan with relative risk of -11.674 of bosutinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: risedronate with relative risk of -11.781 of bosutinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: lubiprostone with relative risk of -11.887 of bosutinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: clarithromycin with relative risk of -11.894 of bosutinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: estramustine with relative risk of -11.980 of bosutinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: donepezil with relative risk of -12.173 of bosutinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: dapagliflozin with relative risk of -12.537 of bosutinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: misoprostol with relative risk of -12.884 of bosutinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: cisatracurium with relative risk of -14.637 of bosutinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó brimonidine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: lurasidone with relative risk of -9.460 of brimonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: everolimus with relative risk of -9.823 of brimonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: lansoprazole with relative risk of -10.009 of brimonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: clarithromycin with relative risk of -10.796 of brimonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: perindopril with relative risk of -11.340 of brimonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: regadenoson with relative risk of -14.385 of brimonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: regadenoson with relative risk of -14.385 of brimonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: irbesartan with relative risk of -14.814 of brimonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: irbesartan with relative risk of -14.814 of brimonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: posaconazole with relative risk of -15.459 of brimonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: posaconazole with relative risk of -15.459 of brimonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: azelastine with relative risk of -15.600 of brimonidine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: ophthalmology\n",
      "Rank 13: azelastine with relative risk of -15.600 of brimonidine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: ophthalmology\n",
      "Rank 14: ropivacaine with relative risk of -16.927 of brimonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: ropivacaine with relative risk of -16.927 of brimonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: sertraline with relative risk of -21.564 of brimonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: sertraline with relative risk of -21.564 of brimonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: sertraline with relative risk of -21.564 of brimonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: mometasone with relative risk of -22.583 of brimonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: mometasone with relative risk of -22.583 of brimonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: mometasone with relative risk of -22.583 of brimonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: ibutilide with relative risk of -24.670 of brimonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: ibutilide with relative risk of -24.670 of brimonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: ibutilide with relative risk of -24.670 of brimonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: tropisetron with relative risk of -24.754 of brimonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: tropisetron with relative risk of -24.754 of brimonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: tropisetron with relative risk of -24.754 of brimonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: paliperidone with relative risk of -24.840 of brimonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: paliperidone with relative risk of -24.840 of brimonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: paliperidone with relative risk of -24.840 of brimonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: glimepiride with relative risk of -24.888 of brimonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: glimepiride with relative risk of -24.888 of brimonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: glimepiride with relative risk of -24.888 of brimonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: pentoxifylline with relative risk of -24.938 of brimonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: pentoxifylline with relative risk of -24.938 of brimonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: pentoxifylline with relative risk of -24.938 of brimonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: darifenacin with relative risk of -25.563 of brimonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: darifenacin with relative risk of -25.563 of brimonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: darifenacin with relative risk of -25.563 of brimonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: terbutaline with relative risk of -26.867 of brimonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: terbutaline with relative risk of -26.867 of brimonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: terbutaline with relative risk of -26.867 of brimonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: esmolol with relative risk of -27.830 of brimonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: esmolol with relative risk of -27.830 of brimonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: esmolol with relative risk of -27.830 of brimonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: azilsartan with relative risk of -29.289 of brimonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: azilsartan with relative risk of -29.289 of brimonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: azilsartan with relative risk of -29.289 of brimonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: tazarotene with relative risk of -31.093 of brimonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: tazarotene with relative risk of -31.093 of brimonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: tazarotene with relative risk of -31.093 of brimonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: dapsone with relative risk of -31.353 of brimonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 53: dapsone with relative risk of -31.353 of brimonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 54: dapsone with relative risk of -31.353 of brimonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 55: isradipine with relative risk of -32.098 of brimonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 56: isradipine with relative risk of -32.098 of brimonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 57: isradipine with relative risk of -32.098 of brimonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 58: felodipine with relative risk of -inf of brimonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 59: felodipine with relative risk of -inf of brimonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 60: felodipine with relative risk of -inf of brimonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.034\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó brinzolamide *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: ropivacaine with relative risk of -9.070 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: levonorgestrel with relative risk of -9.178 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: penbutolol with relative risk of -9.428 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: lurasidone with relative risk of -9.460 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: lansoprazole with relative risk of -10.009 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: trovafloxacin with relative risk of -10.586 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: didanosine with relative risk of -18.019 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: didanosine with relative risk of -18.019 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: sertraline with relative risk of -21.564 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: sertraline with relative risk of -21.564 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: sertraline with relative risk of -21.564 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: irbesartan with relative risk of -22.116 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: irbesartan with relative risk of -22.116 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: irbesartan with relative risk of -22.116 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: regadenoson with relative risk of -22.359 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: regadenoson with relative risk of -22.359 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: regadenoson with relative risk of -22.359 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: mometasone with relative risk of -22.583 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: mometasone with relative risk of -22.583 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: mometasone with relative risk of -22.583 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: azelastine with relative risk of -23.351 of brinzolamide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: ophthalmology\n",
      "Rank 22: azelastine with relative risk of -23.351 of brinzolamide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: ophthalmology\n",
      "Rank 23: azelastine with relative risk of -23.351 of brinzolamide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: ophthalmology\n",
      "Rank 24: posaconazole with relative risk of -23.476 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: posaconazole with relative risk of -23.476 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: posaconazole with relative risk of -23.476 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: etoposide with relative risk of -23.696 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: etoposide with relative risk of -23.696 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: etoposide with relative risk of -23.696 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: ibutilide with relative risk of -24.670 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: ibutilide with relative risk of -24.670 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: ibutilide with relative risk of -24.670 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: tropisetron with relative risk of -24.754 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: tropisetron with relative risk of -24.754 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: tropisetron with relative risk of -24.754 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: paliperidone with relative risk of -24.840 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: paliperidone with relative risk of -24.840 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: paliperidone with relative risk of -24.840 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: glimepiride with relative risk of -24.888 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: glimepiride with relative risk of -24.888 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: glimepiride with relative risk of -24.888 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: pentoxifylline with relative risk of -24.938 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: pentoxifylline with relative risk of -24.938 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: pentoxifylline with relative risk of -24.938 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: fenofibrate with relative risk of -26.239 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: fenofibrate with relative risk of -26.239 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: fenofibrate with relative risk of -26.239 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: terbutaline with relative risk of -26.867 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: terbutaline with relative risk of -26.867 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: terbutaline with relative risk of -26.867 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: esmolol with relative risk of -27.830 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: esmolol with relative risk of -27.830 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 53: esmolol with relative risk of -27.830 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 54: ivacaftor with relative risk of -29.119 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 55: ivacaftor with relative risk of -29.119 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 56: ivacaftor with relative risk of -29.119 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 57: everolimus with relative risk of -29.240 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 58: everolimus with relative risk of -29.240 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 59: everolimus with relative risk of -29.240 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 60: azilsartan with relative risk of -29.289 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 61: azilsartan with relative risk of -29.289 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 62: azilsartan with relative risk of -29.289 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 63: zolmitriptan with relative risk of -29.929 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 64: zolmitriptan with relative risk of -29.929 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 65: zolmitriptan with relative risk of -29.929 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 66: acebutolol with relative risk of -31.973 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 67: acebutolol with relative risk of -31.973 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 68: acebutolol with relative risk of -31.973 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 69: valsartan with relative risk of -32.117 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 70: valsartan with relative risk of -32.117 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 71: valsartan with relative risk of -32.117 of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 72: felodipine with relative risk of -inf of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 73: felodipine with relative risk of -inf of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 74: felodipine with relative risk of -inf of brinzolamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.028\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target bromazepam not found. Exiting ...\n",
      "\n",
      "Drug target bromcresol not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó bromfenac *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó bromocriptine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: verapamil with relative risk of -10.080 of bromocriptine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: topiramate with relative risk of -10.154 of bromocriptine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: betaxolol with relative risk of -10.206 of bromocriptine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: quinaprilat with relative risk of -11.587 of bromocriptine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: nedocromil with relative risk of -17.625 of bromocriptine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: nedocromil with relative risk of -17.625 of bromocriptine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: loperamide with relative risk of -18.158 of bromocriptine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: loperamide with relative risk of -18.158 of bromocriptine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: riluzole with relative risk of -19.832 of bromocriptine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: riluzole with relative risk of -19.832 of bromocriptine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: efinaconazole with relative risk of -inf of bromocriptine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: efinaconazole with relative risk of -inf of bromocriptine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.347\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó budesonide *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: irbesartan with relative risk of -9.727 of budesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: azelastine with relative risk of -10.076 of budesonide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic rhinitis (disorder)\n",
      "Rank 3: pentoxifylline with relative risk of -10.551 of budesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: ribavirin with relative risk of -10.974 of budesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: bumetanide with relative risk of -11.499 of budesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: loratadine with relative risk of -11.555 of budesonide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic rhinitis (disorder)\n",
      "Rank 7: argatroban with relative risk of -11.794 of budesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: nevirapine with relative risk of -11.850 of budesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: lapatinib with relative risk of -11.918 of budesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: afatinib with relative risk of -11.974 of budesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: losartan with relative risk of -12.317 of budesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: celecoxib with relative risk of -12.360 of budesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: perindopril with relative risk of -12.439 of budesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: beclomethasone with relative risk of -12.638 of budesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: temsirolimus with relative risk of -13.036 of budesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: amisulpride with relative risk of -13.075 of budesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: latanoprost with relative risk of -13.172 of budesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: pergolide with relative risk of -13.517 of budesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: domperidone with relative risk of -13.535 of budesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: lidocaine with relative risk of -13.720 of budesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: felodipine with relative risk of -inf of budesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.183\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó bumetanide *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: metoprolol with relative risk of -8.592 of bumetanide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 2: levonorgestrel with relative risk of -8.668 of bumetanide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: ruxolitinib with relative risk of -8.903 of bumetanide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: pentoxifylline with relative risk of -8.945 of bumetanide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 5: milrinone with relative risk of -9.015 of bumetanide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 6: indomethacin with relative risk of -9.646 of bumetanide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: gabapentin with relative risk of -9.937 of bumetanide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: loratadine with relative risk of -9.947 of bumetanide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: telmisartan with relative risk of -10.066 of bumetanide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 10: trovafloxacin with relative risk of -10.076 of bumetanide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: tamsulosin with relative risk of -10.341 of bumetanide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: afatinib with relative risk of -10.364 of bumetanide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: varenicline with relative risk of -10.366 of bumetanide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: bezafibrate with relative risk of -10.648 of bumetanide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 15: quinidine with relative risk of -10.654 of bumetanide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 16: zolmitriptan with relative risk of -10.695 of bumetanide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: fondaparinux with relative risk of -10.932 of bumetanide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: beclomethasone with relative risk of -11.029 of bumetanide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: sumatriptan with relative risk of -11.052 of bumetanide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: citalopram with relative risk of -11.075 of bumetanide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: budesonide with relative risk of -11.396 of bumetanide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: pergolide with relative risk of -11.908 of bumetanide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: aclidinium with relative risk of -11.953 of bumetanide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: caffeine with relative risk of -12.449 of bumetanide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: regadenoson with relative risk of -13.183 of bumetanide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: regadenoson with relative risk of -13.183 of bumetanide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: bromfenac with relative risk of -14.080 of bumetanide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: posaconazole with relative risk of -14.257 of bumetanide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: posaconazole with relative risk of -14.257 of bumetanide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: tropisetron with relative risk of -15.289 of bumetanide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: tropisetron with relative risk of -15.289 of bumetanide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: ibutilide with relative risk of -15.574 of bumetanide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 33: ibutilide with relative risk of -15.574 of bumetanide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 34: ropivacaine with relative risk of -15.724 of bumetanide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: ropivacaine with relative risk of -15.724 of bumetanide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: naproxen with relative risk of -16.353 of bumetanide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: naproxen with relative risk of -16.353 of bumetanide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: pemetrexed with relative risk of -16.432 of bumetanide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: pemetrexed with relative risk of -16.432 of bumetanide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: lansoprazole with relative risk of -16.558 of bumetanide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: lansoprazole with relative risk of -16.558 of bumetanide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: ketorolac with relative risk of -16.614 of bumetanide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: ketorolac with relative risk of -16.614 of bumetanide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: didanosine with relative risk of -16.815 of bumetanide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: didanosine with relative risk of -16.815 of bumetanide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: dutasteride with relative risk of -18.047 of bumetanide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: dutasteride with relative risk of -18.047 of bumetanide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: argatroban with relative risk of -18.448 of bumetanide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: argatroban with relative risk of -18.448 of bumetanide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: cetirizine with relative risk of -18.523 of bumetanide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: cetirizine with relative risk of -18.523 of bumetanide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: ribavirin with relative risk of -18.727 of bumetanide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 53: ribavirin with relative risk of -18.727 of bumetanide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 54: sertraline with relative risk of -19.265 of bumetanide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 55: sertraline with relative risk of -19.265 of bumetanide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 56: sertraline with relative risk of -19.265 of bumetanide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 57: celecoxib with relative risk of -19.420 of bumetanide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 58: celecoxib with relative risk of -19.420 of bumetanide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 59: perindopril with relative risk of -19.498 of bumetanide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 60: perindopril with relative risk of -19.498 of bumetanide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 61: lapatinib with relative risk of -19.671 of bumetanide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 62: lapatinib with relative risk of -19.671 of bumetanide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 63: losartan with relative risk of -20.069 of bumetanide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 64: losartan with relative risk of -20.069 of bumetanide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 65: amisulpride with relative risk of -20.134 of bumetanide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 66: amisulpride with relative risk of -20.134 of bumetanide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 67: latanoprost with relative risk of -20.231 of bumetanide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 68: latanoprost with relative risk of -20.231 of bumetanide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 69: mometasone with relative risk of -20.283 of bumetanide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 70: mometasone with relative risk of -20.283 of bumetanide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 71: mometasone with relative risk of -20.283 of bumetanide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 72: domperidone with relative risk of -20.594 of bumetanide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 73: domperidone with relative risk of -20.594 of bumetanide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 74: temsirolimus with relative risk of -20.789 of bumetanide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 75: temsirolimus with relative risk of -20.789 of bumetanide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 76: azelastine with relative risk of -21.051 of bumetanide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 77: azelastine with relative risk of -21.051 of bumetanide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 78: azelastine with relative risk of -21.051 of bumetanide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 79: etoposide with relative risk of -21.394 of bumetanide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 80: etoposide with relative risk of -21.394 of bumetanide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 81: etoposide with relative risk of -21.394 of bumetanide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 82: lidocaine with relative risk of -21.472 of bumetanide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 83: lidocaine with relative risk of -21.472 of bumetanide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 84: paliperidone with relative risk of -22.539 of bumetanide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 85: paliperidone with relative risk of -22.539 of bumetanide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 86: paliperidone with relative risk of -22.539 of bumetanide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 87: glimepiride with relative risk of -22.587 of bumetanide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 88: glimepiride with relative risk of -22.587 of bumetanide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 89: glimepiride with relative risk of -22.587 of bumetanide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 90: fenofibrate with relative risk of -23.937 of bumetanide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 91: fenofibrate with relative risk of -23.937 of bumetanide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 92: fenofibrate with relative risk of -23.937 of bumetanide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 93: lurasidone with relative risk of -24.628 of bumetanide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 94: lurasidone with relative risk of -24.628 of bumetanide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 95: lurasidone with relative risk of -24.628 of bumetanide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 96: nevirapine with relative risk of -27.866 of bumetanide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 97: nevirapine with relative risk of -27.866 of bumetanide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 98: nevirapine with relative risk of -27.866 of bumetanide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 99: irbesartan with relative risk of -34.590 of bumetanide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 100: irbesartan with relative risk of -34.590 of bumetanide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 101: irbesartan with relative risk of -34.590 of bumetanide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 102: irbesartan with relative risk of -34.590 of bumetanide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 103: irbesartan with relative risk of -34.590 of bumetanide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 104: felodipine with relative risk of -inf of bumetanide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 105: felodipine with relative risk of -inf of bumetanide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 106: felodipine with relative risk of -inf of bumetanide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 107: felodipine with relative risk of -inf of bumetanide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 108: felodipine with relative risk of -inf of bumetanide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.365\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó bupivacaine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: cilostazol with relative risk of -11.956 of bupivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: empagliflozin with relative risk of -12.043 of bupivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: pilocarpine with relative risk of -12.698 of bupivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: raloxifene with relative risk of -12.755 of bupivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: medroxyprogesterone with relative risk of -12.814 of bupivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: pantoprazole with relative risk of -12.828 of bupivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: omeprazole with relative risk of -13.465 of bupivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target buprenorphine not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó bupropion *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: pramipexole with relative risk of -11.929 of bupropion | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: docetaxel with relative risk of -12.046 of bupropion | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: etodolac with relative risk of -12.358 of bupropion | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: metaproterenol with relative risk of -12.759 of bupropion | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: duloxetine with relative risk of -12.992 of bupropion | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Major Depressive Disorder,neurology/psychiatry\n",
      "Rank 6: repaglinide with relative risk of -13.133 of bupropion | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: dalbavancin with relative risk of -13.460 of bupropion | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: trospium with relative risk of -13.502 of bupropion | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: amlodipine with relative risk of -13.806 of bupropion | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.424\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó buspirone *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: idarubicin with relative risk of -8.374 of buspirone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: nimodipine with relative risk of -9.896 of buspirone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: avanafil with relative risk of -10.621 of buspirone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: almotriptan with relative risk of -11.781 of buspirone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 5: bexarotene with relative risk of -16.672 of buspirone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: bexarotene with relative risk of -16.672 of buspirone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.102\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target busulfan not found. Exiting ...\n",
      "\n",
      "Drug target butorphanol not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó cabazitaxel *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: clozapine with relative risk of -8.455 of cabazitaxel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: teniposide with relative risk of -9.213 of cabazitaxel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: mitotane with relative risk of -9.372 of cabazitaxel | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 4: danazol with relative risk of -10.118 of cabazitaxel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: saquinavir with relative risk of -10.466 of cabazitaxel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: canagliflozin with relative risk of -11.007 of cabazitaxel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: gonadorelin with relative risk of -11.024 of cabazitaxel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: phenytoin with relative risk of -11.297 of cabazitaxel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: montelukast with relative risk of -11.391 of cabazitaxel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: dipyridamole with relative risk of -11.658 of cabazitaxel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: mexiletine with relative risk of -11.738 of cabazitaxel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: ranitidine with relative risk of -11.836 of cabazitaxel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: zafirlukast with relative risk of -11.910 of cabazitaxel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: cilazapril with relative risk of -13.715 of cabazitaxel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.103\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó cabergoline *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: trazodone with relative risk of -10.142 of cabergoline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: indacaterol with relative risk of -11.453 of cabergoline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: tafluprost with relative risk of -12.822 of cabergoline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: exenatide with relative risk of -13.011 of cabergoline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 5: lovastatin with relative risk of -13.019 of cabergoline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.197\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó cabozantinib *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: vandetanib with relative risk of -11.340 of cabozantinib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 2: danazol with relative risk of -11.727 of cabozantinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: sildenafil with relative risk of -12.060 of cabozantinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: ciprofloxacin with relative risk of -13.032 of cabozantinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.48\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó caffeine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: irbesartan with relative risk of -9.727 of caffeine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: ribavirin with relative risk of -10.974 of caffeine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: bumetanide with relative risk of -11.499 of caffeine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: argatroban with relative risk of -11.794 of caffeine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: nevirapine with relative risk of -11.850 of caffeine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: lapatinib with relative risk of -11.918 of caffeine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: quinidine with relative risk of -12.264 of caffeine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: losartan with relative risk of -12.317 of caffeine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: celecoxib with relative risk of -12.360 of caffeine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Dysmenorrhea\n",
      "Rank 10: perindopril with relative risk of -12.439 of caffeine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: temsirolimus with relative risk of -13.036 of caffeine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: amisulpride with relative risk of -13.075 of caffeine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: latanoprost with relative risk of -13.172 of caffeine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: domperidone with relative risk of -13.535 of caffeine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: aclidinium with relative risk of -13.563 of caffeine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: lidocaine with relative risk of -13.720 of caffeine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 17: bromfenac with relative risk of -15.690 of caffeine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Pain\n",
      "Rank 18: felodipine with relative risk of -inf of caffeine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.09\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó calcipotriol *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: clozapine with relative risk of -10.063 of calcipotriol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: bimatoprost with relative risk of -11.054 of calcipotriol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: acitretin with relative risk of -11.204 of calcipotriol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Psoriasis,dermatology\n",
      "Rank 4: azathioprine with relative risk of -11.291 of calcipotriol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: nifedipine with relative risk of -11.310 of calcipotriol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: vandetanib with relative risk of -11.340 of calcipotriol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: phentolamine with relative risk of -12.297 of calcipotriol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: nilutamide with relative risk of -12.771 of calcipotriol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.123\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target calcium not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó canagliflozin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: cabazitaxel with relative risk of -9.483 of canagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: danazol with relative risk of -10.628 of canagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: gonadorelin with relative risk of -11.534 of canagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: phenytoin with relative risk of -11.808 of canagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: ketoconazole with relative risk of -11.863 of canagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: montelukast with relative risk of -11.901 of canagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: mexiletine with relative risk of -12.249 of canagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: ranitidine with relative risk of -12.347 of canagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: zafirlukast with relative risk of -12.421 of canagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: cilazapril with relative risk of -14.225 of canagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: mitotane with relative risk of -19.938 of canagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: mitotane with relative risk of -19.938 of canagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: dipyridamole with relative risk of -22.223 of canagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: dipyridamole with relative risk of -22.223 of canagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó candesartan *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: ibandronate with relative risk of -8.808 of candesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: cytarabine with relative risk of -9.353 of candesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: formoterol with relative risk of -9.630 of candesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: frovatriptan with relative risk of -9.792 of candesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: nimodipine with relative risk of -10.119 of candesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: cilostazol with relative risk of -10.570 of candesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 7: allopurinol with relative risk of -10.638 of candesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: avanafil with relative risk of -10.844 of candesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: hydrochlorothiazide with relative risk of -12.121 of candesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,Chronic heart failure,cardiology\n",
      "Rank 10: tasimelteon with relative risk of -19.378 of candesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: tasimelteon with relative risk of -19.378 of candesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: mafenide with relative risk of -30.201 of candesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: mafenide with relative risk of -30.201 of candesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: mafenide with relative risk of -30.201 of candesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: atomoxetine with relative risk of -40.093 of candesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: atomoxetine with relative risk of -40.093 of candesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: atomoxetine with relative risk of -40.093 of candesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: atomoxetine with relative risk of -40.093 of candesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.079\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó capecitabine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: sertraline with relative risk of -8.308 of capecitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: nevirapine with relative risk of -11.157 of capecitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: regadenoson with relative risk of -15.483 of capecitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: regadenoson with relative risk of -15.483 of capecitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: mometasone with relative risk of -15.895 of capecitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: mometasone with relative risk of -15.895 of capecitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: irbesartan with relative risk of -15.911 of capecitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: irbesartan with relative risk of -15.911 of capecitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: etoposide with relative risk of -16.126 of capecitabine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 10: etoposide with relative risk of -16.126 of capecitabine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 11: posaconazole with relative risk of -16.556 of capecitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: posaconazole with relative risk of -16.556 of capecitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: azelastine with relative risk of -16.697 of capecitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: azelastine with relative risk of -16.697 of capecitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: glimepiride with relative risk of -17.542 of capecitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: glimepiride with relative risk of -17.542 of capecitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: tropisetron with relative risk of -17.589 of capecitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: tropisetron with relative risk of -17.589 of capecitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: paliperidone with relative risk of -17.618 of capecitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: paliperidone with relative risk of -17.618 of capecitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: ibutilide with relative risk of -17.873 of capecitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: ibutilide with relative risk of -17.873 of capecitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: fenofibrate with relative risk of -18.669 of capecitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: fenofibrate with relative risk of -18.669 of capecitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: pemetrexed with relative risk of -18.734 of capecitabine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 26: pemetrexed with relative risk of -18.734 of capecitabine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 27: metoprolol with relative risk of -18.870 of capecitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: metoprolol with relative risk of -18.870 of capecitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: milrinone with relative risk of -19.292 of capecitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: milrinone with relative risk of -19.292 of capecitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: indomethacin with relative risk of -19.363 of capecitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: indomethacin with relative risk of -19.363 of capecitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: trovafloxacin with relative risk of -19.793 of capecitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: trovafloxacin with relative risk of -19.793 of capecitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: dutasteride with relative risk of -20.349 of capecitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: dutasteride with relative risk of -20.349 of capecitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: tamsulosin with relative risk of -20.618 of capecitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: tamsulosin with relative risk of -20.618 of capecitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: fondaparinux with relative risk of -21.902 of capecitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: fondaparinux with relative risk of -21.902 of capecitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: felodipine with relative risk of -inf of capecitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: felodipine with relative risk of -inf of capecitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.067\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó capsaicin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: aminophylline with relative risk of -8.831 of capsaicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: entacapone with relative risk of -11.614 of capsaicin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: ipratropium with relative risk of -11.881 of capsaicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: silodosin with relative risk of -12.126 of capsaicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: nefazodone with relative risk of -12.399 of capsaicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: clopidogrel with relative risk of -12.697 of capsaicin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: formoterol with relative risk of -18.768 of capsaicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: formoterol with relative risk of -18.768 of capsaicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: frovatriptan with relative risk of -18.930 of capsaicin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: frovatriptan with relative risk of -18.930 of capsaicin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: nimodipine with relative risk of -19.480 of capsaicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: nimodipine with relative risk of -19.480 of capsaicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: cytarabine with relative risk of -19.695 of capsaicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: cytarabine with relative risk of -19.695 of capsaicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: paclitaxel with relative risk of -20.985 of capsaicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: paclitaxel with relative risk of -20.985 of capsaicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: rasagiline with relative risk of -21.853 of capsaicin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 18: rasagiline with relative risk of -21.853 of capsaicin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 19: rivastigmine with relative risk of -22.666 of capsaicin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 20: rivastigmine with relative risk of -22.666 of capsaicin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 21: sotalol with relative risk of -22.691 of capsaicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: sotalol with relative risk of -22.691 of capsaicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: rofecoxib with relative risk of -22.741 of capsaicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: rofecoxib with relative risk of -22.741 of capsaicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: pimozide with relative risk of -22.814 of capsaicin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 26: pimozide with relative risk of -22.814 of capsaicin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 27: fosinoprilat with relative risk of -25.547 of capsaicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: fosinoprilat with relative risk of -25.547 of capsaicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.299\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó captopril *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: nifedipine with relative risk of -8.269 of captopril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 2: nabumetone with relative risk of -8.657 of captopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: danazol with relative risk of -8.685 of captopril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 4: dabigatran with relative risk of -8.885 of captopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: phentolamine with relative risk of -9.255 of captopril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology,cardiology\n",
      "Rank 6: cyclobenzaprine with relative risk of -9.428 of captopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: exenatide with relative risk of -9.968 of captopril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 8: conivaptan with relative risk of -9.979 of captopril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 9: fosinopril with relative risk of -10.077 of captopril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Chronic heart failure,Hypertensive disease,cardiology\n",
      "Rank 10: iloperidone with relative risk of -15.795 of captopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: iloperidone with relative risk of -15.795 of captopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: anagrelide with relative risk of -16.563 of captopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: anagrelide with relative risk of -16.563 of captopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: albendazole with relative risk of -24.553 of captopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: albendazole with relative risk of -24.553 of captopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: albendazole with relative risk of -24.553 of captopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: telithromycin with relative risk of -118.863 of captopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: telithromycin with relative risk of -118.863 of captopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: telithromycin with relative risk of -118.863 of captopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: telithromycin with relative risk of -118.863 of captopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: telithromycin with relative risk of -118.863 of captopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: telithromycin with relative risk of -118.863 of captopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: telithromycin with relative risk of -118.863 of captopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: telithromycin with relative risk of -118.863 of captopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: telithromycin with relative risk of -118.863 of captopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: telithromycin with relative risk of -118.863 of captopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: telithromycin with relative risk of -118.863 of captopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: telithromycin with relative risk of -118.863 of captopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: telithromycin with relative risk of -118.863 of captopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: telithromycin with relative risk of -118.863 of captopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: telithromycin with relative risk of -118.863 of captopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: telithromycin with relative risk of -118.863 of captopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: treprostinil with relative risk of -122.319 of captopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: treprostinil with relative risk of -122.319 of captopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: treprostinil with relative risk of -122.319 of captopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: treprostinil with relative risk of -122.319 of captopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: treprostinil with relative risk of -122.319 of captopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: treprostinil with relative risk of -122.319 of captopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: treprostinil with relative risk of -122.319 of captopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: treprostinil with relative risk of -122.319 of captopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: treprostinil with relative risk of -122.319 of captopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: treprostinil with relative risk of -122.319 of captopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: treprostinil with relative risk of -122.319 of captopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: treprostinil with relative risk of -122.319 of captopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: treprostinil with relative risk of -122.319 of captopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: treprostinil with relative risk of -122.319 of captopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: treprostinil with relative risk of -122.319 of captopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: treprostinil with relative risk of -122.319 of captopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: cetrorelix with relative risk of -123.462 of captopril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 50: cetrorelix with relative risk of -123.462 of captopril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 51: cetrorelix with relative risk of -123.462 of captopril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 52: cetrorelix with relative risk of -123.462 of captopril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 53: cetrorelix with relative risk of -123.462 of captopril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 54: cetrorelix with relative risk of -123.462 of captopril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 55: cetrorelix with relative risk of -123.462 of captopril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 56: cetrorelix with relative risk of -123.462 of captopril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 57: cetrorelix with relative risk of -123.462 of captopril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 58: cetrorelix with relative risk of -123.462 of captopril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 59: cetrorelix with relative risk of -123.462 of captopril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 60: cetrorelix with relative risk of -123.462 of captopril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 61: cetrorelix with relative risk of -123.462 of captopril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 62: cetrorelix with relative risk of -123.462 of captopril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 63: cetrorelix with relative risk of -123.462 of captopril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 64: cetrorelix with relative risk of -123.462 of captopril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 65: atorvastatin with relative risk of -166.043 of captopril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 66: atorvastatin with relative risk of -166.043 of captopril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 67: atorvastatin with relative risk of -166.043 of captopril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 68: atorvastatin with relative risk of -166.043 of captopril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 69: atorvastatin with relative risk of -166.043 of captopril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 70: atorvastatin with relative risk of -166.043 of captopril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 71: atorvastatin with relative risk of -166.043 of captopril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 72: atorvastatin with relative risk of -166.043 of captopril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 73: atorvastatin with relative risk of -166.043 of captopril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 74: atorvastatin with relative risk of -166.043 of captopril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 75: atorvastatin with relative risk of -166.043 of captopril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 76: atorvastatin with relative risk of -166.043 of captopril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 77: atorvastatin with relative risk of -166.043 of captopril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 78: atorvastatin with relative risk of -166.043 of captopril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 79: atorvastatin with relative risk of -166.043 of captopril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 80: atorvastatin with relative risk of -166.043 of captopril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 81: atorvastatin with relative risk of -166.043 of captopril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 82: atorvastatin with relative risk of -166.043 of captopril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 83: atorvastatin with relative risk of -166.043 of captopril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 84: atorvastatin with relative risk of -166.043 of captopril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 85: atorvastatin with relative risk of -166.043 of captopril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.493\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó carbamazepine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: regadenoson with relative risk of -7.550 of carbamazepine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: sertraline with relative risk of -7.905 of carbamazepine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: mometasone with relative risk of -8.146 of carbamazepine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: posaconazole with relative risk of -8.583 of carbamazepine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: irbesartan with relative risk of -8.633 of carbamazepine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: ciclesonide with relative risk of -8.907 of carbamazepine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: azelastine with relative risk of -8.980 of carbamazepine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: crizotinib with relative risk of -9.277 of carbamazepine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: clomipramine with relative risk of -9.657 of carbamazepine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: sunitinib with relative risk of -9.947 of carbamazepine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: ibutilide with relative risk of -10.018 of carbamazepine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: asenapine with relative risk of -10.525 of carbamazepine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Mixed bipolar I disorder,Bipolar affective disorder, current episode manic,neurology/psychiatry\n",
      "Rank 13: amsacrine with relative risk of -10.531 of carbamazepine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: dofetilide with relative risk of -10.740 of carbamazepine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: sulfasalazine with relative risk of -10.810 of carbamazepine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: ramelteon with relative risk of -10.932 of carbamazepine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 17: tolvaptan with relative risk of -11.872 of carbamazepine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: ambrisentan with relative risk of -11.889 of carbamazepine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: cimetidine with relative risk of -13.211 of carbamazepine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: desoximetasone with relative risk of -inf of carbamazepine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.21\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target carbidopa not found. Exiting ...\n",
      "\n",
      "Drug target carboplatin not found. Exiting ...\n",
      "\n",
      "Drug target carisoprodol not found. Exiting ...\n",
      "\n",
      "Drug target carnitine not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó carvedilol *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: tamoxifen with relative risk of -10.384 of carvedilol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: mitoxantrone with relative risk of -10.473 of carvedilol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: raltitrexed with relative risk of -10.637 of carvedilol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: glipizide with relative risk of -11.479 of carvedilol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: rosuvastatin with relative risk of -11.778 of carvedilol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 6: dexrazoxane with relative risk of -18.409 of carvedilol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 7: dexrazoxane with relative risk of -18.409 of carvedilol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.197\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target cefaclor not found. Exiting ...\n",
      "\n",
      "Drug target cefepime not found. Exiting ...\n",
      "\n",
      "Drug target cefixime not found. Exiting ...\n",
      "\n",
      "Drug target cefotaxime not found. Exiting ...\n",
      "\n",
      "Drug target cefprozil not found. Exiting ...\n",
      "\n",
      "Drug target ceftaroline not found. Exiting ...\n",
      "\n",
      "Drug target ceftazidime not found. Exiting ...\n",
      "\n",
      "Drug target ceftobiprole not found. Exiting ...\n",
      "\n",
      "Drug target ceftriaxone not found. Exiting ...\n",
      "\n",
      "Drug target cefuroxime not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó celecoxib *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: azelastine with relative risk of -8.980 of celecoxib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: pentoxifylline with relative risk of -9.454 of celecoxib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: loratadine with relative risk of -10.457 of celecoxib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: afatinib with relative risk of -10.875 of celecoxib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: quinidine with relative risk of -11.165 of celecoxib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: beclomethasone with relative risk of -11.539 of celecoxib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: budesonide with relative risk of -11.907 of celecoxib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: pergolide with relative risk of -12.419 of celecoxib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: aclidinium with relative risk of -12.464 of celecoxib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: caffeine with relative risk of -12.960 of celecoxib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Dysmenorrhea\n",
      "Rank 11: bromfenac with relative risk of -14.591 of celecoxib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: bumetanide with relative risk of -19.069 of celecoxib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: bumetanide with relative risk of -19.069 of celecoxib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: argatroban with relative risk of -19.652 of celecoxib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: argatroban with relative risk of -19.652 of celecoxib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: nevirapine with relative risk of -19.708 of celecoxib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: nevirapine with relative risk of -19.708 of celecoxib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: ribavirin with relative risk of -19.931 of celecoxib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: ribavirin with relative risk of -19.931 of celecoxib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: perindopril with relative risk of -20.702 of celecoxib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: perindopril with relative risk of -20.702 of celecoxib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: lapatinib with relative risk of -20.875 of celecoxib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: lapatinib with relative risk of -20.875 of celecoxib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: losartan with relative risk of -21.273 of celecoxib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: losartan with relative risk of -21.273 of celecoxib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: domperidone with relative risk of -21.798 of celecoxib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: domperidone with relative risk of -21.798 of celecoxib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: temsirolimus with relative risk of -21.993 of celecoxib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: temsirolimus with relative risk of -21.993 of celecoxib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: irbesartan with relative risk of -22.116 of celecoxib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: irbesartan with relative risk of -22.116 of celecoxib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: irbesartan with relative risk of -22.116 of celecoxib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: lidocaine with relative risk of -22.676 of celecoxib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: lidocaine with relative risk of -22.676 of celecoxib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: amisulpride with relative risk of -32.492 of celecoxib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: amisulpride with relative risk of -32.492 of celecoxib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: amisulpride with relative risk of -32.492 of celecoxib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: latanoprost with relative risk of -32.588 of celecoxib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: latanoprost with relative risk of -32.588 of celecoxib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: latanoprost with relative risk of -32.588 of celecoxib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: felodipine with relative risk of -inf of celecoxib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: felodipine with relative risk of -inf of celecoxib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.023\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target cerivastatin not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó cetirizine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: pemetrexed with relative risk of -9.085 of cetirizine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: ruxolitinib with relative risk of -9.126 of cetirizine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: didanosine with relative risk of -9.286 of cetirizine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: lansoprazole with relative risk of -9.722 of cetirizine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: ketorolac with relative risk of -9.873 of cetirizine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic Conjunctivitis\n",
      "Rank 6: asenapine with relative risk of -10.238 of cetirizine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: telmisartan with relative risk of -10.289 of cetirizine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: trovafloxacin with relative risk of -10.299 of cetirizine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: varenicline with relative risk of -10.589 of cetirizine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: dutasteride with relative risk of -10.701 of cetirizine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: bezafibrate with relative risk of -10.871 of cetirizine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: citalopram with relative risk of -11.298 of cetirizine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: regadenoson with relative risk of -13.693 of cetirizine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: regadenoson with relative risk of -13.693 of cetirizine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: posaconazole with relative risk of -14.766 of cetirizine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: posaconazole with relative risk of -14.766 of cetirizine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: azelastine with relative risk of -14.908 of cetirizine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic rhinitis (disorder),Allergic Conjunctivitis,Rhinitis, Vasomotor,Hay fever\n",
      "Rank 18: azelastine with relative risk of -14.908 of cetirizine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic rhinitis (disorder),Allergic Conjunctivitis,Rhinitis, Vasomotor,Hay fever\n",
      "Rank 19: tropisetron with relative risk of -15.799 of cetirizine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: tropisetron with relative risk of -15.799 of cetirizine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: ibutilide with relative risk of -16.084 of cetirizine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: ibutilide with relative risk of -16.084 of cetirizine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: ropivacaine with relative risk of -16.234 of cetirizine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: ropivacaine with relative risk of -16.234 of cetirizine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: gabapentin with relative risk of -18.200 of cetirizine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: gabapentin with relative risk of -18.200 of cetirizine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: bumetanide with relative risk of -18.376 of cetirizine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: bumetanide with relative risk of -18.376 of cetirizine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: zolmitriptan with relative risk of -19.181 of cetirizine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: zolmitriptan with relative risk of -19.181 of cetirizine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: sertraline with relative risk of -20.179 of cetirizine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: sertraline with relative risk of -20.179 of cetirizine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: sertraline with relative risk of -20.179 of cetirizine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: irbesartan with relative risk of -20.731 of cetirizine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: irbesartan with relative risk of -20.731 of cetirizine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: irbesartan with relative risk of -20.731 of cetirizine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: mometasone with relative risk of -21.198 of cetirizine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic rhinitis (disorder)\n",
      "Rank 38: mometasone with relative risk of -21.198 of cetirizine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic rhinitis (disorder)\n",
      "Rank 39: mometasone with relative risk of -21.198 of cetirizine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic rhinitis (disorder)\n",
      "Rank 40: etoposide with relative risk of -22.310 of cetirizine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: etoposide with relative risk of -22.310 of cetirizine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: etoposide with relative risk of -22.310 of cetirizine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: paliperidone with relative risk of -23.454 of cetirizine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: paliperidone with relative risk of -23.454 of cetirizine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: paliperidone with relative risk of -23.454 of cetirizine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: glimepiride with relative risk of -23.503 of cetirizine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: glimepiride with relative risk of -23.503 of cetirizine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: glimepiride with relative risk of -23.503 of cetirizine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: fenofibrate with relative risk of -24.853 of cetirizine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: fenofibrate with relative risk of -24.853 of cetirizine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: fenofibrate with relative risk of -24.853 of cetirizine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: lurasidone with relative risk of -25.544 of cetirizine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 53: lurasidone with relative risk of -25.544 of cetirizine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 54: lurasidone with relative risk of -25.544 of cetirizine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 55: naproxen with relative risk of -25.715 of cetirizine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Rhinorrhea\n",
      "Rank 56: naproxen with relative risk of -25.715 of cetirizine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Rhinorrhea\n",
      "Rank 57: naproxen with relative risk of -25.715 of cetirizine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Rhinorrhea\n",
      "Rank 58: felodipine with relative risk of -inf of cetirizine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 59: felodipine with relative risk of -inf of cetirizine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 60: felodipine with relative risk of -inf of cetirizine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.096\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó cetrorelix *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: cyclobenzaprine with relative risk of -9.700 of cetrorelix | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: iloperidone with relative risk of -16.354 of cetrorelix | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: iloperidone with relative risk of -16.354 of cetrorelix | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: anagrelide with relative risk of -17.123 of cetrorelix | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: anagrelide with relative risk of -17.123 of cetrorelix | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: albendazole with relative risk of -25.418 of cetrorelix | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: albendazole with relative risk of -25.418 of cetrorelix | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: albendazole with relative risk of -25.418 of cetrorelix | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: captopril with relative risk of -122.118 of cetrorelix | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 10: captopril with relative risk of -122.118 of cetrorelix | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 11: captopril with relative risk of -122.118 of cetrorelix | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 12: captopril with relative risk of -122.118 of cetrorelix | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 13: captopril with relative risk of -122.118 of cetrorelix | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 14: captopril with relative risk of -122.118 of cetrorelix | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 15: captopril with relative risk of -122.118 of cetrorelix | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 16: captopril with relative risk of -122.118 of cetrorelix | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 17: captopril with relative risk of -122.118 of cetrorelix | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 18: captopril with relative risk of -122.118 of cetrorelix | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 19: captopril with relative risk of -122.118 of cetrorelix | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 20: captopril with relative risk of -122.118 of cetrorelix | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 21: captopril with relative risk of -122.118 of cetrorelix | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 22: captopril with relative risk of -122.118 of cetrorelix | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 23: captopril with relative risk of -122.118 of cetrorelix | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 24: captopril with relative risk of -122.118 of cetrorelix | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 25: atorvastatin with relative risk of -122.351 of cetrorelix | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: atorvastatin with relative risk of -122.351 of cetrorelix | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: atorvastatin with relative risk of -122.351 of cetrorelix | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: atorvastatin with relative risk of -122.351 of cetrorelix | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: atorvastatin with relative risk of -122.351 of cetrorelix | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: atorvastatin with relative risk of -122.351 of cetrorelix | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: atorvastatin with relative risk of -122.351 of cetrorelix | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: atorvastatin with relative risk of -122.351 of cetrorelix | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: atorvastatin with relative risk of -122.351 of cetrorelix | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: atorvastatin with relative risk of -122.351 of cetrorelix | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: atorvastatin with relative risk of -122.351 of cetrorelix | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: atorvastatin with relative risk of -122.351 of cetrorelix | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: atorvastatin with relative risk of -122.351 of cetrorelix | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: atorvastatin with relative risk of -122.351 of cetrorelix | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: atorvastatin with relative risk of -122.351 of cetrorelix | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: atorvastatin with relative risk of -122.351 of cetrorelix | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: telithromycin with relative risk of -128.784 of cetrorelix | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: telithromycin with relative risk of -128.784 of cetrorelix | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: telithromycin with relative risk of -128.784 of cetrorelix | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: telithromycin with relative risk of -128.784 of cetrorelix | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: telithromycin with relative risk of -128.784 of cetrorelix | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: telithromycin with relative risk of -128.784 of cetrorelix | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: telithromycin with relative risk of -128.784 of cetrorelix | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: telithromycin with relative risk of -128.784 of cetrorelix | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: telithromycin with relative risk of -128.784 of cetrorelix | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: telithromycin with relative risk of -128.784 of cetrorelix | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: telithromycin with relative risk of -128.784 of cetrorelix | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: telithromycin with relative risk of -128.784 of cetrorelix | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 53: telithromycin with relative risk of -128.784 of cetrorelix | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 54: telithromycin with relative risk of -128.784 of cetrorelix | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 55: telithromycin with relative risk of -128.784 of cetrorelix | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 56: telithromycin with relative risk of -128.784 of cetrorelix | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 57: treprostinil with relative risk of -132.240 of cetrorelix | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 58: treprostinil with relative risk of -132.240 of cetrorelix | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 59: treprostinil with relative risk of -132.240 of cetrorelix | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 60: treprostinil with relative risk of -132.240 of cetrorelix | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 61: treprostinil with relative risk of -132.240 of cetrorelix | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 62: treprostinil with relative risk of -132.240 of cetrorelix | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 63: treprostinil with relative risk of -132.240 of cetrorelix | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 64: treprostinil with relative risk of -132.240 of cetrorelix | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 65: treprostinil with relative risk of -132.240 of cetrorelix | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 66: treprostinil with relative risk of -132.240 of cetrorelix | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 67: treprostinil with relative risk of -132.240 of cetrorelix | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 68: treprostinil with relative risk of -132.240 of cetrorelix | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 69: treprostinil with relative risk of -132.240 of cetrorelix | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 70: treprostinil with relative risk of -132.240 of cetrorelix | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 71: treprostinil with relative risk of -132.240 of cetrorelix | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 72: treprostinil with relative risk of -132.240 of cetrorelix | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.218\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó cevimeline *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: colchicine with relative risk of -9.876 of cevimeline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: rheumatology\n",
      "Rank 2: mifepristone with relative risk of -11.011 of cevimeline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.667\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target chlorhexidine not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó ciclesonide *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: ibandronate with relative risk of -6.537 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: miglustat with relative risk of -6.646 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: pentoxifylline with relative risk of -6.893 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: formoterol with relative risk of -7.343 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: carbamazepine with relative risk of -8.013 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: dabigatran with relative risk of -8.242 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: estramustine with relative risk of -8.301 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: zonisamide with relative risk of -8.501 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: etravirine with relative risk of -8.779 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: linezolid with relative risk of -8.946 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: silodosin with relative risk of -9.132 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: tiotropium with relative risk of -9.165 of ciclesonide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Asthma\n",
      "Rank 13: nefazodone with relative risk of -9.407 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: febuxostat with relative risk of -11.211 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: eplerenone with relative risk of -13.950 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: eplerenone with relative risk of -13.950 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: exemestane with relative risk of -15.261 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: exemestane with relative risk of -15.261 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: ramelteon with relative risk of -19.951 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: ramelteon with relative risk of -19.951 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: ramelteon with relative risk of -19.951 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: indacaterol with relative risk of -20.575 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: indacaterol with relative risk of -20.575 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: indacaterol with relative risk of -20.575 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: sunitinib with relative risk of -25.004 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: sunitinib with relative risk of -25.004 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: sunitinib with relative risk of -25.004 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: sunitinib with relative risk of -25.004 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: clomipramine with relative risk of -31.695 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: clomipramine with relative risk of -31.695 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: clomipramine with relative risk of -31.695 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: clomipramine with relative risk of -31.695 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: clomipramine with relative risk of -31.695 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: meloxicam with relative risk of -60.769 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: meloxicam with relative risk of -60.769 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: meloxicam with relative risk of -60.769 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: meloxicam with relative risk of -60.769 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: meloxicam with relative risk of -60.769 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: meloxicam with relative risk of -60.769 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: meloxicam with relative risk of -60.769 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: meloxicam with relative risk of -60.769 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: meloxicam with relative risk of -60.769 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: meloxicam with relative risk of -60.769 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: darifenacin with relative risk of -62.079 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: darifenacin with relative risk of -62.079 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: darifenacin with relative risk of -62.079 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: darifenacin with relative risk of -62.079 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: darifenacin with relative risk of -62.079 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: darifenacin with relative risk of -62.079 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: darifenacin with relative risk of -62.079 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: darifenacin with relative risk of -62.079 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: darifenacin with relative risk of -62.079 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 53: darifenacin with relative risk of -62.079 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 54: axitinib with relative risk of -64.890 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 55: axitinib with relative risk of -64.890 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 56: axitinib with relative risk of -64.890 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 57: axitinib with relative risk of -64.890 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 58: axitinib with relative risk of -64.890 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 59: axitinib with relative risk of -64.890 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 60: axitinib with relative risk of -64.890 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 61: axitinib with relative risk of -64.890 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 62: axitinib with relative risk of -64.890 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 63: axitinib with relative risk of -64.890 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 64: vinorelbine with relative risk of -66.642 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 65: vinorelbine with relative risk of -66.642 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 66: vinorelbine with relative risk of -66.642 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 67: vinorelbine with relative risk of -66.642 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 68: vinorelbine with relative risk of -66.642 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 69: vinorelbine with relative risk of -66.642 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 70: vinorelbine with relative risk of -66.642 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 71: vinorelbine with relative risk of -66.642 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 72: vinorelbine with relative risk of -66.642 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 73: vinorelbine with relative risk of -66.642 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 74: granisetron with relative risk of -67.530 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 75: granisetron with relative risk of -67.530 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 76: granisetron with relative risk of -67.530 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 77: granisetron with relative risk of -67.530 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 78: granisetron with relative risk of -67.530 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 79: granisetron with relative risk of -67.530 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 80: granisetron with relative risk of -67.530 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 81: granisetron with relative risk of -67.530 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 82: granisetron with relative risk of -67.530 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 83: granisetron with relative risk of -67.530 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 84: apraclonidine with relative risk of -67.687 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 85: apraclonidine with relative risk of -67.687 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 86: apraclonidine with relative risk of -67.687 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 87: apraclonidine with relative risk of -67.687 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 88: apraclonidine with relative risk of -67.687 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 89: apraclonidine with relative risk of -67.687 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 90: apraclonidine with relative risk of -67.687 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 91: apraclonidine with relative risk of -67.687 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 92: apraclonidine with relative risk of -67.687 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 93: apraclonidine with relative risk of -67.687 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 94: pinaverium with relative risk of -70.666 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 95: pinaverium with relative risk of -70.666 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 96: pinaverium with relative risk of -70.666 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 97: pinaverium with relative risk of -70.666 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 98: pinaverium with relative risk of -70.666 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 99: pinaverium with relative risk of -70.666 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 100: pinaverium with relative risk of -70.666 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 101: pinaverium with relative risk of -70.666 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 102: pinaverium with relative risk of -70.666 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 103: pinaverium with relative risk of -70.666 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 104: irbesartan with relative risk of -80.097 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 105: irbesartan with relative risk of -80.097 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 106: irbesartan with relative risk of -80.097 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 107: irbesartan with relative risk of -80.097 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 108: irbesartan with relative risk of -80.097 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 109: irbesartan with relative risk of -80.097 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 110: irbesartan with relative risk of -80.097 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 111: irbesartan with relative risk of -80.097 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 112: irbesartan with relative risk of -80.097 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 113: irbesartan with relative risk of -80.097 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 114: irbesartan with relative risk of -80.097 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 115: irbesartan with relative risk of -80.097 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 116: irbesartan with relative risk of -80.097 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 117: irbesartan with relative risk of -80.097 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 118: irbesartan with relative risk of -80.097 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 119: irbesartan with relative risk of -80.097 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 120: sertraline with relative risk of -80.924 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 121: sertraline with relative risk of -80.924 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 122: sertraline with relative risk of -80.924 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 123: sertraline with relative risk of -80.924 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 124: sertraline with relative risk of -80.924 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 125: sertraline with relative risk of -80.924 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 126: sertraline with relative risk of -80.924 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 127: sertraline with relative risk of -80.924 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 128: sertraline with relative risk of -80.924 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 129: sertraline with relative risk of -80.924 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 130: sertraline with relative risk of -80.924 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 131: sertraline with relative risk of -80.924 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 132: sertraline with relative risk of -80.924 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 133: sertraline with relative risk of -80.924 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 134: sertraline with relative risk of -80.924 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 135: sertraline with relative risk of -80.924 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 136: tadalafil with relative risk of -95.033 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 137: tadalafil with relative risk of -95.033 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 138: tadalafil with relative risk of -95.033 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 139: tadalafil with relative risk of -95.033 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 140: tadalafil with relative risk of -95.033 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 141: tadalafil with relative risk of -95.033 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 142: tadalafil with relative risk of -95.033 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 143: tadalafil with relative risk of -95.033 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 144: tadalafil with relative risk of -95.033 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 145: tadalafil with relative risk of -95.033 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 146: tadalafil with relative risk of -95.033 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 147: tadalafil with relative risk of -95.033 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 148: tadalafil with relative risk of -95.033 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 149: tadalafil with relative risk of -95.033 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 150: tadalafil with relative risk of -95.033 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 151: tadalafil with relative risk of -95.033 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 152: alfuzosin with relative risk of -109.503 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 153: alfuzosin with relative risk of -109.503 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 154: alfuzosin with relative risk of -109.503 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 155: alfuzosin with relative risk of -109.503 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 156: alfuzosin with relative risk of -109.503 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 157: alfuzosin with relative risk of -109.503 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 158: alfuzosin with relative risk of -109.503 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 159: alfuzosin with relative risk of -109.503 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 160: alfuzosin with relative risk of -109.503 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 161: alfuzosin with relative risk of -109.503 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 162: alfuzosin with relative risk of -109.503 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 163: alfuzosin with relative risk of -109.503 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 164: alfuzosin with relative risk of -109.503 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 165: alfuzosin with relative risk of -109.503 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 166: alfuzosin with relative risk of -109.503 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 167: alfuzosin with relative risk of -109.503 of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 168: desoximetasone with relative risk of -inf of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 169: desoximetasone with relative risk of -inf of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 170: desoximetasone with relative risk of -inf of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 171: desoximetasone with relative risk of -inf of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 172: desoximetasone with relative risk of -inf of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 173: desoximetasone with relative risk of -inf of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 174: desoximetasone with relative risk of -inf of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 175: desoximetasone with relative risk of -inf of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 176: desoximetasone with relative risk of -inf of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 177: desoximetasone with relative risk of -inf of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 178: desoximetasone with relative risk of -inf of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 179: desoximetasone with relative risk of -inf of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 180: desoximetasone with relative risk of -inf of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 181: desoximetasone with relative risk of -inf of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 182: desoximetasone with relative risk of -inf of ciclesonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.014\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target cidofovir not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó cilazapril *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: cabazitaxel with relative risk of -10.581 of cilazapril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: mitotane with relative risk of -10.981 of cilazapril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: danazol with relative risk of -11.727 of cilazapril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 4: canagliflozin with relative risk of -12.616 of cilazapril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: gonadorelin with relative risk of -12.633 of cilazapril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: phenytoin with relative risk of -12.906 of cilazapril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: montelukast with relative risk of -13.000 of cilazapril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: dipyridamole with relative risk of -13.267 of cilazapril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 9: mexiletine with relative risk of -13.348 of cilazapril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 10: ranitidine with relative risk of -13.446 of cilazapril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: zafirlukast with relative risk of -13.520 of cilazapril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.189\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó cilostazol *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: cytarabine with relative risk of -10.046 of cilostazol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: formoterol with relative risk of -10.323 of cilostazol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: frovatriptan with relative risk of -10.485 of cilostazol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: nimodipine with relative risk of -10.812 of cilostazol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: atomoxetine with relative risk of -11.027 of cilostazol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: allopurinol with relative risk of -11.331 of cilostazol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: empagliflozin with relative risk of -11.350 of cilostazol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: mafenide with relative risk of -11.477 of cilostazol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: avanafil with relative risk of -11.537 of cilostazol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: candesartan with relative risk of -11.878 of cilostazol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 11: pilocarpine with relative risk of -12.005 of cilostazol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 12: raloxifene with relative risk of -12.062 of cilostazol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: medroxyprogesterone with relative risk of -12.121 of cilostazol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: pantoprazole with relative risk of -12.135 of cilostazol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: bupivacaine with relative risk of -12.632 of cilostazol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: omeprazole with relative risk of -12.772 of cilostazol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: hydrochlorothiazide with relative risk of -12.814 of cilostazol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.073\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó cimetidine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: regadenoson with relative risk of -8.647 of cimetidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: sertraline with relative risk of -8.999 of cimetidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: mometasone with relative risk of -9.242 of cimetidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: posaconazole with relative risk of -9.679 of cimetidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: irbesartan with relative risk of -9.727 of cimetidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: azelastine with relative risk of -10.076 of cimetidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: crizotinib with relative risk of -10.375 of cimetidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: ibutilide with relative risk of -11.114 of cimetidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: asenapine with relative risk of -11.624 of cimetidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: amsacrine with relative risk of -11.630 of cimetidine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: hematologic malignancy\n",
      "Rank 11: carbamazepine with relative risk of -11.698 of cimetidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: dofetilide with relative risk of -11.839 of cimetidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: sulfasalazine with relative risk of -11.908 of cimetidine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "Rank 14: tolvaptan with relative risk of -12.970 of cimetidine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology,gastroenterology\n",
      "Rank 15: ambrisentan with relative risk of -12.988 of cimetidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.075\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target cinacalcet not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó ciprofloxacin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: vandetanib with relative risk of -11.340 of ciprofloxacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: danazol with relative risk of -11.727 of ciprofloxacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: sildenafil with relative risk of -12.060 of ciprofloxacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: cabozantinib with relative risk of -12.382 of ciprofloxacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó cisatracurium *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: bosutinib with relative risk of -10.097 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: dofetilide with relative risk of -10.229 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: clarithromycin with relative risk of -10.286 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: olmesartan with relative risk of -12.725 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: estramustine with relative risk of -26.386 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: estramustine with relative risk of -26.386 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: estramustine with relative risk of -26.386 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: auranofin with relative risk of -27.814 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: auranofin with relative risk of -27.814 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: auranofin with relative risk of -27.814 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: dantrolene with relative risk of -28.606 of cisatracurium | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: dantrolene with relative risk of -28.606 of cisatracurium | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: dantrolene with relative risk of -28.606 of cisatracurium | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: risedronate with relative risk of -28.895 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: risedronate with relative risk of -28.895 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: risedronate with relative risk of -28.895 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: donepezil with relative risk of -29.287 of cisatracurium | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 18: donepezil with relative risk of -29.287 of cisatracurium | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 19: donepezil with relative risk of -29.287 of cisatracurium | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 20: sertraline with relative risk of -34.222 of cisatracurium | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 21: sertraline with relative risk of -34.222 of cisatracurium | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 22: sertraline with relative risk of -34.222 of cisatracurium | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 23: sertraline with relative risk of -34.222 of cisatracurium | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 24: sertraline with relative risk of -34.222 of cisatracurium | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 25: irbesartan with relative risk of -34.590 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: irbesartan with relative risk of -34.590 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: irbesartan with relative risk of -34.590 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: irbesartan with relative risk of -34.590 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: irbesartan with relative risk of -34.590 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: mometasone with relative risk of -36.065 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: mometasone with relative risk of -36.065 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: mometasone with relative risk of -36.065 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: mometasone with relative risk of -36.065 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: mometasone with relative risk of -36.065 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: regadenoson with relative risk of -36.243 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: regadenoson with relative risk of -36.243 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: regadenoson with relative risk of -36.243 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: regadenoson with relative risk of -36.243 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: regadenoson with relative risk of -36.243 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: azelastine with relative risk of -36.761 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: azelastine with relative risk of -36.761 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: azelastine with relative risk of -36.761 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: azelastine with relative risk of -36.761 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: azelastine with relative risk of -36.761 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: posaconazole with relative risk of -37.450 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: posaconazole with relative risk of -37.450 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: posaconazole with relative risk of -37.450 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: posaconazole with relative risk of -37.450 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: posaconazole with relative risk of -37.450 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: ibutilide with relative risk of -38.383 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: ibutilide with relative risk of -38.383 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: ibutilide with relative risk of -38.383 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 53: ibutilide with relative risk of -38.383 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 54: ibutilide with relative risk of -38.383 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 55: telmisartan with relative risk of -45.160 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 56: telmisartan with relative risk of -45.160 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 57: telmisartan with relative risk of -45.160 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 58: telmisartan with relative risk of -45.160 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 59: telmisartan with relative risk of -45.160 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 60: milnacipran with relative risk of -46.827 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 61: milnacipran with relative risk of -46.827 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 62: milnacipran with relative risk of -46.827 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 63: milnacipran with relative risk of -46.827 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 64: milnacipran with relative risk of -46.827 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 65: tolmetin with relative risk of -47.694 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 66: tolmetin with relative risk of -47.694 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 67: tolmetin with relative risk of -47.694 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 68: tolmetin with relative risk of -47.694 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 69: tolmetin with relative risk of -47.694 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 70: progesterone with relative risk of -48.032 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 71: progesterone with relative risk of -48.032 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 72: progesterone with relative risk of -48.032 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 73: progesterone with relative risk of -48.032 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 74: progesterone with relative risk of -48.032 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 75: abiraterone with relative risk of -48.541 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 76: abiraterone with relative risk of -48.541 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 77: abiraterone with relative risk of -48.541 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 78: abiraterone with relative risk of -48.541 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 79: abiraterone with relative risk of -48.541 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 80: lubiprostone with relative risk of -48.928 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 81: lubiprostone with relative risk of -48.928 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 82: lubiprostone with relative risk of -48.928 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 83: lubiprostone with relative risk of -48.928 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 84: lubiprostone with relative risk of -48.928 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 85: dapagliflozin with relative risk of -49.578 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 86: dapagliflozin with relative risk of -49.578 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 87: dapagliflozin with relative risk of -49.578 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 88: dapagliflozin with relative risk of -49.578 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 89: dapagliflozin with relative risk of -49.578 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 90: misoprostol with relative risk of -49.925 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 91: misoprostol with relative risk of -49.925 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 92: misoprostol with relative risk of -49.925 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 93: misoprostol with relative risk of -49.925 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 94: misoprostol with relative risk of -49.925 of cisatracurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.126\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target cisplatin not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó citalopram *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: ropivacaine with relative risk of -9.475 of citalopram | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: levonorgestrel with relative risk of -9.583 of citalopram | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: naproxen with relative risk of -9.699 of citalopram | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: cyclophosphamide with relative risk of -9.777 of citalopram | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: ruxolitinib with relative risk of -9.819 of citalopram | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: lurasidone with relative risk of -9.865 of citalopram | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: bumetanide with relative risk of -10.806 of citalopram | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: gabapentin with relative risk of -10.853 of citalopram | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: telmisartan with relative risk of -10.981 of citalopram | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: trovafloxacin with relative risk of -10.991 of citalopram | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: cetirizine with relative risk of -11.176 of citalopram | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: flutamide with relative risk of -11.292 of citalopram | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: bezafibrate with relative risk of -11.564 of citalopram | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: zolmitriptan with relative risk of -11.611 of citalopram | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: sumatriptan with relative risk of -11.968 of citalopram | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 16: sertraline with relative risk of -15.270 of citalopram | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Depressive disorder,neurology/psychiatry\n",
      "Rank 17: sertraline with relative risk of -15.270 of citalopram | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Depressive disorder,neurology/psychiatry\n",
      "Rank 18: regadenoson with relative risk of -15.483 of citalopram | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: regadenoson with relative risk of -15.483 of citalopram | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: mometasone with relative risk of -15.895 of citalopram | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: mometasone with relative risk of -15.895 of citalopram | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: irbesartan with relative risk of -15.911 of citalopram | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: irbesartan with relative risk of -15.911 of citalopram | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: etoposide with relative risk of -16.126 of citalopram | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: etoposide with relative risk of -16.126 of citalopram | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: posaconazole with relative risk of -16.556 of citalopram | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: posaconazole with relative risk of -16.556 of citalopram | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: azelastine with relative risk of -16.697 of citalopram | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: azelastine with relative risk of -16.697 of citalopram | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: glimepiride with relative risk of -17.542 of citalopram | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: glimepiride with relative risk of -17.542 of citalopram | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: tropisetron with relative risk of -17.589 of citalopram | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: tropisetron with relative risk of -17.589 of citalopram | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: paliperidone with relative risk of -17.618 of citalopram | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 35: paliperidone with relative risk of -17.618 of citalopram | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 36: ibutilide with relative risk of -17.873 of citalopram | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: ibutilide with relative risk of -17.873 of citalopram | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: fenofibrate with relative risk of -18.669 of citalopram | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: fenofibrate with relative risk of -18.669 of citalopram | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: lansoprazole with relative risk of -18.859 of citalopram | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: lansoprazole with relative risk of -18.859 of citalopram | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: ketorolac with relative risk of -18.915 of citalopram | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 43: ketorolac with relative risk of -18.915 of citalopram | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 44: didanosine with relative risk of -19.117 of citalopram | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: didanosine with relative risk of -19.117 of citalopram | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: dutasteride with relative risk of -20.349 of citalopram | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: dutasteride with relative risk of -20.349 of citalopram | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: felodipine with relative risk of -inf of citalopram | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: felodipine with relative risk of -inf of citalopram | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.444\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó cladribine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: irbesartan with relative risk of -9.727 of cladribine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: azelastine with relative risk of -10.076 of cladribine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: naltrexone with relative risk of -12.032 of cladribine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: nicotine with relative risk of -13.313 of cladribine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: desonide with relative risk of -13.368 of cladribine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó clarithromycin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: ibandronate with relative risk of -8.405 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: glimepiride with relative risk of -8.471 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: darifenacin with relative risk of -8.547 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: paliperidone with relative risk of -8.666 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: pentoxifylline with relative risk of -8.764 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: tolmetin with relative risk of -8.862 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: auranofin with relative risk of -8.908 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: esmolol with relative risk of -8.925 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: terbutaline with relative risk of -8.992 of clarithromycin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: pulmonary\n",
      "Rank 10: everolimus with relative risk of -9.131 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: progesterone with relative risk of -9.200 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: brimonidine with relative risk of -9.312 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: risperidone with relative risk of -9.384 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: ketorolac with relative risk of -9.469 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: milnacipran with relative risk of -9.605 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: dantrolene with relative risk of -9.700 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: abiraterone with relative risk of -9.709 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: atropine with relative risk of -9.739 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: tazarotene with relative risk of -9.885 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: bosutinib with relative risk of -9.915 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: risedronate with relative risk of -9.989 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: lubiprostone with relative risk of -10.096 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: dapsone with relative risk of -10.145 of clarithromycin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 24: varenicline with relative risk of -10.183 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: estramustine with relative risk of -10.189 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: dutasteride with relative risk of -10.296 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: donepezil with relative risk of -10.382 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: azilsartan with relative risk of -10.385 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: leflunomide with relative risk of -10.442 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: doxorubicin with relative risk of -10.451 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: vernakalant with relative risk of -10.489 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: ixabepilone with relative risk of -10.548 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: dapagliflozin with relative risk of -10.746 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: isradipine with relative risk of -10.890 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: misoprostol with relative risk of -11.093 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: flecainide with relative risk of -11.164 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: benazepril with relative risk of -11.387 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: vilazodone with relative risk of -11.852 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: pindolol with relative risk of -12.008 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: toremifene with relative risk of -12.140 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: cisatracurium with relative risk of -12.846 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: tropisetron with relative risk of -14.884 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: tropisetron with relative risk of -14.884 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: lansoprazole with relative risk of -16.153 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: lansoprazole with relative risk of -16.153 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: ruxolitinib with relative risk of -16.250 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: ruxolitinib with relative risk of -16.250 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: erlotinib with relative risk of -18.630 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: erlotinib with relative risk of -18.630 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: vemurafenib with relative risk of -18.661 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: vemurafenib with relative risk of -18.661 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: irbesartan with relative risk of -19.126 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 53: irbesartan with relative risk of -19.126 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 54: irbesartan with relative risk of -19.126 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 55: mometasone with relative risk of -19.591 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 56: mometasone with relative risk of -19.591 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 57: mometasone with relative risk of -19.591 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 58: rotigotine with relative risk of -19.997 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 59: rotigotine with relative risk of -19.997 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 60: doxepin with relative risk of -20.204 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 61: doxepin with relative risk of -20.204 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 62: posaconazole with relative risk of -20.483 of clarithromycin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 63: posaconazole with relative risk of -20.483 of clarithromycin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 64: posaconazole with relative risk of -20.483 of clarithromycin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 65: ticagrelor with relative risk of -23.806 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 66: ticagrelor with relative risk of -23.806 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 67: ticagrelor with relative risk of -23.806 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 68: lurasidone with relative risk of -23.935 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 69: lurasidone with relative risk of -23.935 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 70: lurasidone with relative risk of -23.935 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 71: naproxen with relative risk of -24.105 of clarithromycin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: otolaryngology\n",
      "Rank 72: naproxen with relative risk of -24.105 of clarithromycin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: otolaryngology\n",
      "Rank 73: naproxen with relative risk of -24.105 of clarithromycin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: otolaryngology\n",
      "Rank 74: telmisartan with relative risk of -25.051 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 75: telmisartan with relative risk of -25.051 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 76: telmisartan with relative risk of -25.051 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 77: gabapentin with relative risk of -25.664 of clarithromycin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 78: gabapentin with relative risk of -25.664 of clarithromycin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 79: gabapentin with relative risk of -25.664 of clarithromycin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 80: regadenoson with relative risk of -26.573 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 81: regadenoson with relative risk of -26.573 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 82: regadenoson with relative risk of -26.573 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 83: regadenoson with relative risk of -26.573 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 84: delavirdine with relative risk of -27.711 of clarithromycin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 85: delavirdine with relative risk of -27.711 of clarithromycin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 86: delavirdine with relative risk of -27.711 of clarithromycin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 87: clonidine with relative risk of -28.352 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 88: clonidine with relative risk of -28.352 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 89: clonidine with relative risk of -28.352 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 90: ibutilide with relative risk of -28.800 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 91: ibutilide with relative risk of -28.800 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 92: ibutilide with relative risk of -28.800 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 93: ibutilide with relative risk of -28.800 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 94: ropivacaine with relative risk of -31.402 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 95: ropivacaine with relative risk of -31.402 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 96: ropivacaine with relative risk of -31.402 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 97: ropivacaine with relative risk of -31.402 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 98: sertraline with relative risk of -40.588 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 99: sertraline with relative risk of -40.588 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 100: sertraline with relative risk of -40.588 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 101: sertraline with relative risk of -40.588 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 102: sertraline with relative risk of -40.588 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 103: sertraline with relative risk of -40.588 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 104: azelastine with relative risk of -43.520 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 105: azelastine with relative risk of -43.520 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 106: azelastine with relative risk of -43.520 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 107: azelastine with relative risk of -43.520 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 108: azelastine with relative risk of -43.520 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 109: azelastine with relative risk of -43.520 of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 110: felodipine with relative risk of -inf of clarithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.06\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target clevidipine not found. Exiting ...\n",
      "\n",
      "Drug target clindamycin not found. Exiting ...\n",
      "\n",
      "Drug target clobazam not found. Exiting ...\n",
      "\n",
      "Drug target clobetasol not found. Exiting ...\n",
      "\n",
      "Drug target clodronate not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó clofarabine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: macitentan with relative risk of -10.723 of clofarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: bisoprolol with relative risk of -11.370 of clofarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: prasugrel with relative risk of -12.044 of clofarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: crizotinib with relative risk of -25.187 of clofarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: crizotinib with relative risk of -25.187 of clofarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: crizotinib with relative risk of -25.187 of clofarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: travoprost with relative risk of -29.475 of clofarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: travoprost with relative risk of -29.475 of clofarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: travoprost with relative risk of -29.475 of clofarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: ibandronate with relative risk of -29.917 of clofarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: ibandronate with relative risk of -29.917 of clofarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: ibandronate with relative risk of -29.917 of clofarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: ibandronate with relative risk of -29.917 of clofarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: pentoxifylline with relative risk of -30.611 of clofarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: pentoxifylline with relative risk of -30.611 of clofarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: pentoxifylline with relative risk of -30.611 of clofarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: pentoxifylline with relative risk of -30.611 of clofarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: paroxetine with relative risk of -36.124 of clofarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: paroxetine with relative risk of -36.124 of clofarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: paroxetine with relative risk of -36.124 of clofarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: paroxetine with relative risk of -36.124 of clofarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: paroxetine with relative risk of -36.124 of clofarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: moxifloxacin with relative risk of -39.578 of clofarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: moxifloxacin with relative risk of -39.578 of clofarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: moxifloxacin with relative risk of -39.578 of clofarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: moxifloxacin with relative risk of -39.578 of clofarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: nabumetone with relative risk of -41.822 of clofarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: nabumetone with relative risk of -41.822 of clofarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: nabumetone with relative risk of -41.822 of clofarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: nabumetone with relative risk of -41.822 of clofarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: nabumetone with relative risk of -41.822 of clofarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target clomiphene not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó clomipramine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: carbamazepine with relative risk of -9.753 of clomipramine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: silodosin with relative risk of -10.874 of clomipramine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: nefazodone with relative risk of -11.147 of clomipramine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: ciclesonide with relative risk of -32.684 of clomipramine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: ciclesonide with relative risk of -32.684 of clomipramine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: ciclesonide with relative risk of -32.684 of clomipramine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: ciclesonide with relative risk of -32.684 of clomipramine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: ciclesonide with relative risk of -32.684 of clomipramine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: sunitinib with relative risk of -32.868 of clomipramine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: sunitinib with relative risk of -32.868 of clomipramine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: sunitinib with relative risk of -32.868 of clomipramine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: sunitinib with relative risk of -32.868 of clomipramine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: ramelteon with relative risk of -34.546 of clomipramine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: ramelteon with relative risk of -34.546 of clomipramine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: ramelteon with relative risk of -34.546 of clomipramine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 16: ramelteon with relative risk of -34.546 of clomipramine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 17: desoximetasone with relative risk of -inf of clomipramine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: desoximetasone with relative risk of -inf of clomipramine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: desoximetasone with relative risk of -inf of clomipramine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: desoximetasone with relative risk of -inf of clomipramine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: desoximetasone with relative risk of -inf of clomipramine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: desoximetasone with relative risk of -inf of clomipramine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: desoximetasone with relative risk of -inf of clomipramine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.342\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target clonazepam not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó clonidine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: mometasone with relative risk of -8.146 of clonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: posaconazole with relative risk of -8.583 of clonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: irbesartan with relative risk of -8.633 of clonidine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 4: ibandronate with relative risk of -9.095 of clonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: tropisetron with relative risk of -9.382 of clonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: lansoprazole with relative risk of -10.009 of clonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: risperidone with relative risk of -10.077 of clonidine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: ketorolac with relative risk of -10.160 of clonidine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Severe pain,neurology/psychiatry\n",
      "Rank 9: vemurafenib with relative risk of -10.216 of clonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: atropine with relative risk of -10.432 of clonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: varenicline with relative risk of -10.876 of clonidine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: dutasteride with relative risk of -10.988 of clonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: leflunomide with relative risk of -11.135 of clonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: doxorubicin with relative risk of -11.144 of clonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: vernakalant with relative risk of -11.183 of clonidine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 16: ixabepilone with relative risk of -11.242 of clonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: doxepin with relative risk of -11.759 of clonidine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 18: flecainide with relative risk of -11.857 of clonidine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 19: benazepril with relative risk of -12.080 of clonidine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 20: vilazodone with relative risk of -12.545 of clonidine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 21: pindolol with relative risk of -12.701 of clonidine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 22: toremifene with relative risk of -12.834 of clonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: regadenoson with relative risk of -14.385 of clonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: regadenoson with relative risk of -14.385 of clonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: ibutilide with relative risk of -16.776 of clonidine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 26: ibutilide with relative risk of -16.776 of clonidine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 27: ropivacaine with relative risk of -16.927 of clonidine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 28: ropivacaine with relative risk of -16.927 of clonidine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 29: naproxen with relative risk of -17.557 of clonidine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 30: naproxen with relative risk of -17.557 of clonidine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 31: lurasidone with relative risk of -17.569 of clonidine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 32: lurasidone with relative risk of -17.569 of clonidine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 33: ticagrelor with relative risk of -17.727 of clonidine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 34: ticagrelor with relative risk of -17.727 of clonidine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 35: ruxolitinib with relative risk of -17.859 of clonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: ruxolitinib with relative risk of -17.859 of clonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: telmisartan with relative risk of -18.685 of clonidine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 38: telmisartan with relative risk of -18.685 of clonidine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 39: gabapentin with relative risk of -18.893 of clonidine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 40: gabapentin with relative risk of -18.893 of clonidine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 41: delavirdine with relative risk of -19.553 of clonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: delavirdine with relative risk of -19.553 of clonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: erlotinib with relative risk of -20.239 of clonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: erlotinib with relative risk of -20.239 of clonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: sertraline with relative risk of -21.564 of clonidine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 46: sertraline with relative risk of -21.564 of clonidine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 47: sertraline with relative risk of -21.564 of clonidine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 48: rotigotine with relative risk of -21.606 of clonidine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 49: rotigotine with relative risk of -21.606 of clonidine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 50: azelastine with relative risk of -23.351 of clonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: azelastine with relative risk of -23.351 of clonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: azelastine with relative risk of -23.351 of clonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 53: clarithromycin with relative risk of -29.008 of clonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 54: clarithromycin with relative risk of -29.008 of clonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 55: clarithromycin with relative risk of -29.008 of clonidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.343\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó clopidogrel *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: ropivacaine with relative risk of -8.559 of clopidogrel | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: ibandronate with relative risk of -8.586 of clopidogrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: cytarabine with relative risk of -9.130 of clopidogrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: paclitaxel with relative risk of -9.321 of clopidogrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: formoterol with relative risk of -9.408 of clopidogrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: frovatriptan with relative risk of -9.570 of clopidogrel | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: nimodipine with relative risk of -9.896 of clopidogrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: atosiban with relative risk of -10.412 of clopidogrel | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry,cardiology\n",
      "Rank 9: vincristine with relative risk of -10.623 of clopidogrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: desloratadine with relative risk of -10.861 of clopidogrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: rasagiline with relative risk of -10.882 of clopidogrel | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: rivastigmine with relative risk of -11.002 of clopidogrel | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: sotalol with relative risk of -11.026 of clopidogrel | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 14: rofecoxib with relative risk of -11.077 of clopidogrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: pimozide with relative risk of -11.149 of clopidogrel | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 16: desvenlafaxine with relative risk of -11.505 of clopidogrel | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 17: capsaicin with relative risk of -11.601 of clopidogrel | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 18: amoxicillin with relative risk of -12.007 of clopidogrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: diltiazem with relative risk of -12.250 of clopidogrel | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 20: nebivolol with relative risk of -12.735 of clopidogrel | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 21: fosinoprilat with relative risk of -13.883 of clopidogrel | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 22: imatinib with relative risk of -16.676 of clopidogrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: imatinib with relative risk of -16.676 of clopidogrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: gefitinib with relative risk of -17.199 of clopidogrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: gefitinib with relative risk of -17.199 of clopidogrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: gemcitabine with relative risk of -17.883 of clopidogrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: gemcitabine with relative risk of -17.883 of clopidogrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: acyclovir with relative risk of -19.458 of clopidogrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: acyclovir with relative risk of -19.458 of clopidogrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: trimetrexate with relative risk of -25.345 of clopidogrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: trimetrexate with relative risk of -25.345 of clopidogrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: trimetrexate with relative risk of -25.345 of clopidogrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: valdecoxib with relative risk of -25.903 of clopidogrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: valdecoxib with relative risk of -25.903 of clopidogrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: valdecoxib with relative risk of -25.903 of clopidogrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: dihydroergotamine with relative risk of -26.734 of clopidogrel | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 37: dihydroergotamine with relative risk of -26.734 of clopidogrel | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 38: dihydroergotamine with relative risk of -26.734 of clopidogrel | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 39: ramipril with relative risk of -29.847 of clopidogrel | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 40: ramipril with relative risk of -29.847 of clopidogrel | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 41: ramipril with relative risk of -29.847 of clopidogrel | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 42: finasteride with relative risk of -33.430 of clopidogrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: finasteride with relative risk of -33.430 of clopidogrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: finasteride with relative risk of -33.430 of clopidogrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: finasteride with relative risk of -33.430 of clopidogrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: alendronate with relative risk of -34.612 of clopidogrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: alendronate with relative risk of -34.612 of clopidogrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: alendronate with relative risk of -34.612 of clopidogrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: alendronate with relative risk of -34.612 of clopidogrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: aminophylline with relative risk of -41.728 of clopidogrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: aminophylline with relative risk of -41.728 of clopidogrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: aminophylline with relative risk of -41.728 of clopidogrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 53: aminophylline with relative risk of -41.728 of clopidogrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 54: aminophylline with relative risk of -41.728 of clopidogrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.445\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó clozapine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: cabazitaxel with relative risk of -8.280 of clozapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: teniposide with relative risk of -8.520 of clozapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: topotecan with relative risk of -8.533 of clozapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: bimatoprost with relative risk of -8.752 of clozapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: acitretin with relative risk of -8.902 of clozapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: azathioprine with relative risk of -8.993 of clozapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: nifedipine with relative risk of -9.009 of clozapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: danazol with relative risk of -9.425 of clozapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: metolazone with relative risk of -9.657 of clozapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: allopurinol with relative risk of -9.723 of clozapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: saquinavir with relative risk of -9.773 of clozapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: nalbuphine with relative risk of -9.779 of clozapine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: darunavir with relative risk of -9.881 of clozapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: phentolamine with relative risk of -9.996 of clozapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: efavirenz with relative risk of -10.297 of clozapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: nilutamide with relative risk of -10.469 of clozapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: oxcarbazepine with relative risk of -10.755 of clozapine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 18: galantamine with relative risk of -10.848 of clozapine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 19: voriconazole with relative risk of -11.255 of clozapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: vandetanib with relative risk of -15.980 of clozapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: vandetanib with relative risk of -15.980 of clozapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: calcipotriol with relative risk of -inf of clozapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.054\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó colchicine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: dabrafenib with relative risk of -8.399 of colchicine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: dofetilide with relative risk of -8.950 of colchicine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: disopyramide with relative risk of -9.206 of colchicine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: cevimeline with relative risk of -10.284 of colchicine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: rheumatology\n",
      "Rank 5: pitavastatin with relative risk of -10.938 of colchicine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 6: mifepristone with relative risk of -16.036 of colchicine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 7: mifepristone with relative risk of -16.036 of colchicine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 8: trametinib with relative risk of -30.857 of colchicine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: trametinib with relative risk of -30.857 of colchicine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: trametinib with relative risk of -30.857 of colchicine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: trametinib with relative risk of -30.857 of colchicine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: fluvoxamine with relative risk of -78.238 of colchicine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: fluvoxamine with relative risk of -78.238 of colchicine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: fluvoxamine with relative risk of -78.238 of colchicine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: fluvoxamine with relative risk of -78.238 of colchicine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: fluvoxamine with relative risk of -78.238 of colchicine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: fluvoxamine with relative risk of -78.238 of colchicine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: fluvoxamine with relative risk of -78.238 of colchicine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: fluvoxamine with relative risk of -78.238 of colchicine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: fluvoxamine with relative risk of -78.238 of colchicine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: fluvoxamine with relative risk of -78.238 of colchicine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: fluvoxamine with relative risk of -78.238 of colchicine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.206\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target colesevelam not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó conivaptan *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: captopril with relative risk of -8.154 of conivaptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 2: atorvastatin with relative risk of -9.640 of conivaptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: emedastine with relative risk of -10.876 of conivaptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: desoximetasone with relative risk of -inf of conivaptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.48\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target conjugated not found. Exiting ...\n",
      "\n",
      "Drug target copolymer not found. Exiting ...\n",
      "\n",
      "Drug target copper not found. Exiting ...\n",
      "\n",
      "Drug target cortisol not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó crizotinib *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: regadenoson with relative risk of -6.860 of crizotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: sertraline with relative risk of -7.217 of crizotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: mometasone with relative risk of -7.456 of crizotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: posaconazole with relative risk of -7.893 of crizotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: irbesartan with relative risk of -7.946 of crizotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: azelastine with relative risk of -8.291 of crizotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: miglustat with relative risk of -8.532 of crizotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: ibutilide with relative risk of -9.328 of crizotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: asenapine with relative risk of -9.833 of crizotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: amsacrine with relative risk of -9.838 of crizotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: carbamazepine with relative risk of -9.907 of crizotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: argatroban with relative risk of -10.003 of crizotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: dofetilide with relative risk of -10.047 of crizotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: sulfasalazine with relative risk of -10.117 of crizotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: macitentan with relative risk of -10.541 of crizotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: travoprost with relative risk of -10.570 of crizotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: etravirine with relative risk of -10.675 of crizotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: linezolid with relative risk of -10.840 of crizotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: tolvaptan with relative risk of -11.179 of crizotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: bisoprolol with relative risk of -11.188 of crizotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: ambrisentan with relative risk of -11.196 of crizotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: doxazosin with relative risk of -11.519 of crizotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: prasugrel with relative risk of -11.861 of crizotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: cimetidine with relative risk of -12.518 of crizotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: ibandronate with relative risk of -14.546 of crizotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: ibandronate with relative risk of -14.546 of crizotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: moxifloxacin with relative risk of -19.063 of crizotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: moxifloxacin with relative risk of -19.063 of crizotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: pentoxifylline with relative risk of -21.944 of crizotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: pentoxifylline with relative risk of -21.944 of crizotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: pentoxifylline with relative risk of -21.944 of crizotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: clofarabine with relative risk of -24.079 of crizotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: clofarabine with relative risk of -24.079 of crizotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: clofarabine with relative risk of -24.079 of crizotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: paroxetine with relative risk of -26.765 of crizotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: paroxetine with relative risk of -26.765 of crizotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: paroxetine with relative risk of -26.765 of crizotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: paroxetine with relative risk of -26.765 of crizotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: nabumetone with relative risk of -31.458 of crizotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: nabumetone with relative risk of -31.458 of crizotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: nabumetone with relative risk of -31.458 of crizotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: nabumetone with relative risk of -31.458 of crizotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó cyclobenzaprine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: captopril with relative risk of -8.847 of cyclobenzaprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: treprostinil with relative risk of -9.320 of cyclobenzaprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: atorvastatin with relative risk of -10.332 of cyclobenzaprine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: cetrorelix with relative risk of -10.463 of cyclobenzaprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: telithromycin with relative risk of -10.776 of cyclobenzaprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: anagrelide with relative risk of -11.856 of cyclobenzaprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: iloperidone with relative risk of -12.184 of cyclobenzaprine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: albendazole with relative risk of -12.329 of cyclobenzaprine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.175\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó cyclophosphamide *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: didanosine with relative risk of -9.979 of cyclophosphamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: trovafloxacin with relative risk of -10.991 of cyclophosphamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: flutamide with relative risk of -11.292 of cyclophosphamide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 4: dutasteride with relative risk of -11.393 of cyclophosphamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: sumatriptan with relative risk of -11.968 of cyclophosphamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: citalopram with relative risk of -11.991 of cyclophosphamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: sertraline with relative risk of -15.270 of cyclophosphamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: sertraline with relative risk of -15.270 of cyclophosphamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: regadenoson with relative risk of -15.483 of cyclophosphamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: regadenoson with relative risk of -15.483 of cyclophosphamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: mometasone with relative risk of -15.895 of cyclophosphamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: mometasone with relative risk of -15.895 of cyclophosphamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: irbesartan with relative risk of -15.911 of cyclophosphamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: irbesartan with relative risk of -15.911 of cyclophosphamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: etoposide with relative risk of -16.126 of cyclophosphamide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 16: etoposide with relative risk of -16.126 of cyclophosphamide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 17: posaconazole with relative risk of -16.556 of cyclophosphamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: posaconazole with relative risk of -16.556 of cyclophosphamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: azelastine with relative risk of -16.697 of cyclophosphamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: azelastine with relative risk of -16.697 of cyclophosphamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: glimepiride with relative risk of -17.542 of cyclophosphamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: glimepiride with relative risk of -17.542 of cyclophosphamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: tropisetron with relative risk of -17.589 of cyclophosphamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: tropisetron with relative risk of -17.589 of cyclophosphamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: paliperidone with relative risk of -17.618 of cyclophosphamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: paliperidone with relative risk of -17.618 of cyclophosphamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: ibutilide with relative risk of -17.873 of cyclophosphamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: ibutilide with relative risk of -17.873 of cyclophosphamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: levonorgestrel with relative risk of -18.539 of cyclophosphamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: levonorgestrel with relative risk of -18.539 of cyclophosphamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: fenofibrate with relative risk of -18.669 of cyclophosphamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: fenofibrate with relative risk of -18.669 of cyclophosphamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: lansoprazole with relative risk of -18.859 of cyclophosphamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: lansoprazole with relative risk of -18.859 of cyclophosphamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: ketorolac with relative risk of -18.915 of cyclophosphamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: ketorolac with relative risk of -18.915 of cyclophosphamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: ruxolitinib with relative risk of -18.957 of cyclophosphamide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: hematologic malignancy\n",
      "Rank 38: ruxolitinib with relative risk of -18.957 of cyclophosphamide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: hematologic malignancy\n",
      "Rank 39: felodipine with relative risk of -inf of cyclophosphamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: felodipine with relative risk of -inf of cyclophosphamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.121\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target cyproterone not found. Exiting ...\n",
      "\n",
      "Drug target cysteamine not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó cytarabine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: aminophylline with relative risk of -8.138 of cytarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: atomoxetine with relative risk of -10.334 of cytarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: cilostazol with relative risk of -10.570 of cytarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: allopurinol with relative risk of -10.638 of cytarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: nelarabine with relative risk of -10.716 of cytarabine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: hematologic malignancy\n",
      "Rank 6: mafenide with relative risk of -10.784 of cytarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: avanafil with relative risk of -10.844 of cytarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: entacapone with relative risk of -10.921 of cytarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: candesartan with relative risk of -11.185 of cytarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: ipratropium with relative risk of -11.188 of cytarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: silodosin with relative risk of -11.433 of cytarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: nefazodone with relative risk of -11.706 of cytarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: rufinamide with relative risk of -11.958 of cytarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: clopidogrel with relative risk of -12.004 of cytarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: hydrochlorothiazide with relative risk of -12.121 of cytarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: paclitaxel with relative risk of -19.193 of cytarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: paclitaxel with relative risk of -19.193 of cytarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: rasagiline with relative risk of -20.061 of cytarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: rasagiline with relative risk of -20.061 of cytarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: rivastigmine with relative risk of -20.874 of cytarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: rivastigmine with relative risk of -20.874 of cytarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: sotalol with relative risk of -20.899 of cytarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: sotalol with relative risk of -20.899 of cytarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: rofecoxib with relative risk of -20.949 of cytarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: rofecoxib with relative risk of -20.949 of cytarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: pimozide with relative risk of -21.022 of cytarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: pimozide with relative risk of -21.022 of cytarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: capsaicin with relative risk of -21.473 of cytarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: capsaicin with relative risk of -21.473 of cytarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: fosinoprilat with relative risk of -23.756 of cytarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: fosinoprilat with relative risk of -23.756 of cytarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: nimodipine with relative risk of -26.203 of cytarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: nimodipine with relative risk of -26.203 of cytarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: nimodipine with relative risk of -26.203 of cytarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: formoterol with relative risk of -34.601 of cytarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: formoterol with relative risk of -34.601 of cytarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: formoterol with relative risk of -34.601 of cytarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: formoterol with relative risk of -34.601 of cytarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: frovatriptan with relative risk of -34.763 of cytarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: frovatriptan with relative risk of -34.763 of cytarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: frovatriptan with relative risk of -34.763 of cytarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: frovatriptan with relative risk of -34.763 of cytarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.046\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target d-telaprevir not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó dabigatran *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: captopril with relative risk of -8.154 of dabigatran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: vinorelbine with relative risk of -8.817 of dabigatran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: ciclesonide with relative risk of -9.311 of dabigatran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: axitinib with relative risk of -9.365 of dabigatran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: atorvastatin with relative risk of -9.640 of dabigatran | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: darifenacin with relative risk of -9.644 of dabigatran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: granisetron with relative risk of -9.704 of dabigatran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: apraclonidine with relative risk of -9.861 of dabigatran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: meloxicam with relative risk of -10.539 of dabigatran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: nifedipine with relative risk of -10.617 of dabigatran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: indacaterol with relative risk of -10.760 of dabigatran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: nabumetone with relative risk of -10.997 of dabigatran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: danazol with relative risk of -11.034 of dabigatran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: exemestane with relative risk of -11.172 of dabigatran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: etravirine with relative risk of -11.773 of dabigatran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: tiotropium with relative risk of -12.161 of dabigatran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: exenatide with relative risk of -12.318 of dabigatran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: fosinopril with relative risk of -12.426 of dabigatran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: pinaverium with relative risk of -12.840 of dabigatran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: desoximetasone with relative risk of -inf of dabigatran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.056\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó dabrafenib *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: colchicine with relative risk of -9.183 of dabrafenib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: fluvoxamine with relative risk of -9.378 of dabrafenib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: trametinib with relative risk of -9.817 of dabrafenib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Malignant melanoma, metastatic,oncology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.182\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target dacarbazine not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó dalbavancin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: pramipexole with relative risk of -11.929 of dalbavancin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: docetaxel with relative risk of -12.046 of dalbavancin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: etodolac with relative risk of -12.358 of dalbavancin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: metaproterenol with relative risk of -12.759 of dalbavancin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: duloxetine with relative risk of -12.992 of dalbavancin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: bupropion with relative risk of -13.123 of dalbavancin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: repaglinide with relative risk of -13.133 of dalbavancin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: trospium with relative risk of -13.502 of dalbavancin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: amlodipine with relative risk of -13.806 of dalbavancin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target dalteparin not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó danazol *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: captopril with relative risk of -7.463 of danazol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 2: clozapine with relative risk of -8.678 of danazol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: atorvastatin with relative risk of -8.949 of danazol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 4: cabazitaxel with relative risk of -9.196 of danazol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: mitotane with relative risk of -9.595 of danazol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: nifedipine with relative risk of -9.924 of danazol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 7: nabumetone with relative risk of -10.305 of danazol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: dabigatran with relative risk of -10.543 of danazol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: sildenafil with relative risk of -10.674 of danazol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: cabozantinib with relative risk of -10.996 of danazol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: efavirenz with relative risk of -11.213 of danazol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: canagliflozin with relative risk of -11.230 of danazol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: gonadorelin with relative risk of -11.247 of danazol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: obstetrics/gynecology\n",
      "Rank 14: phenytoin with relative risk of -11.520 of danazol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: montelukast with relative risk of -11.614 of danazol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: exenatide with relative risk of -11.625 of danazol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: ciprofloxacin with relative risk of -11.646 of danazol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: oxcarbazepine with relative risk of -11.672 of danazol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: fosinopril with relative risk of -11.733 of danazol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 20: dipyridamole with relative risk of -11.881 of danazol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 21: mexiletine with relative risk of -11.962 of danazol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 22: ranitidine with relative risk of -12.060 of danazol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: zafirlukast with relative risk of -12.133 of danazol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: voriconazole with relative risk of -12.171 of danazol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: cilazapril with relative risk of -13.938 of danazol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 26: vandetanib with relative risk of -17.994 of danazol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: vandetanib with relative risk of -17.994 of danazol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.454\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó dantrolene *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: bosutinib with relative risk of -10.608 of dantrolene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: dofetilide with relative risk of -10.740 of dantrolene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: clarithromycin with relative risk of -10.796 of dantrolene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: olmesartan with relative risk of -13.236 of dantrolene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: sertraline with relative risk of -21.564 of dantrolene | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: sertraline with relative risk of -21.564 of dantrolene | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: sertraline with relative risk of -21.564 of dantrolene | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: irbesartan with relative risk of -22.116 of dantrolene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: irbesartan with relative risk of -22.116 of dantrolene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: irbesartan with relative risk of -22.116 of dantrolene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: regadenoson with relative risk of -22.359 of dantrolene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: regadenoson with relative risk of -22.359 of dantrolene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: regadenoson with relative risk of -22.359 of dantrolene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: mometasone with relative risk of -22.583 of dantrolene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: mometasone with relative risk of -22.583 of dantrolene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: mometasone with relative risk of -22.583 of dantrolene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: azelastine with relative risk of -23.351 of dantrolene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: azelastine with relative risk of -23.351 of dantrolene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: azelastine with relative risk of -23.351 of dantrolene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: posaconazole with relative risk of -23.476 of dantrolene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: posaconazole with relative risk of -23.476 of dantrolene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: posaconazole with relative risk of -23.476 of dantrolene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: ibutilide with relative risk of -24.670 of dantrolene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: ibutilide with relative risk of -24.670 of dantrolene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: ibutilide with relative risk of -24.670 of dantrolene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: telmisartan with relative risk of -28.046 of dantrolene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: telmisartan with relative risk of -28.046 of dantrolene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: telmisartan with relative risk of -28.046 of dantrolene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: tolmetin with relative risk of -28.278 of dantrolene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: tolmetin with relative risk of -28.278 of dantrolene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: tolmetin with relative risk of -28.278 of dantrolene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: milnacipran with relative risk of -28.509 of dantrolene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: milnacipran with relative risk of -28.509 of dantrolene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: milnacipran with relative risk of -28.509 of dantrolene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: progesterone with relative risk of -28.615 of dantrolene | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 36: progesterone with relative risk of -28.615 of dantrolene | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 37: progesterone with relative risk of -28.615 of dantrolene | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 38: estramustine with relative risk of -28.689 of dantrolene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: estramustine with relative risk of -28.689 of dantrolene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: estramustine with relative risk of -28.689 of dantrolene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: abiraterone with relative risk of -29.125 of dantrolene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: abiraterone with relative risk of -29.125 of dantrolene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: abiraterone with relative risk of -29.125 of dantrolene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: lubiprostone with relative risk of -29.511 of dantrolene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: lubiprostone with relative risk of -29.511 of dantrolene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: lubiprostone with relative risk of -29.511 of dantrolene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: auranofin with relative risk of -30.116 of dantrolene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: auranofin with relative risk of -30.116 of dantrolene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: auranofin with relative risk of -30.116 of dantrolene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: dapagliflozin with relative risk of -30.162 of dantrolene | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 51: dapagliflozin with relative risk of -30.162 of dantrolene | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 52: dapagliflozin with relative risk of -30.162 of dantrolene | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 53: misoprostol with relative risk of -30.509 of dantrolene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 54: misoprostol with relative risk of -30.509 of dantrolene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 55: misoprostol with relative risk of -30.509 of dantrolene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 56: risedronate with relative risk of -31.197 of dantrolene | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 57: risedronate with relative risk of -31.197 of dantrolene | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 58: risedronate with relative risk of -31.197 of dantrolene | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 59: donepezil with relative risk of -31.589 of dantrolene | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 60: donepezil with relative risk of -31.589 of dantrolene | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 61: donepezil with relative risk of -31.589 of dantrolene | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 62: cisatracurium with relative risk of -32.261 of dantrolene | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 63: cisatracurium with relative risk of -32.261 of dantrolene | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 64: cisatracurium with relative risk of -32.261 of dantrolene | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.169\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó dapagliflozin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: bosutinib with relative risk of -10.097 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: dofetilide with relative risk of -10.229 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: clarithromycin with relative risk of -10.286 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: olmesartan with relative risk of -12.725 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: estramustine with relative risk of -26.386 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: estramustine with relative risk of -26.386 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: estramustine with relative risk of -26.386 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: auranofin with relative risk of -27.814 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: auranofin with relative risk of -27.814 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: auranofin with relative risk of -27.814 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: dantrolene with relative risk of -28.606 of dapagliflozin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 12: dantrolene with relative risk of -28.606 of dapagliflozin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 13: dantrolene with relative risk of -28.606 of dapagliflozin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 14: risedronate with relative risk of -28.895 of dapagliflozin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 15: risedronate with relative risk of -28.895 of dapagliflozin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 16: risedronate with relative risk of -28.895 of dapagliflozin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 17: donepezil with relative risk of -29.287 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: donepezil with relative risk of -29.287 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: donepezil with relative risk of -29.287 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: sertraline with relative risk of -34.222 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: sertraline with relative risk of -34.222 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: sertraline with relative risk of -34.222 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: sertraline with relative risk of -34.222 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: sertraline with relative risk of -34.222 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: irbesartan with relative risk of -34.590 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: irbesartan with relative risk of -34.590 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: irbesartan with relative risk of -34.590 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: irbesartan with relative risk of -34.590 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: irbesartan with relative risk of -34.590 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: mometasone with relative risk of -36.065 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: mometasone with relative risk of -36.065 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: mometasone with relative risk of -36.065 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: mometasone with relative risk of -36.065 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: mometasone with relative risk of -36.065 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: regadenoson with relative risk of -36.243 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: regadenoson with relative risk of -36.243 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: regadenoson with relative risk of -36.243 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: regadenoson with relative risk of -36.243 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: regadenoson with relative risk of -36.243 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: azelastine with relative risk of -36.761 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: azelastine with relative risk of -36.761 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: azelastine with relative risk of -36.761 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: azelastine with relative risk of -36.761 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: azelastine with relative risk of -36.761 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: posaconazole with relative risk of -37.450 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: posaconazole with relative risk of -37.450 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: posaconazole with relative risk of -37.450 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: posaconazole with relative risk of -37.450 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: posaconazole with relative risk of -37.450 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: ibutilide with relative risk of -38.383 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: ibutilide with relative risk of -38.383 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: ibutilide with relative risk of -38.383 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 53: ibutilide with relative risk of -38.383 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 54: ibutilide with relative risk of -38.383 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 55: telmisartan with relative risk of -45.160 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 56: telmisartan with relative risk of -45.160 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 57: telmisartan with relative risk of -45.160 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 58: telmisartan with relative risk of -45.160 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 59: telmisartan with relative risk of -45.160 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 60: milnacipran with relative risk of -46.827 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 61: milnacipran with relative risk of -46.827 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 62: milnacipran with relative risk of -46.827 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 63: milnacipran with relative risk of -46.827 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 64: milnacipran with relative risk of -46.827 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 65: tolmetin with relative risk of -47.694 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 66: tolmetin with relative risk of -47.694 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 67: tolmetin with relative risk of -47.694 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 68: tolmetin with relative risk of -47.694 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 69: tolmetin with relative risk of -47.694 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 70: progesterone with relative risk of -48.032 of dapagliflozin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 71: progesterone with relative risk of -48.032 of dapagliflozin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 72: progesterone with relative risk of -48.032 of dapagliflozin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 73: progesterone with relative risk of -48.032 of dapagliflozin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 74: progesterone with relative risk of -48.032 of dapagliflozin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 75: abiraterone with relative risk of -48.541 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 76: abiraterone with relative risk of -48.541 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 77: abiraterone with relative risk of -48.541 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 78: abiraterone with relative risk of -48.541 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 79: abiraterone with relative risk of -48.541 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 80: lubiprostone with relative risk of -48.928 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 81: lubiprostone with relative risk of -48.928 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 82: lubiprostone with relative risk of -48.928 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 83: lubiprostone with relative risk of -48.928 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 84: lubiprostone with relative risk of -48.928 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 85: misoprostol with relative risk of -49.925 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 86: misoprostol with relative risk of -49.925 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 87: misoprostol with relative risk of -49.925 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 88: misoprostol with relative risk of -49.925 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 89: misoprostol with relative risk of -49.925 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 90: cisatracurium with relative risk of -51.678 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 91: cisatracurium with relative risk of -51.678 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 92: cisatracurium with relative risk of -51.678 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 93: cisatracurium with relative risk of -51.678 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 94: cisatracurium with relative risk of -51.678 of dapagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.102\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó dapsone *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: lurasidone with relative risk of -9.460 of dapsone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: everolimus with relative risk of -9.823 of dapsone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: lansoprazole with relative risk of -10.009 of dapsone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: clarithromycin with relative risk of -10.796 of dapsone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 5: perindopril with relative risk of -11.340 of dapsone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: regadenoson with relative risk of -14.385 of dapsone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: regadenoson with relative risk of -14.385 of dapsone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: irbesartan with relative risk of -14.814 of dapsone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: irbesartan with relative risk of -14.814 of dapsone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: posaconazole with relative risk of -15.459 of dapsone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 11: posaconazole with relative risk of -15.459 of dapsone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 12: azelastine with relative risk of -15.600 of dapsone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: azelastine with relative risk of -15.600 of dapsone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: ropivacaine with relative risk of -16.927 of dapsone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: ropivacaine with relative risk of -16.927 of dapsone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: sertraline with relative risk of -21.564 of dapsone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: sertraline with relative risk of -21.564 of dapsone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: sertraline with relative risk of -21.564 of dapsone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: mometasone with relative risk of -22.583 of dapsone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: dermatology\n",
      "Rank 20: mometasone with relative risk of -22.583 of dapsone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: dermatology\n",
      "Rank 21: mometasone with relative risk of -22.583 of dapsone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: dermatology\n",
      "Rank 22: ibutilide with relative risk of -24.670 of dapsone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: ibutilide with relative risk of -24.670 of dapsone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: ibutilide with relative risk of -24.670 of dapsone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: tropisetron with relative risk of -24.754 of dapsone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: tropisetron with relative risk of -24.754 of dapsone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: tropisetron with relative risk of -24.754 of dapsone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: paliperidone with relative risk of -24.840 of dapsone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: paliperidone with relative risk of -24.840 of dapsone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: paliperidone with relative risk of -24.840 of dapsone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: glimepiride with relative risk of -24.888 of dapsone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: glimepiride with relative risk of -24.888 of dapsone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: glimepiride with relative risk of -24.888 of dapsone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: pentoxifylline with relative risk of -24.938 of dapsone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: pentoxifylline with relative risk of -24.938 of dapsone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: pentoxifylline with relative risk of -24.938 of dapsone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: darifenacin with relative risk of -25.563 of dapsone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: darifenacin with relative risk of -25.563 of dapsone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: darifenacin with relative risk of -25.563 of dapsone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: terbutaline with relative risk of -26.867 of dapsone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: terbutaline with relative risk of -26.867 of dapsone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: terbutaline with relative risk of -26.867 of dapsone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: esmolol with relative risk of -27.830 of dapsone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: esmolol with relative risk of -27.830 of dapsone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: esmolol with relative risk of -27.830 of dapsone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: azilsartan with relative risk of -29.289 of dapsone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: azilsartan with relative risk of -29.289 of dapsone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: azilsartan with relative risk of -29.289 of dapsone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: brimonidine with relative risk of -30.520 of dapsone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: brimonidine with relative risk of -30.520 of dapsone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: brimonidine with relative risk of -30.520 of dapsone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: tazarotene with relative risk of -31.093 of dapsone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Acne Vulgaris,dermatology\n",
      "Rank 53: tazarotene with relative risk of -31.093 of dapsone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Acne Vulgaris,dermatology\n",
      "Rank 54: tazarotene with relative risk of -31.093 of dapsone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Acne Vulgaris,dermatology\n",
      "Rank 55: isradipine with relative risk of -32.098 of dapsone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 56: isradipine with relative risk of -32.098 of dapsone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 57: isradipine with relative risk of -32.098 of dapsone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 58: felodipine with relative risk of -inf of dapsone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 59: felodipine with relative risk of -inf of dapsone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 60: felodipine with relative risk of -inf of dapsone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.138\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó darifenacin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: ibandronate with relative risk of -7.637 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: miglustat with relative risk of -7.761 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: lurasidone with relative risk of -7.997 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: everolimus with relative risk of -8.358 of darifenacin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: urology\n",
      "Rank 5: formoterol with relative risk of -8.456 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: lansoprazole with relative risk of -8.547 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: clarithromycin with relative risk of -9.332 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: dabigatran with relative risk of -9.364 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: estramustine with relative risk of -9.418 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: zonisamide with relative risk of -9.623 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: perindopril with relative risk of -9.875 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: etravirine with relative risk of -9.902 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: linezolid with relative risk of -10.068 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: tiotropium with relative risk of -10.289 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: regadenoson with relative risk of -11.137 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: regadenoson with relative risk of -11.137 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: irbesartan with relative risk of -11.577 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: irbesartan with relative risk of -11.577 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: posaconazole with relative risk of -12.210 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: posaconazole with relative risk of -12.210 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: febuxostat with relative risk of -12.335 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: azelastine with relative risk of -12.355 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: azelastine with relative risk of -12.355 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: ropivacaine with relative risk of -13.672 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: ropivacaine with relative risk of -13.672 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: sertraline with relative risk of -15.926 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: sertraline with relative risk of -15.926 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: sertraline with relative risk of -15.926 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: eplerenone with relative risk of -16.251 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: eplerenone with relative risk of -16.251 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: mometasone with relative risk of -16.939 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: mometasone with relative risk of -16.939 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: mometasone with relative risk of -16.939 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: exemestane with relative risk of -17.563 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: exemestane with relative risk of -17.563 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: ibutilide with relative risk of -19.025 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: ibutilide with relative risk of -19.025 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: ibutilide with relative risk of -19.025 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: tropisetron with relative risk of -19.105 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: tropisetron with relative risk of -19.105 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: tropisetron with relative risk of -19.105 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: paliperidone with relative risk of -19.191 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: paliperidone with relative risk of -19.191 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: paliperidone with relative risk of -19.191 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: glimepiride with relative risk of -19.238 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: glimepiride with relative risk of -19.238 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: glimepiride with relative risk of -19.238 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: terbutaline with relative risk of -21.213 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: terbutaline with relative risk of -21.213 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: terbutaline with relative risk of -21.213 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: esmolol with relative risk of -22.175 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: esmolol with relative risk of -22.175 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 53: esmolol with relative risk of -22.175 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 54: azilsartan with relative risk of -23.635 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 55: azilsartan with relative risk of -23.635 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 56: azilsartan with relative risk of -23.635 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 57: indacaterol with relative risk of -24.116 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 58: indacaterol with relative risk of -24.116 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 59: indacaterol with relative risk of -24.116 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 60: brimonidine with relative risk of -24.864 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 61: brimonidine with relative risk of -24.864 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 62: brimonidine with relative risk of -24.864 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 63: tazarotene with relative risk of -25.437 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 64: tazarotene with relative risk of -25.437 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 65: tazarotene with relative risk of -25.437 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 66: pentoxifylline with relative risk of -25.653 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 67: pentoxifylline with relative risk of -25.653 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 68: pentoxifylline with relative risk of -25.653 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 69: pentoxifylline with relative risk of -25.653 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 70: dapsone with relative risk of -25.697 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 71: dapsone with relative risk of -25.697 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 72: dapsone with relative risk of -25.697 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 73: isradipine with relative risk of -26.442 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 74: isradipine with relative risk of -26.442 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 75: isradipine with relative risk of -26.442 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 76: ciclesonide with relative risk of -62.869 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 77: ciclesonide with relative risk of -62.869 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 78: ciclesonide with relative risk of -62.869 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 79: ciclesonide with relative risk of -62.869 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 80: ciclesonide with relative risk of -62.869 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 81: ciclesonide with relative risk of -62.869 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 82: ciclesonide with relative risk of -62.869 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 83: ciclesonide with relative risk of -62.869 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 84: ciclesonide with relative risk of -62.869 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 85: ciclesonide with relative risk of -62.869 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 86: meloxicam with relative risk of -75.665 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 87: meloxicam with relative risk of -75.665 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 88: meloxicam with relative risk of -75.665 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 89: meloxicam with relative risk of -75.665 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 90: meloxicam with relative risk of -75.665 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 91: meloxicam with relative risk of -75.665 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 92: meloxicam with relative risk of -75.665 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 93: meloxicam with relative risk of -75.665 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 94: meloxicam with relative risk of -75.665 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 95: meloxicam with relative risk of -75.665 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 96: axitinib with relative risk of -79.790 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 97: axitinib with relative risk of -79.790 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 98: axitinib with relative risk of -79.790 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 99: axitinib with relative risk of -79.790 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 100: axitinib with relative risk of -79.790 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 101: axitinib with relative risk of -79.790 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 102: axitinib with relative risk of -79.790 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 103: axitinib with relative risk of -79.790 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 104: axitinib with relative risk of -79.790 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 105: axitinib with relative risk of -79.790 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 106: vinorelbine with relative risk of -81.544 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 107: vinorelbine with relative risk of -81.544 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 108: vinorelbine with relative risk of -81.544 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 109: vinorelbine with relative risk of -81.544 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 110: vinorelbine with relative risk of -81.544 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 111: vinorelbine with relative risk of -81.544 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 112: vinorelbine with relative risk of -81.544 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 113: vinorelbine with relative risk of -81.544 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 114: vinorelbine with relative risk of -81.544 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 115: vinorelbine with relative risk of -81.544 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 116: granisetron with relative risk of -82.432 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 117: granisetron with relative risk of -82.432 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 118: granisetron with relative risk of -82.432 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 119: granisetron with relative risk of -82.432 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 120: granisetron with relative risk of -82.432 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 121: granisetron with relative risk of -82.432 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 122: granisetron with relative risk of -82.432 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 123: granisetron with relative risk of -82.432 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 124: granisetron with relative risk of -82.432 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 125: granisetron with relative risk of -82.432 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 126: apraclonidine with relative risk of -82.589 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 127: apraclonidine with relative risk of -82.589 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 128: apraclonidine with relative risk of -82.589 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 129: apraclonidine with relative risk of -82.589 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 130: apraclonidine with relative risk of -82.589 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 131: apraclonidine with relative risk of -82.589 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 132: apraclonidine with relative risk of -82.589 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 133: apraclonidine with relative risk of -82.589 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 134: apraclonidine with relative risk of -82.589 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 135: apraclonidine with relative risk of -82.589 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 136: pinaverium with relative risk of -85.568 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 137: pinaverium with relative risk of -85.568 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 138: pinaverium with relative risk of -85.568 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 139: pinaverium with relative risk of -85.568 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 140: pinaverium with relative risk of -85.568 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 141: pinaverium with relative risk of -85.568 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 142: pinaverium with relative risk of -85.568 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 143: pinaverium with relative risk of -85.568 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 144: pinaverium with relative risk of -85.568 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 145: pinaverium with relative risk of -85.568 of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 146: desoximetasone with relative risk of -inf of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 147: desoximetasone with relative risk of -inf of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 148: desoximetasone with relative risk of -inf of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 149: felodipine with relative risk of -inf of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 150: desoximetasone with relative risk of -inf of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 151: desoximetasone with relative risk of -inf of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 152: desoximetasone with relative risk of -inf of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 153: desoximetasone with relative risk of -inf of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 154: desoximetasone with relative risk of -inf of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 155: desoximetasone with relative risk of -inf of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 156: desoximetasone with relative risk of -inf of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 157: felodipine with relative risk of -inf of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 158: felodipine with relative risk of -inf of darifenacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.044\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó darunavir *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: clozapine with relative risk of -8.965 of darunavir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: topotecan with relative risk of -27.948 of darunavir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: topotecan with relative risk of -27.948 of darunavir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: topotecan with relative risk of -27.948 of darunavir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: metolazone with relative risk of -30.277 of darunavir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: metolazone with relative risk of -30.277 of darunavir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: metolazone with relative risk of -30.277 of darunavir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: nalbuphine with relative risk of -31.497 of darunavir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: nalbuphine with relative risk of -31.497 of darunavir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: nalbuphine with relative risk of -31.497 of darunavir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó dasatinib *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: podophyllotoxin with relative risk of -11.110 of dasatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: degarelix with relative risk of -11.759 of dasatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: eliglustat with relative risk of -12.452 of dasatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó deferasirox *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: ponatinib with relative risk of -11.976 of deferasirox | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó degarelix *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: metronidazole with relative risk of -9.964 of degarelix | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: podophyllotoxin with relative risk of -10.012 of degarelix | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: loxapine with relative risk of -10.378 of degarelix | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: avanafil with relative risk of -11.132 of degarelix | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: dasatinib with relative risk of -11.279 of degarelix | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: eliglustat with relative risk of -11.354 of degarelix | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target delamanid not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó delavirdine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: regadenoson with relative risk of -7.550 of delavirdine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: ibandronate with relative risk of -9.095 of delavirdine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: ruxolitinib with relative risk of -9.413 of delavirdine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: lurasidone with relative risk of -9.460 of delavirdine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: ibutilide with relative risk of -10.018 of delavirdine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: varenicline with relative risk of -10.876 of delavirdine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: ixabepilone with relative risk of -11.242 of delavirdine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: benazepril with relative risk of -12.080 of delavirdine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: toremifene with relative risk of -12.834 of delavirdine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: telmisartan with relative risk of -18.685 of delavirdine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: telmisartan with relative risk of -18.685 of delavirdine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: clonidine with relative risk of -20.194 of delavirdine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: clonidine with relative risk of -20.194 of delavirdine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: erlotinib with relative risk of -20.239 of delavirdine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: erlotinib with relative risk of -20.239 of delavirdine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: vemurafenib with relative risk of -20.271 of delavirdine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: vemurafenib with relative risk of -20.271 of delavirdine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: sertraline with relative risk of -21.564 of delavirdine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: sertraline with relative risk of -21.564 of delavirdine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: sertraline with relative risk of -21.564 of delavirdine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: rotigotine with relative risk of -21.606 of delavirdine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: rotigotine with relative risk of -21.606 of delavirdine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: doxepin with relative risk of -21.814 of delavirdine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: doxepin with relative risk of -21.814 of delavirdine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: azelastine with relative risk of -23.351 of delavirdine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: azelastine with relative risk of -23.351 of delavirdine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: azelastine with relative risk of -23.351 of delavirdine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: ropivacaine with relative risk of -26.001 of delavirdine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: ropivacaine with relative risk of -26.001 of delavirdine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: ropivacaine with relative risk of -26.001 of delavirdine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: ticagrelor with relative risk of -26.801 of delavirdine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: ticagrelor with relative risk of -26.801 of delavirdine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: ticagrelor with relative risk of -26.801 of delavirdine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: naproxen with relative risk of -27.101 of delavirdine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: naproxen with relative risk of -27.101 of delavirdine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: naproxen with relative risk of -27.101 of delavirdine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: gabapentin with relative risk of -28.660 of delavirdine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 38: gabapentin with relative risk of -28.660 of delavirdine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 39: gabapentin with relative risk of -28.660 of delavirdine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 40: clarithromycin with relative risk of -29.008 of delavirdine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 41: clarithromycin with relative risk of -29.008 of delavirdine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 42: clarithromycin with relative risk of -29.008 of delavirdine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.035\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target deprenyl not found. Exiting ...\n",
      "\n",
      "Drug target desflurane not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó desloratadine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: aminophylline with relative risk of -8.138 of desloratadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: finasteride with relative risk of -9.712 of desloratadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: valdecoxib with relative risk of -10.111 of desloratadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: dihydroergotamine with relative risk of -10.536 of desloratadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: alendronate with relative risk of -10.894 of desloratadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: ramipril with relative risk of -11.347 of desloratadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: clopidogrel with relative risk of -12.004 of desloratadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target desmopressin not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó desonide *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: irbesartan with relative risk of -9.727 of desonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: azelastine with relative risk of -10.076 of desonide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic rhinitis (disorder)\n",
      "Rank 3: naltrexone with relative risk of -12.032 of desonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: cladribine with relative risk of -12.497 of desonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: nicotine with relative risk of -13.313 of desonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.219\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó desoximetasone *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: miglustat with relative risk of -6.807 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: pentoxifylline with relative risk of -7.051 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: formoterol with relative risk of -7.503 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: ketorolac with relative risk of -7.747 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: loratadine with relative risk of -8.035 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: carbamazepine with relative risk of -8.175 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: nabumetone with relative risk of -8.183 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: dabigatran with relative risk of -8.404 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: estramustine with relative risk of -8.462 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: zonisamide with relative risk of -8.663 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: etravirine with relative risk of -8.942 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: linezolid with relative risk of -9.108 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: silodosin with relative risk of -9.294 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: tiotropium with relative risk of -9.328 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: conivaptan with relative risk of -9.498 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: nefazodone with relative risk of -9.569 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: febuxostat with relative risk of -11.373 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: paroxetine with relative risk of -14.194 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: paroxetine with relative risk of -14.194 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: paroxetine with relative risk of -14.194 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: eplerenone with relative risk of -14.279 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: eplerenone with relative risk of -14.279 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: emedastine with relative risk of -15.294 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: emedastine with relative risk of -15.294 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: exemestane with relative risk of -15.590 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: exemestane with relative risk of -15.590 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: ibandronate with relative risk of -15.689 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: ibandronate with relative risk of -15.689 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: ibandronate with relative risk of -15.689 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: indacaterol with relative risk of -21.076 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: indacaterol with relative risk of -21.076 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: indacaterol with relative risk of -21.076 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: sunitinib with relative risk of -32.845 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: sunitinib with relative risk of -32.845 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: sunitinib with relative risk of -32.845 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: sunitinib with relative risk of -32.845 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: sunitinib with relative risk of -32.845 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: ramelteon with relative risk of -43.405 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: ramelteon with relative risk of -43.405 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: ramelteon with relative risk of -43.405 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: ramelteon with relative risk of -43.405 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: ramelteon with relative risk of -43.405 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: ramelteon with relative risk of -43.405 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: clomipramine with relative risk of -49.007 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: clomipramine with relative risk of -49.007 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: clomipramine with relative risk of -49.007 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: clomipramine with relative risk of -49.007 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: clomipramine with relative risk of -49.007 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: clomipramine with relative risk of -49.007 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: clomipramine with relative risk of -49.007 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: meloxicam with relative risk of -62.634 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: meloxicam with relative risk of -62.634 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 53: meloxicam with relative risk of -62.634 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 54: meloxicam with relative risk of -62.634 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 55: meloxicam with relative risk of -62.634 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 56: meloxicam with relative risk of -62.634 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 57: meloxicam with relative risk of -62.634 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 58: meloxicam with relative risk of -62.634 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 59: meloxicam with relative risk of -62.634 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 60: meloxicam with relative risk of -62.634 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 61: darifenacin with relative risk of -63.945 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 62: darifenacin with relative risk of -63.945 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 63: darifenacin with relative risk of -63.945 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 64: darifenacin with relative risk of -63.945 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 65: darifenacin with relative risk of -63.945 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 66: darifenacin with relative risk of -63.945 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 67: darifenacin with relative risk of -63.945 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 68: darifenacin with relative risk of -63.945 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 69: darifenacin with relative risk of -63.945 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 70: darifenacin with relative risk of -63.945 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 71: axitinib with relative risk of -66.756 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 72: axitinib with relative risk of -66.756 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 73: axitinib with relative risk of -66.756 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 74: axitinib with relative risk of -66.756 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 75: axitinib with relative risk of -66.756 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 76: axitinib with relative risk of -66.756 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 77: axitinib with relative risk of -66.756 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 78: axitinib with relative risk of -66.756 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 79: axitinib with relative risk of -66.756 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 80: axitinib with relative risk of -66.756 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 81: vinorelbine with relative risk of -68.509 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 82: vinorelbine with relative risk of -68.509 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 83: vinorelbine with relative risk of -68.509 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 84: vinorelbine with relative risk of -68.509 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 85: vinorelbine with relative risk of -68.509 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 86: vinorelbine with relative risk of -68.509 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 87: vinorelbine with relative risk of -68.509 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 88: vinorelbine with relative risk of -68.509 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 89: vinorelbine with relative risk of -68.509 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 90: vinorelbine with relative risk of -68.509 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 91: granisetron with relative risk of -69.396 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 92: granisetron with relative risk of -69.396 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 93: granisetron with relative risk of -69.396 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 94: granisetron with relative risk of -69.396 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 95: granisetron with relative risk of -69.396 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 96: granisetron with relative risk of -69.396 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 97: granisetron with relative risk of -69.396 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 98: granisetron with relative risk of -69.396 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 99: granisetron with relative risk of -69.396 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 100: granisetron with relative risk of -69.396 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 101: apraclonidine with relative risk of -69.553 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 102: apraclonidine with relative risk of -69.553 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 103: apraclonidine with relative risk of -69.553 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 104: apraclonidine with relative risk of -69.553 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 105: apraclonidine with relative risk of -69.553 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 106: apraclonidine with relative risk of -69.553 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 107: apraclonidine with relative risk of -69.553 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 108: apraclonidine with relative risk of -69.553 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 109: apraclonidine with relative risk of -69.553 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 110: apraclonidine with relative risk of -69.553 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 111: pinaverium with relative risk of -72.532 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 112: pinaverium with relative risk of -72.532 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 113: pinaverium with relative risk of -72.532 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 114: pinaverium with relative risk of -72.532 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 115: pinaverium with relative risk of -72.532 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 116: pinaverium with relative risk of -72.532 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 117: pinaverium with relative risk of -72.532 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 118: pinaverium with relative risk of -72.532 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 119: pinaverium with relative risk of -72.532 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 120: pinaverium with relative risk of -72.532 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 121: ciclesonide with relative risk of -80.818 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 122: ciclesonide with relative risk of -80.818 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 123: ciclesonide with relative risk of -80.818 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 124: ciclesonide with relative risk of -80.818 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 125: ciclesonide with relative risk of -80.818 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 126: ciclesonide with relative risk of -80.818 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 127: ciclesonide with relative risk of -80.818 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 128: ciclesonide with relative risk of -80.818 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 129: ciclesonide with relative risk of -80.818 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 130: ciclesonide with relative risk of -80.818 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 131: ciclesonide with relative risk of -80.818 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 132: ciclesonide with relative risk of -80.818 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 133: ciclesonide with relative risk of -80.818 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 134: ciclesonide with relative risk of -80.818 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 135: ciclesonide with relative risk of -80.818 of desoximetasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó desvenlafaxine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: aminophylline with relative risk of -9.523 of desvenlafaxine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: ropivacaine with relative risk of -10.167 of desvenlafaxine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: ibandronate with relative risk of -10.192 of desvenlafaxine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: imatinib with relative risk of -10.310 of desvenlafaxine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: gemcitabine with relative risk of -10.824 of desvenlafaxine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: gefitinib with relative risk of -10.832 of desvenlafaxine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: trimetrexate with relative risk of -10.939 of desvenlafaxine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: finasteride with relative risk of -11.097 of desvenlafaxine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: valdecoxib with relative risk of -11.496 of desvenlafaxine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: acyclovir with relative risk of -11.705 of desvenlafaxine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: dihydroergotamine with relative risk of -11.922 of desvenlafaxine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: atosiban with relative risk of -12.021 of desvenlafaxine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: vincristine with relative risk of -12.233 of desvenlafaxine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: alendronate with relative risk of -12.279 of desvenlafaxine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: ramipril with relative risk of -12.733 of desvenlafaxine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: clopidogrel with relative risk of -13.390 of desvenlafaxine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 17: amoxicillin with relative risk of -13.617 of desvenlafaxine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: diltiazem with relative risk of -13.859 of desvenlafaxine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: nebivolol with relative risk of -14.345 of desvenlafaxine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.208\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó dexamethasone *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: linagliptin with relative risk of -12.770 of dexamethasone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 2: lenalidomide with relative risk of -15.903 of dexamethasone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Multiple Myeloma\n",
      "Rank 3: lenalidomide with relative risk of -15.903 of dexamethasone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Multiple Myeloma\n",
      "Rank 4: amiodarone with relative risk of -16.364 of dexamethasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: amiodarone with relative risk of -16.364 of dexamethasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: penbutolol with relative risk of -17.247 of dexamethasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: penbutolol with relative risk of -17.247 of dexamethasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: fluvastatin with relative risk of -18.941 of dexamethasone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 9: fluvastatin with relative risk of -18.941 of dexamethasone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 10: sitagliptin with relative risk of -21.188 of dexamethasone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 11: sitagliptin with relative risk of -21.188 of dexamethasone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.748\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó dexmedetomidine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: quetiapine with relative risk of -22.344 of dexmedetomidine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: quetiapine with relative risk of -22.344 of dexmedetomidine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: oxybutynin with relative risk of -22.688 of dexmedetomidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: oxybutynin with relative risk of -22.688 of dexmedetomidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.72\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó dexrazoxane *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: tamoxifen with relative risk of -11.077 of dexrazoxane | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: mitoxantrone with relative risk of -11.166 of dexrazoxane | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: raltitrexed with relative risk of -11.330 of dexrazoxane | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: glipizide with relative risk of -12.172 of dexrazoxane | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: rosuvastatin with relative risk of -12.471 of dexrazoxane | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 6: carvedilol with relative risk of -20.672 of dexrazoxane | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 7: carvedilol with relative risk of -20.672 of dexrazoxane | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.197\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target diazepam not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó diclofenac *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: lenalidomide with relative risk of -6.733 of diclofenac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: amiloride with relative risk of -10.485 of diclofenac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: salmeterol with relative risk of -10.681 of diclofenac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: roflumilast with relative risk of -11.309 of diclofenac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: torasemide with relative risk of -11.759 of diclofenac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: lamotrigine with relative risk of -16.944 of diclofenac | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: lamotrigine with relative risk of -16.944 of diclofenac | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: raltitrexed with relative risk of -17.173 of diclofenac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: raltitrexed with relative risk of -17.173 of diclofenac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: pentostatin with relative risk of -32.483 of diclofenac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: pentostatin with relative risk of -32.483 of diclofenac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: pentostatin with relative risk of -32.483 of diclofenac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: pentostatin with relative risk of -32.483 of diclofenac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: norfloxacin with relative risk of -42.255 of diclofenac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: norfloxacin with relative risk of -42.255 of diclofenac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: norfloxacin with relative risk of -42.255 of diclofenac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: norfloxacin with relative risk of -42.255 of diclofenac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: norfloxacin with relative risk of -42.255 of diclofenac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.089\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target dicyclomine not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó didanosine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: metoprolol with relative risk of -8.410 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: naproxen with relative risk of -8.602 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: cyclophosphamide with relative risk of -8.679 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: milrinone with relative risk of -8.833 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: gabapentin with relative risk of -9.755 of didanosine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 6: telmisartan with relative risk of -9.884 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: nevirapine with relative risk of -10.059 of didanosine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 8: cetirizine with relative risk of -10.078 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: tamsulosin with relative risk of -10.158 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: flutamide with relative risk of -10.193 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: bezafibrate with relative risk of -10.466 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: fondaparinux with relative risk of -10.749 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: pentoxifylline with relative risk of -15.011 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: pentoxifylline with relative risk of -15.011 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: levonorgestrel with relative risk of -15.832 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: levonorgestrel with relative risk of -15.832 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: pemetrexed with relative risk of -16.027 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: pemetrexed with relative risk of -16.027 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: terbutaline with relative risk of -16.051 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: terbutaline with relative risk of -16.051 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: ruxolitinib with relative risk of -16.250 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: ruxolitinib with relative risk of -16.250 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: esmolol with relative risk of -16.454 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: esmolol with relative risk of -16.454 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: indomethacin with relative risk of -16.656 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: indomethacin with relative risk of -16.656 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: ivacaftor with relative risk of -17.050 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: ivacaftor with relative risk of -17.050 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: everolimus with relative risk of -17.170 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: everolimus with relative risk of -17.170 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: bumetanide with relative risk of -17.460 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: bumetanide with relative risk of -17.460 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: azilsartan with relative risk of -17.913 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: azilsartan with relative risk of -17.913 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: brinzolamide with relative risk of -18.866 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: brinzolamide with relative risk of -18.866 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: acebutolol with relative risk of -19.211 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: acebutolol with relative risk of -19.211 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: valsartan with relative risk of -19.354 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: valsartan with relative risk of -19.354 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: sumatriptan with relative risk of -20.008 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: sumatriptan with relative risk of -20.008 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: citalopram with relative risk of -20.031 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: citalopram with relative risk of -20.031 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: ropivacaine with relative risk of -23.006 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: ropivacaine with relative risk of -23.006 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: ropivacaine with relative risk of -23.006 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: ketorolac with relative risk of -23.673 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: ketorolac with relative risk of -23.673 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: ketorolac with relative risk of -23.673 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: lurasidone with relative risk of -23.935 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: lurasidone with relative risk of -23.935 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 53: lurasidone with relative risk of -23.935 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 54: trovafloxacin with relative risk of -25.061 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 55: trovafloxacin with relative risk of -25.061 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 56: trovafloxacin with relative risk of -25.061 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 57: dutasteride with relative risk of -25.800 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 58: dutasteride with relative risk of -25.800 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 59: dutasteride with relative risk of -25.800 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 60: zolmitriptan with relative risk of -26.933 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 61: zolmitriptan with relative risk of -26.933 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 62: zolmitriptan with relative risk of -26.933 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 63: etoposide with relative risk of -37.313 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 64: etoposide with relative risk of -37.313 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 65: etoposide with relative risk of -37.313 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 66: etoposide with relative risk of -37.313 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 67: etoposide with relative risk of -37.313 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 68: glimepiride with relative risk of -38.003 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 69: glimepiride with relative risk of -38.003 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 70: glimepiride with relative risk of -38.003 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 71: glimepiride with relative risk of -38.003 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 72: glimepiride with relative risk of -38.003 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 73: fenofibrate with relative risk of -39.857 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 74: fenofibrate with relative risk of -39.857 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 75: fenofibrate with relative risk of -39.857 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 76: fenofibrate with relative risk of -39.857 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 77: fenofibrate with relative risk of -39.857 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 78: sertraline with relative risk of -40.588 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 79: sertraline with relative risk of -40.588 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 80: sertraline with relative risk of -40.588 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 81: sertraline with relative risk of -40.588 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 82: sertraline with relative risk of -40.588 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 83: sertraline with relative risk of -40.588 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 84: irbesartan with relative risk of -40.861 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 85: irbesartan with relative risk of -40.861 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 86: irbesartan with relative risk of -40.861 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 87: irbesartan with relative risk of -40.861 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 88: irbesartan with relative risk of -40.861 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 89: irbesartan with relative risk of -40.861 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 90: lansoprazole with relative risk of -41.010 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 91: lansoprazole with relative risk of -41.010 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 92: lansoprazole with relative risk of -41.010 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 93: lansoprazole with relative risk of -41.010 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 94: lansoprazole with relative risk of -41.010 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 95: mometasone with relative risk of -42.861 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 96: mometasone with relative risk of -42.861 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 97: mometasone with relative risk of -42.861 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 98: mometasone with relative risk of -42.861 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 99: mometasone with relative risk of -42.861 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 100: mometasone with relative risk of -42.861 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 101: regadenoson with relative risk of -43.253 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 102: regadenoson with relative risk of -43.253 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 103: regadenoson with relative risk of -43.253 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 104: regadenoson with relative risk of -43.253 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 105: regadenoson with relative risk of -43.253 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 106: regadenoson with relative risk of -43.253 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 107: azelastine with relative risk of -43.520 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 108: azelastine with relative risk of -43.520 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 109: azelastine with relative risk of -43.520 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 110: azelastine with relative risk of -43.520 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 111: azelastine with relative risk of -43.520 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 112: azelastine with relative risk of -43.520 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 113: posaconazole with relative risk of -44.509 of didanosine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 114: posaconazole with relative risk of -44.509 of didanosine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 115: posaconazole with relative risk of -44.509 of didanosine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 116: posaconazole with relative risk of -44.509 of didanosine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 117: posaconazole with relative risk of -44.509 of didanosine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 118: posaconazole with relative risk of -44.509 of didanosine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 119: ibutilide with relative risk of -45.302 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 120: ibutilide with relative risk of -45.302 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 121: ibutilide with relative risk of -45.302 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 122: ibutilide with relative risk of -45.302 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 123: ibutilide with relative risk of -45.302 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 124: ibutilide with relative risk of -45.302 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 125: tropisetron with relative risk of -46.604 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 126: tropisetron with relative risk of -46.604 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 127: tropisetron with relative risk of -46.604 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 128: tropisetron with relative risk of -46.604 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 129: tropisetron with relative risk of -46.604 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 130: tropisetron with relative risk of -46.604 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 131: paliperidone with relative risk of -46.885 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 132: paliperidone with relative risk of -46.885 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 133: paliperidone with relative risk of -46.885 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 134: paliperidone with relative risk of -46.885 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 135: paliperidone with relative risk of -46.885 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 136: paliperidone with relative risk of -46.885 of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 137: felodipine with relative risk of -inf of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 138: felodipine with relative risk of -inf of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 139: felodipine with relative risk of -inf of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 140: felodipine with relative risk of -inf of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 141: felodipine with relative risk of -inf of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 142: felodipine with relative risk of -inf of didanosine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.071\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target digoxin not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó dihydroergotamine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: ropivacaine with relative risk of -8.378 of dihydroergotamine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: ibandronate with relative risk of -8.405 of dihydroergotamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: imatinib with relative risk of -8.519 of dihydroergotamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: gemcitabine with relative risk of -9.033 of dihydroergotamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: atosiban with relative risk of -10.229 of dihydroergotamine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: vincristine with relative risk of -10.441 of dihydroergotamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: desloratadine with relative risk of -10.678 of dihydroergotamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: desvenlafaxine with relative risk of -11.323 of dihydroergotamine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: amoxicillin with relative risk of -11.825 of dihydroergotamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: diltiazem with relative risk of -12.068 of dihydroergotamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: nebivolol with relative risk of -12.553 of dihydroergotamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: acyclovir with relative risk of -19.052 of dihydroergotamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: acyclovir with relative risk of -19.052 of dihydroergotamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: gefitinib with relative risk of -25.462 of dihydroergotamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: gefitinib with relative risk of -25.462 of dihydroergotamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: gefitinib with relative risk of -25.462 of dihydroergotamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: clopidogrel with relative risk of -28.020 of dihydroergotamine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 18: clopidogrel with relative risk of -28.020 of dihydroergotamine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 19: clopidogrel with relative risk of -28.020 of dihydroergotamine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 20: ramipril with relative risk of -29.154 of dihydroergotamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: ramipril with relative risk of -29.154 of dihydroergotamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: ramipril with relative risk of -29.154 of dihydroergotamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: aminophylline with relative risk of -30.758 of dihydroergotamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: aminophylline with relative risk of -30.758 of dihydroergotamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: aminophylline with relative risk of -30.758 of dihydroergotamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: aminophylline with relative risk of -30.758 of dihydroergotamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: alendronate with relative risk of -42.692 of dihydroergotamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: alendronate with relative risk of -42.692 of dihydroergotamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: alendronate with relative risk of -42.692 of dihydroergotamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: alendronate with relative risk of -42.692 of dihydroergotamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: alendronate with relative risk of -42.692 of dihydroergotamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: trimetrexate with relative risk of -43.481 of dihydroergotamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: trimetrexate with relative risk of -43.481 of dihydroergotamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: trimetrexate with relative risk of -43.481 of dihydroergotamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: trimetrexate with relative risk of -43.481 of dihydroergotamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: trimetrexate with relative risk of -43.481 of dihydroergotamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: finasteride with relative risk of -51.748 of dihydroergotamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: finasteride with relative risk of -51.748 of dihydroergotamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: finasteride with relative risk of -51.748 of dihydroergotamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: finasteride with relative risk of -51.748 of dihydroergotamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: finasteride with relative risk of -51.748 of dihydroergotamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: finasteride with relative risk of -51.748 of dihydroergotamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: valdecoxib with relative risk of -55.191 of dihydroergotamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: valdecoxib with relative risk of -55.191 of dihydroergotamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: valdecoxib with relative risk of -55.191 of dihydroergotamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: valdecoxib with relative risk of -55.191 of dihydroergotamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: valdecoxib with relative risk of -55.191 of dihydroergotamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: valdecoxib with relative risk of -55.191 of dihydroergotamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.335\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó diltiazem *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: aminophylline with relative risk of -9.523 of diltiazem | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: ropivacaine with relative risk of -10.167 of diltiazem | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: ibandronate with relative risk of -10.192 of diltiazem | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: imatinib with relative risk of -10.310 of diltiazem | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: gemcitabine with relative risk of -10.824 of diltiazem | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: gefitinib with relative risk of -10.832 of diltiazem | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: trimetrexate with relative risk of -10.939 of diltiazem | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: finasteride with relative risk of -11.097 of diltiazem | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: valdecoxib with relative risk of -11.496 of diltiazem | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: acyclovir with relative risk of -11.705 of diltiazem | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: dihydroergotamine with relative risk of -11.922 of diltiazem | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: atosiban with relative risk of -12.021 of diltiazem | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 13: vincristine with relative risk of -12.233 of diltiazem | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: alendronate with relative risk of -12.279 of diltiazem | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: ramipril with relative risk of -12.733 of diltiazem | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 16: desvenlafaxine with relative risk of -13.114 of diltiazem | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: clopidogrel with relative risk of -13.390 of diltiazem | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 18: amoxicillin with relative risk of -13.617 of diltiazem | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: nebivolol with relative risk of -14.345 of diltiazem | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.074\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó dipyridamole *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: cabazitaxel with relative risk of -9.888 of dipyridamole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: danazol with relative risk of -11.034 of dipyridamole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 3: gonadorelin with relative risk of -11.940 of dipyridamole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: phenytoin with relative risk of -12.213 of dipyridamole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: montelukast with relative risk of -12.307 of dipyridamole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: mexiletine with relative risk of -12.655 of dipyridamole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 7: ranitidine with relative risk of -12.753 of dipyridamole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: zafirlukast with relative risk of -12.826 of dipyridamole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: cilazapril with relative risk of -14.631 of dipyridamole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 10: mitotane with relative risk of -21.036 of dipyridamole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: mitotane with relative risk of -21.036 of dipyridamole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: canagliflozin with relative risk of -21.978 of dipyridamole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: canagliflozin with relative risk of -21.978 of dipyridamole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.245\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó disopyramide *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: colchicine with relative risk of -9.876 of disopyramide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: fluvoxamine with relative risk of -10.071 of disopyramide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: dofetilide with relative risk of -11.839 of disopyramide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: pitavastatin with relative risk of -13.829 of disopyramide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó docetaxel *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: pramipexole with relative risk of -11.929 of docetaxel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: etodolac with relative risk of -12.358 of docetaxel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: metaproterenol with relative risk of -12.759 of docetaxel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: duloxetine with relative risk of -12.992 of docetaxel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: bupropion with relative risk of -13.123 of docetaxel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: repaglinide with relative risk of -13.133 of docetaxel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: dalbavancin with relative risk of -13.460 of docetaxel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: trospium with relative risk of -13.502 of docetaxel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: amlodipine with relative risk of -13.806 of docetaxel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó dofetilide *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó dolasetron *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: fluoxetine with relative risk of -28.054 of dolasetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: fluoxetine with relative risk of -28.054 of dolasetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: fluoxetine with relative risk of -28.054 of dolasetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: alogliptin with relative risk of -37.573 of dolasetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: alogliptin with relative risk of -37.573 of dolasetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: alogliptin with relative risk of -37.573 of dolasetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: alogliptin with relative risk of -37.573 of dolasetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: simvastatin with relative risk of -53.900 of dolasetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: simvastatin with relative risk of -53.900 of dolasetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: simvastatin with relative risk of -53.900 of dolasetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: simvastatin with relative risk of -53.900 of dolasetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: simvastatin with relative risk of -53.900 of dolasetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: simvastatin with relative risk of -53.900 of dolasetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó dolutegravir *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: paroxetine with relative risk of -49.534 of dolutegravir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: paroxetine with relative risk of -49.534 of dolutegravir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: paroxetine with relative risk of -49.534 of dolutegravir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: paroxetine with relative risk of -49.534 of dolutegravir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: paroxetine with relative risk of -49.534 of dolutegravir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: paroxetine with relative risk of -49.534 of dolutegravir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: paroxetine with relative risk of -49.534 of dolutegravir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: tadalafil with relative risk of -52.298 of dolutegravir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: tadalafil with relative risk of -52.298 of dolutegravir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: tadalafil with relative risk of -52.298 of dolutegravir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: tadalafil with relative risk of -52.298 of dolutegravir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: tadalafil with relative risk of -52.298 of dolutegravir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: tadalafil with relative risk of -52.298 of dolutegravir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: tadalafil with relative risk of -52.298 of dolutegravir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: ticagrelor with relative risk of -60.287 of dolutegravir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: ticagrelor with relative risk of -60.287 of dolutegravir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: ticagrelor with relative risk of -60.287 of dolutegravir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: ticagrelor with relative risk of -60.287 of dolutegravir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: ticagrelor with relative risk of -60.287 of dolutegravir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: ticagrelor with relative risk of -60.287 of dolutegravir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: ticagrelor with relative risk of -60.287 of dolutegravir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó domperidone *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: azelastine with relative risk of -8.980 of domperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: ibandronate with relative risk of -9.095 of domperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: miglustat with relative risk of -9.224 of domperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: terbutaline with relative risk of -9.684 of domperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: ketorolac with relative risk of -10.160 of domperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: dronedarone with relative risk of -10.872 of domperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: afatinib with relative risk of -10.875 of domperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: estramustine with relative risk of -10.882 of domperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: quinidine with relative risk of -11.165 of domperidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 10: beclomethasone with relative risk of -11.539 of domperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: fluconazole with relative risk of -11.630 of domperidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 12: bisoprolol with relative risk of -11.881 of domperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: budesonide with relative risk of -11.907 of domperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: pergolide with relative risk of -12.419 of domperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: aclidinium with relative risk of -12.464 of domperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: caffeine with relative risk of -12.960 of domperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: bromfenac with relative risk of -14.591 of domperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: irbesartan with relative risk of -14.814 of domperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: irbesartan with relative risk of -14.814 of domperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: pentoxifylline with relative risk of -16.618 of domperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: pentoxifylline with relative risk of -16.618 of domperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: bumetanide with relative risk of -19.069 of domperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: bumetanide with relative risk of -19.069 of domperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: loratadine with relative risk of -19.125 of domperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: loratadine with relative risk of -19.125 of domperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: nevirapine with relative risk of -19.708 of domperidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 27: nevirapine with relative risk of -19.708 of domperidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 28: ribavirin with relative risk of -19.931 of domperidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 29: ribavirin with relative risk of -19.931 of domperidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 30: celecoxib with relative risk of -20.624 of domperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: celecoxib with relative risk of -20.624 of domperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: perindopril with relative risk of -20.702 of domperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: perindopril with relative risk of -20.702 of domperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: lapatinib with relative risk of -20.875 of domperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: lapatinib with relative risk of -20.875 of domperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: losartan with relative risk of -21.273 of domperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: losartan with relative risk of -21.273 of domperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: amisulpride with relative risk of -21.338 of domperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: amisulpride with relative risk of -21.338 of domperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: latanoprost with relative risk of -21.435 of domperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: latanoprost with relative risk of -21.435 of domperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: temsirolimus with relative risk of -21.993 of domperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: temsirolimus with relative risk of -21.993 of domperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: lidocaine with relative risk of -22.676 of domperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: lidocaine with relative risk of -22.676 of domperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: argatroban with relative risk of -30.112 of domperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: argatroban with relative risk of -30.112 of domperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: argatroban with relative risk of -30.112 of domperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: felodipine with relative risk of -inf of domperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: felodipine with relative risk of -inf of domperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.077\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó donepezil *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: bosutinib with relative risk of -10.608 of donepezil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: dofetilide with relative risk of -10.740 of donepezil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: clarithromycin with relative risk of -10.796 of donepezil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: olmesartan with relative risk of -13.236 of donepezil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: sertraline with relative risk of -21.564 of donepezil | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: sertraline with relative risk of -21.564 of donepezil | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: sertraline with relative risk of -21.564 of donepezil | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: irbesartan with relative risk of -22.116 of donepezil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: irbesartan with relative risk of -22.116 of donepezil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: irbesartan with relative risk of -22.116 of donepezil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: regadenoson with relative risk of -22.359 of donepezil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: regadenoson with relative risk of -22.359 of donepezil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: regadenoson with relative risk of -22.359 of donepezil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: mometasone with relative risk of -22.583 of donepezil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: mometasone with relative risk of -22.583 of donepezil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: mometasone with relative risk of -22.583 of donepezil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: azelastine with relative risk of -23.351 of donepezil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: azelastine with relative risk of -23.351 of donepezil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: azelastine with relative risk of -23.351 of donepezil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: posaconazole with relative risk of -23.476 of donepezil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: posaconazole with relative risk of -23.476 of donepezil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: posaconazole with relative risk of -23.476 of donepezil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: ibutilide with relative risk of -24.670 of donepezil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: ibutilide with relative risk of -24.670 of donepezil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: ibutilide with relative risk of -24.670 of donepezil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: telmisartan with relative risk of -28.046 of donepezil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: telmisartan with relative risk of -28.046 of donepezil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: telmisartan with relative risk of -28.046 of donepezil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: tolmetin with relative risk of -28.278 of donepezil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: tolmetin with relative risk of -28.278 of donepezil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: tolmetin with relative risk of -28.278 of donepezil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: milnacipran with relative risk of -28.509 of donepezil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: milnacipran with relative risk of -28.509 of donepezil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: milnacipran with relative risk of -28.509 of donepezil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: progesterone with relative risk of -28.615 of donepezil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: progesterone with relative risk of -28.615 of donepezil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: progesterone with relative risk of -28.615 of donepezil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: estramustine with relative risk of -28.689 of donepezil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: estramustine with relative risk of -28.689 of donepezil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: estramustine with relative risk of -28.689 of donepezil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: abiraterone with relative risk of -29.125 of donepezil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: abiraterone with relative risk of -29.125 of donepezil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: abiraterone with relative risk of -29.125 of donepezil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: lubiprostone with relative risk of -29.511 of donepezil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: lubiprostone with relative risk of -29.511 of donepezil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: lubiprostone with relative risk of -29.511 of donepezil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: auranofin with relative risk of -30.116 of donepezil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: auranofin with relative risk of -30.116 of donepezil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: auranofin with relative risk of -30.116 of donepezil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: dapagliflozin with relative risk of -30.162 of donepezil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: dapagliflozin with relative risk of -30.162 of donepezil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: dapagliflozin with relative risk of -30.162 of donepezil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 53: misoprostol with relative risk of -30.509 of donepezil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 54: misoprostol with relative risk of -30.509 of donepezil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 55: misoprostol with relative risk of -30.509 of donepezil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 56: dantrolene with relative risk of -30.908 of donepezil | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 57: dantrolene with relative risk of -30.908 of donepezil | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 58: dantrolene with relative risk of -30.908 of donepezil | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 59: risedronate with relative risk of -31.197 of donepezil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 60: risedronate with relative risk of -31.197 of donepezil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 61: risedronate with relative risk of -31.197 of donepezil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 62: cisatracurium with relative risk of -32.261 of donepezil | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 63: cisatracurium with relative risk of -32.261 of donepezil | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 64: cisatracurium with relative risk of -32.261 of donepezil | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.129\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target doripenem not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó doxazosin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: miglustat with relative risk of -10.322 of doxazosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: crizotinib with relative risk of -10.375 of doxazosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: pentoxifylline with relative risk of -10.551 of doxazosin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 4: nabumetone with relative risk of -11.689 of doxazosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: argatroban with relative risk of -11.794 of doxazosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: etravirine with relative risk of -12.466 of doxazosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: linezolid with relative risk of -12.632 of doxazosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.129\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó doxepin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: regadenoson with relative risk of -7.955 of doxepin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: ibandronate with relative risk of -9.500 of doxepin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: ruxolitinib with relative risk of -9.819 of doxepin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: lurasidone with relative risk of -9.865 of doxepin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Depression, Bipolar,neurology/psychiatry\n",
      "Rank 5: erlotinib with relative risk of -10.590 of doxepin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: vemurafenib with relative risk of -10.621 of doxepin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: telmisartan with relative risk of -10.981 of doxepin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: clonidine with relative risk of -11.238 of doxepin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: varenicline with relative risk of -11.282 of doxepin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: rotigotine with relative risk of -11.957 of doxepin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: benazepril with relative risk of -12.485 of doxepin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: sertraline with relative risk of -15.270 of doxepin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Depressive disorder,neurology/psychiatry\n",
      "Rank 13: sertraline with relative risk of -15.270 of doxepin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Depressive disorder,neurology/psychiatry\n",
      "Rank 14: azelastine with relative risk of -16.697 of doxepin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: azelastine with relative risk of -16.697 of doxepin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: ropivacaine with relative risk of -18.025 of doxepin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 17: ropivacaine with relative risk of -18.025 of doxepin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 18: naproxen with relative risk of -18.655 of doxepin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 19: naproxen with relative risk of -18.655 of doxepin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 20: ticagrelor with relative risk of -18.826 of doxepin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: ticagrelor with relative risk of -18.826 of doxepin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: gabapentin with relative risk of -19.991 of doxepin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 23: gabapentin with relative risk of -19.991 of doxepin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 24: clarithromycin with relative risk of -20.340 of doxepin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: clarithromycin with relative risk of -20.340 of doxepin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: delavirdine with relative risk of -20.651 of doxepin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: delavirdine with relative risk of -20.651 of doxepin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.274\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó doxercalciferol *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: iloperidone with relative risk of -12.184 of doxercalciferol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: rabeprazole with relative risk of -12.198 of doxercalciferol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: levocabastine with relative risk of -12.358 of doxercalciferol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: levetiracetam with relative risk of -12.648 of doxercalciferol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: fluconazole with relative risk of -12.728 of doxercalciferol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: guanfacine with relative risk of -12.760 of doxercalciferol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: mirtazapine with relative risk of -12.850 of doxercalciferol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: fosphenytoin with relative risk of -12.906 of doxercalciferol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: reboxetine with relative risk of -13.131 of doxercalciferol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: ropinirole with relative risk of -13.248 of doxercalciferol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: vardenafil with relative risk of -13.293 of doxercalciferol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: rilpivirine with relative risk of -13.450 of doxercalciferol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó doxorubicin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: regadenoson with relative risk of -8.647 of doxorubicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: sertraline with relative risk of -8.999 of doxorubicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: mometasone with relative risk of -9.242 of doxorubicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: posaconazole with relative risk of -9.679 of doxorubicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: irbesartan with relative risk of -9.727 of doxorubicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: azelastine with relative risk of -10.076 of doxorubicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: tropisetron with relative risk of -10.479 of doxorubicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: ruxolitinib with relative risk of -10.512 of doxorubicin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: hematologic malignancy\n",
      "Rank 9: lurasidone with relative risk of -10.558 of doxorubicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: lansoprazole with relative risk of -11.107 of doxorubicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: ibutilide with relative risk of -11.114 of doxorubicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: risperidone with relative risk of -11.175 of doxorubicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: ketorolac with relative risk of -11.258 of doxorubicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: atropine with relative risk of -11.531 of doxorubicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: clarithromycin with relative risk of -11.894 of doxorubicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: clonidine with relative risk of -11.931 of doxorubicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: dutasteride with relative risk of -12.086 of doxorubicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: leflunomide with relative risk of -12.233 of doxorubicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: vernakalant with relative risk of -12.281 of doxorubicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: flecainide with relative risk of -12.956 of doxorubicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: vilazodone with relative risk of -13.644 of doxorubicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: pindolol with relative risk of -13.800 of doxorubicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.034\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target doxycycline not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó dronedarone *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: ibandronate with relative risk of -8.808 of dronedarone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: terbutaline with relative risk of -9.397 of dronedarone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: meloxicam with relative risk of -9.847 of dronedarone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: ketorolac with relative risk of -9.873 of dronedarone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: loratadine with relative risk of -10.170 of dronedarone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: argatroban with relative risk of -10.408 of dronedarone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: estramustine with relative risk of -10.594 of dronedarone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: fluconazole with relative risk of -11.342 of dronedarone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: bisoprolol with relative risk of -11.593 of dronedarone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 10: domperidone with relative risk of -12.149 of dronedarone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: pentoxifylline with relative risk of -15.926 of dronedarone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 12: pentoxifylline with relative risk of -15.926 of dronedarone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 13: miglustat with relative risk of -16.506 of dronedarone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: miglustat with relative risk of -16.506 of dronedarone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.088\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó duloxetine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: pramipexole with relative risk of -11.929 of duloxetine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: docetaxel with relative risk of -12.046 of duloxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: etodolac with relative risk of -12.358 of duloxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: metaproterenol with relative risk of -12.759 of duloxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: bupropion with relative risk of -13.123 of duloxetine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Depressive disorder,Major Depressive Disorder,neurology/psychiatry\n",
      "Rank 6: repaglinide with relative risk of -13.133 of duloxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: dalbavancin with relative risk of -13.460 of duloxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: trospium with relative risk of -13.502 of duloxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: amlodipine with relative risk of -13.806 of duloxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.424\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó dutasteride *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: naproxen with relative risk of -8.448 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: cyclophosphamide with relative risk of -8.525 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: risperidone with relative risk of -9.231 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: atropine with relative risk of -9.585 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: gabapentin with relative risk of -9.601 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: telmisartan with relative risk of -9.730 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: cetirizine with relative risk of -9.924 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: clarithromycin with relative risk of -9.950 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: clonidine with relative risk of -9.985 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: flutamide with relative risk of -10.039 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: leflunomide with relative risk of -10.288 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: doxorubicin with relative risk of -10.297 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: bezafibrate with relative risk of -10.312 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: vernakalant with relative risk of -10.335 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: zolmitriptan with relative risk of -10.359 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: flecainide with relative risk of -11.010 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: vilazodone with relative risk of -11.698 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: pindolol with relative risk of -11.854 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: ropivacaine with relative risk of -14.982 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: ropivacaine with relative risk of -14.982 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: levonorgestrel with relative risk of -15.496 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: levonorgestrel with relative risk of -15.496 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: bumetanide with relative risk of -17.124 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: bumetanide with relative risk of -17.124 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: nevirapine with relative risk of -17.763 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: nevirapine with relative risk of -17.763 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: capecitabine with relative risk of -18.462 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: capecitabine with relative risk of -18.462 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: sumatriptan with relative risk of -19.671 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: sumatriptan with relative risk of -19.671 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: citalopram with relative risk of -19.695 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: citalopram with relative risk of -19.695 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: lurasidone with relative risk of -23.376 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: lurasidone with relative risk of -23.376 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: lurasidone with relative risk of -23.376 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: ruxolitinib with relative risk of -24.071 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: ruxolitinib with relative risk of -24.071 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: ruxolitinib with relative risk of -24.071 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: didanosine with relative risk of -24.231 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: didanosine with relative risk of -24.231 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: didanosine with relative risk of -24.231 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: fondaparinux with relative risk of -28.402 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: fondaparinux with relative risk of -28.402 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: fondaparinux with relative risk of -28.402 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: ketorolac with relative risk of -30.971 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: ketorolac with relative risk of -30.971 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: ketorolac with relative risk of -30.971 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: ketorolac with relative risk of -30.971 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: lansoprazole with relative risk of -31.138 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: lansoprazole with relative risk of -31.138 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: lansoprazole with relative risk of -31.138 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: lansoprazole with relative risk of -31.138 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 53: sertraline with relative risk of -31.181 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 54: sertraline with relative risk of -31.181 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 55: sertraline with relative risk of -31.181 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 56: sertraline with relative risk of -31.181 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 57: sertraline with relative risk of -31.181 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 58: pemetrexed with relative risk of -32.293 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 59: pemetrexed with relative risk of -32.293 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 60: pemetrexed with relative risk of -32.293 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 61: pemetrexed with relative risk of -32.293 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 62: indomethacin with relative risk of -32.517 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 63: indomethacin with relative risk of -32.517 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 64: indomethacin with relative risk of -32.517 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 65: indomethacin with relative risk of -32.517 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 66: trovafloxacin with relative risk of -32.947 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 67: trovafloxacin with relative risk of -32.947 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 68: trovafloxacin with relative risk of -32.947 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 69: trovafloxacin with relative risk of -32.947 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 70: metoprolol with relative risk of -33.633 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 71: metoprolol with relative risk of -33.633 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 72: metoprolol with relative risk of -33.633 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 73: metoprolol with relative risk of -33.633 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 74: milrinone with relative risk of -34.055 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 75: milrinone with relative risk of -34.055 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 76: milrinone with relative risk of -34.055 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 77: milrinone with relative risk of -34.055 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 78: tamsulosin with relative risk of -35.381 of dutasteride | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Prostatic Hypertrophy,urology\n",
      "Rank 79: tamsulosin with relative risk of -35.381 of dutasteride | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Prostatic Hypertrophy,urology\n",
      "Rank 80: tamsulosin with relative risk of -35.381 of dutasteride | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Prostatic Hypertrophy,urology\n",
      "Rank 81: tamsulosin with relative risk of -35.381 of dutasteride | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Prostatic Hypertrophy,urology\n",
      "Rank 82: etoposide with relative risk of -36.061 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 83: etoposide with relative risk of -36.061 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 84: etoposide with relative risk of -36.061 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 85: etoposide with relative risk of -36.061 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 86: etoposide with relative risk of -36.061 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 87: paliperidone with relative risk of -36.426 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 88: paliperidone with relative risk of -36.426 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 89: paliperidone with relative risk of -36.426 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 90: paliperidone with relative risk of -36.426 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 91: paliperidone with relative risk of -36.426 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 92: glimepiride with relative risk of -36.751 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 93: glimepiride with relative risk of -36.751 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 94: glimepiride with relative risk of -36.751 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 95: glimepiride with relative risk of -36.751 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 96: glimepiride with relative risk of -36.751 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 97: fenofibrate with relative risk of -38.604 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 98: fenofibrate with relative risk of -38.604 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 99: fenofibrate with relative risk of -38.604 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 100: fenofibrate with relative risk of -38.604 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 101: fenofibrate with relative risk of -38.604 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 102: irbesartan with relative risk of -47.154 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 103: irbesartan with relative risk of -47.154 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 104: irbesartan with relative risk of -47.154 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 105: irbesartan with relative risk of -47.154 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 106: irbesartan with relative risk of -47.154 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 107: irbesartan with relative risk of -47.154 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 108: irbesartan with relative risk of -47.154 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 109: mometasone with relative risk of -49.697 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 110: mometasone with relative risk of -49.697 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 111: mometasone with relative risk of -49.697 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 112: mometasone with relative risk of -49.697 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 113: mometasone with relative risk of -49.697 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 114: mometasone with relative risk of -49.697 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 115: mometasone with relative risk of -49.697 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 116: regadenoson with relative risk of -50.312 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 117: regadenoson with relative risk of -50.312 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 118: regadenoson with relative risk of -50.312 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 119: regadenoson with relative risk of -50.312 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 120: regadenoson with relative risk of -50.312 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 121: regadenoson with relative risk of -50.312 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 122: regadenoson with relative risk of -50.312 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 123: azelastine with relative risk of -50.316 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 124: azelastine with relative risk of -50.316 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 125: azelastine with relative risk of -50.316 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 126: azelastine with relative risk of -50.316 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 127: azelastine with relative risk of -50.316 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 128: azelastine with relative risk of -50.316 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 129: azelastine with relative risk of -50.316 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 130: posaconazole with relative risk of -51.619 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 131: posaconazole with relative risk of -51.619 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 132: posaconazole with relative risk of -51.619 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 133: posaconazole with relative risk of -51.619 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 134: posaconazole with relative risk of -51.619 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 135: posaconazole with relative risk of -51.619 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 136: posaconazole with relative risk of -51.619 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 137: ibutilide with relative risk of -52.266 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 138: ibutilide with relative risk of -52.266 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 139: ibutilide with relative risk of -52.266 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 140: ibutilide with relative risk of -52.266 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 141: ibutilide with relative risk of -52.266 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 142: ibutilide with relative risk of -52.266 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 143: ibutilide with relative risk of -52.266 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 144: tropisetron with relative risk of -54.020 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 145: tropisetron with relative risk of -54.020 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 146: tropisetron with relative risk of -54.020 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 147: tropisetron with relative risk of -54.020 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 148: tropisetron with relative risk of -54.020 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 149: tropisetron with relative risk of -54.020 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 150: tropisetron with relative risk of -54.020 of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 151: felodipine with relative risk of -inf of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 152: felodipine with relative risk of -inf of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 153: felodipine with relative risk of -inf of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 154: felodipine with relative risk of -inf of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 155: felodipine with relative risk of -inf of dutasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.009\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target ecallantide not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó efavirenz *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: clozapine with relative risk of -10.063 of efavirenz | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: vandetanib with relative risk of -11.340 of efavirenz | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: danazol with relative risk of -11.727 of efavirenz | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: oxcarbazepine with relative risk of -13.058 of efavirenz | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: voriconazole with relative risk of -13.558 of efavirenz | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.088\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó efinaconazole *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: olopatadine with relative risk of -10.008 of efinaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: vismodegib with relative risk of -15.092 of efinaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: vismodegib with relative risk of -15.092 of efinaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: bromocriptine with relative risk of -17.586 of efinaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: bromocriptine with relative risk of -17.586 of efinaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: trazodone with relative risk of -23.566 of efinaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: trazodone with relative risk of -23.566 of efinaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: trazodone with relative risk of -23.566 of efinaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: trazodone with relative risk of -23.566 of efinaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: verapamil with relative risk of -25.229 of efinaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: verapamil with relative risk of -25.229 of efinaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: verapamil with relative risk of -25.229 of efinaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: verapamil with relative risk of -25.229 of efinaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: riluzole with relative risk of -29.324 of efinaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: riluzole with relative risk of -29.324 of efinaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: riluzole with relative risk of -29.324 of efinaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: riluzole with relative risk of -29.324 of efinaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: nedocromil with relative risk of -32.098 of efinaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: nedocromil with relative risk of -32.098 of efinaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: nedocromil with relative risk of -32.098 of efinaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: nedocromil with relative risk of -32.098 of efinaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: nedocromil with relative risk of -32.098 of efinaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: betaxolol with relative risk of -34.137 of efinaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: betaxolol with relative risk of -34.137 of efinaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: betaxolol with relative risk of -34.137 of efinaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: betaxolol with relative risk of -34.137 of efinaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: betaxolol with relative risk of -34.137 of efinaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: topiramate with relative risk of -34.536 of efinaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: topiramate with relative risk of -34.536 of efinaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: topiramate with relative risk of -34.536 of efinaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: topiramate with relative risk of -34.536 of efinaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: topiramate with relative risk of -34.536 of efinaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: quinaprilat with relative risk of -44.414 of efinaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: quinaprilat with relative risk of -44.414 of efinaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: quinaprilat with relative risk of -44.414 of efinaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: quinaprilat with relative risk of -44.414 of efinaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: quinaprilat with relative risk of -44.414 of efinaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: quinaprilat with relative risk of -44.414 of efinaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: loperamide with relative risk of -54.153 of efinaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: loperamide with relative risk of -54.153 of efinaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: loperamide with relative risk of -54.153 of efinaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: loperamide with relative risk of -54.153 of efinaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: loperamide with relative risk of -54.153 of efinaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: loperamide with relative risk of -54.153 of efinaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: loperamide with relative risk of -54.153 of efinaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: loperamide with relative risk of -54.153 of efinaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó eletriptan *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: penbutolol with relative risk of -10.524 of eletriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: amoxapine with relative risk of -12.231 of eletriptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.333\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó eliglustat *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: podophyllotoxin with relative risk of -11.110 of eliglustat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: degarelix with relative risk of -11.759 of eliglustat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: dasatinib with relative risk of -12.378 of eliglustat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target eltrombopag not found. Exiting ...\n",
      "\n",
      "Drug target elvitegravir not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó emedastine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: conivaptan with relative risk of -12.330 of emedastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: desoximetasone with relative risk of -inf of emedastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: desoximetasone with relative risk of -inf of emedastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó empagliflozin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: cilostazol with relative risk of -10.858 of empagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: pilocarpine with relative risk of -11.599 of empagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: raloxifene with relative risk of -11.657 of empagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: medroxyprogesterone with relative risk of -11.716 of empagliflozin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 5: pantoprazole with relative risk of -11.730 of empagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: bupivacaine with relative risk of -12.227 of empagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: omeprazole with relative risk of -12.366 of empagliflozin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.096\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target emtricitabine not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó entacapone *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: cytarabine with relative risk of -10.046 of entacapone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: paclitaxel with relative risk of -10.237 of entacapone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: formoterol with relative risk of -10.323 of entacapone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: frovatriptan with relative risk of -10.485 of entacapone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 5: nimodipine with relative risk of -10.812 of entacapone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: rasagiline with relative risk of -11.798 of entacapone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Parkinson Disease,neurology/psychiatry\n",
      "Rank 7: ipratropium with relative risk of -11.881 of entacapone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: rivastigmine with relative risk of -11.918 of entacapone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: sotalol with relative risk of -11.943 of entacapone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: rofecoxib with relative risk of -11.993 of entacapone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: pimozide with relative risk of -12.066 of entacapone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: silodosin with relative risk of -12.126 of entacapone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: nefazodone with relative risk of -12.399 of entacapone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: capsaicin with relative risk of -12.517 of entacapone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: fosinoprilat with relative risk of -14.799 of entacapone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.212\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target entecavir not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó eplerenone *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: ibandronate with relative risk of -9.095 of eplerenone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: rosiglitazone with relative risk of -9.176 of eplerenone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: miglustat with relative risk of -9.224 of eplerenone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: formoterol with relative risk of -9.918 of eplerenone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: indacaterol with relative risk of -10.355 of eplerenone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: estramustine with relative risk of -10.882 of eplerenone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: linezolid with relative risk of -11.533 of eplerenone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: febuxostat with relative risk of -13.801 of eplerenone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: ciclesonide with relative risk of -15.296 of eplerenone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: ciclesonide with relative risk of -15.296 of eplerenone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: vinorelbine with relative risk of -16.269 of eplerenone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: vinorelbine with relative risk of -16.269 of eplerenone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: axitinib with relative risk of -16.712 of eplerenone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: axitinib with relative risk of -16.712 of eplerenone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: darifenacin with relative risk of -16.808 of eplerenone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: darifenacin with relative risk of -16.808 of eplerenone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: granisetron with relative risk of -17.156 of eplerenone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: granisetron with relative risk of -17.156 of eplerenone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: apraclonidine with relative risk of -17.313 of eplerenone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: apraclonidine with relative risk of -17.313 of eplerenone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: meloxicam with relative risk of -17.549 of eplerenone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: meloxicam with relative risk of -17.549 of eplerenone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: pinaverium with relative risk of -20.292 of eplerenone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: pinaverium with relative risk of -20.292 of eplerenone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: desoximetasone with relative risk of -inf of eplerenone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: desoximetasone with relative risk of -inf of eplerenone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó eprosartan *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: metronidazole with relative risk of -11.062 of eprosartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: umeclidinium with relative risk of -12.334 of eprosartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: indinavir with relative risk of -13.596 of eprosartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: rivaroxaban with relative risk of -13.820 of eprosartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.12\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target eribulin not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó erlotinib *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: regadenoson with relative risk of -7.955 of erlotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: ibandronate with relative risk of -9.500 of erlotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: ruxolitinib with relative risk of -9.819 of erlotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: lurasidone with relative risk of -9.865 of erlotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: ibutilide with relative risk of -10.422 of erlotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: vemurafenib with relative risk of -10.621 of erlotinib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 7: varenicline with relative risk of -11.282 of erlotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: ixabepilone with relative risk of -11.647 of erlotinib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 9: doxepin with relative risk of -12.164 of erlotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: benazepril with relative risk of -12.485 of erlotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: toremifene with relative risk of -13.239 of erlotinib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 12: sertraline with relative risk of -15.270 of erlotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: sertraline with relative risk of -15.270 of erlotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: azelastine with relative risk of -16.697 of erlotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: azelastine with relative risk of -16.697 of erlotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: ropivacaine with relative risk of -18.025 of erlotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: ropivacaine with relative risk of -18.025 of erlotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: naproxen with relative risk of -18.655 of erlotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: naproxen with relative risk of -18.655 of erlotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: ticagrelor with relative risk of -18.826 of erlotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: ticagrelor with relative risk of -18.826 of erlotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: telmisartan with relative risk of -19.783 of erlotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: telmisartan with relative risk of -19.783 of erlotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: gabapentin with relative risk of -19.991 of erlotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: gabapentin with relative risk of -19.991 of erlotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: clarithromycin with relative risk of -20.340 of erlotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: clarithromycin with relative risk of -20.340 of erlotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: delavirdine with relative risk of -20.651 of erlotinib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: HIV Infections\n",
      "Rank 29: delavirdine with relative risk of -20.651 of erlotinib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: HIV Infections\n",
      "Rank 30: clonidine with relative risk of -21.293 of erlotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: clonidine with relative risk of -21.293 of erlotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: rotigotine with relative risk of -22.705 of erlotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: rotigotine with relative risk of -22.705 of erlotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.111\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target ertapenem not found. Exiting ...\n",
      "\n",
      "Drug target eslicarbazepine not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó esmolol *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: levonorgestrel with relative risk of -8.486 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: penbutolol with relative risk of -8.738 of esmolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 3: trovafloxacin with relative risk of -9.894 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: clarithromycin with relative risk of -10.104 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: perindopril with relative risk of -10.648 of esmolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 6: lurasidone with relative risk of -15.960 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: lurasidone with relative risk of -15.960 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: lansoprazole with relative risk of -16.153 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: lansoprazole with relative risk of -16.153 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: didanosine with relative risk of -16.410 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: didanosine with relative risk of -16.410 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: etoposide with relative risk of -20.701 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: etoposide with relative risk of -20.701 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: etoposide with relative risk of -20.701 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: darifenacin with relative risk of -22.569 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: darifenacin with relative risk of -22.569 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: darifenacin with relative risk of -22.569 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: ropivacaine with relative risk of -23.006 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: ropivacaine with relative risk of -23.006 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: ropivacaine with relative risk of -23.006 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: fenofibrate with relative risk of -23.245 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: fenofibrate with relative risk of -23.245 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: fenofibrate with relative risk of -23.245 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: ivacaftor with relative risk of -26.124 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: ivacaftor with relative risk of -26.124 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: ivacaftor with relative risk of -26.124 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: zolmitriptan with relative risk of -26.933 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: zolmitriptan with relative risk of -26.933 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: zolmitriptan with relative risk of -26.933 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: brimonidine with relative risk of -27.524 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: brimonidine with relative risk of -27.524 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: brimonidine with relative risk of -27.524 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: tazarotene with relative risk of -28.097 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: tazarotene with relative risk of -28.097 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: tazarotene with relative risk of -28.097 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: dapsone with relative risk of -28.358 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: dapsone with relative risk of -28.358 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: dapsone with relative risk of -28.358 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: brinzolamide with relative risk of -28.633 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: brinzolamide with relative risk of -28.633 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: brinzolamide with relative risk of -28.633 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: acebutolol with relative risk of -28.978 of esmolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 43: acebutolol with relative risk of -28.978 of esmolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 44: acebutolol with relative risk of -28.978 of esmolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 45: isradipine with relative risk of -29.102 of esmolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 46: isradipine with relative risk of -29.102 of esmolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 47: isradipine with relative risk of -29.102 of esmolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 48: valsartan with relative risk of -29.121 of esmolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 49: valsartan with relative risk of -29.121 of esmolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 50: valsartan with relative risk of -29.121 of esmolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 51: irbesartan with relative risk of -32.800 of esmolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 52: irbesartan with relative risk of -32.800 of esmolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 53: irbesartan with relative risk of -32.800 of esmolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 54: irbesartan with relative risk of -32.800 of esmolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 55: irbesartan with relative risk of -32.800 of esmolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 56: regadenoson with relative risk of -34.452 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 57: regadenoson with relative risk of -34.452 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 58: regadenoson with relative risk of -34.452 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 59: regadenoson with relative risk of -34.452 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 60: regadenoson with relative risk of -34.452 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 61: azelastine with relative risk of -34.970 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 62: azelastine with relative risk of -34.970 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 63: azelastine with relative risk of -34.970 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 64: azelastine with relative risk of -34.970 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 65: azelastine with relative risk of -34.970 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 66: posaconazole with relative risk of -35.659 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 67: posaconazole with relative risk of -35.659 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 68: posaconazole with relative risk of -35.659 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 69: posaconazole with relative risk of -35.659 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 70: posaconazole with relative risk of -35.659 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 71: everolimus with relative risk of -36.587 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 72: everolimus with relative risk of -36.587 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 73: everolimus with relative risk of -36.587 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 74: everolimus with relative risk of -36.587 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 75: sertraline with relative risk of -40.588 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 76: sertraline with relative risk of -40.588 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 77: sertraline with relative risk of -40.588 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 78: sertraline with relative risk of -40.588 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 79: sertraline with relative risk of -40.588 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 80: sertraline with relative risk of -40.588 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 81: mometasone with relative risk of -42.861 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 82: mometasone with relative risk of -42.861 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 83: mometasone with relative risk of -42.861 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 84: mometasone with relative risk of -42.861 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 85: mometasone with relative risk of -42.861 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 86: mometasone with relative risk of -42.861 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 87: ibutilide with relative risk of -45.302 of esmolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 88: ibutilide with relative risk of -45.302 of esmolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 89: ibutilide with relative risk of -45.302 of esmolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 90: ibutilide with relative risk of -45.302 of esmolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 91: ibutilide with relative risk of -45.302 of esmolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 92: ibutilide with relative risk of -45.302 of esmolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 93: tropisetron with relative risk of -46.604 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 94: tropisetron with relative risk of -46.604 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 95: tropisetron with relative risk of -46.604 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 96: tropisetron with relative risk of -46.604 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 97: tropisetron with relative risk of -46.604 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 98: tropisetron with relative risk of -46.604 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 99: paliperidone with relative risk of -46.885 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 100: paliperidone with relative risk of -46.885 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 101: paliperidone with relative risk of -46.885 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 102: paliperidone with relative risk of -46.885 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 103: paliperidone with relative risk of -46.885 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 104: paliperidone with relative risk of -46.885 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 105: pentoxifylline with relative risk of -46.982 of esmolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 106: pentoxifylline with relative risk of -46.982 of esmolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 107: pentoxifylline with relative risk of -46.982 of esmolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 108: pentoxifylline with relative risk of -46.982 of esmolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 109: pentoxifylline with relative risk of -46.982 of esmolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 110: pentoxifylline with relative risk of -46.982 of esmolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 111: glimepiride with relative risk of -47.364 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 112: glimepiride with relative risk of -47.364 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 113: glimepiride with relative risk of -47.364 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 114: glimepiride with relative risk of -47.364 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 115: glimepiride with relative risk of -47.364 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 116: glimepiride with relative risk of -47.364 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 117: terbutaline with relative risk of -52.244 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 118: terbutaline with relative risk of -52.244 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 119: terbutaline with relative risk of -52.244 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 120: terbutaline with relative risk of -52.244 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 121: terbutaline with relative risk of -52.244 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 122: terbutaline with relative risk of -52.244 of esmolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 123: azilsartan with relative risk of -57.662 of esmolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 124: azilsartan with relative risk of -57.662 of esmolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 125: azilsartan with relative risk of -57.662 of esmolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 126: azilsartan with relative risk of -57.662 of esmolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 127: azilsartan with relative risk of -57.662 of esmolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 128: azilsartan with relative risk of -57.662 of esmolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 129: felodipine with relative risk of -inf of esmolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 130: felodipine with relative risk of -inf of esmolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 131: felodipine with relative risk of -inf of esmolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 132: felodipine with relative risk of -inf of esmolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 133: felodipine with relative risk of -inf of esmolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 134: felodipine with relative risk of -inf of esmolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.22\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó esomeprazole *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: verapamil with relative risk of -17.937 of esomeprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: verapamil with relative risk of -17.937 of esomeprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target estazolam not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó estradiol *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: mirabegron with relative risk of -13.755 of estradiol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó estramustine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: vinorelbine with relative risk of -7.566 of estramustine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 2: ciclesonide with relative risk of -8.066 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: axitinib with relative risk of -8.115 of estramustine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 4: darifenacin with relative risk of -8.393 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: granisetron with relative risk of -8.453 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: pentoxifylline with relative risk of -8.610 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: apraclonidine with relative risk of -8.610 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: terbutaline with relative risk of -8.838 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: meloxicam with relative risk of -9.289 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: eplerenone with relative risk of -9.300 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: ketorolac with relative risk of -9.315 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: indacaterol with relative risk of -9.508 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: loratadine with relative risk of -9.610 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: bosutinib with relative risk of -9.761 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: argatroban with relative risk of -9.849 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: dofetilide with relative risk of -9.893 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: clarithromycin with relative risk of -9.950 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: dronedarone with relative risk of -10.025 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: linezolid with relative risk of -10.686 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: fluconazole with relative risk of -10.783 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: bisoprolol with relative risk of -11.033 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: pinaverium with relative risk of -11.589 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: domperidone with relative risk of -11.589 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: olmesartan with relative risk of -12.389 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: febuxostat with relative risk of -12.954 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: ibandronate with relative risk of -14.211 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: ibandronate with relative risk of -14.211 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: miglustat with relative risk of -15.254 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: miglustat with relative risk of -15.254 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: sertraline with relative risk of -18.016 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: sertraline with relative risk of -18.016 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: sertraline with relative risk of -18.016 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: irbesartan with relative risk of -18.568 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: irbesartan with relative risk of -18.568 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: irbesartan with relative risk of -18.568 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: regadenoson with relative risk of -18.808 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: regadenoson with relative risk of -18.808 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: regadenoson with relative risk of -18.808 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: mometasone with relative risk of -19.032 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: mometasone with relative risk of -19.032 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: mometasone with relative risk of -19.032 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: azelastine with relative risk of -19.800 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: azelastine with relative risk of -19.800 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: azelastine with relative risk of -19.800 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: posaconazole with relative risk of -19.924 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: posaconazole with relative risk of -19.924 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: posaconazole with relative risk of -19.924 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: ibutilide with relative risk of -21.119 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: ibutilide with relative risk of -21.119 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: ibutilide with relative risk of -21.119 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: telmisartan with relative risk of -24.492 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: telmisartan with relative risk of -24.492 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 53: telmisartan with relative risk of -24.492 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 54: tolmetin with relative risk of -24.723 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 55: tolmetin with relative risk of -24.723 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 56: tolmetin with relative risk of -24.723 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 57: milnacipran with relative risk of -24.955 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 58: milnacipran with relative risk of -24.955 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 59: milnacipran with relative risk of -24.955 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 60: progesterone with relative risk of -25.060 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 61: progesterone with relative risk of -25.060 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 62: progesterone with relative risk of -25.060 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 63: abiraterone with relative risk of -25.570 of estramustine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 64: abiraterone with relative risk of -25.570 of estramustine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 65: abiraterone with relative risk of -25.570 of estramustine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 66: lubiprostone with relative risk of -25.956 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 67: lubiprostone with relative risk of -25.956 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 68: lubiprostone with relative risk of -25.956 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 69: auranofin with relative risk of -26.561 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 70: auranofin with relative risk of -26.561 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 71: auranofin with relative risk of -26.561 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 72: dapagliflozin with relative risk of -26.607 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 73: dapagliflozin with relative risk of -26.607 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 74: dapagliflozin with relative risk of -26.607 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 75: misoprostol with relative risk of -26.954 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 76: misoprostol with relative risk of -26.954 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 77: misoprostol with relative risk of -26.954 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 78: dantrolene with relative risk of -27.353 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 79: dantrolene with relative risk of -27.353 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 80: dantrolene with relative risk of -27.353 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 81: risedronate with relative risk of -27.642 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 82: risedronate with relative risk of -27.642 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 83: risedronate with relative risk of -27.642 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 84: donepezil with relative risk of -28.034 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 85: donepezil with relative risk of -28.034 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 86: donepezil with relative risk of -28.034 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 87: cisatracurium with relative risk of -28.706 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 88: cisatracurium with relative risk of -28.706 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 89: cisatracurium with relative risk of -28.706 of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 90: desoximetasone with relative risk of -inf of estramustine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.272\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó etodolac *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: pramipexole with relative risk of -11.929 of etodolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: docetaxel with relative risk of -12.046 of etodolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: metaproterenol with relative risk of -12.759 of etodolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: duloxetine with relative risk of -12.992 of etodolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: bupropion with relative risk of -13.123 of etodolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: repaglinide with relative risk of -13.133 of etodolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: dalbavancin with relative risk of -13.460 of etodolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: trospium with relative risk of -13.502 of etodolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: amlodipine with relative risk of -13.806 of etodolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó etoposide *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: penbutolol with relative risk of -7.900 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: telmisartan with relative risk of -9.039 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: varenicline with relative risk of -9.337 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: flutamide with relative risk of -9.346 of etoposide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 5: bezafibrate with relative risk of -9.618 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: gabapentin with relative risk of -15.482 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: gabapentin with relative risk of -15.482 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: cyclophosphamide with relative risk of -16.015 of etoposide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Multiple Myeloma,Neuroblastoma,oncology\n",
      "Rank 9: cyclophosphamide with relative risk of -16.015 of etoposide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Multiple Myeloma,Neuroblastoma,oncology\n",
      "Rank 10: nevirapine with relative risk of -16.297 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: nevirapine with relative risk of -16.297 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: capecitabine with relative risk of -16.996 of etoposide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 13: capecitabine with relative risk of -16.996 of etoposide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 14: sumatriptan with relative risk of -18.205 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: sumatriptan with relative risk of -18.205 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: citalopram with relative risk of -18.229 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: citalopram with relative risk of -18.229 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: pentoxifylline with relative risk of -19.048 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: pentoxifylline with relative risk of -19.048 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: pentoxifylline with relative risk of -19.048 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: terbutaline with relative risk of -20.972 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: terbutaline with relative risk of -20.972 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: terbutaline with relative risk of -20.972 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: naproxen with relative risk of -21.205 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: naproxen with relative risk of -21.205 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: naproxen with relative risk of -21.205 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: ruxolitinib with relative risk of -21.730 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: ruxolitinib with relative risk of -21.730 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: ruxolitinib with relative risk of -21.730 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: indomethacin with relative risk of -21.731 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: indomethacin with relative risk of -21.731 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: indomethacin with relative risk of -21.731 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: metoprolol with relative risk of -21.930 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: metoprolol with relative risk of -21.930 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: metoprolol with relative risk of -21.930 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: esmolol with relative risk of -21.934 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: esmolol with relative risk of -21.934 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: esmolol with relative risk of -21.934 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: milrinone with relative risk of -22.353 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: milrinone with relative risk of -22.353 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: milrinone with relative risk of -22.353 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: ivacaftor with relative risk of -23.223 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: ivacaftor with relative risk of -23.223 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: ivacaftor with relative risk of -23.223 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: bumetanide with relative risk of -23.228 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: bumetanide with relative risk of -23.228 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: bumetanide with relative risk of -23.228 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: everolimus with relative risk of -23.343 of etoposide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 49: everolimus with relative risk of -23.343 of etoposide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 50: everolimus with relative risk of -23.343 of etoposide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 51: azilsartan with relative risk of -23.394 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: azilsartan with relative risk of -23.394 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 53: azilsartan with relative risk of -23.394 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 54: tamsulosin with relative risk of -23.678 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 55: tamsulosin with relative risk of -23.678 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 56: tamsulosin with relative risk of -23.678 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 57: cetirizine with relative risk of -24.290 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 58: cetirizine with relative risk of -24.290 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 59: cetirizine with relative risk of -24.290 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 60: brinzolamide with relative risk of -25.731 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 61: brinzolamide with relative risk of -25.731 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 62: brinzolamide with relative risk of -25.731 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 63: fondaparinux with relative risk of -26.060 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 64: fondaparinux with relative risk of -26.060 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 65: fondaparinux with relative risk of -26.060 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 66: acebutolol with relative risk of -26.076 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 67: acebutolol with relative risk of -26.076 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 68: acebutolol with relative risk of -26.076 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 69: valsartan with relative risk of -26.219 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 70: valsartan with relative risk of -26.219 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 71: valsartan with relative risk of -26.219 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 72: ropivacaine with relative risk of -27.203 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 73: ropivacaine with relative risk of -27.203 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 74: ropivacaine with relative risk of -27.203 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 75: ropivacaine with relative risk of -27.203 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 76: pemetrexed with relative risk of -28.941 of etoposide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Non-Small Cell Lung Carcinoma,oncology\n",
      "Rank 77: pemetrexed with relative risk of -28.941 of etoposide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Non-Small Cell Lung Carcinoma,oncology\n",
      "Rank 78: pemetrexed with relative risk of -28.941 of etoposide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Non-Small Cell Lung Carcinoma,oncology\n",
      "Rank 79: pemetrexed with relative risk of -28.941 of etoposide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Non-Small Cell Lung Carcinoma,oncology\n",
      "Rank 80: lurasidone with relative risk of -36.443 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 81: lurasidone with relative risk of -36.443 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 82: lurasidone with relative risk of -36.443 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 83: lurasidone with relative risk of -36.443 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 84: lurasidone with relative risk of -36.443 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 85: trovafloxacin with relative risk of -37.569 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 86: trovafloxacin with relative risk of -37.569 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 87: trovafloxacin with relative risk of -37.569 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 88: trovafloxacin with relative risk of -37.569 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 89: trovafloxacin with relative risk of -37.569 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 90: didanosine with relative risk of -38.502 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 91: didanosine with relative risk of -38.502 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 92: didanosine with relative risk of -38.502 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 93: didanosine with relative risk of -38.502 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 94: didanosine with relative risk of -38.502 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 95: dutasteride with relative risk of -38.818 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 96: dutasteride with relative risk of -38.818 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 97: dutasteride with relative risk of -38.818 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 98: dutasteride with relative risk of -38.818 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 99: dutasteride with relative risk of -38.818 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 100: zolmitriptan with relative risk of -41.743 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 101: zolmitriptan with relative risk of -41.743 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 102: zolmitriptan with relative risk of -41.743 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 103: zolmitriptan with relative risk of -41.743 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 104: zolmitriptan with relative risk of -41.743 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 105: ketorolac with relative risk of -50.733 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 106: ketorolac with relative risk of -50.733 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 107: ketorolac with relative risk of -50.733 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 108: ketorolac with relative risk of -50.733 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 109: ketorolac with relative risk of -50.733 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 110: ketorolac with relative risk of -50.733 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 111: ketorolac with relative risk of -50.733 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 112: lansoprazole with relative risk of -51.370 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 113: lansoprazole with relative risk of -51.370 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 114: lansoprazole with relative risk of -51.370 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 115: lansoprazole with relative risk of -51.370 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 116: lansoprazole with relative risk of -51.370 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 117: lansoprazole with relative risk of -51.370 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 118: lansoprazole with relative risk of -51.370 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 119: levonorgestrel with relative risk of -55.885 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 120: levonorgestrel with relative risk of -55.885 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 121: levonorgestrel with relative risk of -55.885 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 122: levonorgestrel with relative risk of -55.885 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 123: levonorgestrel with relative risk of -55.885 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 124: levonorgestrel with relative risk of -55.885 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 125: levonorgestrel with relative risk of -55.885 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 126: sertraline with relative risk of -83.259 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 127: sertraline with relative risk of -83.259 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 128: sertraline with relative risk of -83.259 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 129: sertraline with relative risk of -83.259 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 130: sertraline with relative risk of -83.259 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 131: sertraline with relative risk of -83.259 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 132: sertraline with relative risk of -83.259 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 133: sertraline with relative risk of -83.259 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 134: sertraline with relative risk of -83.259 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 135: sertraline with relative risk of -83.259 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 136: sertraline with relative risk of -83.259 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 137: sertraline with relative risk of -83.259 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 138: sertraline with relative risk of -83.259 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 139: tropisetron with relative risk of -87.835 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 140: tropisetron with relative risk of -87.835 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 141: tropisetron with relative risk of -87.835 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 142: tropisetron with relative risk of -87.835 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 143: tropisetron with relative risk of -87.835 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 144: tropisetron with relative risk of -87.835 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 145: tropisetron with relative risk of -87.835 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 146: tropisetron with relative risk of -87.835 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 147: tropisetron with relative risk of -87.835 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 148: tropisetron with relative risk of -87.835 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 149: tropisetron with relative risk of -87.835 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 150: tropisetron with relative risk of -87.835 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 151: azelastine with relative risk of -89.342 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 152: azelastine with relative risk of -89.342 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 153: azelastine with relative risk of -89.342 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 154: azelastine with relative risk of -89.342 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 155: azelastine with relative risk of -89.342 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 156: azelastine with relative risk of -89.342 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 157: azelastine with relative risk of -89.342 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 158: azelastine with relative risk of -89.342 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 159: azelastine with relative risk of -89.342 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 160: azelastine with relative risk of -89.342 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 161: azelastine with relative risk of -89.342 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 162: azelastine with relative risk of -89.342 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 163: azelastine with relative risk of -89.342 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 164: regadenoson with relative risk of -91.213 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 165: regadenoson with relative risk of -91.213 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 166: regadenoson with relative risk of -91.213 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 167: regadenoson with relative risk of -91.213 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 168: regadenoson with relative risk of -91.213 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 169: regadenoson with relative risk of -91.213 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 170: regadenoson with relative risk of -91.213 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 171: regadenoson with relative risk of -91.213 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 172: regadenoson with relative risk of -91.213 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 173: regadenoson with relative risk of -91.213 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 174: regadenoson with relative risk of -91.213 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 175: regadenoson with relative risk of -91.213 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 176: regadenoson with relative risk of -91.213 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 177: irbesartan with relative risk of -91.900 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 178: irbesartan with relative risk of -91.900 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 179: irbesartan with relative risk of -91.900 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 180: irbesartan with relative risk of -91.900 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 181: irbesartan with relative risk of -91.900 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 182: irbesartan with relative risk of -91.900 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 183: irbesartan with relative risk of -91.900 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 184: irbesartan with relative risk of -91.900 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 185: irbesartan with relative risk of -91.900 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 186: irbesartan with relative risk of -91.900 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 187: irbesartan with relative risk of -91.900 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 188: irbesartan with relative risk of -91.900 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 189: irbesartan with relative risk of -91.900 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 190: irbesartan with relative risk of -91.900 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 191: ibutilide with relative risk of -92.474 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 192: ibutilide with relative risk of -92.474 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 193: ibutilide with relative risk of -92.474 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 194: ibutilide with relative risk of -92.474 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 195: ibutilide with relative risk of -92.474 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 196: ibutilide with relative risk of -92.474 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 197: ibutilide with relative risk of -92.474 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 198: ibutilide with relative risk of -92.474 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 199: ibutilide with relative risk of -92.474 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 200: ibutilide with relative risk of -92.474 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 201: ibutilide with relative risk of -92.474 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 202: ibutilide with relative risk of -92.474 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 203: ibutilide with relative risk of -92.474 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 204: posaconazole with relative risk of -92.899 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 205: posaconazole with relative risk of -92.899 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 206: posaconazole with relative risk of -92.899 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 207: posaconazole with relative risk of -92.899 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 208: posaconazole with relative risk of -92.899 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 209: posaconazole with relative risk of -92.899 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 210: posaconazole with relative risk of -92.899 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 211: posaconazole with relative risk of -92.899 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 212: posaconazole with relative risk of -92.899 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 213: posaconazole with relative risk of -92.899 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 214: posaconazole with relative risk of -92.899 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 215: posaconazole with relative risk of -92.899 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 216: posaconazole with relative risk of -92.899 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 217: mometasone with relative risk of -98.799 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 218: mometasone with relative risk of -98.799 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 219: mometasone with relative risk of -98.799 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 220: mometasone with relative risk of -98.799 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 221: mometasone with relative risk of -98.799 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 222: mometasone with relative risk of -98.799 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 223: mometasone with relative risk of -98.799 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 224: mometasone with relative risk of -98.799 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 225: mometasone with relative risk of -98.799 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 226: mometasone with relative risk of -98.799 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 227: mometasone with relative risk of -98.799 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 228: mometasone with relative risk of -98.799 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 229: mometasone with relative risk of -98.799 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 230: mometasone with relative risk of -98.799 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 231: paliperidone with relative risk of -109.557 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 232: paliperidone with relative risk of -109.557 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 233: paliperidone with relative risk of -109.557 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 234: paliperidone with relative risk of -109.557 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 235: paliperidone with relative risk of -109.557 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 236: paliperidone with relative risk of -109.557 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 237: paliperidone with relative risk of -109.557 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 238: paliperidone with relative risk of -109.557 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 239: paliperidone with relative risk of -109.557 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 240: paliperidone with relative risk of -109.557 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 241: paliperidone with relative risk of -109.557 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 242: paliperidone with relative risk of -109.557 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 243: paliperidone with relative risk of -109.557 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 244: paliperidone with relative risk of -109.557 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 245: glimepiride with relative risk of -112.090 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 246: glimepiride with relative risk of -112.090 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 247: glimepiride with relative risk of -112.090 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 248: glimepiride with relative risk of -112.090 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 249: glimepiride with relative risk of -112.090 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 250: glimepiride with relative risk of -112.090 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 251: glimepiride with relative risk of -112.090 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 252: glimepiride with relative risk of -112.090 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 253: glimepiride with relative risk of -112.090 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 254: glimepiride with relative risk of -112.090 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 255: glimepiride with relative risk of -112.090 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 256: glimepiride with relative risk of -112.090 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 257: glimepiride with relative risk of -112.090 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 258: glimepiride with relative risk of -112.090 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 259: fenofibrate with relative risk of -119.338 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 260: fenofibrate with relative risk of -119.338 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 261: fenofibrate with relative risk of -119.338 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 262: fenofibrate with relative risk of -119.338 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 263: fenofibrate with relative risk of -119.338 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 264: fenofibrate with relative risk of -119.338 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 265: fenofibrate with relative risk of -119.338 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 266: fenofibrate with relative risk of -119.338 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 267: fenofibrate with relative risk of -119.338 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 268: fenofibrate with relative risk of -119.338 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 269: fenofibrate with relative risk of -119.338 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 270: fenofibrate with relative risk of -119.338 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 271: fenofibrate with relative risk of -119.338 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 272: fenofibrate with relative risk of -119.338 of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 273: felodipine with relative risk of -inf of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 274: felodipine with relative risk of -inf of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 275: felodipine with relative risk of -inf of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 276: felodipine with relative risk of -inf of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 277: felodipine with relative risk of -inf of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 278: felodipine with relative risk of -inf of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 279: felodipine with relative risk of -inf of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 280: felodipine with relative risk of -inf of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 281: felodipine with relative risk of -inf of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 282: felodipine with relative risk of -inf of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 283: felodipine with relative risk of -inf of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 284: felodipine with relative risk of -inf of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 285: felodipine with relative risk of -inf of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 286: felodipine with relative risk of -inf of etoposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.122\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó etravirine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: vinorelbine with relative risk of -8.817 of etravirine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: ciclesonide with relative risk of -9.311 of etravirine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: axitinib with relative risk of -9.365 of etravirine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: miglustat with relative risk of -9.629 of etravirine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: darifenacin with relative risk of -9.644 of etravirine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: crizotinib with relative risk of -9.682 of etravirine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: granisetron with relative risk of -9.704 of etravirine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: pentoxifylline with relative risk of -9.859 of etravirine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: apraclonidine with relative risk of -9.861 of etravirine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: meloxicam with relative risk of -10.539 of etravirine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: indacaterol with relative risk of -10.760 of etravirine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: nabumetone with relative risk of -10.997 of etravirine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: argatroban with relative risk of -11.101 of etravirine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: exemestane with relative risk of -11.172 of etravirine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: dabigatran with relative risk of -11.236 of etravirine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: linezolid with relative risk of -11.939 of etravirine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 17: tiotropium with relative risk of -12.161 of etravirine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: doxazosin with relative risk of -12.618 of etravirine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: pinaverium with relative risk of -12.840 of etravirine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: desoximetasone with relative risk of -inf of etravirine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.017\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó everolimus *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: levonorgestrel with relative risk of -8.891 of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: darifenacin with relative risk of -8.952 of everolimus | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: urology\n",
      "Rank 3: penbutolol with relative risk of -9.141 of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: brimonidine with relative risk of -9.717 of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: tazarotene with relative risk of -10.290 of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: trovafloxacin with relative risk of -10.299 of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: clarithromycin with relative risk of -10.509 of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: dapsone with relative risk of -10.551 of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: isradipine with relative risk of -11.295 of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: ropivacaine with relative risk of -16.234 of everolimus | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: ropivacaine with relative risk of -16.234 of everolimus | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: lurasidone with relative risk of -16.876 of everolimus | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: lurasidone with relative risk of -16.876 of everolimus | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: lansoprazole with relative risk of -17.068 of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: lansoprazole with relative risk of -17.068 of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: didanosine with relative risk of -17.326 of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: didanosine with relative risk of -17.326 of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: etoposide with relative risk of -22.310 of everolimus | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 19: etoposide with relative risk of -22.310 of everolimus | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 20: etoposide with relative risk of -22.310 of everolimus | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 21: fenofibrate with relative risk of -24.853 of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: fenofibrate with relative risk of -24.853 of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: fenofibrate with relative risk of -24.853 of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: ivacaftor with relative risk of -27.733 of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: ivacaftor with relative risk of -27.733 of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: ivacaftor with relative risk of -27.733 of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: sertraline with relative risk of -27.881 of everolimus | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 28: sertraline with relative risk of -27.881 of everolimus | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 29: sertraline with relative risk of -27.881 of everolimus | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 30: sertraline with relative risk of -27.881 of everolimus | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 31: irbesartan with relative risk of -28.342 of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: irbesartan with relative risk of -28.342 of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: irbesartan with relative risk of -28.342 of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: irbesartan with relative risk of -28.342 of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: zolmitriptan with relative risk of -28.542 of everolimus | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 36: zolmitriptan with relative risk of -28.542 of everolimus | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 37: zolmitriptan with relative risk of -28.542 of everolimus | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 38: regadenoson with relative risk of -29.279 of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: regadenoson with relative risk of -29.279 of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: regadenoson with relative risk of -29.279 of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: regadenoson with relative risk of -29.279 of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: mometasone with relative risk of -29.306 of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: mometasone with relative risk of -29.306 of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: mometasone with relative risk of -29.306 of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: mometasone with relative risk of -29.306 of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: azelastine with relative risk of -30.038 of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: azelastine with relative risk of -30.038 of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: azelastine with relative risk of -30.038 of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: azelastine with relative risk of -30.038 of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: brinzolamide with relative risk of -30.242 of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: brinzolamide with relative risk of -30.242 of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: brinzolamide with relative risk of -30.242 of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 53: posaconazole with relative risk of -30.439 of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 54: posaconazole with relative risk of -30.439 of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 55: posaconazole with relative risk of -30.439 of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 56: posaconazole with relative risk of -30.439 of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 57: acebutolol with relative risk of -30.587 of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 58: acebutolol with relative risk of -30.587 of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 59: acebutolol with relative risk of -30.587 of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 60: valsartan with relative risk of -30.730 of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 61: valsartan with relative risk of -30.730 of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 62: valsartan with relative risk of -30.730 of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 63: ibutilide with relative risk of -31.506 of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 64: ibutilide with relative risk of -31.506 of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 65: ibutilide with relative risk of -31.506 of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 66: ibutilide with relative risk of -31.506 of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 67: tropisetron with relative risk of -31.975 of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 68: tropisetron with relative risk of -31.975 of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 69: tropisetron with relative risk of -31.975 of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 70: tropisetron with relative risk of -31.975 of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 71: paliperidone with relative risk of -32.122 of everolimus | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 72: paliperidone with relative risk of -32.122 of everolimus | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 73: paliperidone with relative risk of -32.122 of everolimus | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 74: paliperidone with relative risk of -32.122 of everolimus | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 75: pentoxifylline with relative risk of -32.220 of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 76: pentoxifylline with relative risk of -32.220 of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 77: pentoxifylline with relative risk of -32.220 of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 78: pentoxifylline with relative risk of -32.220 of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 79: glimepiride with relative risk of -32.304 of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 80: glimepiride with relative risk of -32.304 of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 81: glimepiride with relative risk of -32.304 of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 82: glimepiride with relative risk of -32.304 of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 83: terbutaline with relative risk of -35.130 of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 84: terbutaline with relative risk of -35.130 of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 85: terbutaline with relative risk of -35.130 of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 86: terbutaline with relative risk of -35.130 of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 87: esmolol with relative risk of -36.786 of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 88: esmolol with relative risk of -36.786 of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 89: esmolol with relative risk of -36.786 of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 90: esmolol with relative risk of -36.786 of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 91: azilsartan with relative risk of -38.246 of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 92: azilsartan with relative risk of -38.246 of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 93: azilsartan with relative risk of -38.246 of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 94: azilsartan with relative risk of -38.246 of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 95: felodipine with relative risk of -inf of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 96: felodipine with relative risk of -inf of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 97: felodipine with relative risk of -inf of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 98: felodipine with relative risk of -inf of everolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.249\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó exemestane *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: dabigatran with relative risk of -11.236 of exemestane | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: etravirine with relative risk of -11.773 of exemestane | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: tiotropium with relative risk of -12.161 of exemestane | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: ciclesonide with relative risk of -16.393 of exemestane | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: ciclesonide with relative risk of -16.393 of exemestane | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: vinorelbine with relative risk of -17.367 of exemestane | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 7: vinorelbine with relative risk of -17.367 of exemestane | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 8: axitinib with relative risk of -17.810 of exemestane | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 9: axitinib with relative risk of -17.810 of exemestane | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 10: darifenacin with relative risk of -17.906 of exemestane | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: darifenacin with relative risk of -17.906 of exemestane | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: granisetron with relative risk of -18.255 of exemestane | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: granisetron with relative risk of -18.255 of exemestane | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: apraclonidine with relative risk of -18.412 of exemestane | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: apraclonidine with relative risk of -18.412 of exemestane | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: meloxicam with relative risk of -18.647 of exemestane | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: meloxicam with relative risk of -18.647 of exemestane | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: indacaterol with relative risk of -20.410 of exemestane | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: indacaterol with relative risk of -20.410 of exemestane | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: pinaverium with relative risk of -21.391 of exemestane | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: pinaverium with relative risk of -21.391 of exemestane | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: desoximetasone with relative risk of -inf of exemestane | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: desoximetasone with relative risk of -inf of exemestane | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.146\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó exenatide *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: captopril with relative risk of -8.154 of exenatide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 2: trazodone with relative risk of -9.450 of exenatide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: atorvastatin with relative risk of -9.640 of exenatide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: nifedipine with relative risk of -10.617 of exenatide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: indacaterol with relative risk of -10.760 of exenatide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: nabumetone with relative risk of -10.997 of exenatide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: danazol with relative risk of -11.034 of exenatide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: dabigatran with relative risk of -11.236 of exenatide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: tafluprost with relative risk of -12.129 of exenatide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: lovastatin with relative risk of -12.326 of exenatide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 11: fosinopril with relative risk of -12.426 of exenatide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: cabergoline with relative risk of -12.543 of exenatide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.381\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target ezetimibe not found. Exiting ...\n",
      "\n",
      "Drug target famciclovir not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó famotidine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: ifosfamide with relative risk of -21.450 of famotidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: ifosfamide with relative risk of -21.450 of famotidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó febuxostat *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: vinorelbine with relative risk of -9.510 of febuxostat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: ciclesonide with relative risk of -10.002 of febuxostat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: axitinib with relative risk of -10.058 of febuxostat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: ibandronate with relative risk of -10.192 of febuxostat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: miglustat with relative risk of -10.322 of febuxostat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: darifenacin with relative risk of -10.336 of febuxostat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: granisetron with relative risk of -10.397 of febuxostat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: apraclonidine with relative risk of -10.554 of febuxostat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: meloxicam with relative risk of -11.231 of febuxostat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: eplerenone with relative risk of -11.246 of febuxostat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: indacaterol with relative risk of -11.453 of febuxostat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: estramustine with relative risk of -11.980 of febuxostat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: linezolid with relative risk of -12.632 of febuxostat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: pinaverium with relative risk of -13.533 of febuxostat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: desoximetasone with relative risk of -inf of febuxostat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó felbamate *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: triamcinolone with relative risk of -22.375 of felbamate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: triamcinolone with relative risk of -22.375 of felbamate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: nadolol with relative risk of -23.427 of felbamate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: nadolol with relative risk of -23.427 of felbamate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó felodipine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: penbutolol with relative risk of -7.551 of felodipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 2: loratadine with relative risk of -8.563 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: telmisartan with relative risk of -8.684 of felodipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 4: clarithromycin with relative risk of -8.903 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: afatinib with relative risk of -8.978 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: varenicline with relative risk of -8.981 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: flutamide with relative risk of -8.990 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: bezafibrate with relative risk of -9.262 of felodipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 9: quinidine with relative risk of -9.268 of felodipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 10: beclomethasone with relative risk of -9.642 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: budesonide with relative risk of -10.009 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: pergolide with relative risk of -10.522 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: aclidinium with relative risk of -10.567 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: caffeine with relative risk of -11.063 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: bromfenac with relative risk of -12.694 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: gabapentin with relative risk of -14.747 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: gabapentin with relative risk of -14.747 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: cyclophosphamide with relative risk of -15.278 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: cyclophosphamide with relative risk of -15.278 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: argatroban with relative risk of -15.505 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: argatroban with relative risk of -15.505 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: ribavirin with relative risk of -15.782 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: ribavirin with relative risk of -15.782 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: capecitabine with relative risk of -16.260 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: capecitabine with relative risk of -16.260 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: celecoxib with relative risk of -16.476 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: celecoxib with relative risk of -16.476 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: lapatinib with relative risk of -16.726 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: lapatinib with relative risk of -16.726 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: losartan with relative risk of -17.125 of felodipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 31: losartan with relative risk of -17.125 of felodipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 32: amisulpride with relative risk of -17.191 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: amisulpride with relative risk of -17.191 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: latanoprost with relative risk of -17.287 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: latanoprost with relative risk of -17.287 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: sumatriptan with relative risk of -17.469 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: sumatriptan with relative risk of -17.469 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: citalopram with relative risk of -17.492 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: citalopram with relative risk of -17.492 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: domperidone with relative risk of -17.650 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: domperidone with relative risk of -17.650 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: temsirolimus with relative risk of -17.844 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: temsirolimus with relative risk of -17.844 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: lidocaine with relative risk of -18.528 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: lidocaine with relative risk of -18.528 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: darifenacin with relative risk of -18.532 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: darifenacin with relative risk of -18.532 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: darifenacin with relative risk of -18.532 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: naproxen with relative risk of -20.065 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: naproxen with relative risk of -20.065 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: naproxen with relative risk of -20.065 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: ruxolitinib with relative risk of -20.589 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 53: ruxolitinib with relative risk of -20.589 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 54: ruxolitinib with relative risk of -20.589 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 55: metoprolol with relative risk of -20.789 of felodipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 56: metoprolol with relative risk of -20.789 of felodipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 57: metoprolol with relative risk of -20.789 of felodipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 58: milrinone with relative risk of -21.211 of felodipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 59: milrinone with relative risk of -21.211 of felodipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 60: milrinone with relative risk of -21.211 of felodipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 61: ivacaftor with relative risk of -22.081 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 62: ivacaftor with relative risk of -22.081 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 63: ivacaftor with relative risk of -22.081 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 64: tamsulosin with relative risk of -22.537 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 65: tamsulosin with relative risk of -22.537 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 66: tamsulosin with relative risk of -22.537 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 67: cetirizine with relative risk of -23.149 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 68: cetirizine with relative risk of -23.149 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 69: cetirizine with relative risk of -23.149 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 70: brimonidine with relative risk of -23.481 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 71: brimonidine with relative risk of -23.481 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 72: brimonidine with relative risk of -23.481 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 73: tazarotene with relative risk of -24.054 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 74: tazarotene with relative risk of -24.054 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 75: tazarotene with relative risk of -24.054 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 76: dapsone with relative risk of -24.314 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 77: dapsone with relative risk of -24.314 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 78: dapsone with relative risk of -24.314 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 79: brinzolamide with relative risk of -24.590 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 80: brinzolamide with relative risk of -24.590 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 81: brinzolamide with relative risk of -24.590 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 82: perindopril with relative risk of -24.817 of felodipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 83: perindopril with relative risk of -24.817 of felodipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 84: perindopril with relative risk of -24.817 of felodipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 85: fondaparinux with relative risk of -24.919 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 86: fondaparinux with relative risk of -24.919 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 87: fondaparinux with relative risk of -24.919 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 88: acebutolol with relative risk of -24.935 of felodipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 89: acebutolol with relative risk of -24.935 of felodipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 90: acebutolol with relative risk of -24.935 of felodipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 91: isradipine with relative risk of -25.059 of felodipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 92: isradipine with relative risk of -25.059 of felodipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 93: isradipine with relative risk of -25.059 of felodipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 94: valsartan with relative risk of -25.078 of felodipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 95: valsartan with relative risk of -25.078 of felodipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 96: valsartan with relative risk of -25.078 of felodipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 97: indomethacin with relative risk of -27.589 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 98: indomethacin with relative risk of -27.589 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 99: indomethacin with relative risk of -27.589 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 100: indomethacin with relative risk of -27.589 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 101: everolimus with relative risk of -30.809 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 102: everolimus with relative risk of -30.809 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 103: everolimus with relative risk of -30.809 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 104: everolimus with relative risk of -30.809 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 105: nevirapine with relative risk of -31.737 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 106: nevirapine with relative risk of -31.737 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 107: nevirapine with relative risk of -31.737 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 108: nevirapine with relative risk of -31.737 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 109: pemetrexed with relative risk of -35.157 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 110: pemetrexed with relative risk of -35.157 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 111: pemetrexed with relative risk of -35.157 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 112: pemetrexed with relative risk of -35.157 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 113: pemetrexed with relative risk of -35.157 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 114: dutasteride with relative risk of -36.772 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 115: dutasteride with relative risk of -36.772 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 116: dutasteride with relative risk of -36.772 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 117: dutasteride with relative risk of -36.772 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 118: dutasteride with relative risk of -36.772 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 119: bumetanide with relative risk of -38.892 of felodipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 120: bumetanide with relative risk of -38.892 of felodipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 121: bumetanide with relative risk of -38.892 of felodipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 122: bumetanide with relative risk of -38.892 of felodipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 123: bumetanide with relative risk of -38.892 of felodipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 124: zolmitriptan with relative risk of -39.696 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 125: zolmitriptan with relative risk of -39.696 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 126: zolmitriptan with relative risk of -39.696 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 127: zolmitriptan with relative risk of -39.696 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 128: zolmitriptan with relative risk of -39.696 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 129: ropivacaine with relative risk of -40.255 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 130: ropivacaine with relative risk of -40.255 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 131: ropivacaine with relative risk of -40.255 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 132: ropivacaine with relative risk of -40.255 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 133: ropivacaine with relative risk of -40.255 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 134: ropivacaine with relative risk of -40.255 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 135: terbutaline with relative risk of -41.680 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 136: terbutaline with relative risk of -41.680 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 137: terbutaline with relative risk of -41.680 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 138: terbutaline with relative risk of -41.680 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 139: terbutaline with relative risk of -41.680 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 140: terbutaline with relative risk of -41.680 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 141: lurasidone with relative risk of -42.436 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 142: lurasidone with relative risk of -42.436 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 143: lurasidone with relative risk of -42.436 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 144: lurasidone with relative risk of -42.436 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 145: lurasidone with relative risk of -42.436 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 146: lurasidone with relative risk of -42.436 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 147: pentoxifylline with relative risk of -43.220 of felodipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 148: pentoxifylline with relative risk of -43.220 of felodipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 149: pentoxifylline with relative risk of -43.220 of felodipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 150: pentoxifylline with relative risk of -43.220 of felodipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 151: pentoxifylline with relative risk of -43.220 of felodipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 152: pentoxifylline with relative risk of -43.220 of felodipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 153: pentoxifylline with relative risk of -43.220 of felodipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 154: trovafloxacin with relative risk of -43.562 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 155: trovafloxacin with relative risk of -43.562 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 156: trovafloxacin with relative risk of -43.562 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 157: trovafloxacin with relative risk of -43.562 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 158: trovafloxacin with relative risk of -43.562 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 159: trovafloxacin with relative risk of -43.562 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 160: didanosine with relative risk of -45.593 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 161: didanosine with relative risk of -45.593 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 162: didanosine with relative risk of -45.593 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 163: didanosine with relative risk of -45.593 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 164: didanosine with relative risk of -45.593 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 165: didanosine with relative risk of -45.593 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 166: esmolol with relative risk of -45.637 of felodipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 167: esmolol with relative risk of -45.637 of felodipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 168: esmolol with relative risk of -45.637 of felodipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 169: esmolol with relative risk of -45.637 of felodipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 170: esmolol with relative risk of -45.637 of felodipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 171: esmolol with relative risk of -45.637 of felodipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 172: azilsartan with relative risk of -47.097 of felodipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 173: azilsartan with relative risk of -47.097 of felodipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 174: azilsartan with relative risk of -47.097 of felodipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 175: azilsartan with relative risk of -47.097 of felodipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 176: azilsartan with relative risk of -47.097 of felodipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 177: azilsartan with relative risk of -47.097 of felodipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 178: ketorolac with relative risk of -47.617 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 179: ketorolac with relative risk of -47.617 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 180: ketorolac with relative risk of -47.617 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 181: ketorolac with relative risk of -47.617 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 182: ketorolac with relative risk of -47.617 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 183: ketorolac with relative risk of -47.617 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 184: ketorolac with relative risk of -47.617 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 185: levonorgestrel with relative risk of -52.768 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 186: levonorgestrel with relative risk of -52.768 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 187: levonorgestrel with relative risk of -52.768 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 188: levonorgestrel with relative risk of -52.768 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 189: levonorgestrel with relative risk of -52.768 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 190: levonorgestrel with relative risk of -52.768 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 191: levonorgestrel with relative risk of -52.768 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 192: lansoprazole with relative risk of -65.103 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 193: lansoprazole with relative risk of -65.103 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 194: lansoprazole with relative risk of -65.103 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 195: lansoprazole with relative risk of -65.103 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 196: lansoprazole with relative risk of -65.103 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 197: lansoprazole with relative risk of -65.103 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 198: lansoprazole with relative risk of -65.103 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 199: lansoprazole with relative risk of -65.103 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 200: lansoprazole with relative risk of -65.103 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 201: sertraline with relative risk of -105.410 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 202: sertraline with relative risk of -105.410 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 203: sertraline with relative risk of -105.410 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 204: sertraline with relative risk of -105.410 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 205: sertraline with relative risk of -105.410 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 206: sertraline with relative risk of -105.410 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 207: sertraline with relative risk of -105.410 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 208: sertraline with relative risk of -105.410 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 209: sertraline with relative risk of -105.410 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 210: sertraline with relative risk of -105.410 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 211: sertraline with relative risk of -105.410 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 212: sertraline with relative risk of -105.410 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 213: sertraline with relative risk of -105.410 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 214: sertraline with relative risk of -105.410 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 215: sertraline with relative risk of -105.410 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 216: sertraline with relative risk of -105.410 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 217: sertraline with relative risk of -105.410 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 218: etoposide with relative risk of -106.229 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 219: etoposide with relative risk of -106.229 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 220: etoposide with relative risk of -106.229 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 221: etoposide with relative risk of -106.229 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 222: etoposide with relative risk of -106.229 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 223: etoposide with relative risk of -106.229 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 224: etoposide with relative risk of -106.229 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 225: etoposide with relative risk of -106.229 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 226: etoposide with relative risk of -106.229 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 227: etoposide with relative risk of -106.229 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 228: etoposide with relative risk of -106.229 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 229: etoposide with relative risk of -106.229 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 230: etoposide with relative risk of -106.229 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 231: etoposide with relative risk of -106.229 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 232: regadenoson with relative risk of -108.083 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 233: regadenoson with relative risk of -108.083 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 234: regadenoson with relative risk of -108.083 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 235: regadenoson with relative risk of -108.083 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 236: regadenoson with relative risk of -108.083 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 237: regadenoson with relative risk of -108.083 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 238: regadenoson with relative risk of -108.083 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 239: regadenoson with relative risk of -108.083 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 240: regadenoson with relative risk of -108.083 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 241: regadenoson with relative risk of -108.083 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 242: regadenoson with relative risk of -108.083 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 243: regadenoson with relative risk of -108.083 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 244: regadenoson with relative risk of -108.083 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 245: regadenoson with relative risk of -108.083 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 246: regadenoson with relative risk of -108.083 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 247: regadenoson with relative risk of -108.083 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 248: fenofibrate with relative risk of -108.772 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 249: fenofibrate with relative risk of -108.772 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 250: fenofibrate with relative risk of -108.772 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 251: fenofibrate with relative risk of -108.772 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 252: fenofibrate with relative risk of -108.772 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 253: fenofibrate with relative risk of -108.772 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 254: fenofibrate with relative risk of -108.772 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 255: fenofibrate with relative risk of -108.772 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 256: fenofibrate with relative risk of -108.772 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 257: fenofibrate with relative risk of -108.772 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 258: fenofibrate with relative risk of -108.772 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 259: fenofibrate with relative risk of -108.772 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 260: fenofibrate with relative risk of -108.772 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 261: fenofibrate with relative risk of -108.772 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 262: posaconazole with relative risk of -110.032 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 263: posaconazole with relative risk of -110.032 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 264: posaconazole with relative risk of -110.032 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 265: posaconazole with relative risk of -110.032 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 266: posaconazole with relative risk of -110.032 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 267: posaconazole with relative risk of -110.032 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 268: posaconazole with relative risk of -110.032 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 269: posaconazole with relative risk of -110.032 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 270: posaconazole with relative risk of -110.032 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 271: posaconazole with relative risk of -110.032 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 272: posaconazole with relative risk of -110.032 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 273: posaconazole with relative risk of -110.032 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 274: posaconazole with relative risk of -110.032 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 275: posaconazole with relative risk of -110.032 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 276: posaconazole with relative risk of -110.032 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 277: posaconazole with relative risk of -110.032 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 278: azelastine with relative risk of -113.720 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 279: azelastine with relative risk of -113.720 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 280: azelastine with relative risk of -113.720 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 281: azelastine with relative risk of -113.720 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 282: azelastine with relative risk of -113.720 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 283: azelastine with relative risk of -113.720 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 284: azelastine with relative risk of -113.720 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 285: azelastine with relative risk of -113.720 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 286: azelastine with relative risk of -113.720 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 287: azelastine with relative risk of -113.720 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 288: azelastine with relative risk of -113.720 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 289: azelastine with relative risk of -113.720 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 290: azelastine with relative risk of -113.720 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 291: azelastine with relative risk of -113.720 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 292: azelastine with relative risk of -113.720 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 293: azelastine with relative risk of -113.720 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 294: azelastine with relative risk of -113.720 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 295: tropisetron with relative risk of -116.651 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 296: tropisetron with relative risk of -116.651 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 297: tropisetron with relative risk of -116.651 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 298: tropisetron with relative risk of -116.651 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 299: tropisetron with relative risk of -116.651 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 300: tropisetron with relative risk of -116.651 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 301: tropisetron with relative risk of -116.651 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 302: tropisetron with relative risk of -116.651 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 303: tropisetron with relative risk of -116.651 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 304: tropisetron with relative risk of -116.651 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 305: tropisetron with relative risk of -116.651 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 306: tropisetron with relative risk of -116.651 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 307: tropisetron with relative risk of -116.651 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 308: tropisetron with relative risk of -116.651 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 309: tropisetron with relative risk of -116.651 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 310: tropisetron with relative risk of -116.651 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 311: ibutilide with relative risk of -117.895 of felodipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 312: ibutilide with relative risk of -117.895 of felodipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 313: ibutilide with relative risk of -117.895 of felodipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 314: ibutilide with relative risk of -117.895 of felodipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 315: ibutilide with relative risk of -117.895 of felodipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 316: ibutilide with relative risk of -117.895 of felodipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 317: ibutilide with relative risk of -117.895 of felodipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 318: ibutilide with relative risk of -117.895 of felodipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 319: ibutilide with relative risk of -117.895 of felodipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 320: ibutilide with relative risk of -117.895 of felodipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 321: ibutilide with relative risk of -117.895 of felodipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 322: ibutilide with relative risk of -117.895 of felodipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 323: ibutilide with relative risk of -117.895 of felodipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 324: ibutilide with relative risk of -117.895 of felodipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 325: ibutilide with relative risk of -117.895 of felodipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 326: ibutilide with relative risk of -117.895 of felodipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 327: ibutilide with relative risk of -117.895 of felodipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 328: irbesartan with relative risk of -121.699 of felodipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 329: irbesartan with relative risk of -121.699 of felodipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 330: irbesartan with relative risk of -121.699 of felodipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 331: irbesartan with relative risk of -121.699 of felodipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 332: irbesartan with relative risk of -121.699 of felodipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 333: irbesartan with relative risk of -121.699 of felodipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 334: irbesartan with relative risk of -121.699 of felodipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 335: irbesartan with relative risk of -121.699 of felodipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 336: irbesartan with relative risk of -121.699 of felodipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 337: irbesartan with relative risk of -121.699 of felodipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 338: irbesartan with relative risk of -121.699 of felodipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 339: irbesartan with relative risk of -121.699 of felodipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 340: irbesartan with relative risk of -121.699 of felodipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 341: irbesartan with relative risk of -121.699 of felodipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 342: irbesartan with relative risk of -121.699 of felodipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 343: irbesartan with relative risk of -121.699 of felodipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 344: irbesartan with relative risk of -121.699 of felodipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 345: irbesartan with relative risk of -121.699 of felodipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 346: irbesartan with relative risk of -121.699 of felodipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 347: mometasone with relative risk of -122.817 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 348: mometasone with relative risk of -122.817 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 349: mometasone with relative risk of -122.817 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 350: mometasone with relative risk of -122.817 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 351: mometasone with relative risk of -122.817 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 352: mometasone with relative risk of -122.817 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 353: mometasone with relative risk of -122.817 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 354: mometasone with relative risk of -122.817 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 355: mometasone with relative risk of -122.817 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 356: mometasone with relative risk of -122.817 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 357: mometasone with relative risk of -122.817 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 358: mometasone with relative risk of -122.817 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 359: mometasone with relative risk of -122.817 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 360: mometasone with relative risk of -122.817 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 361: mometasone with relative risk of -122.817 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 362: mometasone with relative risk of -122.817 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 363: mometasone with relative risk of -122.817 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 364: mometasone with relative risk of -122.817 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 365: glimepiride with relative risk of -133.422 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 366: glimepiride with relative risk of -133.422 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 367: glimepiride with relative risk of -133.422 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 368: glimepiride with relative risk of -133.422 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 369: glimepiride with relative risk of -133.422 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 370: glimepiride with relative risk of -133.422 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 371: glimepiride with relative risk of -133.422 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 372: glimepiride with relative risk of -133.422 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 373: glimepiride with relative risk of -133.422 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 374: glimepiride with relative risk of -133.422 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 375: glimepiride with relative risk of -133.422 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 376: glimepiride with relative risk of -133.422 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 377: glimepiride with relative risk of -133.422 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 378: glimepiride with relative risk of -133.422 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 379: glimepiride with relative risk of -133.422 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 380: glimepiride with relative risk of -133.422 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 381: glimepiride with relative risk of -133.422 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 382: paliperidone with relative risk of -139.739 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 383: paliperidone with relative risk of -139.739 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 384: paliperidone with relative risk of -139.739 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 385: paliperidone with relative risk of -139.739 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 386: paliperidone with relative risk of -139.739 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 387: paliperidone with relative risk of -139.739 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 388: paliperidone with relative risk of -139.739 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 389: paliperidone with relative risk of -139.739 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 390: paliperidone with relative risk of -139.739 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 391: paliperidone with relative risk of -139.739 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 392: paliperidone with relative risk of -139.739 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 393: paliperidone with relative risk of -139.739 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 394: paliperidone with relative risk of -139.739 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 395: paliperidone with relative risk of -139.739 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 396: paliperidone with relative risk of -139.739 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 397: paliperidone with relative risk of -139.739 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 398: paliperidone with relative risk of -139.739 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 399: paliperidone with relative risk of -139.739 of felodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.326\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó fenofibrate *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: penbutolol with relative risk of -7.900 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: telmisartan with relative risk of -9.039 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: varenicline with relative risk of -9.337 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: flutamide with relative risk of -9.346 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: bezafibrate with relative risk of -9.618 of fenofibrate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hyperlipidemia,Hypercholesterolemia\n",
      "Rank 6: gabapentin with relative risk of -15.482 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: gabapentin with relative risk of -15.482 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: cyclophosphamide with relative risk of -16.015 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: cyclophosphamide with relative risk of -16.015 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: nevirapine with relative risk of -16.297 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: nevirapine with relative risk of -16.297 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: capecitabine with relative risk of -16.996 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: capecitabine with relative risk of -16.996 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: sumatriptan with relative risk of -18.205 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: sumatriptan with relative risk of -18.205 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: citalopram with relative risk of -18.229 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: citalopram with relative risk of -18.229 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: pentoxifylline with relative risk of -19.048 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: pentoxifylline with relative risk of -19.048 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: pentoxifylline with relative risk of -19.048 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: terbutaline with relative risk of -20.972 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: terbutaline with relative risk of -20.972 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: terbutaline with relative risk of -20.972 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: naproxen with relative risk of -21.205 of fenofibrate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 25: naproxen with relative risk of -21.205 of fenofibrate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 26: naproxen with relative risk of -21.205 of fenofibrate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 27: ruxolitinib with relative risk of -21.730 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: ruxolitinib with relative risk of -21.730 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: ruxolitinib with relative risk of -21.730 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: indomethacin with relative risk of -21.731 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: indomethacin with relative risk of -21.731 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: indomethacin with relative risk of -21.731 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: metoprolol with relative risk of -21.930 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: metoprolol with relative risk of -21.930 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: metoprolol with relative risk of -21.930 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: esmolol with relative risk of -21.934 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: esmolol with relative risk of -21.934 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: esmolol with relative risk of -21.934 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: milrinone with relative risk of -22.353 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: milrinone with relative risk of -22.353 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: milrinone with relative risk of -22.353 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: ivacaftor with relative risk of -23.223 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: ivacaftor with relative risk of -23.223 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: ivacaftor with relative risk of -23.223 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: bumetanide with relative risk of -23.228 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: bumetanide with relative risk of -23.228 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: bumetanide with relative risk of -23.228 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: everolimus with relative risk of -23.343 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: everolimus with relative risk of -23.343 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: everolimus with relative risk of -23.343 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: azilsartan with relative risk of -23.394 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: azilsartan with relative risk of -23.394 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 53: azilsartan with relative risk of -23.394 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 54: tamsulosin with relative risk of -23.678 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 55: tamsulosin with relative risk of -23.678 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 56: tamsulosin with relative risk of -23.678 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 57: cetirizine with relative risk of -24.290 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 58: cetirizine with relative risk of -24.290 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 59: cetirizine with relative risk of -24.290 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 60: brinzolamide with relative risk of -25.731 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 61: brinzolamide with relative risk of -25.731 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 62: brinzolamide with relative risk of -25.731 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 63: fondaparinux with relative risk of -26.060 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 64: fondaparinux with relative risk of -26.060 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 65: fondaparinux with relative risk of -26.060 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 66: acebutolol with relative risk of -26.076 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 67: acebutolol with relative risk of -26.076 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 68: acebutolol with relative risk of -26.076 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 69: valsartan with relative risk of -26.219 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 70: valsartan with relative risk of -26.219 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 71: valsartan with relative risk of -26.219 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 72: ropivacaine with relative risk of -27.203 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 73: ropivacaine with relative risk of -27.203 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 74: ropivacaine with relative risk of -27.203 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 75: ropivacaine with relative risk of -27.203 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 76: pemetrexed with relative risk of -28.941 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 77: pemetrexed with relative risk of -28.941 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 78: pemetrexed with relative risk of -28.941 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 79: pemetrexed with relative risk of -28.941 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 80: lurasidone with relative risk of -36.443 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 81: lurasidone with relative risk of -36.443 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 82: lurasidone with relative risk of -36.443 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 83: lurasidone with relative risk of -36.443 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 84: lurasidone with relative risk of -36.443 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 85: trovafloxacin with relative risk of -37.569 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 86: trovafloxacin with relative risk of -37.569 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 87: trovafloxacin with relative risk of -37.569 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 88: trovafloxacin with relative risk of -37.569 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 89: trovafloxacin with relative risk of -37.569 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 90: didanosine with relative risk of -38.502 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 91: didanosine with relative risk of -38.502 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 92: didanosine with relative risk of -38.502 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 93: didanosine with relative risk of -38.502 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 94: didanosine with relative risk of -38.502 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 95: dutasteride with relative risk of -38.818 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 96: dutasteride with relative risk of -38.818 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 97: dutasteride with relative risk of -38.818 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 98: dutasteride with relative risk of -38.818 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 99: dutasteride with relative risk of -38.818 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 100: zolmitriptan with relative risk of -41.743 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 101: zolmitriptan with relative risk of -41.743 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 102: zolmitriptan with relative risk of -41.743 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 103: zolmitriptan with relative risk of -41.743 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 104: zolmitriptan with relative risk of -41.743 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 105: ketorolac with relative risk of -50.733 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 106: ketorolac with relative risk of -50.733 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 107: ketorolac with relative risk of -50.733 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 108: ketorolac with relative risk of -50.733 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 109: ketorolac with relative risk of -50.733 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 110: ketorolac with relative risk of -50.733 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 111: ketorolac with relative risk of -50.733 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 112: lansoprazole with relative risk of -51.370 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 113: lansoprazole with relative risk of -51.370 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 114: lansoprazole with relative risk of -51.370 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 115: lansoprazole with relative risk of -51.370 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 116: lansoprazole with relative risk of -51.370 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 117: lansoprazole with relative risk of -51.370 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 118: lansoprazole with relative risk of -51.370 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 119: levonorgestrel with relative risk of -55.885 of fenofibrate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 120: levonorgestrel with relative risk of -55.885 of fenofibrate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 121: levonorgestrel with relative risk of -55.885 of fenofibrate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 122: levonorgestrel with relative risk of -55.885 of fenofibrate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 123: levonorgestrel with relative risk of -55.885 of fenofibrate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 124: levonorgestrel with relative risk of -55.885 of fenofibrate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 125: levonorgestrel with relative risk of -55.885 of fenofibrate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 126: sertraline with relative risk of -83.259 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 127: sertraline with relative risk of -83.259 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 128: sertraline with relative risk of -83.259 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 129: sertraline with relative risk of -83.259 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 130: sertraline with relative risk of -83.259 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 131: sertraline with relative risk of -83.259 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 132: sertraline with relative risk of -83.259 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 133: sertraline with relative risk of -83.259 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 134: sertraline with relative risk of -83.259 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 135: sertraline with relative risk of -83.259 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 136: sertraline with relative risk of -83.259 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 137: sertraline with relative risk of -83.259 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 138: sertraline with relative risk of -83.259 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 139: tropisetron with relative risk of -87.835 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 140: tropisetron with relative risk of -87.835 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 141: tropisetron with relative risk of -87.835 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 142: tropisetron with relative risk of -87.835 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 143: tropisetron with relative risk of -87.835 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 144: tropisetron with relative risk of -87.835 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 145: tropisetron with relative risk of -87.835 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 146: tropisetron with relative risk of -87.835 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 147: tropisetron with relative risk of -87.835 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 148: tropisetron with relative risk of -87.835 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 149: tropisetron with relative risk of -87.835 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 150: tropisetron with relative risk of -87.835 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 151: azelastine with relative risk of -89.342 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 152: azelastine with relative risk of -89.342 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 153: azelastine with relative risk of -89.342 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 154: azelastine with relative risk of -89.342 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 155: azelastine with relative risk of -89.342 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 156: azelastine with relative risk of -89.342 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 157: azelastine with relative risk of -89.342 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 158: azelastine with relative risk of -89.342 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 159: azelastine with relative risk of -89.342 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 160: azelastine with relative risk of -89.342 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 161: azelastine with relative risk of -89.342 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 162: azelastine with relative risk of -89.342 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 163: azelastine with relative risk of -89.342 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 164: regadenoson with relative risk of -91.213 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 165: regadenoson with relative risk of -91.213 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 166: regadenoson with relative risk of -91.213 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 167: regadenoson with relative risk of -91.213 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 168: regadenoson with relative risk of -91.213 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 169: regadenoson with relative risk of -91.213 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 170: regadenoson with relative risk of -91.213 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 171: regadenoson with relative risk of -91.213 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 172: regadenoson with relative risk of -91.213 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 173: regadenoson with relative risk of -91.213 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 174: regadenoson with relative risk of -91.213 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 175: regadenoson with relative risk of -91.213 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 176: regadenoson with relative risk of -91.213 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 177: irbesartan with relative risk of -91.900 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 178: irbesartan with relative risk of -91.900 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 179: irbesartan with relative risk of -91.900 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 180: irbesartan with relative risk of -91.900 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 181: irbesartan with relative risk of -91.900 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 182: irbesartan with relative risk of -91.900 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 183: irbesartan with relative risk of -91.900 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 184: irbesartan with relative risk of -91.900 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 185: irbesartan with relative risk of -91.900 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 186: irbesartan with relative risk of -91.900 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 187: irbesartan with relative risk of -91.900 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 188: irbesartan with relative risk of -91.900 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 189: irbesartan with relative risk of -91.900 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 190: irbesartan with relative risk of -91.900 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 191: ibutilide with relative risk of -92.474 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 192: ibutilide with relative risk of -92.474 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 193: ibutilide with relative risk of -92.474 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 194: ibutilide with relative risk of -92.474 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 195: ibutilide with relative risk of -92.474 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 196: ibutilide with relative risk of -92.474 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 197: ibutilide with relative risk of -92.474 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 198: ibutilide with relative risk of -92.474 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 199: ibutilide with relative risk of -92.474 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 200: ibutilide with relative risk of -92.474 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 201: ibutilide with relative risk of -92.474 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 202: ibutilide with relative risk of -92.474 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 203: ibutilide with relative risk of -92.474 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 204: posaconazole with relative risk of -92.899 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 205: posaconazole with relative risk of -92.899 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 206: posaconazole with relative risk of -92.899 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 207: posaconazole with relative risk of -92.899 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 208: posaconazole with relative risk of -92.899 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 209: posaconazole with relative risk of -92.899 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 210: posaconazole with relative risk of -92.899 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 211: posaconazole with relative risk of -92.899 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 212: posaconazole with relative risk of -92.899 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 213: posaconazole with relative risk of -92.899 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 214: posaconazole with relative risk of -92.899 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 215: posaconazole with relative risk of -92.899 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 216: posaconazole with relative risk of -92.899 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 217: mometasone with relative risk of -98.799 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 218: mometasone with relative risk of -98.799 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 219: mometasone with relative risk of -98.799 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 220: mometasone with relative risk of -98.799 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 221: mometasone with relative risk of -98.799 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 222: mometasone with relative risk of -98.799 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 223: mometasone with relative risk of -98.799 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 224: mometasone with relative risk of -98.799 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 225: mometasone with relative risk of -98.799 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 226: mometasone with relative risk of -98.799 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 227: mometasone with relative risk of -98.799 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 228: mometasone with relative risk of -98.799 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 229: mometasone with relative risk of -98.799 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 230: mometasone with relative risk of -98.799 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 231: paliperidone with relative risk of -109.557 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 232: paliperidone with relative risk of -109.557 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 233: paliperidone with relative risk of -109.557 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 234: paliperidone with relative risk of -109.557 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 235: paliperidone with relative risk of -109.557 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 236: paliperidone with relative risk of -109.557 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 237: paliperidone with relative risk of -109.557 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 238: paliperidone with relative risk of -109.557 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 239: paliperidone with relative risk of -109.557 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 240: paliperidone with relative risk of -109.557 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 241: paliperidone with relative risk of -109.557 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 242: paliperidone with relative risk of -109.557 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 243: paliperidone with relative risk of -109.557 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 244: paliperidone with relative risk of -109.557 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 245: glimepiride with relative risk of -112.090 of fenofibrate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 246: glimepiride with relative risk of -112.090 of fenofibrate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 247: glimepiride with relative risk of -112.090 of fenofibrate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 248: glimepiride with relative risk of -112.090 of fenofibrate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 249: glimepiride with relative risk of -112.090 of fenofibrate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 250: glimepiride with relative risk of -112.090 of fenofibrate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 251: glimepiride with relative risk of -112.090 of fenofibrate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 252: glimepiride with relative risk of -112.090 of fenofibrate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 253: glimepiride with relative risk of -112.090 of fenofibrate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 254: glimepiride with relative risk of -112.090 of fenofibrate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 255: glimepiride with relative risk of -112.090 of fenofibrate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 256: glimepiride with relative risk of -112.090 of fenofibrate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 257: glimepiride with relative risk of -112.090 of fenofibrate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 258: glimepiride with relative risk of -112.090 of fenofibrate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 259: etoposide with relative risk of -116.794 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 260: etoposide with relative risk of -116.794 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 261: etoposide with relative risk of -116.794 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 262: etoposide with relative risk of -116.794 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 263: etoposide with relative risk of -116.794 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 264: etoposide with relative risk of -116.794 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 265: etoposide with relative risk of -116.794 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 266: etoposide with relative risk of -116.794 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 267: etoposide with relative risk of -116.794 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 268: etoposide with relative risk of -116.794 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 269: etoposide with relative risk of -116.794 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 270: etoposide with relative risk of -116.794 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 271: etoposide with relative risk of -116.794 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 272: etoposide with relative risk of -116.794 of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 273: felodipine with relative risk of -inf of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 274: felodipine with relative risk of -inf of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 275: felodipine with relative risk of -inf of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 276: felodipine with relative risk of -inf of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 277: felodipine with relative risk of -inf of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 278: felodipine with relative risk of -inf of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 279: felodipine with relative risk of -inf of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 280: felodipine with relative risk of -inf of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 281: felodipine with relative risk of -inf of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 282: felodipine with relative risk of -inf of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 283: felodipine with relative risk of -inf of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 284: felodipine with relative risk of -inf of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 285: felodipine with relative risk of -inf of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 286: felodipine with relative risk of -inf of fenofibrate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.069\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target fenofibric not found. Exiting ...\n",
      "\n",
      "Drug target fentanyl not found. Exiting ...\n",
      "\n",
      "Drug target ferumoxytol not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó fesoterodine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: nelarabine with relative risk of -11.409 of fesoterodine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: sparfloxacin with relative risk of -20.729 of fesoterodine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: sparfloxacin with relative risk of -20.729 of fesoterodine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó fexofenadine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: paricalcitol with relative risk of -10.955 of fexofenadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target fidaxomicin not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó finasteride *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: ropivacaine with relative risk of -7.868 of finasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: ibandronate with relative risk of -7.897 of finasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: atosiban with relative risk of -9.718 of finasteride | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 4: vincristine with relative risk of -9.930 of finasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: desloratadine with relative risk of -10.168 of finasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: desvenlafaxine with relative risk of -10.812 of finasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: amoxicillin with relative risk of -11.314 of finasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: diltiazem with relative risk of -11.557 of finasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: nebivolol with relative risk of -12.042 of finasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: acyclovir with relative risk of -17.954 of finasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: acyclovir with relative risk of -17.954 of finasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: imatinib with relative risk of -23.148 of finasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: imatinib with relative risk of -23.148 of finasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: imatinib with relative risk of -23.148 of finasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: gemcitabine with relative risk of -25.453 of finasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: gemcitabine with relative risk of -25.453 of finasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: gemcitabine with relative risk of -25.453 of finasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: ramipril with relative risk of -27.362 of finasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: ramipril with relative risk of -27.362 of finasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: ramipril with relative risk of -27.362 of finasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: clopidogrel with relative risk of -35.030 of finasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: clopidogrel with relative risk of -35.030 of finasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: clopidogrel with relative risk of -35.030 of finasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: clopidogrel with relative risk of -35.030 of finasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: gefitinib with relative risk of -42.344 of finasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: gefitinib with relative risk of -42.344 of finasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: gefitinib with relative risk of -42.344 of finasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: gefitinib with relative risk of -42.344 of finasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: gefitinib with relative risk of -42.344 of finasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: trimetrexate with relative risk of -49.287 of finasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: trimetrexate with relative risk of -49.287 of finasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: trimetrexate with relative risk of -49.287 of finasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: trimetrexate with relative risk of -49.287 of finasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: trimetrexate with relative risk of -49.287 of finasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: trimetrexate with relative risk of -49.287 of finasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: dihydroergotamine with relative risk of -52.061 of finasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: dihydroergotamine with relative risk of -52.061 of finasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: dihydroergotamine with relative risk of -52.061 of finasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: dihydroergotamine with relative risk of -52.061 of finasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: dihydroergotamine with relative risk of -52.061 of finasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: dihydroergotamine with relative risk of -52.061 of finasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: aminophylline with relative risk of -54.055 of finasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: aminophylline with relative risk of -54.055 of finasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: aminophylline with relative risk of -54.055 of finasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: aminophylline with relative risk of -54.055 of finasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: aminophylline with relative risk of -54.055 of finasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: aminophylline with relative risk of -54.055 of finasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: aminophylline with relative risk of -54.055 of finasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: valdecoxib with relative risk of -60.458 of finasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: valdecoxib with relative risk of -60.458 of finasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: valdecoxib with relative risk of -60.458 of finasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: valdecoxib with relative risk of -60.458 of finasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 53: valdecoxib with relative risk of -60.458 of finasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 54: valdecoxib with relative risk of -60.458 of finasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 55: valdecoxib with relative risk of -60.458 of finasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 56: alendronate with relative risk of -66.747 of finasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 57: alendronate with relative risk of -66.747 of finasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 58: alendronate with relative risk of -66.747 of finasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 59: alendronate with relative risk of -66.747 of finasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 60: alendronate with relative risk of -66.747 of finasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 61: alendronate with relative risk of -66.747 of finasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 62: alendronate with relative risk of -66.747 of finasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 63: alendronate with relative risk of -66.747 of finasteride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.07\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó flecainide *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: regadenoson with relative risk of -8.647 of flecainide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: sertraline with relative risk of -8.999 of flecainide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: mometasone with relative risk of -9.242 of flecainide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: posaconazole with relative risk of -9.679 of flecainide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: irbesartan with relative risk of -9.727 of flecainide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 6: azelastine with relative risk of -10.076 of flecainide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: tropisetron with relative risk of -10.479 of flecainide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: ruxolitinib with relative risk of -10.512 of flecainide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: lurasidone with relative risk of -10.558 of flecainide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: lansoprazole with relative risk of -11.107 of flecainide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: ibutilide with relative risk of -11.114 of flecainide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 12: risperidone with relative risk of -11.175 of flecainide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: ketorolac with relative risk of -11.258 of flecainide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: atropine with relative risk of -11.531 of flecainide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: clarithromycin with relative risk of -11.894 of flecainide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: clonidine with relative risk of -11.931 of flecainide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 17: dutasteride with relative risk of -12.086 of flecainide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: leflunomide with relative risk of -12.233 of flecainide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: doxorubicin with relative risk of -12.242 of flecainide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: vernakalant with relative risk of -12.281 of flecainide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 21: vilazodone with relative risk of -13.644 of flecainide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: pindolol with relative risk of -13.800 of flecainide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.122\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target florbetapir not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó fluconazole *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: ibandronate with relative risk of -9.500 of fluconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: miglustat with relative risk of -9.629 of fluconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: pentoxifylline with relative risk of -9.859 of fluconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: terbutaline with relative risk of -10.090 of fluconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: ketorolac with relative risk of -10.565 of fluconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: loratadine with relative risk of -10.862 of fluconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: doxercalciferol with relative risk of -11.049 of fluconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: argatroban with relative risk of -11.101 of fluconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: dronedarone with relative risk of -11.277 of fluconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: estramustine with relative risk of -11.287 of fluconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: iloperidone with relative risk of -11.491 of fluconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: rabeprazole with relative risk of -11.504 of fluconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: levocabastine with relative risk of -11.664 of fluconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: levetiracetam with relative risk of -11.955 of fluconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: guanfacine with relative risk of -12.067 of fluconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: mirtazapine with relative risk of -12.157 of fluconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: fosphenytoin with relative risk of -12.213 of fluconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: bisoprolol with relative risk of -12.286 of fluconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: reboxetine with relative risk of -12.438 of fluconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: ropinirole with relative risk of -12.554 of fluconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: vardenafil with relative risk of -12.599 of fluconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: rilpivirine with relative risk of -12.757 of fluconazole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 23: domperidone with relative risk of -12.842 of fluconazole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.024\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó fludarabine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: belinostat with relative risk of -11.616 of fludarabine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Peripheral T-Cell Lymphoma,hematologic malignancy\n",
      "Rank 2: palonosetron with relative risk of -12.669 of fludarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: timolol with relative risk of -12.719 of fludarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: quinapril with relative risk of -13.217 of fludarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.48\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó flumazenil *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: nalmefene with relative risk of -11.697 of flumazenil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: thalidomide with relative risk of -12.415 of flumazenil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: ranolazine with relative risk of -13.623 of flumazenil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó flunisolide *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: olanzapine with relative risk of -13.044 of flunisolide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target fluocinolone not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó fluocinonide *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: propranolol with relative risk of -30.177 of fluocinonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: propranolol with relative risk of -30.177 of fluocinonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: propranolol with relative risk of -30.177 of fluocinonide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó fluoxetine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: alogliptin with relative risk of -10.809 of fluoxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: simvastatin with relative risk of -27.830 of fluoxetine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: simvastatin with relative risk of -27.830 of fluoxetine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: simvastatin with relative risk of -27.830 of fluoxetine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 5: dolasetron with relative risk of -28.054 of fluoxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: dolasetron with relative risk of -28.054 of fluoxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: dolasetron with relative risk of -28.054 of fluoxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.418\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó flutamide *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: etoposide with relative risk of -8.636 of flutamide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 2: regadenoson with relative risk of -8.647 of flutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: sertraline with relative risk of -8.999 of flutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: mometasone with relative risk of -9.242 of flutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: posaconazole with relative risk of -9.679 of flutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: irbesartan with relative risk of -9.727 of flutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: azelastine with relative risk of -10.076 of flutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: glimepiride with relative risk of -10.259 of flutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: levonorgestrel with relative risk of -10.276 of flutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: paliperidone with relative risk of -10.454 of flutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: cyclophosphamide with relative risk of -10.470 of flutamide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 12: tropisetron with relative risk of -10.479 of flutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: ruxolitinib with relative risk of -10.512 of flutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: didanosine with relative risk of -10.672 of flutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: lansoprazole with relative risk of -11.107 of flutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: ibutilide with relative risk of -11.114 of flutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: fenofibrate with relative risk of -11.179 of flutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: ketorolac with relative risk of -11.258 of flutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: trovafloxacin with relative risk of -11.684 of flutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: dutasteride with relative risk of -12.086 of flutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: sumatriptan with relative risk of -12.661 of flutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: citalopram with relative risk of -12.685 of flutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: felodipine with relative risk of -inf of flutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.292\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target fluticasone not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó fluvastatin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: paroxetine with relative risk of -7.232 of fluvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: regorafenib with relative risk of -7.811 of fluvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: bexarotene with relative risk of -7.822 of fluvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: tolcapone with relative risk of -8.931 of fluvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: zileuton with relative risk of -10.001 of fluvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: adapalene with relative risk of -10.024 of fluvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: liraglutide with relative risk of -10.073 of fluvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 8: fosinopril with relative risk of -10.635 of fluvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 9: linagliptin with relative risk of -10.978 of fluvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 10: dexamethasone with relative risk of -18.055 of fluvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 11: dexamethasone with relative risk of -18.055 of fluvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 12: sitagliptin with relative risk of -25.156 of fluvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 13: sitagliptin with relative risk of -25.156 of fluvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 14: sitagliptin with relative risk of -25.156 of fluvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 15: tizanidine with relative risk of -28.498 of fluvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: tizanidine with relative risk of -28.498 of fluvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: tizanidine with relative risk of -28.498 of fluvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: tizanidine with relative risk of -28.498 of fluvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: nisoldipine with relative risk of -29.600 of fluvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 20: nisoldipine with relative risk of -29.600 of fluvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 21: nisoldipine with relative risk of -29.600 of fluvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 22: nisoldipine with relative risk of -29.600 of fluvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 23: irinotecan with relative risk of -32.792 of fluvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: irinotecan with relative risk of -32.792 of fluvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: irinotecan with relative risk of -32.792 of fluvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: irinotecan with relative risk of -32.792 of fluvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: ketoprofen with relative risk of -33.022 of fluvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: ketoprofen with relative risk of -33.022 of fluvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: ketoprofen with relative risk of -33.022 of fluvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: ketoprofen with relative risk of -33.022 of fluvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: propafenone with relative risk of -34.493 of fluvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 32: propafenone with relative risk of -34.493 of fluvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 33: propafenone with relative risk of -34.493 of fluvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 34: propafenone with relative risk of -34.493 of fluvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 35: lenalidomide with relative risk of -44.295 of fluvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: lenalidomide with relative risk of -44.295 of fluvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: lenalidomide with relative risk of -44.295 of fluvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: lenalidomide with relative risk of -44.295 of fluvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: lenalidomide with relative risk of -44.295 of fluvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: lenalidomide with relative risk of -44.295 of fluvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: lenalidomide with relative risk of -44.295 of fluvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: penbutolol with relative risk of -68.279 of fluvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 43: penbutolol with relative risk of -68.279 of fluvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 44: penbutolol with relative risk of -68.279 of fluvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 45: penbutolol with relative risk of -68.279 of fluvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 46: penbutolol with relative risk of -68.279 of fluvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 47: penbutolol with relative risk of -68.279 of fluvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 48: penbutolol with relative risk of -68.279 of fluvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 49: penbutolol with relative risk of -68.279 of fluvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 50: penbutolol with relative risk of -68.279 of fluvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 51: penbutolol with relative risk of -68.279 of fluvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 52: amiodarone with relative risk of -73.795 of fluvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 53: amiodarone with relative risk of -73.795 of fluvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 54: amiodarone with relative risk of -73.795 of fluvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 55: amiodarone with relative risk of -73.795 of fluvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 56: amiodarone with relative risk of -73.795 of fluvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 57: amiodarone with relative risk of -73.795 of fluvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 58: amiodarone with relative risk of -73.795 of fluvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 59: amiodarone with relative risk of -73.795 of fluvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 60: amiodarone with relative risk of -73.795 of fluvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 61: amiodarone with relative risk of -73.795 of fluvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 62: amiodarone with relative risk of -73.795 of fluvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.325\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó fluvoxamine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: frovatriptan with relative risk of -8.475 of fluvoxamine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: pazopanib with relative risk of -8.554 of fluvoxamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: dabrafenib with relative risk of -8.581 of fluvoxamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: dofetilide with relative risk of -9.132 of fluvoxamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: disopyramide with relative risk of -9.389 of fluvoxamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: venlafaxine with relative risk of -10.070 of fluvoxamine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Phobia, Social,neurology/psychiatry\n",
      "Rank 7: piroxicam with relative risk of -10.783 of fluvoxamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: tofacitinib with relative risk of -10.893 of fluvoxamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: pitavastatin with relative risk of -11.120 of fluvoxamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: trametinib with relative risk of -31.664 of fluvoxamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: trametinib with relative risk of -31.664 of fluvoxamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: trametinib with relative risk of -31.664 of fluvoxamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: trametinib with relative risk of -31.664 of fluvoxamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: colchicine with relative risk of -78.225 of fluvoxamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: colchicine with relative risk of -78.225 of fluvoxamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: colchicine with relative risk of -78.225 of fluvoxamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: colchicine with relative risk of -78.225 of fluvoxamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: colchicine with relative risk of -78.225 of fluvoxamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: colchicine with relative risk of -78.225 of fluvoxamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: colchicine with relative risk of -78.225 of fluvoxamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: colchicine with relative risk of -78.225 of fluvoxamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: colchicine with relative risk of -78.225 of fluvoxamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: colchicine with relative risk of -78.225 of fluvoxamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: colchicine with relative risk of -78.225 of fluvoxamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.309\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó fondaparinux *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: ropivacaine with relative risk of -9.070 of fondaparinux | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: levonorgestrel with relative risk of -9.178 of fondaparinux | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: ruxolitinib with relative risk of -9.413 of fondaparinux | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: hematology\n",
      "Rank 4: lurasidone with relative risk of -9.460 of fondaparinux | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: didanosine with relative risk of -9.573 of fondaparinux | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: lansoprazole with relative risk of -10.009 of fondaparinux | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: ketorolac with relative risk of -10.160 of fondaparinux | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: bumetanide with relative risk of -10.401 of fondaparinux | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: sumatriptan with relative risk of -11.562 of fondaparinux | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: sertraline with relative risk of -14.173 of fondaparinux | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: sertraline with relative risk of -14.173 of fondaparinux | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: trovafloxacin with relative risk of -18.695 of fondaparinux | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: trovafloxacin with relative risk of -18.695 of fondaparinux | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: nevirapine with relative risk of -19.708 of fondaparinux | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: nevirapine with relative risk of -19.708 of fondaparinux | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: capecitabine with relative risk of -20.408 of fondaparinux | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: capecitabine with relative risk of -20.408 of fondaparinux | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: irbesartan with relative risk of -22.116 of fondaparinux | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: irbesartan with relative risk of -22.116 of fondaparinux | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: irbesartan with relative risk of -22.116 of fondaparinux | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: regadenoson with relative risk of -22.359 of fondaparinux | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: regadenoson with relative risk of -22.359 of fondaparinux | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: regadenoson with relative risk of -22.359 of fondaparinux | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: mometasone with relative risk of -22.583 of fondaparinux | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: mometasone with relative risk of -22.583 of fondaparinux | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: mometasone with relative risk of -22.583 of fondaparinux | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: azelastine with relative risk of -23.351 of fondaparinux | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: azelastine with relative risk of -23.351 of fondaparinux | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: azelastine with relative risk of -23.351 of fondaparinux | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: posaconazole with relative risk of -23.476 of fondaparinux | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: posaconazole with relative risk of -23.476 of fondaparinux | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: posaconazole with relative risk of -23.476 of fondaparinux | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: etoposide with relative risk of -23.696 of fondaparinux | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: etoposide with relative risk of -23.696 of fondaparinux | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: etoposide with relative risk of -23.696 of fondaparinux | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: ibutilide with relative risk of -24.670 of fondaparinux | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: ibutilide with relative risk of -24.670 of fondaparinux | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: ibutilide with relative risk of -24.670 of fondaparinux | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: tropisetron with relative risk of -24.754 of fondaparinux | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: tropisetron with relative risk of -24.754 of fondaparinux | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: tropisetron with relative risk of -24.754 of fondaparinux | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: paliperidone with relative risk of -24.840 of fondaparinux | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: paliperidone with relative risk of -24.840 of fondaparinux | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: paliperidone with relative risk of -24.840 of fondaparinux | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: glimepiride with relative risk of -24.888 of fondaparinux | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: glimepiride with relative risk of -24.888 of fondaparinux | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: glimepiride with relative risk of -24.888 of fondaparinux | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: fenofibrate with relative risk of -26.239 of fondaparinux | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: fenofibrate with relative risk of -26.239 of fondaparinux | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: fenofibrate with relative risk of -26.239 of fondaparinux | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: pemetrexed with relative risk of -27.180 of fondaparinux | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: pemetrexed with relative risk of -27.180 of fondaparinux | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 53: pemetrexed with relative risk of -27.180 of fondaparinux | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 54: indomethacin with relative risk of -27.626 of fondaparinux | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 55: indomethacin with relative risk of -27.626 of fondaparinux | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 56: indomethacin with relative risk of -27.626 of fondaparinux | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 57: metoprolol with relative risk of -27.826 of fondaparinux | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 58: metoprolol with relative risk of -27.826 of fondaparinux | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 59: metoprolol with relative risk of -27.826 of fondaparinux | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 60: milrinone with relative risk of -28.249 of fondaparinux | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 61: milrinone with relative risk of -28.249 of fondaparinux | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 62: milrinone with relative risk of -28.249 of fondaparinux | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 63: dutasteride with relative risk of -28.795 of fondaparinux | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 64: dutasteride with relative risk of -28.795 of fondaparinux | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 65: dutasteride with relative risk of -28.795 of fondaparinux | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 66: tamsulosin with relative risk of -29.574 of fondaparinux | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 67: tamsulosin with relative risk of -29.574 of fondaparinux | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 68: tamsulosin with relative risk of -29.574 of fondaparinux | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 69: felodipine with relative risk of -inf of fondaparinux | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 70: felodipine with relative risk of -inf of fondaparinux | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 71: felodipine with relative risk of -inf of fondaparinux | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.069\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó formoterol *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: vinorelbine with relative risk of -7.116 of formoterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: aminophylline with relative risk of -7.129 of formoterol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Pulmonary Emphysema,pulmonary\n",
      "Rank 3: ciclesonide with relative risk of -7.621 of formoterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: axitinib with relative risk of -7.664 of formoterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: darifenacin with relative risk of -7.944 of formoterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: granisetron with relative risk of -8.003 of formoterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: apraclonidine with relative risk of -8.160 of formoterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: meloxicam with relative risk of -8.839 of formoterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: eplerenone with relative risk of -8.849 of formoterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: atomoxetine with relative risk of -9.324 of formoterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: cilostazol with relative risk of -9.559 of formoterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: allopurinol with relative risk of -9.628 of formoterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: nelarabine with relative risk of -9.705 of formoterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: mafenide with relative risk of -9.773 of formoterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: avanafil with relative risk of -9.833 of formoterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: entacapone with relative risk of -9.909 of formoterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: umeclidinium with relative risk of -9.937 of formoterol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Chronic Obstructive Airway Disease,pulmonary\n",
      "Rank 18: candesartan with relative risk of -10.174 of formoterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: ipratropium with relative risk of -10.176 of formoterol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: pulmonary\n",
      "Rank 20: silodosin with relative risk of -10.422 of formoterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: nefazodone with relative risk of -10.695 of formoterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: rufinamide with relative risk of -10.946 of formoterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: clopidogrel with relative risk of -10.994 of formoterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: hydrochlorothiazide with relative risk of -11.110 of formoterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: pinaverium with relative risk of -11.139 of formoterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: rosiglitazone with relative risk of -13.760 of formoterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: rosiglitazone with relative risk of -13.760 of formoterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: paclitaxel with relative risk of -16.977 of formoterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: paclitaxel with relative risk of -16.977 of formoterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: rasagiline with relative risk of -17.846 of formoterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: rasagiline with relative risk of -17.846 of formoterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: rivastigmine with relative risk of -18.659 of formoterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: rivastigmine with relative risk of -18.659 of formoterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: sotalol with relative risk of -18.683 of formoterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: sotalol with relative risk of -18.683 of formoterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: rofecoxib with relative risk of -18.734 of formoterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: rofecoxib with relative risk of -18.734 of formoterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: pimozide with relative risk of -18.806 of formoterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: pimozide with relative risk of -18.806 of formoterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: capsaicin with relative risk of -19.258 of formoterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: capsaicin with relative risk of -19.258 of formoterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: fosinoprilat with relative risk of -21.540 of formoterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: fosinoprilat with relative risk of -21.540 of formoterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: frovatriptan with relative risk of -28.966 of formoterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: frovatriptan with relative risk of -28.966 of formoterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: frovatriptan with relative risk of -28.966 of formoterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: frovatriptan with relative risk of -28.966 of formoterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: nimodipine with relative risk of -30.054 of formoterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: nimodipine with relative risk of -30.054 of formoterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: nimodipine with relative risk of -30.054 of formoterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: nimodipine with relative risk of -30.054 of formoterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: cytarabine with relative risk of -33.312 of formoterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 53: cytarabine with relative risk of -33.312 of formoterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 54: cytarabine with relative risk of -33.312 of formoterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 55: cytarabine with relative risk of -33.312 of formoterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 56: desoximetasone with relative risk of -inf of formoterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.133\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target fosaprepitant not found. Exiting ...\n",
      "\n",
      "Drug target foscarnet not found. Exiting ...\n",
      "\n",
      "Drug target fosfomycin not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó fosinopril *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: captopril with relative risk of -7.463 of fosinopril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Chronic heart failure,Hypertensive disease,cardiology\n",
      "Rank 2: idarubicin with relative risk of -8.597 of fosinopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: atorvastatin with relative risk of -8.949 of fosinopril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 4: fluvastatin with relative risk of -9.899 of fosinopril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 5: nifedipine with relative risk of -9.924 of fosinopril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 6: bicalutamide with relative risk of -9.929 of fosinopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: tolcapone with relative risk of -10.026 of fosinopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: nabumetone with relative risk of -10.305 of fosinopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: danazol with relative risk of -10.341 of fosinopril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 10: dabigatran with relative risk of -10.543 of fosinopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: letrozole with relative risk of -11.417 of fosinopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: gemfibrozil with relative risk of -11.472 of fosinopril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 13: maprotiline with relative risk of -11.568 of fosinopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: exenatide with relative risk of -11.625 of fosinopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: apremilast with relative risk of -12.371 of fosinopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.596\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó fosinoprilat *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: aminophylline with relative risk of -8.831 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: entacapone with relative risk of -11.614 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: ipratropium with relative risk of -11.881 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: silodosin with relative risk of -12.126 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: nefazodone with relative risk of -12.399 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: clopidogrel with relative risk of -12.697 of fosinoprilat | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 7: formoterol with relative risk of -18.768 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: formoterol with relative risk of -18.768 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: frovatriptan with relative risk of -18.930 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: frovatriptan with relative risk of -18.930 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: nimodipine with relative risk of -19.480 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: nimodipine with relative risk of -19.480 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: cytarabine with relative risk of -19.695 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: cytarabine with relative risk of -19.695 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: paclitaxel with relative risk of -20.985 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: paclitaxel with relative risk of -20.985 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: rasagiline with relative risk of -21.853 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: rasagiline with relative risk of -21.853 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: rivastigmine with relative risk of -22.666 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: rivastigmine with relative risk of -22.666 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: sotalol with relative risk of -22.691 of fosinoprilat | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 22: sotalol with relative risk of -22.691 of fosinoprilat | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 23: rofecoxib with relative risk of -22.741 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: rofecoxib with relative risk of -22.741 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: pimozide with relative risk of -22.814 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: pimozide with relative risk of -22.814 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: capsaicin with relative risk of -23.265 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: capsaicin with relative risk of -23.265 of fosinoprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.066\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó fosphenytoin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: doxercalciferol with relative risk of -11.743 of fosphenytoin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: iloperidone with relative risk of -12.184 of fosphenytoin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: rabeprazole with relative risk of -12.198 of fosphenytoin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: levocabastine with relative risk of -12.358 of fosphenytoin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: levetiracetam with relative risk of -12.648 of fosphenytoin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Epilepsy characterized by intractable complex partial seizures,neurology/psychiatry\n",
      "Rank 6: fluconazole with relative risk of -12.728 of fosphenytoin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: guanfacine with relative risk of -12.760 of fosphenytoin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: mirtazapine with relative risk of -12.850 of fosphenytoin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: reboxetine with relative risk of -13.131 of fosphenytoin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: ropinirole with relative risk of -13.248 of fosphenytoin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: vardenafil with relative risk of -13.293 of fosphenytoin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: rilpivirine with relative risk of -13.450 of fosphenytoin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.334\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target fospropofol not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó frovatriptan *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: aminophylline with relative risk of -7.129 of frovatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: fluvoxamine with relative risk of -7.679 of frovatriptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: meloxicam with relative risk of -8.839 of frovatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: pazopanib with relative risk of -8.864 of frovatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: atomoxetine with relative risk of -9.324 of frovatriptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: cilostazol with relative risk of -9.559 of frovatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: allopurinol with relative risk of -9.628 of frovatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: nelarabine with relative risk of -9.705 of frovatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: mafenide with relative risk of -9.773 of frovatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: avanafil with relative risk of -9.833 of frovatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: entacapone with relative risk of -9.909 of frovatriptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: candesartan with relative risk of -10.174 of frovatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: ipratropium with relative risk of -10.176 of frovatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: gonadorelin with relative risk of -10.236 of frovatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: silodosin with relative risk of -10.422 of frovatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: montelukast with relative risk of -10.602 of frovatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: nefazodone with relative risk of -10.695 of frovatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: rufinamide with relative risk of -10.946 of frovatriptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 19: clopidogrel with relative risk of -10.994 of frovatriptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 20: hydrochlorothiazide with relative risk of -11.110 of frovatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: paclitaxel with relative risk of -16.977 of frovatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: paclitaxel with relative risk of -16.977 of frovatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: rasagiline with relative risk of -17.846 of frovatriptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 24: rasagiline with relative risk of -17.846 of frovatriptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 25: rivastigmine with relative risk of -18.659 of frovatriptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 26: rivastigmine with relative risk of -18.659 of frovatriptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 27: sotalol with relative risk of -18.683 of frovatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: sotalol with relative risk of -18.683 of frovatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: rofecoxib with relative risk of -18.734 of frovatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: rofecoxib with relative risk of -18.734 of frovatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: pimozide with relative risk of -18.806 of frovatriptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 32: pimozide with relative risk of -18.806 of frovatriptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 33: capsaicin with relative risk of -19.258 of frovatriptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 34: capsaicin with relative risk of -19.258 of frovatriptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 35: fosinoprilat with relative risk of -21.540 of frovatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: fosinoprilat with relative risk of -21.540 of frovatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: formoterol with relative risk of -28.804 of frovatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: formoterol with relative risk of -28.804 of frovatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: formoterol with relative risk of -28.804 of frovatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: formoterol with relative risk of -28.804 of frovatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: nimodipine with relative risk of -30.054 of frovatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: nimodipine with relative risk of -30.054 of frovatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: nimodipine with relative risk of -30.054 of frovatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: nimodipine with relative risk of -30.054 of frovatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: cytarabine with relative risk of -33.312 of frovatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: cytarabine with relative risk of -33.312 of frovatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: cytarabine with relative risk of -33.312 of frovatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: cytarabine with relative risk of -33.312 of frovatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.266\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target fusidic not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó gabapentin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: ibandronate with relative risk of -8.405 of gabapentin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: ruxolitinib with relative risk of -8.721 of gabapentin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: didanosine with relative risk of -8.881 of gabapentin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 4: indomethacin with relative risk of -9.464 of gabapentin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: ketorolac with relative risk of -9.469 of gabapentin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: bumetanide with relative risk of -9.708 of gabapentin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: varenicline with relative risk of -10.183 of gabapentin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: dutasteride with relative risk of -10.296 of gabapentin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: bezafibrate with relative risk of -10.466 of gabapentin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: ixabepilone with relative risk of -10.548 of gabapentin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: citalopram with relative risk of -10.893 of gabapentin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: benazepril with relative risk of -11.387 of gabapentin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: toremifene with relative risk of -12.140 of gabapentin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: etoposide with relative risk of -13.420 of gabapentin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: etoposide with relative risk of -13.420 of gabapentin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: glimepiride with relative risk of -14.836 of gabapentin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: glimepiride with relative risk of -14.836 of gabapentin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: fenofibrate with relative risk of -15.963 of gabapentin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: fenofibrate with relative risk of -15.963 of gabapentin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: lansoprazole with relative risk of -16.153 of gabapentin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: lansoprazole with relative risk of -16.153 of gabapentin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: cetirizine with relative risk of -18.118 of gabapentin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: cetirizine with relative risk of -18.118 of gabapentin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: zolmitriptan with relative risk of -18.265 of gabapentin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 25: zolmitriptan with relative risk of -18.265 of gabapentin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 26: clonidine with relative risk of -18.585 of gabapentin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 27: clonidine with relative risk of -18.585 of gabapentin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 28: erlotinib with relative risk of -18.630 of gabapentin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: erlotinib with relative risk of -18.630 of gabapentin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: vemurafenib with relative risk of -18.661 of gabapentin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: vemurafenib with relative risk of -18.661 of gabapentin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: irbesartan with relative risk of -19.126 of gabapentin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: irbesartan with relative risk of -19.126 of gabapentin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: irbesartan with relative risk of -19.126 of gabapentin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: mometasone with relative risk of -19.591 of gabapentin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: mometasone with relative risk of -19.591 of gabapentin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: mometasone with relative risk of -19.591 of gabapentin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: rotigotine with relative risk of -19.997 of gabapentin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Restless Legs Syndrome,neurology/psychiatry\n",
      "Rank 39: rotigotine with relative risk of -19.997 of gabapentin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Restless Legs Syndrome,neurology/psychiatry\n",
      "Rank 40: doxepin with relative risk of -20.204 of gabapentin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 41: doxepin with relative risk of -20.204 of gabapentin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 42: posaconazole with relative risk of -20.483 of gabapentin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 43: posaconazole with relative risk of -20.483 of gabapentin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 44: posaconazole with relative risk of -20.483 of gabapentin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 45: tropisetron with relative risk of -21.760 of gabapentin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: tropisetron with relative risk of -21.760 of gabapentin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: tropisetron with relative risk of -21.760 of gabapentin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: paliperidone with relative risk of -21.846 of gabapentin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 49: paliperidone with relative risk of -21.846 of gabapentin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 50: paliperidone with relative risk of -21.846 of gabapentin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 51: ticagrelor with relative risk of -23.806 of gabapentin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: ticagrelor with relative risk of -23.806 of gabapentin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 53: ticagrelor with relative risk of -23.806 of gabapentin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 54: lurasidone with relative risk of -23.935 of gabapentin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 55: lurasidone with relative risk of -23.935 of gabapentin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 56: lurasidone with relative risk of -23.935 of gabapentin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 57: telmisartan with relative risk of -25.051 of gabapentin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 58: telmisartan with relative risk of -25.051 of gabapentin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 59: telmisartan with relative risk of -25.051 of gabapentin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 60: clarithromycin with relative risk of -26.013 of gabapentin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 61: clarithromycin with relative risk of -26.013 of gabapentin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 62: clarithromycin with relative risk of -26.013 of gabapentin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 63: regadenoson with relative risk of -26.573 of gabapentin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 64: regadenoson with relative risk of -26.573 of gabapentin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 65: regadenoson with relative risk of -26.573 of gabapentin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 66: regadenoson with relative risk of -26.573 of gabapentin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 67: delavirdine with relative risk of -27.711 of gabapentin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 68: delavirdine with relative risk of -27.711 of gabapentin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 69: delavirdine with relative risk of -27.711 of gabapentin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 70: ibutilide with relative risk of -28.800 of gabapentin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 71: ibutilide with relative risk of -28.800 of gabapentin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 72: ibutilide with relative risk of -28.800 of gabapentin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 73: ibutilide with relative risk of -28.800 of gabapentin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 74: ropivacaine with relative risk of -40.581 of gabapentin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 75: ropivacaine with relative risk of -40.581 of gabapentin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 76: ropivacaine with relative risk of -40.581 of gabapentin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 77: ropivacaine with relative risk of -40.581 of gabapentin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 78: ropivacaine with relative risk of -40.581 of gabapentin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 79: sertraline with relative risk of -40.588 of gabapentin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 80: sertraline with relative risk of -40.588 of gabapentin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 81: sertraline with relative risk of -40.588 of gabapentin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 82: sertraline with relative risk of -40.588 of gabapentin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 83: sertraline with relative risk of -40.588 of gabapentin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 84: sertraline with relative risk of -40.588 of gabapentin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 85: naproxen with relative risk of -42.934 of gabapentin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 86: naproxen with relative risk of -42.934 of gabapentin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 87: naproxen with relative risk of -42.934 of gabapentin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 88: naproxen with relative risk of -42.934 of gabapentin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 89: naproxen with relative risk of -42.934 of gabapentin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 90: azelastine with relative risk of -43.520 of gabapentin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 91: azelastine with relative risk of -43.520 of gabapentin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 92: azelastine with relative risk of -43.520 of gabapentin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 93: azelastine with relative risk of -43.520 of gabapentin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 94: azelastine with relative risk of -43.520 of gabapentin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 95: azelastine with relative risk of -43.520 of gabapentin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 96: felodipine with relative risk of -inf of gabapentin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 97: felodipine with relative risk of -inf of gabapentin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.291\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target gadobenate not found. Exiting ...\n",
      "\n",
      "Drug target gadobutrol not found. Exiting ...\n",
      "\n",
      "Drug target gadolinium not found. Exiting ...\n",
      "\n",
      "Drug target gadopentetate not found. Exiting ...\n",
      "\n",
      "Drug target gadoteridol not found. Exiting ...\n",
      "\n",
      "Drug target gadoversetamide not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó galantamine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: clozapine with relative risk of -9.370 of galantamine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: bimatoprost with relative risk of -10.361 of galantamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.667\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target ganciclovir not found. Exiting ...\n",
      "\n",
      "Drug target gatifloxacin not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó gefitinib *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: ropivacaine with relative risk of -8.559 of gefitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: ibandronate with relative risk of -8.586 of gefitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: acyclovir with relative risk of -10.096 of gefitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: atosiban with relative risk of -10.412 of gefitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: vincristine with relative risk of -10.623 of gefitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: ramipril with relative risk of -11.124 of gefitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: desvenlafaxine with relative risk of -11.505 of gefitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: amoxicillin with relative risk of -12.007 of gefitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: diltiazem with relative risk of -12.250 of gefitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: nebivolol with relative risk of -12.735 of gefitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: clopidogrel with relative risk of -19.757 of gefitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: clopidogrel with relative risk of -19.757 of gefitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: aminophylline with relative risk of -23.054 of gefitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: aminophylline with relative risk of -23.054 of gefitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: aminophylline with relative risk of -23.054 of gefitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: imatinib with relative risk of -25.632 of gefitinib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 17: imatinib with relative risk of -25.632 of gefitinib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 18: imatinib with relative risk of -25.632 of gefitinib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 19: dihydroergotamine with relative risk of -26.734 of gefitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: dihydroergotamine with relative risk of -26.734 of gefitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: dihydroergotamine with relative risk of -26.734 of gefitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: gemcitabine with relative risk of -27.938 of gefitinib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Non-Small Cell Lung Carcinoma,oncology\n",
      "Rank 23: gemcitabine with relative risk of -27.938 of gefitinib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Non-Small Cell Lung Carcinoma,oncology\n",
      "Rank 24: gemcitabine with relative risk of -27.938 of gefitinib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Non-Small Cell Lung Carcinoma,oncology\n",
      "Rank 25: alendronate with relative risk of -34.612 of gefitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: alendronate with relative risk of -34.612 of gefitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: alendronate with relative risk of -34.612 of gefitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: alendronate with relative risk of -34.612 of gefitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: trimetrexate with relative risk of -34.707 of gefitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: trimetrexate with relative risk of -34.707 of gefitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: trimetrexate with relative risk of -34.707 of gefitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: trimetrexate with relative risk of -34.707 of gefitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: valdecoxib with relative risk of -35.264 of gefitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: valdecoxib with relative risk of -35.264 of gefitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: valdecoxib with relative risk of -35.264 of gefitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: valdecoxib with relative risk of -35.264 of gefitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: finasteride with relative risk of -43.302 of gefitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: finasteride with relative risk of -43.302 of gefitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: finasteride with relative risk of -43.302 of gefitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: finasteride with relative risk of -43.302 of gefitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: finasteride with relative risk of -43.302 of gefitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.071\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó gemcitabine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: ropivacaine with relative risk of -9.070 of gemcitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: ibandronate with relative risk of -9.095 of gemcitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: acyclovir with relative risk of -10.607 of gemcitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: dihydroergotamine with relative risk of -10.824 of gemcitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: atosiban with relative risk of -10.922 of gemcitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: vincristine with relative risk of -11.134 of gemcitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: ramipril with relative risk of -11.635 of gemcitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: desvenlafaxine with relative risk of -12.016 of gemcitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: amoxicillin with relative risk of -12.518 of gemcitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: diltiazem with relative risk of -12.761 of gemcitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: nebivolol with relative risk of -13.246 of gemcitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: trimetrexate with relative risk of -18.104 of gemcitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: trimetrexate with relative risk of -18.104 of gemcitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: valdecoxib with relative risk of -18.661 of gemcitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: valdecoxib with relative risk of -18.661 of gemcitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: clopidogrel with relative risk of -20.960 of gemcitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: clopidogrel with relative risk of -20.960 of gemcitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: aminophylline with relative risk of -25.356 of gemcitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: aminophylline with relative risk of -25.356 of gemcitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: aminophylline with relative risk of -25.356 of gemcitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: finasteride with relative risk of -26.930 of gemcitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: finasteride with relative risk of -26.930 of gemcitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: finasteride with relative risk of -26.930 of gemcitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: imatinib with relative risk of -27.935 of gemcitabine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 25: imatinib with relative risk of -27.935 of gemcitabine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 26: imatinib with relative risk of -27.935 of gemcitabine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 27: alendronate with relative risk of -28.112 of gemcitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: alendronate with relative risk of -28.112 of gemcitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: alendronate with relative risk of -28.112 of gemcitabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: gefitinib with relative risk of -28.457 of gemcitabine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Non-Small Cell Lung Carcinoma,oncology\n",
      "Rank 31: gefitinib with relative risk of -28.457 of gemcitabine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Non-Small Cell Lung Carcinoma,oncology\n",
      "Rank 32: gefitinib with relative risk of -28.457 of gemcitabine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Non-Small Cell Lung Carcinoma,oncology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.053\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target gemeprost not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó gemfibrozil *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: idarubicin with relative risk of -9.290 of gemfibrozil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: bicalutamide with relative risk of -10.622 of gemfibrozil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: letrozole with relative risk of -12.110 of gemfibrozil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: maprotiline with relative risk of -12.261 of gemfibrozil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: fosinopril with relative risk of -12.426 of gemfibrozil | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 6: apremilast with relative risk of -13.064 of gemfibrozil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.082\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target gemifloxacin not found. Exiting ...\n",
      "\n",
      "Drug target gliclazide not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó glimepiride *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: penbutolol with relative risk of -7.710 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: telmisartan with relative risk of -8.846 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: clarithromycin with relative risk of -9.065 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: varenicline with relative risk of -9.143 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: flutamide with relative risk of -9.152 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: bezafibrate with relative risk of -9.424 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: perindopril with relative risk of -9.607 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: gabapentin with relative risk of -15.081 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: gabapentin with relative risk of -15.081 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: cyclophosphamide with relative risk of -15.613 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: cyclophosphamide with relative risk of -15.613 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: nevirapine with relative risk of -15.895 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: nevirapine with relative risk of -15.895 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: capecitabine with relative risk of -16.594 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: capecitabine with relative risk of -16.594 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: sumatriptan with relative risk of -17.803 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: sumatriptan with relative risk of -17.803 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: citalopram with relative risk of -17.827 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: citalopram with relative risk of -17.827 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: darifenacin with relative risk of -19.047 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: darifenacin with relative risk of -19.047 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: darifenacin with relative risk of -19.047 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: naproxen with relative risk of -20.581 of glimepiride | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 24: naproxen with relative risk of -20.581 of glimepiride | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 25: naproxen with relative risk of -20.581 of glimepiride | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 26: ruxolitinib with relative risk of -21.105 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: ruxolitinib with relative risk of -21.105 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: ruxolitinib with relative risk of -21.105 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: indomethacin with relative risk of -21.107 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: indomethacin with relative risk of -21.107 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: indomethacin with relative risk of -21.107 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: metoprolol with relative risk of -21.305 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: metoprolol with relative risk of -21.305 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: metoprolol with relative risk of -21.305 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: milrinone with relative risk of -21.728 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: milrinone with relative risk of -21.728 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: milrinone with relative risk of -21.728 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: ivacaftor with relative risk of -22.598 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: ivacaftor with relative risk of -22.598 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: ivacaftor with relative risk of -22.598 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: bumetanide with relative risk of -22.603 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: bumetanide with relative risk of -22.603 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: bumetanide with relative risk of -22.603 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: tamsulosin with relative risk of -23.053 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: tamsulosin with relative risk of -23.053 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: tamsulosin with relative risk of -23.053 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: cetirizine with relative risk of -23.666 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: cetirizine with relative risk of -23.666 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: cetirizine with relative risk of -23.666 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: brimonidine with relative risk of -23.998 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: brimonidine with relative risk of -23.998 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: brimonidine with relative risk of -23.998 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 53: tazarotene with relative risk of -24.571 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 54: tazarotene with relative risk of -24.571 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 55: tazarotene with relative risk of -24.571 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 56: dapsone with relative risk of -24.831 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 57: dapsone with relative risk of -24.831 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 58: dapsone with relative risk of -24.831 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 59: brinzolamide with relative risk of -25.106 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 60: brinzolamide with relative risk of -25.106 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 61: brinzolamide with relative risk of -25.106 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 62: fondaparinux with relative risk of -25.435 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 63: fondaparinux with relative risk of -25.435 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 64: fondaparinux with relative risk of -25.435 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 65: acebutolol with relative risk of -25.451 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 66: acebutolol with relative risk of -25.451 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 67: acebutolol with relative risk of -25.451 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 68: isradipine with relative risk of -25.576 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 69: isradipine with relative risk of -25.576 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 70: isradipine with relative risk of -25.576 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 71: valsartan with relative risk of -25.595 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 72: valsartan with relative risk of -25.595 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 73: valsartan with relative risk of -25.595 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 74: pemetrexed with relative risk of -28.075 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 75: pemetrexed with relative risk of -28.075 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 76: pemetrexed with relative risk of -28.075 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 77: pemetrexed with relative risk of -28.075 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 78: everolimus with relative risk of -31.520 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 79: everolimus with relative risk of -31.520 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 80: everolimus with relative risk of -31.520 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 81: everolimus with relative risk of -31.520 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 82: trovafloxacin with relative risk of -36.441 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 83: trovafloxacin with relative risk of -36.441 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 84: trovafloxacin with relative risk of -36.441 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 85: trovafloxacin with relative risk of -36.441 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 86: trovafloxacin with relative risk of -36.441 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 87: didanosine with relative risk of -37.374 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 88: didanosine with relative risk of -37.374 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 89: didanosine with relative risk of -37.374 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 90: didanosine with relative risk of -37.374 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 91: didanosine with relative risk of -37.374 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 92: pentoxifylline with relative risk of -37.565 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 93: pentoxifylline with relative risk of -37.565 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 94: pentoxifylline with relative risk of -37.565 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 95: pentoxifylline with relative risk of -37.565 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 96: pentoxifylline with relative risk of -37.565 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 97: pentoxifylline with relative risk of -37.565 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 98: dutasteride with relative risk of -37.690 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 99: dutasteride with relative risk of -37.690 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 100: dutasteride with relative risk of -37.690 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 101: dutasteride with relative risk of -37.690 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 102: dutasteride with relative risk of -37.690 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 103: zolmitriptan with relative risk of -40.615 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 104: zolmitriptan with relative risk of -40.615 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 105: zolmitriptan with relative risk of -40.615 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 106: zolmitriptan with relative risk of -40.615 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 107: zolmitriptan with relative risk of -40.615 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 108: ropivacaine with relative risk of -41.396 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 109: ropivacaine with relative risk of -41.396 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 110: ropivacaine with relative risk of -41.396 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 111: ropivacaine with relative risk of -41.396 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 112: ropivacaine with relative risk of -41.396 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 113: ropivacaine with relative risk of -41.396 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 114: terbutaline with relative risk of -42.822 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 115: terbutaline with relative risk of -42.822 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 116: terbutaline with relative risk of -42.822 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 117: terbutaline with relative risk of -42.822 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 118: terbutaline with relative risk of -42.822 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 119: terbutaline with relative risk of -42.822 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 120: lurasidone with relative risk of -43.578 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 121: lurasidone with relative risk of -43.578 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 122: lurasidone with relative risk of -43.578 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 123: lurasidone with relative risk of -43.578 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 124: lurasidone with relative risk of -43.578 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 125: lurasidone with relative risk of -43.578 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 126: esmolol with relative risk of -46.779 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 127: esmolol with relative risk of -46.779 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 128: esmolol with relative risk of -46.779 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 129: esmolol with relative risk of -46.779 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 130: esmolol with relative risk of -46.779 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 131: esmolol with relative risk of -46.779 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 132: azilsartan with relative risk of -48.238 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 133: azilsartan with relative risk of -48.238 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 134: azilsartan with relative risk of -48.238 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 135: azilsartan with relative risk of -48.238 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 136: azilsartan with relative risk of -48.238 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 137: azilsartan with relative risk of -48.238 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 138: ketorolac with relative risk of -48.999 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 139: ketorolac with relative risk of -48.999 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 140: ketorolac with relative risk of -48.999 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 141: ketorolac with relative risk of -48.999 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 142: ketorolac with relative risk of -48.999 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 143: ketorolac with relative risk of -48.999 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 144: ketorolac with relative risk of -48.999 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 145: levonorgestrel with relative risk of -54.150 of glimepiride | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 146: levonorgestrel with relative risk of -54.150 of glimepiride | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 147: levonorgestrel with relative risk of -54.150 of glimepiride | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 148: levonorgestrel with relative risk of -54.150 of glimepiride | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 149: levonorgestrel with relative risk of -54.150 of glimepiride | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 150: levonorgestrel with relative risk of -54.150 of glimepiride | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 151: levonorgestrel with relative risk of -54.150 of glimepiride | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 152: lansoprazole with relative risk of -58.080 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 153: lansoprazole with relative risk of -58.080 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 154: lansoprazole with relative risk of -58.080 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 155: lansoprazole with relative risk of -58.080 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 156: lansoprazole with relative risk of -58.080 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 157: lansoprazole with relative risk of -58.080 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 158: lansoprazole with relative risk of -58.080 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 159: lansoprazole with relative risk of -58.080 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 160: azelastine with relative risk of -101.343 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 161: azelastine with relative risk of -101.343 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 162: azelastine with relative risk of -101.343 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 163: azelastine with relative risk of -101.343 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 164: azelastine with relative risk of -101.343 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 165: azelastine with relative risk of -101.343 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 166: azelastine with relative risk of -101.343 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 167: azelastine with relative risk of -101.343 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 168: azelastine with relative risk of -101.343 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 169: azelastine with relative risk of -101.343 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 170: azelastine with relative risk of -101.343 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 171: azelastine with relative risk of -101.343 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 172: azelastine with relative risk of -101.343 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 173: azelastine with relative risk of -101.343 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 174: azelastine with relative risk of -101.343 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 175: irbesartan with relative risk of -102.095 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 176: irbesartan with relative risk of -102.095 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 177: irbesartan with relative risk of -102.095 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 178: irbesartan with relative risk of -102.095 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 179: irbesartan with relative risk of -102.095 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 180: irbesartan with relative risk of -102.095 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 181: irbesartan with relative risk of -102.095 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 182: irbesartan with relative risk of -102.095 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 183: irbesartan with relative risk of -102.095 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 184: irbesartan with relative risk of -102.095 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 185: irbesartan with relative risk of -102.095 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 186: irbesartan with relative risk of -102.095 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 187: irbesartan with relative risk of -102.095 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 188: irbesartan with relative risk of -102.095 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 189: irbesartan with relative risk of -102.095 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 190: irbesartan with relative risk of -102.095 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 191: sertraline with relative risk of -102.927 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 192: sertraline with relative risk of -102.927 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 193: sertraline with relative risk of -102.927 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 194: sertraline with relative risk of -102.927 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 195: sertraline with relative risk of -102.927 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 196: sertraline with relative risk of -102.927 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 197: sertraline with relative risk of -102.927 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 198: sertraline with relative risk of -102.927 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 199: sertraline with relative risk of -102.927 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 200: sertraline with relative risk of -102.927 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 201: sertraline with relative risk of -102.927 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 202: sertraline with relative risk of -102.927 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 203: sertraline with relative risk of -102.927 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 204: sertraline with relative risk of -102.927 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 205: sertraline with relative risk of -102.927 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 206: sertraline with relative risk of -102.927 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 207: regadenoson with relative risk of -103.999 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 208: regadenoson with relative risk of -103.999 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 209: regadenoson with relative risk of -103.999 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 210: regadenoson with relative risk of -103.999 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 211: regadenoson with relative risk of -103.999 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 212: regadenoson with relative risk of -103.999 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 213: regadenoson with relative risk of -103.999 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 214: regadenoson with relative risk of -103.999 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 215: regadenoson with relative risk of -103.999 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 216: regadenoson with relative risk of -103.999 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 217: regadenoson with relative risk of -103.999 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 218: regadenoson with relative risk of -103.999 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 219: regadenoson with relative risk of -103.999 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 220: regadenoson with relative risk of -103.999 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 221: regadenoson with relative risk of -103.999 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 222: posaconazole with relative risk of -105.852 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 223: posaconazole with relative risk of -105.852 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 224: posaconazole with relative risk of -105.852 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 225: posaconazole with relative risk of -105.852 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 226: posaconazole with relative risk of -105.852 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 227: posaconazole with relative risk of -105.852 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 228: posaconazole with relative risk of -105.852 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 229: posaconazole with relative risk of -105.852 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 230: posaconazole with relative risk of -105.852 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 231: posaconazole with relative risk of -105.852 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 232: posaconazole with relative risk of -105.852 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 233: posaconazole with relative risk of -105.852 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 234: posaconazole with relative risk of -105.852 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 235: posaconazole with relative risk of -105.852 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 236: posaconazole with relative risk of -105.852 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 237: etoposide with relative risk of -110.272 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 238: etoposide with relative risk of -110.272 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 239: etoposide with relative risk of -110.272 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 240: etoposide with relative risk of -110.272 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 241: etoposide with relative risk of -110.272 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 242: etoposide with relative risk of -110.272 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 243: etoposide with relative risk of -110.272 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 244: etoposide with relative risk of -110.272 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 245: etoposide with relative risk of -110.272 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 246: etoposide with relative risk of -110.272 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 247: etoposide with relative risk of -110.272 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 248: etoposide with relative risk of -110.272 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 249: etoposide with relative risk of -110.272 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 250: etoposide with relative risk of -110.272 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 251: tropisetron with relative risk of -111.779 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 252: tropisetron with relative risk of -111.779 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 253: tropisetron with relative risk of -111.779 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 254: tropisetron with relative risk of -111.779 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 255: tropisetron with relative risk of -111.779 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 256: tropisetron with relative risk of -111.779 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 257: tropisetron with relative risk of -111.779 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 258: tropisetron with relative risk of -111.779 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 259: tropisetron with relative risk of -111.779 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 260: tropisetron with relative risk of -111.779 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 261: tropisetron with relative risk of -111.779 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 262: tropisetron with relative risk of -111.779 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 263: tropisetron with relative risk of -111.779 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 264: tropisetron with relative risk of -111.779 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 265: tropisetron with relative risk of -111.779 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 266: fenofibrate with relative risk of -112.816 of glimepiride | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 267: fenofibrate with relative risk of -112.816 of glimepiride | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 268: fenofibrate with relative risk of -112.816 of glimepiride | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 269: fenofibrate with relative risk of -112.816 of glimepiride | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 270: fenofibrate with relative risk of -112.816 of glimepiride | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 271: fenofibrate with relative risk of -112.816 of glimepiride | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 272: fenofibrate with relative risk of -112.816 of glimepiride | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 273: fenofibrate with relative risk of -112.816 of glimepiride | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 274: fenofibrate with relative risk of -112.816 of glimepiride | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 275: fenofibrate with relative risk of -112.816 of glimepiride | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 276: fenofibrate with relative risk of -112.816 of glimepiride | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 277: fenofibrate with relative risk of -112.816 of glimepiride | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 278: fenofibrate with relative risk of -112.816 of glimepiride | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 279: fenofibrate with relative risk of -112.816 of glimepiride | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 280: ibutilide with relative risk of -114.531 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 281: ibutilide with relative risk of -114.531 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 282: ibutilide with relative risk of -114.531 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 283: ibutilide with relative risk of -114.531 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 284: ibutilide with relative risk of -114.531 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 285: ibutilide with relative risk of -114.531 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 286: ibutilide with relative risk of -114.531 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 287: ibutilide with relative risk of -114.531 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 288: ibutilide with relative risk of -114.531 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 289: ibutilide with relative risk of -114.531 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 290: ibutilide with relative risk of -114.531 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 291: ibutilide with relative risk of -114.531 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 292: ibutilide with relative risk of -114.531 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 293: ibutilide with relative risk of -114.531 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 294: ibutilide with relative risk of -114.531 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 295: ibutilide with relative risk of -114.531 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 296: mometasone with relative risk of -120.648 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 297: mometasone with relative risk of -120.648 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 298: mometasone with relative risk of -120.648 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 299: mometasone with relative risk of -120.648 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 300: mometasone with relative risk of -120.648 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 301: mometasone with relative risk of -120.648 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 302: mometasone with relative risk of -120.648 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 303: mometasone with relative risk of -120.648 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 304: mometasone with relative risk of -120.648 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 305: mometasone with relative risk of -120.648 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 306: mometasone with relative risk of -120.648 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 307: mometasone with relative risk of -120.648 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 308: mometasone with relative risk of -120.648 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 309: mometasone with relative risk of -120.648 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 310: mometasone with relative risk of -120.648 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 311: mometasone with relative risk of -120.648 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 312: mometasone with relative risk of -120.648 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 313: paliperidone with relative risk of -135.625 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 314: paliperidone with relative risk of -135.625 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 315: paliperidone with relative risk of -135.625 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 316: paliperidone with relative risk of -135.625 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 317: paliperidone with relative risk of -135.625 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 318: paliperidone with relative risk of -135.625 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 319: paliperidone with relative risk of -135.625 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 320: paliperidone with relative risk of -135.625 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 321: paliperidone with relative risk of -135.625 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 322: paliperidone with relative risk of -135.625 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 323: paliperidone with relative risk of -135.625 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 324: paliperidone with relative risk of -135.625 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 325: paliperidone with relative risk of -135.625 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 326: paliperidone with relative risk of -135.625 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 327: paliperidone with relative risk of -135.625 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 328: paliperidone with relative risk of -135.625 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 329: paliperidone with relative risk of -135.625 of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 330: felodipine with relative risk of -inf of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 331: felodipine with relative risk of -inf of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 332: felodipine with relative risk of -inf of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 333: felodipine with relative risk of -inf of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 334: felodipine with relative risk of -inf of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 335: felodipine with relative risk of -inf of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 336: felodipine with relative risk of -inf of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 337: felodipine with relative risk of -inf of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 338: felodipine with relative risk of -inf of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 339: felodipine with relative risk of -inf of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 340: felodipine with relative risk of -inf of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 341: felodipine with relative risk of -inf of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 342: felodipine with relative risk of -inf of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 343: felodipine with relative risk of -inf of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 344: felodipine with relative risk of -inf of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 345: felodipine with relative risk of -inf of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 346: felodipine with relative risk of -inf of glimepiride | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.035\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó glipizide *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: dexrazoxane with relative risk of -10.146 of glipizide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: carvedilol with relative risk of -11.716 of glipizide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: mitoxantrone with relative risk of -11.859 of glipizide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target glutamine not found. Exiting ...\n",
      "\n",
      "Drug target glycerol not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó glycopyrrolate *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: adenosine with relative risk of -19.080 of glycopyrrolate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: adenosine with relative risk of -19.080 of glycopyrrolate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target gold not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó gonadorelin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: cabazitaxel with relative risk of -9.888 of gonadorelin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: mitotane with relative risk of -10.288 of gonadorelin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: frovatriptan with relative risk of -10.485 of gonadorelin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: danazol with relative risk of -11.034 of gonadorelin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: obstetrics/gynecology\n",
      "Rank 5: canagliflozin with relative risk of -11.923 of gonadorelin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: phenytoin with relative risk of -12.213 of gonadorelin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: dipyridamole with relative risk of -12.574 of gonadorelin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: mexiletine with relative risk of -12.655 of gonadorelin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: ranitidine with relative risk of -12.753 of gonadorelin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: zafirlukast with relative risk of -12.826 of gonadorelin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: cilazapril with relative risk of -14.631 of gonadorelin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: montelukast with relative risk of -23.055 of gonadorelin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: montelukast with relative risk of -23.055 of gonadorelin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.079\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó granisetron *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: ibandronate with relative risk of -7.897 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: miglustat with relative risk of -8.022 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: pentoxifylline with relative risk of -8.256 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: formoterol with relative risk of -8.717 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: dabigatran with relative risk of -9.627 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: estramustine with relative risk of -9.680 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: zonisamide with relative risk of -9.885 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: etravirine with relative risk of -10.164 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: linezolid with relative risk of -10.330 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: tiotropium with relative risk of -10.551 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: febuxostat with relative risk of -12.597 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: eplerenone with relative risk of -16.801 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: eplerenone with relative risk of -16.801 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: exemestane with relative risk of -18.113 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: exemestane with relative risk of -18.113 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: indacaterol with relative risk of -24.984 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: indacaterol with relative risk of -24.984 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: indacaterol with relative risk of -24.984 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: ciclesonide with relative risk of -68.521 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: ciclesonide with relative risk of -68.521 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: ciclesonide with relative risk of -68.521 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: ciclesonide with relative risk of -68.521 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: ciclesonide with relative risk of -68.521 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: ciclesonide with relative risk of -68.521 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: ciclesonide with relative risk of -68.521 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: ciclesonide with relative risk of -68.521 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: ciclesonide with relative risk of -68.521 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: ciclesonide with relative risk of -68.521 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: meloxicam with relative risk of -81.320 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: meloxicam with relative risk of -81.320 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: meloxicam with relative risk of -81.320 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: meloxicam with relative risk of -81.320 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: meloxicam with relative risk of -81.320 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: meloxicam with relative risk of -81.320 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: meloxicam with relative risk of -81.320 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: meloxicam with relative risk of -81.320 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: meloxicam with relative risk of -81.320 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: meloxicam with relative risk of -81.320 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: darifenacin with relative risk of -82.634 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: darifenacin with relative risk of -82.634 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: darifenacin with relative risk of -82.634 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: darifenacin with relative risk of -82.634 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: darifenacin with relative risk of -82.634 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: darifenacin with relative risk of -82.634 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: darifenacin with relative risk of -82.634 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: darifenacin with relative risk of -82.634 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: darifenacin with relative risk of -82.634 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: darifenacin with relative risk of -82.634 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: axitinib with relative risk of -85.446 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: axitinib with relative risk of -85.446 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: axitinib with relative risk of -85.446 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: axitinib with relative risk of -85.446 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 53: axitinib with relative risk of -85.446 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 54: axitinib with relative risk of -85.446 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 55: axitinib with relative risk of -85.446 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 56: axitinib with relative risk of -85.446 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 57: axitinib with relative risk of -85.446 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 58: axitinib with relative risk of -85.446 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 59: vinorelbine with relative risk of -87.200 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 60: vinorelbine with relative risk of -87.200 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 61: vinorelbine with relative risk of -87.200 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 62: vinorelbine with relative risk of -87.200 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 63: vinorelbine with relative risk of -87.200 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 64: vinorelbine with relative risk of -87.200 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 65: vinorelbine with relative risk of -87.200 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 66: vinorelbine with relative risk of -87.200 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 67: vinorelbine with relative risk of -87.200 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 68: vinorelbine with relative risk of -87.200 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 69: apraclonidine with relative risk of -88.245 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 70: apraclonidine with relative risk of -88.245 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 71: apraclonidine with relative risk of -88.245 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 72: apraclonidine with relative risk of -88.245 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 73: apraclonidine with relative risk of -88.245 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 74: apraclonidine with relative risk of -88.245 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 75: apraclonidine with relative risk of -88.245 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 76: apraclonidine with relative risk of -88.245 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 77: apraclonidine with relative risk of -88.245 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 78: apraclonidine with relative risk of -88.245 of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 79: pinaverium with relative risk of -91.224 of granisetron | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "Rank 80: pinaverium with relative risk of -91.224 of granisetron | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "Rank 81: pinaverium with relative risk of -91.224 of granisetron | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "Rank 82: pinaverium with relative risk of -91.224 of granisetron | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "Rank 83: pinaverium with relative risk of -91.224 of granisetron | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "Rank 84: pinaverium with relative risk of -91.224 of granisetron | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "Rank 85: pinaverium with relative risk of -91.224 of granisetron | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "Rank 86: pinaverium with relative risk of -91.224 of granisetron | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "Rank 87: pinaverium with relative risk of -91.224 of granisetron | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "Rank 88: pinaverium with relative risk of -91.224 of granisetron | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "Rank 89: desoximetasone with relative risk of -inf of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 90: desoximetasone with relative risk of -inf of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 91: desoximetasone with relative risk of -inf of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 92: desoximetasone with relative risk of -inf of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 93: desoximetasone with relative risk of -inf of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 94: desoximetasone with relative risk of -inf of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 95: desoximetasone with relative risk of -inf of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 96: desoximetasone with relative risk of -inf of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 97: desoximetasone with relative risk of -inf of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 98: desoximetasone with relative risk of -inf of granisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.023\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó guanfacine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: doxercalciferol with relative risk of -11.743 of guanfacine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: iloperidone with relative risk of -12.184 of guanfacine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: rabeprazole with relative risk of -12.198 of guanfacine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: levocabastine with relative risk of -12.358 of guanfacine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: levetiracetam with relative risk of -12.648 of guanfacine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: fluconazole with relative risk of -12.728 of guanfacine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: mirtazapine with relative risk of -12.850 of guanfacine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: fosphenytoin with relative risk of -12.906 of guanfacine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: reboxetine with relative risk of -13.131 of guanfacine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: ropinirole with relative risk of -13.248 of guanfacine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: vardenafil with relative risk of -13.293 of guanfacine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: rilpivirine with relative risk of -13.450 of guanfacine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó halofantrine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: terazosin with relative risk of -21.534 of halofantrine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: terazosin with relative risk of -21.534 of halofantrine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: trandolapril with relative risk of -23.063 of halofantrine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: trandolapril with relative risk of -23.063 of halofantrine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó hydrochlorothiazide *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: cytarabine with relative risk of -10.046 of hydrochlorothiazide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: formoterol with relative risk of -10.323 of hydrochlorothiazide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: frovatriptan with relative risk of -10.485 of hydrochlorothiazide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: nimodipine with relative risk of -10.812 of hydrochlorothiazide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: nabumetone with relative risk of -10.997 of hydrochlorothiazide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: atomoxetine with relative risk of -11.027 of hydrochlorothiazide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: cilostazol with relative risk of -11.263 of hydrochlorothiazide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 8: mafenide with relative risk of -11.477 of hydrochlorothiazide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: avanafil with relative risk of -11.537 of hydrochlorothiazide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: candesartan with relative risk of -11.878 of hydrochlorothiazide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,Chronic heart failure,cardiology\n",
      "Rank 11: allopurinol with relative risk of -20.981 of hydrochlorothiazide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: allopurinol with relative risk of -20.981 of hydrochlorothiazide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.078\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target hydrocodone not found. Exiting ...\n",
      "\n",
      "Drug target hydromorphone not found. Exiting ...\n",
      "\n",
      "Drug target hydroxocobalamin not found. Exiting ...\n",
      "\n",
      "Drug target hydroxybutyrate not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó ibandronate *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: regadenoson with relative risk of -5.624 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: sertraline with relative risk of -5.993 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: vinorelbine with relative risk of -6.473 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: aminophylline with relative risk of -6.487 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: ciclesonide with relative risk of -6.991 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: axitinib with relative risk of -7.022 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: azelastine with relative risk of -7.058 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: imatinib with relative risk of -7.269 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: darifenacin with relative risk of -7.302 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: naproxen with relative risk of -7.353 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: granisetron with relative risk of -7.360 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: ruxolitinib with relative risk of -7.471 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: apraclonidine with relative risk of -7.517 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: lurasidone with relative risk of -7.520 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: terbutaline with relative risk of -7.745 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: gemcitabine with relative risk of -7.781 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: gefitinib with relative risk of -7.791 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: topotecan with relative risk of -7.794 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: trimetrexate with relative risk of -7.900 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: ticagrelor with relative risk of -7.931 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: finasteride with relative risk of -8.061 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: meloxicam with relative risk of -8.199 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: eplerenone with relative risk of -8.203 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: erlotinib with relative risk of -8.239 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: delavirdine with relative risk of -8.247 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: indacaterol with relative risk of -8.411 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: valdecoxib with relative risk of -8.457 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: gabapentin with relative risk of -8.505 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: telmisartan with relative risk of -8.636 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: acyclovir with relative risk of -8.662 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: atomoxetine with relative risk of -8.678 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: argatroban with relative risk of -8.752 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: tasimelteon with relative risk of -8.765 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: clarithromycin with relative risk of -8.854 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: dihydroergotamine with relative risk of -8.882 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: clonidine with relative risk of -8.888 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: dronedarone with relative risk of -8.928 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: varenicline with relative risk of -8.932 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: atosiban with relative risk of -8.977 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: naltrexone with relative risk of -8.990 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: mafenide with relative risk of -9.128 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: zonisamide with relative risk of -9.144 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: vincristine with relative risk of -9.188 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: alendronate with relative risk of -9.242 of ibandronate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: orthopedics\n",
      "Rank 45: candesartan with relative risk of -9.529 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: rotigotine with relative risk of -9.606 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: fluconazole with relative risk of -9.685 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: ramipril with relative risk of -9.690 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: doxepin with relative risk of -9.814 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: desvenlafaxine with relative risk of -10.070 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: benazepril with relative risk of -10.134 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: clopidogrel with relative risk of -10.349 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 53: domperidone with relative risk of -10.492 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 54: pinaverium with relative risk of -10.496 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 55: amoxicillin with relative risk of -10.572 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 56: prasugrel with relative risk of -10.609 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 57: ospemifene with relative risk of -10.687 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 58: diltiazem with relative risk of -10.815 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 59: nebivolol with relative risk of -11.300 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 60: febuxostat with relative risk of -11.855 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 61: ropivacaine with relative risk of -12.685 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 62: ropivacaine with relative risk of -12.685 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 63: crizotinib with relative risk of -13.477 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 64: crizotinib with relative risk of -13.477 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 65: loratadine with relative risk of -14.879 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 66: loratadine with relative risk of -14.879 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 67: estramustine with relative risk of -14.900 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 68: estramustine with relative risk of -14.900 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 69: travoprost with relative risk of -16.376 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 70: travoprost with relative risk of -16.376 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 71: linezolid with relative risk of -16.647 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 72: linezolid with relative risk of -16.647 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 73: bisoprolol with relative risk of -17.687 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 74: bisoprolol with relative risk of -17.687 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 75: ketorolac with relative risk of -19.481 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 76: ketorolac with relative risk of -19.481 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 77: ketorolac with relative risk of -19.481 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 78: miglustat with relative risk of -25.976 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 79: miglustat with relative risk of -25.976 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 80: miglustat with relative risk of -25.976 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 81: miglustat with relative risk of -25.976 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 82: clofarabine with relative risk of -27.739 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 83: clofarabine with relative risk of -27.739 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 84: clofarabine with relative risk of -27.739 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 85: clofarabine with relative risk of -27.739 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 86: nabumetone with relative risk of -31.908 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 87: nabumetone with relative risk of -31.908 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 88: nabumetone with relative risk of -31.908 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 89: nabumetone with relative risk of -31.908 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 90: nabumetone with relative risk of -31.908 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 91: moxifloxacin with relative risk of -32.490 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 92: moxifloxacin with relative risk of -32.490 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 93: moxifloxacin with relative risk of -32.490 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 94: moxifloxacin with relative risk of -32.490 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 95: pentoxifylline with relative risk of -57.113 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 96: pentoxifylline with relative risk of -57.113 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 97: pentoxifylline with relative risk of -57.113 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 98: pentoxifylline with relative risk of -57.113 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 99: pentoxifylline with relative risk of -57.113 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 100: pentoxifylline with relative risk of -57.113 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 101: pentoxifylline with relative risk of -57.113 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 102: pentoxifylline with relative risk of -57.113 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 103: pentoxifylline with relative risk of -57.113 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 104: paroxetine with relative risk of -71.138 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 105: paroxetine with relative risk of -71.138 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 106: paroxetine with relative risk of -71.138 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 107: paroxetine with relative risk of -71.138 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 108: paroxetine with relative risk of -71.138 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 109: paroxetine with relative risk of -71.138 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 110: paroxetine with relative risk of -71.138 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 111: paroxetine with relative risk of -71.138 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 112: paroxetine with relative risk of -71.138 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 113: paroxetine with relative risk of -71.138 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 114: paroxetine with relative risk of -71.138 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 115: paroxetine with relative risk of -71.138 of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 116: desoximetasone with relative risk of -inf of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 117: desoximetasone with relative risk of -inf of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 118: desoximetasone with relative risk of -inf of ibandronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.004\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target ibuprofen not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó ibutilide *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: crizotinib with relative risk of -7.049 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: penbutolol with relative risk of -7.224 of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 3: ticagrelor with relative risk of -7.646 of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 4: risperidone with relative risk of -7.849 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: erlotinib with relative risk of -7.952 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: delavirdine with relative risk of -7.960 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: vemurafenib with relative risk of -7.983 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: atropine with relative risk of -8.198 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: asenapine with relative risk of -8.296 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: amsacrine with relative risk of -8.298 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: carbamazepine with relative risk of -8.368 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: bosutinib with relative risk of -8.374 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: sulfasalazine with relative risk of -8.577 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: flutamide with relative risk of -8.653 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: leflunomide with relative risk of -8.902 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: doxorubicin with relative risk of -8.910 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: bezafibrate with relative risk of -8.925 of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 18: vernakalant with relative risk of -8.949 of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 19: ixabepilone with relative risk of -9.008 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: perindopril with relative risk of -9.109 of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 21: rotigotine with relative risk of -9.319 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: flecainide with relative risk of -9.624 of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 23: tolvaptan with relative risk of -9.638 of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 24: ambrisentan with relative risk of -9.656 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: vilazodone with relative risk of -10.312 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: pindolol with relative risk of -10.468 of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 27: toremifene with relative risk of -10.600 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: cimetidine with relative risk of -10.977 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: olmesartan with relative risk of -11.002 of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 30: bumetanide with relative risk of -14.236 of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 31: bumetanide with relative risk of -14.236 of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 32: cyclophosphamide with relative risk of -14.591 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: cyclophosphamide with relative risk of -14.591 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: nevirapine with relative risk of -14.874 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: nevirapine with relative risk of -14.874 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: cetirizine with relative risk of -14.893 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: cetirizine with relative risk of -14.893 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: dofetilide with relative risk of -15.267 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: dofetilide with relative risk of -15.267 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: clonidine with relative risk of -15.359 of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 41: clonidine with relative risk of -15.359 of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 42: capecitabine with relative risk of -15.572 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: capecitabine with relative risk of -15.572 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: sumatriptan with relative risk of -16.781 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: sumatriptan with relative risk of -16.781 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: citalopram with relative risk of -16.805 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: citalopram with relative risk of -16.805 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: darifenacin with relative risk of -17.480 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: darifenacin with relative risk of -17.480 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: darifenacin with relative risk of -17.480 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: naproxen with relative risk of -19.011 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: naproxen with relative risk of -19.011 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 53: naproxen with relative risk of -19.011 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 54: estramustine with relative risk of -20.598 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 55: estramustine with relative risk of -20.598 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 56: estramustine with relative risk of -20.598 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 57: ivacaftor with relative risk of -21.026 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 58: ivacaftor with relative risk of -21.026 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 59: ivacaftor with relative risk of -21.026 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 60: auranofin with relative risk of -22.022 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 61: auranofin with relative risk of -22.022 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 62: auranofin with relative risk of -22.022 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 63: brimonidine with relative risk of -22.425 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 64: brimonidine with relative risk of -22.425 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 65: brimonidine with relative risk of -22.425 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 66: dantrolene with relative risk of -22.814 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 67: dantrolene with relative risk of -22.814 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 68: dantrolene with relative risk of -22.814 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 69: tazarotene with relative risk of -22.999 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 70: tazarotene with relative risk of -22.999 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 71: tazarotene with relative risk of -22.999 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 72: risedronate with relative risk of -23.103 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 73: risedronate with relative risk of -23.103 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 74: risedronate with relative risk of -23.103 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 75: dapsone with relative risk of -23.259 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 76: dapsone with relative risk of -23.259 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 77: dapsone with relative risk of -23.259 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 78: donepezil with relative risk of -23.495 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 79: donepezil with relative risk of -23.495 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 80: donepezil with relative risk of -23.495 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 81: brinzolamide with relative risk of -23.534 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 82: brinzolamide with relative risk of -23.534 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 83: brinzolamide with relative risk of -23.534 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 84: fondaparinux with relative risk of -23.863 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 85: fondaparinux with relative risk of -23.863 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 86: fondaparinux with relative risk of -23.863 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 87: acebutolol with relative risk of -23.879 of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 88: acebutolol with relative risk of -23.879 of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 89: acebutolol with relative risk of -23.879 of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 90: isradipine with relative risk of -24.004 of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 91: isradipine with relative risk of -24.004 of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 92: isradipine with relative risk of -24.004 of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 93: valsartan with relative risk of -24.022 of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 94: valsartan with relative risk of -24.022 of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 95: valsartan with relative risk of -24.022 of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 96: ruxolitinib with relative risk of -26.657 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 97: ruxolitinib with relative risk of -26.657 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 98: ruxolitinib with relative risk of -26.657 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 99: ruxolitinib with relative risk of -26.657 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 100: gabapentin with relative risk of -27.691 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 101: gabapentin with relative risk of -27.691 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 102: gabapentin with relative risk of -27.691 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 103: gabapentin with relative risk of -27.691 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 104: clarithromycin with relative risk of -28.040 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 105: clarithromycin with relative risk of -28.040 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 106: clarithromycin with relative risk of -28.040 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 107: clarithromycin with relative risk of -28.040 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 108: everolimus with relative risk of -29.368 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 109: everolimus with relative risk of -29.368 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 110: everolimus with relative risk of -29.368 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 111: everolimus with relative risk of -29.368 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 112: pentoxifylline with relative risk of -34.155 of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 113: pentoxifylline with relative risk of -34.155 of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 114: pentoxifylline with relative risk of -34.155 of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 115: pentoxifylline with relative risk of -34.155 of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 116: pentoxifylline with relative risk of -34.155 of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 117: pentoxifylline with relative risk of -34.155 of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 118: milnacipran with relative risk of -35.333 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 119: milnacipran with relative risk of -35.333 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 120: milnacipran with relative risk of -35.333 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 121: milnacipran with relative risk of -35.333 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 122: milnacipran with relative risk of -35.333 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 123: metoprolol with relative risk of -35.747 of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 124: metoprolol with relative risk of -35.747 of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 125: metoprolol with relative risk of -35.747 of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 126: metoprolol with relative risk of -35.747 of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 127: metoprolol with relative risk of -35.747 of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 128: milrinone with relative risk of -36.170 of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 129: milrinone with relative risk of -36.170 of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 130: milrinone with relative risk of -36.170 of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 131: milrinone with relative risk of -36.170 of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 132: milrinone with relative risk of -36.170 of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 133: tolmetin with relative risk of -36.199 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 134: tolmetin with relative risk of -36.199 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 135: tolmetin with relative risk of -36.199 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 136: tolmetin with relative risk of -36.199 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 137: tolmetin with relative risk of -36.199 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 138: progesterone with relative risk of -36.536 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 139: progesterone with relative risk of -36.536 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 140: progesterone with relative risk of -36.536 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 141: progesterone with relative risk of -36.536 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 142: progesterone with relative risk of -36.536 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 143: abiraterone with relative risk of -37.046 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 144: abiraterone with relative risk of -37.046 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 145: abiraterone with relative risk of -37.046 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 146: abiraterone with relative risk of -37.046 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 147: abiraterone with relative risk of -37.046 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 148: lubiprostone with relative risk of -37.432 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 149: lubiprostone with relative risk of -37.432 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 150: lubiprostone with relative risk of -37.432 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 151: lubiprostone with relative risk of -37.432 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 152: lubiprostone with relative risk of -37.432 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 153: tamsulosin with relative risk of -37.495 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 154: tamsulosin with relative risk of -37.495 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 155: tamsulosin with relative risk of -37.495 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 156: tamsulosin with relative risk of -37.495 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 157: tamsulosin with relative risk of -37.495 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 158: zolmitriptan with relative risk of -37.850 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 159: zolmitriptan with relative risk of -37.850 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 160: zolmitriptan with relative risk of -37.850 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 161: zolmitriptan with relative risk of -37.850 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 162: zolmitriptan with relative risk of -37.850 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 163: dapagliflozin with relative risk of -38.083 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 164: dapagliflozin with relative risk of -38.083 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 165: dapagliflozin with relative risk of -38.083 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 166: dapagliflozin with relative risk of -38.083 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 167: dapagliflozin with relative risk of -38.083 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 168: misoprostol with relative risk of -38.430 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 169: misoprostol with relative risk of -38.430 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 170: misoprostol with relative risk of -38.430 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 171: misoprostol with relative risk of -38.430 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 172: misoprostol with relative risk of -38.430 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 173: terbutaline with relative risk of -39.407 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 174: terbutaline with relative risk of -39.407 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 175: terbutaline with relative risk of -39.407 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 176: terbutaline with relative risk of -39.407 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 177: terbutaline with relative risk of -39.407 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 178: terbutaline with relative risk of -39.407 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 179: lurasidone with relative risk of -40.163 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 180: lurasidone with relative risk of -40.163 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 181: lurasidone with relative risk of -40.163 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 182: lurasidone with relative risk of -40.163 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 183: lurasidone with relative risk of -40.163 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 184: lurasidone with relative risk of -40.163 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 185: cisatracurium with relative risk of -40.182 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 186: cisatracurium with relative risk of -40.182 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 187: cisatracurium with relative risk of -40.182 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 188: cisatracurium with relative risk of -40.182 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 189: cisatracurium with relative risk of -40.182 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 190: pemetrexed with relative risk of -41.328 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 191: pemetrexed with relative risk of -41.328 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 192: pemetrexed with relative risk of -41.328 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 193: pemetrexed with relative risk of -41.328 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 194: pemetrexed with relative risk of -41.328 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 195: pemetrexed with relative risk of -41.328 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 196: didanosine with relative risk of -43.319 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 197: didanosine with relative risk of -43.319 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 198: didanosine with relative risk of -43.319 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 199: didanosine with relative risk of -43.319 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 200: didanosine with relative risk of -43.319 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 201: didanosine with relative risk of -43.319 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 202: esmolol with relative risk of -43.363 of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 203: esmolol with relative risk of -43.363 of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 204: esmolol with relative risk of -43.363 of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 205: esmolol with relative risk of -43.363 of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 206: esmolol with relative risk of -43.363 of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 207: esmolol with relative risk of -43.363 of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 208: azilsartan with relative risk of -44.823 of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 209: azilsartan with relative risk of -44.823 of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 210: azilsartan with relative risk of -44.823 of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 211: azilsartan with relative risk of -44.823 of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 212: azilsartan with relative risk of -44.823 of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 213: azilsartan with relative risk of -44.823 of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 214: ropivacaine with relative risk of -45.504 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 215: ropivacaine with relative risk of -45.504 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 216: ropivacaine with relative risk of -45.504 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 217: ropivacaine with relative risk of -45.504 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 218: ropivacaine with relative risk of -45.504 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 219: ropivacaine with relative risk of -45.504 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 220: ropivacaine with relative risk of -45.504 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 221: indomethacin with relative risk of -49.074 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 222: indomethacin with relative risk of -49.074 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 223: indomethacin with relative risk of -49.074 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 224: indomethacin with relative risk of -49.074 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 225: indomethacin with relative risk of -49.074 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 226: indomethacin with relative risk of -49.074 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 227: indomethacin with relative risk of -49.074 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 228: telmisartan with relative risk of -49.494 of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 229: telmisartan with relative risk of -49.494 of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 230: telmisartan with relative risk of -49.494 of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 231: telmisartan with relative risk of -49.494 of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 232: telmisartan with relative risk of -49.494 of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 233: telmisartan with relative risk of -49.494 of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 234: telmisartan with relative risk of -49.494 of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 235: trovafloxacin with relative risk of -49.504 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 236: trovafloxacin with relative risk of -49.504 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 237: trovafloxacin with relative risk of -49.504 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 238: trovafloxacin with relative risk of -49.504 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 239: trovafloxacin with relative risk of -49.504 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 240: trovafloxacin with relative risk of -49.504 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 241: trovafloxacin with relative risk of -49.504 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 242: levonorgestrel with relative risk of -50.041 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 243: levonorgestrel with relative risk of -50.041 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 244: levonorgestrel with relative risk of -50.041 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 245: levonorgestrel with relative risk of -50.041 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 246: levonorgestrel with relative risk of -50.041 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 247: levonorgestrel with relative risk of -50.041 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 248: levonorgestrel with relative risk of -50.041 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 249: dutasteride with relative risk of -51.851 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 250: dutasteride with relative risk of -51.851 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 251: dutasteride with relative risk of -51.851 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 252: dutasteride with relative risk of -51.851 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 253: dutasteride with relative risk of -51.851 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 254: dutasteride with relative risk of -51.851 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 255: dutasteride with relative risk of -51.851 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 256: ketorolac with relative risk of -52.371 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 257: ketorolac with relative risk of -52.371 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 258: ketorolac with relative risk of -52.371 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 259: ketorolac with relative risk of -52.371 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 260: ketorolac with relative risk of -52.371 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 261: ketorolac with relative risk of -52.371 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 262: ketorolac with relative risk of -52.371 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 263: ketorolac with relative risk of -52.371 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 264: lansoprazole with relative risk of -79.667 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 265: lansoprazole with relative risk of -79.667 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 266: lansoprazole with relative risk of -79.667 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 267: lansoprazole with relative risk of -79.667 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 268: lansoprazole with relative risk of -79.667 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 269: lansoprazole with relative risk of -79.667 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 270: lansoprazole with relative risk of -79.667 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 271: lansoprazole with relative risk of -79.667 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 272: lansoprazole with relative risk of -79.667 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 273: lansoprazole with relative risk of -79.667 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 274: lansoprazole with relative risk of -79.667 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 275: etoposide with relative risk of -89.302 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 276: etoposide with relative risk of -89.302 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 277: etoposide with relative risk of -89.302 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 278: etoposide with relative risk of -89.302 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 279: etoposide with relative risk of -89.302 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 280: etoposide with relative risk of -89.302 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 281: etoposide with relative risk of -89.302 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 282: etoposide with relative risk of -89.302 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 283: etoposide with relative risk of -89.302 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 284: etoposide with relative risk of -89.302 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 285: etoposide with relative risk of -89.302 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 286: etoposide with relative risk of -89.302 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 287: etoposide with relative risk of -89.302 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 288: fenofibrate with relative risk of -91.846 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 289: fenofibrate with relative risk of -91.846 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 290: fenofibrate with relative risk of -91.846 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 291: fenofibrate with relative risk of -91.846 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 292: fenofibrate with relative risk of -91.846 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 293: fenofibrate with relative risk of -91.846 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 294: fenofibrate with relative risk of -91.846 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 295: fenofibrate with relative risk of -91.846 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 296: fenofibrate with relative risk of -91.846 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 297: fenofibrate with relative risk of -91.846 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 298: fenofibrate with relative risk of -91.846 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 299: fenofibrate with relative risk of -91.846 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 300: fenofibrate with relative risk of -91.846 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 301: glimepiride with relative risk of -113.177 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 302: glimepiride with relative risk of -113.177 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 303: glimepiride with relative risk of -113.177 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 304: glimepiride with relative risk of -113.177 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 305: glimepiride with relative risk of -113.177 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 306: glimepiride with relative risk of -113.177 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 307: glimepiride with relative risk of -113.177 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 308: glimepiride with relative risk of -113.177 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 309: glimepiride with relative risk of -113.177 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 310: glimepiride with relative risk of -113.177 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 311: glimepiride with relative risk of -113.177 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 312: glimepiride with relative risk of -113.177 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 313: glimepiride with relative risk of -113.177 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 314: glimepiride with relative risk of -113.177 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 315: glimepiride with relative risk of -113.177 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 316: glimepiride with relative risk of -113.177 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 317: paliperidone with relative risk of -128.597 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 318: paliperidone with relative risk of -128.597 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 319: paliperidone with relative risk of -128.597 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 320: paliperidone with relative risk of -128.597 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 321: paliperidone with relative risk of -128.597 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 322: paliperidone with relative risk of -128.597 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 323: paliperidone with relative risk of -128.597 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 324: paliperidone with relative risk of -128.597 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 325: paliperidone with relative risk of -128.597 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 326: paliperidone with relative risk of -128.597 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 327: paliperidone with relative risk of -128.597 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 328: paliperidone with relative risk of -128.597 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 329: paliperidone with relative risk of -128.597 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 330: paliperidone with relative risk of -128.597 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 331: paliperidone with relative risk of -128.597 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 332: paliperidone with relative risk of -128.597 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 333: paliperidone with relative risk of -128.597 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 334: paliperidone with relative risk of -128.597 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 335: tropisetron with relative risk of -147.226 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 336: tropisetron with relative risk of -147.226 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 337: tropisetron with relative risk of -147.226 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 338: tropisetron with relative risk of -147.226 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 339: tropisetron with relative risk of -147.226 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 340: tropisetron with relative risk of -147.226 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 341: tropisetron with relative risk of -147.226 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 342: tropisetron with relative risk of -147.226 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 343: tropisetron with relative risk of -147.226 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 344: tropisetron with relative risk of -147.226 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 345: tropisetron with relative risk of -147.226 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 346: tropisetron with relative risk of -147.226 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 347: tropisetron with relative risk of -147.226 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 348: tropisetron with relative risk of -147.226 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 349: tropisetron with relative risk of -147.226 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 350: tropisetron with relative risk of -147.226 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 351: tropisetron with relative risk of -147.226 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 352: tropisetron with relative risk of -147.226 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 353: tropisetron with relative risk of -147.226 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 354: tropisetron with relative risk of -147.226 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 355: sertraline with relative risk of -159.232 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 356: sertraline with relative risk of -159.232 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 357: sertraline with relative risk of -159.232 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 358: sertraline with relative risk of -159.232 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 359: sertraline with relative risk of -159.232 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 360: sertraline with relative risk of -159.232 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 361: sertraline with relative risk of -159.232 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 362: sertraline with relative risk of -159.232 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 363: sertraline with relative risk of -159.232 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 364: sertraline with relative risk of -159.232 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 365: sertraline with relative risk of -159.232 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 366: sertraline with relative risk of -159.232 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 367: sertraline with relative risk of -159.232 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 368: sertraline with relative risk of -159.232 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 369: sertraline with relative risk of -159.232 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 370: sertraline with relative risk of -159.232 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 371: sertraline with relative risk of -159.232 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 372: sertraline with relative risk of -159.232 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 373: sertraline with relative risk of -159.232 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 374: sertraline with relative risk of -159.232 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 375: sertraline with relative risk of -159.232 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 376: sertraline with relative risk of -159.232 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 377: sertraline with relative risk of -159.232 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 378: sertraline with relative risk of -159.232 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 379: sertraline with relative risk of -159.232 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 380: irbesartan with relative risk of -166.087 of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 381: irbesartan with relative risk of -166.087 of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 382: irbesartan with relative risk of -166.087 of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 383: irbesartan with relative risk of -166.087 of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 384: irbesartan with relative risk of -166.087 of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 385: irbesartan with relative risk of -166.087 of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 386: irbesartan with relative risk of -166.087 of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 387: irbesartan with relative risk of -166.087 of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 388: irbesartan with relative risk of -166.087 of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 389: irbesartan with relative risk of -166.087 of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 390: irbesartan with relative risk of -166.087 of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 391: irbesartan with relative risk of -166.087 of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 392: irbesartan with relative risk of -166.087 of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 393: irbesartan with relative risk of -166.087 of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 394: irbesartan with relative risk of -166.087 of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 395: irbesartan with relative risk of -166.087 of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 396: irbesartan with relative risk of -166.087 of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 397: irbesartan with relative risk of -166.087 of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 398: irbesartan with relative risk of -166.087 of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 399: irbesartan with relative risk of -166.087 of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 400: irbesartan with relative risk of -166.087 of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 401: irbesartan with relative risk of -166.087 of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 402: irbesartan with relative risk of -166.087 of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 403: irbesartan with relative risk of -166.087 of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 404: irbesartan with relative risk of -166.087 of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 405: irbesartan with relative risk of -166.087 of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 406: regadenoson with relative risk of -183.855 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 407: regadenoson with relative risk of -183.855 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 408: regadenoson with relative risk of -183.855 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 409: regadenoson with relative risk of -183.855 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 410: regadenoson with relative risk of -183.855 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 411: regadenoson with relative risk of -183.855 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 412: regadenoson with relative risk of -183.855 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 413: regadenoson with relative risk of -183.855 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 414: regadenoson with relative risk of -183.855 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 415: regadenoson with relative risk of -183.855 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 416: regadenoson with relative risk of -183.855 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 417: regadenoson with relative risk of -183.855 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 418: regadenoson with relative risk of -183.855 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 419: regadenoson with relative risk of -183.855 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 420: regadenoson with relative risk of -183.855 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 421: regadenoson with relative risk of -183.855 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 422: regadenoson with relative risk of -183.855 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 423: regadenoson with relative risk of -183.855 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 424: regadenoson with relative risk of -183.855 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 425: regadenoson with relative risk of -183.855 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 426: regadenoson with relative risk of -183.855 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 427: regadenoson with relative risk of -183.855 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 428: regadenoson with relative risk of -183.855 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 429: regadenoson with relative risk of -183.855 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 430: regadenoson with relative risk of -183.855 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 431: azelastine with relative risk of -183.989 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 432: azelastine with relative risk of -183.989 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 433: azelastine with relative risk of -183.989 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 434: azelastine with relative risk of -183.989 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 435: azelastine with relative risk of -183.989 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 436: azelastine with relative risk of -183.989 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 437: azelastine with relative risk of -183.989 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 438: azelastine with relative risk of -183.989 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 439: azelastine with relative risk of -183.989 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 440: azelastine with relative risk of -183.989 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 441: azelastine with relative risk of -183.989 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 442: azelastine with relative risk of -183.989 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 443: azelastine with relative risk of -183.989 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 444: azelastine with relative risk of -183.989 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 445: azelastine with relative risk of -183.989 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 446: azelastine with relative risk of -183.989 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 447: azelastine with relative risk of -183.989 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 448: azelastine with relative risk of -183.989 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 449: azelastine with relative risk of -183.989 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 450: azelastine with relative risk of -183.989 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 451: azelastine with relative risk of -183.989 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 452: azelastine with relative risk of -183.989 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 453: azelastine with relative risk of -183.989 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 454: azelastine with relative risk of -183.989 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 455: azelastine with relative risk of -183.989 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 456: azelastine with relative risk of -183.989 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 457: posaconazole with relative risk of -188.106 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 458: posaconazole with relative risk of -188.106 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 459: posaconazole with relative risk of -188.106 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 460: posaconazole with relative risk of -188.106 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 461: posaconazole with relative risk of -188.106 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 462: posaconazole with relative risk of -188.106 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 463: posaconazole with relative risk of -188.106 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 464: posaconazole with relative risk of -188.106 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 465: posaconazole with relative risk of -188.106 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 466: posaconazole with relative risk of -188.106 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 467: posaconazole with relative risk of -188.106 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 468: posaconazole with relative risk of -188.106 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 469: posaconazole with relative risk of -188.106 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 470: posaconazole with relative risk of -188.106 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 471: posaconazole with relative risk of -188.106 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 472: posaconazole with relative risk of -188.106 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 473: posaconazole with relative risk of -188.106 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 474: posaconazole with relative risk of -188.106 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 475: posaconazole with relative risk of -188.106 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 476: posaconazole with relative risk of -188.106 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 477: posaconazole with relative risk of -188.106 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 478: posaconazole with relative risk of -188.106 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 479: posaconazole with relative risk of -188.106 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 480: posaconazole with relative risk of -188.106 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 481: posaconazole with relative risk of -188.106 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 482: mometasone with relative risk of -195.843 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 483: mometasone with relative risk of -195.843 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 484: mometasone with relative risk of -195.843 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 485: mometasone with relative risk of -195.843 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 486: mometasone with relative risk of -195.843 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 487: mometasone with relative risk of -195.843 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 488: mometasone with relative risk of -195.843 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 489: mometasone with relative risk of -195.843 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 490: mometasone with relative risk of -195.843 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 491: mometasone with relative risk of -195.843 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 492: mometasone with relative risk of -195.843 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 493: mometasone with relative risk of -195.843 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 494: mometasone with relative risk of -195.843 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 495: mometasone with relative risk of -195.843 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 496: mometasone with relative risk of -195.843 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 497: mometasone with relative risk of -195.843 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 498: mometasone with relative risk of -195.843 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 499: mometasone with relative risk of -195.843 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 500: mometasone with relative risk of -195.843 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 501: mometasone with relative risk of -195.843 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 502: mometasone with relative risk of -195.843 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 503: mometasone with relative risk of -195.843 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 504: mometasone with relative risk of -195.843 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 505: mometasone with relative risk of -195.843 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 506: mometasone with relative risk of -195.843 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 507: mometasone with relative risk of -195.843 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 508: mometasone with relative risk of -195.843 of ibutilide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 509: felodipine with relative risk of -inf of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 510: felodipine with relative risk of -inf of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 511: felodipine with relative risk of -inf of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 512: felodipine with relative risk of -inf of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 513: felodipine with relative risk of -inf of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 514: felodipine with relative risk of -inf of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 515: felodipine with relative risk of -inf of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 516: felodipine with relative risk of -inf of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 517: felodipine with relative risk of -inf of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 518: felodipine with relative risk of -inf of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 519: felodipine with relative risk of -inf of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 520: felodipine with relative risk of -inf of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 521: felodipine with relative risk of -inf of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 522: felodipine with relative risk of -inf of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 523: felodipine with relative risk of -inf of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 524: felodipine with relative risk of -inf of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 525: felodipine with relative risk of -inf of ibutilide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.247\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target icodextrin not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó idarubicin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: bexarotene with relative risk of -9.612 of idarubicin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: hematologic malignancy\n",
      "Rank 2: bicalutamide with relative risk of -10.622 of idarubicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: buspirone with relative risk of -11.548 of idarubicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: letrozole with relative risk of -12.110 of idarubicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: gemfibrozil with relative risk of -12.165 of idarubicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: maprotiline with relative risk of -12.261 of idarubicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: fosinopril with relative risk of -12.426 of idarubicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: apremilast with relative risk of -13.064 of idarubicin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.368\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó ifosfamide *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: famotidine with relative risk of -23.219 of ifosfamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: famotidine with relative risk of -23.219 of ifosfamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó iloperidone *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: doxercalciferol with relative risk of -10.356 of iloperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: rabeprazole with relative risk of -10.811 of iloperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: albendazole with relative risk of -10.943 of iloperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: levocabastine with relative risk of -10.971 of iloperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: cyclobenzaprine with relative risk of -11.086 of iloperidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: levetiracetam with relative risk of -11.262 of iloperidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: fluconazole with relative risk of -11.342 of iloperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: guanfacine with relative risk of -11.373 of iloperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: mirtazapine with relative risk of -11.464 of iloperidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: fosphenytoin with relative risk of -11.520 of iloperidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: reboxetine with relative risk of -11.745 of iloperidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: ropinirole with relative risk of -11.861 of iloperidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: vardenafil with relative risk of -11.906 of iloperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: rilpivirine with relative risk of -12.064 of iloperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: captopril with relative risk of -14.116 of iloperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: captopril with relative risk of -14.116 of iloperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: treprostinil with relative risk of -14.876 of iloperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: treprostinil with relative risk of -14.876 of iloperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: atorvastatin with relative risk of -15.553 of iloperidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 20: atorvastatin with relative risk of -15.553 of iloperidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 21: cetrorelix with relative risk of -16.019 of iloperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: cetrorelix with relative risk of -16.019 of iloperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: telithromycin with relative risk of -16.208 of iloperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: telithromycin with relative risk of -16.208 of iloperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: anagrelide with relative risk of -20.119 of iloperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: anagrelide with relative risk of -20.119 of iloperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.222\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó iloprost *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: nilotinib with relative risk of -12.350 of iloprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: tolterodine with relative risk of -13.771 of iloprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó imatinib *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: ropivacaine with relative risk of -8.559 of imatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: ibandronate with relative risk of -8.586 of imatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: acyclovir with relative risk of -10.096 of imatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: dihydroergotamine with relative risk of -10.313 of imatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: atosiban with relative risk of -10.412 of imatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: vincristine with relative risk of -10.623 of imatinib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: hematologic malignancy\n",
      "Rank 7: ramipril with relative risk of -11.124 of imatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: desvenlafaxine with relative risk of -11.505 of imatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: amoxicillin with relative risk of -12.007 of imatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: diltiazem with relative risk of -12.250 of imatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: nebivolol with relative risk of -12.735 of imatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: trimetrexate with relative risk of -16.900 of imatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: trimetrexate with relative risk of -16.900 of imatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: valdecoxib with relative risk of -17.457 of imatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: valdecoxib with relative risk of -17.457 of imatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: clopidogrel with relative risk of -19.757 of imatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: clopidogrel with relative risk of -19.757 of imatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: aminophylline with relative risk of -23.054 of imatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: aminophylline with relative risk of -23.054 of imatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: aminophylline with relative risk of -23.054 of imatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: finasteride with relative risk of -24.629 of imatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: finasteride with relative risk of -24.629 of imatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: finasteride with relative risk of -24.629 of imatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: alendronate with relative risk of -25.810 of imatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: alendronate with relative risk of -25.810 of imatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: alendronate with relative risk of -25.810 of imatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: gefitinib with relative risk of -26.155 of imatinib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 28: gefitinib with relative risk of -26.155 of imatinib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 29: gefitinib with relative risk of -26.155 of imatinib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 30: gemcitabine with relative risk of -27.938 of imatinib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 31: gemcitabine with relative risk of -27.938 of imatinib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 32: gemcitabine with relative risk of -27.938 of imatinib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.091\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target imiquimod not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó indacaterol *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: trazodone with relative risk of -8.759 of indacaterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: ibandronate with relative risk of -8.808 of indacaterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: miglustat with relative risk of -8.936 of indacaterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: eplerenone with relative risk of -9.860 of indacaterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: dabigatran with relative risk of -10.543 of indacaterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: estramustine with relative risk of -10.594 of indacaterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: etravirine with relative risk of -11.080 of indacaterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: linezolid with relative risk of -11.246 of indacaterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: tafluprost with relative risk of -11.436 of indacaterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: tiotropium with relative risk of -11.468 of indacaterol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: pulmonary\n",
      "Rank 11: exenatide with relative risk of -11.625 of indacaterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: lovastatin with relative risk of -11.633 of indacaterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: cabergoline with relative risk of -11.850 of indacaterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: febuxostat with relative risk of -13.513 of indacaterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: exemestane with relative risk of -20.128 of indacaterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: exemestane with relative risk of -20.128 of indacaterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: ciclesonide with relative risk of -21.426 of indacaterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: ciclesonide with relative risk of -21.426 of indacaterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: ciclesonide with relative risk of -21.426 of indacaterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: vinorelbine with relative risk of -23.957 of indacaterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: vinorelbine with relative risk of -23.957 of indacaterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: vinorelbine with relative risk of -23.957 of indacaterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: darifenacin with relative risk of -24.177 of indacaterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: darifenacin with relative risk of -24.177 of indacaterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: darifenacin with relative risk of -24.177 of indacaterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: axitinib with relative risk of -24.282 of indacaterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: axitinib with relative risk of -24.282 of indacaterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: axitinib with relative risk of -24.282 of indacaterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: meloxicam with relative risk of -24.751 of indacaterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: meloxicam with relative risk of -24.751 of indacaterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: meloxicam with relative risk of -24.751 of indacaterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: granisetron with relative risk of -24.844 of indacaterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: granisetron with relative risk of -24.844 of indacaterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: granisetron with relative risk of -24.844 of indacaterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: apraclonidine with relative risk of -25.001 of indacaterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: apraclonidine with relative risk of -25.001 of indacaterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: apraclonidine with relative risk of -25.001 of indacaterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: pinaverium with relative risk of -27.980 of indacaterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: pinaverium with relative risk of -27.980 of indacaterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: pinaverium with relative risk of -27.980 of indacaterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: desoximetasone with relative risk of -inf of indacaterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: desoximetasone with relative risk of -inf of indacaterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: desoximetasone with relative risk of -inf of indacaterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.023\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó indapamide *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: aripiprazole with relative risk of -12.821 of indapamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó indinavir *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: metronidazole with relative risk of -11.062 of indinavir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: umeclidinium with relative risk of -12.334 of indinavir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: rivaroxaban with relative risk of -13.820 of indinavir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: eprosartan with relative risk of -13.931 of indinavir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó indomethacin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: ropivacaine with relative risk of -8.091 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: levonorgestrel with relative risk of -8.199 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: ruxolitinib with relative risk of -8.434 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: lurasidone with relative risk of -8.481 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: ketorolac with relative risk of -9.182 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: bumetanide with relative risk of -9.421 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: gabapentin with relative risk of -9.468 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: sumatriptan with relative risk of -10.582 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: didanosine with relative risk of -15.786 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: didanosine with relative risk of -15.786 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: nevirapine with relative risk of -17.475 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: nevirapine with relative risk of -17.475 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: capecitabine with relative risk of -18.175 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: capecitabine with relative risk of -18.175 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: etoposide with relative risk of -19.673 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: etoposide with relative risk of -19.673 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: etoposide with relative risk of -19.673 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: glimepiride with relative risk of -20.866 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: glimepiride with relative risk of -20.866 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: glimepiride with relative risk of -20.866 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: fenofibrate with relative risk of -22.216 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: fenofibrate with relative risk of -22.216 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: fenofibrate with relative risk of -22.216 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: lansoprazole with relative risk of -22.693 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: lansoprazole with relative risk of -22.693 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: lansoprazole with relative risk of -22.693 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: sertraline with relative risk of -23.640 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: sertraline with relative risk of -23.640 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: sertraline with relative risk of -23.640 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: sertraline with relative risk of -23.640 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: fondaparinux with relative risk of -27.932 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: fondaparinux with relative risk of -27.932 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: fondaparinux with relative risk of -27.932 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: dutasteride with relative risk of -33.215 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: dutasteride with relative risk of -33.215 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: dutasteride with relative risk of -33.215 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: dutasteride with relative risk of -33.215 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: paliperidone with relative risk of -35.446 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: paliperidone with relative risk of -35.446 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: paliperidone with relative risk of -35.446 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: paliperidone with relative risk of -35.446 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: paliperidone with relative risk of -35.446 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: regadenoson with relative risk of -39.922 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: regadenoson with relative risk of -39.922 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: regadenoson with relative risk of -39.922 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: regadenoson with relative risk of -39.922 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: regadenoson with relative risk of -39.922 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: regadenoson with relative risk of -39.922 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: trovafloxacin with relative risk of -41.145 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: trovafloxacin with relative risk of -41.145 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: trovafloxacin with relative risk of -41.145 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: trovafloxacin with relative risk of -41.145 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 53: trovafloxacin with relative risk of -41.145 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 54: posaconazole with relative risk of -41.178 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 55: posaconazole with relative risk of -41.178 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 56: posaconazole with relative risk of -41.178 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 57: posaconazole with relative risk of -41.178 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 58: posaconazole with relative risk of -41.178 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 59: posaconazole with relative risk of -41.178 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 60: metoprolol with relative risk of -43.217 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 61: metoprolol with relative risk of -43.217 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 62: metoprolol with relative risk of -43.217 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 63: metoprolol with relative risk of -43.217 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 64: metoprolol with relative risk of -43.217 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 65: milrinone with relative risk of -43.640 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 66: milrinone with relative risk of -43.640 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 67: milrinone with relative risk of -43.640 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 68: milrinone with relative risk of -43.640 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 69: milrinone with relative risk of -43.640 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 70: tamsulosin with relative risk of -44.965 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 71: tamsulosin with relative risk of -44.965 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 72: tamsulosin with relative risk of -44.965 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 73: tamsulosin with relative risk of -44.965 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 74: tamsulosin with relative risk of -44.965 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 75: azelastine with relative risk of -48.238 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 76: azelastine with relative risk of -48.238 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 77: azelastine with relative risk of -48.238 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 78: azelastine with relative risk of -48.238 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 79: azelastine with relative risk of -48.238 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 80: azelastine with relative risk of -48.238 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 81: azelastine with relative risk of -48.238 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 82: ibutilide with relative risk of -50.187 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 83: ibutilide with relative risk of -50.187 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 84: ibutilide with relative risk of -50.187 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 85: ibutilide with relative risk of -50.187 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 86: ibutilide with relative risk of -50.187 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 87: ibutilide with relative risk of -50.187 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 88: ibutilide with relative risk of -50.187 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 89: pemetrexed with relative risk of -50.834 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 90: pemetrexed with relative risk of -50.834 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 91: pemetrexed with relative risk of -50.834 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 92: pemetrexed with relative risk of -50.834 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 93: pemetrexed with relative risk of -50.834 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 94: pemetrexed with relative risk of -50.834 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 95: tropisetron with relative risk of -51.941 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 96: tropisetron with relative risk of -51.941 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 97: tropisetron with relative risk of -51.941 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 98: tropisetron with relative risk of -51.941 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 99: tropisetron with relative risk of -51.941 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 100: tropisetron with relative risk of -51.941 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 101: tropisetron with relative risk of -51.941 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 102: irbesartan with relative risk of -53.471 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 103: irbesartan with relative risk of -53.471 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 104: irbesartan with relative risk of -53.471 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 105: irbesartan with relative risk of -53.471 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 106: irbesartan with relative risk of -53.471 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 107: irbesartan with relative risk of -53.471 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 108: irbesartan with relative risk of -53.471 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 109: irbesartan with relative risk of -53.471 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 110: mometasone with relative risk of -56.574 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 111: mometasone with relative risk of -56.574 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 112: mometasone with relative risk of -56.574 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 113: mometasone with relative risk of -56.574 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 114: mometasone with relative risk of -56.574 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 115: mometasone with relative risk of -56.574 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 116: mometasone with relative risk of -56.574 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 117: mometasone with relative risk of -56.574 of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 118: felodipine with relative risk of -inf of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 119: felodipine with relative risk of -inf of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 120: felodipine with relative risk of -inf of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 121: felodipine with relative risk of -inf of indomethacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target insulin not found. Exiting ...\n",
      "\n",
      "Drug target iodixanol not found. Exiting ...\n",
      "\n",
      "Drug target iohexol not found. Exiting ...\n",
      "\n",
      "Drug target iopamidol not found. Exiting ...\n",
      "\n",
      "Drug target iopromide not found. Exiting ...\n",
      "\n",
      "Drug target iotrolan not found. Exiting ...\n",
      "\n",
      "Drug target ioversol not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó ipratropium *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: cytarabine with relative risk of -10.739 of ipratropium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: paclitaxel with relative risk of -10.930 of ipratropium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: formoterol with relative risk of -11.015 of ipratropium | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: pulmonary\n",
      "Rank 4: frovatriptan with relative risk of -11.178 of ipratropium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: nimodipine with relative risk of -11.504 of ipratropium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: entacapone with relative risk of -12.307 of ipratropium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: rasagiline with relative risk of -12.491 of ipratropium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: rivastigmine with relative risk of -12.611 of ipratropium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: sotalol with relative risk of -12.636 of ipratropium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: rofecoxib with relative risk of -12.686 of ipratropium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: pimozide with relative risk of -12.759 of ipratropium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: silodosin with relative risk of -12.819 of ipratropium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: nefazodone with relative risk of -13.092 of ipratropium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: capsaicin with relative risk of -13.210 of ipratropium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: fosinoprilat with relative risk of -15.493 of ipratropium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.1\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó irbesartan *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: crizotinib with relative risk of -6.494 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: penbutolol with relative risk of -6.690 of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 3: risperidone with relative risk of -7.294 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: atropine with relative risk of -7.639 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: loratadine with relative risk of -7.672 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: amsacrine with relative risk of -7.738 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: asenapine with relative risk of -7.740 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: carbamazepine with relative risk of -7.810 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: bosutinib with relative risk of -7.815 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: sulfasalazine with relative risk of -8.019 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: clonidine with relative risk of -8.043 of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 12: afatinib with relative risk of -8.082 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: varenicline with relative risk of -8.087 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: flutamide with relative risk of -8.093 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: naltrexone with relative risk of -8.146 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: leflunomide with relative risk of -8.344 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: doxorubicin with relative risk of -8.351 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: bezafibrate with relative risk of -8.366 of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 19: quinidine with relative risk of -8.372 of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 20: vernakalant with relative risk of -8.389 of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 21: cladribine with relative risk of -8.605 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: beclomethasone with relative risk of -8.746 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: flecainide with relative risk of -9.064 of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 24: tolvaptan with relative risk of -9.079 of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 25: ambrisentan with relative risk of -9.096 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: budesonide with relative risk of -9.113 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: nicotine with relative risk of -9.421 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: desonide with relative risk of -9.476 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: pergolide with relative risk of -9.626 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: aclidinium with relative risk of -9.671 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: vilazodone with relative risk of -9.752 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: pindolol with relative risk of -9.908 of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 33: caffeine with relative risk of -10.167 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: cimetidine with relative risk of -10.418 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: olmesartan with relative risk of -10.443 of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 36: darifenacin with relative risk of -10.859 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: darifenacin with relative risk of -10.859 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: bromfenac with relative risk of -11.798 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: brimonidine with relative risk of -13.397 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: brimonidine with relative risk of -13.397 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: cyclophosphamide with relative risk of -13.456 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: cyclophosphamide with relative risk of -13.456 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: argatroban with relative risk of -13.685 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: argatroban with relative risk of -13.685 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: ribavirin with relative risk of -13.959 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: ribavirin with relative risk of -13.959 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: tazarotene with relative risk of -13.970 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: tazarotene with relative risk of -13.970 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: dofetilide with relative risk of -14.133 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: dofetilide with relative risk of -14.133 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: dapsone with relative risk of -14.231 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: dapsone with relative risk of -14.231 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 53: capecitabine with relative risk of -14.437 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 54: capecitabine with relative risk of -14.437 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 55: perindopril with relative risk of -14.733 of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 56: perindopril with relative risk of -14.733 of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 57: lapatinib with relative risk of -14.903 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 58: lapatinib with relative risk of -14.903 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 59: isradipine with relative risk of -14.975 of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 60: isradipine with relative risk of -14.975 of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 61: losartan with relative risk of -15.302 of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Diabetic Nephropathy,Hypertensive disease,cardiology,nephrology\n",
      "Rank 62: losartan with relative risk of -15.302 of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Diabetic Nephropathy,Hypertensive disease,cardiology,nephrology\n",
      "Rank 63: sumatriptan with relative risk of -15.646 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 64: sumatriptan with relative risk of -15.646 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 65: citalopram with relative risk of -15.670 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 66: citalopram with relative risk of -15.670 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 67: domperidone with relative risk of -15.829 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 68: domperidone with relative risk of -15.829 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 69: temsirolimus with relative risk of -16.021 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 70: temsirolimus with relative risk of -16.021 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 71: lidocaine with relative risk of -16.705 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 72: lidocaine with relative risk of -16.705 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 73: naproxen with relative risk of -17.287 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 74: naproxen with relative risk of -17.287 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 75: naproxen with relative risk of -17.287 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 76: gabapentin with relative risk of -18.844 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 77: gabapentin with relative risk of -18.844 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 78: gabapentin with relative risk of -18.844 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 79: estramustine with relative risk of -18.875 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 80: estramustine with relative risk of -18.875 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 81: estramustine with relative risk of -18.875 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 82: clarithromycin with relative risk of -19.193 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 83: clarithromycin with relative risk of -19.193 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 84: clarithromycin with relative risk of -19.193 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 85: ivacaftor with relative risk of -19.300 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 86: ivacaftor with relative risk of -19.300 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 87: ivacaftor with relative risk of -19.300 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 88: auranofin with relative risk of -20.295 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 89: auranofin with relative risk of -20.295 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 90: auranofin with relative risk of -20.295 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 91: cetirizine with relative risk of -20.368 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 92: cetirizine with relative risk of -20.368 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 93: cetirizine with relative risk of -20.368 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 94: dantrolene with relative risk of -21.087 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 95: dantrolene with relative risk of -21.087 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 96: dantrolene with relative risk of -21.087 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 97: risedronate with relative risk of -21.376 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 98: risedronate with relative risk of -21.376 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 99: risedronate with relative risk of -21.376 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 100: donepezil with relative risk of -21.768 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 101: donepezil with relative risk of -21.768 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 102: donepezil with relative risk of -21.768 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 103: brinzolamide with relative risk of -21.807 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 104: brinzolamide with relative risk of -21.807 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 105: brinzolamide with relative risk of -21.807 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 106: celecoxib with relative risk of -21.956 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 107: celecoxib with relative risk of -21.956 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 108: celecoxib with relative risk of -21.956 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 109: fondaparinux with relative risk of -22.136 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 110: fondaparinux with relative risk of -22.136 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 111: fondaparinux with relative risk of -22.136 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 112: acebutolol with relative risk of -22.152 of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 113: acebutolol with relative risk of -22.152 of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 114: acebutolol with relative risk of -22.152 of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 115: valsartan with relative risk of -22.295 of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 116: valsartan with relative risk of -22.295 of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 117: valsartan with relative risk of -22.295 of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 118: amisulpride with relative risk of -22.670 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 119: amisulpride with relative risk of -22.670 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 120: amisulpride with relative risk of -22.670 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 121: latanoprost with relative risk of -22.767 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 122: latanoprost with relative risk of -22.767 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 123: latanoprost with relative risk of -22.767 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 124: ruxolitinib with relative risk of -24.322 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 125: ruxolitinib with relative risk of -24.322 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 126: ruxolitinib with relative risk of -24.322 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 127: ruxolitinib with relative risk of -24.322 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 128: everolimus with relative risk of -27.031 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 129: everolimus with relative risk of -27.031 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 130: everolimus with relative risk of -27.031 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 131: everolimus with relative risk of -27.031 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 132: nevirapine with relative risk of -27.959 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 133: nevirapine with relative risk of -27.959 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 134: nevirapine with relative risk of -27.959 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 135: nevirapine with relative risk of -27.959 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 136: terbutaline with relative risk of -29.122 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 137: terbutaline with relative risk of -29.122 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 138: terbutaline with relative risk of -29.122 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 139: terbutaline with relative risk of -29.122 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 140: terbutaline with relative risk of -29.122 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 141: pentoxifylline with relative risk of -30.553 of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 142: pentoxifylline with relative risk of -30.553 of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 143: pentoxifylline with relative risk of -30.553 of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 144: pentoxifylline with relative risk of -30.553 of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 145: pentoxifylline with relative risk of -30.553 of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 146: pentoxifylline with relative risk of -30.553 of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 147: esmolol with relative risk of -31.689 of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 148: esmolol with relative risk of -31.689 of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 149: esmolol with relative risk of -31.689 of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 150: esmolol with relative risk of -31.689 of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 151: esmolol with relative risk of -31.689 of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 152: milnacipran with relative risk of -32.368 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 153: milnacipran with relative risk of -32.368 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 154: milnacipran with relative risk of -32.368 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 155: milnacipran with relative risk of -32.368 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 156: milnacipran with relative risk of -32.368 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 157: metoprolol with relative risk of -32.782 of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 158: metoprolol with relative risk of -32.782 of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 159: metoprolol with relative risk of -32.782 of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 160: metoprolol with relative risk of -32.782 of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 161: metoprolol with relative risk of -32.782 of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 162: azilsartan with relative risk of -33.148 of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 163: azilsartan with relative risk of -33.148 of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 164: azilsartan with relative risk of -33.148 of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 165: azilsartan with relative risk of -33.148 of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 166: azilsartan with relative risk of -33.148 of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 167: milrinone with relative risk of -33.204 of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 168: milrinone with relative risk of -33.204 of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 169: milrinone with relative risk of -33.204 of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 170: milrinone with relative risk of -33.204 of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 171: milrinone with relative risk of -33.204 of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 172: tolmetin with relative risk of -33.233 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 173: tolmetin with relative risk of -33.233 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 174: tolmetin with relative risk of -33.233 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 175: tolmetin with relative risk of -33.233 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 176: tolmetin with relative risk of -33.233 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 177: progesterone with relative risk of -33.571 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 178: progesterone with relative risk of -33.571 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 179: progesterone with relative risk of -33.571 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 180: progesterone with relative risk of -33.571 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 181: progesterone with relative risk of -33.571 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 182: bumetanide with relative risk of -34.079 of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 183: bumetanide with relative risk of -34.079 of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 184: bumetanide with relative risk of -34.079 of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 185: bumetanide with relative risk of -34.079 of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 186: bumetanide with relative risk of -34.079 of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 187: abiraterone with relative risk of -34.080 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 188: abiraterone with relative risk of -34.080 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 189: abiraterone with relative risk of -34.080 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 190: abiraterone with relative risk of -34.080 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 191: abiraterone with relative risk of -34.080 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 192: ropivacaine with relative risk of -34.372 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 193: ropivacaine with relative risk of -34.372 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 194: ropivacaine with relative risk of -34.372 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 195: ropivacaine with relative risk of -34.372 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 196: ropivacaine with relative risk of -34.372 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 197: ropivacaine with relative risk of -34.372 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 198: lubiprostone with relative risk of -34.467 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 199: lubiprostone with relative risk of -34.467 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 200: lubiprostone with relative risk of -34.467 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 201: lubiprostone with relative risk of -34.467 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 202: lubiprostone with relative risk of -34.467 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 203: tamsulosin with relative risk of -34.530 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 204: tamsulosin with relative risk of -34.530 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 205: tamsulosin with relative risk of -34.530 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 206: tamsulosin with relative risk of -34.530 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 207: tamsulosin with relative risk of -34.530 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 208: zolmitriptan with relative risk of -34.884 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 209: zolmitriptan with relative risk of -34.884 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 210: zolmitriptan with relative risk of -34.884 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 211: zolmitriptan with relative risk of -34.884 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 212: zolmitriptan with relative risk of -34.884 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 213: dapagliflozin with relative risk of -35.117 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 214: dapagliflozin with relative risk of -35.117 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 215: dapagliflozin with relative risk of -35.117 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 216: dapagliflozin with relative risk of -35.117 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 217: dapagliflozin with relative risk of -35.117 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 218: misoprostol with relative risk of -35.464 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 219: misoprostol with relative risk of -35.464 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 220: misoprostol with relative risk of -35.464 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 221: misoprostol with relative risk of -35.464 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 222: misoprostol with relative risk of -35.464 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 223: cisatracurium with relative risk of -37.217 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 224: cisatracurium with relative risk of -37.217 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 225: cisatracurium with relative risk of -37.217 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 226: cisatracurium with relative risk of -37.217 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 227: cisatracurium with relative risk of -37.217 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 228: telmisartan with relative risk of -37.666 of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 229: telmisartan with relative risk of -37.666 of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 230: telmisartan with relative risk of -37.666 of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 231: telmisartan with relative risk of -37.666 of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 232: telmisartan with relative risk of -37.666 of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 233: telmisartan with relative risk of -37.666 of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 234: didanosine with relative risk of -39.705 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 235: didanosine with relative risk of -39.705 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 236: didanosine with relative risk of -39.705 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 237: didanosine with relative risk of -39.705 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 238: didanosine with relative risk of -39.705 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 239: didanosine with relative risk of -39.705 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 240: lurasidone with relative risk of -44.095 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 241: lurasidone with relative risk of -44.095 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 242: lurasidone with relative risk of -44.095 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 243: lurasidone with relative risk of -44.095 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 244: lurasidone with relative risk of -44.095 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 245: lurasidone with relative risk of -44.095 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 246: lurasidone with relative risk of -44.095 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 247: levonorgestrel with relative risk of -45.757 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 248: levonorgestrel with relative risk of -45.757 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 249: levonorgestrel with relative risk of -45.757 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 250: levonorgestrel with relative risk of -45.757 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 251: levonorgestrel with relative risk of -45.757 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 252: levonorgestrel with relative risk of -45.757 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 253: levonorgestrel with relative risk of -45.757 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 254: pemetrexed with relative risk of -45.952 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 255: pemetrexed with relative risk of -45.952 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 256: pemetrexed with relative risk of -45.952 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 257: pemetrexed with relative risk of -45.952 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 258: pemetrexed with relative risk of -45.952 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 259: pemetrexed with relative risk of -45.952 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 260: pemetrexed with relative risk of -45.952 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 261: ketorolac with relative risk of -47.397 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 262: ketorolac with relative risk of -47.397 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 263: ketorolac with relative risk of -47.397 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 264: ketorolac with relative risk of -47.397 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 265: ketorolac with relative risk of -47.397 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 266: ketorolac with relative risk of -47.397 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 267: ketorolac with relative risk of -47.397 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 268: ketorolac with relative risk of -47.397 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 269: dutasteride with relative risk of -47.567 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 270: dutasteride with relative risk of -47.567 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 271: dutasteride with relative risk of -47.567 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 272: dutasteride with relative risk of -47.567 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 273: dutasteride with relative risk of -47.567 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 274: dutasteride with relative risk of -47.567 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 275: dutasteride with relative risk of -47.567 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 276: indomethacin with relative risk of -53.186 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 277: indomethacin with relative risk of -53.186 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 278: indomethacin with relative risk of -53.186 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 279: indomethacin with relative risk of -53.186 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 280: indomethacin with relative risk of -53.186 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 281: indomethacin with relative risk of -53.186 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 282: indomethacin with relative risk of -53.186 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 283: indomethacin with relative risk of -53.186 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 284: trovafloxacin with relative risk of -53.616 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 285: trovafloxacin with relative risk of -53.616 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 286: trovafloxacin with relative risk of -53.616 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 287: trovafloxacin with relative risk of -53.616 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 288: trovafloxacin with relative risk of -53.616 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 289: trovafloxacin with relative risk of -53.616 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 290: trovafloxacin with relative risk of -53.616 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 291: trovafloxacin with relative risk of -53.616 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 292: lansoprazole with relative risk of -72.455 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 293: lansoprazole with relative risk of -72.455 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 294: lansoprazole with relative risk of -72.455 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 295: lansoprazole with relative risk of -72.455 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 296: lansoprazole with relative risk of -72.455 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 297: lansoprazole with relative risk of -72.455 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 298: lansoprazole with relative risk of -72.455 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 299: lansoprazole with relative risk of -72.455 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 300: lansoprazole with relative risk of -72.455 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 301: lansoprazole with relative risk of -72.455 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 302: lansoprazole with relative risk of -72.455 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 303: ciclesonide with relative risk of -80.169 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 304: ciclesonide with relative risk of -80.169 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 305: ciclesonide with relative risk of -80.169 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 306: ciclesonide with relative risk of -80.169 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 307: ciclesonide with relative risk of -80.169 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 308: ciclesonide with relative risk of -80.169 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 309: ciclesonide with relative risk of -80.169 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 310: ciclesonide with relative risk of -80.169 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 311: ciclesonide with relative risk of -80.169 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 312: ciclesonide with relative risk of -80.169 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 313: ciclesonide with relative risk of -80.169 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 314: ciclesonide with relative risk of -80.169 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 315: ciclesonide with relative risk of -80.169 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 316: ciclesonide with relative risk of -80.169 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 317: ciclesonide with relative risk of -80.169 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 318: ciclesonide with relative risk of -80.169 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 319: etoposide with relative risk of -89.556 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 320: etoposide with relative risk of -89.556 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 321: etoposide with relative risk of -89.556 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 322: etoposide with relative risk of -89.556 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 323: etoposide with relative risk of -89.556 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 324: etoposide with relative risk of -89.556 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 325: etoposide with relative risk of -89.556 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 326: etoposide with relative risk of -89.556 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 327: etoposide with relative risk of -89.556 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 328: etoposide with relative risk of -89.556 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 329: etoposide with relative risk of -89.556 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 330: etoposide with relative risk of -89.556 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 331: etoposide with relative risk of -89.556 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 332: etoposide with relative risk of -89.556 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 333: tadalafil with relative risk of -91.060 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 334: tadalafil with relative risk of -91.060 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 335: tadalafil with relative risk of -91.060 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 336: tadalafil with relative risk of -91.060 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 337: tadalafil with relative risk of -91.060 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 338: tadalafil with relative risk of -91.060 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 339: tadalafil with relative risk of -91.060 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 340: tadalafil with relative risk of -91.060 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 341: tadalafil with relative risk of -91.060 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 342: tadalafil with relative risk of -91.060 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 343: tadalafil with relative risk of -91.060 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 344: tadalafil with relative risk of -91.060 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 345: tadalafil with relative risk of -91.060 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 346: tadalafil with relative risk of -91.060 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 347: tadalafil with relative risk of -91.060 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 348: tadalafil with relative risk of -91.060 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 349: fenofibrate with relative risk of -92.099 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 350: fenofibrate with relative risk of -92.099 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 351: fenofibrate with relative risk of -92.099 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 352: fenofibrate with relative risk of -92.099 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 353: fenofibrate with relative risk of -92.099 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 354: fenofibrate with relative risk of -92.099 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 355: fenofibrate with relative risk of -92.099 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 356: fenofibrate with relative risk of -92.099 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 357: fenofibrate with relative risk of -92.099 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 358: fenofibrate with relative risk of -92.099 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 359: fenofibrate with relative risk of -92.099 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 360: fenofibrate with relative risk of -92.099 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 361: fenofibrate with relative risk of -92.099 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 362: fenofibrate with relative risk of -92.099 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 363: glimepiride with relative risk of -101.569 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 364: glimepiride with relative risk of -101.569 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 365: glimepiride with relative risk of -101.569 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 366: glimepiride with relative risk of -101.569 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 367: glimepiride with relative risk of -101.569 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 368: glimepiride with relative risk of -101.569 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 369: glimepiride with relative risk of -101.569 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 370: glimepiride with relative risk of -101.569 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 371: glimepiride with relative risk of -101.569 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 372: glimepiride with relative risk of -101.569 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 373: glimepiride with relative risk of -101.569 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 374: glimepiride with relative risk of -101.569 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 375: glimepiride with relative risk of -101.569 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 376: glimepiride with relative risk of -101.569 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 377: glimepiride with relative risk of -101.569 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 378: glimepiride with relative risk of -101.569 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 379: alfuzosin with relative risk of -105.528 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 380: alfuzosin with relative risk of -105.528 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 381: alfuzosin with relative risk of -105.528 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 382: alfuzosin with relative risk of -105.528 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 383: alfuzosin with relative risk of -105.528 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 384: alfuzosin with relative risk of -105.528 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 385: alfuzosin with relative risk of -105.528 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 386: alfuzosin with relative risk of -105.528 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 387: alfuzosin with relative risk of -105.528 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 388: alfuzosin with relative risk of -105.528 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 389: alfuzosin with relative risk of -105.528 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 390: alfuzosin with relative risk of -105.528 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 391: alfuzosin with relative risk of -105.528 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 392: alfuzosin with relative risk of -105.528 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 393: alfuzosin with relative risk of -105.528 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 394: alfuzosin with relative risk of -105.528 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 395: paliperidone with relative risk of -114.909 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 396: paliperidone with relative risk of -114.909 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 397: paliperidone with relative risk of -114.909 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 398: paliperidone with relative risk of -114.909 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 399: paliperidone with relative risk of -114.909 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 400: paliperidone with relative risk of -114.909 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 401: paliperidone with relative risk of -114.909 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 402: paliperidone with relative risk of -114.909 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 403: paliperidone with relative risk of -114.909 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 404: paliperidone with relative risk of -114.909 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 405: paliperidone with relative risk of -114.909 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 406: paliperidone with relative risk of -114.909 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 407: paliperidone with relative risk of -114.909 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 408: paliperidone with relative risk of -114.909 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 409: paliperidone with relative risk of -114.909 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 410: paliperidone with relative risk of -114.909 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 411: paliperidone with relative risk of -114.909 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 412: paliperidone with relative risk of -114.909 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 413: tropisetron with relative risk of -121.555 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 414: tropisetron with relative risk of -121.555 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 415: tropisetron with relative risk of -121.555 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 416: tropisetron with relative risk of -121.555 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 417: tropisetron with relative risk of -121.555 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 418: tropisetron with relative risk of -121.555 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 419: tropisetron with relative risk of -121.555 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 420: tropisetron with relative risk of -121.555 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 421: tropisetron with relative risk of -121.555 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 422: tropisetron with relative risk of -121.555 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 423: tropisetron with relative risk of -121.555 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 424: tropisetron with relative risk of -121.555 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 425: tropisetron with relative risk of -121.555 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 426: tropisetron with relative risk of -121.555 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 427: tropisetron with relative risk of -121.555 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 428: tropisetron with relative risk of -121.555 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 429: tropisetron with relative risk of -121.555 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 430: tropisetron with relative risk of -121.555 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 431: tropisetron with relative risk of -121.555 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 432: regadenoson with relative risk of -160.173 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 433: regadenoson with relative risk of -160.173 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 434: regadenoson with relative risk of -160.173 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 435: regadenoson with relative risk of -160.173 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 436: regadenoson with relative risk of -160.173 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 437: regadenoson with relative risk of -160.173 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 438: regadenoson with relative risk of -160.173 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 439: regadenoson with relative risk of -160.173 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 440: regadenoson with relative risk of -160.173 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 441: regadenoson with relative risk of -160.173 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 442: regadenoson with relative risk of -160.173 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 443: regadenoson with relative risk of -160.173 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 444: regadenoson with relative risk of -160.173 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 445: regadenoson with relative risk of -160.173 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 446: regadenoson with relative risk of -160.173 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 447: regadenoson with relative risk of -160.173 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 448: regadenoson with relative risk of -160.173 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 449: regadenoson with relative risk of -160.173 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 450: regadenoson with relative risk of -160.173 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 451: regadenoson with relative risk of -160.173 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 452: regadenoson with relative risk of -160.173 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 453: regadenoson with relative risk of -160.173 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 454: regadenoson with relative risk of -160.173 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 455: regadenoson with relative risk of -160.173 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 456: regadenoson with relative risk of -160.173 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 457: posaconazole with relative risk of -164.423 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 458: posaconazole with relative risk of -164.423 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 459: posaconazole with relative risk of -164.423 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 460: posaconazole with relative risk of -164.423 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 461: posaconazole with relative risk of -164.423 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 462: posaconazole with relative risk of -164.423 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 463: posaconazole with relative risk of -164.423 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 464: posaconazole with relative risk of -164.423 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 465: posaconazole with relative risk of -164.423 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 466: posaconazole with relative risk of -164.423 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 467: posaconazole with relative risk of -164.423 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 468: posaconazole with relative risk of -164.423 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 469: posaconazole with relative risk of -164.423 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 470: posaconazole with relative risk of -164.423 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 471: posaconazole with relative risk of -164.423 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 472: posaconazole with relative risk of -164.423 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 473: posaconazole with relative risk of -164.423 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 474: posaconazole with relative risk of -164.423 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 475: posaconazole with relative risk of -164.423 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 476: posaconazole with relative risk of -164.423 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 477: posaconazole with relative risk of -164.423 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 478: posaconazole with relative risk of -164.423 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 479: posaconazole with relative risk of -164.423 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 480: posaconazole with relative risk of -164.423 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 481: posaconazole with relative risk of -164.423 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 482: ibutilide with relative risk of -166.915 of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 483: ibutilide with relative risk of -166.915 of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 484: ibutilide with relative risk of -166.915 of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 485: ibutilide with relative risk of -166.915 of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 486: ibutilide with relative risk of -166.915 of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 487: ibutilide with relative risk of -166.915 of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 488: ibutilide with relative risk of -166.915 of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 489: ibutilide with relative risk of -166.915 of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 490: ibutilide with relative risk of -166.915 of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 491: ibutilide with relative risk of -166.915 of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 492: ibutilide with relative risk of -166.915 of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 493: ibutilide with relative risk of -166.915 of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 494: ibutilide with relative risk of -166.915 of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 495: ibutilide with relative risk of -166.915 of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 496: ibutilide with relative risk of -166.915 of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 497: ibutilide with relative risk of -166.915 of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 498: ibutilide with relative risk of -166.915 of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 499: ibutilide with relative risk of -166.915 of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 500: ibutilide with relative risk of -166.915 of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 501: ibutilide with relative risk of -166.915 of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 502: ibutilide with relative risk of -166.915 of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 503: ibutilide with relative risk of -166.915 of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 504: ibutilide with relative risk of -166.915 of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 505: ibutilide with relative risk of -166.915 of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 506: ibutilide with relative risk of -166.915 of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 507: ibutilide with relative risk of -166.915 of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 508: azelastine with relative risk of -184.327 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 509: azelastine with relative risk of -184.327 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 510: azelastine with relative risk of -184.327 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 511: azelastine with relative risk of -184.327 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 512: azelastine with relative risk of -184.327 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 513: azelastine with relative risk of -184.327 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 514: azelastine with relative risk of -184.327 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 515: azelastine with relative risk of -184.327 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 516: azelastine with relative risk of -184.327 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 517: azelastine with relative risk of -184.327 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 518: azelastine with relative risk of -184.327 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 519: azelastine with relative risk of -184.327 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 520: azelastine with relative risk of -184.327 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 521: azelastine with relative risk of -184.327 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 522: azelastine with relative risk of -184.327 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 523: azelastine with relative risk of -184.327 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 524: azelastine with relative risk of -184.327 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 525: azelastine with relative risk of -184.327 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 526: azelastine with relative risk of -184.327 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 527: azelastine with relative risk of -184.327 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 528: azelastine with relative risk of -184.327 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 529: azelastine with relative risk of -184.327 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 530: azelastine with relative risk of -184.327 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 531: azelastine with relative risk of -184.327 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 532: azelastine with relative risk of -184.327 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 533: azelastine with relative risk of -184.327 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 534: azelastine with relative risk of -184.327 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 535: azelastine with relative risk of -184.327 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 536: azelastine with relative risk of -184.327 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 537: mometasone with relative risk of -185.827 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 538: mometasone with relative risk of -185.827 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 539: mometasone with relative risk of -185.827 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 540: mometasone with relative risk of -185.827 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 541: mometasone with relative risk of -185.827 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 542: mometasone with relative risk of -185.827 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 543: mometasone with relative risk of -185.827 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 544: mometasone with relative risk of -185.827 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 545: mometasone with relative risk of -185.827 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 546: mometasone with relative risk of -185.827 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 547: mometasone with relative risk of -185.827 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 548: mometasone with relative risk of -185.827 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 549: mometasone with relative risk of -185.827 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 550: mometasone with relative risk of -185.827 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 551: mometasone with relative risk of -185.827 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 552: mometasone with relative risk of -185.827 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 553: mometasone with relative risk of -185.827 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 554: mometasone with relative risk of -185.827 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 555: mometasone with relative risk of -185.827 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 556: mometasone with relative risk of -185.827 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 557: mometasone with relative risk of -185.827 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 558: mometasone with relative risk of -185.827 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 559: mometasone with relative risk of -185.827 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 560: mometasone with relative risk of -185.827 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 561: mometasone with relative risk of -185.827 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 562: mometasone with relative risk of -185.827 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 563: mometasone with relative risk of -185.827 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 564: mometasone with relative risk of -185.827 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 565: mometasone with relative risk of -185.827 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 566: sertraline with relative risk of -269.098 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 567: sertraline with relative risk of -269.098 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 568: sertraline with relative risk of -269.098 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 569: sertraline with relative risk of -269.098 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 570: sertraline with relative risk of -269.098 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 571: sertraline with relative risk of -269.098 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 572: sertraline with relative risk of -269.098 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 573: sertraline with relative risk of -269.098 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 574: sertraline with relative risk of -269.098 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 575: sertraline with relative risk of -269.098 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 576: sertraline with relative risk of -269.098 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 577: sertraline with relative risk of -269.098 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 578: sertraline with relative risk of -269.098 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 579: sertraline with relative risk of -269.098 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 580: sertraline with relative risk of -269.098 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 581: sertraline with relative risk of -269.098 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 582: sertraline with relative risk of -269.098 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 583: sertraline with relative risk of -269.098 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 584: sertraline with relative risk of -269.098 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 585: sertraline with relative risk of -269.098 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 586: sertraline with relative risk of -269.098 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 587: sertraline with relative risk of -269.098 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 588: sertraline with relative risk of -269.098 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 589: sertraline with relative risk of -269.098 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 590: sertraline with relative risk of -269.098 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 591: sertraline with relative risk of -269.098 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 592: sertraline with relative risk of -269.098 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 593: sertraline with relative risk of -269.098 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 594: sertraline with relative risk of -269.098 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 595: sertraline with relative risk of -269.098 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 596: sertraline with relative risk of -269.098 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 597: sertraline with relative risk of -269.098 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 598: sertraline with relative risk of -269.098 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 599: sertraline with relative risk of -269.098 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 600: sertraline with relative risk of -269.098 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 601: sertraline with relative risk of -269.098 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 602: sertraline with relative risk of -269.098 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 603: sertraline with relative risk of -269.098 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 604: sertraline with relative risk of -269.098 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 605: sertraline with relative risk of -269.098 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 606: sertraline with relative risk of -269.098 of irbesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 607: felodipine with relative risk of -inf of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 608: felodipine with relative risk of -inf of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 609: felodipine with relative risk of -inf of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 610: felodipine with relative risk of -inf of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 611: felodipine with relative risk of -inf of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 612: felodipine with relative risk of -inf of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 613: felodipine with relative risk of -inf of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 614: felodipine with relative risk of -inf of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 615: felodipine with relative risk of -inf of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 616: felodipine with relative risk of -inf of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 617: felodipine with relative risk of -inf of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 618: felodipine with relative risk of -inf of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 619: felodipine with relative risk of -inf of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 620: felodipine with relative risk of -inf of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 621: felodipine with relative risk of -inf of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 622: felodipine with relative risk of -inf of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 623: felodipine with relative risk of -inf of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 624: felodipine with relative risk of -inf of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 625: felodipine with relative risk of -inf of irbesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.193\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target irbesartan-hydrochlorothiazide not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó irinotecan *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: paroxetine with relative risk of -8.320 of irinotecan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: zileuton with relative risk of -11.100 of irinotecan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: penbutolol with relative risk of -22.620 of irinotecan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: penbutolol with relative risk of -22.620 of irinotecan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: penbutolol with relative risk of -22.620 of irinotecan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: amiodarone with relative risk of -29.451 of irinotecan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: amiodarone with relative risk of -29.451 of irinotecan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: amiodarone with relative risk of -29.451 of irinotecan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: amiodarone with relative risk of -29.451 of irinotecan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: fluvastatin with relative risk of -34.551 of irinotecan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: fluvastatin with relative risk of -34.551 of irinotecan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: fluvastatin with relative risk of -34.551 of irinotecan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: fluvastatin with relative risk of -34.551 of irinotecan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: nisoldipine with relative risk of -35.803 of irinotecan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: nisoldipine with relative risk of -35.803 of irinotecan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: nisoldipine with relative risk of -35.803 of irinotecan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: nisoldipine with relative risk of -35.803 of irinotecan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target iron not found. Exiting ...\n",
      "\n",
      "Drug target isosorbide-5-mononitrate not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó isradipine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: lurasidone with relative risk of -9.460 of isradipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: everolimus with relative risk of -9.823 of isradipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: lansoprazole with relative risk of -10.009 of isradipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: clarithromycin with relative risk of -10.796 of isradipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: perindopril with relative risk of -11.340 of isradipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 6: regadenoson with relative risk of -14.385 of isradipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: regadenoson with relative risk of -14.385 of isradipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: irbesartan with relative risk of -14.814 of isradipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 9: irbesartan with relative risk of -14.814 of isradipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 10: posaconazole with relative risk of -15.459 of isradipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: posaconazole with relative risk of -15.459 of isradipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: azelastine with relative risk of -15.600 of isradipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: azelastine with relative risk of -15.600 of isradipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: ropivacaine with relative risk of -16.927 of isradipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: ropivacaine with relative risk of -16.927 of isradipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: sertraline with relative risk of -21.564 of isradipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: sertraline with relative risk of -21.564 of isradipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: sertraline with relative risk of -21.564 of isradipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: mometasone with relative risk of -22.583 of isradipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: mometasone with relative risk of -22.583 of isradipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: mometasone with relative risk of -22.583 of isradipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: ibutilide with relative risk of -24.670 of isradipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 23: ibutilide with relative risk of -24.670 of isradipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 24: ibutilide with relative risk of -24.670 of isradipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 25: tropisetron with relative risk of -24.754 of isradipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: tropisetron with relative risk of -24.754 of isradipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: tropisetron with relative risk of -24.754 of isradipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: paliperidone with relative risk of -24.840 of isradipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: paliperidone with relative risk of -24.840 of isradipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: paliperidone with relative risk of -24.840 of isradipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: glimepiride with relative risk of -24.888 of isradipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: glimepiride with relative risk of -24.888 of isradipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: glimepiride with relative risk of -24.888 of isradipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: pentoxifylline with relative risk of -24.938 of isradipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 35: pentoxifylline with relative risk of -24.938 of isradipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 36: pentoxifylline with relative risk of -24.938 of isradipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 37: darifenacin with relative risk of -25.563 of isradipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: darifenacin with relative risk of -25.563 of isradipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: darifenacin with relative risk of -25.563 of isradipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: terbutaline with relative risk of -26.867 of isradipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: terbutaline with relative risk of -26.867 of isradipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: terbutaline with relative risk of -26.867 of isradipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: esmolol with relative risk of -27.830 of isradipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 44: esmolol with relative risk of -27.830 of isradipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 45: esmolol with relative risk of -27.830 of isradipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 46: azilsartan with relative risk of -29.289 of isradipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 47: azilsartan with relative risk of -29.289 of isradipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 48: azilsartan with relative risk of -29.289 of isradipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 49: brimonidine with relative risk of -30.520 of isradipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: brimonidine with relative risk of -30.520 of isradipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: brimonidine with relative risk of -30.520 of isradipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: tazarotene with relative risk of -31.093 of isradipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 53: tazarotene with relative risk of -31.093 of isradipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 54: tazarotene with relative risk of -31.093 of isradipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 55: dapsone with relative risk of -31.353 of isradipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 56: dapsone with relative risk of -31.353 of isradipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 57: dapsone with relative risk of -31.353 of isradipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 58: felodipine with relative risk of -inf of isradipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 59: felodipine with relative risk of -inf of isradipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 60: felodipine with relative risk of -inf of isradipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.179\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target itraconazole not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó ivacaftor *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: ropivacaine with relative risk of -8.782 of ivacaftor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: levonorgestrel with relative risk of -8.891 of ivacaftor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: penbutolol with relative risk of -9.141 of ivacaftor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: lurasidone with relative risk of -9.173 of ivacaftor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: lansoprazole with relative risk of -9.722 of ivacaftor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: trovafloxacin with relative risk of -10.299 of ivacaftor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: didanosine with relative risk of -17.326 of ivacaftor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: didanosine with relative risk of -17.326 of ivacaftor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: sertraline with relative risk of -20.179 of ivacaftor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: sertraline with relative risk of -20.179 of ivacaftor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: sertraline with relative risk of -20.179 of ivacaftor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: irbesartan with relative risk of -20.731 of ivacaftor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: irbesartan with relative risk of -20.731 of ivacaftor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: irbesartan with relative risk of -20.731 of ivacaftor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: regadenoson with relative risk of -20.974 of ivacaftor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: regadenoson with relative risk of -20.974 of ivacaftor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: regadenoson with relative risk of -20.974 of ivacaftor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: mometasone with relative risk of -21.198 of ivacaftor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: mometasone with relative risk of -21.198 of ivacaftor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: mometasone with relative risk of -21.198 of ivacaftor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: azelastine with relative risk of -21.966 of ivacaftor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: azelastine with relative risk of -21.966 of ivacaftor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: azelastine with relative risk of -21.966 of ivacaftor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: posaconazole with relative risk of -22.090 of ivacaftor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: posaconazole with relative risk of -22.090 of ivacaftor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: posaconazole with relative risk of -22.090 of ivacaftor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: etoposide with relative risk of -22.310 of ivacaftor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: etoposide with relative risk of -22.310 of ivacaftor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: etoposide with relative risk of -22.310 of ivacaftor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: ibutilide with relative risk of -23.285 of ivacaftor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: ibutilide with relative risk of -23.285 of ivacaftor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: ibutilide with relative risk of -23.285 of ivacaftor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: tropisetron with relative risk of -23.368 of ivacaftor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: tropisetron with relative risk of -23.368 of ivacaftor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: tropisetron with relative risk of -23.368 of ivacaftor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: paliperidone with relative risk of -23.454 of ivacaftor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: paliperidone with relative risk of -23.454 of ivacaftor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: paliperidone with relative risk of -23.454 of ivacaftor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: glimepiride with relative risk of -23.503 of ivacaftor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: glimepiride with relative risk of -23.503 of ivacaftor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: glimepiride with relative risk of -23.503 of ivacaftor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: pentoxifylline with relative risk of -23.552 of ivacaftor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: pentoxifylline with relative risk of -23.552 of ivacaftor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: pentoxifylline with relative risk of -23.552 of ivacaftor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: fenofibrate with relative risk of -24.853 of ivacaftor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: fenofibrate with relative risk of -24.853 of ivacaftor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: fenofibrate with relative risk of -24.853 of ivacaftor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: terbutaline with relative risk of -25.481 of ivacaftor | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: pulmonary\n",
      "Rank 49: terbutaline with relative risk of -25.481 of ivacaftor | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: pulmonary\n",
      "Rank 50: terbutaline with relative risk of -25.481 of ivacaftor | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: pulmonary\n",
      "Rank 51: esmolol with relative risk of -26.444 of ivacaftor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: esmolol with relative risk of -26.444 of ivacaftor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 53: esmolol with relative risk of -26.444 of ivacaftor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 54: everolimus with relative risk of -27.854 of ivacaftor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 55: everolimus with relative risk of -27.854 of ivacaftor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 56: everolimus with relative risk of -27.854 of ivacaftor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 57: azilsartan with relative risk of -27.903 of ivacaftor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 58: azilsartan with relative risk of -27.903 of ivacaftor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 59: azilsartan with relative risk of -27.903 of ivacaftor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 60: zolmitriptan with relative risk of -28.542 of ivacaftor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 61: zolmitriptan with relative risk of -28.542 of ivacaftor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 62: zolmitriptan with relative risk of -28.542 of ivacaftor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 63: brinzolamide with relative risk of -30.242 of ivacaftor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 64: brinzolamide with relative risk of -30.242 of ivacaftor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 65: brinzolamide with relative risk of -30.242 of ivacaftor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 66: acebutolol with relative risk of -30.587 of ivacaftor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 67: acebutolol with relative risk of -30.587 of ivacaftor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 68: acebutolol with relative risk of -30.587 of ivacaftor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 69: valsartan with relative risk of -30.730 of ivacaftor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 70: valsartan with relative risk of -30.730 of ivacaftor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 71: valsartan with relative risk of -30.730 of ivacaftor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 72: felodipine with relative risk of -inf of ivacaftor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 73: felodipine with relative risk of -inf of ivacaftor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 74: felodipine with relative risk of -inf of ivacaftor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.013\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó ivermectin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: bicalutamide with relative risk of -10.217 of ivermectin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: sildenafil with relative risk of -10.962 of ivermectin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó ixabepilone *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: sertraline with relative risk of -8.999 of ixabepilone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: azelastine with relative risk of -10.076 of ixabepilone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: ropivacaine with relative risk of -10.167 of ixabepilone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: naproxen with relative risk of -10.392 of ixabepilone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: ticagrelor with relative risk of -10.968 of ixabepilone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: ibutilide with relative risk of -11.114 of ixabepilone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: erlotinib with relative risk of -11.283 of ixabepilone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 8: delavirdine with relative risk of -11.290 of ixabepilone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: vemurafenib with relative risk of -11.314 of ixabepilone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 10: gabapentin with relative risk of -11.546 of ixabepilone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: telmisartan with relative risk of -11.674 of ixabepilone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: clarithromycin with relative risk of -11.894 of ixabepilone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: clonidine with relative risk of -11.931 of ixabepilone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: rotigotine with relative risk of -12.650 of ixabepilone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: toremifene with relative risk of -13.932 of ixabepilone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Carcinoma breast stage IV,oncology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.097\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó ketoconazole *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: canagliflozin with relative risk of -12.616 of ketoconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó ketoprofen *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: amiodarone with relative risk of -29.451 of ketoprofen | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: amiodarone with relative risk of -29.451 of ketoprofen | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: amiodarone with relative risk of -29.451 of ketoprofen | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: amiodarone with relative risk of -29.451 of ketoprofen | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: lenalidomide with relative risk of -29.786 of ketoprofen | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: lenalidomide with relative risk of -29.786 of ketoprofen | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: lenalidomide with relative risk of -29.786 of ketoprofen | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: lenalidomide with relative risk of -29.786 of ketoprofen | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: penbutolol with relative risk of -30.802 of ketoprofen | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: penbutolol with relative risk of -30.802 of ketoprofen | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: penbutolol with relative risk of -30.802 of ketoprofen | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: penbutolol with relative risk of -30.802 of ketoprofen | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: fluvastatin with relative risk of -34.551 of ketoprofen | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: fluvastatin with relative risk of -34.551 of ketoprofen | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: fluvastatin with relative risk of -34.551 of ketoprofen | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: fluvastatin with relative risk of -34.551 of ketoprofen | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: tizanidine with relative risk of -34.701 of ketoprofen | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: tizanidine with relative risk of -34.701 of ketoprofen | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: tizanidine with relative risk of -34.701 of ketoprofen | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: tizanidine with relative risk of -34.701 of ketoprofen | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: propafenone with relative risk of -40.698 of ketoprofen | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: propafenone with relative risk of -40.698 of ketoprofen | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: propafenone with relative risk of -40.698 of ketoprofen | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: propafenone with relative risk of -40.698 of ketoprofen | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó ketorolac *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: paroxetine with relative risk of -7.232 of ketorolac | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: metoprolol with relative risk of -7.718 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: miglustat with relative risk of -7.841 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: naproxen with relative risk of -7.910 of ketorolac | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 5: pemetrexed with relative risk of -7.989 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: pentoxifylline with relative risk of -8.075 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: milrinone with relative risk of -8.141 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: terbutaline with relative risk of -8.301 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: topotecan with relative risk of -8.352 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: risperidone with relative risk of -8.693 of ketorolac | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: indomethacin with relative risk of -8.772 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: atropine with relative risk of -9.046 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: gabapentin with relative risk of -9.063 of ketorolac | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: loratadine with relative risk of -9.072 of ketorolac | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic Conjunctivitis,neurology/psychiatry\n",
      "Rank 15: telmisartan with relative risk of -9.192 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: trovafloxacin with relative risk of -9.203 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: nabumetone with relative risk of -9.211 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: argatroban with relative risk of -9.311 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: nevirapine with relative risk of -9.367 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: cetirizine with relative risk of -9.386 of ketorolac | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic Conjunctivitis\n",
      "Rank 21: clarithromycin with relative risk of -9.412 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: clonidine with relative risk of -9.447 of ketorolac | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Severe pain,neurology/psychiatry\n",
      "Rank 23: tamsulosin with relative risk of -9.466 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: dronedarone with relative risk of -9.487 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: estramustine with relative risk of -9.498 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: flutamide with relative risk of -9.500 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: leflunomide with relative risk of -9.749 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: doxorubicin with relative risk of -9.758 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: bezafibrate with relative risk of -9.773 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: vernakalant with relative risk of -9.796 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: zolmitriptan with relative risk of -9.821 of ketorolac | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 32: fondaparinux with relative risk of -10.057 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: fluconazole with relative risk of -10.244 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: flecainide with relative risk of -10.471 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: bisoprolol with relative risk of -10.495 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: domperidone with relative risk of -11.051 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: vilazodone with relative risk of -11.159 of ketorolac | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 38: ospemifene with relative risk of -11.247 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: pindolol with relative risk of -11.315 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: ropivacaine with relative risk of -13.839 of ketorolac | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 41: ropivacaine with relative risk of -13.839 of ketorolac | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 42: bumetanide with relative risk of -15.979 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: bumetanide with relative risk of -15.979 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: cyclophosphamide with relative risk of -16.336 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: cyclophosphamide with relative risk of -16.336 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: sumatriptan with relative risk of -18.526 of ketorolac | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 47: sumatriptan with relative risk of -18.526 of ketorolac | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 48: citalopram with relative risk of -18.550 of ketorolac | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 49: citalopram with relative risk of -18.550 of ketorolac | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 50: ibandronate with relative risk of -18.975 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: ibandronate with relative risk of -18.975 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: ibandronate with relative risk of -18.975 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 53: lurasidone with relative risk of -21.539 of ketorolac | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 54: lurasidone with relative risk of -21.539 of ketorolac | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 55: lurasidone with relative risk of -21.539 of ketorolac | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 56: didanosine with relative risk of -22.393 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 57: didanosine with relative risk of -22.393 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 58: didanosine with relative risk of -22.393 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 59: ruxolitinib with relative risk of -30.378 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 60: ruxolitinib with relative risk of -30.378 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 61: ruxolitinib with relative risk of -30.378 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 62: ruxolitinib with relative risk of -30.378 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 63: dutasteride with relative risk of -31.260 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 64: dutasteride with relative risk of -31.260 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 65: dutasteride with relative risk of -31.260 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 66: dutasteride with relative risk of -31.260 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 67: levonorgestrel with relative risk of -47.143 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 68: levonorgestrel with relative risk of -47.143 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 69: levonorgestrel with relative risk of -47.143 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 70: levonorgestrel with relative risk of -47.143 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 71: levonorgestrel with relative risk of -47.143 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 72: levonorgestrel with relative risk of -47.143 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 73: sertraline with relative risk of -47.198 of ketorolac | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 74: sertraline with relative risk of -47.198 of ketorolac | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 75: sertraline with relative risk of -47.198 of ketorolac | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 76: sertraline with relative risk of -47.198 of ketorolac | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 77: sertraline with relative risk of -47.198 of ketorolac | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 78: sertraline with relative risk of -47.198 of ketorolac | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 79: sertraline with relative risk of -47.198 of ketorolac | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 80: sertraline with relative risk of -47.198 of ketorolac | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 81: irbesartan with relative risk of -47.274 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 82: irbesartan with relative risk of -47.274 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 83: irbesartan with relative risk of -47.274 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 84: irbesartan with relative risk of -47.274 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 85: irbesartan with relative risk of -47.274 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 86: irbesartan with relative risk of -47.274 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 87: irbesartan with relative risk of -47.274 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 88: irbesartan with relative risk of -47.274 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 89: tropisetron with relative risk of -47.348 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 90: tropisetron with relative risk of -47.348 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 91: tropisetron with relative risk of -47.348 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 92: tropisetron with relative risk of -47.348 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 93: tropisetron with relative risk of -47.348 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 94: tropisetron with relative risk of -47.348 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 95: tropisetron with relative risk of -47.348 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 96: paliperidone with relative risk of -47.703 of ketorolac | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 97: paliperidone with relative risk of -47.703 of ketorolac | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 98: paliperidone with relative risk of -47.703 of ketorolac | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 99: paliperidone with relative risk of -47.703 of ketorolac | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 100: paliperidone with relative risk of -47.703 of ketorolac | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 101: paliperidone with relative risk of -47.703 of ketorolac | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 102: paliperidone with relative risk of -47.703 of ketorolac | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 103: etoposide with relative risk of -48.264 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 104: etoposide with relative risk of -48.264 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 105: etoposide with relative risk of -48.264 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 106: etoposide with relative risk of -48.264 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 107: etoposide with relative risk of -48.264 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 108: etoposide with relative risk of -48.264 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 109: etoposide with relative risk of -48.264 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 110: glimepiride with relative risk of -48.348 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 111: glimepiride with relative risk of -48.348 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 112: glimepiride with relative risk of -48.348 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 113: glimepiride with relative risk of -48.348 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 114: glimepiride with relative risk of -48.348 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 115: glimepiride with relative risk of -48.348 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 116: glimepiride with relative risk of -48.348 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 117: mometasone with relative risk of -50.373 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 118: mometasone with relative risk of -50.373 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 119: mometasone with relative risk of -50.373 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 120: mometasone with relative risk of -50.373 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 121: mometasone with relative risk of -50.373 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 122: mometasone with relative risk of -50.373 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 123: mometasone with relative risk of -50.373 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 124: mometasone with relative risk of -50.373 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 125: fenofibrate with relative risk of -50.808 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 126: fenofibrate with relative risk of -50.808 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 127: fenofibrate with relative risk of -50.808 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 128: fenofibrate with relative risk of -50.808 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 129: fenofibrate with relative risk of -50.808 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 130: fenofibrate with relative risk of -50.808 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 131: fenofibrate with relative risk of -50.808 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 132: azelastine with relative risk of -50.952 of ketorolac | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic Conjunctivitis\n",
      "Rank 133: azelastine with relative risk of -50.952 of ketorolac | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic Conjunctivitis\n",
      "Rank 134: azelastine with relative risk of -50.952 of ketorolac | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic Conjunctivitis\n",
      "Rank 135: azelastine with relative risk of -50.952 of ketorolac | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic Conjunctivitis\n",
      "Rank 136: azelastine with relative risk of -50.952 of ketorolac | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic Conjunctivitis\n",
      "Rank 137: azelastine with relative risk of -50.952 of ketorolac | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic Conjunctivitis\n",
      "Rank 138: azelastine with relative risk of -50.952 of ketorolac | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic Conjunctivitis\n",
      "Rank 139: azelastine with relative risk of -50.952 of ketorolac | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic Conjunctivitis\n",
      "Rank 140: regadenoson with relative risk of -51.221 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 141: regadenoson with relative risk of -51.221 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 142: regadenoson with relative risk of -51.221 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 143: regadenoson with relative risk of -51.221 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 144: regadenoson with relative risk of -51.221 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 145: regadenoson with relative risk of -51.221 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 146: regadenoson with relative risk of -51.221 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 147: regadenoson with relative risk of -51.221 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 148: posaconazole with relative risk of -52.582 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 149: posaconazole with relative risk of -52.582 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 150: posaconazole with relative risk of -52.582 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 151: posaconazole with relative risk of -52.582 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 152: posaconazole with relative risk of -52.582 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 153: posaconazole with relative risk of -52.582 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 154: posaconazole with relative risk of -52.582 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 155: posaconazole with relative risk of -52.582 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 156: lansoprazole with relative risk of -52.836 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 157: lansoprazole with relative risk of -52.836 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 158: lansoprazole with relative risk of -52.836 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 159: lansoprazole with relative risk of -52.836 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 160: lansoprazole with relative risk of -52.836 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 161: lansoprazole with relative risk of -52.836 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 162: lansoprazole with relative risk of -52.836 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 163: ibutilide with relative risk of -53.075 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 164: ibutilide with relative risk of -53.075 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 165: ibutilide with relative risk of -53.075 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 166: ibutilide with relative risk of -53.075 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 167: ibutilide with relative risk of -53.075 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 168: ibutilide with relative risk of -53.075 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 169: ibutilide with relative risk of -53.075 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 170: ibutilide with relative risk of -53.075 of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 171: felodipine with relative risk of -inf of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 172: felodipine with relative risk of -inf of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 173: felodipine with relative risk of -inf of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 174: felodipine with relative risk of -inf of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 175: felodipine with relative risk of -inf of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 176: felodipine with relative risk of -inf of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 177: felodipine with relative risk of -inf of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 178: desoximetasone with relative risk of -inf of ketorolac | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.36\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó labetalol *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: vandetanib with relative risk of -11.340 of labetalol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: ziprasidone with relative risk of -13.260 of labetalol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: loteprednol with relative risk of -14.040 of labetalol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target lacosamide not found. Exiting ...\n",
      "\n",
      "Drug target lamivudine not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó lamotrigine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: pentostatin with relative risk of -9.457 of lamotrigine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: amiloride with relative risk of -11.401 of lamotrigine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: diclofenac with relative risk of -16.574 of lamotrigine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: diclofenac with relative risk of -16.574 of lamotrigine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 5: norfloxacin with relative risk of -28.080 of lamotrigine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: norfloxacin with relative risk of -28.080 of lamotrigine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: norfloxacin with relative risk of -28.080 of lamotrigine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.225\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target lanreotide not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó lansoprazole *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: metoprolol with relative risk of -7.805 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: darifenacin with relative risk of -7.944 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: naproxen with relative risk of -7.997 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: milrinone with relative risk of -8.228 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: ivacaftor with relative risk of -8.405 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: brimonidine with relative risk of -8.706 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: risperidone with relative risk of -8.779 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: atropine with relative risk of -9.133 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: telmisartan with relative risk of -9.279 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: tazarotene with relative risk of -9.279 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: nevirapine with relative risk of -9.454 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: cetirizine with relative risk of -9.472 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: clonidine with relative risk of -9.534 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: dapsone with relative risk of -9.540 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: tamsulosin with relative risk of -9.553 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: flutamide with relative risk of -9.587 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: brinzolamide with relative risk of -9.815 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: leflunomide with relative risk of -9.836 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: doxorubicin with relative risk of -9.845 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: bezafibrate with relative risk of -9.860 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: vernakalant with relative risk of -9.883 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: fondaparinux with relative risk of -10.144 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: acebutolol with relative risk of -10.160 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: isradipine with relative risk of -10.284 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: valsartan with relative risk of -10.303 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: flecainide with relative risk of -10.558 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: vilazodone with relative risk of -11.246 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: pindolol with relative risk of -11.402 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: pentoxifylline with relative risk of -13.715 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: pentoxifylline with relative risk of -13.715 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: pemetrexed with relative risk of -14.729 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: pemetrexed with relative risk of -14.729 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: terbutaline with relative risk of -14.753 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: terbutaline with relative risk of -14.753 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: esmolol with relative risk of -15.155 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: esmolol with relative risk of -15.155 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: trovafloxacin with relative risk of -15.788 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: trovafloxacin with relative risk of -15.788 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: everolimus with relative risk of -15.872 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: everolimus with relative risk of -15.872 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: gabapentin with relative risk of -15.985 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: gabapentin with relative risk of -15.985 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: bumetanide with relative risk of -16.161 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: bumetanide with relative risk of -16.161 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: clarithromycin with relative risk of -16.334 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: clarithromycin with relative risk of -16.334 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: cyclophosphamide with relative risk of -16.518 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: cyclophosphamide with relative risk of -16.518 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: azilsartan with relative risk of -16.615 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: azilsartan with relative risk of -16.615 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: zolmitriptan with relative risk of -16.966 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: zolmitriptan with relative risk of -16.966 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 53: sumatriptan with relative risk of -18.708 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 54: sumatriptan with relative risk of -18.708 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 55: citalopram with relative risk of -18.732 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 56: citalopram with relative risk of -18.732 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 57: ropivacaine with relative risk of -20.897 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 58: ropivacaine with relative risk of -20.897 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 59: ropivacaine with relative risk of -20.897 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 60: indomethacin with relative risk of -22.522 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 61: indomethacin with relative risk of -22.522 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 62: indomethacin with relative risk of -22.522 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 63: lurasidone with relative risk of -29.578 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 64: lurasidone with relative risk of -29.578 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 65: lurasidone with relative risk of -29.578 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 66: lurasidone with relative risk of -29.578 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 67: ruxolitinib with relative risk of -30.783 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 68: ruxolitinib with relative risk of -30.783 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 69: ruxolitinib with relative risk of -30.783 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 70: ruxolitinib with relative risk of -30.783 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 71: dutasteride with relative risk of -31.665 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 72: dutasteride with relative risk of -31.665 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 73: dutasteride with relative risk of -31.665 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 74: dutasteride with relative risk of -31.665 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 75: levonorgestrel with relative risk of -38.475 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 76: levonorgestrel with relative risk of -38.475 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 77: levonorgestrel with relative risk of -38.475 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 78: levonorgestrel with relative risk of -38.475 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 79: levonorgestrel with relative risk of -38.475 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 80: didanosine with relative risk of -39.968 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 81: didanosine with relative risk of -39.968 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 82: didanosine with relative risk of -39.968 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 83: didanosine with relative risk of -39.968 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 84: didanosine with relative risk of -39.968 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 85: etoposide with relative risk of -49.140 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 86: etoposide with relative risk of -49.140 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 87: etoposide with relative risk of -49.140 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 88: etoposide with relative risk of -49.140 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 89: etoposide with relative risk of -49.140 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 90: etoposide with relative risk of -49.140 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 91: etoposide with relative risk of -49.140 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 92: fenofibrate with relative risk of -51.683 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 93: fenofibrate with relative risk of -51.683 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 94: fenofibrate with relative risk of -51.683 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 95: fenofibrate with relative risk of -51.683 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 96: fenofibrate with relative risk of -51.683 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 97: fenofibrate with relative risk of -51.683 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 98: fenofibrate with relative risk of -51.683 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 99: ketorolac with relative risk of -53.074 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 100: ketorolac with relative risk of -53.074 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 101: ketorolac with relative risk of -53.074 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 102: ketorolac with relative risk of -53.074 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 103: ketorolac with relative risk of -53.074 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 104: ketorolac with relative risk of -53.074 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 105: ketorolac with relative risk of -53.074 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 106: glimepiride with relative risk of -57.668 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 107: glimepiride with relative risk of -57.668 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 108: glimepiride with relative risk of -57.668 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 109: glimepiride with relative risk of -57.668 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 110: glimepiride with relative risk of -57.668 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 111: glimepiride with relative risk of -57.668 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 112: glimepiride with relative risk of -57.668 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 113: glimepiride with relative risk of -57.668 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 114: irbesartan with relative risk of -72.569 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 115: irbesartan with relative risk of -72.569 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 116: irbesartan with relative risk of -72.569 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 117: irbesartan with relative risk of -72.569 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 118: irbesartan with relative risk of -72.569 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 119: irbesartan with relative risk of -72.569 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 120: irbesartan with relative risk of -72.569 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 121: irbesartan with relative risk of -72.569 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 122: irbesartan with relative risk of -72.569 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 123: irbesartan with relative risk of -72.569 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 124: irbesartan with relative risk of -72.569 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 125: sertraline with relative risk of -72.810 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 126: sertraline with relative risk of -72.810 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 127: sertraline with relative risk of -72.810 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 128: sertraline with relative risk of -72.810 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 129: sertraline with relative risk of -72.810 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 130: sertraline with relative risk of -72.810 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 131: sertraline with relative risk of -72.810 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 132: sertraline with relative risk of -72.810 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 133: sertraline with relative risk of -72.810 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 134: sertraline with relative risk of -72.810 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 135: sertraline with relative risk of -72.810 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 136: paliperidone with relative risk of -74.955 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 137: paliperidone with relative risk of -74.955 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 138: paliperidone with relative risk of -74.955 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 139: paliperidone with relative risk of -74.955 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 140: paliperidone with relative risk of -74.955 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 141: paliperidone with relative risk of -74.955 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 142: paliperidone with relative risk of -74.955 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 143: paliperidone with relative risk of -74.955 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 144: paliperidone with relative risk of -74.955 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 145: paliperidone with relative risk of -74.955 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 146: mometasone with relative risk of -77.466 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 147: mometasone with relative risk of -77.466 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 148: mometasone with relative risk of -77.466 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 149: mometasone with relative risk of -77.466 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 150: mometasone with relative risk of -77.466 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 151: mometasone with relative risk of -77.466 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 152: mometasone with relative risk of -77.466 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 153: mometasone with relative risk of -77.466 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 154: mometasone with relative risk of -77.466 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 155: mometasone with relative risk of -77.466 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 156: mometasone with relative risk of -77.466 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 157: azelastine with relative risk of -77.911 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 158: azelastine with relative risk of -77.911 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 159: azelastine with relative risk of -77.911 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 160: azelastine with relative risk of -77.911 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 161: azelastine with relative risk of -77.911 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 162: azelastine with relative risk of -77.911 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 163: azelastine with relative risk of -77.911 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 164: azelastine with relative risk of -77.911 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 165: azelastine with relative risk of -77.911 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 166: azelastine with relative risk of -77.911 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 167: azelastine with relative risk of -77.911 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 168: regadenoson with relative risk of -79.090 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 169: regadenoson with relative risk of -79.090 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 170: regadenoson with relative risk of -79.090 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 171: regadenoson with relative risk of -79.090 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 172: regadenoson with relative risk of -79.090 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 173: regadenoson with relative risk of -79.090 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 174: regadenoson with relative risk of -79.090 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 175: regadenoson with relative risk of -79.090 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 176: regadenoson with relative risk of -79.090 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 177: regadenoson with relative risk of -79.090 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 178: regadenoson with relative risk of -79.090 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 179: ibutilide with relative risk of -80.609 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 180: ibutilide with relative risk of -80.609 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 181: ibutilide with relative risk of -80.609 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 182: ibutilide with relative risk of -80.609 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 183: ibutilide with relative risk of -80.609 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 184: ibutilide with relative risk of -80.609 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 185: ibutilide with relative risk of -80.609 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 186: ibutilide with relative risk of -80.609 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 187: ibutilide with relative risk of -80.609 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 188: ibutilide with relative risk of -80.609 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 189: ibutilide with relative risk of -80.609 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 190: posaconazole with relative risk of -80.633 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 191: posaconazole with relative risk of -80.633 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 192: posaconazole with relative risk of -80.633 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 193: posaconazole with relative risk of -80.633 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 194: posaconazole with relative risk of -80.633 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 195: posaconazole with relative risk of -80.633 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 196: posaconazole with relative risk of -80.633 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 197: posaconazole with relative risk of -80.633 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 198: posaconazole with relative risk of -80.633 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 199: posaconazole with relative risk of -80.633 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 200: posaconazole with relative risk of -80.633 of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 201: tropisetron with relative risk of -84.488 of lansoprazole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "Rank 202: tropisetron with relative risk of -84.488 of lansoprazole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "Rank 203: tropisetron with relative risk of -84.488 of lansoprazole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "Rank 204: tropisetron with relative risk of -84.488 of lansoprazole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "Rank 205: tropisetron with relative risk of -84.488 of lansoprazole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "Rank 206: tropisetron with relative risk of -84.488 of lansoprazole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "Rank 207: tropisetron with relative risk of -84.488 of lansoprazole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "Rank 208: tropisetron with relative risk of -84.488 of lansoprazole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "Rank 209: tropisetron with relative risk of -84.488 of lansoprazole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "Rank 210: tropisetron with relative risk of -84.488 of lansoprazole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "Rank 211: tropisetron with relative risk of -84.488 of lansoprazole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "Rank 212: felodipine with relative risk of -inf of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 213: felodipine with relative risk of -inf of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 214: felodipine with relative risk of -inf of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 215: felodipine with relative risk of -inf of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 216: felodipine with relative risk of -inf of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 217: felodipine with relative risk of -inf of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 218: felodipine with relative risk of -inf of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 219: felodipine with relative risk of -inf of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 220: felodipine with relative risk of -inf of lansoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.009\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target lanthanum not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó lapatinib *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: azelastine with relative risk of -9.384 of lapatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: pentoxifylline with relative risk of -9.859 of lapatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: loratadine with relative risk of -10.862 of lapatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: afatinib with relative risk of -11.280 of lapatinib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 5: quinidine with relative risk of -11.571 of lapatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: beclomethasone with relative risk of -11.945 of lapatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: budesonide with relative risk of -12.312 of lapatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: pergolide with relative risk of -12.824 of lapatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: aclidinium with relative risk of -12.870 of lapatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: caffeine with relative risk of -13.366 of lapatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: bromfenac with relative risk of -14.997 of lapatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: irbesartan with relative risk of -15.911 of lapatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: irbesartan with relative risk of -15.911 of lapatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: bumetanide with relative risk of -20.168 of lapatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: bumetanide with relative risk of -20.168 of lapatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: argatroban with relative risk of -20.750 of lapatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: argatroban with relative risk of -20.750 of lapatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: nevirapine with relative risk of -20.807 of lapatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: nevirapine with relative risk of -20.807 of lapatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: ribavirin with relative risk of -21.029 of lapatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: ribavirin with relative risk of -21.029 of lapatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: celecoxib with relative risk of -21.722 of lapatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: celecoxib with relative risk of -21.722 of lapatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: perindopril with relative risk of -21.801 of lapatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: perindopril with relative risk of -21.801 of lapatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: losartan with relative risk of -22.372 of lapatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: losartan with relative risk of -22.372 of lapatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: amisulpride with relative risk of -22.437 of lapatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: amisulpride with relative risk of -22.437 of lapatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: latanoprost with relative risk of -22.533 of lapatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: latanoprost with relative risk of -22.533 of lapatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: domperidone with relative risk of -22.897 of lapatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: domperidone with relative risk of -22.897 of lapatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: temsirolimus with relative risk of -23.091 of lapatinib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 35: temsirolimus with relative risk of -23.091 of lapatinib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 36: lidocaine with relative risk of -23.775 of lapatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: lidocaine with relative risk of -23.775 of lapatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: felodipine with relative risk of -inf of lapatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: felodipine with relative risk of -inf of lapatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.072\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó latanoprost *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: azelastine with relative risk of -8.980 of latanoprost | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: ophthalmology\n",
      "Rank 2: pentoxifylline with relative risk of -9.454 of latanoprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: loratadine with relative risk of -10.457 of latanoprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: afatinib with relative risk of -10.875 of latanoprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: quinidine with relative risk of -11.165 of latanoprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: beclomethasone with relative risk of -11.539 of latanoprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: budesonide with relative risk of -11.907 of latanoprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: pergolide with relative risk of -12.419 of latanoprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: aclidinium with relative risk of -12.464 of latanoprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: caffeine with relative risk of -12.960 of latanoprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: bromfenac with relative risk of -14.591 of latanoprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: bumetanide with relative risk of -19.069 of latanoprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: bumetanide with relative risk of -19.069 of latanoprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: argatroban with relative risk of -19.652 of latanoprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: argatroban with relative risk of -19.652 of latanoprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: nevirapine with relative risk of -19.708 of latanoprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: nevirapine with relative risk of -19.708 of latanoprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: ribavirin with relative risk of -19.931 of latanoprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: ribavirin with relative risk of -19.931 of latanoprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: perindopril with relative risk of -20.702 of latanoprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: perindopril with relative risk of -20.702 of latanoprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: lapatinib with relative risk of -20.875 of latanoprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: lapatinib with relative risk of -20.875 of latanoprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: losartan with relative risk of -21.273 of latanoprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: losartan with relative risk of -21.273 of latanoprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: domperidone with relative risk of -21.798 of latanoprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: domperidone with relative risk of -21.798 of latanoprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: temsirolimus with relative risk of -21.993 of latanoprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: temsirolimus with relative risk of -21.993 of latanoprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: irbesartan with relative risk of -22.116 of latanoprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: irbesartan with relative risk of -22.116 of latanoprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: irbesartan with relative risk of -22.116 of latanoprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: lidocaine with relative risk of -22.676 of latanoprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: lidocaine with relative risk of -22.676 of latanoprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: celecoxib with relative risk of -31.777 of latanoprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: celecoxib with relative risk of -31.777 of latanoprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: celecoxib with relative risk of -31.777 of latanoprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: amisulpride with relative risk of -32.492 of latanoprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: amisulpride with relative risk of -32.492 of latanoprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: amisulpride with relative risk of -32.492 of latanoprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: felodipine with relative risk of -inf of latanoprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: felodipine with relative risk of -inf of latanoprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.231\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó leflunomide *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: regadenoson with relative risk of -7.955 of leflunomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: sertraline with relative risk of -8.308 of leflunomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: mometasone with relative risk of -8.550 of leflunomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: posaconazole with relative risk of -8.987 of leflunomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: irbesartan with relative risk of -9.036 of leflunomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: azelastine with relative risk of -9.384 of leflunomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: tropisetron with relative risk of -9.787 of leflunomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: ruxolitinib with relative risk of -9.819 of leflunomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: lurasidone with relative risk of -9.865 of leflunomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: lansoprazole with relative risk of -10.414 of leflunomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: ibutilide with relative risk of -10.422 of leflunomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: risperidone with relative risk of -10.482 of leflunomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: ketorolac with relative risk of -10.565 of leflunomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: atropine with relative risk of -10.837 of leflunomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: clarithromycin with relative risk of -11.201 of leflunomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: clonidine with relative risk of -11.238 of leflunomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: dutasteride with relative risk of -11.393 of leflunomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: doxorubicin with relative risk of -11.549 of leflunomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: vernakalant with relative risk of -11.588 of leflunomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: flecainide with relative risk of -12.263 of leflunomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: vilazodone with relative risk of -12.951 of leflunomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: pindolol with relative risk of -13.107 of leflunomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó lenalidomide *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: diclofenac with relative risk of -7.298 of lenalidomide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Pain\n",
      "Rank 2: pentostatin with relative risk of -7.628 of lenalidomide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: hematologic malignancy\n",
      "Rank 3: adapalene with relative risk of -9.290 of lenalidomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: liraglutide with relative risk of -9.339 of lenalidomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: linagliptin with relative risk of -10.244 of lenalidomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: roflumilast with relative risk of -10.393 of lenalidomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: dexamethasone with relative risk of -16.541 of lenalidomide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Multiple Myeloma,Lymphoma, Non-Hodgkin\n",
      "Rank 8: dexamethasone with relative risk of -16.541 of lenalidomide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Multiple Myeloma,Lymphoma, Non-Hodgkin\n",
      "Rank 9: bexarotene with relative risk of -20.192 of lenalidomide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: hematologic malignancy\n",
      "Rank 10: bexarotene with relative risk of -20.192 of lenalidomide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: hematologic malignancy\n",
      "Rank 11: bexarotene with relative risk of -20.192 of lenalidomide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: hematologic malignancy\n",
      "Rank 12: regorafenib with relative risk of -21.970 of lenalidomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: regorafenib with relative risk of -21.970 of lenalidomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: regorafenib with relative risk of -21.970 of lenalidomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: tizanidine with relative risk of -25.259 of lenalidomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: tizanidine with relative risk of -25.259 of lenalidomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: tizanidine with relative risk of -25.259 of lenalidomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: tizanidine with relative risk of -25.259 of lenalidomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: ketoprofen with relative risk of -29.781 of lenalidomide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Pain\n",
      "Rank 20: ketoprofen with relative risk of -29.781 of lenalidomide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Pain\n",
      "Rank 21: ketoprofen with relative risk of -29.781 of lenalidomide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Pain\n",
      "Rank 22: ketoprofen with relative risk of -29.781 of lenalidomide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Pain\n",
      "Rank 23: sitagliptin with relative risk of -31.159 of lenalidomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: sitagliptin with relative risk of -31.159 of lenalidomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: sitagliptin with relative risk of -31.159 of lenalidomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: sitagliptin with relative risk of -31.159 of lenalidomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: propafenone with relative risk of -31.252 of lenalidomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: propafenone with relative risk of -31.252 of lenalidomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: propafenone with relative risk of -31.252 of lenalidomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: propafenone with relative risk of -31.252 of lenalidomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: fluvastatin with relative risk of -45.819 of lenalidomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: fluvastatin with relative risk of -45.819 of lenalidomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: fluvastatin with relative risk of -45.819 of lenalidomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: fluvastatin with relative risk of -45.819 of lenalidomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: fluvastatin with relative risk of -45.819 of lenalidomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: fluvastatin with relative risk of -45.819 of lenalidomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: fluvastatin with relative risk of -45.819 of lenalidomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: amiodarone with relative risk of -128.559 of lenalidomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: amiodarone with relative risk of -128.559 of lenalidomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: amiodarone with relative risk of -128.559 of lenalidomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: amiodarone with relative risk of -128.559 of lenalidomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: amiodarone with relative risk of -128.559 of lenalidomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: amiodarone with relative risk of -128.559 of lenalidomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: amiodarone with relative risk of -128.559 of lenalidomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: amiodarone with relative risk of -128.559 of lenalidomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: amiodarone with relative risk of -128.559 of lenalidomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: amiodarone with relative risk of -128.559 of lenalidomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: amiodarone with relative risk of -128.559 of lenalidomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: amiodarone with relative risk of -128.559 of lenalidomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: amiodarone with relative risk of -128.559 of lenalidomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: amiodarone with relative risk of -128.559 of lenalidomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: amiodarone with relative risk of -128.559 of lenalidomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 53: amiodarone with relative risk of -128.559 of lenalidomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 54: amiodarone with relative risk of -128.559 of lenalidomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 55: amiodarone with relative risk of -128.559 of lenalidomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 56: amiodarone with relative risk of -128.559 of lenalidomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 57: amiodarone with relative risk of -128.559 of lenalidomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 58: penbutolol with relative risk of -164.708 of lenalidomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 59: penbutolol with relative risk of -164.708 of lenalidomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 60: penbutolol with relative risk of -164.708 of lenalidomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 61: penbutolol with relative risk of -164.708 of lenalidomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 62: penbutolol with relative risk of -164.708 of lenalidomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 63: penbutolol with relative risk of -164.708 of lenalidomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 64: penbutolol with relative risk of -164.708 of lenalidomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 65: penbutolol with relative risk of -164.708 of lenalidomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 66: penbutolol with relative risk of -164.708 of lenalidomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 67: penbutolol with relative risk of -164.708 of lenalidomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 68: penbutolol with relative risk of -164.708 of lenalidomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 69: penbutolol with relative risk of -164.708 of lenalidomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 70: penbutolol with relative risk of -164.708 of lenalidomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 71: penbutolol with relative risk of -164.708 of lenalidomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 72: penbutolol with relative risk of -164.708 of lenalidomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 73: penbutolol with relative risk of -164.708 of lenalidomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 74: penbutolol with relative risk of -164.708 of lenalidomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 75: penbutolol with relative risk of -164.708 of lenalidomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 76: penbutolol with relative risk of -164.708 of lenalidomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 77: penbutolol with relative risk of -164.708 of lenalidomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 78: penbutolol with relative risk of -164.708 of lenalidomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 79: penbutolol with relative risk of -164.708 of lenalidomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 80: penbutolol with relative risk of -164.708 of lenalidomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.456\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó lercanidipine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: mivacurium with relative risk of -11.194 of lercanidipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: alosetron with relative risk of -11.783 of lercanidipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó letrozole *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: idarubicin with relative risk of -9.983 of letrozole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: bicalutamide with relative risk of -11.315 of letrozole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 3: gemfibrozil with relative risk of -12.858 of letrozole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: maprotiline with relative risk of -12.954 of letrozole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: fosinopril with relative risk of -13.119 of letrozole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: apremilast with relative risk of -13.757 of letrozole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.204\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target leucovorin not found. Exiting ...\n",
      "\n",
      "Drug target leuprorelin not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó levetiracetam *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: doxercalciferol with relative risk of -11.049 of levetiracetam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: iloperidone with relative risk of -11.491 of levetiracetam | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: fluconazole with relative risk of -12.035 of levetiracetam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: guanfacine with relative risk of -12.067 of levetiracetam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: mirtazapine with relative risk of -12.157 of levetiracetam | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: fosphenytoin with relative risk of -12.213 of levetiracetam | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Epilepsy characterized by intractable complex partial seizures,neurology/psychiatry\n",
      "Rank 7: reboxetine with relative risk of -12.438 of levetiracetam | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: ropinirole with relative risk of -12.554 of levetiracetam | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: vardenafil with relative risk of -12.599 of levetiracetam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: rilpivirine with relative risk of -12.757 of levetiracetam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: rabeprazole with relative risk of -22.253 of levetiracetam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: rabeprazole with relative risk of -22.253 of levetiracetam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: levocabastine with relative risk of -22.412 of levetiracetam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: levocabastine with relative risk of -22.412 of levetiracetam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.349\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó levocabastine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: doxercalciferol with relative risk of -11.049 of levocabastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: iloperidone with relative risk of -11.491 of levocabastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: fluconazole with relative risk of -12.035 of levocabastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: guanfacine with relative risk of -12.067 of levocabastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: mirtazapine with relative risk of -12.157 of levocabastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: fosphenytoin with relative risk of -12.213 of levocabastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: reboxetine with relative risk of -12.438 of levocabastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: ropinirole with relative risk of -12.554 of levocabastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: vardenafil with relative risk of -12.599 of levocabastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: rilpivirine with relative risk of -12.757 of levocabastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: rabeprazole with relative risk of -22.253 of levocabastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: rabeprazole with relative risk of -22.253 of levocabastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: levetiracetam with relative risk of -22.703 of levocabastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: levetiracetam with relative risk of -22.703 of levocabastine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target levodopa/carbidopa not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó levonorgestrel *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: ropivacaine with relative risk of -8.224 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: metoprolol with relative risk of -8.256 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: pemetrexed with relative risk of -8.527 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: penbutolol with relative risk of -8.585 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: pentoxifylline with relative risk of -8.610 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: lurasidone with relative risk of -8.614 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: milrinone with relative risk of -8.679 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: esmolol with relative risk of -8.771 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: terbutaline with relative risk of -8.838 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: ivacaftor with relative risk of -8.856 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: everolimus with relative risk of -8.977 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: indomethacin with relative risk of -9.310 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: bumetanide with relative risk of -9.554 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: trovafloxacin with relative risk of -9.740 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: nevirapine with relative risk of -9.905 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: tamsulosin with relative risk of -10.004 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: flutamide with relative risk of -10.039 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: azilsartan with relative risk of -10.231 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: brinzolamide with relative risk of -10.266 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: zolmitriptan with relative risk of -10.359 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: fondaparinux with relative risk of -10.595 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: acebutolol with relative risk of -10.611 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: citalopram with relative risk of -10.739 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: valsartan with relative risk of -10.755 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: didanosine with relative risk of -16.073 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: didanosine with relative risk of -16.073 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: dutasteride with relative risk of -17.306 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: dutasteride with relative risk of -17.306 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: cyclophosphamide with relative risk of -17.481 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: cyclophosphamide with relative risk of -17.481 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: sumatriptan with relative risk of -19.671 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: sumatriptan with relative risk of -19.671 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: ruxolitinib with relative risk of -24.071 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: ruxolitinib with relative risk of -24.071 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: ruxolitinib with relative risk of -24.071 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: lansoprazole with relative risk of -39.757 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: lansoprazole with relative risk of -39.757 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: lansoprazole with relative risk of -39.757 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: lansoprazole with relative risk of -39.757 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: lansoprazole with relative risk of -39.757 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: tropisetron with relative risk of -44.659 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: tropisetron with relative risk of -44.659 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: tropisetron with relative risk of -44.659 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: tropisetron with relative risk of -44.659 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: tropisetron with relative risk of -44.659 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: tropisetron with relative risk of -44.659 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: sertraline with relative risk of -46.979 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: sertraline with relative risk of -46.979 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: sertraline with relative risk of -46.979 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: sertraline with relative risk of -46.979 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: sertraline with relative risk of -46.979 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: sertraline with relative risk of -46.979 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 53: sertraline with relative risk of -46.979 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 54: irbesartan with relative risk of -47.154 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 55: irbesartan with relative risk of -47.154 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 56: irbesartan with relative risk of -47.154 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 57: irbesartan with relative risk of -47.154 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 58: irbesartan with relative risk of -47.154 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 59: irbesartan with relative risk of -47.154 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 60: irbesartan with relative risk of -47.154 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 61: ketorolac with relative risk of -48.663 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 62: ketorolac with relative risk of -48.663 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 63: ketorolac with relative risk of -48.663 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 64: ketorolac with relative risk of -48.663 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 65: ketorolac with relative risk of -48.663 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 66: ketorolac with relative risk of -48.663 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 67: mometasone with relative risk of -49.697 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 68: mometasone with relative risk of -49.697 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 69: mometasone with relative risk of -49.697 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 70: mometasone with relative risk of -49.697 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 71: mometasone with relative risk of -49.697 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 72: mometasone with relative risk of -49.697 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 73: mometasone with relative risk of -49.697 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 74: regadenoson with relative risk of -50.312 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 75: regadenoson with relative risk of -50.312 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 76: regadenoson with relative risk of -50.312 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 77: regadenoson with relative risk of -50.312 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 78: regadenoson with relative risk of -50.312 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 79: regadenoson with relative risk of -50.312 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 80: regadenoson with relative risk of -50.312 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 81: azelastine with relative risk of -50.316 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 82: azelastine with relative risk of -50.316 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 83: azelastine with relative risk of -50.316 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 84: azelastine with relative risk of -50.316 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 85: azelastine with relative risk of -50.316 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 86: azelastine with relative risk of -50.316 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 87: azelastine with relative risk of -50.316 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 88: posaconazole with relative risk of -51.619 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 89: posaconazole with relative risk of -51.619 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 90: posaconazole with relative risk of -51.619 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 91: posaconazole with relative risk of -51.619 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 92: posaconazole with relative risk of -51.619 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 93: posaconazole with relative risk of -51.619 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 94: posaconazole with relative risk of -51.619 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 95: ibutilide with relative risk of -52.266 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 96: ibutilide with relative risk of -52.266 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 97: ibutilide with relative risk of -52.266 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 98: ibutilide with relative risk of -52.266 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 99: ibutilide with relative risk of -52.266 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 100: ibutilide with relative risk of -52.266 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 101: ibutilide with relative risk of -52.266 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 102: paliperidone with relative risk of -54.374 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 103: paliperidone with relative risk of -54.374 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 104: paliperidone with relative risk of -54.374 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 105: paliperidone with relative risk of -54.374 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 106: paliperidone with relative risk of -54.374 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 107: paliperidone with relative risk of -54.374 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 108: paliperidone with relative risk of -54.374 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 109: etoposide with relative risk of -54.937 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 110: etoposide with relative risk of -54.937 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 111: etoposide with relative risk of -54.937 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 112: etoposide with relative risk of -54.937 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 113: etoposide with relative risk of -54.937 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 114: etoposide with relative risk of -54.937 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 115: etoposide with relative risk of -54.937 of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 116: glimepiride with relative risk of -55.021 of levonorgestrel | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 117: glimepiride with relative risk of -55.021 of levonorgestrel | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 118: glimepiride with relative risk of -55.021 of levonorgestrel | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 119: glimepiride with relative risk of -55.021 of levonorgestrel | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 120: glimepiride with relative risk of -55.021 of levonorgestrel | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 121: glimepiride with relative risk of -55.021 of levonorgestrel | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 122: glimepiride with relative risk of -55.021 of levonorgestrel | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 123: fenofibrate with relative risk of -57.481 of levonorgestrel | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 124: fenofibrate with relative risk of -57.481 of levonorgestrel | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 125: fenofibrate with relative risk of -57.481 of levonorgestrel | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 126: fenofibrate with relative risk of -57.481 of levonorgestrel | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 127: fenofibrate with relative risk of -57.481 of levonorgestrel | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 128: fenofibrate with relative risk of -57.481 of levonorgestrel | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 129: fenofibrate with relative risk of -57.481 of levonorgestrel | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 130: felodipine with relative risk of -inf of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 131: felodipine with relative risk of -inf of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 132: felodipine with relative risk of -inf of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 133: felodipine with relative risk of -inf of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 134: felodipine with relative risk of -inf of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 135: felodipine with relative risk of -inf of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 136: felodipine with relative risk of -inf of levonorgestrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.021\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó lidocaine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: azelastine with relative risk of -9.384 of lidocaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: pentoxifylline with relative risk of -9.859 of lidocaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: loratadine with relative risk of -10.862 of lidocaine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: afatinib with relative risk of -11.280 of lidocaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: quinidine with relative risk of -11.571 of lidocaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: beclomethasone with relative risk of -11.945 of lidocaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: budesonide with relative risk of -12.312 of lidocaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: pergolide with relative risk of -12.824 of lidocaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: aclidinium with relative risk of -12.870 of lidocaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: caffeine with relative risk of -13.366 of lidocaine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Pain,neurology/psychiatry\n",
      "Rank 11: bromfenac with relative risk of -14.997 of lidocaine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Pain\n",
      "Rank 12: irbesartan with relative risk of -15.911 of lidocaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: irbesartan with relative risk of -15.911 of lidocaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: bumetanide with relative risk of -20.168 of lidocaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: bumetanide with relative risk of -20.168 of lidocaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: argatroban with relative risk of -20.750 of lidocaine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: hematology\n",
      "Rank 17: argatroban with relative risk of -20.750 of lidocaine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: hematology\n",
      "Rank 18: nevirapine with relative risk of -20.807 of lidocaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: nevirapine with relative risk of -20.807 of lidocaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: ribavirin with relative risk of -21.029 of lidocaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: ribavirin with relative risk of -21.029 of lidocaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: celecoxib with relative risk of -21.722 of lidocaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: celecoxib with relative risk of -21.722 of lidocaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: perindopril with relative risk of -21.801 of lidocaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: perindopril with relative risk of -21.801 of lidocaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: lapatinib with relative risk of -21.973 of lidocaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: lapatinib with relative risk of -21.973 of lidocaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: losartan with relative risk of -22.372 of lidocaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: losartan with relative risk of -22.372 of lidocaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: amisulpride with relative risk of -22.437 of lidocaine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 31: amisulpride with relative risk of -22.437 of lidocaine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 32: latanoprost with relative risk of -22.533 of lidocaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: latanoprost with relative risk of -22.533 of lidocaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: domperidone with relative risk of -22.897 of lidocaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: domperidone with relative risk of -22.897 of lidocaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: temsirolimus with relative risk of -23.091 of lidocaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: temsirolimus with relative risk of -23.091 of lidocaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: felodipine with relative risk of -inf of lidocaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: felodipine with relative risk of -inf of lidocaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.167\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target linaclotide not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó linagliptin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: lenalidomide with relative risk of -9.026 of linagliptin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: amiodarone with relative risk of -9.864 of linagliptin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: penbutolol with relative risk of -10.524 of linagliptin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: fluvastatin with relative risk of -11.284 of linagliptin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 5: dexamethasone with relative risk of -12.190 of linagliptin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 6: sitagliptin with relative risk of -12.232 of linagliptin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Diabetes Mellitus, Non-Insulin-Dependent,endocrinology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.252\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó linezolid *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: vinorelbine with relative risk of -8.412 of linezolid | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: ciclesonide with relative risk of -8.907 of linezolid | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: axitinib with relative risk of -8.960 of linezolid | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: darifenacin with relative risk of -9.239 of linezolid | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: crizotinib with relative risk of -9.277 of linezolid | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: granisetron with relative risk of -9.299 of linezolid | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: pentoxifylline with relative risk of -9.454 of linezolid | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: apraclonidine with relative risk of -9.456 of linezolid | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: meloxicam with relative risk of -10.134 of linezolid | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: eplerenone with relative risk of -10.147 of linezolid | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: indacaterol with relative risk of -10.355 of linezolid | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: loratadine with relative risk of -10.457 of linezolid | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: nabumetone with relative risk of -10.592 of linezolid | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: argatroban with relative risk of -10.696 of linezolid | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: estramustine with relative risk of -10.882 of linezolid | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: etravirine with relative risk of -11.368 of linezolid | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 17: doxazosin with relative risk of -12.212 of linezolid | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: pinaverium with relative risk of -12.435 of linezolid | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: febuxostat with relative risk of -13.801 of linezolid | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: ibandronate with relative risk of -16.153 of linezolid | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: ibandronate with relative risk of -16.153 of linezolid | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: miglustat with relative risk of -26.406 of linezolid | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: miglustat with relative risk of -26.406 of linezolid | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: miglustat with relative risk of -26.406 of linezolid | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: desoximetasone with relative risk of -inf of linezolid | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.016\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó liraglutide *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: lenalidomide with relative risk of -9.026 of liraglutide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: amiodarone with relative risk of -9.864 of liraglutide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: regorafenib with relative risk of -10.294 of liraglutide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: bexarotene with relative risk of -10.305 of liraglutide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: penbutolol with relative risk of -10.524 of liraglutide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: fluvastatin with relative risk of -11.284 of liraglutide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 7: sitagliptin with relative risk of -12.232 of liraglutide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Diabetes Mellitus, Non-Insulin-Dependent,endocrinology\n",
      "Rank 8: adapalene with relative risk of -12.508 of liraglutide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.114\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target lisdexamfetamine not found. Exiting ...\n",
      "\n",
      "Drug target lodoxamide not found. Exiting ...\n",
      "\n",
      "Drug target lomefloxacin not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó loperamide *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: verapamil with relative risk of -12.918 of loperamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: verapamil with relative risk of -12.918 of loperamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: pamidronate with relative risk of -14.073 of loperamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: pamidronate with relative risk of -14.073 of loperamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: vismodegib with relative risk of -14.715 of loperamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: vismodegib with relative risk of -14.715 of loperamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: bromocriptine with relative risk of -17.209 of loperamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: bromocriptine with relative risk of -17.209 of loperamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: pravastatin with relative risk of -17.936 of loperamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: pravastatin with relative risk of -17.936 of loperamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: olopatadine with relative risk of -23.635 of loperamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: olopatadine with relative risk of -23.635 of loperamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: olopatadine with relative risk of -23.635 of loperamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: nedocromil with relative risk of -31.051 of loperamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: nedocromil with relative risk of -31.051 of loperamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: nedocromil with relative risk of -31.051 of loperamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: nedocromil with relative risk of -31.051 of loperamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: nedocromil with relative risk of -31.051 of loperamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: trazodone with relative risk of -34.930 of loperamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: trazodone with relative risk of -34.930 of loperamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: trazodone with relative risk of -34.930 of loperamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: trazodone with relative risk of -34.930 of loperamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: trazodone with relative risk of -34.930 of loperamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: trazodone with relative risk of -34.930 of loperamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: riluzole with relative risk of -44.337 of loperamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: riluzole with relative risk of -44.337 of loperamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: riluzole with relative risk of -44.337 of loperamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: riluzole with relative risk of -44.337 of loperamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: riluzole with relative risk of -44.337 of loperamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: riluzole with relative risk of -44.337 of loperamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: betaxolol with relative risk of -48.148 of loperamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: betaxolol with relative risk of -48.148 of loperamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: betaxolol with relative risk of -48.148 of loperamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: betaxolol with relative risk of -48.148 of loperamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: betaxolol with relative risk of -48.148 of loperamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: betaxolol with relative risk of -48.148 of loperamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: betaxolol with relative risk of -48.148 of loperamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: quinaprilat with relative risk of -59.870 of loperamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: quinaprilat with relative risk of -59.870 of loperamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: quinaprilat with relative risk of -59.870 of loperamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: quinaprilat with relative risk of -59.870 of loperamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: quinaprilat with relative risk of -59.870 of loperamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: quinaprilat with relative risk of -59.870 of loperamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: quinaprilat with relative risk of -59.870 of loperamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: quinaprilat with relative risk of -59.870 of loperamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: topiramate with relative risk of -75.549 of loperamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: topiramate with relative risk of -75.549 of loperamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: topiramate with relative risk of -75.549 of loperamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: topiramate with relative risk of -75.549 of loperamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: topiramate with relative risk of -75.549 of loperamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: topiramate with relative risk of -75.549 of loperamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: topiramate with relative risk of -75.549 of loperamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 53: topiramate with relative risk of -75.549 of loperamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 54: topiramate with relative risk of -75.549 of loperamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 55: topiramate with relative risk of -75.549 of loperamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 56: efinaconazole with relative risk of -inf of loperamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 57: efinaconazole with relative risk of -inf of loperamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 58: efinaconazole with relative risk of -inf of loperamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 59: efinaconazole with relative risk of -inf of loperamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 60: efinaconazole with relative risk of -inf of loperamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 61: efinaconazole with relative risk of -inf of loperamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 62: efinaconazole with relative risk of -inf of loperamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 63: efinaconazole with relative risk of -inf of loperamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó loratadine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: irbesartan with relative risk of -8.126 of loratadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: azelastine with relative risk of -8.472 of loratadine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic rhinitis (disorder),Allergic Conjunctivitis,Rhinitis, Vasomotor,Hay fever\n",
      "Rank 3: terbutaline with relative risk of -9.174 of loratadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: ribavirin with relative risk of -9.365 of loratadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: ketorolac with relative risk of -9.650 of loratadine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic Conjunctivitis,neurology/psychiatry\n",
      "Rank 6: bumetanide with relative risk of -9.890 of loratadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: nabumetone with relative risk of -10.082 of loratadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: nevirapine with relative risk of -10.241 of loratadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: lapatinib with relative risk of -10.309 of loratadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: dronedarone with relative risk of -10.361 of loratadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: afatinib with relative risk of -10.364 of loratadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: estramustine with relative risk of -10.372 of loratadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: losartan with relative risk of -10.708 of loratadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: celecoxib with relative risk of -10.751 of loratadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: perindopril with relative risk of -10.830 of loratadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: linezolid with relative risk of -11.023 of loratadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: beclomethasone with relative risk of -11.029 of loratadine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: allergy\n",
      "Rank 18: fluconazole with relative risk of -11.119 of loratadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: bisoprolol with relative risk of -11.370 of loratadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: budesonide with relative risk of -11.396 of loratadine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic rhinitis (disorder)\n",
      "Rank 21: temsirolimus with relative risk of -11.427 of loratadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: amisulpride with relative risk of -11.466 of loratadine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 23: latanoprost with relative risk of -11.563 of loratadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: pergolide with relative risk of -11.908 of loratadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: lidocaine with relative risk of -12.111 of loratadine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 26: paroxetine with relative risk of -13.962 of loratadine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 27: paroxetine with relative risk of -13.962 of loratadine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 28: ibandronate with relative risk of -14.951 of loratadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: ibandronate with relative risk of -14.951 of loratadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: pentoxifylline with relative risk of -15.416 of loratadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: pentoxifylline with relative risk of -15.416 of loratadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: miglustat with relative risk of -15.995 of loratadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: miglustat with relative risk of -15.995 of loratadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: argatroban with relative risk of -18.448 of loratadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: argatroban with relative risk of -18.448 of loratadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: domperidone with relative risk of -20.594 of loratadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: domperidone with relative risk of -20.594 of loratadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: felodipine with relative risk of -inf of loratadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: desoximetasone with relative risk of -inf of loratadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.228\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target lorazepam not found. Exiting ...\n",
      "\n",
      "Drug target lorcaserin not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó losartan *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: azelastine with relative risk of -9.384 of losartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: pentoxifylline with relative risk of -9.859 of losartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 3: loratadine with relative risk of -10.862 of losartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: afatinib with relative risk of -11.280 of losartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: quinidine with relative risk of -11.571 of losartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 6: beclomethasone with relative risk of -11.945 of losartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: budesonide with relative risk of -12.312 of losartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: pergolide with relative risk of -12.824 of losartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: aclidinium with relative risk of -12.870 of losartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: caffeine with relative risk of -13.366 of losartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: bromfenac with relative risk of -14.997 of losartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: irbesartan with relative risk of -15.911 of losartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,Diabetic Nephropathy,cardiology,nephrology\n",
      "Rank 13: irbesartan with relative risk of -15.911 of losartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,Diabetic Nephropathy,cardiology,nephrology\n",
      "Rank 14: bumetanide with relative risk of -20.168 of losartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 15: bumetanide with relative risk of -20.168 of losartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 16: argatroban with relative risk of -20.750 of losartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: argatroban with relative risk of -20.750 of losartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: nevirapine with relative risk of -20.807 of losartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: nevirapine with relative risk of -20.807 of losartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: ribavirin with relative risk of -21.029 of losartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: ribavirin with relative risk of -21.029 of losartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: celecoxib with relative risk of -21.722 of losartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: celecoxib with relative risk of -21.722 of losartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: perindopril with relative risk of -21.801 of losartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 25: perindopril with relative risk of -21.801 of losartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 26: lapatinib with relative risk of -21.973 of losartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: lapatinib with relative risk of -21.973 of losartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: amisulpride with relative risk of -22.437 of losartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: amisulpride with relative risk of -22.437 of losartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: latanoprost with relative risk of -22.533 of losartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: latanoprost with relative risk of -22.533 of losartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: domperidone with relative risk of -22.897 of losartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: domperidone with relative risk of -22.897 of losartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: temsirolimus with relative risk of -23.091 of losartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: temsirolimus with relative risk of -23.091 of losartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: lidocaine with relative risk of -23.775 of losartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: lidocaine with relative risk of -23.775 of losartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: felodipine with relative risk of -inf of losartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 39: felodipine with relative risk of -inf of losartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.266\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó loteprednol *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: vandetanib with relative risk of -11.340 of loteprednol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: labetalol with relative risk of -12.973 of loteprednol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: ziprasidone with relative risk of -13.260 of loteprednol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó lovastatin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: indacaterol with relative risk of -10.355 of lovastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: exenatide with relative risk of -11.913 of lovastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 3: cabergoline with relative risk of -12.137 of lovastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 4: tafluprost with relative risk of -21.778 of lovastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: tafluprost with relative risk of -21.778 of lovastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: trazodone with relative risk of -23.855 of lovastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: trazodone with relative risk of -23.855 of lovastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: trazodone with relative risk of -23.855 of lovastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.307\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó loxapine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: degarelix with relative risk of -10.373 of loxapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: umeclidinium with relative risk of -10.948 of loxapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: metronidazole with relative risk of -35.880 of loxapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: metronidazole with relative risk of -35.880 of loxapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: metronidazole with relative risk of -35.880 of loxapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: metronidazole with relative risk of -35.880 of loxapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó lubiprostone *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: bosutinib with relative risk of -10.097 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: dofetilide with relative risk of -10.229 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: clarithromycin with relative risk of -10.286 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: olmesartan with relative risk of -12.725 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: estramustine with relative risk of -26.386 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: estramustine with relative risk of -26.386 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: estramustine with relative risk of -26.386 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: auranofin with relative risk of -27.814 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: auranofin with relative risk of -27.814 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: auranofin with relative risk of -27.814 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: dantrolene with relative risk of -28.606 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: dantrolene with relative risk of -28.606 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: dantrolene with relative risk of -28.606 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: risedronate with relative risk of -28.895 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: risedronate with relative risk of -28.895 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: risedronate with relative risk of -28.895 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: donepezil with relative risk of -29.287 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: donepezil with relative risk of -29.287 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: donepezil with relative risk of -29.287 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: sertraline with relative risk of -34.222 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: sertraline with relative risk of -34.222 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: sertraline with relative risk of -34.222 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: sertraline with relative risk of -34.222 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: sertraline with relative risk of -34.222 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: irbesartan with relative risk of -34.590 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: irbesartan with relative risk of -34.590 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: irbesartan with relative risk of -34.590 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: irbesartan with relative risk of -34.590 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: irbesartan with relative risk of -34.590 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: mometasone with relative risk of -36.065 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: mometasone with relative risk of -36.065 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: mometasone with relative risk of -36.065 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: mometasone with relative risk of -36.065 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: mometasone with relative risk of -36.065 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: regadenoson with relative risk of -36.243 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: regadenoson with relative risk of -36.243 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: regadenoson with relative risk of -36.243 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: regadenoson with relative risk of -36.243 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: regadenoson with relative risk of -36.243 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: azelastine with relative risk of -36.761 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: azelastine with relative risk of -36.761 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: azelastine with relative risk of -36.761 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: azelastine with relative risk of -36.761 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: azelastine with relative risk of -36.761 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: posaconazole with relative risk of -37.450 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: posaconazole with relative risk of -37.450 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: posaconazole with relative risk of -37.450 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: posaconazole with relative risk of -37.450 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: posaconazole with relative risk of -37.450 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: ibutilide with relative risk of -38.383 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: ibutilide with relative risk of -38.383 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: ibutilide with relative risk of -38.383 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 53: ibutilide with relative risk of -38.383 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 54: ibutilide with relative risk of -38.383 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 55: telmisartan with relative risk of -45.160 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 56: telmisartan with relative risk of -45.160 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 57: telmisartan with relative risk of -45.160 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 58: telmisartan with relative risk of -45.160 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 59: telmisartan with relative risk of -45.160 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 60: milnacipran with relative risk of -46.827 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 61: milnacipran with relative risk of -46.827 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 62: milnacipran with relative risk of -46.827 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 63: milnacipran with relative risk of -46.827 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 64: milnacipran with relative risk of -46.827 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 65: tolmetin with relative risk of -47.694 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 66: tolmetin with relative risk of -47.694 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 67: tolmetin with relative risk of -47.694 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 68: tolmetin with relative risk of -47.694 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 69: tolmetin with relative risk of -47.694 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 70: progesterone with relative risk of -48.032 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 71: progesterone with relative risk of -48.032 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 72: progesterone with relative risk of -48.032 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 73: progesterone with relative risk of -48.032 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 74: progesterone with relative risk of -48.032 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 75: abiraterone with relative risk of -48.541 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 76: abiraterone with relative risk of -48.541 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 77: abiraterone with relative risk of -48.541 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 78: abiraterone with relative risk of -48.541 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 79: abiraterone with relative risk of -48.541 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 80: dapagliflozin with relative risk of -49.578 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 81: dapagliflozin with relative risk of -49.578 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 82: dapagliflozin with relative risk of -49.578 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 83: dapagliflozin with relative risk of -49.578 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 84: dapagliflozin with relative risk of -49.578 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 85: misoprostol with relative risk of -49.925 of lubiprostone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "Rank 86: misoprostol with relative risk of -49.925 of lubiprostone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "Rank 87: misoprostol with relative risk of -49.925 of lubiprostone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "Rank 88: misoprostol with relative risk of -49.925 of lubiprostone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "Rank 89: misoprostol with relative risk of -49.925 of lubiprostone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "Rank 90: cisatracurium with relative risk of -51.678 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 91: cisatracurium with relative risk of -51.678 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 92: cisatracurium with relative risk of -51.678 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 93: cisatracurium with relative risk of -51.678 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 94: cisatracurium with relative risk of -51.678 of lubiprostone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.011\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó lurasidone *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: ibandronate with relative risk of -8.119 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: metoprolol with relative risk of -8.123 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: levonorgestrel with relative risk of -8.199 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: darifenacin with relative risk of -8.260 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: milrinone with relative risk of -8.546 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: ivacaftor with relative risk of -8.723 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: ticagrelor with relative risk of -8.891 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: brimonidine with relative risk of -9.024 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: risperidone with relative risk of -9.097 of lurasidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 10: indomethacin with relative risk of -9.177 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: erlotinib with relative risk of -9.204 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: delavirdine with relative risk of -9.211 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: atropine with relative risk of -9.451 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: tazarotene with relative risk of -9.597 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: nevirapine with relative risk of -9.772 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: dapsone with relative risk of -9.858 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: tamsulosin with relative risk of -9.871 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: brinzolamide with relative risk of -10.133 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: leflunomide with relative risk of -10.154 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: doxorubicin with relative risk of -10.163 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: bezafibrate with relative risk of -10.178 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: vernakalant with relative risk of -10.202 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: fondaparinux with relative risk of -10.462 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: acebutolol with relative risk of -10.478 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: rotigotine with relative risk of -10.571 of lurasidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 26: sumatriptan with relative risk of -10.582 of lurasidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 27: isradipine with relative risk of -10.603 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: citalopram with relative risk of -10.605 of lurasidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 29: valsartan with relative risk of -10.621 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: doxepin with relative risk of -10.778 of lurasidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Depression, Bipolar,neurology/psychiatry\n",
      "Rank 31: flecainide with relative risk of -10.877 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: benazepril with relative risk of -11.099 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: vilazodone with relative risk of -11.564 of lurasidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 34: pindolol with relative risk of -11.720 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: pentoxifylline with relative risk of -14.388 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: pentoxifylline with relative risk of -14.388 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: pemetrexed with relative risk of -15.403 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: pemetrexed with relative risk of -15.403 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: terbutaline with relative risk of -15.427 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: terbutaline with relative risk of -15.427 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: esmolol with relative risk of -15.830 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: esmolol with relative risk of -15.830 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: telmisartan with relative risk of -16.452 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: telmisartan with relative risk of -16.452 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: trovafloxacin with relative risk of -16.463 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: trovafloxacin with relative risk of -16.463 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: everolimus with relative risk of -16.546 of lurasidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 48: everolimus with relative risk of -16.546 of lurasidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 49: azilsartan with relative risk of -17.290 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: azilsartan with relative risk of -17.290 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: clonidine with relative risk of -17.961 of lurasidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 52: clonidine with relative risk of -17.961 of lurasidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 53: varenicline with relative risk of -18.005 of lurasidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 54: varenicline with relative risk of -18.005 of lurasidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 55: ketorolac with relative risk of -22.644 of lurasidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 56: ketorolac with relative risk of -22.644 of lurasidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 57: ketorolac with relative risk of -22.644 of lurasidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 58: ruxolitinib with relative risk of -23.601 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 59: ruxolitinib with relative risk of -23.601 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 60: ruxolitinib with relative risk of -23.601 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 61: didanosine with relative risk of -23.761 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 62: didanosine with relative risk of -23.761 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 63: didanosine with relative risk of -23.761 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 64: gabapentin with relative risk of -24.635 of lurasidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 65: gabapentin with relative risk of -24.635 of lurasidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 66: gabapentin with relative risk of -24.635 of lurasidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 67: dutasteride with relative risk of -24.770 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 68: dutasteride with relative risk of -24.770 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 69: dutasteride with relative risk of -24.770 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 70: clarithromycin with relative risk of -24.984 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 71: clarithromycin with relative risk of -24.984 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 72: clarithromycin with relative risk of -24.984 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 73: bumetanide with relative risk of -25.099 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 74: bumetanide with relative risk of -25.099 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 75: bumetanide with relative risk of -25.099 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 76: zolmitriptan with relative risk of -25.904 of lurasidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 77: zolmitriptan with relative risk of -25.904 of lurasidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 78: zolmitriptan with relative risk of -25.904 of lurasidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 79: cetirizine with relative risk of -26.162 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 80: cetirizine with relative risk of -26.162 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 81: cetirizine with relative risk of -26.162 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 82: lansoprazole with relative risk of -30.445 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 83: lansoprazole with relative risk of -30.445 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 84: lansoprazole with relative risk of -30.445 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 85: lansoprazole with relative risk of -30.445 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 86: naproxen with relative risk of -31.521 of lurasidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 87: naproxen with relative risk of -31.521 of lurasidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 88: naproxen with relative risk of -31.521 of lurasidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 89: naproxen with relative risk of -31.521 of lurasidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 90: etoposide with relative risk of -35.080 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 91: etoposide with relative risk of -35.080 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 92: etoposide with relative risk of -35.080 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 93: etoposide with relative risk of -35.080 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 94: etoposide with relative risk of -35.080 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 95: fenofibrate with relative risk of -37.624 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 96: fenofibrate with relative risk of -37.624 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 97: fenofibrate with relative risk of -37.624 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 98: fenofibrate with relative risk of -37.624 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 99: fenofibrate with relative risk of -37.624 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 100: posaconazole with relative risk of -41.178 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 101: posaconazole with relative risk of -41.178 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 102: posaconazole with relative risk of -41.178 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 103: posaconazole with relative risk of -41.178 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 104: posaconazole with relative risk of -41.178 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 105: posaconazole with relative risk of -41.178 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 106: ibutilide with relative risk of -41.972 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 107: ibutilide with relative risk of -41.972 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 108: ibutilide with relative risk of -41.972 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 109: ibutilide with relative risk of -41.972 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 110: ibutilide with relative risk of -41.972 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 111: ibutilide with relative risk of -41.972 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 112: tropisetron with relative risk of -43.273 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 113: tropisetron with relative risk of -43.273 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 114: tropisetron with relative risk of -43.273 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 115: tropisetron with relative risk of -43.273 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 116: tropisetron with relative risk of -43.273 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 117: tropisetron with relative risk of -43.273 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 118: paliperidone with relative risk of -43.554 of lurasidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 119: paliperidone with relative risk of -43.554 of lurasidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 120: paliperidone with relative risk of -43.554 of lurasidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 121: paliperidone with relative risk of -43.554 of lurasidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 122: paliperidone with relative risk of -43.554 of lurasidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 123: paliperidone with relative risk of -43.554 of lurasidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 124: glimepiride with relative risk of -44.033 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 125: glimepiride with relative risk of -44.033 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 126: glimepiride with relative risk of -44.033 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 127: glimepiride with relative risk of -44.033 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 128: glimepiride with relative risk of -44.033 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 129: glimepiride with relative risk of -44.033 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 130: irbesartan with relative risk of -45.076 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 131: irbesartan with relative risk of -45.076 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 132: irbesartan with relative risk of -45.076 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 133: irbesartan with relative risk of -45.076 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 134: irbesartan with relative risk of -45.076 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 135: irbesartan with relative risk of -45.076 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 136: irbesartan with relative risk of -45.076 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 137: ropivacaine with relative risk of -47.486 of lurasidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 138: ropivacaine with relative risk of -47.486 of lurasidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 139: ropivacaine with relative risk of -47.486 of lurasidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 140: ropivacaine with relative risk of -47.486 of lurasidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 141: ropivacaine with relative risk of -47.486 of lurasidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 142: ropivacaine with relative risk of -47.486 of lurasidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 143: mometasone with relative risk of -47.619 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 144: mometasone with relative risk of -47.619 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 145: mometasone with relative risk of -47.619 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 146: mometasone with relative risk of -47.619 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 147: mometasone with relative risk of -47.619 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 148: mometasone with relative risk of -47.619 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 149: mometasone with relative risk of -47.619 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 150: regadenoson with relative risk of -48.233 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 151: regadenoson with relative risk of -48.233 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 152: regadenoson with relative risk of -48.233 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 153: regadenoson with relative risk of -48.233 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 154: regadenoson with relative risk of -48.233 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 155: regadenoson with relative risk of -48.233 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 156: regadenoson with relative risk of -48.233 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 157: azelastine with relative risk of -48.238 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 158: azelastine with relative risk of -48.238 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 159: azelastine with relative risk of -48.238 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 160: azelastine with relative risk of -48.238 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 161: azelastine with relative risk of -48.238 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 162: azelastine with relative risk of -48.238 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 163: azelastine with relative risk of -48.238 of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 164: sertraline with relative risk of -53.396 of lurasidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 165: sertraline with relative risk of -53.396 of lurasidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 166: sertraline with relative risk of -53.396 of lurasidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 167: sertraline with relative risk of -53.396 of lurasidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 168: sertraline with relative risk of -53.396 of lurasidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 169: sertraline with relative risk of -53.396 of lurasidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 170: sertraline with relative risk of -53.396 of lurasidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 171: sertraline with relative risk of -53.396 of lurasidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 172: felodipine with relative risk of -inf of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 173: felodipine with relative risk of -inf of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 174: felodipine with relative risk of -inf of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 175: felodipine with relative risk of -inf of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 176: felodipine with relative risk of -inf of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 177: felodipine with relative risk of -inf of lurasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.127\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó macitentan *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: clofarabine with relative risk of -9.449 of macitentan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: paroxetine with relative risk of -9.702 of macitentan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: crizotinib with relative risk of -10.375 of macitentan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: nabumetone with relative risk of -11.689 of macitentan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: travoprost with relative risk of -12.361 of macitentan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó mafenide *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: ibandronate with relative risk of -9.095 of mafenide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: cytarabine with relative risk of -9.640 of mafenide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: formoterol with relative risk of -9.918 of mafenide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: frovatriptan with relative risk of -10.080 of mafenide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: nimodipine with relative risk of -10.406 of mafenide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: cilostazol with relative risk of -10.858 of mafenide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: allopurinol with relative risk of -10.926 of mafenide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: avanafil with relative risk of -11.132 of mafenide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: hydrochlorothiazide with relative risk of -12.409 of mafenide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: tasimelteon with relative risk of -20.071 of mafenide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: tasimelteon with relative risk of -20.071 of mafenide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: atomoxetine with relative risk of -30.038 of mafenide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: atomoxetine with relative risk of -30.038 of mafenide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: atomoxetine with relative risk of -30.038 of mafenide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: candesartan with relative risk of -30.889 of mafenide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: candesartan with relative risk of -30.889 of mafenide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: candesartan with relative risk of -30.889 of mafenide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target malvidin not found. Exiting ...\n",
      "\n",
      "Drug target mannitol not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó maprotiline *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: idarubicin with relative risk of -9.983 of maprotiline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: bicalutamide with relative risk of -11.315 of maprotiline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: letrozole with relative risk of -12.803 of maprotiline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: gemfibrozil with relative risk of -12.858 of maprotiline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: fosinopril with relative risk of -13.119 of maprotiline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: apremilast with relative risk of -13.757 of maprotiline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target maraviroc not found. Exiting ...\n",
      "\n",
      "Drug target meclofenamate not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó medroxyprogesterone *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: cilostazol with relative risk of -11.956 of medroxyprogesterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: empagliflozin with relative risk of -12.043 of medroxyprogesterone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 3: pilocarpine with relative risk of -12.698 of medroxyprogesterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: raloxifene with relative risk of -12.755 of medroxyprogesterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: pantoprazole with relative risk of -12.828 of medroxyprogesterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: bupivacaine with relative risk of -13.325 of medroxyprogesterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: omeprazole with relative risk of -13.465 of medroxyprogesterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.193\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target mefloquine not found. Exiting ...\n",
      "\n",
      "Drug target megestrol not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó meloxicam *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: ibandronate with relative risk of -7.496 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: miglustat with relative risk of -7.618 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: formoterol with relative risk of -8.313 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: frovatriptan with relative risk of -8.475 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: dabigatran with relative risk of -9.221 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: dronedarone with relative risk of -9.264 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: estramustine with relative risk of -9.276 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: zonisamide with relative risk of -9.480 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: etravirine with relative risk of -9.759 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: linezolid with relative risk of -9.925 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: tiotropium with relative risk of -10.146 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: nelfinavir with relative risk of -10.843 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: febuxostat with relative risk of -12.191 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: pentoxifylline with relative risk of -13.072 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: pentoxifylline with relative risk of -13.072 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: eplerenone with relative risk of -15.954 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: eplerenone with relative risk of -15.954 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: exemestane with relative risk of -17.266 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: exemestane with relative risk of -17.266 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: indacaterol with relative risk of -23.652 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: indacaterol with relative risk of -23.652 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: indacaterol with relative risk of -23.652 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: ciclesonide with relative risk of -60.520 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: ciclesonide with relative risk of -60.520 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: ciclesonide with relative risk of -60.520 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: ciclesonide with relative risk of -60.520 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: ciclesonide with relative risk of -60.520 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: ciclesonide with relative risk of -60.520 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: ciclesonide with relative risk of -60.520 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: ciclesonide with relative risk of -60.520 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: ciclesonide with relative risk of -60.520 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: ciclesonide with relative risk of -60.520 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: darifenacin with relative risk of -74.627 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: darifenacin with relative risk of -74.627 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: darifenacin with relative risk of -74.627 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: darifenacin with relative risk of -74.627 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: darifenacin with relative risk of -74.627 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: darifenacin with relative risk of -74.627 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: darifenacin with relative risk of -74.627 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: darifenacin with relative risk of -74.627 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: darifenacin with relative risk of -74.627 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: darifenacin with relative risk of -74.627 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: axitinib with relative risk of -77.439 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: axitinib with relative risk of -77.439 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: axitinib with relative risk of -77.439 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: axitinib with relative risk of -77.439 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: axitinib with relative risk of -77.439 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: axitinib with relative risk of -77.439 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: axitinib with relative risk of -77.439 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: axitinib with relative risk of -77.439 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: axitinib with relative risk of -77.439 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: axitinib with relative risk of -77.439 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 53: vinorelbine with relative risk of -79.193 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 54: vinorelbine with relative risk of -79.193 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 55: vinorelbine with relative risk of -79.193 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 56: vinorelbine with relative risk of -79.193 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 57: vinorelbine with relative risk of -79.193 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 58: vinorelbine with relative risk of -79.193 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 59: vinorelbine with relative risk of -79.193 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 60: vinorelbine with relative risk of -79.193 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 61: vinorelbine with relative risk of -79.193 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 62: vinorelbine with relative risk of -79.193 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 63: granisetron with relative risk of -80.080 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 64: granisetron with relative risk of -80.080 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 65: granisetron with relative risk of -80.080 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 66: granisetron with relative risk of -80.080 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 67: granisetron with relative risk of -80.080 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 68: granisetron with relative risk of -80.080 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 69: granisetron with relative risk of -80.080 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 70: granisetron with relative risk of -80.080 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 71: granisetron with relative risk of -80.080 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 72: granisetron with relative risk of -80.080 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 73: apraclonidine with relative risk of -80.237 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 74: apraclonidine with relative risk of -80.237 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 75: apraclonidine with relative risk of -80.237 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 76: apraclonidine with relative risk of -80.237 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 77: apraclonidine with relative risk of -80.237 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 78: apraclonidine with relative risk of -80.237 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 79: apraclonidine with relative risk of -80.237 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 80: apraclonidine with relative risk of -80.237 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 81: apraclonidine with relative risk of -80.237 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 82: apraclonidine with relative risk of -80.237 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 83: pinaverium with relative risk of -83.217 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 84: pinaverium with relative risk of -83.217 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 85: pinaverium with relative risk of -83.217 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 86: pinaverium with relative risk of -83.217 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 87: pinaverium with relative risk of -83.217 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 88: pinaverium with relative risk of -83.217 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 89: pinaverium with relative risk of -83.217 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 90: pinaverium with relative risk of -83.217 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 91: pinaverium with relative risk of -83.217 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 92: pinaverium with relative risk of -83.217 of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 93: desoximetasone with relative risk of -inf of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 94: desoximetasone with relative risk of -inf of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 95: desoximetasone with relative risk of -inf of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 96: desoximetasone with relative risk of -inf of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 97: desoximetasone with relative risk of -inf of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 98: desoximetasone with relative risk of -inf of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 99: desoximetasone with relative risk of -inf of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 100: desoximetasone with relative risk of -inf of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 101: desoximetasone with relative risk of -inf of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 102: desoximetasone with relative risk of -inf of meloxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target melphalan not found. Exiting ...\n",
      "\n",
      "Drug target memantine not found. Exiting ...\n",
      "\n",
      "Drug target meropenem not found. Exiting ...\n",
      "\n",
      "Drug target mesna not found. Exiting ...\n",
      "\n",
      "Drug target metaiodobenzylguanidine not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó metaproterenol *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: pramipexole with relative risk of -11.929 of metaproterenol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: docetaxel with relative risk of -12.046 of metaproterenol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: etodolac with relative risk of -12.358 of metaproterenol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: duloxetine with relative risk of -12.992 of metaproterenol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: bupropion with relative risk of -13.123 of metaproterenol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: repaglinide with relative risk of -13.133 of metaproterenol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: dalbavancin with relative risk of -13.460 of metaproterenol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: trospium with relative risk of -13.502 of metaproterenol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: amlodipine with relative risk of -13.806 of metaproterenol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target metformin not found. Exiting ...\n",
      "\n",
      "Drug target methyl not found. Exiting ...\n",
      "\n",
      "Drug target methylphenidate not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó metolazone *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: clozapine with relative risk of -8.678 of metolazone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: topotecan with relative risk of -26.562 of metolazone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: topotecan with relative risk of -26.562 of metolazone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: topotecan with relative risk of -26.562 of metolazone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: nalbuphine with relative risk of -30.111 of metolazone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: nalbuphine with relative risk of -30.111 of metolazone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: nalbuphine with relative risk of -30.111 of metolazone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: darunavir with relative risk of -30.213 of metolazone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: darunavir with relative risk of -30.213 of metolazone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: darunavir with relative risk of -30.213 of metolazone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó metoprolol *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: ropivacaine with relative risk of -8.559 of metoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: levonorgestrel with relative risk of -8.668 of metoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: ruxolitinib with relative risk of -8.903 of metoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: lurasidone with relative risk of -8.950 of metoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: didanosine with relative risk of -9.063 of metoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: lansoprazole with relative risk of -9.499 of metoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: ketorolac with relative risk of -9.650 of metoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: bumetanide with relative risk of -9.890 of metoprolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 9: sumatriptan with relative risk of -11.052 of metoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: sertraline with relative risk of -12.973 of metoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: sertraline with relative risk of -12.973 of metoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: nevirapine with relative risk of -18.504 of metoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: nevirapine with relative risk of -18.504 of metoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: capecitabine with relative risk of -19.204 of metoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: capecitabine with relative risk of -19.204 of metoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: etoposide with relative risk of -21.394 of metoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: etoposide with relative risk of -21.394 of metoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: etoposide with relative risk of -21.394 of metoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: paliperidone with relative risk of -22.539 of metoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: paliperidone with relative risk of -22.539 of metoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: paliperidone with relative risk of -22.539 of metoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: glimepiride with relative risk of -22.587 of metoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: glimepiride with relative risk of -22.587 of metoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: glimepiride with relative risk of -22.587 of metoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: fenofibrate with relative risk of -23.937 of metoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: fenofibrate with relative risk of -23.937 of metoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: fenofibrate with relative risk of -23.937 of metoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: regadenoson with relative risk of -27.670 of metoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: regadenoson with relative risk of -27.670 of metoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: regadenoson with relative risk of -27.670 of metoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: regadenoson with relative risk of -27.670 of metoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: azelastine with relative risk of -28.430 of metoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: azelastine with relative risk of -28.430 of metoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: azelastine with relative risk of -28.430 of metoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: azelastine with relative risk of -28.430 of metoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: posaconazole with relative risk of -28.831 of metoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: posaconazole with relative risk of -28.831 of metoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: posaconazole with relative risk of -28.831 of metoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: posaconazole with relative risk of -28.831 of metoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: fondaparinux with relative risk of -29.655 of metoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: fondaparinux with relative risk of -29.655 of metoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: fondaparinux with relative risk of -29.655 of metoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: irbesartan with relative risk of -34.590 of metoprolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 44: irbesartan with relative risk of -34.590 of metoprolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 45: irbesartan with relative risk of -34.590 of metoprolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 46: irbesartan with relative risk of -34.590 of metoprolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 47: irbesartan with relative risk of -34.590 of metoprolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 48: trovafloxacin with relative risk of -34.892 of metoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: trovafloxacin with relative risk of -34.892 of metoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: trovafloxacin with relative risk of -34.892 of metoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: trovafloxacin with relative risk of -34.892 of metoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: dutasteride with relative risk of -35.854 of metoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 53: dutasteride with relative risk of -35.854 of metoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 54: dutasteride with relative risk of -35.854 of metoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 55: dutasteride with relative risk of -35.854 of metoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 56: mometasone with relative risk of -36.065 of metoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 57: mometasone with relative risk of -36.065 of metoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 58: mometasone with relative risk of -36.065 of metoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 59: mometasone with relative risk of -36.065 of metoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 60: mometasone with relative risk of -36.065 of metoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 61: ibutilide with relative risk of -38.383 of metoprolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 62: ibutilide with relative risk of -38.383 of metoprolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 63: ibutilide with relative risk of -38.383 of metoprolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 64: ibutilide with relative risk of -38.383 of metoprolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 65: ibutilide with relative risk of -38.383 of metoprolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 66: tropisetron with relative risk of -39.258 of metoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 67: tropisetron with relative risk of -39.258 of metoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 68: tropisetron with relative risk of -39.258 of metoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 69: tropisetron with relative risk of -39.258 of metoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 70: tropisetron with relative risk of -39.258 of metoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 71: indomethacin with relative risk of -44.740 of metoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 72: indomethacin with relative risk of -44.740 of metoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 73: indomethacin with relative risk of -44.740 of metoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 74: indomethacin with relative risk of -44.740 of metoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 75: indomethacin with relative risk of -44.740 of metoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 76: pemetrexed with relative risk of -44.804 of metoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 77: pemetrexed with relative risk of -44.804 of metoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 78: pemetrexed with relative risk of -44.804 of metoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 79: pemetrexed with relative risk of -44.804 of metoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 80: pemetrexed with relative risk of -44.804 of metoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 81: milrinone with relative risk of -47.665 of metoprolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 82: milrinone with relative risk of -47.665 of metoprolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 83: milrinone with relative risk of -47.665 of metoprolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 84: milrinone with relative risk of -47.665 of metoprolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 85: milrinone with relative risk of -47.665 of metoprolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 86: tamsulosin with relative risk of -48.991 of metoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 87: tamsulosin with relative risk of -48.991 of metoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 88: tamsulosin with relative risk of -48.991 of metoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 89: tamsulosin with relative risk of -48.991 of metoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 90: tamsulosin with relative risk of -48.991 of metoprolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 91: felodipine with relative risk of -inf of metoprolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 92: felodipine with relative risk of -inf of metoprolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 93: felodipine with relative risk of -inf of metoprolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.08\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó metronidazole *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: degarelix with relative risk of -9.680 of metronidazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: sparfloxacin with relative risk of -9.982 of metronidazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: indinavir with relative risk of -11.516 of metronidazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: rivaroxaban with relative risk of -11.741 of metronidazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: eprosartan with relative risk of -11.852 of metronidazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: umeclidinium with relative risk of -26.627 of metronidazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: umeclidinium with relative risk of -26.627 of metronidazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: umeclidinium with relative risk of -26.627 of metronidazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: loxapine with relative risk of -35.601 of metronidazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: loxapine with relative risk of -35.601 of metronidazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: loxapine with relative risk of -35.601 of metronidazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: loxapine with relative risk of -35.601 of metronidazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó mexiletine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: cabazitaxel with relative risk of -10.581 of mexiletine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: mitotane with relative risk of -10.981 of mexiletine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: danazol with relative risk of -11.727 of mexiletine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 4: canagliflozin with relative risk of -12.616 of mexiletine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: gonadorelin with relative risk of -12.633 of mexiletine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: phenytoin with relative risk of -12.906 of mexiletine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: montelukast with relative risk of -13.000 of mexiletine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: dipyridamole with relative risk of -13.267 of mexiletine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 9: ranitidine with relative risk of -13.446 of mexiletine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: zafirlukast with relative risk of -13.520 of mexiletine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: cilazapril with relative risk of -15.324 of mexiletine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.182\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target miconazole not found. Exiting ...\n",
      "\n",
      "Drug target midazolam not found. Exiting ...\n",
      "\n",
      "Drug target midodrine not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó mifepristone *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: cevimeline with relative risk of -12.481 of mifepristone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: colchicine with relative risk of -17.097 of mifepristone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 3: colchicine with relative risk of -17.097 of mifepristone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.455\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó miglustat *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: vinorelbine with relative risk of -7.315 of miglustat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: ciclesonide with relative risk of -7.818 of miglustat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: axitinib with relative risk of -7.864 of miglustat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: darifenacin with relative risk of -8.143 of miglustat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: crizotinib with relative risk of -8.180 of miglustat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: granisetron with relative risk of -8.203 of miglustat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: apraclonidine with relative risk of -8.360 of miglustat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: terbutaline with relative risk of -8.588 of miglustat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: meloxicam with relative risk of -9.039 of miglustat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: eplerenone with relative risk of -9.049 of miglustat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: ketorolac with relative risk of -9.065 of miglustat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: indacaterol with relative risk of -9.257 of miglustat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: nabumetone with relative risk of -9.497 of miglustat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: naltrexone with relative risk of -9.835 of miglustat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: etravirine with relative risk of -10.270 of miglustat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: fluconazole with relative risk of -10.531 of miglustat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: bisoprolol with relative risk of -10.782 of miglustat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: doxazosin with relative risk of -11.114 of miglustat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: domperidone with relative risk of -11.338 of miglustat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: pinaverium with relative risk of -11.339 of miglustat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: febuxostat with relative risk of -12.702 of miglustat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: pentoxifylline with relative risk of -14.138 of miglustat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: pentoxifylline with relative risk of -14.138 of miglustat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: loratadine with relative risk of -16.641 of miglustat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: loratadine with relative risk of -16.641 of miglustat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: estramustine with relative risk of -16.661 of miglustat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: estramustine with relative risk of -16.661 of miglustat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: argatroban with relative risk of -17.168 of miglustat | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: hematology\n",
      "Rank 29: argatroban with relative risk of -17.168 of miglustat | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: hematology\n",
      "Rank 30: dronedarone with relative risk of -17.344 of miglustat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: dronedarone with relative risk of -17.344 of miglustat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: ibandronate with relative risk of -26.694 of miglustat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: ibandronate with relative risk of -26.694 of miglustat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: ibandronate with relative risk of -26.694 of miglustat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: ibandronate with relative risk of -26.694 of miglustat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: linezolid with relative risk of -27.618 of miglustat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: linezolid with relative risk of -27.618 of miglustat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: linezolid with relative risk of -27.618 of miglustat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: desoximetasone with relative risk of -inf of miglustat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.017\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó milnacipran *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: bosutinib with relative risk of -9.915 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: dofetilide with relative risk of -10.047 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: clarithromycin with relative risk of -10.104 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: olmesartan with relative risk of -12.543 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: estramustine with relative risk of -25.693 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: estramustine with relative risk of -25.693 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: estramustine with relative risk of -25.693 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: auranofin with relative risk of -27.121 of milnacipran | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: rheumatology\n",
      "Rank 9: auranofin with relative risk of -27.121 of milnacipran | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: rheumatology\n",
      "Rank 10: auranofin with relative risk of -27.121 of milnacipran | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: rheumatology\n",
      "Rank 11: dantrolene with relative risk of -27.912 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: dantrolene with relative risk of -27.912 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: dantrolene with relative risk of -27.912 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: risedronate with relative risk of -28.202 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: risedronate with relative risk of -28.202 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: risedronate with relative risk of -28.202 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: donepezil with relative risk of -28.594 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: donepezil with relative risk of -28.594 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: donepezil with relative risk of -28.594 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: sertraline with relative risk of -32.432 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: sertraline with relative risk of -32.432 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: sertraline with relative risk of -32.432 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: sertraline with relative risk of -32.432 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: sertraline with relative risk of -32.432 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: irbesartan with relative risk of -32.800 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: irbesartan with relative risk of -32.800 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: irbesartan with relative risk of -32.800 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: irbesartan with relative risk of -32.800 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: irbesartan with relative risk of -32.800 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: mometasone with relative risk of -34.274 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: mometasone with relative risk of -34.274 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: mometasone with relative risk of -34.274 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: mometasone with relative risk of -34.274 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: mometasone with relative risk of -34.274 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: regadenoson with relative risk of -34.452 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: regadenoson with relative risk of -34.452 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: regadenoson with relative risk of -34.452 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: regadenoson with relative risk of -34.452 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: regadenoson with relative risk of -34.452 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: azelastine with relative risk of -34.970 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: azelastine with relative risk of -34.970 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: azelastine with relative risk of -34.970 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: azelastine with relative risk of -34.970 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: azelastine with relative risk of -34.970 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: posaconazole with relative risk of -35.659 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: posaconazole with relative risk of -35.659 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: posaconazole with relative risk of -35.659 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: posaconazole with relative risk of -35.659 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: posaconazole with relative risk of -35.659 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: ibutilide with relative risk of -36.592 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: ibutilide with relative risk of -36.592 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: ibutilide with relative risk of -36.592 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 53: ibutilide with relative risk of -36.592 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 54: ibutilide with relative risk of -36.592 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 55: telmisartan with relative risk of -43.368 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 56: telmisartan with relative risk of -43.368 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 57: telmisartan with relative risk of -43.368 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 58: telmisartan with relative risk of -43.368 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 59: telmisartan with relative risk of -43.368 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 60: tolmetin with relative risk of -45.902 of milnacipran | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: rheumatology\n",
      "Rank 61: tolmetin with relative risk of -45.902 of milnacipran | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: rheumatology\n",
      "Rank 62: tolmetin with relative risk of -45.902 of milnacipran | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: rheumatology\n",
      "Rank 63: tolmetin with relative risk of -45.902 of milnacipran | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: rheumatology\n",
      "Rank 64: tolmetin with relative risk of -45.902 of milnacipran | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: rheumatology\n",
      "Rank 65: progesterone with relative risk of -46.240 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 66: progesterone with relative risk of -46.240 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 67: progesterone with relative risk of -46.240 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 68: progesterone with relative risk of -46.240 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 69: progesterone with relative risk of -46.240 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 70: abiraterone with relative risk of -46.749 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 71: abiraterone with relative risk of -46.749 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 72: abiraterone with relative risk of -46.749 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 73: abiraterone with relative risk of -46.749 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 74: abiraterone with relative risk of -46.749 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 75: lubiprostone with relative risk of -47.136 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 76: lubiprostone with relative risk of -47.136 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 77: lubiprostone with relative risk of -47.136 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 78: lubiprostone with relative risk of -47.136 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 79: lubiprostone with relative risk of -47.136 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 80: dapagliflozin with relative risk of -47.786 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 81: dapagliflozin with relative risk of -47.786 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 82: dapagliflozin with relative risk of -47.786 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 83: dapagliflozin with relative risk of -47.786 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 84: dapagliflozin with relative risk of -47.786 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 85: misoprostol with relative risk of -48.133 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 86: misoprostol with relative risk of -48.133 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 87: misoprostol with relative risk of -48.133 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 88: misoprostol with relative risk of -48.133 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 89: misoprostol with relative risk of -48.133 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 90: cisatracurium with relative risk of -49.886 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 91: cisatracurium with relative risk of -49.886 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 92: cisatracurium with relative risk of -49.886 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 93: cisatracurium with relative risk of -49.886 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 94: cisatracurium with relative risk of -49.886 of milnacipran | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.081\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó milrinone *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: ropivacaine with relative risk of -8.559 of milrinone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: levonorgestrel with relative risk of -8.668 of milrinone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: ruxolitinib with relative risk of -8.903 of milrinone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: lurasidone with relative risk of -8.950 of milrinone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: didanosine with relative risk of -9.063 of milrinone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: lansoprazole with relative risk of -9.499 of milrinone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: ketorolac with relative risk of -9.650 of milrinone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: bumetanide with relative risk of -9.890 of milrinone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 9: sumatriptan with relative risk of -11.052 of milrinone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: sertraline with relative risk of -12.973 of milrinone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: sertraline with relative risk of -12.973 of milrinone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: nevirapine with relative risk of -18.504 of milrinone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: nevirapine with relative risk of -18.504 of milrinone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: capecitabine with relative risk of -19.204 of milrinone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: capecitabine with relative risk of -19.204 of milrinone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: etoposide with relative risk of -21.394 of milrinone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: etoposide with relative risk of -21.394 of milrinone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: etoposide with relative risk of -21.394 of milrinone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: paliperidone with relative risk of -22.539 of milrinone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: paliperidone with relative risk of -22.539 of milrinone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: paliperidone with relative risk of -22.539 of milrinone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: glimepiride with relative risk of -22.587 of milrinone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: glimepiride with relative risk of -22.587 of milrinone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: glimepiride with relative risk of -22.587 of milrinone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: fenofibrate with relative risk of -23.937 of milrinone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: fenofibrate with relative risk of -23.937 of milrinone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: fenofibrate with relative risk of -23.937 of milrinone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: regadenoson with relative risk of -27.670 of milrinone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: regadenoson with relative risk of -27.670 of milrinone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: regadenoson with relative risk of -27.670 of milrinone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: regadenoson with relative risk of -27.670 of milrinone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: azelastine with relative risk of -28.430 of milrinone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: azelastine with relative risk of -28.430 of milrinone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: azelastine with relative risk of -28.430 of milrinone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: azelastine with relative risk of -28.430 of milrinone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: posaconazole with relative risk of -28.831 of milrinone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: posaconazole with relative risk of -28.831 of milrinone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: posaconazole with relative risk of -28.831 of milrinone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: posaconazole with relative risk of -28.831 of milrinone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: fondaparinux with relative risk of -29.655 of milrinone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: fondaparinux with relative risk of -29.655 of milrinone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: fondaparinux with relative risk of -29.655 of milrinone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: irbesartan with relative risk of -34.590 of milrinone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 44: irbesartan with relative risk of -34.590 of milrinone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 45: irbesartan with relative risk of -34.590 of milrinone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 46: irbesartan with relative risk of -34.590 of milrinone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 47: irbesartan with relative risk of -34.590 of milrinone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 48: trovafloxacin with relative risk of -34.892 of milrinone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: trovafloxacin with relative risk of -34.892 of milrinone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: trovafloxacin with relative risk of -34.892 of milrinone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: trovafloxacin with relative risk of -34.892 of milrinone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: dutasteride with relative risk of -35.854 of milrinone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 53: dutasteride with relative risk of -35.854 of milrinone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 54: dutasteride with relative risk of -35.854 of milrinone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 55: dutasteride with relative risk of -35.854 of milrinone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 56: mometasone with relative risk of -36.065 of milrinone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 57: mometasone with relative risk of -36.065 of milrinone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 58: mometasone with relative risk of -36.065 of milrinone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 59: mometasone with relative risk of -36.065 of milrinone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 60: mometasone with relative risk of -36.065 of milrinone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 61: ibutilide with relative risk of -38.383 of milrinone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 62: ibutilide with relative risk of -38.383 of milrinone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 63: ibutilide with relative risk of -38.383 of milrinone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 64: ibutilide with relative risk of -38.383 of milrinone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 65: ibutilide with relative risk of -38.383 of milrinone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 66: tropisetron with relative risk of -39.258 of milrinone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 67: tropisetron with relative risk of -39.258 of milrinone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 68: tropisetron with relative risk of -39.258 of milrinone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 69: tropisetron with relative risk of -39.258 of milrinone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 70: tropisetron with relative risk of -39.258 of milrinone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 71: indomethacin with relative risk of -44.740 of milrinone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 72: indomethacin with relative risk of -44.740 of milrinone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 73: indomethacin with relative risk of -44.740 of milrinone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 74: indomethacin with relative risk of -44.740 of milrinone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 75: indomethacin with relative risk of -44.740 of milrinone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 76: pemetrexed with relative risk of -44.804 of milrinone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 77: pemetrexed with relative risk of -44.804 of milrinone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 78: pemetrexed with relative risk of -44.804 of milrinone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 79: pemetrexed with relative risk of -44.804 of milrinone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 80: pemetrexed with relative risk of -44.804 of milrinone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 81: metoprolol with relative risk of -47.243 of milrinone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 82: metoprolol with relative risk of -47.243 of milrinone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 83: metoprolol with relative risk of -47.243 of milrinone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 84: metoprolol with relative risk of -47.243 of milrinone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 85: metoprolol with relative risk of -47.243 of milrinone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 86: tamsulosin with relative risk of -48.991 of milrinone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 87: tamsulosin with relative risk of -48.991 of milrinone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 88: tamsulosin with relative risk of -48.991 of milrinone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 89: tamsulosin with relative risk of -48.991 of milrinone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 90: tamsulosin with relative risk of -48.991 of milrinone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 91: felodipine with relative risk of -inf of milrinone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 92: felodipine with relative risk of -inf of milrinone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 93: felodipine with relative risk of -inf of milrinone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.08\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target minocycline not found. Exiting ...\n",
      "\n",
      "Drug target mipomersen not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó mirabegron *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: estradiol with relative risk of -13.031 of mirabegron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó mirtazapine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: doxercalciferol with relative risk of -11.743 of mirtazapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: iloperidone with relative risk of -12.184 of mirtazapine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: rabeprazole with relative risk of -12.198 of mirtazapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: levocabastine with relative risk of -12.358 of mirtazapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: levetiracetam with relative risk of -12.648 of mirtazapine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: fluconazole with relative risk of -12.728 of mirtazapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: guanfacine with relative risk of -12.760 of mirtazapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: fosphenytoin with relative risk of -12.906 of mirtazapine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: reboxetine with relative risk of -13.131 of mirtazapine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Major Depressive Disorder,neurology/psychiatry\n",
      "Rank 10: ropinirole with relative risk of -13.248 of mirtazapine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: vardenafil with relative risk of -13.293 of mirtazapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: rilpivirine with relative risk of -13.450 of mirtazapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.334\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó misoprostol *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: bosutinib with relative risk of -10.097 of misoprostol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: dofetilide with relative risk of -10.229 of misoprostol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: clarithromycin with relative risk of -10.286 of misoprostol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: olmesartan with relative risk of -12.725 of misoprostol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: estramustine with relative risk of -26.386 of misoprostol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: estramustine with relative risk of -26.386 of misoprostol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: estramustine with relative risk of -26.386 of misoprostol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: auranofin with relative risk of -27.814 of misoprostol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: auranofin with relative risk of -27.814 of misoprostol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: auranofin with relative risk of -27.814 of misoprostol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: dantrolene with relative risk of -28.606 of misoprostol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: dantrolene with relative risk of -28.606 of misoprostol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: dantrolene with relative risk of -28.606 of misoprostol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: risedronate with relative risk of -28.895 of misoprostol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: risedronate with relative risk of -28.895 of misoprostol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: risedronate with relative risk of -28.895 of misoprostol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: donepezil with relative risk of -29.287 of misoprostol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: donepezil with relative risk of -29.287 of misoprostol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: donepezil with relative risk of -29.287 of misoprostol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: sertraline with relative risk of -34.222 of misoprostol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: sertraline with relative risk of -34.222 of misoprostol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: sertraline with relative risk of -34.222 of misoprostol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: sertraline with relative risk of -34.222 of misoprostol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: sertraline with relative risk of -34.222 of misoprostol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: irbesartan with relative risk of -34.590 of misoprostol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: irbesartan with relative risk of -34.590 of misoprostol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: irbesartan with relative risk of -34.590 of misoprostol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: irbesartan with relative risk of -34.590 of misoprostol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: irbesartan with relative risk of -34.590 of misoprostol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: mometasone with relative risk of -36.065 of misoprostol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: mometasone with relative risk of -36.065 of misoprostol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: mometasone with relative risk of -36.065 of misoprostol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: mometasone with relative risk of -36.065 of misoprostol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: mometasone with relative risk of -36.065 of misoprostol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: regadenoson with relative risk of -36.243 of misoprostol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: regadenoson with relative risk of -36.243 of misoprostol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: regadenoson with relative risk of -36.243 of misoprostol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: regadenoson with relative risk of -36.243 of misoprostol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: regadenoson with relative risk of -36.243 of misoprostol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: azelastine with relative risk of -36.761 of misoprostol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: azelastine with relative risk of -36.761 of misoprostol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: azelastine with relative risk of -36.761 of misoprostol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: azelastine with relative risk of -36.761 of misoprostol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: azelastine with relative risk of -36.761 of misoprostol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: posaconazole with relative risk of -37.450 of misoprostol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: posaconazole with relative risk of -37.450 of misoprostol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: posaconazole with relative risk of -37.450 of misoprostol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: posaconazole with relative risk of -37.450 of misoprostol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: posaconazole with relative risk of -37.450 of misoprostol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: ibutilide with relative risk of -38.383 of misoprostol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: ibutilide with relative risk of -38.383 of misoprostol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: ibutilide with relative risk of -38.383 of misoprostol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 53: ibutilide with relative risk of -38.383 of misoprostol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 54: ibutilide with relative risk of -38.383 of misoprostol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 55: telmisartan with relative risk of -45.160 of misoprostol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 56: telmisartan with relative risk of -45.160 of misoprostol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 57: telmisartan with relative risk of -45.160 of misoprostol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 58: telmisartan with relative risk of -45.160 of misoprostol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 59: telmisartan with relative risk of -45.160 of misoprostol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 60: milnacipran with relative risk of -46.827 of misoprostol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 61: milnacipran with relative risk of -46.827 of misoprostol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 62: milnacipran with relative risk of -46.827 of misoprostol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 63: milnacipran with relative risk of -46.827 of misoprostol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 64: milnacipran with relative risk of -46.827 of misoprostol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 65: tolmetin with relative risk of -47.694 of misoprostol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 66: tolmetin with relative risk of -47.694 of misoprostol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 67: tolmetin with relative risk of -47.694 of misoprostol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 68: tolmetin with relative risk of -47.694 of misoprostol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 69: tolmetin with relative risk of -47.694 of misoprostol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 70: progesterone with relative risk of -48.032 of misoprostol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 71: progesterone with relative risk of -48.032 of misoprostol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 72: progesterone with relative risk of -48.032 of misoprostol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 73: progesterone with relative risk of -48.032 of misoprostol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 74: progesterone with relative risk of -48.032 of misoprostol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 75: abiraterone with relative risk of -48.541 of misoprostol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 76: abiraterone with relative risk of -48.541 of misoprostol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 77: abiraterone with relative risk of -48.541 of misoprostol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 78: abiraterone with relative risk of -48.541 of misoprostol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 79: abiraterone with relative risk of -48.541 of misoprostol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 80: lubiprostone with relative risk of -48.928 of misoprostol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "Rank 81: lubiprostone with relative risk of -48.928 of misoprostol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "Rank 82: lubiprostone with relative risk of -48.928 of misoprostol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "Rank 83: lubiprostone with relative risk of -48.928 of misoprostol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "Rank 84: lubiprostone with relative risk of -48.928 of misoprostol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "Rank 85: dapagliflozin with relative risk of -49.578 of misoprostol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 86: dapagliflozin with relative risk of -49.578 of misoprostol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 87: dapagliflozin with relative risk of -49.578 of misoprostol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 88: dapagliflozin with relative risk of -49.578 of misoprostol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 89: dapagliflozin with relative risk of -49.578 of misoprostol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 90: cisatracurium with relative risk of -51.678 of misoprostol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 91: cisatracurium with relative risk of -51.678 of misoprostol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 92: cisatracurium with relative risk of -51.678 of misoprostol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 93: cisatracurium with relative risk of -51.678 of misoprostol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 94: cisatracurium with relative risk of -51.678 of misoprostol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.012\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target mitomycin not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó mitotane *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: cabazitaxel with relative risk of -9.888 of mitotane | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 2: danazol with relative risk of -11.034 of mitotane | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: gonadorelin with relative risk of -11.940 of mitotane | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: phenytoin with relative risk of -12.213 of mitotane | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: montelukast with relative risk of -12.307 of mitotane | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: mexiletine with relative risk of -12.655 of mitotane | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: ranitidine with relative risk of -12.753 of mitotane | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: zafirlukast with relative risk of -12.826 of mitotane | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: cilazapril with relative risk of -14.631 of mitotane | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: canagliflozin with relative risk of -21.978 of mitotane | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: canagliflozin with relative risk of -21.978 of mitotane | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: dipyridamole with relative risk of -23.322 of mitotane | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: dipyridamole with relative risk of -23.322 of mitotane | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.314\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó mitoxantrone *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: dexrazoxane with relative risk of -10.146 of mitoxantrone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: carvedilol with relative risk of -11.716 of mitoxantrone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: glipizide with relative risk of -12.866 of mitoxantrone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó mivacurium *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: alosetron with relative risk of -12.476 of mivacurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: lercanidipine with relative risk of -13.636 of mivacurium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target modafinil not found. Exiting ...\n",
      "\n",
      "Drug target moexiprilat not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó mometasone *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: crizotinib with relative risk of -6.948 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: penbutolol with relative risk of -7.126 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: risperidone with relative risk of -7.748 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: atropine with relative risk of -8.097 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: asenapine with relative risk of -8.195 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: amsacrine with relative risk of -8.196 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: carbamazepine with relative risk of -8.267 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: bosutinib with relative risk of -8.272 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: sulfasalazine with relative risk of -8.476 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: clonidine with relative risk of -8.499 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: varenicline with relative risk of -8.543 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: flutamide with relative risk of -8.551 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: leflunomide with relative risk of -8.801 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: doxorubicin with relative risk of -8.808 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: bezafibrate with relative risk of -8.823 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: vernakalant with relative risk of -8.847 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: perindopril with relative risk of -9.007 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: flecainide with relative risk of -9.522 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: tolvaptan with relative risk of -9.536 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: ambrisentan with relative risk of -9.554 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: vilazodone with relative risk of -10.210 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: pindolol with relative risk of -10.366 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: cimetidine with relative risk of -10.875 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: olmesartan with relative risk of -10.901 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: cyclophosphamide with relative risk of -14.383 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: cyclophosphamide with relative risk of -14.383 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: nevirapine with relative risk of -14.667 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: nevirapine with relative risk of -14.667 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: dofetilide with relative risk of -15.060 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: dofetilide with relative risk of -15.060 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: capecitabine with relative risk of -15.365 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: capecitabine with relative risk of -15.365 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: sumatriptan with relative risk of -16.574 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: sumatriptan with relative risk of -16.574 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: citalopram with relative risk of -16.597 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: citalopram with relative risk of -16.597 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: darifenacin with relative risk of -17.165 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: darifenacin with relative risk of -17.165 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: darifenacin with relative risk of -17.165 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: naproxen with relative risk of -18.695 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: naproxen with relative risk of -18.695 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: naproxen with relative risk of -18.695 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: gabapentin with relative risk of -20.252 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: gabapentin with relative risk of -20.252 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: gabapentin with relative risk of -20.252 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: estramustine with relative risk of -20.283 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: estramustine with relative risk of -20.283 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: estramustine with relative risk of -20.283 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: clarithromycin with relative risk of -20.601 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: clarithromycin with relative risk of -20.601 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: clarithromycin with relative risk of -20.601 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: ivacaftor with relative risk of -20.710 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 53: ivacaftor with relative risk of -20.710 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 54: ivacaftor with relative risk of -20.710 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 55: bumetanide with relative risk of -20.716 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 56: bumetanide with relative risk of -20.716 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 57: bumetanide with relative risk of -20.716 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 58: auranofin with relative risk of -21.706 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 59: auranofin with relative risk of -21.706 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 60: auranofin with relative risk of -21.706 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 61: cetirizine with relative risk of -21.778 of mometasone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic rhinitis (disorder)\n",
      "Rank 62: cetirizine with relative risk of -21.778 of mometasone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic rhinitis (disorder)\n",
      "Rank 63: cetirizine with relative risk of -21.778 of mometasone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic rhinitis (disorder)\n",
      "Rank 64: brimonidine with relative risk of -22.109 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 65: brimonidine with relative risk of -22.109 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 66: brimonidine with relative risk of -22.109 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 67: dantrolene with relative risk of -22.497 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 68: dantrolene with relative risk of -22.497 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 69: dantrolene with relative risk of -22.497 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 70: tazarotene with relative risk of -22.682 of mometasone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: dermatology\n",
      "Rank 71: tazarotene with relative risk of -22.682 of mometasone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: dermatology\n",
      "Rank 72: tazarotene with relative risk of -22.682 of mometasone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: dermatology\n",
      "Rank 73: risedronate with relative risk of -22.787 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 74: risedronate with relative risk of -22.787 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 75: risedronate with relative risk of -22.787 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 76: dapsone with relative risk of -22.943 of mometasone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: dermatology\n",
      "Rank 77: dapsone with relative risk of -22.943 of mometasone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: dermatology\n",
      "Rank 78: dapsone with relative risk of -22.943 of mometasone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: dermatology\n",
      "Rank 79: donepezil with relative risk of -23.179 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 80: donepezil with relative risk of -23.179 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 81: donepezil with relative risk of -23.179 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 82: brinzolamide with relative risk of -23.218 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 83: brinzolamide with relative risk of -23.218 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 84: brinzolamide with relative risk of -23.218 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 85: fondaparinux with relative risk of -23.547 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 86: fondaparinux with relative risk of -23.547 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 87: fondaparinux with relative risk of -23.547 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 88: acebutolol with relative risk of -23.563 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 89: acebutolol with relative risk of -23.563 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 90: acebutolol with relative risk of -23.563 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 91: isradipine with relative risk of -23.687 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 92: isradipine with relative risk of -23.687 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 93: isradipine with relative risk of -23.687 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 94: valsartan with relative risk of -23.706 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 95: valsartan with relative risk of -23.706 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 96: valsartan with relative risk of -23.706 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 97: ruxolitinib with relative risk of -26.228 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 98: ruxolitinib with relative risk of -26.228 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 99: ruxolitinib with relative risk of -26.228 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 100: ruxolitinib with relative risk of -26.228 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 101: everolimus with relative risk of -28.938 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 102: everolimus with relative risk of -28.938 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 103: everolimus with relative risk of -28.938 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 104: everolimus with relative risk of -28.938 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 105: pentoxifylline with relative risk of -33.487 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 106: pentoxifylline with relative risk of -33.487 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 107: pentoxifylline with relative risk of -33.487 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 108: pentoxifylline with relative risk of -33.487 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 109: pentoxifylline with relative risk of -33.487 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 110: pentoxifylline with relative risk of -33.487 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 111: milnacipran with relative risk of -34.785 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 112: milnacipran with relative risk of -34.785 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 113: milnacipran with relative risk of -34.785 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 114: milnacipran with relative risk of -34.785 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 115: milnacipran with relative risk of -34.785 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 116: metoprolol with relative risk of -35.200 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 117: metoprolol with relative risk of -35.200 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 118: metoprolol with relative risk of -35.200 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 119: metoprolol with relative risk of -35.200 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 120: metoprolol with relative risk of -35.200 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 121: milrinone with relative risk of -35.622 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 122: milrinone with relative risk of -35.622 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 123: milrinone with relative risk of -35.622 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 124: milrinone with relative risk of -35.622 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 125: milrinone with relative risk of -35.622 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 126: tolmetin with relative risk of -35.651 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 127: tolmetin with relative risk of -35.651 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 128: tolmetin with relative risk of -35.651 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 129: tolmetin with relative risk of -35.651 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 130: tolmetin with relative risk of -35.651 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 131: progesterone with relative risk of -35.989 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 132: progesterone with relative risk of -35.989 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 133: progesterone with relative risk of -35.989 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 134: progesterone with relative risk of -35.989 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 135: progesterone with relative risk of -35.989 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 136: abiraterone with relative risk of -36.498 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 137: abiraterone with relative risk of -36.498 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 138: abiraterone with relative risk of -36.498 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 139: abiraterone with relative risk of -36.498 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 140: abiraterone with relative risk of -36.498 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 141: lubiprostone with relative risk of -36.885 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 142: lubiprostone with relative risk of -36.885 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 143: lubiprostone with relative risk of -36.885 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 144: lubiprostone with relative risk of -36.885 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 145: lubiprostone with relative risk of -36.885 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 146: tamsulosin with relative risk of -36.948 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 147: tamsulosin with relative risk of -36.948 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 148: tamsulosin with relative risk of -36.948 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 149: tamsulosin with relative risk of -36.948 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 150: tamsulosin with relative risk of -36.948 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 151: zolmitriptan with relative risk of -37.302 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 152: zolmitriptan with relative risk of -37.302 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 153: zolmitriptan with relative risk of -37.302 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 154: zolmitriptan with relative risk of -37.302 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 155: zolmitriptan with relative risk of -37.302 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 156: ropivacaine with relative risk of -37.313 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 157: ropivacaine with relative risk of -37.313 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 158: ropivacaine with relative risk of -37.313 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 159: ropivacaine with relative risk of -37.313 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 160: ropivacaine with relative risk of -37.313 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 161: ropivacaine with relative risk of -37.313 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 162: dapagliflozin with relative risk of -37.535 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 163: dapagliflozin with relative risk of -37.535 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 164: dapagliflozin with relative risk of -37.535 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 165: dapagliflozin with relative risk of -37.535 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 166: dapagliflozin with relative risk of -37.535 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 167: misoprostol with relative risk of -37.882 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 168: misoprostol with relative risk of -37.882 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 169: misoprostol with relative risk of -37.882 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 170: misoprostol with relative risk of -37.882 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 171: misoprostol with relative risk of -37.882 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 172: terbutaline with relative risk of -38.738 of mometasone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Asthma\n",
      "Rank 173: terbutaline with relative risk of -38.738 of mometasone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Asthma\n",
      "Rank 174: terbutaline with relative risk of -38.738 of mometasone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Asthma\n",
      "Rank 175: terbutaline with relative risk of -38.738 of mometasone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Asthma\n",
      "Rank 176: terbutaline with relative risk of -38.738 of mometasone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Asthma\n",
      "Rank 177: terbutaline with relative risk of -38.738 of mometasone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Asthma\n",
      "Rank 178: cisatracurium with relative risk of -39.635 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 179: cisatracurium with relative risk of -39.635 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 180: cisatracurium with relative risk of -39.635 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 181: cisatracurium with relative risk of -39.635 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 182: cisatracurium with relative risk of -39.635 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 183: telmisartan with relative risk of -40.609 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 184: telmisartan with relative risk of -40.609 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 185: telmisartan with relative risk of -40.609 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 186: telmisartan with relative risk of -40.609 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 187: telmisartan with relative risk of -40.609 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 188: telmisartan with relative risk of -40.609 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 189: didanosine with relative risk of -42.649 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 190: didanosine with relative risk of -42.649 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 191: didanosine with relative risk of -42.649 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 192: didanosine with relative risk of -42.649 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 193: didanosine with relative risk of -42.649 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 194: didanosine with relative risk of -42.649 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 195: esmolol with relative risk of -42.693 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 196: esmolol with relative risk of -42.693 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 197: esmolol with relative risk of -42.693 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 198: esmolol with relative risk of -42.693 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 199: esmolol with relative risk of -42.693 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 200: esmolol with relative risk of -42.693 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 201: azilsartan with relative risk of -44.153 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 202: azilsartan with relative risk of -44.153 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 203: azilsartan with relative risk of -44.153 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 204: azilsartan with relative risk of -44.153 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 205: azilsartan with relative risk of -44.153 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 206: azilsartan with relative risk of -44.153 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 207: lurasidone with relative risk of -47.581 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 208: lurasidone with relative risk of -47.581 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 209: lurasidone with relative risk of -47.581 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 210: lurasidone with relative risk of -47.581 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 211: lurasidone with relative risk of -47.581 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 212: lurasidone with relative risk of -47.581 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 213: lurasidone with relative risk of -47.581 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 214: levonorgestrel with relative risk of -49.244 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 215: levonorgestrel with relative risk of -49.244 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 216: levonorgestrel with relative risk of -49.244 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 217: levonorgestrel with relative risk of -49.244 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 218: levonorgestrel with relative risk of -49.244 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 219: levonorgestrel with relative risk of -49.244 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 220: levonorgestrel with relative risk of -49.244 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 221: pemetrexed with relative risk of -49.438 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 222: pemetrexed with relative risk of -49.438 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 223: pemetrexed with relative risk of -49.438 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 224: pemetrexed with relative risk of -49.438 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 225: pemetrexed with relative risk of -49.438 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 226: pemetrexed with relative risk of -49.438 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 227: pemetrexed with relative risk of -49.438 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 228: dutasteride with relative risk of -51.053 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 229: dutasteride with relative risk of -51.053 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 230: dutasteride with relative risk of -51.053 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 231: dutasteride with relative risk of -51.053 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 232: dutasteride with relative risk of -51.053 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 233: dutasteride with relative risk of -51.053 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 234: dutasteride with relative risk of -51.053 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 235: ketorolac with relative risk of -51.440 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 236: ketorolac with relative risk of -51.440 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 237: ketorolac with relative risk of -51.440 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 238: ketorolac with relative risk of -51.440 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 239: ketorolac with relative risk of -51.440 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 240: ketorolac with relative risk of -51.440 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 241: ketorolac with relative risk of -51.440 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 242: ketorolac with relative risk of -51.440 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 243: indomethacin with relative risk of -57.231 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 244: indomethacin with relative risk of -57.231 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 245: indomethacin with relative risk of -57.231 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 246: indomethacin with relative risk of -57.231 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 247: indomethacin with relative risk of -57.231 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 248: indomethacin with relative risk of -57.231 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 249: indomethacin with relative risk of -57.231 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 250: indomethacin with relative risk of -57.231 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 251: trovafloxacin with relative risk of -57.662 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 252: trovafloxacin with relative risk of -57.662 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 253: trovafloxacin with relative risk of -57.662 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 254: trovafloxacin with relative risk of -57.662 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 255: trovafloxacin with relative risk of -57.662 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 256: trovafloxacin with relative risk of -57.662 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 257: trovafloxacin with relative risk of -57.662 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 258: trovafloxacin with relative risk of -57.662 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 259: lansoprazole with relative risk of -78.295 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 260: lansoprazole with relative risk of -78.295 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 261: lansoprazole with relative risk of -78.295 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 262: lansoprazole with relative risk of -78.295 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 263: lansoprazole with relative risk of -78.295 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 264: lansoprazole with relative risk of -78.295 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 265: lansoprazole with relative risk of -78.295 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 266: lansoprazole with relative risk of -78.295 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 267: lansoprazole with relative risk of -78.295 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 268: lansoprazole with relative risk of -78.295 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 269: lansoprazole with relative risk of -78.295 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 270: etoposide with relative risk of -97.398 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 271: etoposide with relative risk of -97.398 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 272: etoposide with relative risk of -97.398 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 273: etoposide with relative risk of -97.398 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 274: etoposide with relative risk of -97.398 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 275: etoposide with relative risk of -97.398 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 276: etoposide with relative risk of -97.398 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 277: etoposide with relative risk of -97.398 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 278: etoposide with relative risk of -97.398 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 279: etoposide with relative risk of -97.398 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 280: etoposide with relative risk of -97.398 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 281: etoposide with relative risk of -97.398 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 282: etoposide with relative risk of -97.398 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 283: etoposide with relative risk of -97.398 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 284: fenofibrate with relative risk of -99.942 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 285: fenofibrate with relative risk of -99.942 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 286: fenofibrate with relative risk of -99.942 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 287: fenofibrate with relative risk of -99.942 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 288: fenofibrate with relative risk of -99.942 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 289: fenofibrate with relative risk of -99.942 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 290: fenofibrate with relative risk of -99.942 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 291: fenofibrate with relative risk of -99.942 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 292: fenofibrate with relative risk of -99.942 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 293: fenofibrate with relative risk of -99.942 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 294: fenofibrate with relative risk of -99.942 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 295: fenofibrate with relative risk of -99.942 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 296: fenofibrate with relative risk of -99.942 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 297: fenofibrate with relative risk of -99.942 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 298: glimepiride with relative risk of -121.065 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 299: glimepiride with relative risk of -121.065 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 300: glimepiride with relative risk of -121.065 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 301: glimepiride with relative risk of -121.065 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 302: glimepiride with relative risk of -121.065 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 303: glimepiride with relative risk of -121.065 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 304: glimepiride with relative risk of -121.065 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 305: glimepiride with relative risk of -121.065 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 306: glimepiride with relative risk of -121.065 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 307: glimepiride with relative risk of -121.065 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 308: glimepiride with relative risk of -121.065 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 309: glimepiride with relative risk of -121.065 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 310: glimepiride with relative risk of -121.065 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 311: glimepiride with relative risk of -121.065 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 312: glimepiride with relative risk of -121.065 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 313: glimepiride with relative risk of -121.065 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 314: glimepiride with relative risk of -121.065 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 315: paliperidone with relative risk of -136.275 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 316: paliperidone with relative risk of -136.275 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 317: paliperidone with relative risk of -136.275 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 318: paliperidone with relative risk of -136.275 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 319: paliperidone with relative risk of -136.275 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 320: paliperidone with relative risk of -136.275 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 321: paliperidone with relative risk of -136.275 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 322: paliperidone with relative risk of -136.275 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 323: paliperidone with relative risk of -136.275 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 324: paliperidone with relative risk of -136.275 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 325: paliperidone with relative risk of -136.275 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 326: paliperidone with relative risk of -136.275 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 327: paliperidone with relative risk of -136.275 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 328: paliperidone with relative risk of -136.275 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 329: paliperidone with relative risk of -136.275 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 330: paliperidone with relative risk of -136.275 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 331: paliperidone with relative risk of -136.275 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 332: paliperidone with relative risk of -136.275 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 333: paliperidone with relative risk of -136.275 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 334: tropisetron with relative risk of -143.921 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 335: tropisetron with relative risk of -143.921 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 336: tropisetron with relative risk of -143.921 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 337: tropisetron with relative risk of -143.921 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 338: tropisetron with relative risk of -143.921 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 339: tropisetron with relative risk of -143.921 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 340: tropisetron with relative risk of -143.921 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 341: tropisetron with relative risk of -143.921 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 342: tropisetron with relative risk of -143.921 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 343: tropisetron with relative risk of -143.921 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 344: tropisetron with relative risk of -143.921 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 345: tropisetron with relative risk of -143.921 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 346: tropisetron with relative risk of -143.921 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 347: tropisetron with relative risk of -143.921 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 348: tropisetron with relative risk of -143.921 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 349: tropisetron with relative risk of -143.921 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 350: tropisetron with relative risk of -143.921 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 351: tropisetron with relative risk of -143.921 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 352: tropisetron with relative risk of -143.921 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 353: tropisetron with relative risk of -143.921 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 354: sertraline with relative risk of -162.343 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 355: sertraline with relative risk of -162.343 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 356: sertraline with relative risk of -162.343 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 357: sertraline with relative risk of -162.343 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 358: sertraline with relative risk of -162.343 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 359: sertraline with relative risk of -162.343 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 360: sertraline with relative risk of -162.343 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 361: sertraline with relative risk of -162.343 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 362: sertraline with relative risk of -162.343 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 363: sertraline with relative risk of -162.343 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 364: sertraline with relative risk of -162.343 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 365: sertraline with relative risk of -162.343 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 366: sertraline with relative risk of -162.343 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 367: sertraline with relative risk of -162.343 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 368: sertraline with relative risk of -162.343 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 369: sertraline with relative risk of -162.343 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 370: sertraline with relative risk of -162.343 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 371: sertraline with relative risk of -162.343 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 372: sertraline with relative risk of -162.343 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 373: sertraline with relative risk of -162.343 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 374: sertraline with relative risk of -162.343 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 375: sertraline with relative risk of -162.343 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 376: sertraline with relative risk of -162.343 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 377: sertraline with relative risk of -162.343 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 378: sertraline with relative risk of -162.343 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 379: sertraline with relative risk of -162.343 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 380: regadenoson with relative risk of -178.440 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 381: regadenoson with relative risk of -178.440 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 382: regadenoson with relative risk of -178.440 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 383: regadenoson with relative risk of -178.440 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 384: regadenoson with relative risk of -178.440 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 385: regadenoson with relative risk of -178.440 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 386: regadenoson with relative risk of -178.440 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 387: regadenoson with relative risk of -178.440 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 388: regadenoson with relative risk of -178.440 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 389: regadenoson with relative risk of -178.440 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 390: regadenoson with relative risk of -178.440 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 391: regadenoson with relative risk of -178.440 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 392: regadenoson with relative risk of -178.440 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 393: regadenoson with relative risk of -178.440 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 394: regadenoson with relative risk of -178.440 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 395: regadenoson with relative risk of -178.440 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 396: regadenoson with relative risk of -178.440 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 397: regadenoson with relative risk of -178.440 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 398: regadenoson with relative risk of -178.440 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 399: regadenoson with relative risk of -178.440 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 400: regadenoson with relative risk of -178.440 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 401: regadenoson with relative risk of -178.440 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 402: regadenoson with relative risk of -178.440 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 403: regadenoson with relative risk of -178.440 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 404: regadenoson with relative risk of -178.440 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 405: posaconazole with relative risk of -182.691 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 406: posaconazole with relative risk of -182.691 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 407: posaconazole with relative risk of -182.691 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 408: posaconazole with relative risk of -182.691 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 409: posaconazole with relative risk of -182.691 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 410: posaconazole with relative risk of -182.691 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 411: posaconazole with relative risk of -182.691 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 412: posaconazole with relative risk of -182.691 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 413: posaconazole with relative risk of -182.691 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 414: posaconazole with relative risk of -182.691 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 415: posaconazole with relative risk of -182.691 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 416: posaconazole with relative risk of -182.691 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 417: posaconazole with relative risk of -182.691 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 418: posaconazole with relative risk of -182.691 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 419: posaconazole with relative risk of -182.691 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 420: posaconazole with relative risk of -182.691 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 421: posaconazole with relative risk of -182.691 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 422: posaconazole with relative risk of -182.691 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 423: posaconazole with relative risk of -182.691 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 424: posaconazole with relative risk of -182.691 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 425: posaconazole with relative risk of -182.691 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 426: posaconazole with relative risk of -182.691 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 427: posaconazole with relative risk of -182.691 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 428: posaconazole with relative risk of -182.691 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 429: posaconazole with relative risk of -182.691 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 430: irbesartan with relative risk of -186.770 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 431: irbesartan with relative risk of -186.770 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 432: irbesartan with relative risk of -186.770 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 433: irbesartan with relative risk of -186.770 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 434: irbesartan with relative risk of -186.770 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 435: irbesartan with relative risk of -186.770 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 436: irbesartan with relative risk of -186.770 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 437: irbesartan with relative risk of -186.770 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 438: irbesartan with relative risk of -186.770 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 439: irbesartan with relative risk of -186.770 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 440: irbesartan with relative risk of -186.770 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 441: irbesartan with relative risk of -186.770 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 442: irbesartan with relative risk of -186.770 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 443: irbesartan with relative risk of -186.770 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 444: irbesartan with relative risk of -186.770 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 445: irbesartan with relative risk of -186.770 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 446: irbesartan with relative risk of -186.770 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 447: irbesartan with relative risk of -186.770 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 448: irbesartan with relative risk of -186.770 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 449: irbesartan with relative risk of -186.770 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 450: irbesartan with relative risk of -186.770 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 451: irbesartan with relative risk of -186.770 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 452: irbesartan with relative risk of -186.770 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 453: irbesartan with relative risk of -186.770 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 454: irbesartan with relative risk of -186.770 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 455: irbesartan with relative risk of -186.770 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 456: irbesartan with relative risk of -186.770 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 457: irbesartan with relative risk of -186.770 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 458: irbesartan with relative risk of -186.770 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 459: azelastine with relative risk of -187.830 of mometasone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic rhinitis (disorder)\n",
      "Rank 460: azelastine with relative risk of -187.830 of mometasone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic rhinitis (disorder)\n",
      "Rank 461: azelastine with relative risk of -187.830 of mometasone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic rhinitis (disorder)\n",
      "Rank 462: azelastine with relative risk of -187.830 of mometasone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic rhinitis (disorder)\n",
      "Rank 463: azelastine with relative risk of -187.830 of mometasone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic rhinitis (disorder)\n",
      "Rank 464: azelastine with relative risk of -187.830 of mometasone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic rhinitis (disorder)\n",
      "Rank 465: azelastine with relative risk of -187.830 of mometasone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic rhinitis (disorder)\n",
      "Rank 466: azelastine with relative risk of -187.830 of mometasone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic rhinitis (disorder)\n",
      "Rank 467: azelastine with relative risk of -187.830 of mometasone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic rhinitis (disorder)\n",
      "Rank 468: azelastine with relative risk of -187.830 of mometasone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic rhinitis (disorder)\n",
      "Rank 469: azelastine with relative risk of -187.830 of mometasone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic rhinitis (disorder)\n",
      "Rank 470: azelastine with relative risk of -187.830 of mometasone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic rhinitis (disorder)\n",
      "Rank 471: azelastine with relative risk of -187.830 of mometasone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic rhinitis (disorder)\n",
      "Rank 472: azelastine with relative risk of -187.830 of mometasone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic rhinitis (disorder)\n",
      "Rank 473: azelastine with relative risk of -187.830 of mometasone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic rhinitis (disorder)\n",
      "Rank 474: azelastine with relative risk of -187.830 of mometasone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic rhinitis (disorder)\n",
      "Rank 475: azelastine with relative risk of -187.830 of mometasone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic rhinitis (disorder)\n",
      "Rank 476: azelastine with relative risk of -187.830 of mometasone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic rhinitis (disorder)\n",
      "Rank 477: azelastine with relative risk of -187.830 of mometasone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic rhinitis (disorder)\n",
      "Rank 478: azelastine with relative risk of -187.830 of mometasone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic rhinitis (disorder)\n",
      "Rank 479: azelastine with relative risk of -187.830 of mometasone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic rhinitis (disorder)\n",
      "Rank 480: azelastine with relative risk of -187.830 of mometasone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic rhinitis (disorder)\n",
      "Rank 481: azelastine with relative risk of -187.830 of mometasone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic rhinitis (disorder)\n",
      "Rank 482: azelastine with relative risk of -187.830 of mometasone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic rhinitis (disorder)\n",
      "Rank 483: azelastine with relative risk of -187.830 of mometasone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic rhinitis (disorder)\n",
      "Rank 484: azelastine with relative risk of -187.830 of mometasone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic rhinitis (disorder)\n",
      "Rank 485: azelastine with relative risk of -187.830 of mometasone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Allergic rhinitis (disorder)\n",
      "Rank 486: ibutilide with relative risk of -197.614 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 487: ibutilide with relative risk of -197.614 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 488: ibutilide with relative risk of -197.614 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 489: ibutilide with relative risk of -197.614 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 490: ibutilide with relative risk of -197.614 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 491: ibutilide with relative risk of -197.614 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 492: ibutilide with relative risk of -197.614 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 493: ibutilide with relative risk of -197.614 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 494: ibutilide with relative risk of -197.614 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 495: ibutilide with relative risk of -197.614 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 496: ibutilide with relative risk of -197.614 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 497: ibutilide with relative risk of -197.614 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 498: ibutilide with relative risk of -197.614 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 499: ibutilide with relative risk of -197.614 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 500: ibutilide with relative risk of -197.614 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 501: ibutilide with relative risk of -197.614 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 502: ibutilide with relative risk of -197.614 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 503: ibutilide with relative risk of -197.614 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 504: ibutilide with relative risk of -197.614 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 505: ibutilide with relative risk of -197.614 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 506: ibutilide with relative risk of -197.614 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 507: ibutilide with relative risk of -197.614 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 508: ibutilide with relative risk of -197.614 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 509: ibutilide with relative risk of -197.614 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 510: ibutilide with relative risk of -197.614 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 511: ibutilide with relative risk of -197.614 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 512: ibutilide with relative risk of -197.614 of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 513: felodipine with relative risk of -inf of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 514: felodipine with relative risk of -inf of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 515: felodipine with relative risk of -inf of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 516: felodipine with relative risk of -inf of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 517: felodipine with relative risk of -inf of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 518: felodipine with relative risk of -inf of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 519: felodipine with relative risk of -inf of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 520: felodipine with relative risk of -inf of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 521: felodipine with relative risk of -inf of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 522: felodipine with relative risk of -inf of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 523: felodipine with relative risk of -inf of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 524: felodipine with relative risk of -inf of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 525: felodipine with relative risk of -inf of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 526: felodipine with relative risk of -inf of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 527: felodipine with relative risk of -inf of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 528: felodipine with relative risk of -inf of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 529: felodipine with relative risk of -inf of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 530: felodipine with relative risk of -inf of mometasone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.032\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target monoethanolamine not found. Exiting ...\n",
      "\n",
      "Drug target monomethylfumarate not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó montelukast *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: cabazitaxel with relative risk of -9.888 of montelukast | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: mitotane with relative risk of -10.288 of montelukast | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: frovatriptan with relative risk of -10.485 of montelukast | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: danazol with relative risk of -11.034 of montelukast | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: canagliflozin with relative risk of -11.923 of montelukast | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: phenytoin with relative risk of -12.213 of montelukast | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: dipyridamole with relative risk of -12.574 of montelukast | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: mexiletine with relative risk of -12.655 of montelukast | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: ranitidine with relative risk of -12.753 of montelukast | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: zafirlukast with relative risk of -12.826 of montelukast | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: pulmonary\n",
      "Rank 11: cilazapril with relative risk of -14.631 of montelukast | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: gonadorelin with relative risk of -22.688 of montelukast | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: gonadorelin with relative risk of -22.688 of montelukast | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.031\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target morphine not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó moxifloxacin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: bisoprolol with relative risk of -11.593 of moxifloxacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: prasugrel with relative risk of -12.267 of moxifloxacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: crizotinib with relative risk of -17.029 of moxifloxacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: crizotinib with relative risk of -17.029 of moxifloxacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: travoprost with relative risk of -19.931 of moxifloxacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: travoprost with relative risk of -19.931 of moxifloxacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: paroxetine with relative risk of -29.470 of moxifloxacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: paroxetine with relative risk of -29.470 of moxifloxacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: paroxetine with relative risk of -29.470 of moxifloxacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: paroxetine with relative risk of -29.470 of moxifloxacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: ibandronate with relative risk of -31.526 of moxifloxacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: ibandronate with relative risk of -31.526 of moxifloxacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: ibandronate with relative risk of -31.526 of moxifloxacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: ibandronate with relative risk of -31.526 of moxifloxacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: pentoxifylline with relative risk of -32.220 of moxifloxacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: pentoxifylline with relative risk of -32.220 of moxifloxacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: pentoxifylline with relative risk of -32.220 of moxifloxacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: pentoxifylline with relative risk of -32.220 of moxifloxacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: nabumetone with relative risk of -34.165 of moxifloxacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: nabumetone with relative risk of -34.165 of moxifloxacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: nabumetone with relative risk of -34.165 of moxifloxacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: nabumetone with relative risk of -34.165 of moxifloxacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: clofarabine with relative risk of -36.436 of moxifloxacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: clofarabine with relative risk of -36.436 of moxifloxacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: clofarabine with relative risk of -36.436 of moxifloxacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: clofarabine with relative risk of -36.436 of moxifloxacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target mupirocin not found. Exiting ...\n",
      "\n",
      "Drug target mycophenolate not found. Exiting ...\n",
      "\n",
      "Drug target mycophenolic not found. Exiting ...\n",
      "\n",
      "Drug target n-3 not found. Exiting ...\n",
      "\n",
      "Drug target nabilone not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó nabumetone *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: captopril with relative risk of -6.151 of nabumetone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: miglustat with relative risk of -7.618 of nabumetone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: atorvastatin with relative risk of -7.637 of nabumetone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: telithromycin with relative risk of -8.079 of nabumetone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: topotecan with relative risk of -8.129 of nabumetone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: ketorolac with relative risk of -8.557 of nabumetone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: nifedipine with relative risk of -8.604 of nabumetone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: loratadine with relative risk of -8.850 of nabumetone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: danazol with relative risk of -9.020 of nabumetone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: argatroban with relative risk of -9.088 of nabumetone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: dabigatran with relative risk of -9.221 of nabumetone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: allopurinol with relative risk of -9.318 of nabumetone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: rheumatology\n",
      "Rank 13: macitentan with relative risk of -9.625 of nabumetone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: etravirine with relative risk of -9.759 of nabumetone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: linezolid with relative risk of -9.925 of nabumetone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: bisoprolol with relative risk of -10.272 of nabumetone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: exenatide with relative risk of -10.304 of nabumetone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: fosinopril with relative risk of -10.413 of nabumetone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: doxazosin with relative risk of -10.603 of nabumetone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: hydrochlorothiazide with relative risk of -10.800 of nabumetone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: prasugrel with relative risk of -10.945 of nabumetone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: asenapine with relative risk of -15.640 of nabumetone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: asenapine with relative risk of -15.640 of nabumetone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: travoprost with relative risk of -25.657 of nabumetone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: travoprost with relative risk of -25.657 of nabumetone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: travoprost with relative risk of -25.657 of nabumetone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: crizotinib with relative risk of -29.228 of nabumetone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: crizotinib with relative risk of -29.228 of nabumetone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: crizotinib with relative risk of -29.228 of nabumetone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: crizotinib with relative risk of -29.228 of nabumetone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: ibandronate with relative risk of -30.747 of nabumetone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: ibandronate with relative risk of -30.747 of nabumetone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: ibandronate with relative risk of -30.747 of nabumetone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: ibandronate with relative risk of -30.747 of nabumetone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: ibandronate with relative risk of -30.747 of nabumetone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: moxifloxacin with relative risk of -33.968 of nabumetone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: moxifloxacin with relative risk of -33.968 of nabumetone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: moxifloxacin with relative risk of -33.968 of nabumetone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: moxifloxacin with relative risk of -33.968 of nabumetone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: pentoxifylline with relative risk of -38.469 of nabumetone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: pentoxifylline with relative risk of -38.469 of nabumetone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: pentoxifylline with relative risk of -38.469 of nabumetone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: pentoxifylline with relative risk of -38.469 of nabumetone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: pentoxifylline with relative risk of -38.469 of nabumetone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: pentoxifylline with relative risk of -38.469 of nabumetone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: clofarabine with relative risk of -38.483 of nabumetone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: clofarabine with relative risk of -38.483 of nabumetone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: clofarabine with relative risk of -38.483 of nabumetone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: clofarabine with relative risk of -38.483 of nabumetone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: clofarabine with relative risk of -38.483 of nabumetone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: paroxetine with relative risk of -40.773 of nabumetone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: paroxetine with relative risk of -40.773 of nabumetone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 53: paroxetine with relative risk of -40.773 of nabumetone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 54: paroxetine with relative risk of -40.773 of nabumetone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 55: paroxetine with relative risk of -40.773 of nabumetone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 56: paroxetine with relative risk of -40.773 of nabumetone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 57: paroxetine with relative risk of -40.773 of nabumetone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 58: desoximetasone with relative risk of -inf of nabumetone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.018\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó nadolol *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: felbamate with relative risk of -22.256 of nadolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: felbamate with relative risk of -22.256 of nadolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: triamcinolone with relative risk of -22.375 of nadolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: triamcinolone with relative risk of -22.375 of nadolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target naftifine not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó nalbuphine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: clozapine with relative risk of -8.965 of nalbuphine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: topotecan with relative risk of -27.948 of nalbuphine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: topotecan with relative risk of -27.948 of nalbuphine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: topotecan with relative risk of -27.948 of nalbuphine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: metolazone with relative risk of -30.277 of nalbuphine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: metolazone with relative risk of -30.277 of nalbuphine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: metolazone with relative risk of -30.277 of nalbuphine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: darunavir with relative risk of -31.599 of nalbuphine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: darunavir with relative risk of -31.599 of nalbuphine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: darunavir with relative risk of -31.599 of nalbuphine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.341\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó nalmefene *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: flumazenil with relative risk of -10.653 of nalmefene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: thalidomide with relative risk of -10.805 of nalmefene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: ranolazine with relative risk of -12.013 of nalmefene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó naltrexone *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: irbesartan with relative risk of -8.347 of naltrexone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: azelastine with relative risk of -8.694 of naltrexone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: ibandronate with relative risk of -8.808 of naltrexone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: miglustat with relative risk of -8.936 of naltrexone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: cladribine with relative risk of -11.111 of naltrexone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: nicotine with relative risk of -11.927 of naltrexone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: desonide with relative risk of -11.982 of naltrexone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Crohn Disease\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.119\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó naproxen *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: ibandronate with relative risk of -8.251 of naproxen | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: pemetrexed with relative risk of -8.527 of naproxen | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: ruxolitinib with relative risk of -8.567 of naproxen | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: didanosine with relative risk of -8.727 of naproxen | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: lansoprazole with relative risk of -9.164 of naproxen | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: ketorolac with relative risk of -9.315 of naproxen | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: trovafloxacin with relative risk of -9.740 of naproxen | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: dutasteride with relative risk of -10.142 of naproxen | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: bezafibrate with relative risk of -10.312 of naproxen | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: ixabepilone with relative risk of -10.394 of naproxen | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: citalopram with relative risk of -10.739 of naproxen | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: benazepril with relative risk of -11.233 of naproxen | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: toremifene with relative risk of -11.986 of naproxen | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: posaconazole with relative risk of -13.517 of naproxen | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: posaconazole with relative risk of -13.517 of naproxen | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: tropisetron with relative risk of -14.549 of naproxen | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: tropisetron with relative risk of -14.549 of naproxen | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: bumetanide with relative risk of -17.124 of naproxen | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: bumetanide with relative risk of -17.124 of naproxen | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: zolmitriptan with relative risk of -17.929 of naproxen | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Migraine Disorders,neurology/psychiatry\n",
      "Rank 21: zolmitriptan with relative risk of -17.929 of naproxen | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Migraine Disorders,neurology/psychiatry\n",
      "Rank 22: clonidine with relative risk of -18.248 of naproxen | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 23: clonidine with relative risk of -18.248 of naproxen | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 24: varenicline with relative risk of -18.292 of naproxen | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 25: varenicline with relative risk of -18.292 of naproxen | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 26: erlotinib with relative risk of -18.293 of naproxen | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: erlotinib with relative risk of -18.293 of naproxen | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: vemurafenib with relative risk of -18.325 of naproxen | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: vemurafenib with relative risk of -18.325 of naproxen | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: irbesartan with relative risk of -18.568 of naproxen | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: irbesartan with relative risk of -18.568 of naproxen | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: irbesartan with relative risk of -18.568 of naproxen | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: regadenoson with relative risk of -18.808 of naproxen | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: regadenoson with relative risk of -18.808 of naproxen | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: regadenoson with relative risk of -18.808 of naproxen | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: mometasone with relative risk of -19.032 of naproxen | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: mometasone with relative risk of -19.032 of naproxen | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: mometasone with relative risk of -19.032 of naproxen | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: rotigotine with relative risk of -19.660 of naproxen | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 40: rotigotine with relative risk of -19.660 of naproxen | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 41: doxepin with relative risk of -19.868 of naproxen | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 42: doxepin with relative risk of -19.868 of naproxen | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 43: etoposide with relative risk of -20.142 of naproxen | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: etoposide with relative risk of -20.142 of naproxen | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: etoposide with relative risk of -20.142 of naproxen | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: ibutilide with relative risk of -21.119 of naproxen | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: ibutilide with relative risk of -21.119 of naproxen | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: ibutilide with relative risk of -21.119 of naproxen | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: paliperidone with relative risk of -21.287 of naproxen | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 50: paliperidone with relative risk of -21.287 of naproxen | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 51: paliperidone with relative risk of -21.287 of naproxen | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 52: glimepiride with relative risk of -21.336 of naproxen | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 53: glimepiride with relative risk of -21.336 of naproxen | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 54: glimepiride with relative risk of -21.336 of naproxen | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 55: fenofibrate with relative risk of -22.686 of naproxen | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 56: fenofibrate with relative risk of -22.686 of naproxen | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 57: fenofibrate with relative risk of -22.686 of naproxen | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 58: ticagrelor with relative risk of -23.247 of naproxen | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 59: ticagrelor with relative risk of -23.247 of naproxen | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 60: ticagrelor with relative risk of -23.247 of naproxen | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 61: telmisartan with relative risk of -24.492 of naproxen | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 62: telmisartan with relative risk of -24.492 of naproxen | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 63: telmisartan with relative risk of -24.492 of naproxen | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 64: clarithromycin with relative risk of -25.454 of naproxen | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: otolaryngology\n",
      "Rank 65: clarithromycin with relative risk of -25.454 of naproxen | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: otolaryngology\n",
      "Rank 66: clarithromycin with relative risk of -25.454 of naproxen | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: otolaryngology\n",
      "Rank 67: cetirizine with relative risk of -26.632 of naproxen | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Rhinorrhea\n",
      "Rank 68: cetirizine with relative risk of -26.632 of naproxen | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Rhinorrhea\n",
      "Rank 69: cetirizine with relative risk of -26.632 of naproxen | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Rhinorrhea\n",
      "Rank 70: delavirdine with relative risk of -27.151 of naproxen | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 71: delavirdine with relative risk of -27.151 of naproxen | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 72: delavirdine with relative risk of -27.151 of naproxen | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 73: lurasidone with relative risk of -31.821 of naproxen | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 74: lurasidone with relative risk of -31.821 of naproxen | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 75: lurasidone with relative risk of -31.821 of naproxen | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 76: lurasidone with relative risk of -31.821 of naproxen | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 77: azelastine with relative risk of -33.719 of naproxen | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 78: azelastine with relative risk of -33.719 of naproxen | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 79: azelastine with relative risk of -33.719 of naproxen | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 80: azelastine with relative risk of -33.719 of naproxen | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 81: azelastine with relative risk of -33.719 of naproxen | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 82: sertraline with relative risk of -38.644 of naproxen | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 83: sertraline with relative risk of -38.644 of naproxen | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 84: sertraline with relative risk of -38.644 of naproxen | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 85: sertraline with relative risk of -38.644 of naproxen | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 86: sertraline with relative risk of -38.644 of naproxen | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 87: sertraline with relative risk of -38.644 of naproxen | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 88: ropivacaine with relative risk of -39.328 of naproxen | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 89: ropivacaine with relative risk of -39.328 of naproxen | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 90: ropivacaine with relative risk of -39.328 of naproxen | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 91: ropivacaine with relative risk of -39.328 of naproxen | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 92: ropivacaine with relative risk of -39.328 of naproxen | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 93: gabapentin with relative risk of -43.933 of naproxen | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 94: gabapentin with relative risk of -43.933 of naproxen | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 95: gabapentin with relative risk of -43.933 of naproxen | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 96: gabapentin with relative risk of -43.933 of naproxen | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 97: gabapentin with relative risk of -43.933 of naproxen | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 98: felodipine with relative risk of -inf of naproxen | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 99: felodipine with relative risk of -inf of naproxen | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 100: felodipine with relative risk of -inf of naproxen | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.216\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó naratriptan *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: bicalutamide with relative risk of -11.315 of naratriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: acamprosate with relative risk of -13.072 of naratriptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: scopolamine with relative risk of -13.221 of naratriptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.455\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó nateglinide *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: ulipristal with relative risk of -12.185 of nateglinide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  1.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó nebivolol *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: aminophylline with relative risk of -9.523 of nebivolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: ropivacaine with relative risk of -10.167 of nebivolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: ibandronate with relative risk of -10.192 of nebivolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: imatinib with relative risk of -10.310 of nebivolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: gemcitabine with relative risk of -10.824 of nebivolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: gefitinib with relative risk of -10.832 of nebivolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: trimetrexate with relative risk of -10.939 of nebivolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: finasteride with relative risk of -11.097 of nebivolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: valdecoxib with relative risk of -11.496 of nebivolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: acyclovir with relative risk of -11.705 of nebivolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: dihydroergotamine with relative risk of -11.922 of nebivolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: atosiban with relative risk of -12.021 of nebivolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 13: vincristine with relative risk of -12.233 of nebivolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: alendronate with relative risk of -12.279 of nebivolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: ramipril with relative risk of -12.733 of nebivolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 16: desvenlafaxine with relative risk of -13.114 of nebivolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: clopidogrel with relative risk of -13.390 of nebivolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 18: amoxicillin with relative risk of -13.617 of nebivolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: diltiazem with relative risk of -13.859 of nebivolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.074\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó nedocromil *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: trazodone with relative risk of -12.205 of nedocromil | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: trazodone with relative risk of -12.205 of nedocromil | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: betaxolol with relative risk of -13.775 of nedocromil | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: ophthalmology\n",
      "Rank 4: betaxolol with relative risk of -13.775 of nedocromil | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: ophthalmology\n",
      "Rank 5: topiramate with relative risk of -13.817 of nedocromil | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: topiramate with relative risk of -13.817 of nedocromil | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: quinaprilat with relative risk of -15.355 of nedocromil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: quinaprilat with relative risk of -15.355 of nedocromil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: bromocriptine with relative risk of -17.452 of nedocromil | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: bromocriptine with relative risk of -17.452 of nedocromil | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: riluzole with relative risk of -21.770 of nedocromil | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: riluzole with relative risk of -21.770 of nedocromil | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: riluzole with relative risk of -21.770 of nedocromil | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: loperamide with relative risk of -31.827 of nedocromil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: loperamide with relative risk of -31.827 of nedocromil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: loperamide with relative risk of -31.827 of nedocromil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: loperamide with relative risk of -31.827 of nedocromil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: loperamide with relative risk of -31.827 of nedocromil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: verapamil with relative risk of -38.221 of nedocromil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: verapamil with relative risk of -38.221 of nedocromil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: verapamil with relative risk of -38.221 of nedocromil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: verapamil with relative risk of -38.221 of nedocromil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: verapamil with relative risk of -38.221 of nedocromil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: verapamil with relative risk of -38.221 of nedocromil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: efinaconazole with relative risk of -inf of nedocromil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: efinaconazole with relative risk of -inf of nedocromil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: efinaconazole with relative risk of -inf of nedocromil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: efinaconazole with relative risk of -inf of nedocromil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: efinaconazole with relative risk of -inf of nedocromil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.735\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó nefazodone *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó nelarabine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: cytarabine with relative risk of -10.046 of nelarabine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: hematologic malignancy\n",
      "Rank 2: formoterol with relative risk of -10.323 of nelarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: frovatriptan with relative risk of -10.485 of nelarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: sparfloxacin with relative risk of -11.368 of nelarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: fesoterodine with relative risk of -12.610 of nelarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: rufinamide with relative risk of -12.651 of nelarabine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.408\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó nelfinavir *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: meloxicam with relative risk of -11.231 of nelfinavir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target nesiritide not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó nevirapine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: ropivacaine with relative risk of -8.782 of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: levonorgestrel with relative risk of -8.891 of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: ruxolitinib with relative risk of -9.126 of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: pentoxifylline with relative risk of -9.167 of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: lurasidone with relative risk of -9.173 of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: didanosine with relative risk of -9.286 of nevirapine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: HIV Infections,infectious disease\n",
      "Rank 7: lansoprazole with relative risk of -9.722 of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: ketorolac with relative risk of -9.873 of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: capecitabine with relative risk of -10.066 of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: loratadine with relative risk of -10.170 of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: trovafloxacin with relative risk of -10.299 of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: afatinib with relative risk of -10.587 of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: quinidine with relative risk of -10.877 of nevirapine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 14: beclomethasone with relative risk of -11.252 of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: sumatriptan with relative risk of -11.275 of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: budesonide with relative risk of -11.619 of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: pergolide with relative risk of -12.131 of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: aclidinium with relative risk of -12.176 of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: caffeine with relative risk of -12.672 of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: sertraline with relative risk of -13.482 of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: sertraline with relative risk of -13.482 of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: regadenoson with relative risk of -13.693 of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: regadenoson with relative risk of -13.693 of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: mometasone with relative risk of -14.106 of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: mometasone with relative risk of -14.106 of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: bromfenac with relative risk of -14.304 of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: etoposide with relative risk of -14.335 of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: etoposide with relative risk of -14.335 of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: posaconazole with relative risk of -14.766 of nevirapine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 30: posaconazole with relative risk of -14.766 of nevirapine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 31: glimepiride with relative risk of -15.751 of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: glimepiride with relative risk of -15.751 of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: tropisetron with relative risk of -15.799 of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: tropisetron with relative risk of -15.799 of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: paliperidone with relative risk of -15.828 of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: paliperidone with relative risk of -15.828 of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: ibutilide with relative risk of -16.084 of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: ibutilide with relative risk of -16.084 of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: fenofibrate with relative risk of -16.878 of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: fenofibrate with relative risk of -16.878 of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: pemetrexed with relative risk of -16.943 of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: pemetrexed with relative risk of -16.943 of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: metoprolol with relative risk of -17.078 of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: metoprolol with relative risk of -17.078 of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: milrinone with relative risk of -17.501 of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: milrinone with relative risk of -17.501 of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: indomethacin with relative risk of -17.572 of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: indomethacin with relative risk of -17.572 of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: dutasteride with relative risk of -18.558 of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: dutasteride with relative risk of -18.558 of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: tamsulosin with relative risk of -18.826 of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: tamsulosin with relative risk of -18.826 of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 53: argatroban with relative risk of -18.959 of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 54: argatroban with relative risk of -18.959 of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 55: ribavirin with relative risk of -19.237 of nevirapine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 56: ribavirin with relative risk of -19.237 of nevirapine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 57: celecoxib with relative risk of -19.931 of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 58: celecoxib with relative risk of -19.931 of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 59: perindopril with relative risk of -20.009 of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 60: perindopril with relative risk of -20.009 of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 61: fondaparinux with relative risk of -20.111 of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 62: fondaparinux with relative risk of -20.111 of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 63: lapatinib with relative risk of -20.182 of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 64: lapatinib with relative risk of -20.182 of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 65: losartan with relative risk of -20.580 of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 66: losartan with relative risk of -20.580 of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 67: amisulpride with relative risk of -20.645 of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 68: amisulpride with relative risk of -20.645 of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 69: latanoprost with relative risk of -20.742 of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 70: latanoprost with relative risk of -20.742 of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 71: domperidone with relative risk of -21.105 of nevirapine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 72: domperidone with relative risk of -21.105 of nevirapine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 73: temsirolimus with relative risk of -21.300 of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 74: temsirolimus with relative risk of -21.300 of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 75: azelastine with relative risk of -21.966 of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 76: azelastine with relative risk of -21.966 of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 77: azelastine with relative risk of -21.966 of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 78: lidocaine with relative risk of -21.983 of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 79: lidocaine with relative risk of -21.983 of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 80: bumetanide with relative risk of -27.738 of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 81: bumetanide with relative risk of -27.738 of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 82: bumetanide with relative risk of -27.738 of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 83: irbesartan with relative risk of -28.342 of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 84: irbesartan with relative risk of -28.342 of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 85: irbesartan with relative risk of -28.342 of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 86: irbesartan with relative risk of -28.342 of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 87: felodipine with relative risk of -inf of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 88: felodipine with relative risk of -inf of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 89: felodipine with relative risk of -inf of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 90: felodipine with relative risk of -inf of nevirapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.074\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target niacin not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó nicardipine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: quinapril with relative risk of -13.910 of nicardipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  1.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó nicotine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: irbesartan with relative risk of -9.727 of nicotine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: azelastine with relative risk of -10.076 of nicotine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: naltrexone with relative risk of -12.032 of nicotine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: cladribine with relative risk of -12.497 of nicotine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: desonide with relative risk of -13.368 of nicotine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.146\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó nifedipine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: captopril with relative risk of -7.241 of nifedipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 2: clozapine with relative risk of -8.455 of nifedipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: atorvastatin with relative risk of -8.727 of nifedipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Angina Pectoris,Hypertensive disease,Angina Pectoris, Variant,cardiology\n",
      "Rank 4: sunitinib with relative risk of -9.437 of nifedipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: bimatoprost with relative risk of -9.445 of nifedipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: vandetanib with relative risk of -9.731 of nifedipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: nabumetone with relative risk of -10.082 of nifedipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: danazol with relative risk of -10.118 of nifedipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 9: dabigatran with relative risk of -10.320 of nifedipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: exenatide with relative risk of -11.402 of nifedipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: fosinopril with relative risk of -11.510 of nifedipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 12: phentolamine with relative risk of -18.951 of nifedipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 13: phentolamine with relative risk of -18.951 of nifedipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 14: acitretin with relative risk of -18.956 of nifedipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: acitretin with relative risk of -18.956 of nifedipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: nilutamide with relative risk of -20.523 of nifedipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: nilutamide with relative risk of -20.523 of nifedipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: azathioprine with relative risk of -24.399 of nifedipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: azathioprine with relative risk of -24.399 of nifedipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: azathioprine with relative risk of -24.399 of nifedipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: calcipotriol with relative risk of -inf of nifedipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.469\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó nilotinib *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: iloprost with relative risk of -12.393 of nilotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: tolterodine with relative risk of -13.771 of nilotinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó nilutamide *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: clozapine with relative risk of -9.370 of nilutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: bimatoprost with relative risk of -10.361 of nilutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: vandetanib with relative risk of -10.647 of nilutamide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 4: azathioprine with relative risk of -18.949 of nilutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: azathioprine with relative risk of -18.949 of nilutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: nifedipine with relative risk of -19.978 of nilutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: nifedipine with relative risk of -19.978 of nilutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: phentolamine with relative risk of -21.254 of nilutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: phentolamine with relative risk of -21.254 of nilutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: acitretin with relative risk of -21.259 of nilutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: acitretin with relative risk of -21.259 of nilutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: calcipotriol with relative risk of -inf of nilutamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.107\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó nimodipine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: aminophylline with relative risk of -7.329 of nimodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: atomoxetine with relative risk of -9.524 of nimodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: cilostazol with relative risk of -9.759 of nimodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: allopurinol with relative risk of -9.828 of nimodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: mafenide with relative risk of -9.974 of nimodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: buspirone with relative risk of -10.045 of nimodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: entacapone with relative risk of -10.110 of nimodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: candesartan with relative risk of -10.375 of nimodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: ipratropium with relative risk of -10.377 of nimodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: silodosin with relative risk of -10.622 of nimodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: nefazodone with relative risk of -10.896 of nimodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: almotriptan with relative risk of -11.193 of nimodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: clopidogrel with relative risk of -11.194 of nimodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: hydrochlorothiazide with relative risk of -11.311 of nimodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: paclitaxel with relative risk of -17.401 of nimodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: paclitaxel with relative risk of -17.401 of nimodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: avanafil with relative risk of -18.009 of nimodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: avanafil with relative risk of -18.009 of nimodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: rasagiline with relative risk of -18.269 of nimodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: rasagiline with relative risk of -18.269 of nimodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: rivastigmine with relative risk of -19.083 of nimodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: rivastigmine with relative risk of -19.083 of nimodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: sotalol with relative risk of -19.107 of nimodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: sotalol with relative risk of -19.107 of nimodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: rofecoxib with relative risk of -19.158 of nimodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: rofecoxib with relative risk of -19.158 of nimodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: pimozide with relative risk of -19.230 of nimodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: pimozide with relative risk of -19.230 of nimodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: capsaicin with relative risk of -19.682 of nimodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: capsaicin with relative risk of -19.682 of nimodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: fosinoprilat with relative risk of -21.964 of nimodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: fosinoprilat with relative risk of -21.964 of nimodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: cytarabine with relative risk of -24.626 of nimodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: cytarabine with relative risk of -24.626 of nimodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: cytarabine with relative risk of -24.626 of nimodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: formoterol with relative risk of -29.766 of nimodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: formoterol with relative risk of -29.766 of nimodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: formoterol with relative risk of -29.766 of nimodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: formoterol with relative risk of -29.766 of nimodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: frovatriptan with relative risk of -29.928 of nimodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: frovatriptan with relative risk of -29.928 of nimodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: frovatriptan with relative risk of -29.928 of nimodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: frovatriptan with relative risk of -29.928 of nimodipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó nisoldipine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: paroxetine with relative risk of -7.764 of nisoldipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: zileuton with relative risk of -10.540 of nisoldipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: penbutolol with relative risk of -20.455 of nisoldipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 4: penbutolol with relative risk of -20.455 of nisoldipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 5: penbutolol with relative risk of -20.455 of nisoldipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 6: amiodarone with relative risk of -25.899 of nisoldipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 7: amiodarone with relative risk of -25.899 of nisoldipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 8: amiodarone with relative risk of -25.899 of nisoldipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 9: amiodarone with relative risk of -25.899 of nisoldipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 10: fluvastatin with relative risk of -30.997 of nisoldipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 11: fluvastatin with relative risk of -30.997 of nisoldipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 12: fluvastatin with relative risk of -30.997 of nisoldipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 13: fluvastatin with relative risk of -30.997 of nisoldipine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 14: irinotecan with relative risk of -35.441 of nisoldipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: irinotecan with relative risk of -35.441 of nisoldipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: irinotecan with relative risk of -35.441 of nisoldipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: irinotecan with relative risk of -35.441 of nisoldipine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.488\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target nitazoxanide not found. Exiting ...\n",
      "\n",
      "Drug target nitrofurantoin not found. Exiting ...\n",
      "\n",
      "Drug target nitrogen not found. Exiting ...\n",
      "\n",
      "Drug target nitroglycerin not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó nizatidine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: anastrozole with relative risk of -12.733 of nizatidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó norfloxacin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: amiloride with relative risk of -10.996 of norfloxacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: raltitrexed with relative risk of -18.271 of norfloxacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: raltitrexed with relative risk of -18.271 of norfloxacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: pentostatin with relative risk of -25.473 of norfloxacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: pentostatin with relative risk of -25.473 of norfloxacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: pentostatin with relative risk of -25.473 of norfloxacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: lamotrigine with relative risk of -27.116 of norfloxacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: lamotrigine with relative risk of -27.116 of norfloxacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: lamotrigine with relative risk of -27.116 of norfloxacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: diclofenac with relative risk of -40.921 of norfloxacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: diclofenac with relative risk of -40.921 of norfloxacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: diclofenac with relative risk of -40.921 of norfloxacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: diclofenac with relative risk of -40.921 of norfloxacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: diclofenac with relative risk of -40.921 of norfloxacin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target o291 not found. Exiting ...\n",
      "\n",
      "Drug target ofatumumab not found. Exiting ...\n",
      "\n",
      "Drug target ofloxacin not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó olanzapine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: flunisolide with relative risk of -13.237 of olanzapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó olmesartan *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: regadenoson with relative risk of -8.647 of olmesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: sertraline with relative risk of -8.999 of olmesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: mometasone with relative risk of -9.242 of olmesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: posaconazole with relative risk of -9.679 of olmesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: irbesartan with relative risk of -9.727 of olmesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 6: azelastine with relative risk of -10.076 of olmesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: tolmetin with relative risk of -10.653 of olmesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: auranofin with relative risk of -10.700 of olmesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: progesterone with relative risk of -10.991 of olmesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: ibutilide with relative risk of -11.114 of olmesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 11: milnacipran with relative risk of -11.395 of olmesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: dantrolene with relative risk of -11.491 of olmesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: abiraterone with relative risk of -11.500 of olmesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: telmisartan with relative risk of -11.674 of olmesartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 15: risedronate with relative risk of -11.781 of olmesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: lubiprostone with relative risk of -11.887 of olmesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: estramustine with relative risk of -11.980 of olmesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: donepezil with relative risk of -12.173 of olmesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: dapagliflozin with relative risk of -12.537 of olmesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: misoprostol with relative risk of -12.884 of olmesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: cisatracurium with relative risk of -14.637 of olmesartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.102\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target olodaterol not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó olopatadine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: vismodegib with relative risk of -8.774 of olopatadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: trazodone with relative risk of -21.554 of olopatadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: trazodone with relative risk of -21.554 of olopatadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: trazodone with relative risk of -21.554 of olopatadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: loperamide with relative risk of -23.139 of olopatadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: loperamide with relative risk of -23.139 of olopatadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: loperamide with relative risk of -23.139 of olopatadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: betaxolol with relative risk of -24.007 of olopatadine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: ophthalmology\n",
      "Rank 9: betaxolol with relative risk of -24.007 of olopatadine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: ophthalmology\n",
      "Rank 10: betaxolol with relative risk of -24.007 of olopatadine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: ophthalmology\n",
      "Rank 11: topiramate with relative risk of -24.154 of olopatadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: topiramate with relative risk of -24.154 of olopatadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: topiramate with relative risk of -24.154 of olopatadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: quinaprilat with relative risk of -25.811 of olopatadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: quinaprilat with relative risk of -25.811 of olopatadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: quinaprilat with relative risk of -25.811 of olopatadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: efinaconazole with relative risk of -inf of olopatadine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.098\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target olsalazine not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó omeprazole *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: cilostazol with relative risk of -11.956 of omeprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: empagliflozin with relative risk of -12.043 of omeprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: pilocarpine with relative risk of -12.698 of omeprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: raloxifene with relative risk of -12.755 of omeprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: medroxyprogesterone with relative risk of -12.814 of omeprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: pantoprazole with relative risk of -12.828 of omeprazole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Erosive esophagitis,Zollinger-Ellison syndrome,Gastroesophageal reflux disease,Peptic Ulcer,gastroenterology\n",
      "Rank 7: bupivacaine with relative risk of -13.325 of omeprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.064\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó ondansetron *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: rizatriptan with relative risk of -13.308 of ondansetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó orlistat *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: trimethoprim with relative risk of -22.759 of orlistat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: trimethoprim with relative risk of -22.759 of orlistat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target oseltamivir not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó ospemifene *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: ibandronate with relative risk of -10.192 of ospemifene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: ketorolac with relative risk of -11.258 of ospemifene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target oxaliplatin not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó oxcarbazepine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: clozapine with relative risk of -10.063 of oxcarbazepine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: vandetanib with relative risk of -11.340 of oxcarbazepine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: danazol with relative risk of -11.727 of oxcarbazepine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: efavirenz with relative risk of -12.600 of oxcarbazepine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: voriconazole with relative risk of -13.558 of oxcarbazepine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.438\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target oxiconazole not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó oxybutynin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: dexmedetomidine with relative risk of -21.729 of oxybutynin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: dexmedetomidine with relative risk of -21.729 of oxybutynin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: quetiapine with relative risk of -22.344 of oxybutynin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: quetiapine with relative risk of -22.344 of oxybutynin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target oxycodone not found. Exiting ...\n",
      "\n",
      "Drug target oxymorphone not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó paclitaxel *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: aminophylline with relative risk of -8.831 of paclitaxel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: entacapone with relative risk of -11.614 of paclitaxel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: ipratropium with relative risk of -11.881 of paclitaxel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: silodosin with relative risk of -12.126 of paclitaxel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: nefazodone with relative risk of -12.399 of paclitaxel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: clopidogrel with relative risk of -12.697 of paclitaxel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: formoterol with relative risk of -18.768 of paclitaxel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: formoterol with relative risk of -18.768 of paclitaxel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: frovatriptan with relative risk of -18.930 of paclitaxel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: frovatriptan with relative risk of -18.930 of paclitaxel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: nimodipine with relative risk of -19.480 of paclitaxel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: nimodipine with relative risk of -19.480 of paclitaxel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: cytarabine with relative risk of -19.695 of paclitaxel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: cytarabine with relative risk of -19.695 of paclitaxel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: rasagiline with relative risk of -21.853 of paclitaxel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: rasagiline with relative risk of -21.853 of paclitaxel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: rivastigmine with relative risk of -22.666 of paclitaxel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: rivastigmine with relative risk of -22.666 of paclitaxel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: sotalol with relative risk of -22.691 of paclitaxel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: sotalol with relative risk of -22.691 of paclitaxel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: rofecoxib with relative risk of -22.741 of paclitaxel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: rofecoxib with relative risk of -22.741 of paclitaxel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: pimozide with relative risk of -22.814 of paclitaxel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: pimozide with relative risk of -22.814 of paclitaxel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: capsaicin with relative risk of -23.265 of paclitaxel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: capsaicin with relative risk of -23.265 of paclitaxel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: fosinoprilat with relative risk of -25.547 of paclitaxel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: fosinoprilat with relative risk of -25.547 of paclitaxel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó paliperidone *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: penbutolol with relative risk of -7.601 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: telmisartan with relative risk of -8.735 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: clarithromycin with relative risk of -8.954 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: varenicline with relative risk of -9.032 of paliperidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 5: flutamide with relative risk of -9.041 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: bezafibrate with relative risk of -9.313 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: perindopril with relative risk of -9.496 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: cyclophosphamide with relative risk of -15.384 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: cyclophosphamide with relative risk of -15.384 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: nevirapine with relative risk of -15.666 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: nevirapine with relative risk of -15.666 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: capecitabine with relative risk of -16.365 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: capecitabine with relative risk of -16.365 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: sumatriptan with relative risk of -17.574 of paliperidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: sumatriptan with relative risk of -17.574 of paliperidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 16: citalopram with relative risk of -17.598 of paliperidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 17: citalopram with relative risk of -17.598 of paliperidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 18: darifenacin with relative risk of -18.694 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: darifenacin with relative risk of -18.694 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: darifenacin with relative risk of -18.694 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: naproxen with relative risk of -20.227 of paliperidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 22: naproxen with relative risk of -20.227 of paliperidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 23: naproxen with relative risk of -20.227 of paliperidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 24: ruxolitinib with relative risk of -20.752 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: ruxolitinib with relative risk of -20.752 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: ruxolitinib with relative risk of -20.752 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: metoprolol with relative risk of -20.951 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: metoprolol with relative risk of -20.951 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: metoprolol with relative risk of -20.951 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: milrinone with relative risk of -21.374 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: milrinone with relative risk of -21.374 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: milrinone with relative risk of -21.374 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: gabapentin with relative risk of -21.785 of paliperidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 34: gabapentin with relative risk of -21.785 of paliperidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 35: gabapentin with relative risk of -21.785 of paliperidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 36: ivacaftor with relative risk of -22.244 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: ivacaftor with relative risk of -22.244 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: ivacaftor with relative risk of -22.244 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: bumetanide with relative risk of -22.249 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: bumetanide with relative risk of -22.249 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: bumetanide with relative risk of -22.249 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: tamsulosin with relative risk of -22.699 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: tamsulosin with relative risk of -22.699 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: tamsulosin with relative risk of -22.699 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: cetirizine with relative risk of -23.311 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: cetirizine with relative risk of -23.311 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: cetirizine with relative risk of -23.311 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: brimonidine with relative risk of -23.644 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: brimonidine with relative risk of -23.644 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: brimonidine with relative risk of -23.644 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: tazarotene with relative risk of -24.217 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: tazarotene with relative risk of -24.217 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 53: tazarotene with relative risk of -24.217 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 54: dapsone with relative risk of -24.477 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 55: dapsone with relative risk of -24.477 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 56: dapsone with relative risk of -24.477 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 57: brinzolamide with relative risk of -24.752 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 58: brinzolamide with relative risk of -24.752 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 59: brinzolamide with relative risk of -24.752 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 60: fondaparinux with relative risk of -25.081 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 61: fondaparinux with relative risk of -25.081 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 62: fondaparinux with relative risk of -25.081 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 63: acebutolol with relative risk of -25.097 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 64: acebutolol with relative risk of -25.097 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 65: acebutolol with relative risk of -25.097 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 66: isradipine with relative risk of -25.222 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 67: isradipine with relative risk of -25.222 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 68: isradipine with relative risk of -25.222 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 69: valsartan with relative risk of -25.240 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 70: valsartan with relative risk of -25.240 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 71: valsartan with relative risk of -25.240 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 72: everolimus with relative risk of -31.032 of paliperidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 73: everolimus with relative risk of -31.032 of paliperidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 74: everolimus with relative risk of -31.032 of paliperidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 75: everolimus with relative risk of -31.032 of paliperidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 76: indomethacin with relative risk of -35.381 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 77: indomethacin with relative risk of -35.381 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 78: indomethacin with relative risk of -35.381 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 79: indomethacin with relative risk of -35.381 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 80: indomethacin with relative risk of -35.381 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 81: pemetrexed with relative risk of -35.444 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 82: pemetrexed with relative risk of -35.444 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 83: pemetrexed with relative risk of -35.444 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 84: pemetrexed with relative risk of -35.444 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 85: pemetrexed with relative risk of -35.444 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 86: pentoxifylline with relative risk of -36.781 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 87: pentoxifylline with relative risk of -36.781 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 88: pentoxifylline with relative risk of -36.781 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 89: pentoxifylline with relative risk of -36.781 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 90: pentoxifylline with relative risk of -36.781 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 91: pentoxifylline with relative risk of -36.781 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 92: dutasteride with relative risk of -37.060 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 93: dutasteride with relative risk of -37.060 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 94: dutasteride with relative risk of -37.060 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 95: dutasteride with relative risk of -37.060 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 96: dutasteride with relative risk of -37.060 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 97: zolmitriptan with relative risk of -39.984 of paliperidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 98: zolmitriptan with relative risk of -39.984 of paliperidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 99: zolmitriptan with relative risk of -39.984 of paliperidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 100: zolmitriptan with relative risk of -39.984 of paliperidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 101: zolmitriptan with relative risk of -39.984 of paliperidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 102: ropivacaine with relative risk of -40.612 of paliperidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 103: ropivacaine with relative risk of -40.612 of paliperidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 104: ropivacaine with relative risk of -40.612 of paliperidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 105: ropivacaine with relative risk of -40.612 of paliperidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 106: ropivacaine with relative risk of -40.612 of paliperidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 107: ropivacaine with relative risk of -40.612 of paliperidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 108: terbutaline with relative risk of -42.037 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 109: terbutaline with relative risk of -42.037 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 110: terbutaline with relative risk of -42.037 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 111: terbutaline with relative risk of -42.037 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 112: terbutaline with relative risk of -42.037 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 113: terbutaline with relative risk of -42.037 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 114: lurasidone with relative risk of -42.793 of paliperidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 115: lurasidone with relative risk of -42.793 of paliperidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 116: lurasidone with relative risk of -42.793 of paliperidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 117: lurasidone with relative risk of -42.793 of paliperidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 118: lurasidone with relative risk of -42.793 of paliperidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 119: lurasidone with relative risk of -42.793 of paliperidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 120: trovafloxacin with relative risk of -43.919 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 121: trovafloxacin with relative risk of -43.919 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 122: trovafloxacin with relative risk of -43.919 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 123: trovafloxacin with relative risk of -43.919 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 124: trovafloxacin with relative risk of -43.919 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 125: trovafloxacin with relative risk of -43.919 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 126: didanosine with relative risk of -45.950 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 127: didanosine with relative risk of -45.950 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 128: didanosine with relative risk of -45.950 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 129: didanosine with relative risk of -45.950 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 130: didanosine with relative risk of -45.950 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 131: didanosine with relative risk of -45.950 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 132: esmolol with relative risk of -45.994 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 133: esmolol with relative risk of -45.994 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 134: esmolol with relative risk of -45.994 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 135: esmolol with relative risk of -45.994 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 136: esmolol with relative risk of -45.994 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 137: esmolol with relative risk of -45.994 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 138: azilsartan with relative risk of -47.453 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 139: azilsartan with relative risk of -47.453 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 140: azilsartan with relative risk of -47.453 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 141: azilsartan with relative risk of -47.453 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 142: azilsartan with relative risk of -47.453 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 143: azilsartan with relative risk of -47.453 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 144: ketorolac with relative risk of -48.047 of paliperidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 145: ketorolac with relative risk of -48.047 of paliperidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 146: ketorolac with relative risk of -48.047 of paliperidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 147: ketorolac with relative risk of -48.047 of paliperidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 148: ketorolac with relative risk of -48.047 of paliperidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 149: ketorolac with relative risk of -48.047 of paliperidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 150: ketorolac with relative risk of -48.047 of paliperidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 151: levonorgestrel with relative risk of -53.198 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 152: levonorgestrel with relative risk of -53.198 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 153: levonorgestrel with relative risk of -53.198 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 154: levonorgestrel with relative risk of -53.198 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 155: levonorgestrel with relative risk of -53.198 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 156: levonorgestrel with relative risk of -53.198 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 157: levonorgestrel with relative risk of -53.198 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 158: lansoprazole with relative risk of -75.062 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 159: lansoprazole with relative risk of -75.062 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 160: lansoprazole with relative risk of -75.062 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 161: lansoprazole with relative risk of -75.062 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 162: lansoprazole with relative risk of -75.062 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 163: lansoprazole with relative risk of -75.062 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 164: lansoprazole with relative risk of -75.062 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 165: lansoprazole with relative risk of -75.062 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 166: lansoprazole with relative risk of -75.062 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 167: lansoprazole with relative risk of -75.062 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 168: etoposide with relative risk of -107.433 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 169: etoposide with relative risk of -107.433 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 170: etoposide with relative risk of -107.433 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 171: etoposide with relative risk of -107.433 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 172: etoposide with relative risk of -107.433 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 173: etoposide with relative risk of -107.433 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 174: etoposide with relative risk of -107.433 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 175: etoposide with relative risk of -107.433 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 176: etoposide with relative risk of -107.433 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 177: etoposide with relative risk of -107.433 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 178: etoposide with relative risk of -107.433 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 179: etoposide with relative risk of -107.433 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 180: etoposide with relative risk of -107.433 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 181: etoposide with relative risk of -107.433 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 182: fenofibrate with relative risk of -109.976 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 183: fenofibrate with relative risk of -109.976 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 184: fenofibrate with relative risk of -109.976 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 185: fenofibrate with relative risk of -109.976 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 186: fenofibrate with relative risk of -109.976 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 187: fenofibrate with relative risk of -109.976 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 188: fenofibrate with relative risk of -109.976 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 189: fenofibrate with relative risk of -109.976 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 190: fenofibrate with relative risk of -109.976 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 191: fenofibrate with relative risk of -109.976 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 192: fenofibrate with relative risk of -109.976 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 193: fenofibrate with relative risk of -109.976 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 194: fenofibrate with relative risk of -109.976 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 195: fenofibrate with relative risk of -109.976 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 196: irbesartan with relative risk of -115.130 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 197: irbesartan with relative risk of -115.130 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 198: irbesartan with relative risk of -115.130 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 199: irbesartan with relative risk of -115.130 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 200: irbesartan with relative risk of -115.130 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 201: irbesartan with relative risk of -115.130 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 202: irbesartan with relative risk of -115.130 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 203: irbesartan with relative risk of -115.130 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 204: irbesartan with relative risk of -115.130 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 205: irbesartan with relative risk of -115.130 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 206: irbesartan with relative risk of -115.130 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 207: irbesartan with relative risk of -115.130 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 208: irbesartan with relative risk of -115.130 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 209: irbesartan with relative risk of -115.130 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 210: irbesartan with relative risk of -115.130 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 211: irbesartan with relative risk of -115.130 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 212: irbesartan with relative risk of -115.130 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 213: irbesartan with relative risk of -115.130 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 214: azelastine with relative risk of -115.616 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 215: azelastine with relative risk of -115.616 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 216: azelastine with relative risk of -115.616 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 217: azelastine with relative risk of -115.616 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 218: azelastine with relative risk of -115.616 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 219: azelastine with relative risk of -115.616 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 220: azelastine with relative risk of -115.616 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 221: azelastine with relative risk of -115.616 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 222: azelastine with relative risk of -115.616 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 223: azelastine with relative risk of -115.616 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 224: azelastine with relative risk of -115.616 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 225: azelastine with relative risk of -115.616 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 226: azelastine with relative risk of -115.616 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 227: azelastine with relative risk of -115.616 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 228: azelastine with relative risk of -115.616 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 229: azelastine with relative risk of -115.616 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 230: azelastine with relative risk of -115.616 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 231: sertraline with relative risk of -116.224 of paliperidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 232: sertraline with relative risk of -116.224 of paliperidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 233: sertraline with relative risk of -116.224 of paliperidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 234: sertraline with relative risk of -116.224 of paliperidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 235: sertraline with relative risk of -116.224 of paliperidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 236: sertraline with relative risk of -116.224 of paliperidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 237: sertraline with relative risk of -116.224 of paliperidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 238: sertraline with relative risk of -116.224 of paliperidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 239: sertraline with relative risk of -116.224 of paliperidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 240: sertraline with relative risk of -116.224 of paliperidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 241: sertraline with relative risk of -116.224 of paliperidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 242: sertraline with relative risk of -116.224 of paliperidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 243: sertraline with relative risk of -116.224 of paliperidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 244: sertraline with relative risk of -116.224 of paliperidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 245: sertraline with relative risk of -116.224 of paliperidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 246: sertraline with relative risk of -116.224 of paliperidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 247: sertraline with relative risk of -116.224 of paliperidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 248: sertraline with relative risk of -116.224 of paliperidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 249: regadenoson with relative risk of -119.178 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 250: regadenoson with relative risk of -119.178 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 251: regadenoson with relative risk of -119.178 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 252: regadenoson with relative risk of -119.178 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 253: regadenoson with relative risk of -119.178 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 254: regadenoson with relative risk of -119.178 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 255: regadenoson with relative risk of -119.178 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 256: regadenoson with relative risk of -119.178 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 257: regadenoson with relative risk of -119.178 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 258: regadenoson with relative risk of -119.178 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 259: regadenoson with relative risk of -119.178 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 260: regadenoson with relative risk of -119.178 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 261: regadenoson with relative risk of -119.178 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 262: regadenoson with relative risk of -119.178 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 263: regadenoson with relative risk of -119.178 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 264: regadenoson with relative risk of -119.178 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 265: regadenoson with relative risk of -119.178 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 266: posaconazole with relative risk of -121.232 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 267: posaconazole with relative risk of -121.232 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 268: posaconazole with relative risk of -121.232 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 269: posaconazole with relative risk of -121.232 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 270: posaconazole with relative risk of -121.232 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 271: posaconazole with relative risk of -121.232 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 272: posaconazole with relative risk of -121.232 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 273: posaconazole with relative risk of -121.232 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 274: posaconazole with relative risk of -121.232 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 275: posaconazole with relative risk of -121.232 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 276: posaconazole with relative risk of -121.232 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 277: posaconazole with relative risk of -121.232 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 278: posaconazole with relative risk of -121.232 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 279: posaconazole with relative risk of -121.232 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 280: posaconazole with relative risk of -121.232 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 281: posaconazole with relative risk of -121.232 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 282: posaconazole with relative risk of -121.232 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 283: tropisetron with relative risk of -128.663 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 284: tropisetron with relative risk of -128.663 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 285: tropisetron with relative risk of -128.663 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 286: tropisetron with relative risk of -128.663 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 287: tropisetron with relative risk of -128.663 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 288: tropisetron with relative risk of -128.663 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 289: tropisetron with relative risk of -128.663 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 290: tropisetron with relative risk of -128.663 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 291: tropisetron with relative risk of -128.663 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 292: tropisetron with relative risk of -128.663 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 293: tropisetron with relative risk of -128.663 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 294: tropisetron with relative risk of -128.663 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 295: tropisetron with relative risk of -128.663 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 296: tropisetron with relative risk of -128.663 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 297: tropisetron with relative risk of -128.663 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 298: tropisetron with relative risk of -128.663 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 299: tropisetron with relative risk of -128.663 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 300: ibutilide with relative risk of -129.645 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 301: ibutilide with relative risk of -129.645 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 302: ibutilide with relative risk of -129.645 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 303: ibutilide with relative risk of -129.645 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 304: ibutilide with relative risk of -129.645 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 305: ibutilide with relative risk of -129.645 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 306: ibutilide with relative risk of -129.645 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 307: ibutilide with relative risk of -129.645 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 308: ibutilide with relative risk of -129.645 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 309: ibutilide with relative risk of -129.645 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 310: ibutilide with relative risk of -129.645 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 311: ibutilide with relative risk of -129.645 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 312: ibutilide with relative risk of -129.645 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 313: ibutilide with relative risk of -129.645 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 314: ibutilide with relative risk of -129.645 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 315: ibutilide with relative risk of -129.645 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 316: ibutilide with relative risk of -129.645 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 317: ibutilide with relative risk of -129.645 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 318: glimepiride with relative risk of -135.319 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 319: glimepiride with relative risk of -135.319 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 320: glimepiride with relative risk of -135.319 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 321: glimepiride with relative risk of -135.319 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 322: glimepiride with relative risk of -135.319 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 323: glimepiride with relative risk of -135.319 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 324: glimepiride with relative risk of -135.319 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 325: glimepiride with relative risk of -135.319 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 326: glimepiride with relative risk of -135.319 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 327: glimepiride with relative risk of -135.319 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 328: glimepiride with relative risk of -135.319 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 329: glimepiride with relative risk of -135.319 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 330: glimepiride with relative risk of -135.319 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 331: glimepiride with relative risk of -135.319 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 332: glimepiride with relative risk of -135.319 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 333: glimepiride with relative risk of -135.319 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 334: glimepiride with relative risk of -135.319 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 335: mometasone with relative risk of -135.553 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 336: mometasone with relative risk of -135.553 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 337: mometasone with relative risk of -135.553 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 338: mometasone with relative risk of -135.553 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 339: mometasone with relative risk of -135.553 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 340: mometasone with relative risk of -135.553 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 341: mometasone with relative risk of -135.553 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 342: mometasone with relative risk of -135.553 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 343: mometasone with relative risk of -135.553 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 344: mometasone with relative risk of -135.553 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 345: mometasone with relative risk of -135.553 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 346: mometasone with relative risk of -135.553 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 347: mometasone with relative risk of -135.553 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 348: mometasone with relative risk of -135.553 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 349: mometasone with relative risk of -135.553 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 350: mometasone with relative risk of -135.553 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 351: mometasone with relative risk of -135.553 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 352: mometasone with relative risk of -135.553 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 353: mometasone with relative risk of -135.553 of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 354: felodipine with relative risk of -inf of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 355: felodipine with relative risk of -inf of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 356: felodipine with relative risk of -inf of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 357: felodipine with relative risk of -inf of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 358: felodipine with relative risk of -inf of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 359: felodipine with relative risk of -inf of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 360: felodipine with relative risk of -inf of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 361: felodipine with relative risk of -inf of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 362: felodipine with relative risk of -inf of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 363: felodipine with relative risk of -inf of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 364: felodipine with relative risk of -inf of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 365: felodipine with relative risk of -inf of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 366: felodipine with relative risk of -inf of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 367: felodipine with relative risk of -inf of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 368: felodipine with relative risk of -inf of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 369: felodipine with relative risk of -inf of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 370: felodipine with relative risk of -inf of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 371: felodipine with relative risk of -inf of paliperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.165\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó palonosetron *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: fludarabine with relative risk of -12.191 of palonosetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: belinostat with relative risk of -12.309 of palonosetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: timolol with relative risk of -13.412 of palonosetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: quinapril with relative risk of -13.910 of palonosetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó pamidronate *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: loperamide with relative risk of -15.858 of pamidronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: loperamide with relative risk of -15.858 of pamidronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: topiramate with relative risk of -16.297 of pamidronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: topiramate with relative risk of -16.297 of pamidronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: pravastatin with relative risk of -20.664 of pamidronate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 6: pravastatin with relative risk of -20.664 of pamidronate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.15\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó pantoprazole *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: cilostazol with relative risk of -11.263 of pantoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: empagliflozin with relative risk of -11.350 of pantoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: pilocarpine with relative risk of -12.005 of pantoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: raloxifene with relative risk of -12.062 of pantoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: medroxyprogesterone with relative risk of -12.121 of pantoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: bupivacaine with relative risk of -12.632 of pantoprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: omeprazole with relative risk of -12.772 of pantoprazole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Erosive esophagitis,Zollinger-Ellison syndrome,Gastroesophageal reflux disease,Peptic Ulcer,gastroenterology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.055\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó paricalcitol *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: fexofenadine with relative risk of -10.973 of paricalcitol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó paroxetine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: amiodarone with relative risk of -6.388 of paroxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: nisoldipine with relative risk of -6.908 of paroxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: penbutolol with relative risk of -7.037 of paroxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: irinotecan with relative risk of -7.101 of paroxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: topotecan with relative risk of -7.315 of paroxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: ketorolac with relative risk of -7.747 of paroxetine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: fluvastatin with relative risk of -7.773 of paroxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: zonisamide with relative risk of -8.663 of paroxetine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: macitentan with relative risk of -8.806 of paroxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: bisoprolol with relative risk of -9.454 of paroxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: prasugrel with relative risk of -10.127 of paroxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: loratadine with relative risk of -13.898 of paroxetine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: loratadine with relative risk of -13.898 of paroxetine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: travoprost with relative risk of -23.081 of paroxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: travoprost with relative risk of -23.081 of paroxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: travoprost with relative risk of -23.081 of paroxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: crizotinib with relative risk of -25.704 of paroxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: crizotinib with relative risk of -25.704 of paroxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: crizotinib with relative risk of -25.704 of paroxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: crizotinib with relative risk of -25.704 of paroxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: moxifloxacin with relative risk of -30.443 of paroxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: moxifloxacin with relative risk of -30.443 of paroxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: moxifloxacin with relative risk of -30.443 of paroxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: moxifloxacin with relative risk of -30.443 of paroxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: clofarabine with relative risk of -33.954 of paroxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: clofarabine with relative risk of -33.954 of paroxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: clofarabine with relative risk of -33.954 of paroxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: clofarabine with relative risk of -33.954 of paroxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: clofarabine with relative risk of -33.954 of paroxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: tadalafil with relative risk of -36.820 of paroxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: tadalafil with relative risk of -36.820 of paroxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: tadalafil with relative risk of -36.820 of paroxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: tadalafil with relative risk of -36.820 of paroxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: tadalafil with relative risk of -36.820 of paroxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: tadalafil with relative risk of -36.820 of paroxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: tadalafil with relative risk of -36.820 of paroxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: nabumetone with relative risk of -41.943 of paroxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: nabumetone with relative risk of -41.943 of paroxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: nabumetone with relative risk of -41.943 of paroxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: nabumetone with relative risk of -41.943 of paroxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: nabumetone with relative risk of -41.943 of paroxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: nabumetone with relative risk of -41.943 of paroxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: nabumetone with relative risk of -41.943 of paroxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: ticagrelor with relative risk of -44.792 of paroxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: ticagrelor with relative risk of -44.792 of paroxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: ticagrelor with relative risk of -44.792 of paroxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: ticagrelor with relative risk of -44.792 of paroxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: ticagrelor with relative risk of -44.792 of paroxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: ticagrelor with relative risk of -44.792 of paroxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: ticagrelor with relative risk of -44.792 of paroxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: pentoxifylline with relative risk of -45.340 of paroxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: pentoxifylline with relative risk of -45.340 of paroxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 53: pentoxifylline with relative risk of -45.340 of paroxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 54: pentoxifylline with relative risk of -45.340 of paroxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 55: pentoxifylline with relative risk of -45.340 of paroxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 56: pentoxifylline with relative risk of -45.340 of paroxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 57: pentoxifylline with relative risk of -45.340 of paroxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 58: pentoxifylline with relative risk of -45.340 of paroxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 59: dolutegravir with relative risk of -49.517 of paroxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 60: dolutegravir with relative risk of -49.517 of paroxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 61: dolutegravir with relative risk of -49.517 of paroxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 62: dolutegravir with relative risk of -49.517 of paroxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 63: dolutegravir with relative risk of -49.517 of paroxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 64: dolutegravir with relative risk of -49.517 of paroxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 65: dolutegravir with relative risk of -49.517 of paroxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 66: ibandronate with relative risk of -71.146 of paroxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 67: ibandronate with relative risk of -71.146 of paroxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 68: ibandronate with relative risk of -71.146 of paroxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 69: ibandronate with relative risk of -71.146 of paroxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 70: ibandronate with relative risk of -71.146 of paroxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 71: ibandronate with relative risk of -71.146 of paroxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 72: ibandronate with relative risk of -71.146 of paroxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 73: ibandronate with relative risk of -71.146 of paroxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 74: ibandronate with relative risk of -71.146 of paroxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 75: ibandronate with relative risk of -71.146 of paroxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 76: ibandronate with relative risk of -71.146 of paroxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 77: ibandronate with relative risk of -71.146 of paroxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 78: desoximetasone with relative risk of -inf of paroxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 79: desoximetasone with relative risk of -inf of paroxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 80: desoximetasone with relative risk of -inf of paroxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.091\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó pazopanib *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: fluvoxamine with relative risk of -8.974 of pazopanib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: frovatriptan with relative risk of -10.080 of pazopanib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó pemetrexed *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: ropivacaine with relative risk of -8.224 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: levonorgestrel with relative risk of -8.332 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: naproxen with relative risk of -8.448 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: ruxolitinib with relative risk of -8.567 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: ketorolac with relative risk of -9.315 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: cetirizine with relative risk of -9.924 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: varenicline with relative risk of -10.029 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: sumatriptan with relative risk of -10.715 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: lurasidone with relative risk of -15.624 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: lurasidone with relative risk of -15.624 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: lansoprazole with relative risk of -15.817 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: lansoprazole with relative risk of -15.817 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: didanosine with relative risk of -16.073 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: didanosine with relative risk of -16.073 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: bumetanide with relative risk of -17.124 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: bumetanide with relative risk of -17.124 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: nevirapine with relative risk of -17.763 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: nevirapine with relative risk of -17.763 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: capecitabine with relative risk of -18.462 of pemetrexed | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 20: capecitabine with relative risk of -18.462 of pemetrexed | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 21: sertraline with relative risk of -24.331 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: sertraline with relative risk of -24.331 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: sertraline with relative risk of -24.331 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: sertraline with relative risk of -24.331 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: etoposide with relative risk of -27.798 of pemetrexed | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Small cell carcinoma of lung,oncology\n",
      "Rank 26: etoposide with relative risk of -27.798 of pemetrexed | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Small cell carcinoma of lung,oncology\n",
      "Rank 27: etoposide with relative risk of -27.798 of pemetrexed | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Small cell carcinoma of lung,oncology\n",
      "Rank 28: etoposide with relative risk of -27.798 of pemetrexed | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Small cell carcinoma of lung,oncology\n",
      "Rank 29: fondaparinux with relative risk of -28.402 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: fondaparinux with relative risk of -28.402 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: fondaparinux with relative risk of -28.402 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: glimepiride with relative risk of -28.751 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: glimepiride with relative risk of -28.751 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: glimepiride with relative risk of -28.751 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: glimepiride with relative risk of -28.751 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: fenofibrate with relative risk of -30.342 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: fenofibrate with relative risk of -30.342 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: fenofibrate with relative risk of -30.342 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: fenofibrate with relative risk of -30.342 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: regadenoson with relative risk of -33.200 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: regadenoson with relative risk of -33.200 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: regadenoson with relative risk of -33.200 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: regadenoson with relative risk of -33.200 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: regadenoson with relative risk of -33.200 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: azelastine with relative risk of -33.719 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: azelastine with relative risk of -33.719 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: azelastine with relative risk of -33.719 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: azelastine with relative risk of -33.719 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: azelastine with relative risk of -33.719 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: dutasteride with relative risk of -33.908 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: dutasteride with relative risk of -33.908 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: dutasteride with relative risk of -33.908 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 53: dutasteride with relative risk of -33.908 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 54: posaconazole with relative risk of -34.407 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 55: posaconazole with relative risk of -34.407 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 56: posaconazole with relative risk of -34.407 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 57: posaconazole with relative risk of -34.407 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 58: posaconazole with relative risk of -34.407 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 59: paliperidone with relative risk of -36.426 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 60: paliperidone with relative risk of -36.426 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 61: paliperidone with relative risk of -36.426 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 62: paliperidone with relative risk of -36.426 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 63: paliperidone with relative risk of -36.426 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 64: ibutilide with relative risk of -43.357 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 65: ibutilide with relative risk of -43.357 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 66: ibutilide with relative risk of -43.357 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 67: ibutilide with relative risk of -43.357 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 68: ibutilide with relative risk of -43.357 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 69: ibutilide with relative risk of -43.357 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 70: metoprolol with relative risk of -44.198 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 71: metoprolol with relative risk of -44.198 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 72: metoprolol with relative risk of -44.198 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 73: metoprolol with relative risk of -44.198 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 74: metoprolol with relative risk of -44.198 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 75: milrinone with relative risk of -44.621 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 76: milrinone with relative risk of -44.621 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 77: milrinone with relative risk of -44.621 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 78: milrinone with relative risk of -44.621 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 79: milrinone with relative risk of -44.621 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 80: tropisetron with relative risk of -44.659 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 81: tropisetron with relative risk of -44.659 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 82: tropisetron with relative risk of -44.659 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 83: tropisetron with relative risk of -44.659 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 84: tropisetron with relative risk of -44.659 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 85: tropisetron with relative risk of -44.659 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 86: tamsulosin with relative risk of -45.946 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 87: tamsulosin with relative risk of -45.946 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 88: tamsulosin with relative risk of -45.946 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 89: tamsulosin with relative risk of -45.946 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 90: tamsulosin with relative risk of -45.946 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 91: irbesartan with relative risk of -47.154 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 92: irbesartan with relative risk of -47.154 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 93: irbesartan with relative risk of -47.154 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 94: irbesartan with relative risk of -47.154 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 95: irbesartan with relative risk of -47.154 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 96: irbesartan with relative risk of -47.154 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 97: irbesartan with relative risk of -47.154 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 98: mometasone with relative risk of -49.697 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 99: mometasone with relative risk of -49.697 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 100: mometasone with relative risk of -49.697 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 101: mometasone with relative risk of -49.697 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 102: mometasone with relative risk of -49.697 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 103: mometasone with relative risk of -49.697 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 104: mometasone with relative risk of -49.697 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 105: indomethacin with relative risk of -51.750 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 106: indomethacin with relative risk of -51.750 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 107: indomethacin with relative risk of -51.750 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 108: indomethacin with relative risk of -51.750 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 109: indomethacin with relative risk of -51.750 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 110: indomethacin with relative risk of -51.750 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 111: trovafloxacin with relative risk of -52.180 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 112: trovafloxacin with relative risk of -52.180 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 113: trovafloxacin with relative risk of -52.180 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 114: trovafloxacin with relative risk of -52.180 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 115: trovafloxacin with relative risk of -52.180 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 116: trovafloxacin with relative risk of -52.180 of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 117: felodipine with relative risk of -inf of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 118: felodipine with relative risk of -inf of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 119: felodipine with relative risk of -inf of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 120: felodipine with relative risk of -inf of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 121: felodipine with relative risk of -inf of pemetrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.047\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó penbutolol *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: etoposide with relative risk of -5.284 of penbutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: regadenoson with relative risk of -5.309 of penbutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: sertraline with relative risk of -5.685 of penbutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: mometasone with relative risk of -5.911 of penbutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: posaconazole with relative risk of -6.341 of penbutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: paroxetine with relative risk of -6.374 of penbutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: irbesartan with relative risk of -6.418 of penbutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 8: azelastine with relative risk of -6.746 of penbutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: glimepiride with relative risk of -6.911 of penbutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: levonorgestrel with relative risk of -6.916 of penbutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: paliperidone with relative risk of -7.108 of penbutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: tropisetron with relative risk of -7.134 of penbutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: pentoxifylline with relative risk of -7.206 of penbutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 14: esmolol with relative risk of -7.354 of penbutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 15: terbutaline with relative risk of -7.425 of penbutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: ivacaftor with relative risk of -7.438 of penbutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: everolimus with relative risk of -7.558 of penbutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: ibutilide with relative risk of -7.780 of penbutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 19: fenofibrate with relative risk of -7.828 of penbutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: azilsartan with relative risk of -8.814 of penbutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 21: brinzolamide with relative risk of -8.847 of penbutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: amoxapine with relative risk of -8.863 of penbutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: zolmitriptan with relative risk of -8.941 of penbutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: adapalene with relative risk of -9.142 of penbutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: liraglutide with relative risk of -9.191 of penbutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: acebutolol with relative risk of -9.192 of penbutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 27: valsartan with relative risk of -9.335 of penbutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 28: linagliptin with relative risk of -10.096 of penbutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: eletriptan with relative risk of -10.742 of penbutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: dexamethasone with relative risk of -16.238 of penbutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: dexamethasone with relative risk of -16.238 of penbutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: nisoldipine with relative risk of -18.936 of penbutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 33: nisoldipine with relative risk of -18.936 of penbutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 34: nisoldipine with relative risk of -18.936 of penbutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 35: bexarotene with relative risk of -19.729 of penbutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: bexarotene with relative risk of -19.729 of penbutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: bexarotene with relative risk of -19.729 of penbutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: irinotecan with relative risk of -20.739 of penbutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: irinotecan with relative risk of -20.739 of penbutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: irinotecan with relative risk of -20.739 of penbutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: regorafenib with relative risk of -21.508 of penbutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: regorafenib with relative risk of -21.508 of penbutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: regorafenib with relative risk of -21.508 of penbutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: tizanidine with relative risk of -24.630 of penbutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: tizanidine with relative risk of -24.630 of penbutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: tizanidine with relative risk of -24.630 of penbutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: tizanidine with relative risk of -24.630 of penbutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: ketoprofen with relative risk of -29.151 of penbutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: ketoprofen with relative risk of -29.151 of penbutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: ketoprofen with relative risk of -29.151 of penbutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: ketoprofen with relative risk of -29.151 of penbutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: sitagliptin with relative risk of -30.529 of penbutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 53: sitagliptin with relative risk of -30.529 of penbutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 54: sitagliptin with relative risk of -30.529 of penbutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 55: sitagliptin with relative risk of -30.529 of penbutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 56: propafenone with relative risk of -30.622 of penbutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 57: propafenone with relative risk of -30.622 of penbutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 58: propafenone with relative risk of -30.622 of penbutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 59: propafenone with relative risk of -30.622 of penbutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 60: fluvastatin with relative risk of -68.156 of penbutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 61: fluvastatin with relative risk of -68.156 of penbutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 62: fluvastatin with relative risk of -68.156 of penbutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 63: fluvastatin with relative risk of -68.156 of penbutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 64: fluvastatin with relative risk of -68.156 of penbutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 65: fluvastatin with relative risk of -68.156 of penbutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 66: fluvastatin with relative risk of -68.156 of penbutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 67: fluvastatin with relative risk of -68.156 of penbutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 68: fluvastatin with relative risk of -68.156 of penbutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 69: fluvastatin with relative risk of -68.156 of penbutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 70: amiodarone with relative risk of -148.411 of penbutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 71: amiodarone with relative risk of -148.411 of penbutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 72: amiodarone with relative risk of -148.411 of penbutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 73: amiodarone with relative risk of -148.411 of penbutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 74: amiodarone with relative risk of -148.411 of penbutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 75: amiodarone with relative risk of -148.411 of penbutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 76: amiodarone with relative risk of -148.411 of penbutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 77: amiodarone with relative risk of -148.411 of penbutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 78: amiodarone with relative risk of -148.411 of penbutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 79: amiodarone with relative risk of -148.411 of penbutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 80: amiodarone with relative risk of -148.411 of penbutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 81: amiodarone with relative risk of -148.411 of penbutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 82: amiodarone with relative risk of -148.411 of penbutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 83: amiodarone with relative risk of -148.411 of penbutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 84: amiodarone with relative risk of -148.411 of penbutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 85: amiodarone with relative risk of -148.411 of penbutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 86: amiodarone with relative risk of -148.411 of penbutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 87: amiodarone with relative risk of -148.411 of penbutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 88: amiodarone with relative risk of -148.411 of penbutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 89: amiodarone with relative risk of -148.411 of penbutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 90: amiodarone with relative risk of -148.411 of penbutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 91: amiodarone with relative risk of -148.411 of penbutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 92: amiodarone with relative risk of -148.411 of penbutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 93: lenalidomide with relative risk of -163.063 of penbutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 94: lenalidomide with relative risk of -163.063 of penbutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 95: lenalidomide with relative risk of -163.063 of penbutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 96: lenalidomide with relative risk of -163.063 of penbutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 97: lenalidomide with relative risk of -163.063 of penbutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 98: lenalidomide with relative risk of -163.063 of penbutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 99: lenalidomide with relative risk of -163.063 of penbutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 100: lenalidomide with relative risk of -163.063 of penbutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 101: lenalidomide with relative risk of -163.063 of penbutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 102: lenalidomide with relative risk of -163.063 of penbutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 103: lenalidomide with relative risk of -163.063 of penbutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 104: lenalidomide with relative risk of -163.063 of penbutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 105: lenalidomide with relative risk of -163.063 of penbutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 106: lenalidomide with relative risk of -163.063 of penbutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 107: lenalidomide with relative risk of -163.063 of penbutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 108: lenalidomide with relative risk of -163.063 of penbutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 109: lenalidomide with relative risk of -163.063 of penbutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 110: lenalidomide with relative risk of -163.063 of penbutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 111: lenalidomide with relative risk of -163.063 of penbutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 112: lenalidomide with relative risk of -163.063 of penbutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 113: lenalidomide with relative risk of -163.063 of penbutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 114: lenalidomide with relative risk of -163.063 of penbutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 115: lenalidomide with relative risk of -163.063 of penbutolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 116: felodipine with relative risk of -inf of penbutolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.203\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target penciclovir not found. Exiting ...\n",
      "\n",
      "Drug target pentamidine not found. Exiting ...\n",
      "\n",
      "Drug target pentosan not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó pentostatin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: lenalidomide with relative risk of -7.421 of pentostatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: hematologic malignancy\n",
      "Rank 2: lamotrigine with relative risk of -10.185 of pentostatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: amiloride with relative risk of -11.178 of pentostatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: roflumilast with relative risk of -12.002 of pentostatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: raltitrexed with relative risk of -18.677 of pentostatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: raltitrexed with relative risk of -18.677 of pentostatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: norfloxacin with relative risk of -27.164 of pentostatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: norfloxacin with relative risk of -27.164 of pentostatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: norfloxacin with relative risk of -27.164 of pentostatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: diclofenac with relative risk of -32.841 of pentostatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: diclofenac with relative risk of -32.841 of pentostatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: diclofenac with relative risk of -32.841 of pentostatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: diclofenac with relative risk of -32.841 of pentostatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.314\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó pentoxifylline *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: vinorelbine with relative risk of -6.572 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: ciclesonide with relative risk of -7.088 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: axitinib with relative risk of -7.121 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: levonorgestrel with relative risk of -7.336 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: granisetron with relative risk of -7.459 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: penbutolol with relative risk of -7.601 of pentoxifylline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 7: apraclonidine with relative risk of -7.616 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: ribavirin with relative risk of -8.031 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: ketorolac with relative risk of -8.322 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: bumetanide with relative risk of -8.558 of pentoxifylline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 11: trovafloxacin with relative risk of -8.745 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: nevirapine with relative risk of -8.908 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: clarithromycin with relative risk of -8.954 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: lapatinib with relative risk of -8.975 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: afatinib with relative risk of -9.029 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: estramustine with relative risk of -9.040 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: zonisamide with relative risk of -9.244 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: losartan with relative risk of -9.373 of pentoxifylline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 19: celecoxib with relative risk of -9.418 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: etravirine with relative risk of -9.523 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: linezolid with relative risk of -9.689 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: beclomethasone with relative risk of -9.694 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: fluconazole with relative risk of -9.785 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: budesonide with relative risk of -10.061 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: temsirolimus with relative risk of -10.093 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: amisulpride with relative risk of -10.132 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: latanoprost with relative risk of -10.229 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: doxazosin with relative risk of -10.366 of pentoxifylline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 29: pergolide with relative risk of -10.573 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: pinaverium with relative risk of -10.596 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: prasugrel with relative risk of -10.709 of pentoxifylline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 32: lidocaine with relative risk of -10.776 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: miglustat with relative risk of -13.161 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: miglustat with relative risk of -13.161 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: meloxicam with relative risk of -13.515 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: meloxicam with relative risk of -13.515 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: lurasidone with relative risk of -13.530 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: lurasidone with relative risk of -13.530 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: lansoprazole with relative risk of -13.724 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: lansoprazole with relative risk of -13.724 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: didanosine with relative risk of -13.978 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: didanosine with relative risk of -13.978 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: loratadine with relative risk of -15.084 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: loratadine with relative risk of -15.084 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: dronedarone with relative risk of -15.786 of pentoxifylline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 46: dronedarone with relative risk of -15.786 of pentoxifylline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 47: travoprost with relative risk of -16.582 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: travoprost with relative risk of -16.582 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: perindopril with relative risk of -16.660 of pentoxifylline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 50: perindopril with relative risk of -16.660 of pentoxifylline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 51: etoposide with relative risk of -16.827 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: etoposide with relative risk of -16.827 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 53: etoposide with relative risk of -16.827 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 54: domperidone with relative risk of -17.756 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 55: domperidone with relative risk of -17.756 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 56: bisoprolol with relative risk of -17.892 of pentoxifylline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 57: bisoprolol with relative risk of -17.892 of pentoxifylline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 58: ropivacaine with relative risk of -19.129 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 59: ropivacaine with relative risk of -19.129 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 60: ropivacaine with relative risk of -19.129 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 61: fenofibrate with relative risk of -19.370 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 62: fenofibrate with relative risk of -19.370 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 63: fenofibrate with relative risk of -19.370 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 64: crizotinib with relative risk of -20.615 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 65: crizotinib with relative risk of -20.615 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 66: crizotinib with relative risk of -20.615 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 67: ivacaftor with relative risk of -22.244 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 68: ivacaftor with relative risk of -22.244 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 69: ivacaftor with relative risk of -22.244 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 70: zolmitriptan with relative risk of -23.054 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 71: zolmitriptan with relative risk of -23.054 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 72: zolmitriptan with relative risk of -23.054 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 73: argatroban with relative risk of -23.237 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 74: argatroban with relative risk of -23.237 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 75: argatroban with relative risk of -23.237 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 76: brimonidine with relative risk of -23.644 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 77: brimonidine with relative risk of -23.644 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 78: brimonidine with relative risk of -23.644 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 79: tazarotene with relative risk of -24.217 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 80: tazarotene with relative risk of -24.217 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 81: tazarotene with relative risk of -24.217 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 82: dapsone with relative risk of -24.477 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 83: dapsone with relative risk of -24.477 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 84: dapsone with relative risk of -24.477 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 85: brinzolamide with relative risk of -24.752 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 86: brinzolamide with relative risk of -24.752 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 87: brinzolamide with relative risk of -24.752 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 88: darifenacin with relative risk of -25.059 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 89: darifenacin with relative risk of -25.059 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 90: darifenacin with relative risk of -25.059 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 91: darifenacin with relative risk of -25.059 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 92: acebutolol with relative risk of -25.097 of pentoxifylline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 93: acebutolol with relative risk of -25.097 of pentoxifylline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 94: acebutolol with relative risk of -25.097 of pentoxifylline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 95: isradipine with relative risk of -25.222 of pentoxifylline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 96: isradipine with relative risk of -25.222 of pentoxifylline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 97: isradipine with relative risk of -25.222 of pentoxifylline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 98: valsartan with relative risk of -25.240 of pentoxifylline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 99: valsartan with relative risk of -25.240 of pentoxifylline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 100: valsartan with relative risk of -25.240 of pentoxifylline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 101: regadenoson with relative risk of -26.894 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 102: regadenoson with relative risk of -26.894 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 103: regadenoson with relative risk of -26.894 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 104: regadenoson with relative risk of -26.894 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 105: regadenoson with relative risk of -26.894 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 106: posaconazole with relative risk of -28.100 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 107: posaconazole with relative risk of -28.100 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 108: posaconazole with relative risk of -28.100 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 109: posaconazole with relative risk of -28.100 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 110: posaconazole with relative risk of -28.100 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 111: clofarabine with relative risk of -28.174 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 112: clofarabine with relative risk of -28.174 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 113: clofarabine with relative risk of -28.174 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 114: clofarabine with relative risk of -28.174 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 115: sertraline with relative risk of -30.401 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 116: sertraline with relative risk of -30.401 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 117: sertraline with relative risk of -30.401 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 118: sertraline with relative risk of -30.401 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 119: sertraline with relative risk of -30.401 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 120: sertraline with relative risk of -30.401 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 121: irbesartan with relative risk of -30.676 of pentoxifylline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 122: irbesartan with relative risk of -30.676 of pentoxifylline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 123: irbesartan with relative risk of -30.676 of pentoxifylline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 124: irbesartan with relative risk of -30.676 of pentoxifylline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 125: irbesartan with relative risk of -30.676 of pentoxifylline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 126: irbesartan with relative risk of -30.676 of pentoxifylline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 127: everolimus with relative risk of -31.032 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 128: everolimus with relative risk of -31.032 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 129: everolimus with relative risk of -31.032 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 130: everolimus with relative risk of -31.032 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 131: mometasone with relative risk of -32.667 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 132: mometasone with relative risk of -32.667 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 133: mometasone with relative risk of -32.667 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 134: mometasone with relative risk of -32.667 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 135: mometasone with relative risk of -32.667 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 136: mometasone with relative risk of -32.667 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 137: moxifloxacin with relative risk of -32.925 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 138: moxifloxacin with relative risk of -32.925 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 139: moxifloxacin with relative risk of -32.925 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 140: moxifloxacin with relative risk of -32.925 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 141: azelastine with relative risk of -33.326 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 142: azelastine with relative risk of -33.326 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 143: azelastine with relative risk of -33.326 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 144: azelastine with relative risk of -33.326 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 145: azelastine with relative risk of -33.326 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 146: azelastine with relative risk of -33.326 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 147: ibutilide with relative risk of -35.106 of pentoxifylline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 148: ibutilide with relative risk of -35.106 of pentoxifylline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 149: ibutilide with relative risk of -35.106 of pentoxifylline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 150: ibutilide with relative risk of -35.106 of pentoxifylline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 151: ibutilide with relative risk of -35.106 of pentoxifylline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 152: ibutilide with relative risk of -35.106 of pentoxifylline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 153: tropisetron with relative risk of -36.404 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 154: tropisetron with relative risk of -36.404 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 155: tropisetron with relative risk of -36.404 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 156: tropisetron with relative risk of -36.404 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 157: tropisetron with relative risk of -36.404 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 158: tropisetron with relative risk of -36.404 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 159: paliperidone with relative risk of -36.684 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 160: paliperidone with relative risk of -36.684 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 161: paliperidone with relative risk of -36.684 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 162: paliperidone with relative risk of -36.684 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 163: paliperidone with relative risk of -36.684 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 164: paliperidone with relative risk of -36.684 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 165: glimepiride with relative risk of -37.162 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 166: glimepiride with relative risk of -37.162 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 167: glimepiride with relative risk of -37.162 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 168: glimepiride with relative risk of -37.162 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 169: glimepiride with relative risk of -37.162 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 170: glimepiride with relative risk of -37.162 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 171: nabumetone with relative risk of -39.371 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 172: nabumetone with relative risk of -39.371 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 173: nabumetone with relative risk of -39.371 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 174: nabumetone with relative risk of -39.371 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 175: nabumetone with relative risk of -39.371 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 176: nabumetone with relative risk of -39.371 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 177: paroxetine with relative risk of -45.072 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 178: paroxetine with relative risk of -45.072 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 179: paroxetine with relative risk of -45.072 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 180: paroxetine with relative risk of -45.072 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 181: paroxetine with relative risk of -45.072 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 182: paroxetine with relative risk of -45.072 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 183: paroxetine with relative risk of -45.072 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 184: paroxetine with relative risk of -45.072 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 185: esmolol with relative risk of -45.994 of pentoxifylline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 186: esmolol with relative risk of -45.994 of pentoxifylline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 187: esmolol with relative risk of -45.994 of pentoxifylline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 188: esmolol with relative risk of -45.994 of pentoxifylline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 189: esmolol with relative risk of -45.994 of pentoxifylline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 190: esmolol with relative risk of -45.994 of pentoxifylline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 191: azilsartan with relative risk of -47.453 of pentoxifylline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 192: azilsartan with relative risk of -47.453 of pentoxifylline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 193: azilsartan with relative risk of -47.453 of pentoxifylline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 194: azilsartan with relative risk of -47.453 of pentoxifylline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 195: azilsartan with relative risk of -47.453 of pentoxifylline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 196: azilsartan with relative risk of -47.453 of pentoxifylline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 197: terbutaline with relative risk of -50.373 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 198: terbutaline with relative risk of -50.373 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 199: terbutaline with relative risk of -50.373 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 200: terbutaline with relative risk of -50.373 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 201: terbutaline with relative risk of -50.373 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 202: terbutaline with relative risk of -50.373 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 203: terbutaline with relative risk of -50.373 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 204: ibandronate with relative risk of -56.853 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 205: ibandronate with relative risk of -56.853 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 206: ibandronate with relative risk of -56.853 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 207: ibandronate with relative risk of -56.853 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 208: ibandronate with relative risk of -56.853 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 209: ibandronate with relative risk of -56.853 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 210: ibandronate with relative risk of -56.853 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 211: ibandronate with relative risk of -56.853 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 212: ibandronate with relative risk of -56.853 of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 213: felodipine with relative risk of -inf of pentoxifylline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 214: felodipine with relative risk of -inf of pentoxifylline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 215: felodipine with relative risk of -inf of pentoxifylline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 216: felodipine with relative risk of -inf of pentoxifylline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 217: felodipine with relative risk of -inf of pentoxifylline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 218: felodipine with relative risk of -inf of pentoxifylline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 219: desoximetasone with relative risk of -inf of pentoxifylline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 220: felodipine with relative risk of -inf of pentoxifylline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.132\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target perampanel not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó pergolide *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó perindopril *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: sertraline with relative risk of -7.905 of perindopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: mometasone with relative risk of -8.146 of perindopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: azelastine with relative risk of -8.980 of perindopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: glimepiride with relative risk of -9.162 of perindopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: darifenacin with relative risk of -9.239 of perindopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: paliperidone with relative risk of -9.357 of perindopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: tropisetron with relative risk of -9.382 of perindopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: esmolol with relative risk of -9.618 of perindopril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 9: terbutaline with relative risk of -9.684 of perindopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: brimonidine with relative risk of -10.005 of perindopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: ibutilide with relative risk of -10.018 of perindopril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 12: loratadine with relative risk of -10.457 of perindopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: tazarotene with relative risk of -10.578 of perindopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: dapsone with relative risk of -10.838 of perindopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: afatinib with relative risk of -10.875 of perindopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: azilsartan with relative risk of -11.077 of perindopril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 17: quinidine with relative risk of -11.165 of perindopril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 18: beclomethasone with relative risk of -11.539 of perindopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: isradipine with relative risk of -11.583 of perindopril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 20: budesonide with relative risk of -11.907 of perindopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: pergolide with relative risk of -12.419 of perindopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: aclidinium with relative risk of -12.464 of perindopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: caffeine with relative risk of -12.960 of perindopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: bromfenac with relative risk of -14.591 of perindopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: irbesartan with relative risk of -14.814 of perindopril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 26: irbesartan with relative risk of -14.814 of perindopril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 27: pentoxifylline with relative risk of -16.618 of perindopril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 28: pentoxifylline with relative risk of -16.618 of perindopril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 29: bumetanide with relative risk of -19.069 of perindopril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 30: bumetanide with relative risk of -19.069 of perindopril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 31: argatroban with relative risk of -19.652 of perindopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: argatroban with relative risk of -19.652 of perindopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: nevirapine with relative risk of -19.708 of perindopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: nevirapine with relative risk of -19.708 of perindopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: ribavirin with relative risk of -19.931 of perindopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: ribavirin with relative risk of -19.931 of perindopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: celecoxib with relative risk of -20.624 of perindopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: celecoxib with relative risk of -20.624 of perindopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: lapatinib with relative risk of -20.875 of perindopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: lapatinib with relative risk of -20.875 of perindopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: losartan with relative risk of -21.273 of perindopril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 42: losartan with relative risk of -21.273 of perindopril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 43: amisulpride with relative risk of -21.338 of perindopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: amisulpride with relative risk of -21.338 of perindopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: latanoprost with relative risk of -21.435 of perindopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: latanoprost with relative risk of -21.435 of perindopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: domperidone with relative risk of -21.798 of perindopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: domperidone with relative risk of -21.798 of perindopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: temsirolimus with relative risk of -21.993 of perindopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: temsirolimus with relative risk of -21.993 of perindopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: lidocaine with relative risk of -22.676 of perindopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: lidocaine with relative risk of -22.676 of perindopril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 53: felodipine with relative risk of -inf of perindopril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 54: felodipine with relative risk of -inf of perindopril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 55: felodipine with relative risk of -inf of perindopril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.155\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó phentolamine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: captopril with relative risk of -7.463 of phentolamine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology,endocrinology\n",
      "Rank 2: clozapine with relative risk of -8.678 of phentolamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: atorvastatin with relative risk of -8.949 of phentolamine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 4: bimatoprost with relative risk of -9.668 of phentolamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: vandetanib with relative risk of -9.954 of phentolamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: azathioprine with relative risk of -17.158 of phentolamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: azathioprine with relative risk of -17.158 of phentolamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: nifedipine with relative risk of -18.187 of phentolamine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 9: nifedipine with relative risk of -18.187 of phentolamine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 10: acitretin with relative risk of -19.467 of phentolamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: acitretin with relative risk of -19.467 of phentolamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: nilutamide with relative risk of -21.034 of phentolamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: nilutamide with relative risk of -21.034 of phentolamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: calcipotriol with relative risk of -inf of phentolamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.483\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target phenylbutyric not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó phenytoin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: cabazitaxel with relative risk of -10.581 of phenytoin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: mitotane with relative risk of -10.981 of phenytoin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: danazol with relative risk of -11.727 of phenytoin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: canagliflozin with relative risk of -12.616 of phenytoin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: gonadorelin with relative risk of -12.633 of phenytoin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: montelukast with relative risk of -13.000 of phenytoin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: dipyridamole with relative risk of -13.267 of phenytoin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: mexiletine with relative risk of -13.348 of phenytoin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: ranitidine with relative risk of -13.446 of phenytoin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: zafirlukast with relative risk of -13.520 of phenytoin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: cilazapril with relative risk of -15.324 of phenytoin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target phosphate not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó pilocarpine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: cilostazol with relative risk of -11.956 of pilocarpine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 2: empagliflozin with relative risk of -12.043 of pilocarpine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: raloxifene with relative risk of -12.755 of pilocarpine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: medroxyprogesterone with relative risk of -12.814 of pilocarpine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: pantoprazole with relative risk of -12.828 of pilocarpine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: bupivacaine with relative risk of -13.325 of pilocarpine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: omeprazole with relative risk of -13.465 of pilocarpine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.386\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target pimecrolimus not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó pimozide *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: aminophylline with relative risk of -8.831 of pimozide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: entacapone with relative risk of -11.614 of pimozide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: ipratropium with relative risk of -11.881 of pimozide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: silodosin with relative risk of -12.126 of pimozide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: nefazodone with relative risk of -12.399 of pimozide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: clopidogrel with relative risk of -12.697 of pimozide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: formoterol with relative risk of -18.768 of pimozide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: formoterol with relative risk of -18.768 of pimozide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: frovatriptan with relative risk of -18.930 of pimozide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: frovatriptan with relative risk of -18.930 of pimozide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: nimodipine with relative risk of -19.480 of pimozide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: nimodipine with relative risk of -19.480 of pimozide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: cytarabine with relative risk of -19.695 of pimozide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: cytarabine with relative risk of -19.695 of pimozide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: paclitaxel with relative risk of -20.985 of pimozide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: paclitaxel with relative risk of -20.985 of pimozide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: rasagiline with relative risk of -21.853 of pimozide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 18: rasagiline with relative risk of -21.853 of pimozide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 19: rivastigmine with relative risk of -22.666 of pimozide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 20: rivastigmine with relative risk of -22.666 of pimozide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 21: sotalol with relative risk of -22.691 of pimozide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: sotalol with relative risk of -22.691 of pimozide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: rofecoxib with relative risk of -22.741 of pimozide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: rofecoxib with relative risk of -22.741 of pimozide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: capsaicin with relative risk of -23.265 of pimozide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 26: capsaicin with relative risk of -23.265 of pimozide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 27: fosinoprilat with relative risk of -25.547 of pimozide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: fosinoprilat with relative risk of -25.547 of pimozide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.299\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó pinaverium *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: ibandronate with relative risk of -7.897 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: miglustat with relative risk of -8.022 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: pentoxifylline with relative risk of -8.256 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: formoterol with relative risk of -8.717 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: dabigatran with relative risk of -9.627 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: estramustine with relative risk of -9.680 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: zonisamide with relative risk of -9.885 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: etravirine with relative risk of -10.164 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: linezolid with relative risk of -10.330 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: tiotropium with relative risk of -10.551 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: febuxostat with relative risk of -12.597 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: eplerenone with relative risk of -16.801 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: eplerenone with relative risk of -16.801 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: exemestane with relative risk of -18.113 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: exemestane with relative risk of -18.113 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: indacaterol with relative risk of -24.984 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: indacaterol with relative risk of -24.984 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: indacaterol with relative risk of -24.984 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: ciclesonide with relative risk of -68.521 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: ciclesonide with relative risk of -68.521 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: ciclesonide with relative risk of -68.521 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: ciclesonide with relative risk of -68.521 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: ciclesonide with relative risk of -68.521 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: ciclesonide with relative risk of -68.521 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: ciclesonide with relative risk of -68.521 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: ciclesonide with relative risk of -68.521 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: ciclesonide with relative risk of -68.521 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: ciclesonide with relative risk of -68.521 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: meloxicam with relative risk of -81.320 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: meloxicam with relative risk of -81.320 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: meloxicam with relative risk of -81.320 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: meloxicam with relative risk of -81.320 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: meloxicam with relative risk of -81.320 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: meloxicam with relative risk of -81.320 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: meloxicam with relative risk of -81.320 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: meloxicam with relative risk of -81.320 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: meloxicam with relative risk of -81.320 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: meloxicam with relative risk of -81.320 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: darifenacin with relative risk of -82.634 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: darifenacin with relative risk of -82.634 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: darifenacin with relative risk of -82.634 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: darifenacin with relative risk of -82.634 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: darifenacin with relative risk of -82.634 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: darifenacin with relative risk of -82.634 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: darifenacin with relative risk of -82.634 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: darifenacin with relative risk of -82.634 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: darifenacin with relative risk of -82.634 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: darifenacin with relative risk of -82.634 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: axitinib with relative risk of -85.446 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: axitinib with relative risk of -85.446 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: axitinib with relative risk of -85.446 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: axitinib with relative risk of -85.446 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 53: axitinib with relative risk of -85.446 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 54: axitinib with relative risk of -85.446 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 55: axitinib with relative risk of -85.446 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 56: axitinib with relative risk of -85.446 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 57: axitinib with relative risk of -85.446 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 58: axitinib with relative risk of -85.446 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 59: vinorelbine with relative risk of -87.200 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 60: vinorelbine with relative risk of -87.200 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 61: vinorelbine with relative risk of -87.200 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 62: vinorelbine with relative risk of -87.200 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 63: vinorelbine with relative risk of -87.200 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 64: vinorelbine with relative risk of -87.200 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 65: vinorelbine with relative risk of -87.200 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 66: vinorelbine with relative risk of -87.200 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 67: vinorelbine with relative risk of -87.200 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 68: vinorelbine with relative risk of -87.200 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 69: granisetron with relative risk of -88.088 of pinaverium | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "Rank 70: granisetron with relative risk of -88.088 of pinaverium | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "Rank 71: granisetron with relative risk of -88.088 of pinaverium | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "Rank 72: granisetron with relative risk of -88.088 of pinaverium | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "Rank 73: granisetron with relative risk of -88.088 of pinaverium | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "Rank 74: granisetron with relative risk of -88.088 of pinaverium | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "Rank 75: granisetron with relative risk of -88.088 of pinaverium | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "Rank 76: granisetron with relative risk of -88.088 of pinaverium | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "Rank 77: granisetron with relative risk of -88.088 of pinaverium | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "Rank 78: granisetron with relative risk of -88.088 of pinaverium | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "Rank 79: apraclonidine with relative risk of -88.245 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 80: apraclonidine with relative risk of -88.245 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 81: apraclonidine with relative risk of -88.245 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 82: apraclonidine with relative risk of -88.245 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 83: apraclonidine with relative risk of -88.245 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 84: apraclonidine with relative risk of -88.245 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 85: apraclonidine with relative risk of -88.245 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 86: apraclonidine with relative risk of -88.245 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 87: apraclonidine with relative risk of -88.245 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 88: apraclonidine with relative risk of -88.245 of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 89: desoximetasone with relative risk of -inf of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 90: desoximetasone with relative risk of -inf of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 91: desoximetasone with relative risk of -inf of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 92: desoximetasone with relative risk of -inf of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 93: desoximetasone with relative risk of -inf of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 94: desoximetasone with relative risk of -inf of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 95: desoximetasone with relative risk of -inf of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 96: desoximetasone with relative risk of -inf of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 97: desoximetasone with relative risk of -inf of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 98: desoximetasone with relative risk of -inf of pinaverium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.026\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó pindolol *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: regadenoson with relative risk of -8.647 of pindolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: sertraline with relative risk of -8.999 of pindolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: mometasone with relative risk of -9.242 of pindolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: posaconazole with relative risk of -9.679 of pindolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: irbesartan with relative risk of -9.727 of pindolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 6: azelastine with relative risk of -10.076 of pindolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: tropisetron with relative risk of -10.479 of pindolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: ruxolitinib with relative risk of -10.512 of pindolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: lurasidone with relative risk of -10.558 of pindolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: lansoprazole with relative risk of -11.107 of pindolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: ibutilide with relative risk of -11.114 of pindolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 12: risperidone with relative risk of -11.175 of pindolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: ketorolac with relative risk of -11.258 of pindolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: atropine with relative risk of -11.531 of pindolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: clarithromycin with relative risk of -11.894 of pindolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: clonidine with relative risk of -11.931 of pindolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 17: dutasteride with relative risk of -12.086 of pindolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: leflunomide with relative risk of -12.233 of pindolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: doxorubicin with relative risk of -12.242 of pindolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: vernakalant with relative risk of -12.281 of pindolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 21: flecainide with relative risk of -12.956 of pindolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 22: vilazodone with relative risk of -13.644 of pindolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.122\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó pioglitazone *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: prazosin with relative risk of -11.519 of pioglitazone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target pirbuterol not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó piroxicam *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: fluvoxamine with relative risk of -10.071 of piroxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: venlafaxine with relative risk of -12.778 of piroxicam | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: tofacitinib with relative risk of -13.601 of piroxicam | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Rheumatoid Arthritis,rheumatology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.182\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó pitavastatin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: colchicine with relative risk of -9.876 of pitavastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 2: fluvoxamine with relative risk of -10.071 of pitavastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: dofetilide with relative risk of -11.839 of pitavastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: disopyramide with relative risk of -12.097 of pitavastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.48\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó podophyllotoxin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: degarelix with relative risk of -11.759 of podophyllotoxin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: dasatinib with relative risk of -12.378 of podophyllotoxin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: eliglustat with relative risk of -12.452 of podophyllotoxin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target pomalidomide not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó ponatinib *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: deferasirox with relative risk of -12.436 of ponatinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó posaconazole *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: crizotinib with relative risk of -7.161 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: penbutolol with relative risk of -7.334 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: risperidone with relative risk of -7.961 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: atropine with relative risk of -8.312 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: asenapine with relative risk of -8.409 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: amsacrine with relative risk of -8.411 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: carbamazepine with relative risk of -8.481 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: bosutinib with relative risk of -8.488 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: sulfasalazine with relative risk of -8.691 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: clonidine with relative risk of -8.714 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: flutamide with relative risk of -8.766 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: leflunomide with relative risk of -9.016 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: doxorubicin with relative risk of -9.024 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: bezafibrate with relative risk of -9.039 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: vernakalant with relative risk of -9.062 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: flecainide with relative risk of -9.737 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: tolvaptan with relative risk of -9.752 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: ambrisentan with relative risk of -9.769 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: vilazodone with relative risk of -10.425 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: pindolol with relative risk of -10.581 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: cimetidine with relative risk of -11.090 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: olmesartan with relative risk of -11.116 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: darifenacin with relative risk of -12.213 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: darifenacin with relative risk of -12.213 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: naproxen with relative risk of -12.956 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: naproxen with relative risk of -12.956 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: bumetanide with relative risk of -14.467 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: bumetanide with relative risk of -14.467 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: brimonidine with relative risk of -14.762 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: brimonidine with relative risk of -14.762 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: cyclophosphamide with relative risk of -14.822 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: cyclophosphamide with relative risk of -14.822 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: nevirapine with relative risk of -15.105 of posaconazole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 34: nevirapine with relative risk of -15.105 of posaconazole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 35: cetirizine with relative risk of -15.124 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: cetirizine with relative risk of -15.124 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: tazarotene with relative risk of -15.335 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: tazarotene with relative risk of -15.335 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: dofetilide with relative risk of -15.498 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: dofetilide with relative risk of -15.498 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: dapsone with relative risk of -15.596 of posaconazole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 42: dapsone with relative risk of -15.596 of posaconazole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 43: capecitabine with relative risk of -15.803 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: capecitabine with relative risk of -15.803 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: isradipine with relative risk of -16.340 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: isradipine with relative risk of -16.340 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: sumatriptan with relative risk of -17.012 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: sumatriptan with relative risk of -17.012 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: citalopram with relative risk of -17.036 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: citalopram with relative risk of -17.036 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: gabapentin with relative risk of -20.922 of posaconazole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 52: gabapentin with relative risk of -20.922 of posaconazole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 53: gabapentin with relative risk of -20.922 of posaconazole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 54: estramustine with relative risk of -20.952 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 55: estramustine with relative risk of -20.952 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 56: estramustine with relative risk of -20.952 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 57: clarithromycin with relative risk of -21.271 of posaconazole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 58: clarithromycin with relative risk of -21.271 of posaconazole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 59: clarithromycin with relative risk of -21.271 of posaconazole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 60: ivacaftor with relative risk of -21.380 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 61: ivacaftor with relative risk of -21.380 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 62: ivacaftor with relative risk of -21.380 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 63: auranofin with relative risk of -22.376 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 64: auranofin with relative risk of -22.376 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 65: auranofin with relative risk of -22.376 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 66: dantrolene with relative risk of -23.167 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 67: dantrolene with relative risk of -23.167 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 68: dantrolene with relative risk of -23.167 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 69: risedronate with relative risk of -23.457 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 70: risedronate with relative risk of -23.457 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 71: risedronate with relative risk of -23.457 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 72: donepezil with relative risk of -23.849 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 73: donepezil with relative risk of -23.849 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 74: donepezil with relative risk of -23.849 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 75: brinzolamide with relative risk of -23.888 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 76: brinzolamide with relative risk of -23.888 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 77: brinzolamide with relative risk of -23.888 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 78: fondaparinux with relative risk of -24.217 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 79: fondaparinux with relative risk of -24.217 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 80: fondaparinux with relative risk of -24.217 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 81: acebutolol with relative risk of -24.233 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 82: acebutolol with relative risk of -24.233 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 83: acebutolol with relative risk of -24.233 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 84: valsartan with relative risk of -24.376 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 85: valsartan with relative risk of -24.376 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 86: valsartan with relative risk of -24.376 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 87: ruxolitinib with relative risk of -27.138 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 88: ruxolitinib with relative risk of -27.138 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 89: ruxolitinib with relative risk of -27.138 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 90: ruxolitinib with relative risk of -27.138 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 91: metoprolol with relative risk of -27.743 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 92: metoprolol with relative risk of -27.743 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 93: metoprolol with relative risk of -27.743 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 94: metoprolol with relative risk of -27.743 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 95: milrinone with relative risk of -28.166 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 96: milrinone with relative risk of -28.166 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 97: milrinone with relative risk of -28.166 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 98: milrinone with relative risk of -28.166 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 99: pentoxifylline with relative risk of -28.698 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 100: pentoxifylline with relative risk of -28.698 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 101: pentoxifylline with relative risk of -28.698 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 102: pentoxifylline with relative risk of -28.698 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 103: pentoxifylline with relative risk of -28.698 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 104: tamsulosin with relative risk of -29.491 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 105: tamsulosin with relative risk of -29.491 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 106: tamsulosin with relative risk of -29.491 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 107: tamsulosin with relative risk of -29.491 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 108: everolimus with relative risk of -29.849 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 109: everolimus with relative risk of -29.849 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 110: everolimus with relative risk of -29.849 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 111: everolimus with relative risk of -29.849 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 112: terbutaline with relative risk of -32.698 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 113: terbutaline with relative risk of -32.698 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 114: terbutaline with relative risk of -32.698 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 115: terbutaline with relative risk of -32.698 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 116: terbutaline with relative risk of -32.698 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 117: pemetrexed with relative risk of -33.926 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 118: pemetrexed with relative risk of -33.926 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 119: pemetrexed with relative risk of -33.926 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 120: pemetrexed with relative risk of -33.926 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 121: pemetrexed with relative risk of -33.926 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 122: esmolol with relative risk of -35.268 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 123: esmolol with relative risk of -35.268 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 124: esmolol with relative risk of -35.268 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 125: esmolol with relative risk of -35.268 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 126: esmolol with relative risk of -35.268 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 127: milnacipran with relative risk of -35.948 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 128: milnacipran with relative risk of -35.948 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 129: milnacipran with relative risk of -35.948 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 130: milnacipran with relative risk of -35.948 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 131: milnacipran with relative risk of -35.948 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 132: azilsartan with relative risk of -36.728 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 133: azilsartan with relative risk of -36.728 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 134: azilsartan with relative risk of -36.728 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 135: azilsartan with relative risk of -36.728 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 136: azilsartan with relative risk of -36.728 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 137: tolmetin with relative risk of -36.814 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 138: tolmetin with relative risk of -36.814 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 139: tolmetin with relative risk of -36.814 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 140: tolmetin with relative risk of -36.814 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 141: tolmetin with relative risk of -36.814 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 142: progesterone with relative risk of -37.151 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 143: progesterone with relative risk of -37.151 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 144: progesterone with relative risk of -37.151 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 145: progesterone with relative risk of -37.151 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 146: progesterone with relative risk of -37.151 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 147: abiraterone with relative risk of -37.661 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 148: abiraterone with relative risk of -37.661 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 149: abiraterone with relative risk of -37.661 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 150: abiraterone with relative risk of -37.661 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 151: abiraterone with relative risk of -37.661 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 152: lubiprostone with relative risk of -38.047 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 153: lubiprostone with relative risk of -38.047 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 154: lubiprostone with relative risk of -38.047 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 155: lubiprostone with relative risk of -38.047 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 156: lubiprostone with relative risk of -38.047 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 157: zolmitriptan with relative risk of -38.465 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 158: zolmitriptan with relative risk of -38.465 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 159: zolmitriptan with relative risk of -38.465 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 160: zolmitriptan with relative risk of -38.465 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 161: zolmitriptan with relative risk of -38.465 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 162: dapagliflozin with relative risk of -38.698 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 163: dapagliflozin with relative risk of -38.698 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 164: dapagliflozin with relative risk of -38.698 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 165: dapagliflozin with relative risk of -38.698 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 166: dapagliflozin with relative risk of -38.698 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 167: ropivacaine with relative risk of -38.737 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 168: ropivacaine with relative risk of -38.737 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 169: ropivacaine with relative risk of -38.737 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 170: ropivacaine with relative risk of -38.737 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 171: ropivacaine with relative risk of -38.737 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 172: ropivacaine with relative risk of -38.737 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 173: misoprostol with relative risk of -39.045 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 174: misoprostol with relative risk of -39.045 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 175: misoprostol with relative risk of -39.045 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 176: misoprostol with relative risk of -39.045 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 177: misoprostol with relative risk of -39.045 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 178: cisatracurium with relative risk of -40.797 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 179: cisatracurium with relative risk of -40.797 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 180: cisatracurium with relative risk of -40.797 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 181: cisatracurium with relative risk of -40.797 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 182: cisatracurium with relative risk of -40.797 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 183: lurasidone with relative risk of -40.917 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 184: lurasidone with relative risk of -40.917 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 185: lurasidone with relative risk of -40.917 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 186: lurasidone with relative risk of -40.917 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 187: lurasidone with relative risk of -40.917 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 188: lurasidone with relative risk of -40.917 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 189: indomethacin with relative risk of -41.613 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 190: indomethacin with relative risk of -41.613 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 191: indomethacin with relative risk of -41.613 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 192: indomethacin with relative risk of -41.613 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 193: indomethacin with relative risk of -41.613 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 194: indomethacin with relative risk of -41.613 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 195: telmisartan with relative risk of -42.033 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 196: telmisartan with relative risk of -42.033 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 197: telmisartan with relative risk of -42.033 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 198: telmisartan with relative risk of -42.033 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 199: telmisartan with relative risk of -42.033 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 200: telmisartan with relative risk of -42.033 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 201: trovafloxacin with relative risk of -42.043 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 202: trovafloxacin with relative risk of -42.043 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 203: trovafloxacin with relative risk of -42.043 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 204: trovafloxacin with relative risk of -42.043 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 205: trovafloxacin with relative risk of -42.043 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 206: trovafloxacin with relative risk of -42.043 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 207: didanosine with relative risk of -44.074 of posaconazole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 208: didanosine with relative risk of -44.074 of posaconazole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 209: didanosine with relative risk of -44.074 of posaconazole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 210: didanosine with relative risk of -44.074 of posaconazole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 211: didanosine with relative risk of -44.074 of posaconazole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 212: didanosine with relative risk of -44.074 of posaconazole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 213: levonorgestrel with relative risk of -50.943 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 214: levonorgestrel with relative risk of -50.943 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 215: levonorgestrel with relative risk of -50.943 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 216: levonorgestrel with relative risk of -50.943 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 217: levonorgestrel with relative risk of -50.943 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 218: levonorgestrel with relative risk of -50.943 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 219: levonorgestrel with relative risk of -50.943 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 220: dutasteride with relative risk of -52.753 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 221: dutasteride with relative risk of -52.753 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 222: dutasteride with relative risk of -52.753 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 223: dutasteride with relative risk of -52.753 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 224: dutasteride with relative risk of -52.753 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 225: dutasteride with relative risk of -52.753 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 226: dutasteride with relative risk of -52.753 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 227: ketorolac with relative risk of -53.426 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 228: ketorolac with relative risk of -53.426 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 229: ketorolac with relative risk of -53.426 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 230: ketorolac with relative risk of -53.426 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 231: ketorolac with relative risk of -53.426 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 232: ketorolac with relative risk of -53.426 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 233: ketorolac with relative risk of -53.426 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 234: ketorolac with relative risk of -53.426 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 235: lansoprazole with relative risk of -81.240 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 236: lansoprazole with relative risk of -81.240 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 237: lansoprazole with relative risk of -81.240 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 238: lansoprazole with relative risk of -81.240 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 239: lansoprazole with relative risk of -81.240 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 240: lansoprazole with relative risk of -81.240 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 241: lansoprazole with relative risk of -81.240 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 242: lansoprazole with relative risk of -81.240 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 243: lansoprazole with relative risk of -81.240 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 244: lansoprazole with relative risk of -81.240 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 245: lansoprazole with relative risk of -81.240 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 246: etoposide with relative risk of -91.276 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 247: etoposide with relative risk of -91.276 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 248: etoposide with relative risk of -91.276 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 249: etoposide with relative risk of -91.276 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 250: etoposide with relative risk of -91.276 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 251: etoposide with relative risk of -91.276 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 252: etoposide with relative risk of -91.276 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 253: etoposide with relative risk of -91.276 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 254: etoposide with relative risk of -91.276 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 255: etoposide with relative risk of -91.276 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 256: etoposide with relative risk of -91.276 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 257: etoposide with relative risk of -91.276 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 258: etoposide with relative risk of -91.276 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 259: fenofibrate with relative risk of -93.819 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 260: fenofibrate with relative risk of -93.819 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 261: fenofibrate with relative risk of -93.819 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 262: fenofibrate with relative risk of -93.819 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 263: fenofibrate with relative risk of -93.819 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 264: fenofibrate with relative risk of -93.819 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 265: fenofibrate with relative risk of -93.819 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 266: fenofibrate with relative risk of -93.819 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 267: fenofibrate with relative risk of -93.819 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 268: fenofibrate with relative risk of -93.819 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 269: fenofibrate with relative risk of -93.819 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 270: fenofibrate with relative risk of -93.819 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 271: fenofibrate with relative risk of -93.819 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 272: glimepiride with relative risk of -106.046 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 273: glimepiride with relative risk of -106.046 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 274: glimepiride with relative risk of -106.046 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 275: glimepiride with relative risk of -106.046 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 276: glimepiride with relative risk of -106.046 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 277: glimepiride with relative risk of -106.046 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 278: glimepiride with relative risk of -106.046 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 279: glimepiride with relative risk of -106.046 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 280: glimepiride with relative risk of -106.046 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 281: glimepiride with relative risk of -106.046 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 282: glimepiride with relative risk of -106.046 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 283: glimepiride with relative risk of -106.046 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 284: glimepiride with relative risk of -106.046 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 285: glimepiride with relative risk of -106.046 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 286: glimepiride with relative risk of -106.046 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 287: paliperidone with relative risk of -121.732 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 288: paliperidone with relative risk of -121.732 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 289: paliperidone with relative risk of -121.732 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 290: paliperidone with relative risk of -121.732 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 291: paliperidone with relative risk of -121.732 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 292: paliperidone with relative risk of -121.732 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 293: paliperidone with relative risk of -121.732 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 294: paliperidone with relative risk of -121.732 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 295: paliperidone with relative risk of -121.732 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 296: paliperidone with relative risk of -121.732 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 297: paliperidone with relative risk of -121.732 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 298: paliperidone with relative risk of -121.732 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 299: paliperidone with relative risk of -121.732 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 300: paliperidone with relative risk of -121.732 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 301: paliperidone with relative risk of -121.732 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 302: paliperidone with relative risk of -121.732 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 303: paliperidone with relative risk of -121.732 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 304: tropisetron with relative risk of -129.678 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 305: tropisetron with relative risk of -129.678 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 306: tropisetron with relative risk of -129.678 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 307: tropisetron with relative risk of -129.678 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 308: tropisetron with relative risk of -129.678 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 309: tropisetron with relative risk of -129.678 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 310: tropisetron with relative risk of -129.678 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 311: tropisetron with relative risk of -129.678 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 312: tropisetron with relative risk of -129.678 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 313: tropisetron with relative risk of -129.678 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 314: tropisetron with relative risk of -129.678 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 315: tropisetron with relative risk of -129.678 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 316: tropisetron with relative risk of -129.678 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 317: tropisetron with relative risk of -129.678 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 318: tropisetron with relative risk of -129.678 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 319: tropisetron with relative risk of -129.678 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 320: tropisetron with relative risk of -129.678 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 321: tropisetron with relative risk of -129.678 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 322: sertraline with relative risk of -147.650 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 323: sertraline with relative risk of -147.650 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 324: sertraline with relative risk of -147.650 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 325: sertraline with relative risk of -147.650 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 326: sertraline with relative risk of -147.650 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 327: sertraline with relative risk of -147.650 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 328: sertraline with relative risk of -147.650 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 329: sertraline with relative risk of -147.650 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 330: sertraline with relative risk of -147.650 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 331: sertraline with relative risk of -147.650 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 332: sertraline with relative risk of -147.650 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 333: sertraline with relative risk of -147.650 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 334: sertraline with relative risk of -147.650 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 335: sertraline with relative risk of -147.650 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 336: sertraline with relative risk of -147.650 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 337: sertraline with relative risk of -147.650 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 338: sertraline with relative risk of -147.650 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 339: sertraline with relative risk of -147.650 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 340: sertraline with relative risk of -147.650 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 341: sertraline with relative risk of -147.650 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 342: sertraline with relative risk of -147.650 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 343: sertraline with relative risk of -147.650 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 344: sertraline with relative risk of -147.650 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 345: irbesartan with relative risk of -165.144 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 346: irbesartan with relative risk of -165.144 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 347: irbesartan with relative risk of -165.144 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 348: irbesartan with relative risk of -165.144 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 349: irbesartan with relative risk of -165.144 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 350: irbesartan with relative risk of -165.144 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 351: irbesartan with relative risk of -165.144 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 352: irbesartan with relative risk of -165.144 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 353: irbesartan with relative risk of -165.144 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 354: irbesartan with relative risk of -165.144 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 355: irbesartan with relative risk of -165.144 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 356: irbesartan with relative risk of -165.144 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 357: irbesartan with relative risk of -165.144 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 358: irbesartan with relative risk of -165.144 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 359: irbesartan with relative risk of -165.144 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 360: irbesartan with relative risk of -165.144 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 361: irbesartan with relative risk of -165.144 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 362: irbesartan with relative risk of -165.144 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 363: irbesartan with relative risk of -165.144 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 364: irbesartan with relative risk of -165.144 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 365: irbesartan with relative risk of -165.144 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 366: irbesartan with relative risk of -165.144 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 367: irbesartan with relative risk of -165.144 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 368: irbesartan with relative risk of -165.144 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 369: irbesartan with relative risk of -165.144 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 370: azelastine with relative risk of -181.815 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 371: azelastine with relative risk of -181.815 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 372: azelastine with relative risk of -181.815 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 373: azelastine with relative risk of -181.815 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 374: azelastine with relative risk of -181.815 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 375: azelastine with relative risk of -181.815 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 376: azelastine with relative risk of -181.815 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 377: azelastine with relative risk of -181.815 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 378: azelastine with relative risk of -181.815 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 379: azelastine with relative risk of -181.815 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 380: azelastine with relative risk of -181.815 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 381: azelastine with relative risk of -181.815 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 382: azelastine with relative risk of -181.815 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 383: azelastine with relative risk of -181.815 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 384: azelastine with relative risk of -181.815 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 385: azelastine with relative risk of -181.815 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 386: azelastine with relative risk of -181.815 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 387: azelastine with relative risk of -181.815 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 388: azelastine with relative risk of -181.815 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 389: azelastine with relative risk of -181.815 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 390: azelastine with relative risk of -181.815 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 391: azelastine with relative risk of -181.815 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 392: azelastine with relative risk of -181.815 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 393: azelastine with relative risk of -181.815 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 394: azelastine with relative risk of -181.815 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 395: mometasone with relative risk of -182.469 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 396: mometasone with relative risk of -182.469 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 397: mometasone with relative risk of -182.469 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 398: mometasone with relative risk of -182.469 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 399: mometasone with relative risk of -182.469 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 400: mometasone with relative risk of -182.469 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 401: mometasone with relative risk of -182.469 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 402: mometasone with relative risk of -182.469 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 403: mometasone with relative risk of -182.469 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 404: mometasone with relative risk of -182.469 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 405: mometasone with relative risk of -182.469 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 406: mometasone with relative risk of -182.469 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 407: mometasone with relative risk of -182.469 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 408: mometasone with relative risk of -182.469 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 409: mometasone with relative risk of -182.469 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 410: mometasone with relative risk of -182.469 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 411: mometasone with relative risk of -182.469 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 412: mometasone with relative risk of -182.469 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 413: mometasone with relative risk of -182.469 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 414: mometasone with relative risk of -182.469 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 415: mometasone with relative risk of -182.469 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 416: mometasone with relative risk of -182.469 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 417: mometasone with relative risk of -182.469 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 418: mometasone with relative risk of -182.469 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 419: mometasone with relative risk of -182.469 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 420: ibutilide with relative risk of -189.655 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 421: ibutilide with relative risk of -189.655 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 422: ibutilide with relative risk of -189.655 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 423: ibutilide with relative risk of -189.655 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 424: ibutilide with relative risk of -189.655 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 425: ibutilide with relative risk of -189.655 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 426: ibutilide with relative risk of -189.655 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 427: ibutilide with relative risk of -189.655 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 428: ibutilide with relative risk of -189.655 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 429: ibutilide with relative risk of -189.655 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 430: ibutilide with relative risk of -189.655 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 431: ibutilide with relative risk of -189.655 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 432: ibutilide with relative risk of -189.655 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 433: ibutilide with relative risk of -189.655 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 434: ibutilide with relative risk of -189.655 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 435: ibutilide with relative risk of -189.655 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 436: ibutilide with relative risk of -189.655 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 437: ibutilide with relative risk of -189.655 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 438: ibutilide with relative risk of -189.655 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 439: ibutilide with relative risk of -189.655 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 440: ibutilide with relative risk of -189.655 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 441: ibutilide with relative risk of -189.655 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 442: ibutilide with relative risk of -189.655 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 443: ibutilide with relative risk of -189.655 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 444: ibutilide with relative risk of -189.655 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 445: regadenoson with relative risk of -191.949 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 446: regadenoson with relative risk of -191.949 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 447: regadenoson with relative risk of -191.949 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 448: regadenoson with relative risk of -191.949 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 449: regadenoson with relative risk of -191.949 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 450: regadenoson with relative risk of -191.949 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 451: regadenoson with relative risk of -191.949 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 452: regadenoson with relative risk of -191.949 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 453: regadenoson with relative risk of -191.949 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 454: regadenoson with relative risk of -191.949 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 455: regadenoson with relative risk of -191.949 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 456: regadenoson with relative risk of -191.949 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 457: regadenoson with relative risk of -191.949 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 458: regadenoson with relative risk of -191.949 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 459: regadenoson with relative risk of -191.949 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 460: regadenoson with relative risk of -191.949 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 461: regadenoson with relative risk of -191.949 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 462: regadenoson with relative risk of -191.949 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 463: regadenoson with relative risk of -191.949 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 464: regadenoson with relative risk of -191.949 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 465: regadenoson with relative risk of -191.949 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 466: regadenoson with relative risk of -191.949 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 467: regadenoson with relative risk of -191.949 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 468: regadenoson with relative risk of -191.949 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 469: regadenoson with relative risk of -191.949 of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 470: felodipine with relative risk of -inf of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 471: felodipine with relative risk of -inf of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 472: felodipine with relative risk of -inf of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 473: felodipine with relative risk of -inf of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 474: felodipine with relative risk of -inf of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 475: felodipine with relative risk of -inf of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 476: felodipine with relative risk of -inf of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 477: felodipine with relative risk of -inf of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 478: felodipine with relative risk of -inf of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 479: felodipine with relative risk of -inf of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 480: felodipine with relative risk of -inf of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 481: felodipine with relative risk of -inf of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 482: felodipine with relative risk of -inf of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 483: felodipine with relative risk of -inf of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 484: felodipine with relative risk of -inf of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 485: felodipine with relative risk of -inf of posaconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.036\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó pramipexole *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: docetaxel with relative risk of -10.659 of pramipexole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: etodolac with relative risk of -10.971 of pramipexole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: metaproterenol with relative risk of -11.372 of pramipexole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: duloxetine with relative risk of -11.606 of pramipexole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Fibromyalgia,neurology/psychiatry\n",
      "Rank 5: bupropion with relative risk of -11.736 of pramipexole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: repaglinide with relative risk of -11.747 of pramipexole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: dalbavancin with relative risk of -12.074 of pramipexole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: trospium with relative risk of -12.116 of pramipexole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: amlodipine with relative risk of -12.420 of pramipexole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.159\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó prasugrel *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: clofarabine with relative risk of -9.449 of prasugrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: paroxetine with relative risk of -9.702 of prasugrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: ibandronate with relative risk of -10.192 of prasugrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: crizotinib with relative risk of -10.375 of prasugrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: pentoxifylline with relative risk of -10.551 of prasugrel | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 6: nabumetone with relative risk of -11.689 of prasugrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: moxifloxacin with relative risk of -12.814 of prasugrel | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: bisoprolol with relative risk of -12.979 of prasugrel | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.12\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó pravastatin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: loperamide with relative risk of -18.158 of pravastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: loperamide with relative risk of -18.158 of pravastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: topiramate with relative risk of -18.599 of pravastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: topiramate with relative risk of -18.599 of pravastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: pamidronate with relative risk of -19.102 of pravastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 6: pamidronate with relative risk of -19.102 of pravastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.15\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó prazosin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: pioglitazone with relative risk of -11.351 of prazosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target pregabalin not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó progesterone *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: bosutinib with relative risk of -10.097 of progesterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: dofetilide with relative risk of -10.229 of progesterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: clarithromycin with relative risk of -10.286 of progesterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: olmesartan with relative risk of -12.725 of progesterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: estramustine with relative risk of -26.386 of progesterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: estramustine with relative risk of -26.386 of progesterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: estramustine with relative risk of -26.386 of progesterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: auranofin with relative risk of -27.814 of progesterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: auranofin with relative risk of -27.814 of progesterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: auranofin with relative risk of -27.814 of progesterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: dantrolene with relative risk of -28.606 of progesterone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 12: dantrolene with relative risk of -28.606 of progesterone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 13: dantrolene with relative risk of -28.606 of progesterone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 14: risedronate with relative risk of -28.895 of progesterone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 15: risedronate with relative risk of -28.895 of progesterone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 16: risedronate with relative risk of -28.895 of progesterone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 17: donepezil with relative risk of -29.287 of progesterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: donepezil with relative risk of -29.287 of progesterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: donepezil with relative risk of -29.287 of progesterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: sertraline with relative risk of -34.222 of progesterone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: obstetrics/gynecology\n",
      "Rank 21: sertraline with relative risk of -34.222 of progesterone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: obstetrics/gynecology\n",
      "Rank 22: sertraline with relative risk of -34.222 of progesterone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: obstetrics/gynecology\n",
      "Rank 23: sertraline with relative risk of -34.222 of progesterone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: obstetrics/gynecology\n",
      "Rank 24: sertraline with relative risk of -34.222 of progesterone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: obstetrics/gynecology\n",
      "Rank 25: irbesartan with relative risk of -34.590 of progesterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: irbesartan with relative risk of -34.590 of progesterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: irbesartan with relative risk of -34.590 of progesterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: irbesartan with relative risk of -34.590 of progesterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: irbesartan with relative risk of -34.590 of progesterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: mometasone with relative risk of -36.065 of progesterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: mometasone with relative risk of -36.065 of progesterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: mometasone with relative risk of -36.065 of progesterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: mometasone with relative risk of -36.065 of progesterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: mometasone with relative risk of -36.065 of progesterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: regadenoson with relative risk of -36.243 of progesterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: regadenoson with relative risk of -36.243 of progesterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: regadenoson with relative risk of -36.243 of progesterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: regadenoson with relative risk of -36.243 of progesterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: regadenoson with relative risk of -36.243 of progesterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: azelastine with relative risk of -36.761 of progesterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: azelastine with relative risk of -36.761 of progesterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: azelastine with relative risk of -36.761 of progesterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: azelastine with relative risk of -36.761 of progesterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: azelastine with relative risk of -36.761 of progesterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: posaconazole with relative risk of -37.450 of progesterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: posaconazole with relative risk of -37.450 of progesterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: posaconazole with relative risk of -37.450 of progesterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: posaconazole with relative risk of -37.450 of progesterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: posaconazole with relative risk of -37.450 of progesterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: ibutilide with relative risk of -38.383 of progesterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: ibutilide with relative risk of -38.383 of progesterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: ibutilide with relative risk of -38.383 of progesterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 53: ibutilide with relative risk of -38.383 of progesterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 54: ibutilide with relative risk of -38.383 of progesterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 55: telmisartan with relative risk of -45.160 of progesterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 56: telmisartan with relative risk of -45.160 of progesterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 57: telmisartan with relative risk of -45.160 of progesterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 58: telmisartan with relative risk of -45.160 of progesterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 59: telmisartan with relative risk of -45.160 of progesterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 60: milnacipran with relative risk of -46.827 of progesterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 61: milnacipran with relative risk of -46.827 of progesterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 62: milnacipran with relative risk of -46.827 of progesterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 63: milnacipran with relative risk of -46.827 of progesterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 64: milnacipran with relative risk of -46.827 of progesterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 65: tolmetin with relative risk of -47.694 of progesterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 66: tolmetin with relative risk of -47.694 of progesterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 67: tolmetin with relative risk of -47.694 of progesterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 68: tolmetin with relative risk of -47.694 of progesterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 69: tolmetin with relative risk of -47.694 of progesterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 70: abiraterone with relative risk of -48.541 of progesterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 71: abiraterone with relative risk of -48.541 of progesterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 72: abiraterone with relative risk of -48.541 of progesterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 73: abiraterone with relative risk of -48.541 of progesterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 74: abiraterone with relative risk of -48.541 of progesterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 75: lubiprostone with relative risk of -48.928 of progesterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 76: lubiprostone with relative risk of -48.928 of progesterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 77: lubiprostone with relative risk of -48.928 of progesterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 78: lubiprostone with relative risk of -48.928 of progesterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 79: lubiprostone with relative risk of -48.928 of progesterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 80: dapagliflozin with relative risk of -49.578 of progesterone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 81: dapagliflozin with relative risk of -49.578 of progesterone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 82: dapagliflozin with relative risk of -49.578 of progesterone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 83: dapagliflozin with relative risk of -49.578 of progesterone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 84: dapagliflozin with relative risk of -49.578 of progesterone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 85: misoprostol with relative risk of -49.925 of progesterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 86: misoprostol with relative risk of -49.925 of progesterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 87: misoprostol with relative risk of -49.925 of progesterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 88: misoprostol with relative risk of -49.925 of progesterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 89: misoprostol with relative risk of -49.925 of progesterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 90: cisatracurium with relative risk of -51.678 of progesterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 91: cisatracurium with relative risk of -51.678 of progesterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 92: cisatracurium with relative risk of -51.678 of progesterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 93: cisatracurium with relative risk of -51.678 of progesterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 94: cisatracurium with relative risk of -51.678 of progesterone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.145\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó propafenone *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: amiodarone with relative risk of -29.451 of propafenone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 2: amiodarone with relative risk of -29.451 of propafenone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 3: amiodarone with relative risk of -29.451 of propafenone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 4: amiodarone with relative risk of -29.451 of propafenone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 5: lenalidomide with relative risk of -29.786 of propafenone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: lenalidomide with relative risk of -29.786 of propafenone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: lenalidomide with relative risk of -29.786 of propafenone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: lenalidomide with relative risk of -29.786 of propafenone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: penbutolol with relative risk of -30.802 of propafenone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 10: penbutolol with relative risk of -30.802 of propafenone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 11: penbutolol with relative risk of -30.802 of propafenone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 12: penbutolol with relative risk of -30.802 of propafenone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 13: fluvastatin with relative risk of -34.551 of propafenone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 14: fluvastatin with relative risk of -34.551 of propafenone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 15: fluvastatin with relative risk of -34.551 of propafenone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 16: fluvastatin with relative risk of -34.551 of propafenone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 17: tizanidine with relative risk of -34.701 of propafenone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: tizanidine with relative risk of -34.701 of propafenone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: tizanidine with relative risk of -34.701 of propafenone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: tizanidine with relative risk of -34.701 of propafenone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: ketoprofen with relative risk of -39.226 of propafenone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: ketoprofen with relative risk of -39.226 of propafenone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: ketoprofen with relative risk of -39.226 of propafenone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: ketoprofen with relative risk of -39.226 of propafenone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.727\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó propranolol *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: fluocinonide with relative risk of -30.779 of propranolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: fluocinonide with relative risk of -30.779 of propranolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: fluocinonide with relative risk of -30.779 of propranolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target prostacyclin not found. Exiting ...\n",
      "\n",
      "Drug target prostaglandin not found. Exiting ...\n",
      "\n",
      "Drug target pyridostigmine not found. Exiting ...\n",
      "\n",
      "Drug target quazepam not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó quetiapine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: dexmedetomidine with relative risk of -21.729 of quetiapine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: dexmedetomidine with relative risk of -21.729 of quetiapine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: oxybutynin with relative risk of -22.688 of quetiapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: oxybutynin with relative risk of -22.688 of quetiapine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.72\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó quinapril *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: fludarabine with relative risk of -11.498 of quinapril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: belinostat with relative risk of -11.616 of quinapril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: palonosetron with relative risk of -12.669 of quinapril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: timolol with relative risk of -12.719 of quinapril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease\n",
      "Rank 5: nicardipine with relative risk of -13.753 of quinapril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.197\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó quinaprilat *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: bromocriptine with relative risk of -9.883 of quinaprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: nedocromil with relative risk of -13.823 of quinaprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: nedocromil with relative risk of -13.823 of quinaprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: vismodegib with relative risk of -15.939 of quinaprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: vismodegib with relative risk of -15.939 of quinaprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: trazodone with relative risk of -25.433 of quinaprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: trazodone with relative risk of -25.433 of quinaprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: trazodone with relative risk of -25.433 of quinaprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: trazodone with relative risk of -25.433 of quinaprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: olopatadine with relative risk of -25.551 of quinaprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: olopatadine with relative risk of -25.551 of quinaprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: olopatadine with relative risk of -25.551 of quinaprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: riluzole with relative risk of -39.680 of quinaprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: riluzole with relative risk of -39.680 of quinaprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: riluzole with relative risk of -39.680 of quinaprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: riluzole with relative risk of -39.680 of quinaprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: riluzole with relative risk of -39.680 of quinaprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: loperamide with relative risk of -59.114 of quinaprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: loperamide with relative risk of -59.114 of quinaprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: loperamide with relative risk of -59.114 of quinaprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: loperamide with relative risk of -59.114 of quinaprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: loperamide with relative risk of -59.114 of quinaprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: loperamide with relative risk of -59.114 of quinaprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: loperamide with relative risk of -59.114 of quinaprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: loperamide with relative risk of -59.114 of quinaprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: betaxolol with relative risk of -63.152 of quinaprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: betaxolol with relative risk of -63.152 of quinaprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: betaxolol with relative risk of -63.152 of quinaprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: betaxolol with relative risk of -63.152 of quinaprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: betaxolol with relative risk of -63.152 of quinaprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: betaxolol with relative risk of -63.152 of quinaprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: betaxolol with relative risk of -63.152 of quinaprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: betaxolol with relative risk of -63.152 of quinaprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: topiramate with relative risk of -64.111 of quinaprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: topiramate with relative risk of -64.111 of quinaprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: topiramate with relative risk of -64.111 of quinaprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: topiramate with relative risk of -64.111 of quinaprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: topiramate with relative risk of -64.111 of quinaprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: topiramate with relative risk of -64.111 of quinaprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: topiramate with relative risk of -64.111 of quinaprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: topiramate with relative risk of -64.111 of quinaprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: efinaconazole with relative risk of -inf of quinaprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: efinaconazole with relative risk of -inf of quinaprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: efinaconazole with relative risk of -inf of quinaprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: efinaconazole with relative risk of -inf of quinaprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: efinaconazole with relative risk of -inf of quinaprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: efinaconazole with relative risk of -inf of quinaprilat | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó quinidine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: irbesartan with relative risk of -9.727 of quinidine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 2: ribavirin with relative risk of -10.974 of quinidine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 3: bumetanide with relative risk of -11.499 of quinidine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 4: argatroban with relative risk of -11.794 of quinidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: nevirapine with relative risk of -11.850 of quinidine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 6: lapatinib with relative risk of -11.918 of quinidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: losartan with relative risk of -12.317 of quinidine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 8: celecoxib with relative risk of -12.360 of quinidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: perindopril with relative risk of -12.439 of quinidine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 10: temsirolimus with relative risk of -13.036 of quinidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: amisulpride with relative risk of -13.075 of quinidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: latanoprost with relative risk of -13.172 of quinidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: domperidone with relative risk of -13.535 of quinidine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 14: aclidinium with relative risk of -13.563 of quinidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: lidocaine with relative risk of -13.720 of quinidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: caffeine with relative risk of -14.059 of quinidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: bromfenac with relative risk of -15.690 of quinidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: felodipine with relative risk of -inf of quinidine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.692\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó rabeprazole *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: doxercalciferol with relative risk of -11.049 of rabeprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: iloperidone with relative risk of -11.491 of rabeprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: fluconazole with relative risk of -12.035 of rabeprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: guanfacine with relative risk of -12.067 of rabeprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: mirtazapine with relative risk of -12.157 of rabeprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: fosphenytoin with relative risk of -12.213 of rabeprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: reboxetine with relative risk of -12.438 of rabeprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: ropinirole with relative risk of -12.554 of rabeprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: vardenafil with relative risk of -12.599 of rabeprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: rilpivirine with relative risk of -12.757 of rabeprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: levocabastine with relative risk of -22.412 of rabeprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: levocabastine with relative risk of -22.412 of rabeprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: levetiracetam with relative risk of -22.703 of rabeprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: levetiracetam with relative risk of -22.703 of rabeprazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target radium not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó raloxifene *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: cilostazol with relative risk of -11.956 of raloxifene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: empagliflozin with relative risk of -12.043 of raloxifene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: pilocarpine with relative risk of -12.698 of raloxifene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: medroxyprogesterone with relative risk of -12.814 of raloxifene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: pantoprazole with relative risk of -12.828 of raloxifene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: bupivacaine with relative risk of -13.325 of raloxifene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: omeprazole with relative risk of -13.465 of raloxifene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target raltegravir not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó raltitrexed *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: dexrazoxane with relative risk of -8.760 of raltitrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: carvedilol with relative risk of -10.330 of raltitrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: tamoxifen with relative risk of -10.384 of raltitrexed | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 4: rosuvastatin with relative risk of -11.778 of raltitrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: diclofenac with relative risk of -16.574 of raltitrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: diclofenac with relative risk of -16.574 of raltitrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: pentostatin with relative risk of -17.720 of raltitrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: pentostatin with relative risk of -17.720 of raltitrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: norfloxacin with relative risk of -19.006 of raltitrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: norfloxacin with relative risk of -19.006 of raltitrexed | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.114\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó ramelteon *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: carbamazepine with relative risk of -9.907 of ramelteon | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: silodosin with relative risk of -11.028 of ramelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: nefazodone with relative risk of -11.301 of ramelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: ciclesonide with relative risk of -19.820 of ramelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: ciclesonide with relative risk of -19.820 of ramelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: ciclesonide with relative risk of -19.820 of ramelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: clomipramine with relative risk of -33.425 of ramelteon | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: clomipramine with relative risk of -33.425 of ramelteon | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: clomipramine with relative risk of -33.425 of ramelteon | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: clomipramine with relative risk of -33.425 of ramelteon | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: sunitinib with relative risk of -33.715 of ramelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: sunitinib with relative risk of -33.715 of ramelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: sunitinib with relative risk of -33.715 of ramelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: sunitinib with relative risk of -33.715 of ramelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: desoximetasone with relative risk of -inf of ramelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: desoximetasone with relative risk of -inf of ramelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: desoximetasone with relative risk of -inf of ramelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: desoximetasone with relative risk of -inf of ramelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: desoximetasone with relative risk of -inf of ramelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: desoximetasone with relative risk of -inf of ramelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.411\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó ramipril *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: ropivacaine with relative risk of -9.070 of ramipril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: ibandronate with relative risk of -9.095 of ramipril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: imatinib with relative risk of -9.212 of ramipril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: gemcitabine with relative risk of -9.725 of ramipril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: gefitinib with relative risk of -9.734 of ramipril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: atosiban with relative risk of -10.922 of ramipril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 7: vincristine with relative risk of -11.134 of ramipril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: desloratadine with relative risk of -11.371 of ramipril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: desvenlafaxine with relative risk of -12.016 of ramipril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: amoxicillin with relative risk of -12.518 of ramipril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: diltiazem with relative risk of -12.761 of ramipril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 12: nebivolol with relative risk of -13.246 of ramipril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 13: trimetrexate with relative risk of -18.104 of ramipril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: trimetrexate with relative risk of -18.104 of ramipril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: acyclovir with relative risk of -20.662 of ramipril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: acyclovir with relative risk of -20.662 of ramipril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: aminophylline with relative risk of -25.356 of ramipril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: aminophylline with relative risk of -25.356 of ramipril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: aminophylline with relative risk of -25.356 of ramipril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: finasteride with relative risk of -26.930 of ramipril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: finasteride with relative risk of -26.930 of ramipril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: finasteride with relative risk of -26.930 of ramipril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: alendronate with relative risk of -28.112 of ramipril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: alendronate with relative risk of -28.112 of ramipril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: alendronate with relative risk of -28.112 of ramipril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: valdecoxib with relative risk of -28.205 of ramipril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: valdecoxib with relative risk of -28.205 of ramipril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: valdecoxib with relative risk of -28.205 of ramipril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: dihydroergotamine with relative risk of -29.036 of ramipril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: dihydroergotamine with relative risk of -29.036 of ramipril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: dihydroergotamine with relative risk of -29.036 of ramipril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: clopidogrel with relative risk of -31.015 of ramipril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 33: clopidogrel with relative risk of -31.015 of ramipril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 34: clopidogrel with relative risk of -31.015 of ramipril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.105\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target ramiprilat not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó ranitidine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: cabazitaxel with relative risk of -10.581 of ranitidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: mitotane with relative risk of -10.981 of ranitidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: danazol with relative risk of -11.727 of ranitidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: canagliflozin with relative risk of -12.616 of ranitidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: gonadorelin with relative risk of -12.633 of ranitidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: phenytoin with relative risk of -12.906 of ranitidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: montelukast with relative risk of -13.000 of ranitidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: dipyridamole with relative risk of -13.267 of ranitidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: mexiletine with relative risk of -13.348 of ranitidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: zafirlukast with relative risk of -13.520 of ranitidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: cilazapril with relative risk of -15.324 of ranitidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó ranolazine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: nalmefene with relative risk of -11.697 of ranolazine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: flumazenil with relative risk of -12.262 of ranolazine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: thalidomide with relative risk of -12.415 of ranolazine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target rapamycin not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó rasagiline *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: aminophylline with relative risk of -8.425 of rasagiline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: entacapone with relative risk of -11.208 of rasagiline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Parkinson Disease,neurology/psychiatry\n",
      "Rank 3: ipratropium with relative risk of -11.476 of rasagiline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: silodosin with relative risk of -11.721 of rasagiline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: nefazodone with relative risk of -11.994 of rasagiline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: clopidogrel with relative risk of -12.292 of rasagiline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: formoterol with relative risk of -17.669 of rasagiline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: formoterol with relative risk of -17.669 of rasagiline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: frovatriptan with relative risk of -17.832 of rasagiline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: frovatriptan with relative risk of -17.832 of rasagiline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: nimodipine with relative risk of -18.382 of rasagiline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: nimodipine with relative risk of -18.382 of rasagiline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: cytarabine with relative risk of -18.596 of rasagiline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: cytarabine with relative risk of -18.596 of rasagiline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: paclitaxel with relative risk of -19.886 of rasagiline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: paclitaxel with relative risk of -19.886 of rasagiline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: rivastigmine with relative risk of -21.568 of rasagiline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 18: rivastigmine with relative risk of -21.568 of rasagiline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 19: sotalol with relative risk of -21.592 of rasagiline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: sotalol with relative risk of -21.592 of rasagiline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: rofecoxib with relative risk of -21.643 of rasagiline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: rofecoxib with relative risk of -21.643 of rasagiline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: pimozide with relative risk of -21.715 of rasagiline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 24: pimozide with relative risk of -21.715 of rasagiline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 25: capsaicin with relative risk of -22.166 of rasagiline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 26: capsaicin with relative risk of -22.166 of rasagiline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 27: fosinoprilat with relative risk of -24.449 of rasagiline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: fosinoprilat with relative risk of -24.449 of rasagiline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.294\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target rasburicase not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó reboxetine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: doxercalciferol with relative risk of -11.743 of reboxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: iloperidone with relative risk of -12.184 of reboxetine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: rabeprazole with relative risk of -12.198 of reboxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: levocabastine with relative risk of -12.358 of reboxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: levetiracetam with relative risk of -12.648 of reboxetine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: fluconazole with relative risk of -12.728 of reboxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: guanfacine with relative risk of -12.760 of reboxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: mirtazapine with relative risk of -12.850 of reboxetine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Major Depressive Disorder,neurology/psychiatry\n",
      "Rank 9: fosphenytoin with relative risk of -12.906 of reboxetine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: ropinirole with relative risk of -13.248 of reboxetine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: vardenafil with relative risk of -13.293 of reboxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: rilpivirine with relative risk of -13.450 of reboxetine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.334\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó regadenoson *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: ibandronate with relative risk of -6.955 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: crizotinib with relative risk of -7.122 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: penbutolol with relative risk of -7.296 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: ticagrelor with relative risk of -7.720 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: risperidone with relative risk of -7.922 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: erlotinib with relative risk of -8.026 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: delavirdine with relative risk of -8.034 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: atropine with relative risk of -8.272 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: asenapine with relative risk of -8.370 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: amsacrine with relative risk of -8.372 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: carbamazepine with relative risk of -8.442 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: bosutinib with relative risk of -8.448 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: sulfasalazine with relative risk of -8.651 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: varenicline with relative risk of -8.719 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: flutamide with relative risk of -8.727 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: leflunomide with relative risk of -8.976 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: doxorubicin with relative risk of -8.984 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: bezafibrate with relative risk of -8.999 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: vernakalant with relative risk of -9.023 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: rotigotine with relative risk of -9.393 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: doxepin with relative risk of -9.601 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: flecainide with relative risk of -9.698 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: tolvaptan with relative risk of -9.712 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: ambrisentan with relative risk of -9.730 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: benazepril with relative risk of -9.920 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: vilazodone with relative risk of -10.386 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: pindolol with relative risk of -10.542 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: cimetidine with relative risk of -11.051 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: olmesartan with relative risk of -11.076 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: darifenacin with relative risk of -12.134 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: darifenacin with relative risk of -12.134 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: bumetanide with relative risk of -14.387 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: bumetanide with relative risk of -14.387 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: brimonidine with relative risk of -14.682 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: brimonidine with relative risk of -14.682 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: cyclophosphamide with relative risk of -14.742 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: cyclophosphamide with relative risk of -14.742 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: nevirapine with relative risk of -15.025 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: nevirapine with relative risk of -15.025 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: cetirizine with relative risk of -15.044 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: cetirizine with relative risk of -15.044 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: tazarotene with relative risk of -15.255 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: tazarotene with relative risk of -15.255 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: dofetilide with relative risk of -15.418 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: dofetilide with relative risk of -15.418 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: clonidine with relative risk of -15.510 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: clonidine with relative risk of -15.510 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: dapsone with relative risk of -15.516 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: dapsone with relative risk of -15.516 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: capecitabine with relative risk of -15.723 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: capecitabine with relative risk of -15.723 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: isradipine with relative risk of -16.260 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 53: isradipine with relative risk of -16.260 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 54: sumatriptan with relative risk of -16.932 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 55: sumatriptan with relative risk of -16.932 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 56: citalopram with relative risk of -16.956 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 57: citalopram with relative risk of -16.956 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 58: naproxen with relative risk of -19.241 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 59: naproxen with relative risk of -19.241 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 60: naproxen with relative risk of -19.241 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 61: estramustine with relative risk of -20.829 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 62: estramustine with relative risk of -20.829 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 63: estramustine with relative risk of -20.829 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 64: ivacaftor with relative risk of -21.257 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 65: ivacaftor with relative risk of -21.257 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 66: ivacaftor with relative risk of -21.257 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 67: auranofin with relative risk of -22.253 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 68: auranofin with relative risk of -22.253 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 69: auranofin with relative risk of -22.253 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 70: dantrolene with relative risk of -23.045 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 71: dantrolene with relative risk of -23.045 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 72: dantrolene with relative risk of -23.045 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 73: risedronate with relative risk of -23.334 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 74: risedronate with relative risk of -23.334 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 75: risedronate with relative risk of -23.334 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 76: donepezil with relative risk of -23.726 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 77: donepezil with relative risk of -23.726 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 78: donepezil with relative risk of -23.726 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 79: brinzolamide with relative risk of -23.765 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 80: brinzolamide with relative risk of -23.765 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 81: brinzolamide with relative risk of -23.765 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 82: fondaparinux with relative risk of -24.094 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 83: fondaparinux with relative risk of -24.094 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 84: fondaparinux with relative risk of -24.094 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 85: acebutolol with relative risk of -24.110 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 86: acebutolol with relative risk of -24.110 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 87: acebutolol with relative risk of -24.110 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 88: valsartan with relative risk of -24.253 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 89: valsartan with relative risk of -24.253 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 90: valsartan with relative risk of -24.253 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 91: metoprolol with relative risk of -27.576 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 92: metoprolol with relative risk of -27.576 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 93: metoprolol with relative risk of -27.576 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 94: metoprolol with relative risk of -27.576 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 95: milrinone with relative risk of -27.999 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 96: milrinone with relative risk of -27.999 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 97: milrinone with relative risk of -27.999 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 98: milrinone with relative risk of -27.999 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 99: gabapentin with relative risk of -28.005 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 100: gabapentin with relative risk of -28.005 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 101: gabapentin with relative risk of -28.005 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 102: gabapentin with relative risk of -28.005 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 103: clarithromycin with relative risk of -28.354 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 104: clarithromycin with relative risk of -28.354 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 105: clarithromycin with relative risk of -28.354 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 106: clarithromycin with relative risk of -28.354 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 107: pentoxifylline with relative risk of -28.485 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 108: pentoxifylline with relative risk of -28.485 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 109: pentoxifylline with relative risk of -28.485 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 110: pentoxifylline with relative risk of -28.485 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 111: pentoxifylline with relative risk of -28.485 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 112: tamsulosin with relative risk of -29.324 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 113: tamsulosin with relative risk of -29.324 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 114: tamsulosin with relative risk of -29.324 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 115: tamsulosin with relative risk of -29.324 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 116: everolimus with relative risk of -29.682 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 117: everolimus with relative risk of -29.682 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 118: everolimus with relative risk of -29.682 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 119: everolimus with relative risk of -29.682 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 120: terbutaline with relative risk of -32.485 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 121: terbutaline with relative risk of -32.485 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 122: terbutaline with relative risk of -32.485 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 123: terbutaline with relative risk of -32.485 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 124: terbutaline with relative risk of -32.485 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 125: pemetrexed with relative risk of -33.712 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 126: pemetrexed with relative risk of -33.712 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 127: pemetrexed with relative risk of -33.712 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 128: pemetrexed with relative risk of -33.712 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 129: pemetrexed with relative risk of -33.712 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 130: ruxolitinib with relative risk of -34.850 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 131: ruxolitinib with relative risk of -34.850 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 132: ruxolitinib with relative risk of -34.850 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 133: ruxolitinib with relative risk of -34.850 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 134: ruxolitinib with relative risk of -34.850 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 135: esmolol with relative risk of -35.054 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 136: esmolol with relative risk of -35.054 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 137: esmolol with relative risk of -35.054 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 138: esmolol with relative risk of -35.054 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 139: esmolol with relative risk of -35.054 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 140: milnacipran with relative risk of -35.734 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 141: milnacipran with relative risk of -35.734 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 142: milnacipran with relative risk of -35.734 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 143: milnacipran with relative risk of -35.734 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 144: milnacipran with relative risk of -35.734 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 145: azilsartan with relative risk of -36.514 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 146: azilsartan with relative risk of -36.514 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 147: azilsartan with relative risk of -36.514 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 148: azilsartan with relative risk of -36.514 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 149: azilsartan with relative risk of -36.514 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 150: tolmetin with relative risk of -36.600 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 151: tolmetin with relative risk of -36.600 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 152: tolmetin with relative risk of -36.600 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 153: tolmetin with relative risk of -36.600 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 154: tolmetin with relative risk of -36.600 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 155: progesterone with relative risk of -36.938 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 156: progesterone with relative risk of -36.938 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 157: progesterone with relative risk of -36.938 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 158: progesterone with relative risk of -36.938 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 159: progesterone with relative risk of -36.938 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 160: abiraterone with relative risk of -37.447 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 161: abiraterone with relative risk of -37.447 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 162: abiraterone with relative risk of -37.447 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 163: abiraterone with relative risk of -37.447 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 164: abiraterone with relative risk of -37.447 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 165: lubiprostone with relative risk of -37.834 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 166: lubiprostone with relative risk of -37.834 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 167: lubiprostone with relative risk of -37.834 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 168: lubiprostone with relative risk of -37.834 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 169: lubiprostone with relative risk of -37.834 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 170: zolmitriptan with relative risk of -38.251 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 171: zolmitriptan with relative risk of -38.251 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 172: zolmitriptan with relative risk of -38.251 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 173: zolmitriptan with relative risk of -38.251 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 174: zolmitriptan with relative risk of -38.251 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 175: dapagliflozin with relative risk of -38.484 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 176: dapagliflozin with relative risk of -38.484 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 177: dapagliflozin with relative risk of -38.484 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 178: dapagliflozin with relative risk of -38.484 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 179: dapagliflozin with relative risk of -38.484 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 180: misoprostol with relative risk of -38.831 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 181: misoprostol with relative risk of -38.831 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 182: misoprostol with relative risk of -38.831 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 183: misoprostol with relative risk of -38.831 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 184: misoprostol with relative risk of -38.831 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 185: cisatracurium with relative risk of -40.584 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 186: cisatracurium with relative risk of -40.584 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 187: cisatracurium with relative risk of -40.584 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 188: cisatracurium with relative risk of -40.584 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 189: cisatracurium with relative risk of -40.584 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 190: indomethacin with relative risk of -41.351 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 191: indomethacin with relative risk of -41.351 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 192: indomethacin with relative risk of -41.351 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 193: indomethacin with relative risk of -41.351 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 194: indomethacin with relative risk of -41.351 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 195: indomethacin with relative risk of -41.351 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 196: trovafloxacin with relative risk of -41.781 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 197: trovafloxacin with relative risk of -41.781 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 198: trovafloxacin with relative risk of -41.781 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 199: trovafloxacin with relative risk of -41.781 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 200: trovafloxacin with relative risk of -41.781 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 201: trovafloxacin with relative risk of -41.781 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 202: didanosine with relative risk of -43.811 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 203: didanosine with relative risk of -43.811 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 204: didanosine with relative risk of -43.811 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 205: didanosine with relative risk of -43.811 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 206: didanosine with relative risk of -43.811 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 207: didanosine with relative risk of -43.811 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 208: ropivacaine with relative risk of -46.092 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 209: ropivacaine with relative risk of -46.092 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 210: ropivacaine with relative risk of -46.092 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 211: ropivacaine with relative risk of -46.092 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 212: ropivacaine with relative risk of -46.092 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 213: ropivacaine with relative risk of -46.092 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 214: ropivacaine with relative risk of -46.092 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 215: lurasidone with relative risk of -48.966 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 216: lurasidone with relative risk of -48.966 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 217: lurasidone with relative risk of -48.966 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 218: lurasidone with relative risk of -48.966 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 219: lurasidone with relative risk of -48.966 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 220: lurasidone with relative risk of -48.966 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 221: lurasidone with relative risk of -48.966 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 222: telmisartan with relative risk of -50.082 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 223: telmisartan with relative risk of -50.082 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 224: telmisartan with relative risk of -50.082 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 225: telmisartan with relative risk of -50.082 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 226: telmisartan with relative risk of -50.082 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 227: telmisartan with relative risk of -50.082 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 228: telmisartan with relative risk of -50.082 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 229: levonorgestrel with relative risk of -50.629 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 230: levonorgestrel with relative risk of -50.629 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 231: levonorgestrel with relative risk of -50.629 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 232: levonorgestrel with relative risk of -50.629 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 233: levonorgestrel with relative risk of -50.629 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 234: levonorgestrel with relative risk of -50.629 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 235: levonorgestrel with relative risk of -50.629 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 236: dutasteride with relative risk of -52.439 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 237: dutasteride with relative risk of -52.439 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 238: dutasteride with relative risk of -52.439 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 239: dutasteride with relative risk of -52.439 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 240: dutasteride with relative risk of -52.439 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 241: dutasteride with relative risk of -52.439 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 242: dutasteride with relative risk of -52.439 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 243: ketorolac with relative risk of -53.059 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 244: ketorolac with relative risk of -53.059 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 245: ketorolac with relative risk of -53.059 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 246: ketorolac with relative risk of -53.059 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 247: ketorolac with relative risk of -53.059 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 248: ketorolac with relative risk of -53.059 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 249: ketorolac with relative risk of -53.059 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 250: ketorolac with relative risk of -53.059 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 251: lansoprazole with relative risk of -80.690 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 252: lansoprazole with relative risk of -80.690 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 253: lansoprazole with relative risk of -80.690 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 254: lansoprazole with relative risk of -80.690 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 255: lansoprazole with relative risk of -80.690 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 256: lansoprazole with relative risk of -80.690 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 257: lansoprazole with relative risk of -80.690 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 258: lansoprazole with relative risk of -80.690 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 259: lansoprazole with relative risk of -80.690 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 260: lansoprazole with relative risk of -80.690 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 261: lansoprazole with relative risk of -80.690 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 262: etoposide with relative risk of -90.583 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 263: etoposide with relative risk of -90.583 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 264: etoposide with relative risk of -90.583 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 265: etoposide with relative risk of -90.583 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 266: etoposide with relative risk of -90.583 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 267: etoposide with relative risk of -90.583 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 268: etoposide with relative risk of -90.583 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 269: etoposide with relative risk of -90.583 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 270: etoposide with relative risk of -90.583 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 271: etoposide with relative risk of -90.583 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 272: etoposide with relative risk of -90.583 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 273: etoposide with relative risk of -90.583 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 274: etoposide with relative risk of -90.583 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 275: fenofibrate with relative risk of -93.126 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 276: fenofibrate with relative risk of -93.126 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 277: fenofibrate with relative risk of -93.126 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 278: fenofibrate with relative risk of -93.126 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 279: fenofibrate with relative risk of -93.126 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 280: fenofibrate with relative risk of -93.126 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 281: fenofibrate with relative risk of -93.126 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 282: fenofibrate with relative risk of -93.126 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 283: fenofibrate with relative risk of -93.126 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 284: fenofibrate with relative risk of -93.126 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 285: fenofibrate with relative risk of -93.126 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 286: fenofibrate with relative risk of -93.126 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 287: fenofibrate with relative risk of -93.126 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 288: glimepiride with relative risk of -105.186 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 289: glimepiride with relative risk of -105.186 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 290: glimepiride with relative risk of -105.186 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 291: glimepiride with relative risk of -105.186 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 292: glimepiride with relative risk of -105.186 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 293: glimepiride with relative risk of -105.186 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 294: glimepiride with relative risk of -105.186 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 295: glimepiride with relative risk of -105.186 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 296: glimepiride with relative risk of -105.186 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 297: glimepiride with relative risk of -105.186 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 298: glimepiride with relative risk of -105.186 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 299: glimepiride with relative risk of -105.186 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 300: glimepiride with relative risk of -105.186 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 301: glimepiride with relative risk of -105.186 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 302: glimepiride with relative risk of -105.186 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 303: paliperidone with relative risk of -120.671 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 304: paliperidone with relative risk of -120.671 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 305: paliperidone with relative risk of -120.671 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 306: paliperidone with relative risk of -120.671 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 307: paliperidone with relative risk of -120.671 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 308: paliperidone with relative risk of -120.671 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 309: paliperidone with relative risk of -120.671 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 310: paliperidone with relative risk of -120.671 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 311: paliperidone with relative risk of -120.671 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 312: paliperidone with relative risk of -120.671 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 313: paliperidone with relative risk of -120.671 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 314: paliperidone with relative risk of -120.671 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 315: paliperidone with relative risk of -120.671 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 316: paliperidone with relative risk of -120.671 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 317: paliperidone with relative risk of -120.671 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 318: paliperidone with relative risk of -120.671 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 319: paliperidone with relative risk of -120.671 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 320: tropisetron with relative risk of -128.499 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 321: tropisetron with relative risk of -128.499 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 322: tropisetron with relative risk of -128.499 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 323: tropisetron with relative risk of -128.499 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 324: tropisetron with relative risk of -128.499 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 325: tropisetron with relative risk of -128.499 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 326: tropisetron with relative risk of -128.499 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 327: tropisetron with relative risk of -128.499 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 328: tropisetron with relative risk of -128.499 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 329: tropisetron with relative risk of -128.499 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 330: tropisetron with relative risk of -128.499 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 331: tropisetron with relative risk of -128.499 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 332: tropisetron with relative risk of -128.499 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 333: tropisetron with relative risk of -128.499 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 334: tropisetron with relative risk of -128.499 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 335: tropisetron with relative risk of -128.499 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 336: tropisetron with relative risk of -128.499 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 337: tropisetron with relative risk of -128.499 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 338: sertraline with relative risk of -154.533 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 339: sertraline with relative risk of -154.533 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 340: sertraline with relative risk of -154.533 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 341: sertraline with relative risk of -154.533 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 342: sertraline with relative risk of -154.533 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 343: sertraline with relative risk of -154.533 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 344: sertraline with relative risk of -154.533 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 345: sertraline with relative risk of -154.533 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 346: sertraline with relative risk of -154.533 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 347: sertraline with relative risk of -154.533 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 348: sertraline with relative risk of -154.533 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 349: sertraline with relative risk of -154.533 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 350: sertraline with relative risk of -154.533 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 351: sertraline with relative risk of -154.533 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 352: sertraline with relative risk of -154.533 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 353: sertraline with relative risk of -154.533 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 354: sertraline with relative risk of -154.533 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 355: sertraline with relative risk of -154.533 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 356: sertraline with relative risk of -154.533 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 357: sertraline with relative risk of -154.533 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 358: sertraline with relative risk of -154.533 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 359: sertraline with relative risk of -154.533 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 360: sertraline with relative risk of -154.533 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 361: sertraline with relative risk of -154.533 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 362: irbesartan with relative risk of -161.887 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 363: irbesartan with relative risk of -161.887 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 364: irbesartan with relative risk of -161.887 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 365: irbesartan with relative risk of -161.887 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 366: irbesartan with relative risk of -161.887 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 367: irbesartan with relative risk of -161.887 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 368: irbesartan with relative risk of -161.887 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 369: irbesartan with relative risk of -161.887 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 370: irbesartan with relative risk of -161.887 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 371: irbesartan with relative risk of -161.887 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 372: irbesartan with relative risk of -161.887 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 373: irbesartan with relative risk of -161.887 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 374: irbesartan with relative risk of -161.887 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 375: irbesartan with relative risk of -161.887 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 376: irbesartan with relative risk of -161.887 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 377: irbesartan with relative risk of -161.887 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 378: irbesartan with relative risk of -161.887 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 379: irbesartan with relative risk of -161.887 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 380: irbesartan with relative risk of -161.887 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 381: irbesartan with relative risk of -161.887 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 382: irbesartan with relative risk of -161.887 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 383: irbesartan with relative risk of -161.887 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 384: irbesartan with relative risk of -161.887 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 385: irbesartan with relative risk of -161.887 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 386: irbesartan with relative risk of -161.887 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 387: mometasone with relative risk of -179.211 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 388: mometasone with relative risk of -179.211 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 389: mometasone with relative risk of -179.211 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 390: mometasone with relative risk of -179.211 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 391: mometasone with relative risk of -179.211 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 392: mometasone with relative risk of -179.211 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 393: mometasone with relative risk of -179.211 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 394: mometasone with relative risk of -179.211 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 395: mometasone with relative risk of -179.211 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 396: mometasone with relative risk of -179.211 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 397: mometasone with relative risk of -179.211 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 398: mometasone with relative risk of -179.211 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 399: mometasone with relative risk of -179.211 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 400: mometasone with relative risk of -179.211 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 401: mometasone with relative risk of -179.211 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 402: mometasone with relative risk of -179.211 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 403: mometasone with relative risk of -179.211 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 404: mometasone with relative risk of -179.211 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 405: mometasone with relative risk of -179.211 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 406: mometasone with relative risk of -179.211 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 407: mometasone with relative risk of -179.211 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 408: mometasone with relative risk of -179.211 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 409: mometasone with relative risk of -179.211 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 410: mometasone with relative risk of -179.211 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 411: mometasone with relative risk of -179.211 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 412: ibutilide with relative risk of -186.397 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 413: ibutilide with relative risk of -186.397 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 414: ibutilide with relative risk of -186.397 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 415: ibutilide with relative risk of -186.397 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 416: ibutilide with relative risk of -186.397 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 417: ibutilide with relative risk of -186.397 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 418: ibutilide with relative risk of -186.397 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 419: ibutilide with relative risk of -186.397 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 420: ibutilide with relative risk of -186.397 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 421: ibutilide with relative risk of -186.397 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 422: ibutilide with relative risk of -186.397 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 423: ibutilide with relative risk of -186.397 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 424: ibutilide with relative risk of -186.397 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 425: ibutilide with relative risk of -186.397 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 426: ibutilide with relative risk of -186.397 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 427: ibutilide with relative risk of -186.397 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 428: ibutilide with relative risk of -186.397 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 429: ibutilide with relative risk of -186.397 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 430: ibutilide with relative risk of -186.397 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 431: ibutilide with relative risk of -186.397 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 432: ibutilide with relative risk of -186.397 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 433: ibutilide with relative risk of -186.397 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 434: ibutilide with relative risk of -186.397 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 435: ibutilide with relative risk of -186.397 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 436: ibutilide with relative risk of -186.397 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 437: azelastine with relative risk of -189.923 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 438: azelastine with relative risk of -189.923 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 439: azelastine with relative risk of -189.923 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 440: azelastine with relative risk of -189.923 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 441: azelastine with relative risk of -189.923 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 442: azelastine with relative risk of -189.923 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 443: azelastine with relative risk of -189.923 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 444: azelastine with relative risk of -189.923 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 445: azelastine with relative risk of -189.923 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 446: azelastine with relative risk of -189.923 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 447: azelastine with relative risk of -189.923 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 448: azelastine with relative risk of -189.923 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 449: azelastine with relative risk of -189.923 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 450: azelastine with relative risk of -189.923 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 451: azelastine with relative risk of -189.923 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 452: azelastine with relative risk of -189.923 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 453: azelastine with relative risk of -189.923 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 454: azelastine with relative risk of -189.923 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 455: azelastine with relative risk of -189.923 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 456: azelastine with relative risk of -189.923 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 457: azelastine with relative risk of -189.923 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 458: azelastine with relative risk of -189.923 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 459: azelastine with relative risk of -189.923 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 460: azelastine with relative risk of -189.923 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 461: azelastine with relative risk of -189.923 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 462: azelastine with relative risk of -189.923 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 463: posaconazole with relative risk of -192.943 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 464: posaconazole with relative risk of -192.943 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 465: posaconazole with relative risk of -192.943 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 466: posaconazole with relative risk of -192.943 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 467: posaconazole with relative risk of -192.943 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 468: posaconazole with relative risk of -192.943 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 469: posaconazole with relative risk of -192.943 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 470: posaconazole with relative risk of -192.943 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 471: posaconazole with relative risk of -192.943 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 472: posaconazole with relative risk of -192.943 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 473: posaconazole with relative risk of -192.943 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 474: posaconazole with relative risk of -192.943 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 475: posaconazole with relative risk of -192.943 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 476: posaconazole with relative risk of -192.943 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 477: posaconazole with relative risk of -192.943 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 478: posaconazole with relative risk of -192.943 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 479: posaconazole with relative risk of -192.943 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 480: posaconazole with relative risk of -192.943 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 481: posaconazole with relative risk of -192.943 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 482: posaconazole with relative risk of -192.943 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 483: posaconazole with relative risk of -192.943 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 484: posaconazole with relative risk of -192.943 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 485: posaconazole with relative risk of -192.943 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 486: posaconazole with relative risk of -192.943 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 487: posaconazole with relative risk of -192.943 of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 488: felodipine with relative risk of -inf of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 489: felodipine with relative risk of -inf of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 490: felodipine with relative risk of -inf of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 491: felodipine with relative risk of -inf of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 492: felodipine with relative risk of -inf of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 493: felodipine with relative risk of -inf of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 494: felodipine with relative risk of -inf of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 495: felodipine with relative risk of -inf of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 496: felodipine with relative risk of -inf of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 497: felodipine with relative risk of -inf of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 498: felodipine with relative risk of -inf of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 499: felodipine with relative risk of -inf of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 500: felodipine with relative risk of -inf of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 501: felodipine with relative risk of -inf of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 502: felodipine with relative risk of -inf of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 503: felodipine with relative risk of -inf of regadenoson | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó regorafenib *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: amiodarone with relative risk of -8.769 of regorafenib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: fluvastatin with relative risk of -10.186 of regorafenib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: sitagliptin with relative risk of -11.133 of regorafenib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: adapalene with relative risk of -11.410 of regorafenib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: liraglutide with relative risk of -11.459 of regorafenib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: lenalidomide with relative risk of -22.823 of regorafenib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: lenalidomide with relative risk of -22.823 of regorafenib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: lenalidomide with relative risk of -22.823 of regorafenib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: penbutolol with relative risk of -24.006 of regorafenib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: penbutolol with relative risk of -24.006 of regorafenib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: penbutolol with relative risk of -24.006 of regorafenib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: bexarotene with relative risk of -27.930 of regorafenib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: bexarotene with relative risk of -27.930 of regorafenib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: bexarotene with relative risk of -27.930 of regorafenib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target remifentanil not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó repaglinide *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: pramipexole with relative risk of -11.929 of repaglinide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: docetaxel with relative risk of -12.046 of repaglinide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: etodolac with relative risk of -12.358 of repaglinide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: metaproterenol with relative risk of -12.759 of repaglinide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: duloxetine with relative risk of -12.992 of repaglinide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: bupropion with relative risk of -13.123 of repaglinide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: dalbavancin with relative risk of -13.460 of repaglinide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: trospium with relative risk of -13.502 of repaglinide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: amlodipine with relative risk of -13.806 of repaglinide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target rescinnamine not found. Exiting ...\n",
      "\n",
      "Drug target retapamulin not found. Exiting ...\n",
      "\n",
      "Drug target retigabine not found. Exiting ...\n",
      "\n",
      "Drug target retinoic not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó ribavirin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: azelastine with relative risk of -9.384 of ribavirin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: pentoxifylline with relative risk of -9.859 of ribavirin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: loratadine with relative risk of -10.862 of ribavirin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: afatinib with relative risk of -11.280 of ribavirin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: quinidine with relative risk of -11.571 of ribavirin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 6: beclomethasone with relative risk of -11.945 of ribavirin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: budesonide with relative risk of -12.312 of ribavirin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: pergolide with relative risk of -12.824 of ribavirin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: aclidinium with relative risk of -12.870 of ribavirin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: caffeine with relative risk of -13.366 of ribavirin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: bromfenac with relative risk of -14.997 of ribavirin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: irbesartan with relative risk of -15.911 of ribavirin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: irbesartan with relative risk of -15.911 of ribavirin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: bumetanide with relative risk of -20.168 of ribavirin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: bumetanide with relative risk of -20.168 of ribavirin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: argatroban with relative risk of -20.750 of ribavirin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: argatroban with relative risk of -20.750 of ribavirin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: nevirapine with relative risk of -20.807 of ribavirin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 19: nevirapine with relative risk of -20.807 of ribavirin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 20: celecoxib with relative risk of -21.722 of ribavirin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: celecoxib with relative risk of -21.722 of ribavirin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: perindopril with relative risk of -21.801 of ribavirin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: perindopril with relative risk of -21.801 of ribavirin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: lapatinib with relative risk of -21.973 of ribavirin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: lapatinib with relative risk of -21.973 of ribavirin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: losartan with relative risk of -22.372 of ribavirin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: losartan with relative risk of -22.372 of ribavirin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: amisulpride with relative risk of -22.437 of ribavirin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: amisulpride with relative risk of -22.437 of ribavirin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: latanoprost with relative risk of -22.533 of ribavirin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: latanoprost with relative risk of -22.533 of ribavirin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: domperidone with relative risk of -22.897 of ribavirin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 33: domperidone with relative risk of -22.897 of ribavirin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 34: temsirolimus with relative risk of -23.091 of ribavirin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: temsirolimus with relative risk of -23.091 of ribavirin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: lidocaine with relative risk of -23.775 of ribavirin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: lidocaine with relative risk of -23.775 of ribavirin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: felodipine with relative risk of -inf of ribavirin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: felodipine with relative risk of -inf of ribavirin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.087\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target rifabutin not found. Exiting ...\n",
      "\n",
      "Drug target rifaximin not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó rilpivirine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: doxercalciferol with relative risk of -11.743 of rilpivirine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: iloperidone with relative risk of -12.184 of rilpivirine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: rabeprazole with relative risk of -12.198 of rilpivirine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: levocabastine with relative risk of -12.358 of rilpivirine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: levetiracetam with relative risk of -12.648 of rilpivirine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: fluconazole with relative risk of -12.728 of rilpivirine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 7: guanfacine with relative risk of -12.760 of rilpivirine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: mirtazapine with relative risk of -12.850 of rilpivirine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: fosphenytoin with relative risk of -12.906 of rilpivirine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: reboxetine with relative risk of -13.131 of rilpivirine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: ropinirole with relative risk of -13.248 of rilpivirine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: vardenafil with relative risk of -13.293 of rilpivirine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.054\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó riluzole *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: trazodone with relative risk of -8.070 of riluzole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: vismodegib with relative risk of -8.304 of riluzole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: verapamil with relative risk of -8.699 of riluzole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: bromocriptine with relative risk of -18.908 of riluzole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 5: bromocriptine with relative risk of -18.908 of riluzole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: nedocromil with relative risk of -21.018 of riluzole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: nedocromil with relative risk of -21.018 of riluzole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: nedocromil with relative risk of -21.018 of riluzole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: topiramate with relative risk of -22.433 of riluzole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: topiramate with relative risk of -22.433 of riluzole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: topiramate with relative risk of -22.433 of riluzole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: betaxolol with relative risk of -29.919 of riluzole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: betaxolol with relative risk of -29.919 of riluzole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: betaxolol with relative risk of -29.919 of riluzole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: betaxolol with relative risk of -29.919 of riluzole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: quinaprilat with relative risk of -40.461 of riluzole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: quinaprilat with relative risk of -40.461 of riluzole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: quinaprilat with relative risk of -40.461 of riluzole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: quinaprilat with relative risk of -40.461 of riluzole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: quinaprilat with relative risk of -40.461 of riluzole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: loperamide with relative risk of -44.362 of riluzole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: loperamide with relative risk of -44.362 of riluzole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: loperamide with relative risk of -44.362 of riluzole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: loperamide with relative risk of -44.362 of riluzole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: loperamide with relative risk of -44.362 of riluzole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: loperamide with relative risk of -44.362 of riluzole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: efinaconazole with relative risk of -inf of riluzole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: efinaconazole with relative risk of -inf of riluzole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: efinaconazole with relative risk of -inf of riluzole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: efinaconazole with relative risk of -inf of riluzole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.547\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target rimantadine not found. Exiting ...\n",
      "\n",
      "Drug target riociguat not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó risedronate *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: bosutinib with relative risk of -10.608 of risedronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: dofetilide with relative risk of -10.740 of risedronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: clarithromycin with relative risk of -10.796 of risedronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: olmesartan with relative risk of -13.236 of risedronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: sertraline with relative risk of -21.564 of risedronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: sertraline with relative risk of -21.564 of risedronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: sertraline with relative risk of -21.564 of risedronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: irbesartan with relative risk of -22.116 of risedronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: irbesartan with relative risk of -22.116 of risedronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: irbesartan with relative risk of -22.116 of risedronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: regadenoson with relative risk of -22.359 of risedronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: regadenoson with relative risk of -22.359 of risedronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: regadenoson with relative risk of -22.359 of risedronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: mometasone with relative risk of -22.583 of risedronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: mometasone with relative risk of -22.583 of risedronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: mometasone with relative risk of -22.583 of risedronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: azelastine with relative risk of -23.351 of risedronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: azelastine with relative risk of -23.351 of risedronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: azelastine with relative risk of -23.351 of risedronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: posaconazole with relative risk of -23.476 of risedronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: posaconazole with relative risk of -23.476 of risedronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: posaconazole with relative risk of -23.476 of risedronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: ibutilide with relative risk of -24.670 of risedronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: ibutilide with relative risk of -24.670 of risedronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: ibutilide with relative risk of -24.670 of risedronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: telmisartan with relative risk of -28.046 of risedronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: telmisartan with relative risk of -28.046 of risedronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: telmisartan with relative risk of -28.046 of risedronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: tolmetin with relative risk of -28.278 of risedronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: tolmetin with relative risk of -28.278 of risedronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: tolmetin with relative risk of -28.278 of risedronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: milnacipran with relative risk of -28.509 of risedronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: milnacipran with relative risk of -28.509 of risedronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: milnacipran with relative risk of -28.509 of risedronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: progesterone with relative risk of -28.615 of risedronate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 36: progesterone with relative risk of -28.615 of risedronate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 37: progesterone with relative risk of -28.615 of risedronate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 38: estramustine with relative risk of -28.689 of risedronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: estramustine with relative risk of -28.689 of risedronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: estramustine with relative risk of -28.689 of risedronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: abiraterone with relative risk of -29.125 of risedronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: abiraterone with relative risk of -29.125 of risedronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: abiraterone with relative risk of -29.125 of risedronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: lubiprostone with relative risk of -29.511 of risedronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: lubiprostone with relative risk of -29.511 of risedronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: lubiprostone with relative risk of -29.511 of risedronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: auranofin with relative risk of -30.116 of risedronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: auranofin with relative risk of -30.116 of risedronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: auranofin with relative risk of -30.116 of risedronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: dapagliflozin with relative risk of -30.162 of risedronate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 51: dapagliflozin with relative risk of -30.162 of risedronate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 52: dapagliflozin with relative risk of -30.162 of risedronate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 53: misoprostol with relative risk of -30.509 of risedronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 54: misoprostol with relative risk of -30.509 of risedronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 55: misoprostol with relative risk of -30.509 of risedronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 56: dantrolene with relative risk of -30.908 of risedronate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 57: dantrolene with relative risk of -30.908 of risedronate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 58: dantrolene with relative risk of -30.908 of risedronate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 59: donepezil with relative risk of -31.589 of risedronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 60: donepezil with relative risk of -31.589 of risedronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 61: donepezil with relative risk of -31.589 of risedronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 62: cisatracurium with relative risk of -32.261 of risedronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 63: cisatracurium with relative risk of -32.261 of risedronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 64: cisatracurium with relative risk of -32.261 of risedronate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.041\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó risperidone *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: regadenoson with relative risk of -6.860 of risperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: sertraline with relative risk of -7.217 of risperidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: mometasone with relative risk of -7.456 of risperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: posaconazole with relative risk of -7.893 of risperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: irbesartan with relative risk of -7.946 of risperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: azelastine with relative risk of -8.291 of risperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: tropisetron with relative risk of -8.691 of risperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: ruxolitinib with relative risk of -8.721 of risperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: lurasidone with relative risk of -8.768 of risperidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Schizophrenia,neurology/psychiatry\n",
      "Rank 10: lansoprazole with relative risk of -9.317 of risperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: ibutilide with relative risk of -9.328 of risperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: ketorolac with relative risk of -9.469 of risperidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: atropine with relative risk of -9.739 of risperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: clarithromycin with relative risk of -10.104 of risperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: clonidine with relative risk of -10.140 of risperidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 16: dutasteride with relative risk of -10.296 of risperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: leflunomide with relative risk of -10.442 of risperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: doxorubicin with relative risk of -10.451 of risperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: vernakalant with relative risk of -10.489 of risperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: flecainide with relative risk of -11.164 of risperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: vilazodone with relative risk of -11.852 of risperidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 22: pindolol with relative risk of -12.008 of risperidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: tizanidine with relative risk of -15.285 of risperidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 24: tizanidine with relative risk of -15.285 of risperidone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.237\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó ritonavir *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: vismodegib with relative risk of -9.690 of ritonavir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó rivaroxaban *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: metronidazole with relative risk of -11.062 of rivaroxaban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: umeclidinium with relative risk of -12.334 of rivaroxaban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: indinavir with relative risk of -13.596 of rivaroxaban | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: eprosartan with relative risk of -13.931 of rivaroxaban | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.12\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó rivastigmine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: aminophylline with relative risk of -8.831 of rivastigmine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: entacapone with relative risk of -11.614 of rivastigmine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: ipratropium with relative risk of -11.881 of rivastigmine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: silodosin with relative risk of -12.126 of rivastigmine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: nefazodone with relative risk of -12.399 of rivastigmine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: clopidogrel with relative risk of -12.697 of rivastigmine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: formoterol with relative risk of -18.768 of rivastigmine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: formoterol with relative risk of -18.768 of rivastigmine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: frovatriptan with relative risk of -18.930 of rivastigmine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: frovatriptan with relative risk of -18.930 of rivastigmine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: nimodipine with relative risk of -19.480 of rivastigmine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: nimodipine with relative risk of -19.480 of rivastigmine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: cytarabine with relative risk of -19.695 of rivastigmine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: cytarabine with relative risk of -19.695 of rivastigmine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: paclitaxel with relative risk of -20.985 of rivastigmine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: paclitaxel with relative risk of -20.985 of rivastigmine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: rasagiline with relative risk of -21.853 of rivastigmine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 18: rasagiline with relative risk of -21.853 of rivastigmine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 19: sotalol with relative risk of -22.691 of rivastigmine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: sotalol with relative risk of -22.691 of rivastigmine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: rofecoxib with relative risk of -22.741 of rivastigmine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: rofecoxib with relative risk of -22.741 of rivastigmine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: pimozide with relative risk of -22.814 of rivastigmine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 24: pimozide with relative risk of -22.814 of rivastigmine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 25: capsaicin with relative risk of -23.265 of rivastigmine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 26: capsaicin with relative risk of -23.265 of rivastigmine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 27: fosinoprilat with relative risk of -25.547 of rivastigmine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: fosinoprilat with relative risk of -25.547 of rivastigmine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.294\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó rizatriptan *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: ondansetron with relative risk of -12.871 of rizatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó rocuronium *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: balsalazide with relative risk of -11.535 of rocuronium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó rofecoxib *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó roflumilast *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: lenalidomide with relative risk of -9.026 of roflumilast | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: diclofenac with relative risk of -10.508 of roflumilast | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: pentostatin with relative risk of -10.843 of roflumilast | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó ropinirole *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: doxercalciferol with relative risk of -11.743 of ropinirole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: iloperidone with relative risk of -12.184 of ropinirole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: rabeprazole with relative risk of -12.198 of ropinirole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: levocabastine with relative risk of -12.358 of ropinirole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: levetiracetam with relative risk of -12.648 of ropinirole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: fluconazole with relative risk of -12.728 of ropinirole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: guanfacine with relative risk of -12.760 of ropinirole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: mirtazapine with relative risk of -12.850 of ropinirole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: fosphenytoin with relative risk of -12.906 of ropinirole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: reboxetine with relative risk of -13.131 of ropinirole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: vardenafil with relative risk of -13.293 of ropinirole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: rilpivirine with relative risk of -13.450 of ropinirole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.334\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó ropivacaine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: aminophylline with relative risk of -7.224 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: metoprolol with relative risk of -7.900 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: levonorgestrel with relative risk of -7.976 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: imatinib with relative risk of -8.009 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: pemetrexed with relative risk of -8.171 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: milrinone with relative risk of -8.323 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: ivacaftor with relative risk of -8.500 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: gemcitabine with relative risk of -8.522 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: gefitinib with relative risk of -8.531 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: trimetrexate with relative risk of -8.639 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: finasteride with relative risk of -8.798 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: indomethacin with relative risk of -8.954 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: valdecoxib with relative risk of -9.196 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: trovafloxacin with relative risk of -9.384 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: acyclovir with relative risk of -9.403 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: nevirapine with relative risk of -9.549 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: dihydroergotamine with relative risk of -9.621 of ropivacaine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 18: tamsulosin with relative risk of -9.648 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: varenicline with relative risk of -9.673 of ropivacaine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 20: atosiban with relative risk of -9.718 of ropivacaine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 21: brinzolamide with relative risk of -9.910 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: vincristine with relative risk of -9.930 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: bezafibrate with relative risk of -9.955 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: alendronate with relative risk of -9.980 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: ixabepilone with relative risk of -10.038 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: fondaparinux with relative risk of -10.239 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: acebutolol with relative risk of -10.255 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: sumatriptan with relative risk of -10.359 of ropivacaine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 29: citalopram with relative risk of -10.382 of ropivacaine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 30: valsartan with relative risk of -10.398 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: ramipril with relative risk of -10.431 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: desvenlafaxine with relative risk of -10.812 of ropivacaine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 33: benazepril with relative risk of -10.876 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: clopidogrel with relative risk of -11.089 of ropivacaine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 35: amoxicillin with relative risk of -11.314 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: diltiazem with relative risk of -11.557 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: toremifene with relative risk of -11.630 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: nebivolol with relative risk of -12.042 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: ibandronate with relative risk of -13.451 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: ibandronate with relative risk of -13.451 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: darifenacin with relative risk of -14.103 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: darifenacin with relative risk of -14.103 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: ketorolac with relative risk of -15.112 of ropivacaine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 44: ketorolac with relative risk of -15.112 of ropivacaine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 45: ruxolitinib with relative risk of -15.152 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: ruxolitinib with relative risk of -15.152 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: everolimus with relative risk of -16.072 of ropivacaine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 48: everolimus with relative risk of -16.072 of ropivacaine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 49: bumetanide with relative risk of -16.362 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: bumetanide with relative risk of -16.362 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: dutasteride with relative risk of -16.544 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: dutasteride with relative risk of -16.544 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 53: brimonidine with relative risk of -16.659 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 54: brimonidine with relative risk of -16.659 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 55: cetirizine with relative risk of -17.019 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 56: cetirizine with relative risk of -17.019 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 57: tazarotene with relative risk of -17.232 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 58: tazarotene with relative risk of -17.232 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 59: clonidine with relative risk of -17.486 of ropivacaine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 60: clonidine with relative risk of -17.486 of ropivacaine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 61: dapsone with relative risk of -17.492 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 62: dapsone with relative risk of -17.492 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 63: erlotinib with relative risk of -17.531 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 64: erlotinib with relative risk of -17.531 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 65: vemurafenib with relative risk of -17.563 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 66: vemurafenib with relative risk of -17.563 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 67: isradipine with relative risk of -18.237 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 68: isradipine with relative risk of -18.237 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 69: rotigotine with relative risk of -18.898 of ropivacaine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 70: rotigotine with relative risk of -18.898 of ropivacaine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 71: doxepin with relative risk of -19.106 of ropivacaine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 72: doxepin with relative risk of -19.106 of ropivacaine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 73: pentoxifylline with relative risk of -20.155 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 74: pentoxifylline with relative risk of -20.155 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 75: pentoxifylline with relative risk of -20.155 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 76: lansoprazole with relative risk of -21.932 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 77: lansoprazole with relative risk of -21.932 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 78: lansoprazole with relative risk of -21.932 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 79: ticagrelor with relative risk of -22.016 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 80: ticagrelor with relative risk of -22.016 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 81: ticagrelor with relative risk of -22.016 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 82: terbutaline with relative risk of -22.081 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 83: terbutaline with relative risk of -22.081 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 84: terbutaline with relative risk of -22.081 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 85: didanosine with relative risk of -22.999 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 86: didanosine with relative risk of -22.999 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 87: didanosine with relative risk of -22.999 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 88: esmolol with relative risk of -23.043 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 89: esmolol with relative risk of -23.043 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 90: esmolol with relative risk of -23.043 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 91: telmisartan with relative risk of -23.260 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 92: telmisartan with relative risk of -23.260 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 93: telmisartan with relative risk of -23.260 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 94: azilsartan with relative risk of -24.503 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 95: azilsartan with relative risk of -24.503 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 96: azilsartan with relative risk of -24.503 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 97: zolmitriptan with relative risk of -25.142 of ropivacaine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 98: zolmitriptan with relative risk of -25.142 of ropivacaine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 99: zolmitriptan with relative risk of -25.142 of ropivacaine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 100: delavirdine with relative risk of -25.919 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 101: delavirdine with relative risk of -25.919 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 102: delavirdine with relative risk of -25.919 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 103: etoposide with relative risk of -26.008 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 104: etoposide with relative risk of -26.008 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 105: etoposide with relative risk of -26.008 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 106: etoposide with relative risk of -26.008 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 107: fenofibrate with relative risk of -28.552 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 108: fenofibrate with relative risk of -28.552 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 109: fenofibrate with relative risk of -28.552 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 110: fenofibrate with relative risk of -28.552 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 111: clarithromycin with relative risk of -32.618 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 112: clarithromycin with relative risk of -32.618 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 113: clarithromycin with relative risk of -32.618 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 114: clarithromycin with relative risk of -32.618 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 115: irbesartan with relative risk of -35.521 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 116: irbesartan with relative risk of -35.521 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 117: irbesartan with relative risk of -35.521 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 118: irbesartan with relative risk of -35.521 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 119: irbesartan with relative risk of -35.521 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 120: irbesartan with relative risk of -35.521 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 121: mometasone with relative risk of -37.518 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 122: mometasone with relative risk of -37.518 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 123: mometasone with relative risk of -37.518 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 124: mometasone with relative risk of -37.518 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 125: mometasone with relative risk of -37.518 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 126: mometasone with relative risk of -37.518 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 127: posaconazole with relative risk of -39.165 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 128: posaconazole with relative risk of -39.165 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 129: posaconazole with relative risk of -39.165 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 130: posaconazole with relative risk of -39.165 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 131: posaconazole with relative risk of -39.165 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 132: posaconazole with relative risk of -39.165 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 133: naproxen with relative risk of -39.196 of ropivacaine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 134: naproxen with relative risk of -39.196 of ropivacaine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 135: naproxen with relative risk of -39.196 of ropivacaine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 136: naproxen with relative risk of -39.196 of ropivacaine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 137: naproxen with relative risk of -39.196 of ropivacaine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 138: tropisetron with relative risk of -41.260 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 139: tropisetron with relative risk of -41.260 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 140: tropisetron with relative risk of -41.260 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 141: tropisetron with relative risk of -41.260 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 142: tropisetron with relative risk of -41.260 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 143: tropisetron with relative risk of -41.260 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 144: gabapentin with relative risk of -41.448 of ropivacaine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 145: gabapentin with relative risk of -41.448 of ropivacaine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 146: gabapentin with relative risk of -41.448 of ropivacaine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 147: gabapentin with relative risk of -41.448 of ropivacaine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 148: gabapentin with relative risk of -41.448 of ropivacaine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 149: paliperidone with relative risk of -41.540 of ropivacaine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 150: paliperidone with relative risk of -41.540 of ropivacaine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 151: paliperidone with relative risk of -41.540 of ropivacaine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 152: paliperidone with relative risk of -41.540 of ropivacaine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 153: paliperidone with relative risk of -41.540 of ropivacaine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 154: paliperidone with relative risk of -41.540 of ropivacaine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 155: glimepiride with relative risk of -42.019 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 156: glimepiride with relative risk of -42.019 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 157: glimepiride with relative risk of -42.019 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 158: glimepiride with relative risk of -42.019 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 159: glimepiride with relative risk of -42.019 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 160: glimepiride with relative risk of -42.019 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 161: regadenoson with relative risk of -45.527 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 162: regadenoson with relative risk of -45.527 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 163: regadenoson with relative risk of -45.527 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 164: regadenoson with relative risk of -45.527 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 165: regadenoson with relative risk of -45.527 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 166: regadenoson with relative risk of -45.527 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 167: regadenoson with relative risk of -45.527 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 168: ibutilide with relative risk of -47.481 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 169: ibutilide with relative risk of -47.481 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 170: ibutilide with relative risk of -47.481 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 171: ibutilide with relative risk of -47.481 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 172: ibutilide with relative risk of -47.481 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 173: ibutilide with relative risk of -47.481 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 174: ibutilide with relative risk of -47.481 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 175: lurasidone with relative risk of -47.653 of ropivacaine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 176: lurasidone with relative risk of -47.653 of ropivacaine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 177: lurasidone with relative risk of -47.653 of ropivacaine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 178: lurasidone with relative risk of -47.653 of ropivacaine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 179: lurasidone with relative risk of -47.653 of ropivacaine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 180: lurasidone with relative risk of -47.653 of ropivacaine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 181: sertraline with relative risk of -57.539 of ropivacaine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 182: sertraline with relative risk of -57.539 of ropivacaine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 183: sertraline with relative risk of -57.539 of ropivacaine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 184: sertraline with relative risk of -57.539 of ropivacaine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 185: sertraline with relative risk of -57.539 of ropivacaine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 186: sertraline with relative risk of -57.539 of ropivacaine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 187: sertraline with relative risk of -57.539 of ropivacaine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 188: sertraline with relative risk of -57.539 of ropivacaine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 189: sertraline with relative risk of -57.539 of ropivacaine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 190: azelastine with relative risk of -61.727 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 191: azelastine with relative risk of -61.727 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 192: azelastine with relative risk of -61.727 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 193: azelastine with relative risk of -61.727 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 194: azelastine with relative risk of -61.727 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 195: azelastine with relative risk of -61.727 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 196: azelastine with relative risk of -61.727 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 197: azelastine with relative risk of -61.727 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 198: azelastine with relative risk of -61.727 of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 199: felodipine with relative risk of -inf of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 200: felodipine with relative risk of -inf of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 201: felodipine with relative risk of -inf of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 202: felodipine with relative risk of -inf of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 203: felodipine with relative risk of -inf of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 204: felodipine with relative risk of -inf of ropivacaine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.118\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó rosiglitazone *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó rosuvastatin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: dexrazoxane with relative risk of -10.146 of rosuvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 2: carvedilol with relative risk of -11.716 of rosuvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 3: tamoxifen with relative risk of -11.770 of rosuvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: raltitrexed with relative risk of -12.023 of rosuvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.72\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó rotigotine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: regadenoson with relative risk of -7.955 of rotigotine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: ibandronate with relative risk of -9.500 of rotigotine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: ruxolitinib with relative risk of -9.819 of rotigotine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: lurasidone with relative risk of -9.865 of rotigotine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 5: ibutilide with relative risk of -10.422 of rotigotine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: vemurafenib with relative risk of -10.621 of rotigotine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: varenicline with relative risk of -11.282 of rotigotine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: ixabepilone with relative risk of -11.647 of rotigotine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: doxepin with relative risk of -12.164 of rotigotine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: benazepril with relative risk of -12.485 of rotigotine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: toremifene with relative risk of -13.239 of rotigotine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: sertraline with relative risk of -15.270 of rotigotine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: sertraline with relative risk of -15.270 of rotigotine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: azelastine with relative risk of -16.697 of rotigotine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: azelastine with relative risk of -16.697 of rotigotine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: ropivacaine with relative risk of -18.025 of rotigotine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 17: ropivacaine with relative risk of -18.025 of rotigotine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 18: naproxen with relative risk of -18.655 of rotigotine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 19: naproxen with relative risk of -18.655 of rotigotine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 20: ticagrelor with relative risk of -18.826 of rotigotine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: ticagrelor with relative risk of -18.826 of rotigotine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: telmisartan with relative risk of -19.783 of rotigotine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: telmisartan with relative risk of -19.783 of rotigotine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: gabapentin with relative risk of -19.991 of rotigotine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Restless Legs Syndrome,neurology/psychiatry\n",
      "Rank 25: gabapentin with relative risk of -19.991 of rotigotine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Restless Legs Syndrome,neurology/psychiatry\n",
      "Rank 26: clarithromycin with relative risk of -20.340 of rotigotine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: clarithromycin with relative risk of -20.340 of rotigotine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: delavirdine with relative risk of -20.651 of rotigotine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: delavirdine with relative risk of -20.651 of rotigotine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: clonidine with relative risk of -21.293 of rotigotine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 31: clonidine with relative risk of -21.293 of rotigotine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 32: erlotinib with relative risk of -21.338 of rotigotine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: erlotinib with relative risk of -21.338 of rotigotine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.255\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó rufinamide *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: cytarabine with relative risk of -10.739 of rufinamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: formoterol with relative risk of -11.015 of rufinamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: frovatriptan with relative risk of -11.178 of rufinamide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: nelarabine with relative risk of -12.102 of rufinamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.16\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó ruxolitinib *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: ibandronate with relative risk of -8.405 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: metoprolol with relative risk of -8.410 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: naproxen with relative risk of -8.602 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: pemetrexed with relative risk of -8.681 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: milrinone with relative risk of -8.833 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: ticagrelor with relative risk of -9.178 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: risperidone with relative risk of -9.384 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: indomethacin with relative risk of -9.464 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: erlotinib with relative risk of -9.491 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: delavirdine with relative risk of -9.498 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: bumetanide with relative risk of -9.708 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: atropine with relative risk of -9.739 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: gabapentin with relative risk of -9.755 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: asenapine with relative risk of -9.833 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: telmisartan with relative risk of -9.884 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: trovafloxacin with relative risk of -9.894 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: nevirapine with relative risk of -10.059 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: cetirizine with relative risk of -10.078 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: tamsulosin with relative risk of -10.158 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: varenicline with relative risk of -10.183 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: flutamide with relative risk of -10.193 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: leflunomide with relative risk of -10.442 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: doxorubicin with relative risk of -10.451 of ruxolitinib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: hematologic malignancy\n",
      "Rank 24: vernakalant with relative risk of -10.489 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: fondaparinux with relative risk of -10.749 of ruxolitinib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: hematology\n",
      "Rank 26: rotigotine with relative risk of -10.858 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: citalopram with relative risk of -10.893 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: doxepin with relative risk of -11.066 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: flecainide with relative risk of -11.164 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: benazepril with relative risk of -11.387 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: vilazodone with relative risk of -11.852 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: pindolol with relative risk of -12.008 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: ropivacaine with relative risk of -15.318 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: ropivacaine with relative risk of -15.318 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: didanosine with relative risk of -16.410 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: didanosine with relative risk of -16.410 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: clarithromycin with relative risk of -17.633 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: clarithromycin with relative risk of -17.633 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: cyclophosphamide with relative risk of -17.817 of ruxolitinib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: hematologic malignancy\n",
      "Rank 40: cyclophosphamide with relative risk of -17.817 of ruxolitinib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: hematologic malignancy\n",
      "Rank 41: clonidine with relative risk of -18.585 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: clonidine with relative risk of -18.585 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: sumatriptan with relative risk of -20.008 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: sumatriptan with relative risk of -20.008 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: etoposide with relative risk of -20.701 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: etoposide with relative risk of -20.701 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: etoposide with relative risk of -20.701 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: paliperidone with relative risk of -21.846 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: paliperidone with relative risk of -21.846 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: paliperidone with relative risk of -21.846 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: glimepiride with relative risk of -21.895 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: glimepiride with relative risk of -21.895 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 53: glimepiride with relative risk of -21.895 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 54: fenofibrate with relative risk of -23.245 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 55: fenofibrate with relative risk of -23.245 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 56: fenofibrate with relative risk of -23.245 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 57: lurasidone with relative risk of -23.935 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 58: lurasidone with relative risk of -23.935 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 59: lurasidone with relative risk of -23.935 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 60: levonorgestrel with relative risk of -23.990 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 61: levonorgestrel with relative risk of -23.990 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 62: levonorgestrel with relative risk of -23.990 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 63: irbesartan with relative risk of -25.638 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 64: irbesartan with relative risk of -25.638 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 65: irbesartan with relative risk of -25.638 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 66: irbesartan with relative risk of -25.638 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 67: dutasteride with relative risk of -25.800 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 68: dutasteride with relative risk of -25.800 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 69: dutasteride with relative risk of -25.800 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 70: mometasone with relative risk of -26.600 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 71: mometasone with relative risk of -26.600 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 72: mometasone with relative risk of -26.600 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 73: mometasone with relative risk of -26.600 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 74: posaconazole with relative risk of -27.733 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 75: posaconazole with relative risk of -27.733 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 76: posaconazole with relative risk of -27.733 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 77: posaconazole with relative risk of -27.733 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 78: ibutilide with relative risk of -28.800 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 79: ibutilide with relative risk of -28.800 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 80: ibutilide with relative risk of -28.800 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 81: ibutilide with relative risk of -28.800 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 82: tropisetron with relative risk of -29.269 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 83: tropisetron with relative risk of -29.269 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 84: tropisetron with relative risk of -29.269 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 85: tropisetron with relative risk of -29.269 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 86: ketorolac with relative risk of -31.818 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 87: ketorolac with relative risk of -31.818 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 88: ketorolac with relative risk of -31.818 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 89: ketorolac with relative risk of -31.818 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 90: lansoprazole with relative risk of -31.985 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 91: lansoprazole with relative risk of -31.985 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 92: lansoprazole with relative risk of -31.985 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 93: lansoprazole with relative risk of -31.985 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 94: sertraline with relative risk of -32.432 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 95: sertraline with relative risk of -32.432 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 96: sertraline with relative risk of -32.432 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 97: sertraline with relative risk of -32.432 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 98: sertraline with relative risk of -32.432 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 99: regadenoson with relative risk of -34.452 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 100: regadenoson with relative risk of -34.452 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 101: regadenoson with relative risk of -34.452 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 102: regadenoson with relative risk of -34.452 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 103: regadenoson with relative risk of -34.452 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 104: azelastine with relative risk of -34.970 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 105: azelastine with relative risk of -34.970 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 106: azelastine with relative risk of -34.970 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 107: azelastine with relative risk of -34.970 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 108: azelastine with relative risk of -34.970 of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 109: felodipine with relative risk of -inf of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 110: felodipine with relative risk of -inf of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 111: felodipine with relative risk of -inf of ruxolitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.025\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target salbutamol not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó salmeterol *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: diclofenac with relative risk of -10.508 of salmeterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: torasemide with relative risk of -14.062 of salmeterol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target salmon not found. Exiting ...\n",
      "\n",
      "Drug target samarium not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó saquinavir *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: clozapine with relative risk of -10.063 of saquinavir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: cabazitaxel with relative risk of -10.581 of saquinavir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: teniposide with relative risk of -10.822 of saquinavir | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó scopolamine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: bicalutamide with relative risk of -11.315 of scopolamine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: acamprosate with relative risk of -13.072 of scopolamine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: naratriptan with relative risk of -14.015 of scopolamine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.455\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó sertraline *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: ibandronate with relative risk of -6.423 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: crizotinib with relative risk of -6.578 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: penbutolol with relative risk of -6.770 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: risperidone with relative risk of -7.378 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 5: capecitabine with relative risk of -7.647 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: atropine with relative risk of -7.724 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: amsacrine with relative risk of -7.823 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: asenapine with relative risk of -7.825 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 9: carbamazepine with relative risk of -7.895 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Epilepsy,neurology/psychiatry\n",
      "Rank 10: bosutinib with relative risk of -7.900 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: sulfasalazine with relative risk of -8.104 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: flutamide with relative risk of -8.179 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: leflunomide with relative risk of -8.429 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: doxorubicin with relative risk of -8.436 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: bezafibrate with relative risk of -8.451 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: vernakalant with relative risk of -8.474 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: ixabepilone with relative risk of -8.534 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: perindopril with relative risk of -8.636 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: flecainide with relative risk of -9.149 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: tolvaptan with relative risk of -9.164 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: ambrisentan with relative risk of -9.181 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: benazepril with relative risk of -9.372 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: vilazodone with relative risk of -9.837 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 24: pindolol with relative risk of -9.993 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: toremifene with relative risk of -10.126 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: cimetidine with relative risk of -10.503 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: olmesartan with relative risk of -10.528 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: metoprolol with relative risk of -11.978 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: metoprolol with relative risk of -11.978 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: milrinone with relative risk of -12.400 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: milrinone with relative risk of -12.400 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: cyclophosphamide with relative risk of -13.628 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: cyclophosphamide with relative risk of -13.628 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: tamsulosin with relative risk of -13.726 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: tamsulosin with relative risk of -13.726 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: nevirapine with relative risk of -13.913 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: nevirapine with relative risk of -13.913 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: dofetilide with relative risk of -14.305 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: dofetilide with relative risk of -14.305 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: erlotinib with relative risk of -14.440 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: erlotinib with relative risk of -14.440 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: varenicline with relative risk of -14.441 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 43: varenicline with relative risk of -14.441 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 44: vemurafenib with relative risk of -14.472 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: vemurafenib with relative risk of -14.472 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: fondaparinux with relative risk of -15.007 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: fondaparinux with relative risk of -15.007 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: rotigotine with relative risk of -15.807 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 49: rotigotine with relative risk of -15.807 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 50: sumatriptan with relative risk of -15.818 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 51: sumatriptan with relative risk of -15.818 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 52: citalopram with relative risk of -15.842 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Depressive disorder,neurology/psychiatry\n",
      "Rank 53: citalopram with relative risk of -15.842 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Depressive disorder,neurology/psychiatry\n",
      "Rank 54: doxepin with relative risk of -16.015 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Depressive disorder,neurology/psychiatry\n",
      "Rank 55: doxepin with relative risk of -16.015 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Depressive disorder,neurology/psychiatry\n",
      "Rank 56: darifenacin with relative risk of -16.021 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 57: darifenacin with relative risk of -16.021 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 58: darifenacin with relative risk of -16.021 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 59: ticagrelor with relative risk of -17.253 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 60: ticagrelor with relative risk of -17.253 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 61: ticagrelor with relative risk of -17.253 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 62: estramustine with relative risk of -19.135 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 63: estramustine with relative risk of -19.135 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 64: estramustine with relative risk of -19.135 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 65: ivacaftor with relative risk of -19.561 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 66: ivacaftor with relative risk of -19.561 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 67: ivacaftor with relative risk of -19.561 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 68: bumetanide with relative risk of -19.567 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 69: bumetanide with relative risk of -19.567 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 70: bumetanide with relative risk of -19.567 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 71: auranofin with relative risk of -20.556 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 72: auranofin with relative risk of -20.556 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 73: auranofin with relative risk of -20.556 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 74: cetirizine with relative risk of -20.629 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 75: cetirizine with relative risk of -20.629 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 76: cetirizine with relative risk of -20.629 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 77: brimonidine with relative risk of -20.959 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 78: brimonidine with relative risk of -20.959 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 79: brimonidine with relative risk of -20.959 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 80: delavirdine with relative risk of -21.146 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 81: delavirdine with relative risk of -21.146 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 82: delavirdine with relative risk of -21.146 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 83: dantrolene with relative risk of -21.348 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 84: dantrolene with relative risk of -21.348 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 85: dantrolene with relative risk of -21.348 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 86: tazarotene with relative risk of -21.533 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 87: tazarotene with relative risk of -21.533 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 88: tazarotene with relative risk of -21.533 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 89: risedronate with relative risk of -21.637 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 90: risedronate with relative risk of -21.637 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 91: risedronate with relative risk of -21.637 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 92: clonidine with relative risk of -21.787 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 93: clonidine with relative risk of -21.787 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 94: clonidine with relative risk of -21.787 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 95: dapsone with relative risk of -21.793 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 96: dapsone with relative risk of -21.793 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 97: dapsone with relative risk of -21.793 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 98: donepezil with relative risk of -22.029 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 99: donepezil with relative risk of -22.029 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 100: donepezil with relative risk of -22.029 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 101: brinzolamide with relative risk of -22.068 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 102: brinzolamide with relative risk of -22.068 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 103: brinzolamide with relative risk of -22.068 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 104: acebutolol with relative risk of -22.413 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 105: acebutolol with relative risk of -22.413 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 106: acebutolol with relative risk of -22.413 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 107: isradipine with relative risk of -22.538 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 108: isradipine with relative risk of -22.538 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 109: isradipine with relative risk of -22.538 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 110: valsartan with relative risk of -22.556 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 111: valsartan with relative risk of -22.556 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 112: valsartan with relative risk of -22.556 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 113: pemetrexed with relative risk of -23.942 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 114: pemetrexed with relative risk of -23.942 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 115: pemetrexed with relative risk of -23.942 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 116: pemetrexed with relative risk of -23.942 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 117: indomethacin with relative risk of -24.167 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 118: indomethacin with relative risk of -24.167 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 119: indomethacin with relative risk of -24.167 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 120: indomethacin with relative risk of -24.167 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 121: everolimus with relative risk of -27.383 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 122: everolimus with relative risk of -27.383 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 123: everolimus with relative risk of -27.383 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 124: everolimus with relative risk of -27.383 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 125: pentoxifylline with relative risk of -31.091 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 126: pentoxifylline with relative risk of -31.091 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 127: pentoxifylline with relative risk of -31.091 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 128: pentoxifylline with relative risk of -31.091 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 129: pentoxifylline with relative risk of -31.091 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 130: pentoxifylline with relative risk of -31.091 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 131: trovafloxacin with relative risk of -31.160 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 132: trovafloxacin with relative risk of -31.160 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 133: trovafloxacin with relative risk of -31.160 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 134: trovafloxacin with relative risk of -31.160 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 135: trovafloxacin with relative risk of -31.160 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 136: ruxolitinib with relative risk of -31.930 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 137: ruxolitinib with relative risk of -31.930 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 138: ruxolitinib with relative risk of -31.930 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 139: ruxolitinib with relative risk of -31.930 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 140: ruxolitinib with relative risk of -31.930 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 141: dutasteride with relative risk of -32.407 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 142: dutasteride with relative risk of -32.407 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 143: dutasteride with relative risk of -32.407 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 144: dutasteride with relative risk of -32.407 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 145: dutasteride with relative risk of -32.407 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 146: milnacipran with relative risk of -32.813 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 147: milnacipran with relative risk of -32.813 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 148: milnacipran with relative risk of -32.813 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 149: milnacipran with relative risk of -32.813 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 150: milnacipran with relative risk of -32.813 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 151: tolmetin with relative risk of -33.678 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 152: tolmetin with relative risk of -33.678 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 153: tolmetin with relative risk of -33.678 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 154: tolmetin with relative risk of -33.678 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 155: tolmetin with relative risk of -33.678 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 156: progesterone with relative risk of -34.016 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: obstetrics/gynecology\n",
      "Rank 157: progesterone with relative risk of -34.016 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: obstetrics/gynecology\n",
      "Rank 158: progesterone with relative risk of -34.016 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: obstetrics/gynecology\n",
      "Rank 159: progesterone with relative risk of -34.016 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: obstetrics/gynecology\n",
      "Rank 160: progesterone with relative risk of -34.016 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: obstetrics/gynecology\n",
      "Rank 161: abiraterone with relative risk of -34.525 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 162: abiraterone with relative risk of -34.525 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 163: abiraterone with relative risk of -34.525 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 164: abiraterone with relative risk of -34.525 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 165: abiraterone with relative risk of -34.525 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 166: lubiprostone with relative risk of -34.912 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 167: lubiprostone with relative risk of -34.912 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 168: lubiprostone with relative risk of -34.912 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 169: lubiprostone with relative risk of -34.912 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 170: lubiprostone with relative risk of -34.912 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 171: zolmitriptan with relative risk of -35.329 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 172: zolmitriptan with relative risk of -35.329 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 173: zolmitriptan with relative risk of -35.329 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 174: zolmitriptan with relative risk of -35.329 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 175: zolmitriptan with relative risk of -35.329 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 176: dapagliflozin with relative risk of -35.562 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 177: dapagliflozin with relative risk of -35.562 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 178: dapagliflozin with relative risk of -35.562 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 179: dapagliflozin with relative risk of -35.562 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 180: dapagliflozin with relative risk of -35.562 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 181: misoprostol with relative risk of -35.909 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 182: misoprostol with relative risk of -35.909 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 183: misoprostol with relative risk of -35.909 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 184: misoprostol with relative risk of -35.909 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 185: misoprostol with relative risk of -35.909 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 186: terbutaline with relative risk of -36.336 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 187: terbutaline with relative risk of -36.336 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 188: terbutaline with relative risk of -36.336 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 189: terbutaline with relative risk of -36.336 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 190: terbutaline with relative risk of -36.336 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 191: terbutaline with relative risk of -36.336 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 192: cisatracurium with relative risk of -37.662 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 193: cisatracurium with relative risk of -37.662 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 194: cisatracurium with relative risk of -37.662 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 195: cisatracurium with relative risk of -37.662 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 196: cisatracurium with relative risk of -37.662 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 197: naproxen with relative risk of -38.176 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 198: naproxen with relative risk of -38.176 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 199: naproxen with relative risk of -38.176 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 200: naproxen with relative risk of -38.176 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 201: naproxen with relative risk of -38.176 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 202: naproxen with relative risk of -38.176 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 203: didanosine with relative risk of -40.245 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 204: didanosine with relative risk of -40.245 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 205: didanosine with relative risk of -40.245 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 206: didanosine with relative risk of -40.245 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 207: didanosine with relative risk of -40.245 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 208: didanosine with relative risk of -40.245 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 209: esmolol with relative risk of -40.289 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 210: esmolol with relative risk of -40.289 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 211: esmolol with relative risk of -40.289 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 212: esmolol with relative risk of -40.289 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 213: esmolol with relative risk of -40.289 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 214: esmolol with relative risk of -40.289 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 215: gabapentin with relative risk of -41.119 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 216: gabapentin with relative risk of -41.119 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 217: gabapentin with relative risk of -41.119 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 218: gabapentin with relative risk of -41.119 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 219: gabapentin with relative risk of -41.119 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 220: gabapentin with relative risk of -41.119 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 221: clarithromycin with relative risk of -41.468 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 222: clarithromycin with relative risk of -41.468 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 223: clarithromycin with relative risk of -41.468 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 224: clarithromycin with relative risk of -41.468 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 225: clarithromycin with relative risk of -41.468 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 226: clarithromycin with relative risk of -41.468 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 227: azilsartan with relative risk of -41.749 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 228: azilsartan with relative risk of -41.749 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 229: azilsartan with relative risk of -41.749 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 230: azilsartan with relative risk of -41.749 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 231: azilsartan with relative risk of -41.749 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 232: azilsartan with relative risk of -41.749 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 233: levonorgestrel with relative risk of -46.395 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 234: levonorgestrel with relative risk of -46.395 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 235: levonorgestrel with relative risk of -46.395 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 236: levonorgestrel with relative risk of -46.395 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 237: levonorgestrel with relative risk of -46.395 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 238: levonorgestrel with relative risk of -46.395 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 239: levonorgestrel with relative risk of -46.395 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 240: ketorolac with relative risk of -48.135 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 241: ketorolac with relative risk of -48.135 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 242: ketorolac with relative risk of -48.135 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 243: ketorolac with relative risk of -48.135 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 244: ketorolac with relative risk of -48.135 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 245: ketorolac with relative risk of -48.135 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 246: ketorolac with relative risk of -48.135 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 247: ketorolac with relative risk of -48.135 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 248: lurasidone with relative risk of -53.228 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 249: lurasidone with relative risk of -53.228 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 250: lurasidone with relative risk of -53.228 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 251: lurasidone with relative risk of -53.228 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 252: lurasidone with relative risk of -53.228 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 253: lurasidone with relative risk of -53.228 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 254: lurasidone with relative risk of -53.228 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 255: lurasidone with relative risk of -53.228 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 256: telmisartan with relative risk of -54.344 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 257: telmisartan with relative risk of -54.344 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 258: telmisartan with relative risk of -54.344 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 259: telmisartan with relative risk of -54.344 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 260: telmisartan with relative risk of -54.344 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 261: telmisartan with relative risk of -54.344 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 262: telmisartan with relative risk of -54.344 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 263: telmisartan with relative risk of -54.344 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 264: ropivacaine with relative risk of -57.203 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 265: ropivacaine with relative risk of -57.203 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 266: ropivacaine with relative risk of -57.203 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 267: ropivacaine with relative risk of -57.203 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 268: ropivacaine with relative risk of -57.203 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 269: ropivacaine with relative risk of -57.203 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 270: ropivacaine with relative risk of -57.203 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 271: ropivacaine with relative risk of -57.203 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 272: ropivacaine with relative risk of -57.203 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 273: lansoprazole with relative risk of -73.509 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 274: lansoprazole with relative risk of -73.509 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 275: lansoprazole with relative risk of -73.509 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 276: lansoprazole with relative risk of -73.509 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 277: lansoprazole with relative risk of -73.509 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 278: lansoprazole with relative risk of -73.509 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 279: lansoprazole with relative risk of -73.509 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 280: lansoprazole with relative risk of -73.509 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 281: lansoprazole with relative risk of -73.509 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 282: lansoprazole with relative risk of -73.509 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 283: lansoprazole with relative risk of -73.509 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 284: etoposide with relative risk of -81.727 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 285: etoposide with relative risk of -81.727 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 286: etoposide with relative risk of -81.727 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 287: etoposide with relative risk of -81.727 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 288: etoposide with relative risk of -81.727 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 289: etoposide with relative risk of -81.727 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 290: etoposide with relative risk of -81.727 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 291: etoposide with relative risk of -81.727 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 292: etoposide with relative risk of -81.727 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 293: etoposide with relative risk of -81.727 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 294: etoposide with relative risk of -81.727 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 295: etoposide with relative risk of -81.727 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 296: etoposide with relative risk of -81.727 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 297: ciclesonide with relative risk of -81.809 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 298: ciclesonide with relative risk of -81.809 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 299: ciclesonide with relative risk of -81.809 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 300: ciclesonide with relative risk of -81.809 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 301: ciclesonide with relative risk of -81.809 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 302: ciclesonide with relative risk of -81.809 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 303: ciclesonide with relative risk of -81.809 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 304: ciclesonide with relative risk of -81.809 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 305: ciclesonide with relative risk of -81.809 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 306: ciclesonide with relative risk of -81.809 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 307: ciclesonide with relative risk of -81.809 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 308: ciclesonide with relative risk of -81.809 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 309: ciclesonide with relative risk of -81.809 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 310: ciclesonide with relative risk of -81.809 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 311: ciclesonide with relative risk of -81.809 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 312: ciclesonide with relative risk of -81.809 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 313: fenofibrate with relative risk of -84.271 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 314: fenofibrate with relative risk of -84.271 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 315: fenofibrate with relative risk of -84.271 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 316: fenofibrate with relative risk of -84.271 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 317: fenofibrate with relative risk of -84.271 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 318: fenofibrate with relative risk of -84.271 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 319: fenofibrate with relative risk of -84.271 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 320: fenofibrate with relative risk of -84.271 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 321: fenofibrate with relative risk of -84.271 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 322: fenofibrate with relative risk of -84.271 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 323: fenofibrate with relative risk of -84.271 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 324: fenofibrate with relative risk of -84.271 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 325: fenofibrate with relative risk of -84.271 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 326: tadalafil with relative risk of -92.703 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 327: tadalafil with relative risk of -92.703 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 328: tadalafil with relative risk of -92.703 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 329: tadalafil with relative risk of -92.703 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 330: tadalafil with relative risk of -92.703 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 331: tadalafil with relative risk of -92.703 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 332: tadalafil with relative risk of -92.703 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 333: tadalafil with relative risk of -92.703 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 334: tadalafil with relative risk of -92.703 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 335: tadalafil with relative risk of -92.703 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 336: tadalafil with relative risk of -92.703 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 337: tadalafil with relative risk of -92.703 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 338: tadalafil with relative risk of -92.703 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 339: tadalafil with relative risk of -92.703 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 340: tadalafil with relative risk of -92.703 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 341: tadalafil with relative risk of -92.703 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 342: glimepiride with relative risk of -103.213 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 343: glimepiride with relative risk of -103.213 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 344: glimepiride with relative risk of -103.213 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 345: glimepiride with relative risk of -103.213 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 346: glimepiride with relative risk of -103.213 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 347: glimepiride with relative risk of -103.213 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 348: glimepiride with relative risk of -103.213 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 349: glimepiride with relative risk of -103.213 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 350: glimepiride with relative risk of -103.213 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 351: glimepiride with relative risk of -103.213 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 352: glimepiride with relative risk of -103.213 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 353: glimepiride with relative risk of -103.213 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 354: glimepiride with relative risk of -103.213 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 355: glimepiride with relative risk of -103.213 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 356: glimepiride with relative risk of -103.213 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 357: glimepiride with relative risk of -103.213 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 358: tropisetron with relative risk of -106.079 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 359: tropisetron with relative risk of -106.079 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 360: tropisetron with relative risk of -106.079 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 361: tropisetron with relative risk of -106.079 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 362: tropisetron with relative risk of -106.079 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 363: tropisetron with relative risk of -106.079 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 364: tropisetron with relative risk of -106.079 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 365: tropisetron with relative risk of -106.079 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 366: tropisetron with relative risk of -106.079 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 367: tropisetron with relative risk of -106.079 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 368: tropisetron with relative risk of -106.079 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 369: tropisetron with relative risk of -106.079 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 370: tropisetron with relative risk of -106.079 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 371: tropisetron with relative risk of -106.079 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 372: tropisetron with relative risk of -106.079 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 373: tropisetron with relative risk of -106.079 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 374: tropisetron with relative risk of -106.079 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 375: alfuzosin with relative risk of -107.172 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 376: alfuzosin with relative risk of -107.172 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 377: alfuzosin with relative risk of -107.172 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 378: alfuzosin with relative risk of -107.172 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 379: alfuzosin with relative risk of -107.172 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 380: alfuzosin with relative risk of -107.172 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 381: alfuzosin with relative risk of -107.172 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 382: alfuzosin with relative risk of -107.172 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 383: alfuzosin with relative risk of -107.172 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 384: alfuzosin with relative risk of -107.172 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 385: alfuzosin with relative risk of -107.172 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 386: alfuzosin with relative risk of -107.172 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 387: alfuzosin with relative risk of -107.172 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 388: alfuzosin with relative risk of -107.172 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 389: alfuzosin with relative risk of -107.172 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 390: alfuzosin with relative risk of -107.172 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 391: paliperidone with relative risk of -116.816 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 392: paliperidone with relative risk of -116.816 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 393: paliperidone with relative risk of -116.816 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 394: paliperidone with relative risk of -116.816 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 395: paliperidone with relative risk of -116.816 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 396: paliperidone with relative risk of -116.816 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 397: paliperidone with relative risk of -116.816 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 398: paliperidone with relative risk of -116.816 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 399: paliperidone with relative risk of -116.816 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 400: paliperidone with relative risk of -116.816 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 401: paliperidone with relative risk of -116.816 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 402: paliperidone with relative risk of -116.816 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 403: paliperidone with relative risk of -116.816 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 404: paliperidone with relative risk of -116.816 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 405: paliperidone with relative risk of -116.816 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 406: paliperidone with relative risk of -116.816 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 407: paliperidone with relative risk of -116.816 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 408: paliperidone with relative risk of -116.816 of sertraline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 409: posaconazole with relative risk of -147.742 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 410: posaconazole with relative risk of -147.742 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 411: posaconazole with relative risk of -147.742 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 412: posaconazole with relative risk of -147.742 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 413: posaconazole with relative risk of -147.742 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 414: posaconazole with relative risk of -147.742 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 415: posaconazole with relative risk of -147.742 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 416: posaconazole with relative risk of -147.742 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 417: posaconazole with relative risk of -147.742 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 418: posaconazole with relative risk of -147.742 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 419: posaconazole with relative risk of -147.742 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 420: posaconazole with relative risk of -147.742 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 421: posaconazole with relative risk of -147.742 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 422: posaconazole with relative risk of -147.742 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 423: posaconazole with relative risk of -147.742 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 424: posaconazole with relative risk of -147.742 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 425: posaconazole with relative risk of -147.742 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 426: posaconazole with relative risk of -147.742 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 427: posaconazole with relative risk of -147.742 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 428: posaconazole with relative risk of -147.742 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 429: posaconazole with relative risk of -147.742 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 430: posaconazole with relative risk of -147.742 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 431: posaconazole with relative risk of -147.742 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 432: regadenoson with relative risk of -153.631 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 433: regadenoson with relative risk of -153.631 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 434: regadenoson with relative risk of -153.631 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 435: regadenoson with relative risk of -153.631 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 436: regadenoson with relative risk of -153.631 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 437: regadenoson with relative risk of -153.631 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 438: regadenoson with relative risk of -153.631 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 439: regadenoson with relative risk of -153.631 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 440: regadenoson with relative risk of -153.631 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 441: regadenoson with relative risk of -153.631 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 442: regadenoson with relative risk of -153.631 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 443: regadenoson with relative risk of -153.631 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 444: regadenoson with relative risk of -153.631 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 445: regadenoson with relative risk of -153.631 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 446: regadenoson with relative risk of -153.631 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 447: regadenoson with relative risk of -153.631 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 448: regadenoson with relative risk of -153.631 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 449: regadenoson with relative risk of -153.631 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 450: regadenoson with relative risk of -153.631 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 451: regadenoson with relative risk of -153.631 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 452: regadenoson with relative risk of -153.631 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 453: regadenoson with relative risk of -153.631 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 454: regadenoson with relative risk of -153.631 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 455: regadenoson with relative risk of -153.631 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 456: ibutilide with relative risk of -160.873 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 457: ibutilide with relative risk of -160.873 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 458: ibutilide with relative risk of -160.873 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 459: ibutilide with relative risk of -160.873 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 460: ibutilide with relative risk of -160.873 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 461: ibutilide with relative risk of -160.873 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 462: ibutilide with relative risk of -160.873 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 463: ibutilide with relative risk of -160.873 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 464: ibutilide with relative risk of -160.873 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 465: ibutilide with relative risk of -160.873 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 466: ibutilide with relative risk of -160.873 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 467: ibutilide with relative risk of -160.873 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 468: ibutilide with relative risk of -160.873 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 469: ibutilide with relative risk of -160.873 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 470: ibutilide with relative risk of -160.873 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 471: ibutilide with relative risk of -160.873 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 472: ibutilide with relative risk of -160.873 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 473: ibutilide with relative risk of -160.873 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 474: ibutilide with relative risk of -160.873 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 475: ibutilide with relative risk of -160.873 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 476: ibutilide with relative risk of -160.873 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 477: ibutilide with relative risk of -160.873 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 478: ibutilide with relative risk of -160.873 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 479: ibutilide with relative risk of -160.873 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 480: ibutilide with relative risk of -160.873 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 481: mometasone with relative risk of -162.213 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 482: mometasone with relative risk of -162.213 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 483: mometasone with relative risk of -162.213 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 484: mometasone with relative risk of -162.213 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 485: mometasone with relative risk of -162.213 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 486: mometasone with relative risk of -162.213 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 487: mometasone with relative risk of -162.213 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 488: mometasone with relative risk of -162.213 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 489: mometasone with relative risk of -162.213 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 490: mometasone with relative risk of -162.213 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 491: mometasone with relative risk of -162.213 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 492: mometasone with relative risk of -162.213 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 493: mometasone with relative risk of -162.213 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 494: mometasone with relative risk of -162.213 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 495: mometasone with relative risk of -162.213 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 496: mometasone with relative risk of -162.213 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 497: mometasone with relative risk of -162.213 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 498: mometasone with relative risk of -162.213 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 499: mometasone with relative risk of -162.213 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 500: mometasone with relative risk of -162.213 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 501: mometasone with relative risk of -162.213 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 502: mometasone with relative risk of -162.213 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 503: mometasone with relative risk of -162.213 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 504: mometasone with relative risk of -162.213 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 505: mometasone with relative risk of -162.213 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 506: mometasone with relative risk of -162.213 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 507: azelastine with relative risk of -170.018 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 508: azelastine with relative risk of -170.018 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 509: azelastine with relative risk of -170.018 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 510: azelastine with relative risk of -170.018 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 511: azelastine with relative risk of -170.018 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 512: azelastine with relative risk of -170.018 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 513: azelastine with relative risk of -170.018 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 514: azelastine with relative risk of -170.018 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 515: azelastine with relative risk of -170.018 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 516: azelastine with relative risk of -170.018 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 517: azelastine with relative risk of -170.018 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 518: azelastine with relative risk of -170.018 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 519: azelastine with relative risk of -170.018 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 520: azelastine with relative risk of -170.018 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 521: azelastine with relative risk of -170.018 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 522: azelastine with relative risk of -170.018 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 523: azelastine with relative risk of -170.018 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 524: azelastine with relative risk of -170.018 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 525: azelastine with relative risk of -170.018 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 526: azelastine with relative risk of -170.018 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 527: azelastine with relative risk of -170.018 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 528: azelastine with relative risk of -170.018 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 529: azelastine with relative risk of -170.018 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 530: azelastine with relative risk of -170.018 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 531: azelastine with relative risk of -170.018 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 532: azelastine with relative risk of -170.018 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 533: azelastine with relative risk of -170.018 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 534: irbesartan with relative risk of -269.911 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 535: irbesartan with relative risk of -269.911 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 536: irbesartan with relative risk of -269.911 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 537: irbesartan with relative risk of -269.911 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 538: irbesartan with relative risk of -269.911 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 539: irbesartan with relative risk of -269.911 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 540: irbesartan with relative risk of -269.911 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 541: irbesartan with relative risk of -269.911 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 542: irbesartan with relative risk of -269.911 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 543: irbesartan with relative risk of -269.911 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 544: irbesartan with relative risk of -269.911 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 545: irbesartan with relative risk of -269.911 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 546: irbesartan with relative risk of -269.911 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 547: irbesartan with relative risk of -269.911 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 548: irbesartan with relative risk of -269.911 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 549: irbesartan with relative risk of -269.911 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 550: irbesartan with relative risk of -269.911 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 551: irbesartan with relative risk of -269.911 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 552: irbesartan with relative risk of -269.911 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 553: irbesartan with relative risk of -269.911 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 554: irbesartan with relative risk of -269.911 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 555: irbesartan with relative risk of -269.911 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 556: irbesartan with relative risk of -269.911 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 557: irbesartan with relative risk of -269.911 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 558: irbesartan with relative risk of -269.911 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 559: irbesartan with relative risk of -269.911 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 560: irbesartan with relative risk of -269.911 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 561: irbesartan with relative risk of -269.911 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 562: irbesartan with relative risk of -269.911 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 563: irbesartan with relative risk of -269.911 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 564: irbesartan with relative risk of -269.911 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 565: irbesartan with relative risk of -269.911 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 566: irbesartan with relative risk of -269.911 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 567: irbesartan with relative risk of -269.911 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 568: irbesartan with relative risk of -269.911 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 569: irbesartan with relative risk of -269.911 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 570: irbesartan with relative risk of -269.911 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 571: irbesartan with relative risk of -269.911 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 572: irbesartan with relative risk of -269.911 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 573: irbesartan with relative risk of -269.911 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 574: irbesartan with relative risk of -269.911 of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 575: felodipine with relative risk of -inf of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 576: felodipine with relative risk of -inf of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 577: felodipine with relative risk of -inf of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 578: felodipine with relative risk of -inf of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 579: felodipine with relative risk of -inf of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 580: felodipine with relative risk of -inf of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 581: felodipine with relative risk of -inf of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 582: felodipine with relative risk of -inf of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 583: felodipine with relative risk of -inf of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 584: felodipine with relative risk of -inf of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 585: felodipine with relative risk of -inf of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 586: felodipine with relative risk of -inf of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 587: felodipine with relative risk of -inf of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 588: felodipine with relative risk of -inf of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 589: felodipine with relative risk of -inf of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 590: felodipine with relative risk of -inf of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 591: felodipine with relative risk of -inf of sertraline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.165\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target sevelamer not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó sildenafil *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: bicalutamide with relative risk of -10.622 of sildenafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: vandetanib with relative risk of -10.647 of sildenafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: danazol with relative risk of -11.034 of sildenafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: ivermectin with relative risk of -11.168 of sildenafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: cabozantinib with relative risk of -11.689 of sildenafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: ciprofloxacin with relative risk of -12.339 of sildenafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó silodosin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: ciclesonide with relative risk of -9.311 of silodosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: cytarabine with relative risk of -10.046 of silodosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: clomipramine with relative risk of -10.062 of silodosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: paclitaxel with relative risk of -10.237 of silodosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: formoterol with relative risk of -10.323 of silodosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: sunitinib with relative risk of -10.352 of silodosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: frovatriptan with relative risk of -10.485 of silodosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: nimodipine with relative risk of -10.812 of silodosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: ramelteon with relative risk of -11.338 of silodosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: entacapone with relative risk of -11.614 of silodosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: rasagiline with relative risk of -11.798 of silodosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: ipratropium with relative risk of -11.881 of silodosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: rivastigmine with relative risk of -11.918 of silodosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: sotalol with relative risk of -11.943 of silodosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: rofecoxib with relative risk of -11.993 of silodosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: pimozide with relative risk of -12.066 of silodosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: capsaicin with relative risk of -12.517 of silodosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: fosinoprilat with relative risk of -14.799 of silodosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: nefazodone with relative risk of -22.454 of silodosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: nefazodone with relative risk of -22.454 of silodosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: desoximetasone with relative risk of -inf of silodosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó simvastatin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: fluoxetine with relative risk of -27.024 of simvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Depressive disorder,neurology/psychiatry\n",
      "Rank 2: fluoxetine with relative risk of -27.024 of simvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Depressive disorder,neurology/psychiatry\n",
      "Rank 3: fluoxetine with relative risk of -27.024 of simvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Depressive disorder,neurology/psychiatry\n",
      "Rank 4: alogliptin with relative risk of -36.032 of simvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 5: alogliptin with relative risk of -36.032 of simvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 6: alogliptin with relative risk of -36.032 of simvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 7: alogliptin with relative risk of -36.032 of simvastatin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 8: dolasetron with relative risk of -53.094 of simvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: dolasetron with relative risk of -53.094 of simvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: dolasetron with relative risk of -53.094 of simvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: dolasetron with relative risk of -53.094 of simvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: dolasetron with relative risk of -53.094 of simvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: dolasetron with relative risk of -53.094 of simvastatin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.815\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó sitagliptin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: regorafenib with relative risk of -8.908 of sitagliptin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: bexarotene with relative risk of -8.920 of sitagliptin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: adapalene with relative risk of -11.122 of sitagliptin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: liraglutide with relative risk of -11.172 of sitagliptin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Diabetes Mellitus, Non-Insulin-Dependent,endocrinology\n",
      "Rank 5: linagliptin with relative risk of -12.077 of sitagliptin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Diabetes Mellitus, Non-Insulin-Dependent,endocrinology\n",
      "Rank 6: dexamethasone with relative risk of -20.453 of sitagliptin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 7: dexamethasone with relative risk of -20.453 of sitagliptin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 8: fluvastatin with relative risk of -25.307 of sitagliptin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 9: fluvastatin with relative risk of -25.307 of sitagliptin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 10: fluvastatin with relative risk of -25.307 of sitagliptin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "Rank 11: amiodarone with relative risk of -29.451 of sitagliptin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: amiodarone with relative risk of -29.451 of sitagliptin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: amiodarone with relative risk of -29.451 of sitagliptin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: amiodarone with relative risk of -29.451 of sitagliptin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: lenalidomide with relative risk of -29.786 of sitagliptin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: lenalidomide with relative risk of -29.786 of sitagliptin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: lenalidomide with relative risk of -29.786 of sitagliptin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: lenalidomide with relative risk of -29.786 of sitagliptin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: penbutolol with relative risk of -30.802 of sitagliptin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: penbutolol with relative risk of -30.802 of sitagliptin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: penbutolol with relative risk of -30.802 of sitagliptin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: penbutolol with relative risk of -30.802 of sitagliptin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.297\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target sitaxsentan not found. Exiting ...\n",
      "\n",
      "Drug target sodium not found. Exiting ...\n",
      "\n",
      "Drug target sofosbuvir not found. Exiting ...\n",
      "\n",
      "Drug target solifenacin not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó sorafenib *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: amiodarone with relative risk of -16.364 of sorafenib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: amiodarone with relative risk of -16.364 of sorafenib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó sotalol *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: aminophylline with relative risk of -8.831 of sotalol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: entacapone with relative risk of -11.614 of sotalol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: ipratropium with relative risk of -11.881 of sotalol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: silodosin with relative risk of -12.126 of sotalol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: nefazodone with relative risk of -12.399 of sotalol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: clopidogrel with relative risk of -12.697 of sotalol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 7: formoterol with relative risk of -18.768 of sotalol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: formoterol with relative risk of -18.768 of sotalol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: frovatriptan with relative risk of -18.930 of sotalol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: frovatriptan with relative risk of -18.930 of sotalol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: nimodipine with relative risk of -19.480 of sotalol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: nimodipine with relative risk of -19.480 of sotalol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: cytarabine with relative risk of -19.695 of sotalol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: cytarabine with relative risk of -19.695 of sotalol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: paclitaxel with relative risk of -20.985 of sotalol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: paclitaxel with relative risk of -20.985 of sotalol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: rasagiline with relative risk of -21.853 of sotalol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: rasagiline with relative risk of -21.853 of sotalol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: rivastigmine with relative risk of -22.666 of sotalol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: rivastigmine with relative risk of -22.666 of sotalol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: rofecoxib with relative risk of -22.741 of sotalol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: rofecoxib with relative risk of -22.741 of sotalol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: pimozide with relative risk of -22.814 of sotalol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: pimozide with relative risk of -22.814 of sotalol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: capsaicin with relative risk of -23.265 of sotalol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: capsaicin with relative risk of -23.265 of sotalol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: fosinoprilat with relative risk of -25.547 of sotalol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 28: fosinoprilat with relative risk of -25.547 of sotalol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.061\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó sparfloxacin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "Drug target spinosad not found. Exiting ...\n",
      "\n",
      "Drug target stavudine not found. Exiting ...\n",
      "\n",
      "Drug target streptozotocin not found. Exiting ...\n",
      "\n",
      "Drug target sufentanil not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó sulfasalazine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: regadenoson with relative risk of -7.955 of sulfasalazine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: sertraline with relative risk of -8.308 of sulfasalazine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: mometasone with relative risk of -8.550 of sulfasalazine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: posaconazole with relative risk of -8.987 of sulfasalazine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: irbesartan with relative risk of -9.036 of sulfasalazine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: azelastine with relative risk of -9.384 of sulfasalazine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: crizotinib with relative risk of -9.682 of sulfasalazine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: ibutilide with relative risk of -10.422 of sulfasalazine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: asenapine with relative risk of -10.931 of sulfasalazine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: amsacrine with relative risk of -10.937 of sulfasalazine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: carbamazepine with relative risk of -11.005 of sulfasalazine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: dofetilide with relative risk of -11.146 of sulfasalazine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: tolvaptan with relative risk of -12.277 of sulfasalazine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "Rank 14: ambrisentan with relative risk of -12.295 of sulfasalazine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: cimetidine with relative risk of -13.616 of sulfasalazine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.043\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target sulindac not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó sumatriptan *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: ropivacaine with relative risk of -9.475 of sumatriptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: metoprolol with relative risk of -9.508 of sumatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: cyclophosphamide with relative risk of -9.777 of sumatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: pemetrexed with relative risk of -9.778 of sumatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: lurasidone with relative risk of -9.865 of sumatriptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 6: milrinone with relative risk of -9.931 of sumatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: indomethacin with relative risk of -10.561 of sumatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: bumetanide with relative risk of -10.806 of sumatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: trovafloxacin with relative risk of -10.991 of sumatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: nevirapine with relative risk of -11.157 of sumatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: tamsulosin with relative risk of -11.256 of sumatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: flutamide with relative risk of -11.292 of sumatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: fondaparinux with relative risk of -11.848 of sumatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: citalopram with relative risk of -11.991 of sumatriptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: sertraline with relative risk of -15.270 of sumatriptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 16: sertraline with relative risk of -15.270 of sumatriptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 17: regadenoson with relative risk of -15.483 of sumatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: regadenoson with relative risk of -15.483 of sumatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: mometasone with relative risk of -15.895 of sumatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: mometasone with relative risk of -15.895 of sumatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: irbesartan with relative risk of -15.911 of sumatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: irbesartan with relative risk of -15.911 of sumatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: etoposide with relative risk of -16.126 of sumatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: etoposide with relative risk of -16.126 of sumatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: posaconazole with relative risk of -16.556 of sumatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: posaconazole with relative risk of -16.556 of sumatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: azelastine with relative risk of -16.697 of sumatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: azelastine with relative risk of -16.697 of sumatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: glimepiride with relative risk of -17.542 of sumatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: glimepiride with relative risk of -17.542 of sumatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: tropisetron with relative risk of -17.589 of sumatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: tropisetron with relative risk of -17.589 of sumatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: paliperidone with relative risk of -17.618 of sumatriptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 34: paliperidone with relative risk of -17.618 of sumatriptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 35: ibutilide with relative risk of -17.873 of sumatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: ibutilide with relative risk of -17.873 of sumatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: levonorgestrel with relative risk of -18.539 of sumatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: levonorgestrel with relative risk of -18.539 of sumatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: fenofibrate with relative risk of -18.669 of sumatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: fenofibrate with relative risk of -18.669 of sumatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: lansoprazole with relative risk of -18.859 of sumatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: lansoprazole with relative risk of -18.859 of sumatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: ketorolac with relative risk of -18.915 of sumatriptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 44: ketorolac with relative risk of -18.915 of sumatriptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 45: ruxolitinib with relative risk of -18.957 of sumatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: ruxolitinib with relative risk of -18.957 of sumatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: didanosine with relative risk of -19.117 of sumatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: didanosine with relative risk of -19.117 of sumatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: dutasteride with relative risk of -20.349 of sumatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: dutasteride with relative risk of -20.349 of sumatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: felodipine with relative risk of -inf of sumatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: felodipine with relative risk of -inf of sumatriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.332\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó sunitinib *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: nifedipine with relative risk of -9.365 of sunitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: carbamazepine with relative risk of -9.753 of sunitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: silodosin with relative risk of -10.874 of sunitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: nefazodone with relative risk of -11.147 of sunitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: amlexanox with relative risk of -11.745 of sunitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: ciclesonide with relative risk of -25.704 of sunitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: ciclesonide with relative risk of -25.704 of sunitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: ciclesonide with relative risk of -25.704 of sunitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: ciclesonide with relative risk of -25.704 of sunitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: clomipramine with relative risk of -32.578 of sunitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: clomipramine with relative risk of -32.578 of sunitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: clomipramine with relative risk of -32.578 of sunitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: clomipramine with relative risk of -32.578 of sunitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: ramelteon with relative risk of -34.546 of sunitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: ramelteon with relative risk of -34.546 of sunitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: ramelteon with relative risk of -34.546 of sunitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: ramelteon with relative risk of -34.546 of sunitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: desoximetasone with relative risk of -inf of sunitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: desoximetasone with relative risk of -inf of sunitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: desoximetasone with relative risk of -inf of sunitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: desoximetasone with relative risk of -inf of sunitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: desoximetasone with relative risk of -inf of sunitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target suvorexant not found. Exiting ...\n",
      "\n",
      "Drug target tacrolimus not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó tadalafil *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: axitinib with relative risk of -6.890 of tadalafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: paroxetine with relative risk of -36.799 of tadalafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: paroxetine with relative risk of -36.799 of tadalafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: paroxetine with relative risk of -36.799 of tadalafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: paroxetine with relative risk of -36.799 of tadalafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: paroxetine with relative risk of -36.799 of tadalafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: paroxetine with relative risk of -36.799 of tadalafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: paroxetine with relative risk of -36.799 of tadalafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: ticagrelor with relative risk of -47.534 of tadalafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: ticagrelor with relative risk of -47.534 of tadalafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: ticagrelor with relative risk of -47.534 of tadalafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: ticagrelor with relative risk of -47.534 of tadalafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: ticagrelor with relative risk of -47.534 of tadalafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: ticagrelor with relative risk of -47.534 of tadalafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: ticagrelor with relative risk of -47.534 of tadalafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: dolutegravir with relative risk of -52.261 of tadalafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: dolutegravir with relative risk of -52.261 of tadalafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: dolutegravir with relative risk of -52.261 of tadalafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: dolutegravir with relative risk of -52.261 of tadalafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: dolutegravir with relative risk of -52.261 of tadalafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: dolutegravir with relative risk of -52.261 of tadalafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: dolutegravir with relative risk of -52.261 of tadalafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: irbesartan with relative risk of -91.430 of tadalafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: irbesartan with relative risk of -91.430 of tadalafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: irbesartan with relative risk of -91.430 of tadalafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: irbesartan with relative risk of -91.430 of tadalafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: irbesartan with relative risk of -91.430 of tadalafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: irbesartan with relative risk of -91.430 of tadalafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: irbesartan with relative risk of -91.430 of tadalafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: irbesartan with relative risk of -91.430 of tadalafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: irbesartan with relative risk of -91.430 of tadalafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: irbesartan with relative risk of -91.430 of tadalafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: irbesartan with relative risk of -91.430 of tadalafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: irbesartan with relative risk of -91.430 of tadalafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: irbesartan with relative risk of -91.430 of tadalafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: irbesartan with relative risk of -91.430 of tadalafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: irbesartan with relative risk of -91.430 of tadalafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: irbesartan with relative risk of -91.430 of tadalafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: sertraline with relative risk of -92.260 of tadalafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: sertraline with relative risk of -92.260 of tadalafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: sertraline with relative risk of -92.260 of tadalafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: sertraline with relative risk of -92.260 of tadalafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: sertraline with relative risk of -92.260 of tadalafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: sertraline with relative risk of -92.260 of tadalafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: sertraline with relative risk of -92.260 of tadalafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: sertraline with relative risk of -92.260 of tadalafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: sertraline with relative risk of -92.260 of tadalafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: sertraline with relative risk of -92.260 of tadalafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: sertraline with relative risk of -92.260 of tadalafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: sertraline with relative risk of -92.260 of tadalafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: sertraline with relative risk of -92.260 of tadalafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: sertraline with relative risk of -92.260 of tadalafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 53: sertraline with relative risk of -92.260 of tadalafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 54: sertraline with relative risk of -92.260 of tadalafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 55: ciclesonide with relative risk of -95.474 of tadalafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 56: ciclesonide with relative risk of -95.474 of tadalafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 57: ciclesonide with relative risk of -95.474 of tadalafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 58: ciclesonide with relative risk of -95.474 of tadalafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 59: ciclesonide with relative risk of -95.474 of tadalafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 60: ciclesonide with relative risk of -95.474 of tadalafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 61: ciclesonide with relative risk of -95.474 of tadalafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 62: ciclesonide with relative risk of -95.474 of tadalafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 63: ciclesonide with relative risk of -95.474 of tadalafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 64: ciclesonide with relative risk of -95.474 of tadalafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 65: ciclesonide with relative risk of -95.474 of tadalafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 66: ciclesonide with relative risk of -95.474 of tadalafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 67: ciclesonide with relative risk of -95.474 of tadalafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 68: ciclesonide with relative risk of -95.474 of tadalafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 69: ciclesonide with relative risk of -95.474 of tadalafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 70: ciclesonide with relative risk of -95.474 of tadalafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 71: alfuzosin with relative risk of -120.859 of tadalafil | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Prostatic Hypertrophy,urology\n",
      "Rank 72: alfuzosin with relative risk of -120.859 of tadalafil | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Prostatic Hypertrophy,urology\n",
      "Rank 73: alfuzosin with relative risk of -120.859 of tadalafil | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Prostatic Hypertrophy,urology\n",
      "Rank 74: alfuzosin with relative risk of -120.859 of tadalafil | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Prostatic Hypertrophy,urology\n",
      "Rank 75: alfuzosin with relative risk of -120.859 of tadalafil | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Prostatic Hypertrophy,urology\n",
      "Rank 76: alfuzosin with relative risk of -120.859 of tadalafil | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Prostatic Hypertrophy,urology\n",
      "Rank 77: alfuzosin with relative risk of -120.859 of tadalafil | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Prostatic Hypertrophy,urology\n",
      "Rank 78: alfuzosin with relative risk of -120.859 of tadalafil | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Prostatic Hypertrophy,urology\n",
      "Rank 79: alfuzosin with relative risk of -120.859 of tadalafil | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Prostatic Hypertrophy,urology\n",
      "Rank 80: alfuzosin with relative risk of -120.859 of tadalafil | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Prostatic Hypertrophy,urology\n",
      "Rank 81: alfuzosin with relative risk of -120.859 of tadalafil | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Prostatic Hypertrophy,urology\n",
      "Rank 82: alfuzosin with relative risk of -120.859 of tadalafil | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Prostatic Hypertrophy,urology\n",
      "Rank 83: alfuzosin with relative risk of -120.859 of tadalafil | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Prostatic Hypertrophy,urology\n",
      "Rank 84: alfuzosin with relative risk of -120.859 of tadalafil | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Prostatic Hypertrophy,urology\n",
      "Rank 85: alfuzosin with relative risk of -120.859 of tadalafil | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Prostatic Hypertrophy,urology\n",
      "Rank 86: alfuzosin with relative risk of -120.859 of tadalafil | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Prostatic Hypertrophy,urology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.041\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó tafluprost *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: indacaterol with relative risk of -10.760 of tafluprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: exenatide with relative risk of -12.318 of tafluprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: cabergoline with relative risk of -12.543 of tafluprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: trazodone with relative risk of -16.978 of tafluprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: trazodone with relative risk of -16.978 of tafluprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: lovastatin with relative risk of -22.381 of tafluprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: lovastatin with relative risk of -22.381 of tafluprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó tamoxifen *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: dexrazoxane with relative risk of -9.453 of tamoxifen | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: carvedilol with relative risk of -11.023 of tamoxifen | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: raltitrexed with relative risk of -11.330 of tamoxifen | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 4: rosuvastatin with relative risk of -12.471 of tamoxifen | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.16\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó tamsulosin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: ropivacaine with relative risk of -8.559 of tamsulosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: levonorgestrel with relative risk of -8.668 of tamsulosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: ruxolitinib with relative risk of -8.903 of tamsulosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: lurasidone with relative risk of -8.950 of tamsulosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: didanosine with relative risk of -9.063 of tamsulosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: lansoprazole with relative risk of -9.499 of tamsulosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: ketorolac with relative risk of -9.650 of tamsulosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: bumetanide with relative risk of -9.890 of tamsulosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: sumatriptan with relative risk of -11.052 of tamsulosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: sertraline with relative risk of -12.973 of tamsulosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: sertraline with relative risk of -12.973 of tamsulosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: nevirapine with relative risk of -18.504 of tamsulosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: nevirapine with relative risk of -18.504 of tamsulosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: capecitabine with relative risk of -19.204 of tamsulosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: capecitabine with relative risk of -19.204 of tamsulosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: etoposide with relative risk of -21.394 of tamsulosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: etoposide with relative risk of -21.394 of tamsulosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: etoposide with relative risk of -21.394 of tamsulosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: paliperidone with relative risk of -22.539 of tamsulosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: paliperidone with relative risk of -22.539 of tamsulosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: paliperidone with relative risk of -22.539 of tamsulosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: glimepiride with relative risk of -22.587 of tamsulosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: glimepiride with relative risk of -22.587 of tamsulosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: glimepiride with relative risk of -22.587 of tamsulosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: fenofibrate with relative risk of -23.937 of tamsulosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: fenofibrate with relative risk of -23.937 of tamsulosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: fenofibrate with relative risk of -23.937 of tamsulosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: regadenoson with relative risk of -27.670 of tamsulosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: regadenoson with relative risk of -27.670 of tamsulosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: regadenoson with relative risk of -27.670 of tamsulosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: regadenoson with relative risk of -27.670 of tamsulosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: azelastine with relative risk of -28.430 of tamsulosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: azelastine with relative risk of -28.430 of tamsulosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: azelastine with relative risk of -28.430 of tamsulosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: azelastine with relative risk of -28.430 of tamsulosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: posaconazole with relative risk of -28.831 of tamsulosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: posaconazole with relative risk of -28.831 of tamsulosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: posaconazole with relative risk of -28.831 of tamsulosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: posaconazole with relative risk of -28.831 of tamsulosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: fondaparinux with relative risk of -29.655 of tamsulosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: fondaparinux with relative risk of -29.655 of tamsulosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: fondaparinux with relative risk of -29.655 of tamsulosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: irbesartan with relative risk of -34.590 of tamsulosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: irbesartan with relative risk of -34.590 of tamsulosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: irbesartan with relative risk of -34.590 of tamsulosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: irbesartan with relative risk of -34.590 of tamsulosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: irbesartan with relative risk of -34.590 of tamsulosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: trovafloxacin with relative risk of -34.892 of tamsulosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: trovafloxacin with relative risk of -34.892 of tamsulosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: trovafloxacin with relative risk of -34.892 of tamsulosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: trovafloxacin with relative risk of -34.892 of tamsulosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: dutasteride with relative risk of -35.854 of tamsulosin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Prostatic Hypertrophy,urology\n",
      "Rank 53: dutasteride with relative risk of -35.854 of tamsulosin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Prostatic Hypertrophy,urology\n",
      "Rank 54: dutasteride with relative risk of -35.854 of tamsulosin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Prostatic Hypertrophy,urology\n",
      "Rank 55: dutasteride with relative risk of -35.854 of tamsulosin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Prostatic Hypertrophy,urology\n",
      "Rank 56: mometasone with relative risk of -36.065 of tamsulosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 57: mometasone with relative risk of -36.065 of tamsulosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 58: mometasone with relative risk of -36.065 of tamsulosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 59: mometasone with relative risk of -36.065 of tamsulosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 60: mometasone with relative risk of -36.065 of tamsulosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 61: ibutilide with relative risk of -38.383 of tamsulosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 62: ibutilide with relative risk of -38.383 of tamsulosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 63: ibutilide with relative risk of -38.383 of tamsulosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 64: ibutilide with relative risk of -38.383 of tamsulosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 65: ibutilide with relative risk of -38.383 of tamsulosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 66: tropisetron with relative risk of -39.258 of tamsulosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 67: tropisetron with relative risk of -39.258 of tamsulosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 68: tropisetron with relative risk of -39.258 of tamsulosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 69: tropisetron with relative risk of -39.258 of tamsulosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 70: tropisetron with relative risk of -39.258 of tamsulosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 71: indomethacin with relative risk of -44.740 of tamsulosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 72: indomethacin with relative risk of -44.740 of tamsulosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 73: indomethacin with relative risk of -44.740 of tamsulosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 74: indomethacin with relative risk of -44.740 of tamsulosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 75: indomethacin with relative risk of -44.740 of tamsulosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 76: pemetrexed with relative risk of -44.804 of tamsulosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 77: pemetrexed with relative risk of -44.804 of tamsulosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 78: pemetrexed with relative risk of -44.804 of tamsulosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 79: pemetrexed with relative risk of -44.804 of tamsulosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 80: pemetrexed with relative risk of -44.804 of tamsulosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 81: metoprolol with relative risk of -47.243 of tamsulosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 82: metoprolol with relative risk of -47.243 of tamsulosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 83: metoprolol with relative risk of -47.243 of tamsulosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 84: metoprolol with relative risk of -47.243 of tamsulosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 85: metoprolol with relative risk of -47.243 of tamsulosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 86: milrinone with relative risk of -47.665 of tamsulosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 87: milrinone with relative risk of -47.665 of tamsulosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 88: milrinone with relative risk of -47.665 of tamsulosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 89: milrinone with relative risk of -47.665 of tamsulosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 90: milrinone with relative risk of -47.665 of tamsulosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 91: felodipine with relative risk of -inf of tamsulosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 92: felodipine with relative risk of -inf of tamsulosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 93: felodipine with relative risk of -inf of tamsulosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.015\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target tapentadol not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó tasimelteon *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: ibandronate with relative risk of -9.095 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: atomoxetine with relative risk of -19.578 of tasimelteon | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: atomoxetine with relative risk of -19.578 of tasimelteon | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: candesartan with relative risk of -20.429 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: candesartan with relative risk of -20.429 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: mafenide with relative risk of -20.434 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: mafenide with relative risk of -20.434 of tasimelteon | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.321\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó tazarotene *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: lurasidone with relative risk of -9.460 of tazarotene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: everolimus with relative risk of -9.823 of tazarotene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: lansoprazole with relative risk of -10.009 of tazarotene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: clarithromycin with relative risk of -10.796 of tazarotene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: perindopril with relative risk of -11.340 of tazarotene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: regadenoson with relative risk of -14.385 of tazarotene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: regadenoson with relative risk of -14.385 of tazarotene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: irbesartan with relative risk of -14.814 of tazarotene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: irbesartan with relative risk of -14.814 of tazarotene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: posaconazole with relative risk of -15.459 of tazarotene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: posaconazole with relative risk of -15.459 of tazarotene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: azelastine with relative risk of -15.600 of tazarotene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: azelastine with relative risk of -15.600 of tazarotene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: ropivacaine with relative risk of -16.927 of tazarotene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: ropivacaine with relative risk of -16.927 of tazarotene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: sertraline with relative risk of -21.564 of tazarotene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: sertraline with relative risk of -21.564 of tazarotene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: sertraline with relative risk of -21.564 of tazarotene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: mometasone with relative risk of -22.583 of tazarotene | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: dermatology\n",
      "Rank 20: mometasone with relative risk of -22.583 of tazarotene | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: dermatology\n",
      "Rank 21: mometasone with relative risk of -22.583 of tazarotene | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: dermatology\n",
      "Rank 22: ibutilide with relative risk of -24.670 of tazarotene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: ibutilide with relative risk of -24.670 of tazarotene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: ibutilide with relative risk of -24.670 of tazarotene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: tropisetron with relative risk of -24.754 of tazarotene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: tropisetron with relative risk of -24.754 of tazarotene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: tropisetron with relative risk of -24.754 of tazarotene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: paliperidone with relative risk of -24.840 of tazarotene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: paliperidone with relative risk of -24.840 of tazarotene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: paliperidone with relative risk of -24.840 of tazarotene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: glimepiride with relative risk of -24.888 of tazarotene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: glimepiride with relative risk of -24.888 of tazarotene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: glimepiride with relative risk of -24.888 of tazarotene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: pentoxifylline with relative risk of -24.938 of tazarotene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: pentoxifylline with relative risk of -24.938 of tazarotene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: pentoxifylline with relative risk of -24.938 of tazarotene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: darifenacin with relative risk of -25.563 of tazarotene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: darifenacin with relative risk of -25.563 of tazarotene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: darifenacin with relative risk of -25.563 of tazarotene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: terbutaline with relative risk of -26.867 of tazarotene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: terbutaline with relative risk of -26.867 of tazarotene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: terbutaline with relative risk of -26.867 of tazarotene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: esmolol with relative risk of -27.830 of tazarotene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: esmolol with relative risk of -27.830 of tazarotene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: esmolol with relative risk of -27.830 of tazarotene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: azilsartan with relative risk of -29.289 of tazarotene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: azilsartan with relative risk of -29.289 of tazarotene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: azilsartan with relative risk of -29.289 of tazarotene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: brimonidine with relative risk of -30.520 of tazarotene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: brimonidine with relative risk of -30.520 of tazarotene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: brimonidine with relative risk of -30.520 of tazarotene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: dapsone with relative risk of -31.353 of tazarotene | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Acne Vulgaris,dermatology\n",
      "Rank 53: dapsone with relative risk of -31.353 of tazarotene | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Acne Vulgaris,dermatology\n",
      "Rank 54: dapsone with relative risk of -31.353 of tazarotene | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Acne Vulgaris,dermatology\n",
      "Rank 55: isradipine with relative risk of -32.098 of tazarotene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 56: isradipine with relative risk of -32.098 of tazarotene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 57: isradipine with relative risk of -32.098 of tazarotene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 58: felodipine with relative risk of -inf of tazarotene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 59: felodipine with relative risk of -inf of tazarotene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 60: felodipine with relative risk of -inf of tazarotene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.044\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target technetium-99m not found. Exiting ...\n",
      "\n",
      "Drug target teduglutide not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó tegaserod *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "Drug target telavancin not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó telithromycin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: nabumetone with relative risk of -8.809 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: cyclobenzaprine with relative risk of -9.582 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: asenapine with relative risk of -15.264 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: asenapine with relative risk of -15.264 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: iloperidone with relative risk of -16.112 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: iloperidone with relative risk of -16.112 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: anagrelide with relative risk of -16.880 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: anagrelide with relative risk of -16.880 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: albendazole with relative risk of -25.041 of telithromycin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 10: albendazole with relative risk of -25.041 of telithromycin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 11: albendazole with relative risk of -25.041 of telithromycin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 12: captopril with relative risk of -117.088 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: captopril with relative risk of -117.088 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: captopril with relative risk of -117.088 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: captopril with relative risk of -117.088 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: captopril with relative risk of -117.088 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: captopril with relative risk of -117.088 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: captopril with relative risk of -117.088 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: captopril with relative risk of -117.088 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: captopril with relative risk of -117.088 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: captopril with relative risk of -117.088 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: captopril with relative risk of -117.088 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: captopril with relative risk of -117.088 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: captopril with relative risk of -117.088 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: captopril with relative risk of -117.088 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: captopril with relative risk of -117.088 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: captopril with relative risk of -117.088 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: atorvastatin with relative risk of -117.321 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: atorvastatin with relative risk of -117.321 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: atorvastatin with relative risk of -117.321 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: atorvastatin with relative risk of -117.321 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: atorvastatin with relative risk of -117.321 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: atorvastatin with relative risk of -117.321 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: atorvastatin with relative risk of -117.321 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: atorvastatin with relative risk of -117.321 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: atorvastatin with relative risk of -117.321 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: atorvastatin with relative risk of -117.321 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: atorvastatin with relative risk of -117.321 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: atorvastatin with relative risk of -117.321 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: atorvastatin with relative risk of -117.321 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: atorvastatin with relative risk of -117.321 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: atorvastatin with relative risk of -117.321 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: atorvastatin with relative risk of -117.321 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: treprostinil with relative risk of -127.210 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: treprostinil with relative risk of -127.210 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: treprostinil with relative risk of -127.210 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: treprostinil with relative risk of -127.210 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: treprostinil with relative risk of -127.210 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: treprostinil with relative risk of -127.210 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: treprostinil with relative risk of -127.210 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: treprostinil with relative risk of -127.210 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: treprostinil with relative risk of -127.210 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 53: treprostinil with relative risk of -127.210 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 54: treprostinil with relative risk of -127.210 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 55: treprostinil with relative risk of -127.210 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 56: treprostinil with relative risk of -127.210 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 57: treprostinil with relative risk of -127.210 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 58: treprostinil with relative risk of -127.210 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 59: treprostinil with relative risk of -127.210 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 60: cetrorelix with relative risk of -128.353 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 61: cetrorelix with relative risk of -128.353 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 62: cetrorelix with relative risk of -128.353 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 63: cetrorelix with relative risk of -128.353 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 64: cetrorelix with relative risk of -128.353 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 65: cetrorelix with relative risk of -128.353 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 66: cetrorelix with relative risk of -128.353 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 67: cetrorelix with relative risk of -128.353 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 68: cetrorelix with relative risk of -128.353 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 69: cetrorelix with relative risk of -128.353 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 70: cetrorelix with relative risk of -128.353 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 71: cetrorelix with relative risk of -128.353 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 72: cetrorelix with relative risk of -128.353 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 73: cetrorelix with relative risk of -128.353 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 74: cetrorelix with relative risk of -128.353 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 75: cetrorelix with relative risk of -128.353 of telithromycin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.062\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó telmisartan *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: etoposide with relative risk of -6.560 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: ibandronate with relative risk of -8.119 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: glimepiride with relative risk of -8.185 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: paliperidone with relative risk of -8.380 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: tropisetron with relative risk of -8.405 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: ruxolitinib with relative risk of -8.434 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: didanosine with relative risk of -8.594 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: lansoprazole with relative risk of -9.031 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: fenofibrate with relative risk of -9.104 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: ketorolac with relative risk of -9.182 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: vemurafenib with relative risk of -9.235 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: bumetanide with relative risk of -9.421 of telmisartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 13: bosutinib with relative risk of -9.627 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: dofetilide with relative risk of -9.760 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: cetirizine with relative risk of -9.790 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: varenicline with relative risk of -9.896 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: dutasteride with relative risk of -10.009 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: bezafibrate with relative risk of -10.178 of telmisartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 19: zolmitriptan with relative risk of -10.226 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: ixabepilone with relative risk of -10.261 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: citalopram with relative risk of -10.605 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: doxepin with relative risk of -10.778 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: benazepril with relative risk of -11.099 of telmisartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 24: toremifene with relative risk of -11.853 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: olmesartan with relative risk of -12.255 of telmisartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 26: lurasidone with relative risk of -15.336 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: lurasidone with relative risk of -15.336 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: ticagrelor with relative risk of -15.496 of telmisartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 29: ticagrelor with relative risk of -15.496 of telmisartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 30: delavirdine with relative risk of -17.319 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: delavirdine with relative risk of -17.319 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: clonidine with relative risk of -17.961 of telmisartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 33: clonidine with relative risk of -17.961 of telmisartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 34: erlotinib with relative risk of -18.006 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: erlotinib with relative risk of -18.006 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: rotigotine with relative risk of -19.373 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: rotigotine with relative risk of -19.373 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: ropivacaine with relative risk of -21.977 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: ropivacaine with relative risk of -21.977 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: ropivacaine with relative risk of -21.977 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: naproxen with relative risk of -23.076 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: naproxen with relative risk of -23.076 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: naproxen with relative risk of -23.076 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: gabapentin with relative risk of -24.635 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: gabapentin with relative risk of -24.635 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: gabapentin with relative risk of -24.635 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: estramustine with relative risk of -24.664 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: estramustine with relative risk of -24.664 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: estramustine with relative risk of -24.664 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: clarithromycin with relative risk of -24.984 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: clarithromycin with relative risk of -24.984 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: clarithromycin with relative risk of -24.984 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 53: auranofin with relative risk of -26.091 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 54: auranofin with relative risk of -26.091 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 55: auranofin with relative risk of -26.091 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 56: dantrolene with relative risk of -26.883 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 57: dantrolene with relative risk of -26.883 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 58: dantrolene with relative risk of -26.883 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 59: risedronate with relative risk of -27.172 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 60: risedronate with relative risk of -27.172 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 61: risedronate with relative risk of -27.172 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 62: donepezil with relative risk of -27.564 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 63: donepezil with relative risk of -27.564 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 64: donepezil with relative risk of -27.564 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 65: irbesartan with relative risk of -37.532 of telmisartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 66: irbesartan with relative risk of -37.532 of telmisartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 67: irbesartan with relative risk of -37.532 of telmisartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 68: irbesartan with relative risk of -37.532 of telmisartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 69: irbesartan with relative risk of -37.532 of telmisartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 70: irbesartan with relative risk of -37.532 of telmisartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 71: mometasone with relative risk of -39.531 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 72: mometasone with relative risk of -39.531 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 73: mometasone with relative risk of -39.531 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 74: mometasone with relative risk of -39.531 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 75: mometasone with relative risk of -39.531 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 76: mometasone with relative risk of -39.531 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 77: posaconazole with relative risk of -41.178 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 78: posaconazole with relative risk of -41.178 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 79: posaconazole with relative risk of -41.178 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 80: posaconazole with relative risk of -41.178 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 81: posaconazole with relative risk of -41.178 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 82: posaconazole with relative risk of -41.178 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 83: milnacipran with relative risk of -42.802 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 84: milnacipran with relative risk of -42.802 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 85: milnacipran with relative risk of -42.802 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 86: milnacipran with relative risk of -42.802 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 87: milnacipran with relative risk of -42.802 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 88: tolmetin with relative risk of -43.669 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 89: tolmetin with relative risk of -43.669 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 90: tolmetin with relative risk of -43.669 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 91: tolmetin with relative risk of -43.669 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 92: tolmetin with relative risk of -43.669 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 93: progesterone with relative risk of -44.007 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 94: progesterone with relative risk of -44.007 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 95: progesterone with relative risk of -44.007 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 96: progesterone with relative risk of -44.007 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 97: progesterone with relative risk of -44.007 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 98: abiraterone with relative risk of -44.516 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 99: abiraterone with relative risk of -44.516 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 100: abiraterone with relative risk of -44.516 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 101: abiraterone with relative risk of -44.516 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 102: abiraterone with relative risk of -44.516 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 103: lubiprostone with relative risk of -44.903 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 104: lubiprostone with relative risk of -44.903 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 105: lubiprostone with relative risk of -44.903 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 106: lubiprostone with relative risk of -44.903 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 107: lubiprostone with relative risk of -44.903 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 108: dapagliflozin with relative risk of -45.553 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 109: dapagliflozin with relative risk of -45.553 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 110: dapagliflozin with relative risk of -45.553 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 111: dapagliflozin with relative risk of -45.553 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 112: dapagliflozin with relative risk of -45.553 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 113: misoprostol with relative risk of -45.900 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 114: misoprostol with relative risk of -45.900 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 115: misoprostol with relative risk of -45.900 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 116: misoprostol with relative risk of -45.900 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 117: misoprostol with relative risk of -45.900 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 118: cisatracurium with relative risk of -47.653 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 119: cisatracurium with relative risk of -47.653 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 120: cisatracurium with relative risk of -47.653 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 121: cisatracurium with relative risk of -47.653 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 122: cisatracurium with relative risk of -47.653 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 123: regadenoson with relative risk of -48.233 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 124: regadenoson with relative risk of -48.233 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 125: regadenoson with relative risk of -48.233 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 126: regadenoson with relative risk of -48.233 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 127: regadenoson with relative risk of -48.233 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 128: regadenoson with relative risk of -48.233 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 129: regadenoson with relative risk of -48.233 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 130: ibutilide with relative risk of -50.187 of telmisartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 131: ibutilide with relative risk of -50.187 of telmisartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 132: ibutilide with relative risk of -50.187 of telmisartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 133: ibutilide with relative risk of -50.187 of telmisartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 134: ibutilide with relative risk of -50.187 of telmisartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 135: ibutilide with relative risk of -50.187 of telmisartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 136: ibutilide with relative risk of -50.187 of telmisartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 137: sertraline with relative risk of -53.396 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 138: sertraline with relative risk of -53.396 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 139: sertraline with relative risk of -53.396 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 140: sertraline with relative risk of -53.396 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 141: sertraline with relative risk of -53.396 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 142: sertraline with relative risk of -53.396 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 143: sertraline with relative risk of -53.396 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 144: sertraline with relative risk of -53.396 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 145: azelastine with relative risk of -57.152 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 146: azelastine with relative risk of -57.152 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 147: azelastine with relative risk of -57.152 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 148: azelastine with relative risk of -57.152 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 149: azelastine with relative risk of -57.152 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 150: azelastine with relative risk of -57.152 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 151: azelastine with relative risk of -57.152 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 152: azelastine with relative risk of -57.152 of telmisartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 153: felodipine with relative risk of -inf of telmisartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.09\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target temazepam not found. Exiting ...\n",
      "\n",
      "Drug target temozolomide not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó temsirolimus *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: azelastine with relative risk of -9.384 of temsirolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: pentoxifylline with relative risk of -9.859 of temsirolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: loratadine with relative risk of -10.862 of temsirolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: afatinib with relative risk of -11.280 of temsirolimus | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 5: quinidine with relative risk of -11.571 of temsirolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: beclomethasone with relative risk of -11.945 of temsirolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: budesonide with relative risk of -12.312 of temsirolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: pergolide with relative risk of -12.824 of temsirolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: aclidinium with relative risk of -12.870 of temsirolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: caffeine with relative risk of -13.366 of temsirolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: bromfenac with relative risk of -14.997 of temsirolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: irbesartan with relative risk of -15.911 of temsirolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: irbesartan with relative risk of -15.911 of temsirolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: bumetanide with relative risk of -20.168 of temsirolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: bumetanide with relative risk of -20.168 of temsirolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: argatroban with relative risk of -20.750 of temsirolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: argatroban with relative risk of -20.750 of temsirolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: nevirapine with relative risk of -20.807 of temsirolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: nevirapine with relative risk of -20.807 of temsirolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: ribavirin with relative risk of -21.029 of temsirolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: ribavirin with relative risk of -21.029 of temsirolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: celecoxib with relative risk of -21.722 of temsirolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: celecoxib with relative risk of -21.722 of temsirolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: perindopril with relative risk of -21.801 of temsirolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: perindopril with relative risk of -21.801 of temsirolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: lapatinib with relative risk of -21.973 of temsirolimus | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 27: lapatinib with relative risk of -21.973 of temsirolimus | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 28: losartan with relative risk of -22.372 of temsirolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: losartan with relative risk of -22.372 of temsirolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: amisulpride with relative risk of -22.437 of temsirolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: amisulpride with relative risk of -22.437 of temsirolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: latanoprost with relative risk of -22.533 of temsirolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: latanoprost with relative risk of -22.533 of temsirolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: domperidone with relative risk of -22.897 of temsirolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: domperidone with relative risk of -22.897 of temsirolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: lidocaine with relative risk of -23.775 of temsirolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: lidocaine with relative risk of -23.775 of temsirolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: felodipine with relative risk of -inf of temsirolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: felodipine with relative risk of -inf of temsirolimus | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.077\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó teniposide *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: clozapine with relative risk of -9.370 of teniposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: cabazitaxel with relative risk of -9.888 of teniposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: balsalazide with relative risk of -10.842 of teniposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: saquinavir with relative risk of -11.382 of teniposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: bosentan with relative risk of -11.654 of teniposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: apixaban with relative risk of -12.827 of teniposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: tegaserod with relative risk of -12.970 of teniposide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target tenofovir not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó terazosin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: halofantrine with relative risk of -20.640 of terazosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: halofantrine with relative risk of -20.640 of terazosin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: trandolapril with relative risk of -21.271 of terazosin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 4: trandolapril with relative risk of -21.271 of terazosin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.28\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target terbinafine not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó terbutaline *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: ibandronate with relative risk of -8.002 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: levonorgestrel with relative risk of -8.081 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: miglustat with relative risk of -8.127 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: penbutolol with relative risk of -8.336 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: ketorolac with relative risk of -9.065 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: loratadine with relative risk of -9.359 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: trovafloxacin with relative risk of -9.489 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: argatroban with relative risk of -9.598 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: clarithromycin with relative risk of -9.699 of terbutaline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: pulmonary\n",
      "Rank 10: dronedarone with relative risk of -9.774 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: estramustine with relative risk of -9.785 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: perindopril with relative risk of -10.242 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: fluconazole with relative risk of -10.531 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: bisoprolol with relative risk of -10.782 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: domperidone with relative risk of -11.338 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: lurasidone with relative risk of -15.085 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: lurasidone with relative risk of -15.085 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: lansoprazole with relative risk of -15.278 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: lansoprazole with relative risk of -15.278 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: didanosine with relative risk of -15.535 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: didanosine with relative risk of -15.535 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: etoposide with relative risk of -19.268 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: etoposide with relative risk of -19.268 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: etoposide with relative risk of -19.268 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: darifenacin with relative risk of -21.135 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: darifenacin with relative risk of -21.135 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: darifenacin with relative risk of -21.135 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: ropivacaine with relative risk of -21.572 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: ropivacaine with relative risk of -21.572 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: ropivacaine with relative risk of -21.572 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: fenofibrate with relative risk of -21.811 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: fenofibrate with relative risk of -21.811 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: fenofibrate with relative risk of -21.811 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: ivacaftor with relative risk of -24.689 of terbutaline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: pulmonary\n",
      "Rank 35: ivacaftor with relative risk of -24.689 of terbutaline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: pulmonary\n",
      "Rank 36: ivacaftor with relative risk of -24.689 of terbutaline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: pulmonary\n",
      "Rank 37: zolmitriptan with relative risk of -25.498 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: zolmitriptan with relative risk of -25.498 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: zolmitriptan with relative risk of -25.498 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: brimonidine with relative risk of -26.089 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: brimonidine with relative risk of -26.089 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: brimonidine with relative risk of -26.089 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: tazarotene with relative risk of -26.662 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: tazarotene with relative risk of -26.662 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: tazarotene with relative risk of -26.662 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: dapsone with relative risk of -26.922 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: dapsone with relative risk of -26.922 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: dapsone with relative risk of -26.922 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: brinzolamide with relative risk of -27.198 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: brinzolamide with relative risk of -27.198 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: brinzolamide with relative risk of -27.198 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: acebutolol with relative risk of -27.543 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 53: acebutolol with relative risk of -27.543 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 54: acebutolol with relative risk of -27.543 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 55: isradipine with relative risk of -27.667 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 56: isradipine with relative risk of -27.667 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 57: isradipine with relative risk of -27.667 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 58: valsartan with relative risk of -27.686 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 59: valsartan with relative risk of -27.686 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 60: valsartan with relative risk of -27.686 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 61: irbesartan with relative risk of -29.761 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 62: irbesartan with relative risk of -29.761 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 63: irbesartan with relative risk of -29.761 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 64: irbesartan with relative risk of -29.761 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 65: irbesartan with relative risk of -29.761 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 66: regadenoson with relative risk of -31.410 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 67: regadenoson with relative risk of -31.410 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 68: regadenoson with relative risk of -31.410 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 69: regadenoson with relative risk of -31.410 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 70: regadenoson with relative risk of -31.410 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 71: azelastine with relative risk of -31.929 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 72: azelastine with relative risk of -31.929 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 73: azelastine with relative risk of -31.929 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 74: azelastine with relative risk of -31.929 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 75: azelastine with relative risk of -31.929 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 76: posaconazole with relative risk of -32.617 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 77: posaconazole with relative risk of -32.617 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 78: posaconazole with relative risk of -32.617 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 79: posaconazole with relative risk of -32.617 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 80: posaconazole with relative risk of -32.617 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 81: everolimus with relative risk of -34.458 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 82: everolimus with relative risk of -34.458 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 83: everolimus with relative risk of -34.458 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 84: everolimus with relative risk of -34.458 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 85: sertraline with relative risk of -36.162 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 86: sertraline with relative risk of -36.162 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 87: sertraline with relative risk of -36.162 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 88: sertraline with relative risk of -36.162 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 89: sertraline with relative risk of -36.162 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 90: sertraline with relative risk of -36.162 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 91: mometasone with relative risk of -38.434 of terbutaline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Asthma\n",
      "Rank 92: mometasone with relative risk of -38.434 of terbutaline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Asthma\n",
      "Rank 93: mometasone with relative risk of -38.434 of terbutaline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Asthma\n",
      "Rank 94: mometasone with relative risk of -38.434 of terbutaline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Asthma\n",
      "Rank 95: mometasone with relative risk of -38.434 of terbutaline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Asthma\n",
      "Rank 96: mometasone with relative risk of -38.434 of terbutaline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Asthma\n",
      "Rank 97: ibutilide with relative risk of -40.874 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 98: ibutilide with relative risk of -40.874 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 99: ibutilide with relative risk of -40.874 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 100: ibutilide with relative risk of -40.874 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 101: ibutilide with relative risk of -40.874 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 102: ibutilide with relative risk of -40.874 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 103: tropisetron with relative risk of -42.175 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 104: tropisetron with relative risk of -42.175 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 105: tropisetron with relative risk of -42.175 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 106: tropisetron with relative risk of -42.175 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 107: tropisetron with relative risk of -42.175 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 108: tropisetron with relative risk of -42.175 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 109: paliperidone with relative risk of -42.456 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 110: paliperidone with relative risk of -42.456 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 111: paliperidone with relative risk of -42.456 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 112: paliperidone with relative risk of -42.456 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 113: paliperidone with relative risk of -42.456 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 114: paliperidone with relative risk of -42.456 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 115: glimepiride with relative risk of -42.935 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 116: glimepiride with relative risk of -42.935 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 117: glimepiride with relative risk of -42.935 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 118: glimepiride with relative risk of -42.935 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 119: glimepiride with relative risk of -42.935 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 120: glimepiride with relative risk of -42.935 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 121: pentoxifylline with relative risk of -50.890 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 122: pentoxifylline with relative risk of -50.890 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 123: pentoxifylline with relative risk of -50.890 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 124: pentoxifylline with relative risk of -50.890 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 125: pentoxifylline with relative risk of -50.890 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 126: pentoxifylline with relative risk of -50.890 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 127: pentoxifylline with relative risk of -50.890 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 128: esmolol with relative risk of -51.772 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 129: esmolol with relative risk of -51.772 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 130: esmolol with relative risk of -51.772 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 131: esmolol with relative risk of -51.772 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 132: esmolol with relative risk of -51.772 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 133: esmolol with relative risk of -51.772 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 134: azilsartan with relative risk of -53.231 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 135: azilsartan with relative risk of -53.231 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 136: azilsartan with relative risk of -53.231 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 137: azilsartan with relative risk of -53.231 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 138: azilsartan with relative risk of -53.231 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 139: azilsartan with relative risk of -53.231 of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 140: felodipine with relative risk of -inf of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 141: felodipine with relative risk of -inf of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 142: felodipine with relative risk of -inf of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 143: felodipine with relative risk of -inf of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 144: felodipine with relative risk of -inf of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 145: felodipine with relative risk of -inf of terbutaline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.047\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target terconazole not found. Exiting ...\n",
      "\n",
      "Drug target tesamorelin not found. Exiting ...\n",
      "\n",
      "Drug target testosterone not found. Exiting ...\n",
      "\n",
      "Drug target tetrabenazine not found. Exiting ...\n",
      "\n",
      "Drug target tetrahydrobiopterin not found. Exiting ...\n",
      "\n",
      "Drug target tetrofosmin not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó thalidomide *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: nalmefene with relative risk of -11.697 of thalidomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: flumazenil with relative risk of -12.262 of thalidomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: ranolazine with relative risk of -13.623 of thalidomide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target theophylline not found. Exiting ...\n",
      "\n",
      "Drug target thymidine not found. Exiting ...\n",
      "\n",
      "Drug target tiagabine not found. Exiting ...\n",
      "\n",
      "Drug target tiaprofenic not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó ticagrelor *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: regadenoson with relative risk of -6.354 of ticagrelor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: ibandronate with relative risk of -7.897 of ticagrelor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: ruxolitinib with relative risk of -8.211 of ticagrelor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: lurasidone with relative risk of -8.258 of ticagrelor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: ibutilide with relative risk of -8.822 of ticagrelor | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 6: varenicline with relative risk of -9.673 of ticagrelor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: ixabepilone with relative risk of -10.038 of ticagrelor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: benazepril with relative risk of -10.876 of ticagrelor | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 9: toremifene with relative risk of -11.630 of ticagrelor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: telmisartan with relative risk of -15.978 of ticagrelor | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 11: telmisartan with relative risk of -15.978 of ticagrelor | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 12: sertraline with relative risk of -16.789 of ticagrelor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: sertraline with relative risk of -16.789 of ticagrelor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: sertraline with relative risk of -16.789 of ticagrelor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: clonidine with relative risk of -17.486 of ticagrelor | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 16: clonidine with relative risk of -17.486 of ticagrelor | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 17: erlotinib with relative risk of -17.531 of ticagrelor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: erlotinib with relative risk of -17.531 of ticagrelor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: vemurafenib with relative risk of -17.563 of ticagrelor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: vemurafenib with relative risk of -17.563 of ticagrelor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: azelastine with relative risk of -18.572 of ticagrelor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: azelastine with relative risk of -18.572 of ticagrelor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: azelastine with relative risk of -18.572 of ticagrelor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: rotigotine with relative risk of -18.898 of ticagrelor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: rotigotine with relative risk of -18.898 of ticagrelor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: doxepin with relative risk of -19.106 of ticagrelor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: doxepin with relative risk of -19.106 of ticagrelor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: ropivacaine with relative risk of -21.215 of ticagrelor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: ropivacaine with relative risk of -21.215 of ticagrelor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: ropivacaine with relative risk of -21.215 of ticagrelor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: naproxen with relative risk of -22.314 of ticagrelor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: naproxen with relative risk of -22.314 of ticagrelor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: naproxen with relative risk of -22.314 of ticagrelor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: gabapentin with relative risk of -23.873 of ticagrelor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: gabapentin with relative risk of -23.873 of ticagrelor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: gabapentin with relative risk of -23.873 of ticagrelor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: clarithromycin with relative risk of -24.222 of ticagrelor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: clarithromycin with relative risk of -24.222 of ticagrelor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: clarithromycin with relative risk of -24.222 of ticagrelor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: delavirdine with relative risk of -25.919 of ticagrelor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: delavirdine with relative risk of -25.919 of ticagrelor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: delavirdine with relative risk of -25.919 of ticagrelor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: paroxetine with relative risk of -44.750 of ticagrelor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: paroxetine with relative risk of -44.750 of ticagrelor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: paroxetine with relative risk of -44.750 of ticagrelor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: paroxetine with relative risk of -44.750 of ticagrelor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: paroxetine with relative risk of -44.750 of ticagrelor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: paroxetine with relative risk of -44.750 of ticagrelor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: paroxetine with relative risk of -44.750 of ticagrelor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: tadalafil with relative risk of -47.513 of ticagrelor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: tadalafil with relative risk of -47.513 of ticagrelor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: tadalafil with relative risk of -47.513 of ticagrelor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 53: tadalafil with relative risk of -47.513 of ticagrelor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 54: tadalafil with relative risk of -47.513 of ticagrelor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 55: tadalafil with relative risk of -47.513 of ticagrelor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 56: tadalafil with relative risk of -47.513 of ticagrelor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 57: dolutegravir with relative risk of -60.228 of ticagrelor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 58: dolutegravir with relative risk of -60.228 of ticagrelor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 59: dolutegravir with relative risk of -60.228 of ticagrelor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 60: dolutegravir with relative risk of -60.228 of ticagrelor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 61: dolutegravir with relative risk of -60.228 of ticagrelor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 62: dolutegravir with relative risk of -60.228 of ticagrelor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 63: dolutegravir with relative risk of -60.228 of ticagrelor | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.136\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target tigecycline not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó timolol *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: fludarabine with relative risk of -12.191 of timolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: belinostat with relative risk of -12.309 of timolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: palonosetron with relative risk of -13.362 of timolol | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: quinapril with relative risk of -13.910 of timolol | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.12\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target tinidazole not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó tiotropium *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: vinorelbine with relative risk of -9.510 of tiotropium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: ciclesonide with relative risk of -10.002 of tiotropium | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Asthma\n",
      "Rank 3: axitinib with relative risk of -10.058 of tiotropium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: darifenacin with relative risk of -10.336 of tiotropium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: granisetron with relative risk of -10.397 of tiotropium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: apraclonidine with relative risk of -10.554 of tiotropium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: meloxicam with relative risk of -11.231 of tiotropium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: indacaterol with relative risk of -11.453 of tiotropium | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: pulmonary\n",
      "Rank 9: exemestane with relative risk of -11.865 of tiotropium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: dabigatran with relative risk of -11.929 of tiotropium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: etravirine with relative risk of -12.466 of tiotropium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: pinaverium with relative risk of -13.533 of tiotropium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: desoximetasone with relative risk of -inf of tiotropium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.197\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target tipranavir not found. Exiting ...\n",
      "\n",
      "Drug target tirofiban not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó tizanidine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: betaxolol with relative risk of -8.823 of tizanidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: risperidone with relative risk of -16.289 of tizanidine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: risperidone with relative risk of -16.289 of tizanidine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: amiodarone with relative risk of -25.208 of tizanidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: amiodarone with relative risk of -25.208 of tizanidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: amiodarone with relative risk of -25.208 of tizanidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: amiodarone with relative risk of -25.208 of tizanidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: lenalidomide with relative risk of -25.542 of tizanidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: lenalidomide with relative risk of -25.542 of tizanidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: lenalidomide with relative risk of -25.542 of tizanidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: lenalidomide with relative risk of -25.542 of tizanidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: penbutolol with relative risk of -26.558 of tizanidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: penbutolol with relative risk of -26.558 of tizanidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: penbutolol with relative risk of -26.558 of tizanidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: penbutolol with relative risk of -26.558 of tizanidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: fluvastatin with relative risk of -30.304 of tizanidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: fluvastatin with relative risk of -30.304 of tizanidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: fluvastatin with relative risk of -30.304 of tizanidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: fluvastatin with relative risk of -30.304 of tizanidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: ketoprofen with relative risk of -34.978 of tizanidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: ketoprofen with relative risk of -34.978 of tizanidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: ketoprofen with relative risk of -34.978 of tizanidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: ketoprofen with relative risk of -34.978 of tizanidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: propafenone with relative risk of -36.449 of tizanidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: propafenone with relative risk of -36.449 of tizanidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: propafenone with relative risk of -36.449 of tizanidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: propafenone with relative risk of -36.449 of tizanidine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.214\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target tobramycin not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó tofacitinib *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: fluvoxamine with relative risk of -10.071 of tofacitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: venlafaxine with relative risk of -12.778 of tofacitinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: piroxicam with relative risk of -13.491 of tofacitinib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Rheumatoid Arthritis,rheumatology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.182\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó tolcapone *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó tolmetin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: bosutinib with relative risk of -10.097 of tolmetin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: dofetilide with relative risk of -10.229 of tolmetin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: clarithromycin with relative risk of -10.286 of tolmetin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: olmesartan with relative risk of -12.725 of tolmetin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: estramustine with relative risk of -26.386 of tolmetin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: estramustine with relative risk of -26.386 of tolmetin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: estramustine with relative risk of -26.386 of tolmetin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: auranofin with relative risk of -27.814 of tolmetin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Rheumatoid Arthritis,rheumatology\n",
      "Rank 9: auranofin with relative risk of -27.814 of tolmetin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Rheumatoid Arthritis,rheumatology\n",
      "Rank 10: auranofin with relative risk of -27.814 of tolmetin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Rheumatoid Arthritis,rheumatology\n",
      "Rank 11: dantrolene with relative risk of -28.606 of tolmetin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: dantrolene with relative risk of -28.606 of tolmetin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: dantrolene with relative risk of -28.606 of tolmetin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: risedronate with relative risk of -28.895 of tolmetin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: risedronate with relative risk of -28.895 of tolmetin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: risedronate with relative risk of -28.895 of tolmetin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: donepezil with relative risk of -29.287 of tolmetin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: donepezil with relative risk of -29.287 of tolmetin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: donepezil with relative risk of -29.287 of tolmetin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: sertraline with relative risk of -34.222 of tolmetin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: sertraline with relative risk of -34.222 of tolmetin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: sertraline with relative risk of -34.222 of tolmetin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: sertraline with relative risk of -34.222 of tolmetin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: sertraline with relative risk of -34.222 of tolmetin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: irbesartan with relative risk of -34.590 of tolmetin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: irbesartan with relative risk of -34.590 of tolmetin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: irbesartan with relative risk of -34.590 of tolmetin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: irbesartan with relative risk of -34.590 of tolmetin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: irbesartan with relative risk of -34.590 of tolmetin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: mometasone with relative risk of -36.065 of tolmetin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: mometasone with relative risk of -36.065 of tolmetin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: mometasone with relative risk of -36.065 of tolmetin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: mometasone with relative risk of -36.065 of tolmetin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: mometasone with relative risk of -36.065 of tolmetin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: regadenoson with relative risk of -36.243 of tolmetin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: regadenoson with relative risk of -36.243 of tolmetin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: regadenoson with relative risk of -36.243 of tolmetin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: regadenoson with relative risk of -36.243 of tolmetin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: regadenoson with relative risk of -36.243 of tolmetin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: azelastine with relative risk of -36.761 of tolmetin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: azelastine with relative risk of -36.761 of tolmetin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: azelastine with relative risk of -36.761 of tolmetin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: azelastine with relative risk of -36.761 of tolmetin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: azelastine with relative risk of -36.761 of tolmetin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: posaconazole with relative risk of -37.450 of tolmetin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: posaconazole with relative risk of -37.450 of tolmetin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: posaconazole with relative risk of -37.450 of tolmetin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: posaconazole with relative risk of -37.450 of tolmetin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: posaconazole with relative risk of -37.450 of tolmetin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: ibutilide with relative risk of -38.383 of tolmetin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: ibutilide with relative risk of -38.383 of tolmetin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: ibutilide with relative risk of -38.383 of tolmetin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 53: ibutilide with relative risk of -38.383 of tolmetin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 54: ibutilide with relative risk of -38.383 of tolmetin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 55: telmisartan with relative risk of -45.160 of tolmetin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 56: telmisartan with relative risk of -45.160 of tolmetin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 57: telmisartan with relative risk of -45.160 of tolmetin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 58: telmisartan with relative risk of -45.160 of tolmetin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 59: telmisartan with relative risk of -45.160 of tolmetin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 60: milnacipran with relative risk of -46.827 of tolmetin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: rheumatology\n",
      "Rank 61: milnacipran with relative risk of -46.827 of tolmetin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: rheumatology\n",
      "Rank 62: milnacipran with relative risk of -46.827 of tolmetin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: rheumatology\n",
      "Rank 63: milnacipran with relative risk of -46.827 of tolmetin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: rheumatology\n",
      "Rank 64: milnacipran with relative risk of -46.827 of tolmetin | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: rheumatology\n",
      "Rank 65: progesterone with relative risk of -48.032 of tolmetin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 66: progesterone with relative risk of -48.032 of tolmetin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 67: progesterone with relative risk of -48.032 of tolmetin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 68: progesterone with relative risk of -48.032 of tolmetin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 69: progesterone with relative risk of -48.032 of tolmetin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 70: abiraterone with relative risk of -48.541 of tolmetin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 71: abiraterone with relative risk of -48.541 of tolmetin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 72: abiraterone with relative risk of -48.541 of tolmetin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 73: abiraterone with relative risk of -48.541 of tolmetin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 74: abiraterone with relative risk of -48.541 of tolmetin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 75: lubiprostone with relative risk of -48.928 of tolmetin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 76: lubiprostone with relative risk of -48.928 of tolmetin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 77: lubiprostone with relative risk of -48.928 of tolmetin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 78: lubiprostone with relative risk of -48.928 of tolmetin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 79: lubiprostone with relative risk of -48.928 of tolmetin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 80: dapagliflozin with relative risk of -49.578 of tolmetin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 81: dapagliflozin with relative risk of -49.578 of tolmetin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 82: dapagliflozin with relative risk of -49.578 of tolmetin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 83: dapagliflozin with relative risk of -49.578 of tolmetin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 84: dapagliflozin with relative risk of -49.578 of tolmetin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 85: misoprostol with relative risk of -49.925 of tolmetin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 86: misoprostol with relative risk of -49.925 of tolmetin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 87: misoprostol with relative risk of -49.925 of tolmetin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 88: misoprostol with relative risk of -49.925 of tolmetin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 89: misoprostol with relative risk of -49.925 of tolmetin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 90: cisatracurium with relative risk of -51.678 of tolmetin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 91: cisatracurium with relative risk of -51.678 of tolmetin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 92: cisatracurium with relative risk of -51.678 of tolmetin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 93: cisatracurium with relative risk of -51.678 of tolmetin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 94: cisatracurium with relative risk of -51.678 of tolmetin | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.081\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó tolterodine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: nilotinib with relative risk of -12.350 of tolterodine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: iloprost with relative risk of -12.393 of tolterodine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó tolvaptan *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: regadenoson with relative risk of -8.647 of tolvaptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: sertraline with relative risk of -8.999 of tolvaptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: mometasone with relative risk of -9.242 of tolvaptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: posaconazole with relative risk of -9.679 of tolvaptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: irbesartan with relative risk of -9.727 of tolvaptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 6: azelastine with relative risk of -10.076 of tolvaptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: crizotinib with relative risk of -10.375 of tolvaptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: ibutilide with relative risk of -11.114 of tolvaptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 9: asenapine with relative risk of -11.624 of tolvaptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: amsacrine with relative risk of -11.630 of tolvaptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: carbamazepine with relative risk of -11.698 of tolvaptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: dofetilide with relative risk of -11.839 of tolvaptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: sulfasalazine with relative risk of -11.908 of tolvaptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "Rank 14: ambrisentan with relative risk of -12.988 of tolvaptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: cimetidine with relative risk of -14.309 of tolvaptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology,endocrinology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.141\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó topiramate *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: bromocriptine with relative risk of -9.787 of topiramate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 2: nedocromil with relative risk of -13.623 of topiramate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: nedocromil with relative risk of -13.623 of topiramate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: pamidronate with relative risk of -15.096 of topiramate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: pamidronate with relative risk of -15.096 of topiramate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: vismodegib with relative risk of -15.738 of topiramate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: vismodegib with relative risk of -15.738 of topiramate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: pravastatin with relative risk of -18.959 of topiramate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertriglyceridemia\n",
      "Rank 9: pravastatin with relative risk of -18.959 of topiramate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertriglyceridemia\n",
      "Rank 10: riluzole with relative risk of -22.991 of topiramate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 11: riluzole with relative risk of -22.991 of topiramate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 12: riluzole with relative risk of -22.991 of topiramate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: trazodone with relative risk of -24.982 of topiramate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: trazodone with relative risk of -24.982 of topiramate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: trazodone with relative risk of -24.982 of topiramate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 16: trazodone with relative risk of -24.982 of topiramate | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 17: olopatadine with relative risk of -25.233 of topiramate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: olopatadine with relative risk of -25.233 of topiramate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: olopatadine with relative risk of -25.233 of topiramate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: betaxolol with relative risk of -44.116 of topiramate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: betaxolol with relative risk of -44.116 of topiramate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: betaxolol with relative risk of -44.116 of topiramate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: betaxolol with relative risk of -44.116 of topiramate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: betaxolol with relative risk of -44.116 of topiramate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: betaxolol with relative risk of -44.116 of topiramate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: quinaprilat with relative risk of -65.449 of topiramate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: quinaprilat with relative risk of -65.449 of topiramate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: quinaprilat with relative risk of -65.449 of topiramate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: quinaprilat with relative risk of -65.449 of topiramate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: quinaprilat with relative risk of -65.449 of topiramate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: quinaprilat with relative risk of -65.449 of topiramate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: quinaprilat with relative risk of -65.449 of topiramate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: quinaprilat with relative risk of -65.449 of topiramate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: loperamide with relative risk of -76.131 of topiramate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: loperamide with relative risk of -76.131 of topiramate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: loperamide with relative risk of -76.131 of topiramate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: loperamide with relative risk of -76.131 of topiramate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: loperamide with relative risk of -76.131 of topiramate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: loperamide with relative risk of -76.131 of topiramate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: loperamide with relative risk of -76.131 of topiramate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: loperamide with relative risk of -76.131 of topiramate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: loperamide with relative risk of -76.131 of topiramate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: loperamide with relative risk of -76.131 of topiramate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: efinaconazole with relative risk of -inf of topiramate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: efinaconazole with relative risk of -inf of topiramate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: efinaconazole with relative risk of -inf of topiramate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: efinaconazole with relative risk of -inf of topiramate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: efinaconazole with relative risk of -inf of topiramate | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.588\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó topotecan *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: paroxetine with relative risk of -7.917 of topotecan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: clozapine with relative risk of -8.273 of topotecan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: ibandronate with relative risk of -8.405 of topotecan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: ketorolac with relative risk of -9.469 of topotecan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: nabumetone with relative risk of -9.901 of topotecan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: metolazone with relative risk of -27.281 of topotecan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: metolazone with relative risk of -27.281 of topotecan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: metolazone with relative risk of -27.281 of topotecan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: nalbuphine with relative risk of -28.501 of topotecan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: nalbuphine with relative risk of -28.501 of topotecan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: nalbuphine with relative risk of -28.501 of topotecan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: darunavir with relative risk of -28.604 of topotecan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: darunavir with relative risk of -28.604 of topotecan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: darunavir with relative risk of -28.604 of topotecan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó torasemide *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: diclofenac with relative risk of -10.508 of torasemide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: salmeterol with relative risk of -12.983 of torasemide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó toremifene *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: sertraline with relative risk of -8.999 of toremifene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: azelastine with relative risk of -10.076 of toremifene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: ropivacaine with relative risk of -10.167 of toremifene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: naproxen with relative risk of -10.392 of toremifene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: ticagrelor with relative risk of -10.968 of toremifene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: ibutilide with relative risk of -11.114 of toremifene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: erlotinib with relative risk of -11.283 of toremifene | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 8: delavirdine with relative risk of -11.290 of toremifene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: vemurafenib with relative risk of -11.314 of toremifene | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 10: gabapentin with relative risk of -11.546 of toremifene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: telmisartan with relative risk of -11.674 of toremifene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: clarithromycin with relative risk of -11.894 of toremifene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: clonidine with relative risk of -11.931 of toremifene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: ixabepilone with relative risk of -12.340 of toremifene | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Carcinoma breast stage IV,oncology\n",
      "Rank 15: rotigotine with relative risk of -12.650 of toremifene | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.098\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target trabectedin not found. Exiting ...\n",
      "\n",
      "Drug target tramadol not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó trametinib *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: dabrafenib with relative risk of -9.903 of trametinib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Malignant melanoma, metastatic,oncology\n",
      "Rank 2: colchicine with relative risk of -31.726 of trametinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: colchicine with relative risk of -31.726 of trametinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: colchicine with relative risk of -31.726 of trametinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: colchicine with relative risk of -31.726 of trametinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: fluvoxamine with relative risk of -32.547 of trametinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: fluvoxamine with relative risk of -32.547 of trametinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: fluvoxamine with relative risk of -32.547 of trametinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: fluvoxamine with relative risk of -32.547 of trametinib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.353\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó trandolapril *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: terazosin with relative risk of -21.534 of trandolapril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 2: terazosin with relative risk of -21.534 of trandolapril | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 3: halofantrine with relative risk of -22.432 of trandolapril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: halofantrine with relative risk of -22.432 of trandolapril | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.72\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target trandolaprilat not found. Exiting ...\n",
      "\n",
      "Drug target tranexamic not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó travoprost *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: crizotinib with relative risk of -9.277 of travoprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: macitentan with relative risk of -11.234 of travoprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: ibandronate with relative risk of -16.153 of travoprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: ibandronate with relative risk of -16.153 of travoprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: pentoxifylline with relative risk of -16.618 of travoprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: pentoxifylline with relative risk of -16.618 of travoprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: moxifloxacin with relative risk of -20.672 of travoprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: moxifloxacin with relative risk of -20.672 of travoprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: paroxetine with relative risk of -22.849 of travoprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: paroxetine with relative risk of -22.849 of travoprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: paroxetine with relative risk of -22.849 of travoprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: nabumetone with relative risk of -26.595 of travoprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: nabumetone with relative risk of -26.595 of travoprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: nabumetone with relative risk of -26.595 of travoprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: clofarabine with relative risk of -27.074 of travoprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: clofarabine with relative risk of -27.074 of travoprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: clofarabine with relative risk of -27.074 of travoprost | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó trazodone *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: verapamil with relative risk of -7.534 of trazodone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: indacaterol with relative risk of -8.199 of trazodone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: riluzole with relative risk of -8.473 of trazodone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: exenatide with relative risk of -9.754 of trazodone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: cabergoline with relative risk of -9.978 of trazodone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: nedocromil with relative risk of -11.856 of trazodone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: nedocromil with relative risk of -11.856 of trazodone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 8: vismodegib with relative risk of -13.962 of trazodone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: vismodegib with relative risk of -13.962 of trazodone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: tafluprost with relative risk of -17.093 of trazodone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: tafluprost with relative risk of -17.093 of trazodone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: betaxolol with relative risk of -18.454 of trazodone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: betaxolol with relative risk of -18.454 of trazodone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: betaxolol with relative risk of -18.454 of trazodone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: olopatadine with relative risk of -22.477 of trazodone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: olopatadine with relative risk of -22.477 of trazodone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: olopatadine with relative risk of -22.477 of trazodone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: lovastatin with relative risk of -24.573 of trazodone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: lovastatin with relative risk of -24.573 of trazodone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: lovastatin with relative risk of -24.573 of trazodone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: topiramate with relative risk of -24.826 of trazodone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 22: topiramate with relative risk of -24.826 of trazodone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 23: topiramate with relative risk of -24.826 of trazodone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 24: topiramate with relative risk of -24.826 of trazodone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 25: quinaprilat with relative risk of -26.616 of trazodone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: quinaprilat with relative risk of -26.616 of trazodone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: quinaprilat with relative risk of -26.616 of trazodone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: quinaprilat with relative risk of -26.616 of trazodone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: loperamide with relative risk of -35.356 of trazodone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: loperamide with relative risk of -35.356 of trazodone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: loperamide with relative risk of -35.356 of trazodone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: loperamide with relative risk of -35.356 of trazodone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: loperamide with relative risk of -35.356 of trazodone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: loperamide with relative risk of -35.356 of trazodone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: efinaconazole with relative risk of -inf of trazodone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: efinaconazole with relative risk of -inf of trazodone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: efinaconazole with relative risk of -inf of trazodone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: efinaconazole with relative risk of -inf of trazodone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.194\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó treprostinil *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: cyclobenzaprine with relative risk of -9.700 of treprostinil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: iloperidone with relative risk of -16.354 of treprostinil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: iloperidone with relative risk of -16.354 of treprostinil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: anagrelide with relative risk of -17.123 of treprostinil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: anagrelide with relative risk of -17.123 of treprostinil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: albendazole with relative risk of -25.418 of treprostinil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: albendazole with relative risk of -25.418 of treprostinil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: albendazole with relative risk of -25.418 of treprostinil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: captopril with relative risk of -122.118 of treprostinil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: captopril with relative risk of -122.118 of treprostinil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: captopril with relative risk of -122.118 of treprostinil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: captopril with relative risk of -122.118 of treprostinil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: captopril with relative risk of -122.118 of treprostinil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: captopril with relative risk of -122.118 of treprostinil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: captopril with relative risk of -122.118 of treprostinil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: captopril with relative risk of -122.118 of treprostinil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: captopril with relative risk of -122.118 of treprostinil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: captopril with relative risk of -122.118 of treprostinil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: captopril with relative risk of -122.118 of treprostinil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: captopril with relative risk of -122.118 of treprostinil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: captopril with relative risk of -122.118 of treprostinil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: captopril with relative risk of -122.118 of treprostinil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: captopril with relative risk of -122.118 of treprostinil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: captopril with relative risk of -122.118 of treprostinil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: atorvastatin with relative risk of -122.351 of treprostinil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: atorvastatin with relative risk of -122.351 of treprostinil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: atorvastatin with relative risk of -122.351 of treprostinil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: atorvastatin with relative risk of -122.351 of treprostinil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: atorvastatin with relative risk of -122.351 of treprostinil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: atorvastatin with relative risk of -122.351 of treprostinil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: atorvastatin with relative risk of -122.351 of treprostinil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: atorvastatin with relative risk of -122.351 of treprostinil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: atorvastatin with relative risk of -122.351 of treprostinil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: atorvastatin with relative risk of -122.351 of treprostinil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: atorvastatin with relative risk of -122.351 of treprostinil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: atorvastatin with relative risk of -122.351 of treprostinil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: atorvastatin with relative risk of -122.351 of treprostinil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: atorvastatin with relative risk of -122.351 of treprostinil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: atorvastatin with relative risk of -122.351 of treprostinil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: atorvastatin with relative risk of -122.351 of treprostinil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: telithromycin with relative risk of -128.784 of treprostinil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: telithromycin with relative risk of -128.784 of treprostinil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: telithromycin with relative risk of -128.784 of treprostinil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: telithromycin with relative risk of -128.784 of treprostinil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: telithromycin with relative risk of -128.784 of treprostinil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: telithromycin with relative risk of -128.784 of treprostinil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: telithromycin with relative risk of -128.784 of treprostinil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: telithromycin with relative risk of -128.784 of treprostinil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: telithromycin with relative risk of -128.784 of treprostinil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: telithromycin with relative risk of -128.784 of treprostinil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: telithromycin with relative risk of -128.784 of treprostinil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: telithromycin with relative risk of -128.784 of treprostinil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 53: telithromycin with relative risk of -128.784 of treprostinil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 54: telithromycin with relative risk of -128.784 of treprostinil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 55: telithromycin with relative risk of -128.784 of treprostinil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 56: telithromycin with relative risk of -128.784 of treprostinil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 57: cetrorelix with relative risk of -133.383 of treprostinil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 58: cetrorelix with relative risk of -133.383 of treprostinil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 59: cetrorelix with relative risk of -133.383 of treprostinil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 60: cetrorelix with relative risk of -133.383 of treprostinil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 61: cetrorelix with relative risk of -133.383 of treprostinil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 62: cetrorelix with relative risk of -133.383 of treprostinil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 63: cetrorelix with relative risk of -133.383 of treprostinil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 64: cetrorelix with relative risk of -133.383 of treprostinil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 65: cetrorelix with relative risk of -133.383 of treprostinil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 66: cetrorelix with relative risk of -133.383 of treprostinil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 67: cetrorelix with relative risk of -133.383 of treprostinil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 68: cetrorelix with relative risk of -133.383 of treprostinil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 69: cetrorelix with relative risk of -133.383 of treprostinil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 70: cetrorelix with relative risk of -133.383 of treprostinil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 71: cetrorelix with relative risk of -133.383 of treprostinil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 72: cetrorelix with relative risk of -133.383 of treprostinil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó triamcinolone *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: felbamate with relative risk of -22.256 of triamcinolone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: felbamate with relative risk of -22.256 of triamcinolone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: nadolol with relative risk of -23.427 of triamcinolone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: nadolol with relative risk of -23.427 of triamcinolone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target triazolam not found. Exiting ...\n",
      "\n",
      "Drug target trifluorothymidine not found. Exiting ...\n",
      "\n",
      "Drug target triiodothyronine not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó trimethoprim *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: orlistat with relative risk of -21.883 of trimethoprim | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: orlistat with relative risk of -21.883 of trimethoprim | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó trimetrexate *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó tropisetron *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: penbutolol with relative risk of -7.551 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: risperidone with relative risk of -8.183 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: atropine with relative risk of -8.535 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: telmisartan with relative risk of -8.684 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: clonidine with relative risk of -8.937 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: flutamide with relative risk of -8.990 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: leflunomide with relative risk of -9.238 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: doxorubicin with relative risk of -9.247 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: bezafibrate with relative risk of -9.262 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: vernakalant with relative risk of -9.285 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: perindopril with relative risk of -9.445 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: flecainide with relative risk of -9.960 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: vilazodone with relative risk of -10.648 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: pindolol with relative risk of -10.804 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: naproxen with relative risk of -13.412 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: naproxen with relative risk of -13.412 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: bumetanide with relative risk of -14.923 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: bumetanide with relative risk of -14.923 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: clarithromycin with relative risk of -15.096 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: clarithromycin with relative risk of -15.096 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: cyclophosphamide with relative risk of -15.278 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: cyclophosphamide with relative risk of -15.278 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: nevirapine with relative risk of -15.561 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: nevirapine with relative risk of -15.561 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: cetirizine with relative risk of -15.580 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: cetirizine with relative risk of -15.580 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: capecitabine with relative risk of -16.260 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: capecitabine with relative risk of -16.260 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: sumatriptan with relative risk of -17.469 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: sumatriptan with relative risk of -17.469 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: citalopram with relative risk of -17.492 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: citalopram with relative risk of -17.492 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: darifenacin with relative risk of -18.532 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: darifenacin with relative risk of -18.532 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: darifenacin with relative risk of -18.532 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: gabapentin with relative risk of -21.623 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: gabapentin with relative risk of -21.623 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: gabapentin with relative risk of -21.623 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: ivacaftor with relative risk of -22.081 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: ivacaftor with relative risk of -22.081 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: ivacaftor with relative risk of -22.081 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: brimonidine with relative risk of -23.481 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: brimonidine with relative risk of -23.481 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: brimonidine with relative risk of -23.481 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: tazarotene with relative risk of -24.054 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: tazarotene with relative risk of -24.054 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: tazarotene with relative risk of -24.054 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: dapsone with relative risk of -24.314 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: dapsone with relative risk of -24.314 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: dapsone with relative risk of -24.314 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: brinzolamide with relative risk of -24.590 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: brinzolamide with relative risk of -24.590 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 53: brinzolamide with relative risk of -24.590 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 54: fondaparinux with relative risk of -24.919 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 55: fondaparinux with relative risk of -24.919 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 56: fondaparinux with relative risk of -24.919 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 57: acebutolol with relative risk of -24.935 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 58: acebutolol with relative risk of -24.935 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 59: acebutolol with relative risk of -24.935 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 60: isradipine with relative risk of -25.059 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 61: isradipine with relative risk of -25.059 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 62: isradipine with relative risk of -25.059 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 63: valsartan with relative risk of -25.078 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 64: valsartan with relative risk of -25.078 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 65: valsartan with relative risk of -25.078 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 66: ruxolitinib with relative risk of -28.098 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 67: ruxolitinib with relative risk of -28.098 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 68: ruxolitinib with relative risk of -28.098 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 69: ruxolitinib with relative risk of -28.098 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 70: everolimus with relative risk of -30.809 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 71: everolimus with relative risk of -30.809 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 72: everolimus with relative risk of -30.809 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 73: everolimus with relative risk of -30.809 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 74: pentoxifylline with relative risk of -36.425 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 75: pentoxifylline with relative risk of -36.425 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 76: pentoxifylline with relative risk of -36.425 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 77: pentoxifylline with relative risk of -36.425 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 78: pentoxifylline with relative risk of -36.425 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 79: pentoxifylline with relative risk of -36.425 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 80: metoprolol with relative risk of -37.594 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 81: metoprolol with relative risk of -37.594 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 82: metoprolol with relative risk of -37.594 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 83: metoprolol with relative risk of -37.594 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 84: metoprolol with relative risk of -37.594 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 85: milrinone with relative risk of -38.016 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 86: milrinone with relative risk of -38.016 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 87: milrinone with relative risk of -38.016 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 88: milrinone with relative risk of -38.016 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 89: milrinone with relative risk of -38.016 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 90: tamsulosin with relative risk of -39.342 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 91: tamsulosin with relative risk of -39.342 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 92: tamsulosin with relative risk of -39.342 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 93: tamsulosin with relative risk of -39.342 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 94: tamsulosin with relative risk of -39.342 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 95: zolmitriptan with relative risk of -39.696 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 96: zolmitriptan with relative risk of -39.696 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 97: zolmitriptan with relative risk of -39.696 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 98: zolmitriptan with relative risk of -39.696 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 99: zolmitriptan with relative risk of -39.696 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 100: ropivacaine with relative risk of -40.255 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 101: ropivacaine with relative risk of -40.255 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 102: ropivacaine with relative risk of -40.255 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 103: ropivacaine with relative risk of -40.255 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 104: ropivacaine with relative risk of -40.255 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 105: ropivacaine with relative risk of -40.255 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 106: terbutaline with relative risk of -41.680 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 107: terbutaline with relative risk of -41.680 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 108: terbutaline with relative risk of -41.680 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 109: terbutaline with relative risk of -41.680 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 110: terbutaline with relative risk of -41.680 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 111: terbutaline with relative risk of -41.680 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 112: lurasidone with relative risk of -42.436 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 113: lurasidone with relative risk of -42.436 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 114: lurasidone with relative risk of -42.436 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 115: lurasidone with relative risk of -42.436 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 116: lurasidone with relative risk of -42.436 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 117: lurasidone with relative risk of -42.436 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 118: levonorgestrel with relative risk of -43.407 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 119: levonorgestrel with relative risk of -43.407 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 120: levonorgestrel with relative risk of -43.407 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 121: levonorgestrel with relative risk of -43.407 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 122: levonorgestrel with relative risk of -43.407 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 123: levonorgestrel with relative risk of -43.407 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 124: pemetrexed with relative risk of -43.601 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 125: pemetrexed with relative risk of -43.601 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 126: pemetrexed with relative risk of -43.601 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 127: pemetrexed with relative risk of -43.601 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 128: pemetrexed with relative risk of -43.601 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 129: pemetrexed with relative risk of -43.601 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 130: didanosine with relative risk of -45.593 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 131: didanosine with relative risk of -45.593 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 132: didanosine with relative risk of -45.593 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 133: didanosine with relative risk of -45.593 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 134: didanosine with relative risk of -45.593 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 135: didanosine with relative risk of -45.593 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 136: esmolol with relative risk of -45.637 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 137: esmolol with relative risk of -45.637 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 138: esmolol with relative risk of -45.637 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 139: esmolol with relative risk of -45.637 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 140: esmolol with relative risk of -45.637 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 141: esmolol with relative risk of -45.637 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 142: azilsartan with relative risk of -47.097 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 143: azilsartan with relative risk of -47.097 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 144: azilsartan with relative risk of -47.097 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 145: azilsartan with relative risk of -47.097 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 146: azilsartan with relative risk of -47.097 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 147: azilsartan with relative risk of -47.097 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 148: ketorolac with relative risk of -47.617 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 149: ketorolac with relative risk of -47.617 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 150: ketorolac with relative risk of -47.617 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 151: ketorolac with relative risk of -47.617 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 152: ketorolac with relative risk of -47.617 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 153: ketorolac with relative risk of -47.617 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 154: ketorolac with relative risk of -47.617 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 155: indomethacin with relative risk of -51.800 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 156: indomethacin with relative risk of -51.800 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 157: indomethacin with relative risk of -51.800 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 158: indomethacin with relative risk of -51.800 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 159: indomethacin with relative risk of -51.800 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 160: indomethacin with relative risk of -51.800 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 161: indomethacin with relative risk of -51.800 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 162: trovafloxacin with relative risk of -52.230 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 163: trovafloxacin with relative risk of -52.230 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 164: trovafloxacin with relative risk of -52.230 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 165: trovafloxacin with relative risk of -52.230 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 166: trovafloxacin with relative risk of -52.230 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 167: trovafloxacin with relative risk of -52.230 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 168: trovafloxacin with relative risk of -52.230 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 169: dutasteride with relative risk of -54.578 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 170: dutasteride with relative risk of -54.578 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 171: dutasteride with relative risk of -54.578 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 172: dutasteride with relative risk of -54.578 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 173: dutasteride with relative risk of -54.578 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 174: dutasteride with relative risk of -54.578 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 175: dutasteride with relative risk of -54.578 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 176: lansoprazole with relative risk of -84.518 of tropisetron | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "Rank 177: lansoprazole with relative risk of -84.518 of tropisetron | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "Rank 178: lansoprazole with relative risk of -84.518 of tropisetron | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "Rank 179: lansoprazole with relative risk of -84.518 of tropisetron | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "Rank 180: lansoprazole with relative risk of -84.518 of tropisetron | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "Rank 181: lansoprazole with relative risk of -84.518 of tropisetron | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "Rank 182: lansoprazole with relative risk of -84.518 of tropisetron | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "Rank 183: lansoprazole with relative risk of -84.518 of tropisetron | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "Rank 184: lansoprazole with relative risk of -84.518 of tropisetron | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "Rank 185: lansoprazole with relative risk of -84.518 of tropisetron | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "Rank 186: lansoprazole with relative risk of -84.518 of tropisetron | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: gastroenterology\n",
      "Rank 187: etoposide with relative risk of -85.635 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 188: etoposide with relative risk of -85.635 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 189: etoposide with relative risk of -85.635 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 190: etoposide with relative risk of -85.635 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 191: etoposide with relative risk of -85.635 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 192: etoposide with relative risk of -85.635 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 193: etoposide with relative risk of -85.635 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 194: etoposide with relative risk of -85.635 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 195: etoposide with relative risk of -85.635 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 196: etoposide with relative risk of -85.635 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 197: etoposide with relative risk of -85.635 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 198: etoposide with relative risk of -85.635 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 199: fenofibrate with relative risk of -88.179 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 200: fenofibrate with relative risk of -88.179 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 201: fenofibrate with relative risk of -88.179 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 202: fenofibrate with relative risk of -88.179 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 203: fenofibrate with relative risk of -88.179 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 204: fenofibrate with relative risk of -88.179 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 205: fenofibrate with relative risk of -88.179 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 206: fenofibrate with relative risk of -88.179 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 207: fenofibrate with relative risk of -88.179 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 208: fenofibrate with relative risk of -88.179 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 209: fenofibrate with relative risk of -88.179 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 210: fenofibrate with relative risk of -88.179 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 211: sertraline with relative risk of -105.410 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 212: sertraline with relative risk of -105.410 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 213: sertraline with relative risk of -105.410 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 214: sertraline with relative risk of -105.410 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 215: sertraline with relative risk of -105.410 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 216: sertraline with relative risk of -105.410 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 217: sertraline with relative risk of -105.410 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 218: sertraline with relative risk of -105.410 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 219: sertraline with relative risk of -105.410 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 220: sertraline with relative risk of -105.410 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 221: sertraline with relative risk of -105.410 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 222: sertraline with relative risk of -105.410 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 223: sertraline with relative risk of -105.410 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 224: sertraline with relative risk of -105.410 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 225: sertraline with relative risk of -105.410 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 226: sertraline with relative risk of -105.410 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 227: sertraline with relative risk of -105.410 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 228: glimepiride with relative risk of -111.397 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 229: glimepiride with relative risk of -111.397 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 230: glimepiride with relative risk of -111.397 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 231: glimepiride with relative risk of -111.397 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 232: glimepiride with relative risk of -111.397 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 233: glimepiride with relative risk of -111.397 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 234: glimepiride with relative risk of -111.397 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 235: glimepiride with relative risk of -111.397 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 236: glimepiride with relative risk of -111.397 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 237: glimepiride with relative risk of -111.397 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 238: glimepiride with relative risk of -111.397 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 239: glimepiride with relative risk of -111.397 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 240: glimepiride with relative risk of -111.397 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 241: glimepiride with relative risk of -111.397 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 242: glimepiride with relative risk of -111.397 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 243: irbesartan with relative risk of -121.699 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 244: irbesartan with relative risk of -121.699 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 245: irbesartan with relative risk of -121.699 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 246: irbesartan with relative risk of -121.699 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 247: irbesartan with relative risk of -121.699 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 248: irbesartan with relative risk of -121.699 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 249: irbesartan with relative risk of -121.699 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 250: irbesartan with relative risk of -121.699 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 251: irbesartan with relative risk of -121.699 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 252: irbesartan with relative risk of -121.699 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 253: irbesartan with relative risk of -121.699 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 254: irbesartan with relative risk of -121.699 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 255: irbesartan with relative risk of -121.699 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 256: irbesartan with relative risk of -121.699 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 257: irbesartan with relative risk of -121.699 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 258: irbesartan with relative risk of -121.699 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 259: irbesartan with relative risk of -121.699 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 260: irbesartan with relative risk of -121.699 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 261: irbesartan with relative risk of -121.699 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 262: azelastine with relative risk of -122.857 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 263: azelastine with relative risk of -122.857 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 264: azelastine with relative risk of -122.857 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 265: azelastine with relative risk of -122.857 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 266: azelastine with relative risk of -122.857 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 267: azelastine with relative risk of -122.857 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 268: azelastine with relative risk of -122.857 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 269: azelastine with relative risk of -122.857 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 270: azelastine with relative risk of -122.857 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 271: azelastine with relative risk of -122.857 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 272: azelastine with relative risk of -122.857 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 273: azelastine with relative risk of -122.857 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 274: azelastine with relative risk of -122.857 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 275: azelastine with relative risk of -122.857 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 276: azelastine with relative risk of -122.857 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 277: azelastine with relative risk of -122.857 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 278: azelastine with relative risk of -122.857 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 279: azelastine with relative risk of -122.857 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 280: regadenoson with relative risk of -126.929 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 281: regadenoson with relative risk of -126.929 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 282: regadenoson with relative risk of -126.929 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 283: regadenoson with relative risk of -126.929 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 284: regadenoson with relative risk of -126.929 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 285: regadenoson with relative risk of -126.929 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 286: regadenoson with relative risk of -126.929 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 287: regadenoson with relative risk of -126.929 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 288: regadenoson with relative risk of -126.929 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 289: regadenoson with relative risk of -126.929 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 290: regadenoson with relative risk of -126.929 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 291: regadenoson with relative risk of -126.929 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 292: regadenoson with relative risk of -126.929 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 293: regadenoson with relative risk of -126.929 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 294: regadenoson with relative risk of -126.929 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 295: regadenoson with relative risk of -126.929 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 296: regadenoson with relative risk of -126.929 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 297: regadenoson with relative risk of -126.929 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 298: paliperidone with relative risk of -128.587 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 299: paliperidone with relative risk of -128.587 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 300: paliperidone with relative risk of -128.587 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 301: paliperidone with relative risk of -128.587 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 302: paliperidone with relative risk of -128.587 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 303: paliperidone with relative risk of -128.587 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 304: paliperidone with relative risk of -128.587 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 305: paliperidone with relative risk of -128.587 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 306: paliperidone with relative risk of -128.587 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 307: paliperidone with relative risk of -128.587 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 308: paliperidone with relative risk of -128.587 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 309: paliperidone with relative risk of -128.587 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 310: paliperidone with relative risk of -128.587 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 311: paliperidone with relative risk of -128.587 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 312: paliperidone with relative risk of -128.587 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 313: paliperidone with relative risk of -128.587 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 314: paliperidone with relative risk of -128.587 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 315: posaconazole with relative risk of -129.101 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 316: posaconazole with relative risk of -129.101 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 317: posaconazole with relative risk of -129.101 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 318: posaconazole with relative risk of -129.101 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 319: posaconazole with relative risk of -129.101 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 320: posaconazole with relative risk of -129.101 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 321: posaconazole with relative risk of -129.101 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 322: posaconazole with relative risk of -129.101 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 323: posaconazole with relative risk of -129.101 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 324: posaconazole with relative risk of -129.101 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 325: posaconazole with relative risk of -129.101 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 326: posaconazole with relative risk of -129.101 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 327: posaconazole with relative risk of -129.101 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 328: posaconazole with relative risk of -129.101 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 329: posaconazole with relative risk of -129.101 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 330: posaconazole with relative risk of -129.101 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 331: posaconazole with relative risk of -129.101 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 332: posaconazole with relative risk of -129.101 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 333: mometasone with relative risk of -143.122 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 334: mometasone with relative risk of -143.122 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 335: mometasone with relative risk of -143.122 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 336: mometasone with relative risk of -143.122 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 337: mometasone with relative risk of -143.122 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 338: mometasone with relative risk of -143.122 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 339: mometasone with relative risk of -143.122 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 340: mometasone with relative risk of -143.122 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 341: mometasone with relative risk of -143.122 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 342: mometasone with relative risk of -143.122 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 343: mometasone with relative risk of -143.122 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 344: mometasone with relative risk of -143.122 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 345: mometasone with relative risk of -143.122 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 346: mometasone with relative risk of -143.122 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 347: mometasone with relative risk of -143.122 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 348: mometasone with relative risk of -143.122 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 349: mometasone with relative risk of -143.122 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 350: mometasone with relative risk of -143.122 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 351: mometasone with relative risk of -143.122 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 352: mometasone with relative risk of -143.122 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 353: ibutilide with relative risk of -148.197 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 354: ibutilide with relative risk of -148.197 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 355: ibutilide with relative risk of -148.197 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 356: ibutilide with relative risk of -148.197 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 357: ibutilide with relative risk of -148.197 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 358: ibutilide with relative risk of -148.197 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 359: ibutilide with relative risk of -148.197 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 360: ibutilide with relative risk of -148.197 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 361: ibutilide with relative risk of -148.197 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 362: ibutilide with relative risk of -148.197 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 363: ibutilide with relative risk of -148.197 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 364: ibutilide with relative risk of -148.197 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 365: ibutilide with relative risk of -148.197 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 366: ibutilide with relative risk of -148.197 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 367: ibutilide with relative risk of -148.197 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 368: ibutilide with relative risk of -148.197 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 369: ibutilide with relative risk of -148.197 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 370: ibutilide with relative risk of -148.197 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 371: ibutilide with relative risk of -148.197 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 372: ibutilide with relative risk of -148.197 of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 373: felodipine with relative risk of -inf of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 374: felodipine with relative risk of -inf of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 375: felodipine with relative risk of -inf of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 376: felodipine with relative risk of -inf of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 377: felodipine with relative risk of -inf of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 378: felodipine with relative risk of -inf of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 379: felodipine with relative risk of -inf of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 380: felodipine with relative risk of -inf of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 381: felodipine with relative risk of -inf of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 382: felodipine with relative risk of -inf of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 383: felodipine with relative risk of -inf of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 384: felodipine with relative risk of -inf of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 385: felodipine with relative risk of -inf of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 386: felodipine with relative risk of -inf of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 387: felodipine with relative risk of -inf of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 388: felodipine with relative risk of -inf of tropisetron | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.009\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó trospium *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: pramipexole with relative risk of -11.929 of trospium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: docetaxel with relative risk of -12.046 of trospium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: etodolac with relative risk of -12.358 of trospium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: metaproterenol with relative risk of -12.759 of trospium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: duloxetine with relative risk of -12.992 of trospium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: bupropion with relative risk of -13.123 of trospium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: repaglinide with relative risk of -13.133 of trospium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: dalbavancin with relative risk of -13.460 of trospium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: amlodipine with relative risk of -13.806 of trospium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó trovafloxacin *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó ulipristal *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: nateglinide with relative risk of -13.498 of ulipristal | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: endocrinology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  1.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó umeclidinium *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: formoterol with relative risk of -9.630 of umeclidinium | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: pulmonary\n",
      "Rank 2: loxapine with relative risk of -10.090 of umeclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: indinavir with relative risk of -12.209 of umeclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: rivaroxaban with relative risk of -12.434 of umeclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: eprosartan with relative risk of -12.545 of umeclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: metronidazole with relative risk of -26.048 of umeclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: metronidazole with relative risk of -26.048 of umeclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: metronidazole with relative risk of -26.048 of umeclidinium | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.368\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target ustekinumab not found. Exiting ...\n",
      "\n",
      "Drug target v not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó valdecoxib *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "Drug target valganciclovir not found. Exiting ...\n",
      "\n",
      "Drug target valproate not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó valsartan *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: ropivacaine with relative risk of -9.070 of valsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: levonorgestrel with relative risk of -9.178 of valsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: penbutolol with relative risk of -9.428 of valsartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 4: lurasidone with relative risk of -9.460 of valsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: lansoprazole with relative risk of -10.009 of valsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: trovafloxacin with relative risk of -10.586 of valsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: didanosine with relative risk of -18.019 of valsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: didanosine with relative risk of -18.019 of valsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: sertraline with relative risk of -21.564 of valsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: sertraline with relative risk of -21.564 of valsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: sertraline with relative risk of -21.564 of valsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: irbesartan with relative risk of -22.116 of valsartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 13: irbesartan with relative risk of -22.116 of valsartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 14: irbesartan with relative risk of -22.116 of valsartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 15: regadenoson with relative risk of -22.359 of valsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: regadenoson with relative risk of -22.359 of valsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: regadenoson with relative risk of -22.359 of valsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: mometasone with relative risk of -22.583 of valsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: mometasone with relative risk of -22.583 of valsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: mometasone with relative risk of -22.583 of valsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: azelastine with relative risk of -23.351 of valsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: azelastine with relative risk of -23.351 of valsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: azelastine with relative risk of -23.351 of valsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: posaconazole with relative risk of -23.476 of valsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: posaconazole with relative risk of -23.476 of valsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: posaconazole with relative risk of -23.476 of valsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: etoposide with relative risk of -23.696 of valsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: etoposide with relative risk of -23.696 of valsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: etoposide with relative risk of -23.696 of valsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: ibutilide with relative risk of -24.670 of valsartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 31: ibutilide with relative risk of -24.670 of valsartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 32: ibutilide with relative risk of -24.670 of valsartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 33: tropisetron with relative risk of -24.754 of valsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: tropisetron with relative risk of -24.754 of valsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: tropisetron with relative risk of -24.754 of valsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: paliperidone with relative risk of -24.840 of valsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: paliperidone with relative risk of -24.840 of valsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: paliperidone with relative risk of -24.840 of valsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: glimepiride with relative risk of -24.888 of valsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: glimepiride with relative risk of -24.888 of valsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: glimepiride with relative risk of -24.888 of valsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: pentoxifylline with relative risk of -24.938 of valsartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 43: pentoxifylline with relative risk of -24.938 of valsartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 44: pentoxifylline with relative risk of -24.938 of valsartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 45: fenofibrate with relative risk of -26.239 of valsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: fenofibrate with relative risk of -26.239 of valsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: fenofibrate with relative risk of -26.239 of valsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: terbutaline with relative risk of -26.867 of valsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: terbutaline with relative risk of -26.867 of valsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: terbutaline with relative risk of -26.867 of valsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: esmolol with relative risk of -27.830 of valsartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 52: esmolol with relative risk of -27.830 of valsartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 53: esmolol with relative risk of -27.830 of valsartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 54: ivacaftor with relative risk of -29.119 of valsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 55: ivacaftor with relative risk of -29.119 of valsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 56: ivacaftor with relative risk of -29.119 of valsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 57: everolimus with relative risk of -29.240 of valsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 58: everolimus with relative risk of -29.240 of valsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 59: everolimus with relative risk of -29.240 of valsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 60: azilsartan with relative risk of -29.289 of valsartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 61: azilsartan with relative risk of -29.289 of valsartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 62: azilsartan with relative risk of -29.289 of valsartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 63: zolmitriptan with relative risk of -29.929 of valsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 64: zolmitriptan with relative risk of -29.929 of valsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 65: zolmitriptan with relative risk of -29.929 of valsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 66: brinzolamide with relative risk of -31.628 of valsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 67: brinzolamide with relative risk of -31.628 of valsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 68: brinzolamide with relative risk of -31.628 of valsartan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 69: acebutolol with relative risk of -31.973 of valsartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 70: acebutolol with relative risk of -31.973 of valsartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 71: acebutolol with relative risk of -31.973 of valsartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 72: felodipine with relative risk of -inf of valsartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 73: felodipine with relative risk of -inf of valsartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "Rank 74: felodipine with relative risk of -inf of valsartan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Hypertensive disease,cardiology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.189\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó vandetanib *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: bimatoprost with relative risk of -9.263 of vandetanib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: acitretin with relative risk of -9.412 of vandetanib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: azathioprine with relative risk of -9.502 of vandetanib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: nifedipine with relative risk of -9.519 of vandetanib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: sildenafil with relative risk of -10.269 of vandetanib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: phentolamine with relative risk of -10.506 of vandetanib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: cabozantinib with relative risk of -10.590 of vandetanib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 8: efavirenz with relative risk of -10.808 of vandetanib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: nilutamide with relative risk of -10.979 of vandetanib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 10: labetalol with relative risk of -11.181 of vandetanib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: ciprofloxacin with relative risk of -11.240 of vandetanib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: oxcarbazepine with relative risk of -11.266 of vandetanib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: ziprasidone with relative risk of -11.468 of vandetanib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: voriconazole with relative risk of -11.766 of vandetanib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: loteprednol with relative risk of -12.249 of vandetanib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: clozapine with relative risk of -15.214 of vandetanib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: clozapine with relative risk of -15.214 of vandetanib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: danazol with relative risk of -17.975 of vandetanib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: danazol with relative risk of -17.975 of vandetanib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: calcipotriol with relative risk of -inf of vandetanib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.071\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó vardenafil *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: doxercalciferol with relative risk of -11.743 of vardenafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: iloperidone with relative risk of -12.184 of vardenafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: rabeprazole with relative risk of -12.198 of vardenafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: levocabastine with relative risk of -12.358 of vardenafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: levetiracetam with relative risk of -12.648 of vardenafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: fluconazole with relative risk of -12.728 of vardenafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: guanfacine with relative risk of -12.760 of vardenafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: mirtazapine with relative risk of -12.850 of vardenafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: fosphenytoin with relative risk of -12.906 of vardenafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: reboxetine with relative risk of -13.131 of vardenafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: ropinirole with relative risk of -13.248 of vardenafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: rilpivirine with relative risk of -13.450 of vardenafil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó varenicline *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: etoposide with relative risk of -7.538 of varenicline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: regadenoson with relative risk of -7.550 of varenicline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: mometasone with relative risk of -8.146 of varenicline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: irbesartan with relative risk of -8.633 of varenicline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: azelastine with relative risk of -8.980 of varenicline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: ropivacaine with relative risk of -9.070 of varenicline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 7: ibandronate with relative risk of -9.095 of varenicline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: glimepiride with relative risk of -9.162 of varenicline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: paliperidone with relative risk of -9.357 of varenicline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: pemetrexed with relative risk of -9.373 of varenicline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: ruxolitinib with relative risk of -9.413 of varenicline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: ticagrelor with relative risk of -9.870 of varenicline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: fenofibrate with relative risk of -10.082 of varenicline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: erlotinib with relative risk of -10.184 of varenicline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: delavirdine with relative risk of -10.191 of varenicline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: bumetanide with relative risk of -10.401 of varenicline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: gabapentin with relative risk of -10.447 of varenicline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 18: telmisartan with relative risk of -10.576 of varenicline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: trovafloxacin with relative risk of -10.586 of varenicline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: cetirizine with relative risk of -10.771 of varenicline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: clarithromycin with relative risk of -10.796 of varenicline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: clonidine with relative risk of -10.832 of varenicline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 23: rotigotine with relative risk of -11.551 of varenicline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 24: doxepin with relative risk of -11.759 of varenicline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 25: benazepril with relative risk of -12.080 of varenicline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: sertraline with relative risk of -14.173 of varenicline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 27: sertraline with relative risk of -14.173 of varenicline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 28: naproxen with relative risk of -17.557 of varenicline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 29: naproxen with relative risk of -17.557 of varenicline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 30: lurasidone with relative risk of -17.569 of varenicline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 31: lurasidone with relative risk of -17.569 of varenicline | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 32: felodipine with relative risk of -inf of varenicline | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.167\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó vemurafenib *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: ibutilide with relative risk of -10.422 of vemurafenib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: erlotinib with relative risk of -10.590 of vemurafenib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 3: telmisartan with relative risk of -10.981 of vemurafenib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: clonidine with relative risk of -11.238 of vemurafenib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: ixabepilone with relative risk of -11.647 of vemurafenib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 6: rotigotine with relative risk of -11.957 of vemurafenib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: doxepin with relative risk of -12.164 of vemurafenib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: toremifene with relative risk of -13.239 of vemurafenib | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 9: sertraline with relative risk of -15.270 of vemurafenib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: sertraline with relative risk of -15.270 of vemurafenib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: azelastine with relative risk of -16.697 of vemurafenib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: azelastine with relative risk of -16.697 of vemurafenib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: ropivacaine with relative risk of -18.025 of vemurafenib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: ropivacaine with relative risk of -18.025 of vemurafenib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: naproxen with relative risk of -18.655 of vemurafenib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: naproxen with relative risk of -18.655 of vemurafenib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: ticagrelor with relative risk of -18.826 of vemurafenib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: ticagrelor with relative risk of -18.826 of vemurafenib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: gabapentin with relative risk of -19.991 of vemurafenib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: gabapentin with relative risk of -19.991 of vemurafenib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: clarithromycin with relative risk of -20.340 of vemurafenib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: clarithromycin with relative risk of -20.340 of vemurafenib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: delavirdine with relative risk of -20.651 of vemurafenib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: delavirdine with relative risk of -20.651 of vemurafenib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.218\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó venlafaxine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: fluvoxamine with relative risk of -10.071 of venlafaxine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Phobia, Social,neurology/psychiatry\n",
      "Rank 2: piroxicam with relative risk of -13.491 of venlafaxine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: tofacitinib with relative risk of -13.601 of venlafaxine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.545\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó verapamil *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: trazodone with relative risk of -7.217 of verapamil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: riluzole with relative risk of -8.784 of verapamil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: bromocriptine with relative risk of -9.241 of verapamil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: loperamide with relative risk of -13.028 of verapamil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: loperamide with relative risk of -13.028 of verapamil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: esomeprazole with relative risk of -17.488 of verapamil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: esomeprazole with relative risk of -17.488 of verapamil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: nedocromil with relative risk of -37.555 of verapamil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: nedocromil with relative risk of -37.555 of verapamil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: nedocromil with relative risk of -37.555 of verapamil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: nedocromil with relative risk of -37.555 of verapamil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: nedocromil with relative risk of -37.555 of verapamil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: nedocromil with relative risk of -37.555 of verapamil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: efinaconazole with relative risk of -inf of verapamil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: efinaconazole with relative risk of -inf of verapamil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: efinaconazole with relative risk of -inf of verapamil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: efinaconazole with relative risk of -inf of verapamil | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó vernakalant *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: regadenoson with relative risk of -8.647 of vernakalant | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: sertraline with relative risk of -8.999 of vernakalant | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: mometasone with relative risk of -9.242 of vernakalant | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: posaconazole with relative risk of -9.679 of vernakalant | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: irbesartan with relative risk of -9.727 of vernakalant | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 6: azelastine with relative risk of -10.076 of vernakalant | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: tropisetron with relative risk of -10.479 of vernakalant | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: ruxolitinib with relative risk of -10.512 of vernakalant | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: lurasidone with relative risk of -10.558 of vernakalant | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: lansoprazole with relative risk of -11.107 of vernakalant | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: ibutilide with relative risk of -11.114 of vernakalant | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 12: risperidone with relative risk of -11.175 of vernakalant | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: ketorolac with relative risk of -11.258 of vernakalant | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: atropine with relative risk of -11.531 of vernakalant | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: clarithromycin with relative risk of -11.894 of vernakalant | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: clonidine with relative risk of -11.931 of vernakalant | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 17: dutasteride with relative risk of -12.086 of vernakalant | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: leflunomide with relative risk of -12.233 of vernakalant | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: doxorubicin with relative risk of -12.242 of vernakalant | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: flecainide with relative risk of -12.956 of vernakalant | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "Rank 21: vilazodone with relative risk of -13.644 of vernakalant | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: pindolol with relative risk of -13.800 of vernakalant | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: cardiology\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.122\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target vigabatrin not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó vilazodone *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: regadenoson with relative risk of -8.647 of vilazodone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: sertraline with relative risk of -8.999 of vilazodone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: mometasone with relative risk of -9.242 of vilazodone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: posaconazole with relative risk of -9.679 of vilazodone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: irbesartan with relative risk of -9.727 of vilazodone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: azelastine with relative risk of -10.076 of vilazodone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: tropisetron with relative risk of -10.479 of vilazodone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: ruxolitinib with relative risk of -10.512 of vilazodone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: lurasidone with relative risk of -10.558 of vilazodone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: lansoprazole with relative risk of -11.107 of vilazodone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: ibutilide with relative risk of -11.114 of vilazodone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: risperidone with relative risk of -11.175 of vilazodone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 13: ketorolac with relative risk of -11.258 of vilazodone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 14: atropine with relative risk of -11.531 of vilazodone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: clarithromycin with relative risk of -11.894 of vilazodone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: clonidine with relative risk of -11.931 of vilazodone | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 17: dutasteride with relative risk of -12.086 of vilazodone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: leflunomide with relative risk of -12.233 of vilazodone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: doxorubicin with relative risk of -12.242 of vilazodone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: vernakalant with relative risk of -12.281 of vilazodone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: flecainide with relative risk of -12.956 of vilazodone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: pindolol with relative risk of -13.800 of vilazodone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.226\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó vincristine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: aminophylline with relative risk of -9.523 of vincristine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: ropivacaine with relative risk of -10.167 of vincristine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: ibandronate with relative risk of -10.192 of vincristine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: imatinib with relative risk of -10.310 of vincristine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: hematologic malignancy\n",
      "Rank 5: gemcitabine with relative risk of -10.824 of vincristine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: gefitinib with relative risk of -10.832 of vincristine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: trimetrexate with relative risk of -10.939 of vincristine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: finasteride with relative risk of -11.097 of vincristine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: valdecoxib with relative risk of -11.496 of vincristine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: acyclovir with relative risk of -11.705 of vincristine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: dihydroergotamine with relative risk of -11.922 of vincristine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: atosiban with relative risk of -12.021 of vincristine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: alendronate with relative risk of -12.279 of vincristine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: ramipril with relative risk of -12.733 of vincristine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 15: desvenlafaxine with relative risk of -13.114 of vincristine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 16: clopidogrel with relative risk of -13.390 of vincristine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: amoxicillin with relative risk of -13.617 of vincristine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: diltiazem with relative risk of -13.859 of vincristine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: nebivolol with relative risk of -14.345 of vincristine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.07\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target vinflunine not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó vinorelbine *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: ibandronate with relative risk of -7.897 of vinorelbine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: miglustat with relative risk of -8.022 of vinorelbine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: pentoxifylline with relative risk of -8.256 of vinorelbine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: formoterol with relative risk of -8.717 of vinorelbine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: dabigatran with relative risk of -9.627 of vinorelbine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: estramustine with relative risk of -9.680 of vinorelbine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 7: zonisamide with relative risk of -9.885 of vinorelbine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: etravirine with relative risk of -10.164 of vinorelbine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: linezolid with relative risk of -10.330 of vinorelbine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: tiotropium with relative risk of -10.551 of vinorelbine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: febuxostat with relative risk of -12.597 of vinorelbine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: eplerenone with relative risk of -16.801 of vinorelbine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: eplerenone with relative risk of -16.801 of vinorelbine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: exemestane with relative risk of -18.113 of vinorelbine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 15: exemestane with relative risk of -18.113 of vinorelbine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 16: indacaterol with relative risk of -24.984 of vinorelbine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: indacaterol with relative risk of -24.984 of vinorelbine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: indacaterol with relative risk of -24.984 of vinorelbine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: ciclesonide with relative risk of -68.521 of vinorelbine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: ciclesonide with relative risk of -68.521 of vinorelbine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: ciclesonide with relative risk of -68.521 of vinorelbine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 22: ciclesonide with relative risk of -68.521 of vinorelbine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 23: ciclesonide with relative risk of -68.521 of vinorelbine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 24: ciclesonide with relative risk of -68.521 of vinorelbine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: ciclesonide with relative risk of -68.521 of vinorelbine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: ciclesonide with relative risk of -68.521 of vinorelbine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: ciclesonide with relative risk of -68.521 of vinorelbine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 28: ciclesonide with relative risk of -68.521 of vinorelbine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 29: meloxicam with relative risk of -81.320 of vinorelbine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 30: meloxicam with relative risk of -81.320 of vinorelbine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: meloxicam with relative risk of -81.320 of vinorelbine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: meloxicam with relative risk of -81.320 of vinorelbine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: meloxicam with relative risk of -81.320 of vinorelbine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: meloxicam with relative risk of -81.320 of vinorelbine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: meloxicam with relative risk of -81.320 of vinorelbine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: meloxicam with relative risk of -81.320 of vinorelbine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: meloxicam with relative risk of -81.320 of vinorelbine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: meloxicam with relative risk of -81.320 of vinorelbine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: darifenacin with relative risk of -82.634 of vinorelbine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 40: darifenacin with relative risk of -82.634 of vinorelbine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 41: darifenacin with relative risk of -82.634 of vinorelbine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 42: darifenacin with relative risk of -82.634 of vinorelbine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: darifenacin with relative risk of -82.634 of vinorelbine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: darifenacin with relative risk of -82.634 of vinorelbine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: darifenacin with relative risk of -82.634 of vinorelbine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: darifenacin with relative risk of -82.634 of vinorelbine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: darifenacin with relative risk of -82.634 of vinorelbine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: darifenacin with relative risk of -82.634 of vinorelbine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: axitinib with relative risk of -85.446 of vinorelbine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 50: axitinib with relative risk of -85.446 of vinorelbine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 51: axitinib with relative risk of -85.446 of vinorelbine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 52: axitinib with relative risk of -85.446 of vinorelbine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 53: axitinib with relative risk of -85.446 of vinorelbine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 54: axitinib with relative risk of -85.446 of vinorelbine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 55: axitinib with relative risk of -85.446 of vinorelbine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 56: axitinib with relative risk of -85.446 of vinorelbine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 57: axitinib with relative risk of -85.446 of vinorelbine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 58: axitinib with relative risk of -85.446 of vinorelbine | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: oncology\n",
      "Rank 59: granisetron with relative risk of -88.088 of vinorelbine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 60: granisetron with relative risk of -88.088 of vinorelbine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 61: granisetron with relative risk of -88.088 of vinorelbine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 62: granisetron with relative risk of -88.088 of vinorelbine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 63: granisetron with relative risk of -88.088 of vinorelbine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 64: granisetron with relative risk of -88.088 of vinorelbine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 65: granisetron with relative risk of -88.088 of vinorelbine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 66: granisetron with relative risk of -88.088 of vinorelbine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 67: granisetron with relative risk of -88.088 of vinorelbine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 68: granisetron with relative risk of -88.088 of vinorelbine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 69: apraclonidine with relative risk of -88.245 of vinorelbine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 70: apraclonidine with relative risk of -88.245 of vinorelbine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 71: apraclonidine with relative risk of -88.245 of vinorelbine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 72: apraclonidine with relative risk of -88.245 of vinorelbine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 73: apraclonidine with relative risk of -88.245 of vinorelbine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 74: apraclonidine with relative risk of -88.245 of vinorelbine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 75: apraclonidine with relative risk of -88.245 of vinorelbine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 76: apraclonidine with relative risk of -88.245 of vinorelbine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 77: apraclonidine with relative risk of -88.245 of vinorelbine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 78: apraclonidine with relative risk of -88.245 of vinorelbine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 79: pinaverium with relative risk of -91.224 of vinorelbine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 80: pinaverium with relative risk of -91.224 of vinorelbine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 81: pinaverium with relative risk of -91.224 of vinorelbine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 82: pinaverium with relative risk of -91.224 of vinorelbine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 83: pinaverium with relative risk of -91.224 of vinorelbine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 84: pinaverium with relative risk of -91.224 of vinorelbine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 85: pinaverium with relative risk of -91.224 of vinorelbine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 86: pinaverium with relative risk of -91.224 of vinorelbine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 87: pinaverium with relative risk of -91.224 of vinorelbine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 88: pinaverium with relative risk of -91.224 of vinorelbine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 89: desoximetasone with relative risk of -inf of vinorelbine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 90: desoximetasone with relative risk of -inf of vinorelbine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 91: desoximetasone with relative risk of -inf of vinorelbine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 92: desoximetasone with relative risk of -inf of vinorelbine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 93: desoximetasone with relative risk of -inf of vinorelbine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 94: desoximetasone with relative risk of -inf of vinorelbine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 95: desoximetasone with relative risk of -inf of vinorelbine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 96: desoximetasone with relative risk of -inf of vinorelbine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 97: desoximetasone with relative risk of -inf of vinorelbine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 98: desoximetasone with relative risk of -inf of vinorelbine | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.095\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó vismodegib *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: betaxolol with relative risk of -9.801 of vismodegib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: riluzole with relative risk of -10.625 of vismodegib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: olopatadine with relative risk of -11.615 of vismodegib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: ritonavir with relative risk of -11.791 of vismodegib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: trazodone with relative risk of -15.881 of vismodegib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: trazodone with relative risk of -15.881 of vismodegib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: loperamide with relative risk of -17.060 of vismodegib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: loperamide with relative risk of -17.060 of vismodegib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: topiramate with relative risk of -17.500 of vismodegib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: topiramate with relative risk of -17.500 of vismodegib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: quinaprilat with relative risk of -19.040 of vismodegib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: quinaprilat with relative risk of -19.040 of vismodegib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: efinaconazole with relative risk of -inf of vismodegib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: efinaconazole with relative risk of -inf of vismodegib | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target vorapaxar not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó voriconazole *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: clozapine with relative risk of -10.063 of voriconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: vandetanib with relative risk of -11.340 of voriconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: danazol with relative risk of -11.727 of voriconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: efavirenz with relative risk of -12.600 of voriconazole | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: infectious disease\n",
      "Rank 5: oxcarbazepine with relative risk of -13.058 of voriconazole | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.109\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó zafirlukast *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: cabazitaxel with relative risk of -10.581 of zafirlukast | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: mitotane with relative risk of -10.981 of zafirlukast | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: danazol with relative risk of -11.727 of zafirlukast | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: canagliflozin with relative risk of -12.616 of zafirlukast | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: gonadorelin with relative risk of -12.633 of zafirlukast | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: phenytoin with relative risk of -12.906 of zafirlukast | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: montelukast with relative risk of -13.000 of zafirlukast | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: pulmonary\n",
      "Rank 8: dipyridamole with relative risk of -13.267 of zafirlukast | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: mexiletine with relative risk of -13.348 of zafirlukast | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: ranitidine with relative risk of -13.446 of zafirlukast | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: cilazapril with relative risk of -15.324 of zafirlukast | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.047\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target zaleplon not found. Exiting ...\n",
      "\n",
      "Drug target zanamivir not found. Exiting ...\n",
      "\n",
      "Drug target ziconotide not found. Exiting ...\n",
      "\n",
      "Drug target zidovudine not found. Exiting ...\n",
      "\n",
      "Drug target zidovudine/lamivudine not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó zileuton *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: amiodarone with relative risk of -9.864 of zileuton | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: nisoldipine with relative risk of -10.426 of zileuton | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: irinotecan with relative risk of -10.623 of zileuton | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: fluvastatin with relative risk of -11.284 of zileuton | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó ziprasidone *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: vandetanib with relative risk of -10.647 of ziprasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: labetalol with relative risk of -12.280 of ziprasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: loteprednol with relative risk of -13.347 of ziprasidone | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.0\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target zoledronic not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó zolmitriptan *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: levonorgestrel with relative risk of -8.668 of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: penbutolol with relative risk of -8.919 of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 3: ketorolac with relative risk of -9.650 of zolmitriptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 4: bumetanide with relative risk of -9.890 of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: telmisartan with relative risk of -10.066 of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: trovafloxacin with relative risk of -10.076 of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: dutasteride with relative risk of -10.478 of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: bezafibrate with relative risk of -10.648 of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: citalopram with relative risk of -11.075 of zolmitriptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 10: naproxen with relative risk of -16.353 of zolmitriptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Migraine Disorders,neurology/psychiatry\n",
      "Rank 11: naproxen with relative risk of -16.353 of zolmitriptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: Migraine Disorders,neurology/psychiatry\n",
      "Rank 12: lansoprazole with relative risk of -16.558 of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 13: lansoprazole with relative risk of -16.558 of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 14: gabapentin with relative risk of -17.689 of zolmitriptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 15: gabapentin with relative risk of -17.689 of zolmitriptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 16: cetirizine with relative risk of -18.523 of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 17: cetirizine with relative risk of -18.523 of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 18: pentoxifylline with relative risk of -22.636 of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 19: pentoxifylline with relative risk of -22.636 of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 20: pentoxifylline with relative risk of -22.636 of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 21: ropivacaine with relative risk of -23.699 of zolmitriptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 22: ropivacaine with relative risk of -23.699 of zolmitriptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 23: ropivacaine with relative risk of -23.699 of zolmitriptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 24: terbutaline with relative risk of -24.565 of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 25: terbutaline with relative risk of -24.565 of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 26: terbutaline with relative risk of -24.565 of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 27: lurasidone with relative risk of -24.628 of zolmitriptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 28: lurasidone with relative risk of -24.628 of zolmitriptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 29: lurasidone with relative risk of -24.628 of zolmitriptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 30: didanosine with relative risk of -25.483 of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 31: didanosine with relative risk of -25.483 of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 32: didanosine with relative risk of -25.483 of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 33: esmolol with relative risk of -25.527 of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 34: esmolol with relative risk of -25.527 of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 35: esmolol with relative risk of -25.527 of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 36: ivacaftor with relative risk of -26.817 of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 37: ivacaftor with relative risk of -26.817 of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 38: ivacaftor with relative risk of -26.817 of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 39: everolimus with relative risk of -26.937 of zolmitriptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 40: everolimus with relative risk of -26.937 of zolmitriptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 41: everolimus with relative risk of -26.937 of zolmitriptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 42: azilsartan with relative risk of -26.987 of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 43: azilsartan with relative risk of -26.987 of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 44: azilsartan with relative risk of -26.987 of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 45: brinzolamide with relative risk of -29.326 of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 46: brinzolamide with relative risk of -29.326 of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 47: brinzolamide with relative risk of -29.326 of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 48: acebutolol with relative risk of -29.671 of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 49: acebutolol with relative risk of -29.671 of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 50: acebutolol with relative risk of -29.671 of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 51: valsartan with relative risk of -29.814 of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 52: valsartan with relative risk of -29.814 of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 53: valsartan with relative risk of -29.814 of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 54: sertraline with relative risk of -34.222 of zolmitriptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 55: sertraline with relative risk of -34.222 of zolmitriptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 56: sertraline with relative risk of -34.222 of zolmitriptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 57: sertraline with relative risk of -34.222 of zolmitriptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 58: sertraline with relative risk of -34.222 of zolmitriptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 59: irbesartan with relative risk of -34.590 of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 60: irbesartan with relative risk of -34.590 of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 61: irbesartan with relative risk of -34.590 of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 62: irbesartan with relative risk of -34.590 of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 63: irbesartan with relative risk of -34.590 of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 64: mometasone with relative risk of -36.065 of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 65: mometasone with relative risk of -36.065 of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 66: mometasone with relative risk of -36.065 of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 67: mometasone with relative risk of -36.065 of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 68: mometasone with relative risk of -36.065 of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 69: regadenoson with relative risk of -36.243 of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 70: regadenoson with relative risk of -36.243 of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 71: regadenoson with relative risk of -36.243 of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 72: regadenoson with relative risk of -36.243 of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 73: regadenoson with relative risk of -36.243 of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 74: azelastine with relative risk of -36.761 of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 75: azelastine with relative risk of -36.761 of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 76: azelastine with relative risk of -36.761 of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 77: azelastine with relative risk of -36.761 of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 78: azelastine with relative risk of -36.761 of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 79: posaconazole with relative risk of -37.450 of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 80: posaconazole with relative risk of -37.450 of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 81: posaconazole with relative risk of -37.450 of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 82: posaconazole with relative risk of -37.450 of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 83: posaconazole with relative risk of -37.450 of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 84: ibutilide with relative risk of -38.383 of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 85: ibutilide with relative risk of -38.383 of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 86: ibutilide with relative risk of -38.383 of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 87: ibutilide with relative risk of -38.383 of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 88: ibutilide with relative risk of -38.383 of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 89: etoposide with relative risk of -39.105 of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 90: etoposide with relative risk of -39.105 of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 91: etoposide with relative risk of -39.105 of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 92: etoposide with relative risk of -39.105 of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 93: etoposide with relative risk of -39.105 of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 94: tropisetron with relative risk of -39.258 of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 95: tropisetron with relative risk of -39.258 of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 96: tropisetron with relative risk of -39.258 of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 97: tropisetron with relative risk of -39.258 of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 98: tropisetron with relative risk of -39.258 of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 99: paliperidone with relative risk of -39.469 of zolmitriptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 100: paliperidone with relative risk of -39.469 of zolmitriptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 101: paliperidone with relative risk of -39.469 of zolmitriptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 102: paliperidone with relative risk of -39.469 of zolmitriptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 103: paliperidone with relative risk of -39.469 of zolmitriptan | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 104: glimepiride with relative risk of -39.794 of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 105: glimepiride with relative risk of -39.794 of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 106: glimepiride with relative risk of -39.794 of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 107: glimepiride with relative risk of -39.794 of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 108: glimepiride with relative risk of -39.794 of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 109: fenofibrate with relative risk of -41.648 of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 110: fenofibrate with relative risk of -41.648 of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 111: fenofibrate with relative risk of -41.648 of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 112: fenofibrate with relative risk of -41.648 of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 113: fenofibrate with relative risk of -41.648 of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 114: felodipine with relative risk of -inf of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 115: felodipine with relative risk of -inf of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 116: felodipine with relative risk of -inf of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 117: felodipine with relative risk of -inf of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 118: felodipine with relative risk of -inf of zolmitriptan | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.23\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target zolpidem not found. Exiting ...\n",
      "\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ* ùïΩùñÜùñìùñêùñéùñìùñåùñò ùñãùñîùñó zonisamide *‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Rank 1: vinorelbine with relative risk of -8.412 of zonisamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 2: paroxetine with relative risk of -8.606 of zonisamide | Validation: TP (‚ó†‚Äø‚ó†‚úø), can be repurposed for diseases: neurology/psychiatry\n",
      "Rank 3: ciclesonide with relative risk of -8.907 of zonisamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 4: axitinib with relative risk of -8.960 of zonisamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 5: ibandronate with relative risk of -9.095 of zonisamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 6: darifenacin with relative risk of -9.239 of zonisamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 7: granisetron with relative risk of -9.299 of zonisamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 8: pentoxifylline with relative risk of -9.454 of zonisamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 9: apraclonidine with relative risk of -9.456 of zonisamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 10: meloxicam with relative risk of -10.134 of zonisamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 11: pinaverium with relative risk of -12.435 of zonisamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "Rank 12: desoximetasone with relative risk of -inf of zonisamide | Validation: FP („Å§Ôπè<„ÄÇ)\n",
      "\n",
      "ùïªùñóùñäùñàùñéùñòùñéùñîùñì:ÔΩ•Ôæü‚úß  0.161\n",
      "\n",
      "*‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ**‚òÖ*‚Äï‚Äï‚Äï‚Äï*‚òÖ*\n",
      "\n",
      "Drug target zopiclone not found. Exiting ...\n",
      "\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "[0.09940337216530858,\n",
       " 0.45454545454545453,\n",
       " 0.18872909189005468,\n",
       " 0.026853907766708127,\n",
       " 0.0,\n",
       " 0.028552575078280334,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.048768253600258264,\n",
       " 0.0506076152754053,\n",
       " 0.10610320741527811,\n",
       " 0.060097024663645714,\n",
       " 0.0838539153380518,\n",
       " 0.18181818181818182,\n",
       " 0.4536400617197362,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.13533986600886921,\n",
       " 0.17504872537975413,\n",
       " 0.11395364836214522,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.3333333333333333,\n",
       " 0.0281869611820702,\n",
       " 0.020091038563855364,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.026551698509328654,\n",
       " 0.0,\n",
       " 0.1620990247508584,\n",
       " 0.12615034529536684,\n",
       " 0.5041781266019904,\n",
       " 0.2888293850547764,\n",
       " 0.04515716601398219,\n",
       " 0.04027051957072443,\n",
       " 0.043934923741159454,\n",
       " 0.0880797693283447,\n",
       " 0.0,\n",
       " 0.08448710188983058,\n",
       " 0.22030866824695483,\n",
       " 0.0,\n",
       " 0.04572023775024212,\n",
       " 0.4800000000000001,\n",
       " 0.07287352751400343,\n",
       " 0.17476919872763277,\n",
       " 0.23317573921053,\n",
       " 0.11070469552428454,\n",
       " 0.08278481919938838,\n",
       " 0.0,\n",
       " 0.07747293424311694,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.034243770898632994,\n",
       " 0.027936012898473972,\n",
       " 0.34731054044942516,\n",
       " 0.1828809510009685,\n",
       " 0.36523124404881524,\n",
       " 0.0,\n",
       " 0.4241829148548183,\n",
       " 0.10204081632653063,\n",
       " 0.10251482206270539,\n",
       " 0.19708029197080293,\n",
       " 0.4800000000000001,\n",
       " 0.09034569655401456,\n",
       " 0.12264564169951817,\n",
       " 0.0,\n",
       " 0.07947616255721851,\n",
       " 0.06692624510236692,\n",
       " 0.2987519434505721,\n",
       " 0.4933090982328567,\n",
       " 0.21039444667472074,\n",
       " 0.1965105601469238,\n",
       " 0.02311207401705115,\n",
       " 0.09550387262010505,\n",
       " 0.21767997545006318,\n",
       " 0.6666666666666666,\n",
       " 0.014407643067812214,\n",
       " 0.18856542150971797,\n",
       " 0.07260613660556066,\n",
       " 0.0748446381664502,\n",
       " 0.0,\n",
       " 0.12610561136951087,\n",
       " 0.44415630637047826,\n",
       " 0.0,\n",
       " 0.060135832419289284,\n",
       " 0.0,\n",
       " 0.34210460303526274,\n",
       " 0.3431092944767967,\n",
       " 0.4452531628684271,\n",
       " 0.05356879497737102,\n",
       " 0.20578765654943312,\n",
       " 0.4800000000000001,\n",
       " 0.0,\n",
       " 0.17520805957074023,\n",
       " 0.12056506427686822,\n",
       " 0.0462241480341023,\n",
       " 0.055590459304880345,\n",
       " 0.18181818181818182,\n",
       " 0.0,\n",
       " 0.4541162386072181,\n",
       " 0.16906319376384463,\n",
       " 0.10168753025653562,\n",
       " 0.13841770660152186,\n",
       " 0.04430289636163562,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.03517278855120741,\n",
       " 0.0,\n",
       " 0.21897810218978103,\n",
       " 0.0,\n",
       " 0.20766530113305504,\n",
       " 0.7484918350037629,\n",
       " 0.7200000000000001,\n",
       " 0.1965105601469238,\n",
       " 0.08855915256375776,\n",
       " 0.07131080979295772,\n",
       " 0.33462178370857004,\n",
       " 0.07369624990172843,\n",
       " 0.24457391973598439,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.07728383030032178,\n",
       " 0.1285428463363587,\n",
       " 0.12855831037649218,\n",
       " 0.2736278620381584,\n",
       " 0.0,\n",
       " 0.033867874510486645,\n",
       " 0.08775890070519478,\n",
       " 0.4241829148548183,\n",
       " 0.008948372072726307,\n",
       " 0.08759124087591241,\n",
       " 0.0,\n",
       " 0.3333333333333333,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.09641873278236916,\n",
       " 0.21216267184720639,\n",
       " 0.0,\n",
       " 0.12000000000000002,\n",
       " 0.11073493405971112,\n",
       " 0.22030866824695483,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.271558640782565,\n",
       " 0.0,\n",
       " 0.12177035789885231,\n",
       " 0.017372018532775105,\n",
       " 0.2493541465125513,\n",
       " 0.14611470984923652,\n",
       " 0.38132549028725543,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.32603746963187363,\n",
       " 0.06947941295164022,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.0704980092325358,\n",
       " 0.12161645846947476,\n",
       " 0.02381517513029597,\n",
       " 0.4800000000000001,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.41781450872359965,\n",
       " 0.2921328149316305,\n",
       " 0.32466519654007403,\n",
       " 0.30897234867171414,\n",
       " 0.06877217828198373,\n",
       " 0.13259442084872655,\n",
       " 0.5960341440610425,\n",
       " 0.06613927867237057,\n",
       " 0.3338835865660711,\n",
       " 0.26597432095972673,\n",
       " 0.29114722261321335,\n",
       " 0.6666666666666666,\n",
       " 0.07145789575320627,\n",
       " 0.05346060363004344,\n",
       " 0.0816326530612245,\n",
       " 0.03483810364266675,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.07861304562942356,\n",
       " 0.023204193816390904,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.07825995977726369,\n",
       " 0.004246396474700912,\n",
       " 0.24727386440398952,\n",
       " 0.3679369250985546,\n",
       " 0.0,\n",
       " 0.22173293099663258,\n",
       " 0.0,\n",
       " 0.0913496574555549,\n",
       " 0.022988513036853543,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.1004551928192768,\n",
       " 0.1927376453568422,\n",
       " 0.0,\n",
       " 0.17850560985197028,\n",
       " 0.012528890597220342,\n",
       " 0.0,\n",
       " 0.0966283283309234,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.36043728682816795,\n",
       " 0.0,\n",
       " 0.22497704315886133,\n",
       " 0.008941842528476986,\n",
       " 0.07240627177345407,\n",
       " 0.23112074017051143,\n",
       " 0.0,\n",
       " 0.4562666340195527,\n",
       " 0.0,\n",
       " 0.2040816326530612,\n",
       " 0.348916519377708,\n",
       " 0.0,\n",
       " 0.020826217698880288,\n",
       " 0.16719176107866082,\n",
       " 0.25170068027210885,\n",
       " 0.01637858621312102,\n",
       " 0.11388523872098118,\n",
       " 0.0,\n",
       " 0.22799267375166474,\n",
       " 0.2661252324876164,\n",
       " 0.0,\n",
       " 0.3066141042487954,\n",
       " 0.0,\n",
       " 0.011215074915013685,\n",
       " 0.12721602024898446,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.1928374655647383,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.07985950015551577,\n",
       " 0.0,\n",
       " 0.1818757391501714,\n",
       " 0.45454545454545453,\n",
       " 0.01650319361821447,\n",
       " 0.08131347864478475,\n",
       " 0.07985950015551577,\n",
       " 0.0,\n",
       " 0.3338835865660711,\n",
       " 0.011899316338623405,\n",
       " 0.3144521825176942,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.032290919456334596,\n",
       " 0.03144521825176943,\n",
       " 0.0,\n",
       " 0.017935593423046983,\n",
       " 0.0,\n",
       " 0.34141715214740553,\n",
       " 0.0,\n",
       " 0.11937557392102849,\n",
       " 0.21553994989185216,\n",
       " 0.45454545454545453,\n",
       " 1.0,\n",
       " 0.07369624990172843,\n",
       " 0.7351163834786386,\n",
       " 0.4081632653061224,\n",
       " 0.0,\n",
       " 0.07386384210845352,\n",
       " 1.0,\n",
       " 0.145985401459854,\n",
       " 0.4689521588822911,\n",
       " 0.0,\n",
       " 0.1074156310668325,\n",
       " 0.0,\n",
       " 0.48847451640128237,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.10189081555768247,\n",
       " 0.09771942975101243,\n",
       " 0.0642791551882461,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.43795620437956206,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.16489760072204168,\n",
       " 0.0,\n",
       " 0.14965986394557826,\n",
       " 0.05509641873278237,\n",
       " 0.0,\n",
       " 0.0910129821383624,\n",
       " 0.0,\n",
       " 0.04720814083537734,\n",
       " 0.20293215556217814,\n",
       " 0.3144521825176942,\n",
       " 0.13191051217849872,\n",
       " 0.15514178134703557,\n",
       " 0.4826739538785713,\n",
       " 0.0,\n",
       " 0.38567493112947665,\n",
       " 0.2987519434505721,\n",
       " 0.026370325096683054,\n",
       " 0.12220291517095504,\n",
       " 0.0,\n",
       " 0.18181818181818182,\n",
       " 0.4800000000000001,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.03637720186056575,\n",
       " 0.15906859307055687,\n",
       " 0.11957950065703024,\n",
       " 0.14965986394557826,\n",
       " 0.0,\n",
       " 0.14455696681579164,\n",
       " 0.7272869704661372,\n",
       " 0.0,\n",
       " 0.7200000000000001,\n",
       " 0.19708029197080293,\n",
       " 0.0,\n",
       " 0.6923334459599808,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.11380571738246849,\n",
       " 0.41108262267716084,\n",
       " 0.10486932111766631,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.2942992085842703,\n",
       " 0.3338835865660711,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.08692522008626723,\n",
       " 0.053707815533416255,\n",
       " 0.547321916163535,\n",
       " 0.04107540234718554,\n",
       " 0.2367280155624495,\n",
       " 0.0,\n",
       " 0.12000000000000002,\n",
       " 0.2942992085842703,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.3338835865660711,\n",
       " 0.11779896849573994,\n",
       " 0.7200000000000001,\n",
       " 0.2545964205575821,\n",
       " 0.15999999999999998,\n",
       " 0.02534740345856435,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.45454545454545453,\n",
       " 0.16531208205725953,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.8153295875280214,\n",
       " 0.2968546080109639,\n",
       " 0.0,\n",
       " 0.06096449251698604,\n",
       " 0.04327300613753463,\n",
       " 0.33192563495411076,\n",
       " 0.0,\n",
       " 0.04060235133213567,\n",
       " 0.0,\n",
       " 0.15999999999999998,\n",
       " 0.01462294643688941,\n",
       " 0.3213957759412305,\n",
       " 0.04420375364913744,\n",
       " 0.06161972825181908,\n",
       " 0.08951164697361028,\n",
       " 0.07652410532090642,\n",
       " 0.0,\n",
       " 0.28,\n",
       " 0.046976089879905585,\n",
       " 0.0,\n",
       " 0.1364296701397823,\n",
       " 0.12000000000000002,\n",
       " 0.19653261407355888,\n",
       " 0.21414431308710247,\n",
       " 0.18181818181818182,\n",
       " 0.08131347864478475,\n",
       " 0.0,\n",
       " 0.14121681913632955,\n",
       " 0.5878727111348119,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.09806340251405592,\n",
       " 0.35348576237901524,\n",
       " 0.7200000000000001,\n",
       " 0.0,\n",
       " 0.19420404278172884,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.009296116921930542,\n",
       " 0.0,\n",
       " 1.0,\n",
       " 0.3679369250985546,\n",
       " 0.18872909189005468,\n",
       " 0.07059105943476868,\n",
       " 0.0,\n",
       " 0.1671771839538563,\n",
       " 0.21848758941785493,\n",
       " 0.5454545454545455,\n",
       " 0.0,\n",
       " 0.12161645846947476,\n",
       " 0.22593056457636607,\n",
       " 0.07046740295517549,\n",
       " 0.09525701261048806,\n",
       " 0.0,\n",
       " 0.10948905109489052,\n",
       " 0.04730561097107907,\n",
       " 0.0,\n",
       " 0.0,\n",
       " 0.2300248667543774,\n",
       " 0.16112344660024877]"
      ]
     },
     "execution_count": 4,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# runs calc_relative_risk for every drug on our dataset \n",
    "precisions = []\n",
    "for drug_name in drugs:\n",
    "    \n",
    "    try:\n",
    "        prec = main(drug_name)\n",
    "        precisions.append(prec)\n",
    "    except:\n",
    "        print('')\n",
    "\n",
    "precisions"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0.14109584150473722"
      ]
     },
     "execution_count": 5,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "np.mean(precisions)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "425"
      ]
     },
     "execution_count": 6,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(precisions)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0.18403566444437844"
      ]
     },
     "execution_count": 7,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "np.std(precisions)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Check ln(scaled risk score) distribution"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "C:\\Users\\Admin\\AppData\\Local\\Temp/ipykernel_26080/1880836188.py:3: RuntimeWarning: divide by zero encountered in log\n",
      "  ddr['scaled_risk_score_log'] = np.log(ddr.loc[:,'scaled_risk_score'].to_numpy(dtype=float))\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>drug_a</th>\n",
       "      <th>clinical_phase_a</th>\n",
       "      <th>moa_a</th>\n",
       "      <th>target_a</th>\n",
       "      <th>disease_area_a</th>\n",
       "      <th>indication_a</th>\n",
       "      <th>risk_score_a</th>\n",
       "      <th>scaled_risk_score</th>\n",
       "      <th>total_overlaps</th>\n",
       "      <th>drug_b</th>\n",
       "      <th>clinical_phase_b</th>\n",
       "      <th>moa_b</th>\n",
       "      <th>target_b</th>\n",
       "      <th>disease_area_b</th>\n",
       "      <th>indication_b</th>\n",
       "      <th>risk_score_b</th>\n",
       "      <th>gene</th>\n",
       "      <th>scaled_risk_score_log</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>abiraterone</td>\n",
       "      <td>Launched</td>\n",
       "      <td>androgen biosynthesis inhibitor</td>\n",
       "      <td>CYP11B1|CYP17A1</td>\n",
       "      <td>oncology</td>\n",
       "      <td>prostate cancer</td>\n",
       "      <td>0.047161</td>\n",
       "      <td>5.104514e-05</td>\n",
       "      <td>1</td>\n",
       "      <td>mitotane</td>\n",
       "      <td>Launched</td>\n",
       "      <td>antineoplastic agent</td>\n",
       "      <td>CYP11A1|CYP11B1|ESR1</td>\n",
       "      <td>oncology</td>\n",
       "      <td>adrenal cortical carcinoma</td>\n",
       "      <td>0.197996</td>\n",
       "      <td>CYP11B1</td>\n",
       "      <td>-9.882800</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>abiraterone</td>\n",
       "      <td>Launched</td>\n",
       "      <td>androgen biosynthesis inhibitor</td>\n",
       "      <td>CYP11B1|CYP17A1</td>\n",
       "      <td>oncology</td>\n",
       "      <td>prostate cancer</td>\n",
       "      <td>0.047161</td>\n",
       "      <td>6.741792e-05</td>\n",
       "      <td>1</td>\n",
       "      <td>progesterone</td>\n",
       "      <td>Launched</td>\n",
       "      <td>progesterone receptor agonist</td>\n",
       "      <td>CATSPER1|CATSPER2|CATSPER3|CATSPER4|CYP17A1|ES...</td>\n",
       "      <td>obstetrics/gynecology|endocrinology</td>\n",
       "      <td>infertility|amenorrhea</td>\n",
       "      <td>0.078474</td>\n",
       "      <td>CYP17A1</td>\n",
       "      <td>-9.604600</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>acamprosate</td>\n",
       "      <td>Launched</td>\n",
       "      <td>glutamate receptor antagonist</td>\n",
       "      <td>GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABR...</td>\n",
       "      <td>neurology/psychiatry</td>\n",
       "      <td>abstinence from alcohol</td>\n",
       "      <td>0.048947</td>\n",
       "      <td>1.519970e-40</td>\n",
       "      <td>16</td>\n",
       "      <td>amoxapine</td>\n",
       "      <td>Launched</td>\n",
       "      <td>norepinephrine reputake inhibitor</td>\n",
       "      <td>ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|CHRM...</td>\n",
       "      <td>neurology/psychiatry</td>\n",
       "      <td>depression</td>\n",
       "      <td>0.113536</td>\n",
       "      <td>GABRA1</td>\n",
       "      <td>-91.684713</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>acamprosate</td>\n",
       "      <td>Launched</td>\n",
       "      <td>glutamate receptor antagonist</td>\n",
       "      <td>GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABR...</td>\n",
       "      <td>neurology/psychiatry</td>\n",
       "      <td>abstinence from alcohol</td>\n",
       "      <td>0.048947</td>\n",
       "      <td>1.519970e-40</td>\n",
       "      <td>16</td>\n",
       "      <td>amoxapine</td>\n",
       "      <td>Launched</td>\n",
       "      <td>norepinephrine reputake inhibitor</td>\n",
       "      <td>ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|CHRM...</td>\n",
       "      <td>neurology/psychiatry</td>\n",
       "      <td>depression</td>\n",
       "      <td>0.113536</td>\n",
       "      <td>GABRA2</td>\n",
       "      <td>-91.684713</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>acamprosate</td>\n",
       "      <td>Launched</td>\n",
       "      <td>glutamate receptor antagonist</td>\n",
       "      <td>GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABR...</td>\n",
       "      <td>neurology/psychiatry</td>\n",
       "      <td>abstinence from alcohol</td>\n",
       "      <td>0.048947</td>\n",
       "      <td>1.519970e-40</td>\n",
       "      <td>16</td>\n",
       "      <td>amoxapine</td>\n",
       "      <td>Launched</td>\n",
       "      <td>norepinephrine reputake inhibitor</td>\n",
       "      <td>ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|CHRM...</td>\n",
       "      <td>neurology/psychiatry</td>\n",
       "      <td>depression</td>\n",
       "      <td>0.113536</td>\n",
       "      <td>GABRA3</td>\n",
       "      <td>-91.684713</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18737</th>\n",
       "      <td>zonisamide</td>\n",
       "      <td>Launched</td>\n",
       "      <td>sodium channel blocker|T-type calcium channel ...</td>\n",
       "      <td>CA1|CA10|CA11|CA12|CA13|CA14|CA2|CA3|CA4|CA5A|...</td>\n",
       "      <td>neurology/psychiatry</td>\n",
       "      <td>seizures|epilepsy</td>\n",
       "      <td>0.039542</td>\n",
       "      <td>1.245444e-35</td>\n",
       "      <td>15</td>\n",
       "      <td>topiramate</td>\n",
       "      <td>Launched</td>\n",
       "      <td>carbonic anhydrase inhibitor|glutamate recepto...</td>\n",
       "      <td>CA1|CA12|CA2|CA4|CA7|GABRA1|GABRA2|GABRA3|GABR...</td>\n",
       "      <td>neurology/psychiatry</td>\n",
       "      <td>epilepsy|migraine headache</td>\n",
       "      <td>0.041200</td>\n",
       "      <td>SCN9A</td>\n",
       "      <td>-80.370986</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18738</th>\n",
       "      <td>zonisamide</td>\n",
       "      <td>Launched</td>\n",
       "      <td>sodium channel blocker|T-type calcium channel ...</td>\n",
       "      <td>CA1|CA10|CA11|CA12|CA13|CA14|CA2|CA3|CA4|CA5A|...</td>\n",
       "      <td>neurology/psychiatry</td>\n",
       "      <td>seizures|epilepsy</td>\n",
       "      <td>0.039542</td>\n",
       "      <td>9.864365e-05</td>\n",
       "      <td>1</td>\n",
       "      <td>valdecoxib</td>\n",
       "      <td>Withdrawn</td>\n",
       "      <td>cyclooxygenase inhibitor</td>\n",
       "      <td>CA12|PTGS2</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>0.033806</td>\n",
       "      <td>CA12</td>\n",
       "      <td>-9.223997</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18739</th>\n",
       "      <td>zonisamide</td>\n",
       "      <td>Launched</td>\n",
       "      <td>sodium channel blocker|T-type calcium channel ...</td>\n",
       "      <td>CA1|CA10|CA11|CA12|CA13|CA14|CA2|CA3|CA4|CA5A|...</td>\n",
       "      <td>neurology/psychiatry</td>\n",
       "      <td>seizures|epilepsy</td>\n",
       "      <td>0.039542</td>\n",
       "      <td>9.500548e-08</td>\n",
       "      <td>3</td>\n",
       "      <td>verapamil</td>\n",
       "      <td>Launched</td>\n",
       "      <td>calcium channel blocker</td>\n",
       "      <td>CACNA1A|CACNA1B|CACNA1C|CACNA1D|CACNA1F|CACNA1...</td>\n",
       "      <td>cardiology</td>\n",
       "      <td>hypertension</td>\n",
       "      <td>0.025678</td>\n",
       "      <td>CACNA1G</td>\n",
       "      <td>-16.169331</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18740</th>\n",
       "      <td>zonisamide</td>\n",
       "      <td>Launched</td>\n",
       "      <td>sodium channel blocker|T-type calcium channel ...</td>\n",
       "      <td>CA1|CA10|CA11|CA12|CA13|CA14|CA2|CA3|CA4|CA5A|...</td>\n",
       "      <td>neurology/psychiatry</td>\n",
       "      <td>seizures|epilepsy</td>\n",
       "      <td>0.039542</td>\n",
       "      <td>9.500548e-08</td>\n",
       "      <td>3</td>\n",
       "      <td>verapamil</td>\n",
       "      <td>Launched</td>\n",
       "      <td>calcium channel blocker</td>\n",
       "      <td>CACNA1A|CACNA1B|CACNA1C|CACNA1D|CACNA1F|CACNA1...</td>\n",
       "      <td>cardiology</td>\n",
       "      <td>hypertension</td>\n",
       "      <td>0.025678</td>\n",
       "      <td>CACNA1I</td>\n",
       "      <td>-16.169331</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18741</th>\n",
       "      <td>zonisamide</td>\n",
       "      <td>Launched</td>\n",
       "      <td>sodium channel blocker|T-type calcium channel ...</td>\n",
       "      <td>CA1|CA10|CA11|CA12|CA13|CA14|CA2|CA3|CA4|CA5A|...</td>\n",
       "      <td>neurology/psychiatry</td>\n",
       "      <td>seizures|epilepsy</td>\n",
       "      <td>0.039542</td>\n",
       "      <td>9.500548e-08</td>\n",
       "      <td>3</td>\n",
       "      <td>verapamil</td>\n",
       "      <td>Launched</td>\n",
       "      <td>calcium channel blocker</td>\n",
       "      <td>CACNA1A|CACNA1B|CACNA1C|CACNA1D|CACNA1F|CACNA1...</td>\n",
       "      <td>cardiology</td>\n",
       "      <td>hypertension</td>\n",
       "      <td>0.025678</td>\n",
       "      <td>SCN5A</td>\n",
       "      <td>-16.169331</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>18742 rows √ó 18 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "            drug_a clinical_phase_a  \\\n",
       "0      abiraterone         Launched   \n",
       "1      abiraterone         Launched   \n",
       "2      acamprosate         Launched   \n",
       "3      acamprosate         Launched   \n",
       "4      acamprosate         Launched   \n",
       "...            ...              ...   \n",
       "18737   zonisamide         Launched   \n",
       "18738   zonisamide         Launched   \n",
       "18739   zonisamide         Launched   \n",
       "18740   zonisamide         Launched   \n",
       "18741   zonisamide         Launched   \n",
       "\n",
       "                                                   moa_a  \\\n",
       "0                        androgen biosynthesis inhibitor   \n",
       "1                        androgen biosynthesis inhibitor   \n",
       "2                          glutamate receptor antagonist   \n",
       "3                          glutamate receptor antagonist   \n",
       "4                          glutamate receptor antagonist   \n",
       "...                                                  ...   \n",
       "18737  sodium channel blocker|T-type calcium channel ...   \n",
       "18738  sodium channel blocker|T-type calcium channel ...   \n",
       "18739  sodium channel blocker|T-type calcium channel ...   \n",
       "18740  sodium channel blocker|T-type calcium channel ...   \n",
       "18741  sodium channel blocker|T-type calcium channel ...   \n",
       "\n",
       "                                                target_a  \\\n",
       "0                                        CYP11B1|CYP17A1   \n",
       "1                                        CYP11B1|CYP17A1   \n",
       "2      GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABR...   \n",
       "3      GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABR...   \n",
       "4      GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABR...   \n",
       "...                                                  ...   \n",
       "18737  CA1|CA10|CA11|CA12|CA13|CA14|CA2|CA3|CA4|CA5A|...   \n",
       "18738  CA1|CA10|CA11|CA12|CA13|CA14|CA2|CA3|CA4|CA5A|...   \n",
       "18739  CA1|CA10|CA11|CA12|CA13|CA14|CA2|CA3|CA4|CA5A|...   \n",
       "18740  CA1|CA10|CA11|CA12|CA13|CA14|CA2|CA3|CA4|CA5A|...   \n",
       "18741  CA1|CA10|CA11|CA12|CA13|CA14|CA2|CA3|CA4|CA5A|...   \n",
       "\n",
       "             disease_area_a             indication_a  risk_score_a  \\\n",
       "0                  oncology          prostate cancer      0.047161   \n",
       "1                  oncology          prostate cancer      0.047161   \n",
       "2      neurology/psychiatry  abstinence from alcohol      0.048947   \n",
       "3      neurology/psychiatry  abstinence from alcohol      0.048947   \n",
       "4      neurology/psychiatry  abstinence from alcohol      0.048947   \n",
       "...                     ...                      ...           ...   \n",
       "18737  neurology/psychiatry        seizures|epilepsy      0.039542   \n",
       "18738  neurology/psychiatry        seizures|epilepsy      0.039542   \n",
       "18739  neurology/psychiatry        seizures|epilepsy      0.039542   \n",
       "18740  neurology/psychiatry        seizures|epilepsy      0.039542   \n",
       "18741  neurology/psychiatry        seizures|epilepsy      0.039542   \n",
       "\n",
       "       scaled_risk_score  total_overlaps        drug_b clinical_phase_b  \\\n",
       "0           5.104514e-05               1      mitotane         Launched   \n",
       "1           6.741792e-05               1  progesterone         Launched   \n",
       "2           1.519970e-40              16     amoxapine         Launched   \n",
       "3           1.519970e-40              16     amoxapine         Launched   \n",
       "4           1.519970e-40              16     amoxapine         Launched   \n",
       "...                  ...             ...           ...              ...   \n",
       "18737       1.245444e-35              15    topiramate         Launched   \n",
       "18738       9.864365e-05               1    valdecoxib        Withdrawn   \n",
       "18739       9.500548e-08               3     verapamil         Launched   \n",
       "18740       9.500548e-08               3     verapamil         Launched   \n",
       "18741       9.500548e-08               3     verapamil         Launched   \n",
       "\n",
       "                                                   moa_b  \\\n",
       "0                                   antineoplastic agent   \n",
       "1                          progesterone receptor agonist   \n",
       "2                      norepinephrine reputake inhibitor   \n",
       "3                      norepinephrine reputake inhibitor   \n",
       "4                      norepinephrine reputake inhibitor   \n",
       "...                                                  ...   \n",
       "18737  carbonic anhydrase inhibitor|glutamate recepto...   \n",
       "18738                           cyclooxygenase inhibitor   \n",
       "18739                            calcium channel blocker   \n",
       "18740                            calcium channel blocker   \n",
       "18741                            calcium channel blocker   \n",
       "\n",
       "                                                target_b  \\\n",
       "0                                   CYP11A1|CYP11B1|ESR1   \n",
       "1      CATSPER1|CATSPER2|CATSPER3|CATSPER4|CYP17A1|ES...   \n",
       "2      ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|CHRM...   \n",
       "3      ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|CHRM...   \n",
       "4      ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|CHRM...   \n",
       "...                                                  ...   \n",
       "18737  CA1|CA12|CA2|CA4|CA7|GABRA1|GABRA2|GABRA3|GABR...   \n",
       "18738                                         CA12|PTGS2   \n",
       "18739  CACNA1A|CACNA1B|CACNA1C|CACNA1D|CACNA1F|CACNA1...   \n",
       "18740  CACNA1A|CACNA1B|CACNA1C|CACNA1D|CACNA1F|CACNA1...   \n",
       "18741  CACNA1A|CACNA1B|CACNA1C|CACNA1D|CACNA1F|CACNA1...   \n",
       "\n",
       "                            disease_area_b                indication_b  \\\n",
       "0                                 oncology  adrenal cortical carcinoma   \n",
       "1      obstetrics/gynecology|endocrinology      infertility|amenorrhea   \n",
       "2                     neurology/psychiatry                  depression   \n",
       "3                     neurology/psychiatry                  depression   \n",
       "4                     neurology/psychiatry                  depression   \n",
       "...                                    ...                         ...   \n",
       "18737                 neurology/psychiatry  epilepsy|migraine headache   \n",
       "18738                                  NaN                         NaN   \n",
       "18739                           cardiology                hypertension   \n",
       "18740                           cardiology                hypertension   \n",
       "18741                           cardiology                hypertension   \n",
       "\n",
       "       risk_score_b     gene  scaled_risk_score_log  \n",
       "0          0.197996  CYP11B1              -9.882800  \n",
       "1          0.078474  CYP17A1              -9.604600  \n",
       "2          0.113536   GABRA1             -91.684713  \n",
       "3          0.113536   GABRA2             -91.684713  \n",
       "4          0.113536   GABRA3             -91.684713  \n",
       "...             ...      ...                    ...  \n",
       "18737      0.041200    SCN9A             -80.370986  \n",
       "18738      0.033806     CA12              -9.223997  \n",
       "18739      0.025678  CACNA1G             -16.169331  \n",
       "18740      0.025678  CACNA1I             -16.169331  \n",
       "18741      0.025678    SCN5A             -16.169331  \n",
       "\n",
       "[18742 rows x 18 columns]"
      ]
     },
     "execution_count": 3,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "ddr = pd.read_csv('validation data/DDR_full_net_risk_fixed.csv')\n",
    "\n",
    "ddr['scaled_risk_score_log'] = np.log(ddr.loc[:,'scaled_risk_score'].to_numpy(dtype=float))\n",
    "\n",
    "ddr"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 34,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 432x288 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "import matplotlib.pyplot as plt\n",
    "\n",
    "thr = round(np.percentile(ddr['scaled_risk_score_log'], 50),3)\n",
    "\n",
    "_ = plt.hist(ddr['scaled_risk_score_log'], bins='auto', range=(-200,0),  color ='green')\n",
    "plt.title('Distribution of scaled_risk_score_log of Drugs')\n",
    "plt.xlabel('scaled_risk_score_log')\n",
    "plt.ylabel('Fraction of Drugs')\n",
    "\n",
    "plt.axvline(thr, 0, 0.35, color = 'white', ls = '--')\n",
    "plt.text(thr+0.2,20,thr,fontdict=dict(color='white', size=10))\n",
    "\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 33,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 432x288 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "\n",
    "_ = plt.hist(ddr['scaled_risk_score_log'], bins='auto', range=(-200,0),  color ='purple')\n",
    "plt.title('Distribution of scaled_risk_score_log of Drugs on Log Scale')\n",
    "plt.xlabel('scaled_risk_score_log')\n",
    "plt.ylabel('log(Fraction of Drugs)')\n",
    "\n",
    "plt.axvline(thr, 0, 0.8, color = 'white', ls = '--')\n",
    "plt.text(thr+0.2,13,thr,fontdict=dict(color='white', size=10))\n",
    "\n",
    "plt.yscale('log')\n",
    "\n",
    "plt.show()"
   ]
  }
 ],
 "metadata": {
  "interpreter": {
   "hash": "dcacb0086e9a4f4eabd41c33bf4faac5ea0a3337ed3f5eff0680afa930572c04"
  },
  "kernelspec": {
   "display_name": "Python 3.9.7 64-bit",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.9.7"
  },
  "orig_nbformat": 4
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
